Entry	Entry name	Status	Protein names	Gene names	Organism	Length	Allergenic properties	Biotechnological use	Involvement in disease	Disruption phenotype	Mutagenesis	Cross-reference (IntAct)	Cross-reference (STRING)	Cross-reference (PDB)
P62871	GBB1_BOVIN	reviewed	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (Transducin beta chain 1)	GNB1	Bos taurus (Bovine)	340						P62871;	9913.ENSBTAP00000042481;	1A0R;1B9X;1B9Y;1GG2;1GOT;1GP2;1OMW;1TBG;1XHM;2BCJ;2TRC;3AH8;3CIK;3KRW;3KRX;3PSC;3PVU;3PVW;3UZS;3V5W;4MK0;5KDO;5WG3;5WG4;5WG5;6B20;6C2Y;6OY9;6OYA;6PCV;6QNO;6U7C;7BZ2;7D68;7DHI;7DHR;7JJO;7O7F;
P22340	SCRY_SALTM	reviewed	Sucrose porin	scrY	Salmonella typhimurium	505								1A0S;1A0T;1OH2;
P04117	FABP4_MOUSE	reviewed	Fatty acid-binding protein, adipocyte (3T3-L1 lipid-binding protein) (Adipocyte lipid-binding protein) (ALBP) (Adipocyte-type fatty acid-binding protein) (A-FABP) (AFABP) (Fatty acid-binding protein 4) (Myelin P2 protein homolog) (P15) (P2 adipocyte protein) (Protein 422)	Fabp4 Ap2	Mus musculus (Mouse)	132					"MUTAGEN 22;  /note=""K->A: Abolishes ligand-induced translocation to the nucleus; when associated with A-31 and A-32."";  /evidence=""ECO:0000269|PubMed:17516629""; MUTAGEN 31;  /note=""R->A: Abolishes ligand-induced translocation to the nucleus; when associated with A-22 and A-32."";  /evidence=""ECO:0000269|PubMed:17516629""; MUTAGEN 32;  /note=""K->A: Abolishes ligand-induced translocation to the nucleus; when associated with A-22 and A-31."";  /evidence=""ECO:0000269|PubMed:17516629""; MUTAGEN 58;  /note=""F->A: Abolishes ligand-induced translocation to the nucleus."";  /evidence=""ECO:0000269|PubMed:17761196""; MUTAGEN 67;  /note=""L->A: Abolishes export from nucleus; when associated with A-87 and A-92."";  /evidence=""ECO:0000269|PubMed:17516629, ECO:0000269|PubMed:17761196""; MUTAGEN 87;  /note=""L->A: Abolishes export from nucleus; when associated with A-67 and A-92."";  /evidence=""ECO:0000269|PubMed:17516629, ECO:0000269|PubMed:17761196""; MUTAGEN 92;  /note=""L->A: Abolishes export from nucleus; when associated with A-67 and A-87."";  /evidence=""ECO:0000269|PubMed:17516629, ECO:0000269|PubMed:17761196"""		10090.ENSMUSP00000029041;	1A18;1A2D;1AB0;1ACD;1ADL;1ALB;1G74;1G7N;1LIB;1LIC;1LID;1LIE;1LIF;2ANS;2Q9S;2QM9;3HK1;3JS1;3JSQ;5C0N;5D8J;
P18754	RCC1_HUMAN	reviewed	Regulator of chromosome condensation (Cell cycle regulatory protein) (Chromosome condensation protein 1)	RCC1 CHC1	Homo sapiens (Human)	421					"MUTAGEN 2;  /note=""S->A: Does not abolish N-terminal methylation."";  /evidence=""ECO:0000269|PubMed:17435751""; MUTAGEN 2;  /note=""S->Q: Does not abolish N-terminal methylation."";  /evidence=""ECO:0000269|PubMed:17435751""; MUTAGEN 3;  /note=""P->Q: Abolishes N-terminal methylation."";  /evidence=""ECO:0000269|PubMed:17435751""; MUTAGEN 4;  /note=""K->Q: Abolishes N-terminal methylation."";  /evidence=""ECO:0000269|PubMed:17435751, ECO:0000269|PubMed:20668449""; MUTAGEN 4;  /note=""K->R: Strongly impairs N-terminal methylation and subcellular localization."";  /evidence=""ECO:0000269|PubMed:17435751, ECO:0000269|PubMed:20668449""; MUTAGEN 9;  /note=""R->A: Decreases KPNA4 binding. Strongly decreases KPNA4 binding; when associated with A-21."";  /evidence=""ECO:0000269|PubMed:29042532""; MUTAGEN 11;  /note=""S->E: Phosphomimetic mutant. Decreases KPNA4 binding by about 10%."";  /evidence=""ECO:0000269|PubMed:29042532""; MUTAGEN 21;  /note=""K->A: Decreases KPNA4 binding. Strongly decreases KPNA4 binding; when associated with A-9."";  /evidence=""ECO:0000269|PubMed:29042532""; MUTAGEN 182;  /note=""D->A: Abolishes interaction with Ran and impairs chromosome localization."";  /evidence=""ECO:0000269|PubMed:12194828, ECO:0000269|PubMed:17435751"""	P18754;	9606.ENSP00000362937;	1A12;1I2M;5E1B;5E1D;5E1M;5E1O;5E2A;5E2B;5TBK;6DUB;
P53041	PPP5_HUMAN	reviewed	Serine/threonine-protein phosphatase 5 (PP5) (EC 3.1.3.16) (Protein phosphatase T) (PP-T) (PPT)	PPP5C PPP5	Homo sapiens (Human)	499					"MUTAGEN 32;  /note=""K->A: Loss of interaction with HSP90AA1. No effect on interaction with S100A1, S100A2 and S100A6."";  /evidence=""ECO:0000269|PubMed:22399290""; MUTAGEN 74;  /note=""R->A: Loss of interaction with HSP90AA1. No effect on interaction with S100A1, S100A2 and S100A6."";  /evidence=""ECO:0000269|PubMed:22399290""; MUTAGEN 83;  /note=""G->N: No effect on interaction with HSP90AA1."";  /evidence=""ECO:0000269|PubMed:16531226""; MUTAGEN 93;  /note=""K->E: Decreases interaction with RAC1 and translocation to the membrane in presence of active RAC1."";  /evidence=""ECO:0000269|PubMed:19948726""; MUTAGEN 97;  /note=""K->A: Loss of interaction with HSP90AA1. No effect on interaction with S100A1, S100A2 and S100A6. Loss of interaction with RAF1."";  /evidence=""ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:22399290""; MUTAGEN 101;  /note=""R->A: Loss of interaction with HSP90AA1. No effect on interaction with S100A1, S100A2 and S100A6."";  /evidence=""ECO:0000269|PubMed:22399290""; MUTAGEN 304;  /note=""H->Q: Catalytically inactive; no effect on interaction with CRY2 but increases the stability of the interaction with CSNK1E. No effect on RAF1 phosphorylation."";  /evidence=""ECO:0000269|PubMed:16790549, ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:19948726"""	P53041;	9606.ENSP00000012443;	1A17;1S95;1WAO;2BUG;3H60;3H61;3H62;3H63;3H64;3H66;3H67;3H68;3H69;4ZVZ;4ZX2;5HPE;5UI1;5WG8;
P0A749	MURA_ECOLI	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (UDP-N-acetylglucosamine enolpyruvyl transferase) (EPT)	murA murZ b3189 JW3156	Escherichia coli (strain K12)	419						P0A749;	511145.b3189;	1A2N;1UAE;2Z2C;3ISS;3KQJ;3KR6;3SWD;
P08046	EGR1_MOUSE	reviewed	Early growth response protein 1 (EGR-1) (Nerve growth factor-induced protein A) (NGFI-A) (Transcription factor Zif268) (Zinc finger protein Krox-24)	Egr1 Egr-1 Krox-24	Mus musculus (Mouse)	533				DISRUPTION PHENOTYPE: Mice appear grossly normal, but females are anestrous and infertile with an uterus weight that is roughly 30% of that of wild-type. Ovaries contain normal numbers of follicles, but lack corpora lutea. Serum progesterone levels are strongly reduced; estradiol levels are normal. The level of luteinizing hormone (LHB) in the pituitary is strongly reduced in males and not detectable in females (PubMed:8703054). Responses to ischemia and hypoxia are blunted, leading to reduced tissue damage in response to ischemia and increased survival (PubMed:11100120). Liver regeneration is impaired after partial hepatectomy, due to impaired mitotic progress and reduced proliferation of hepatocytes (PubMed:15265859). Untreated mutant mice do not display an increased tendency to develop tumors, but develop tumors earlier than wild-type when treated first with a tumor initiator, and then with a tumor promoter (PubMed:15958557). Mice lack daily rhythmicity in the expression of the core-clock gene ARNTL/BMAL1 and display a reduced and altered locomotor activity and altered temperature regulation (PubMed:29138967). {ECO:0000269|PubMed:11100120, ECO:0000269|PubMed:15265859, ECO:0000269|PubMed:15958557, ECO:0000269|PubMed:29138967, ECO:0000269|PubMed:8703054}.		P08046;	10090.ENSMUSP00000069616;	1A1F;1A1G;1A1H;1A1I;1A1J;1A1K;1A1L;1AAY;1F2I;1G2D;1G2F;1JK1;1JK2;1LLM;1P47;1ZAA;
O85465	GUN5_SALAG	reviewed	Endoglucanase 5A (EC 3.2.1.4) (Alkaline cellulase) (Endo-1,4-beta-glucanase 5A)	cel5A	Salipaludibacillus agaradhaerens (Bacillus agaradhaerens)	400								1A3H;1E5J;1H11;1H2J;1H5V;1HF6;1OCQ;1QHZ;1QI0;1QI2;1W3K;1W3L;2A3H;2V38;3A3H;4A3H;5A3H;6A3H;7A3H;8A3H;
P81245	OBP_PIG	reviewed	Odorant-binding protein (OBP)		Sus scrofa (Pig)	157							9823.ENSSSCP00000030644;	1A3Y;1DZJ;1DZK;1DZM;1DZP;1E00;1E02;1E06;1HQP;
P27907	NRAM_INBBE	reviewed	Neuraminidase (EC 3.2.1.18)		Influenza B virus (strain B/Beijing/1/1987)	465								1A4G;1A4Q;1NSB;1NSC;1NSD;
P63103	1433Z_BOVIN	reviewed	14-3-3 protein zeta/delta (Factor activating exoenzyme S) (FAS) (Protein kinase C inhibitor protein 1) (KCIP-1)	YWHAZ	Bos taurus (Bovine)	245						P63103;	9913.ENSBTAP00000000289;	1A37;1A38;1A4O;2V7D;
Q06121	TRPC_SACS2	reviewed	Indole-3-glycerol phosphate synthase (IGPS) (EC 4.1.1.48)	trpC SSO0895	Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) (Sulfolobus solfataricus)	248							273057.SSO0895;	1A53;1IGS;1JUK;1JUL;1LBF;1LBL;2C3Z;3NYZ;3NZ1;3TC6;3TC7;4A29;4A2R;4A2S;4IWW;4IX0;4LNY;4OU1;5AN7;5AOU;5K7J;6NW4;
P13489	RINI_HUMAN	reviewed	Ribonuclease inhibitor (Placental ribonuclease inhibitor) (Placental RNase inhibitor) (Ribonuclease/angiogenin inhibitor 1) (RAI)	RNH1 PRI RNH	Homo sapiens (Human)	461					"MUTAGEN 262;  /note=""W->A: Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-264 and A-319."";  /evidence=""ECO:0000269|PubMed:12578357""; MUTAGEN 264;  /note=""W->A: Substantially decreased binding affinity for RNASE2. Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-262 and A-319."";  /evidence=""ECO:0000269|PubMed:12578357""; MUTAGEN 319;  /note=""W->A: Substantially decreased binding affinity for RNASE2. Binding affinity decreased 5000-fold over the wild type for RNASE2; when associated with A-262 and A-264."";  /evidence=""ECO:0000269|PubMed:12578357""; MUTAGEN 376;  /note=""W->A: 40-fold reduction in binding affinity for RNASE2."";  /evidence=""ECO:0000269|PubMed:15755456""; MUTAGEN 435..436;  /note=""YD->AA: Substantially decreases binding affinity for RNASE1, ANG and RNASE2."";  /evidence=""ECO:0000269|PubMed:10413501, ECO:0000269|PubMed:12578357""; MUTAGEN 458;  /note=""R->A: 25-fold reduction in binding affinity for RNASE2."";  /evidence=""ECO:0000269|PubMed:15755456""; MUTAGEN 461;  /note=""Missing: A significant decrease in binding affinity with RNASE1, slight decrease for the ANG ligand, no real change in binding affinity for RNASE2."";  /evidence=""ECO:0000269|PubMed:12578357, ECO:0000269|PubMed:9050852"""	P13489;	9606.ENSP00000433999;	1A4Y;1Z7X;2BEX;2Q4G;
P20436	RPAB3_YEAST	reviewed	DNA-directed RNA polymerases I, II, and III subunit RPABC3 (RNA polymerases I, II, and III subunit ABC3) (ABC14.4) (ABC14.5) (DNA-directed RNA polymerases I, II, and III 14.5 kDa polypeptide)	RPB8 YOR224C YOR50-14	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	146						P20436;	4932.YOR224C;	1A1D;1I3Q;1I50;1I6H;1K83;1NIK;1NT9;1PQV;1R5U;1R9S;1R9T;1SFO;1TWA;1TWC;1TWF;1TWG;1TWH;1WCM;1Y1V;1Y1W;1Y1Y;1Y77;2B63;2B8K;2E2H;2E2I;2E2J;2JA5;2JA6;2JA7;2JA8;2NVQ;2NVT;2NVX;2NVY;2NVZ;2R7Z;2R92;2R93;2VUM;2YU9;3CQZ;3FKI;3GTG;3GTJ;3GTK;3GTL;3GTM;3GTO;3GTP;3GTQ;3H3V;3HOU;3HOV;3HOW;3HOX;3HOY;3HOZ;3I4M;3I4N;3J0K;3J1N;3K1F;3K7A;3M3Y;3M4O;3PO2;3PO3;3QT1;3RZD;3RZO;3S14;3S15;3S16;3S17;3S1M;3S1N;3S1Q;3S1R;3S2D;3S2H;4A3B;4A3C;4A3D;4A3E;4A3F;4A3G;4A3I;4A3J;4A3K;4A3L;4A3M;4A93;4BBR;4BBS;4BXX;4BXZ;4BY1;4BY7;4C2M;4C3H;4C3I;4C3J;4V1M;4V1N;4V1O;4X67;4X6A;4Y52;4Y7N;4YM7;5C3E;5C44;5C4A;5C4J;5C4X;5FJ8;5FJ9;5FJA;5FMF;5FYW;5FZ5;5G5L;5IP7;5IP9;5LMX;5M3F;5M3M;5M5W;5M5X;5M5Y;5M64;5N5Y;5N5Z;5N60;5N61;5OA1;5OQJ;5OQM;5OT2;5SVA;5U5Q;5VVR;5VVS;5W4U;5W51;5W5Y;5W64;5W65;5W66;6BLO;6BLP;6BM2;6BM4;6BQF;6CNB;6CNC;6CND;6CNF;6EU0;6EU1;6EU2;6EU3;6F40;6F41;6F42;6F44;6GYK;6GYL;6GYM;6H67;6H68;6HKO;6HLQ;6HLR;6HLS;6I84;6O6C;6RQH;6RQL;6RQT;6RRD;6RUI;6RUO;6RWE;6TPS;6TUT;6UPX;6UPY;6UPZ;6UQ0;6UQ1;6UQ2;6UQ3;7KED;7KEE;7KEF;7O4I;7O4J;7O72;7O73;7O75;
P02693	FABPI_RAT	reviewed	Fatty acid-binding protein, intestinal (Fatty acid-binding protein 2) (Intestinal-type fatty acid-binding protein) (I-FABP)	Fabp2 Fabpi	Rattus norvegicus (Rat)	132					"MUTAGEN 45;  /note=""G->V: Small reduction in stability, impaired ligand binding."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 55;  /note=""N->V: No reduction in stability."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 61;  /note=""V->N: Reduced thermodynamic stability."";  /evidence=""ECO:0000269|PubMed:10692339""; MUTAGEN 66;  /note=""G->V: Large reduction in stability."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 76;  /note=""G->V: Reduced stability."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 81;  /note=""G->V: Large reduction in stability."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 87;  /note=""G->V: No reduction in stability, impaired ligand binding."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 98;  /note=""D->V: Reduced stability."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 100;  /note=""G->V: Large reduction in stability."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 111;  /note=""G->V: Small reduction in stability, impaired ligand binding."";  /evidence=""ECO:0000269|PubMed:10082380""; MUTAGEN 122;  /note=""G->V: Large reduction in stability."";  /evidence=""ECO:0000269|PubMed:10082380"""		10116.ENSRNOP00000030244;	1A57;1AEL;1DC9;1ICM;1ICN;1IFB;1IFC;1SA8;1T8V;1URE;2IFB;3AKN;
P00929	TRPA_SALTY	reviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA STM1727	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	268						P00929;		1A50;1A5A;1A5B;1A5S;1BEU;1BKS;1C29;1C8V;1C9D;1CW2;1CX9;1FUY;1K3U;1K7E;1K7F;1K7X;1K8X;1K8Y;1K8Z;1KFB;1KFC;1KFE;1KFJ;1KFK;1QOP;1QOQ;1TJP;1TTP;1TTQ;1UBS;1WBJ;2CLE;2CLF;2CLH;2CLI;2CLK;2CLL;2CLM;2CLO;2J9X;2J9Y;2J9Z;2RH9;2RHG;2TRS;2TSY;2TYS;2WSY;3CEP;3PR2;4HN4;4HPJ;4HPX;4HT3;4KKX;4WX2;4XUG;4Y6G;4ZQC;5BW6;5CGQ;6C73;6D0V;6DUC;6DZ4;6DZO;6O1H;6OSO;6OUY;6VFD;6VNT;6WDU;6X0C;6XE3;
P06632	DKGA_CORSC	reviewed	2,5-diketo-D-gluconic acid reductase A (2,5-DKG reductase A) (2,5-DKGR A) (25DKGR-A) (EC 1.1.1.346) (AKR5C)	dkgA	Corynebacterium sp. (strain ATCC 31090)	278		BIOTECHNOLOGY: Introduced by genetic manipulation and expressed in Erwinia herbicola by Anderson et al. The resultant organism is able to convert in a single fermentative step D-glucose into 2-keto-L-gulonic acid, a key precursor in the industrial production of L-ascorbic acid (vitamin C). However, the technology still needs some working on and is not used in commercial production at present.			"MUTAGEN 22;  /note=""F->Y: Tighter binding of NADH.""; MUTAGEN 232;  /note=""K->G: Tighter binding of NADH.""; MUTAGEN 238;  /note=""R->H: Tighter binding of NADH.""; MUTAGEN 272;  /note=""A->G: Tighter binding of NADH."""			1A80;1HW6;1M9H;
P42771	CDN2A_HUMAN	reviewed	Cyclin-dependent kinase inhibitor 2A (Cyclin-dependent kinase 4 inhibitor A) (CDK4I) (Multiple tumor suppressor 1) (MTS-1) (p16-INK4a) (p16-INK4) (p16INK4A)	CDKN2A CDKN2 MTS1	Homo sapiens (Human)	156			DISEASE: Note=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.; DISEASE: Melanoma, cutaneous malignant 2 (CMM2) [MIM:155601]: A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. {ECO:0000269|PubMed:10651484, ECO:0000269|PubMed:10874641, ECO:0000269|PubMed:11506491, ECO:0000269|PubMed:12019208, ECO:0000269|PubMed:14646619, ECO:0000269|PubMed:19260062, ECO:0000269|PubMed:7987387, ECO:0000269|PubMed:8595405, ECO:0000269|PubMed:8653684, ECO:0000269|PubMed:8710906, ECO:0000269|PubMed:9328469, ECO:0000269|PubMed:9425228}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; DISEASE: Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719]: An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Melanoma-astrocytoma syndrome (MASTS) [MIM:155755]: Characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. {ECO:0000269|PubMed:11136714}. Note=The disease is caused by variants affecting the gene represented in this entry.			P42771;	9606.ENSP00000418915;	1A5E;1BI7;1DC2;2A5E;
P09661	RU2A_HUMAN	reviewed	U2 small nuclear ribonucleoprotein A' (U2 snRNP A')	SNRPA1	Homo sapiens (Human)	255					"MUTAGEN 15;  /note=""Y->D: Results in defective spliceosome assembly."";  /evidence=""ECO:0000269|PubMed:27035939""; MUTAGEN 27;  /note=""R->Q: No change in spliceosome assembly."";  /evidence=""ECO:0000269|PubMed:27035939""; MUTAGEN 68;  /note=""T->K: No change in spliceosome assembly."";  /evidence=""ECO:0000269|PubMed:27035939""; MUTAGEN 72;  /note=""N->K: No change in spliceosome assembly."";  /evidence=""ECO:0000269|PubMed:27035939""; MUTAGEN 73;  /note=""N->K: No change in spliceosome assembly."";  /evidence=""ECO:0000269|PubMed:27035939""; MUTAGEN 92;  /note=""E->V: Results in defective spliceosome assembly."";  /evidence=""ECO:0000269|PubMed:27035939""; MUTAGEN 148;  /note=""Q->R: Results in defective spliceosome assembly."";  /evidence=""ECO:0000269|PubMed:27035939"""	P09661;	9606.ENSP00000254193;	1A9N;5MQF;5O9Z;5XJC;5YZG;5Z56;5Z57;5Z58;6AH0;6AHD;6FF7;6ICZ;6ID0;6ID1;6QDV;6QX9;6Y53;6Y5Q;7A5P;7ABG;7ABI;
P14668	ANXA5_RAT	reviewed	Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)	Anxa5 Anx5	Rattus norvegicus (Rat)	319						P14668;	10116.ENSRNOP00000019552;	1A8A;1A8B;1BC0;1BC1;1BC3;1BCW;1BCY;1BCZ;1G5N;1N41;1N42;1N44;2H0K;2H0L;2H0M;2IE6;2IE7;2RAN;
P26256	ANX12_HYDVU	reviewed	Annexin-B12 (Annexin XII) (Annexin-12)	ANXB12	Hydra vulgaris (Hydra) (Hydra attenuata)	316								1AEI;1DM5;
P07204	TRBM_HUMAN	reviewed	Thrombomodulin (TM) (Fetomodulin) (CD antigen CD141)	THBD THRM	Homo sapiens (Human)	575			DISEASE: Thrombophilia due to thrombomodulin defect (THPH12) [MIM:614486]: A hemostatic disorder characterized by a tendency to thrombosis. {ECO:0000269|PubMed:12139752, ECO:0000269|PubMed:7811989, ECO:0000269|PubMed:9198186}. Note=The disease may be caused by variants affecting the gene represented in this entry. The role of thrombomodulin in thrombosis is controversial. It is likely that genetic or environmental risk factors in addition to THBD variation are involved in the pathogenesis of venous thrombosis.; DISEASE: Hemolytic uremic syndrome atypical 6 (AHUS6) [MIM:612926]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. {ECO:0000269|PubMed:19625716, ECO:0000269|PubMed:20513133}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype.			P07204;	9606.ENSP00000366307;	1ADX;1DQB;1DX5;1EGT;1FGD;1FGE;1HLT;1TMR;1ZAQ;2ADX;3GIS;5TO3;
P11073	PLYC_DICCH	reviewed	Pectate lyase C (EC 4.2.2.2)	pelC	Dickeya chrysanthemi (Pectobacterium chrysanthemi) (Erwinia chrysanthemi)	375								1AIR;1O88;1O8D;1O8E;1O8F;1O8G;1O8H;1O8I;1O8J;1O8K;1O8L;1O8M;1PLU;2EWE;2PEC;
P50097	IMDH_TRIFO	reviewed	Inosine-5'-monophosphate dehydrogenase (IMP dehydrogenase) (IMPD) (IMPDH) (EC 1.1.1.205)	IMPDH	Tritrichomonas foetus (Trichomonas foetus) (Tritrichomonas suis)	503					"MUTAGEN 319;  /note=""C->S: Has less than 0.06% of the wild-type activity."";  /evidence=""ECO:0000269|PubMed:10029522"""			1AK5;1LRT;1ME7;1ME8;1ME9;1MEH;1MEI;1MEW;1PVN;
Q03023	APRA_PSEAE	reviewed	Serralysin (EC 3.4.24.40) (Alkaline metalloproteinase) (AP)	aprA PA1249	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	479								1AKL;1JIW;1KAP;3VI1;
P17153	ANXA5_CHICK	reviewed	Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)	ANXA5 ANX5	Gallus gallus (Chicken)	321						P17153;	9031.ENSGALP00000019365;	1ALA;1YII;1YJ0;
P04789	TPIS_TRYBB	reviewed	Triosephosphate isomerase, glycosomal (TIM) (Triose-phosphate isomerase) (EC 5.3.1.1)		Trypanosoma brucei brucei	250								1AG1;1DKW;1IIG;1IIH;1KV5;1ML1;1MSS;1MTM;1TPD;1TPE;1TPF;1TRD;1TRI;1TSI;1TTI;1TTJ;2J24;2J27;2V0T;2V2C;2V2D;2V2H;2V5L;2VEI;2VEK;2VEL;2VEM;2VEN;2WSQ;2WSR;2X16;2X1R;2X1S;2X1T;2X1U;2X2G;2Y6Z;2Y70;3Q37;3TIM;4JEQ;4PC8;4PCF;4TIM;5I3F;5I3G;5I3H;5I3I;5I3J;5I3K;5TIM;6TIM;
P01130	LDLR_HUMAN	reviewed	Low-density lipoprotein receptor (LDL receptor)	LDLR	Homo sapiens (Human)	860			DISEASE: Hypercholesterolemia, familial, 1 (FHCL1) [MIM:143890]: A form of hypercholesterolemia, a disorder of lipoprotein metabolism characterized by elevated serum low-density lipoprotein (LDL) cholesterol levels, which result in excess deposition of cholesterol in tissues and leads to xanthelasma, xanthomas, accelerated atherosclerosis and increased risk of premature coronary heart disease. FHCL1 inheritance is autosomal dominant. {ECO:0000269|PubMed:10090484, ECO:0000269|PubMed:10206683, ECO:0000269|PubMed:10422803, ECO:0000269|PubMed:10447263, ECO:0000269|PubMed:10532689, ECO:0000269|PubMed:10660340, ECO:0000269|PubMed:10882754, ECO:0000269|PubMed:10978268, ECO:0000269|PubMed:10980548, ECO:0000269|PubMed:11298688, ECO:0000269|PubMed:11462246, ECO:0000269|PubMed:1446662, ECO:0000269|PubMed:1464748, ECO:0000269|PubMed:17142622, ECO:0000269|PubMed:17347910, ECO:0000269|PubMed:1867200, ECO:0000269|PubMed:19318025, ECO:0000269|PubMed:19319977, ECO:0000269|PubMed:22160468, ECO:0000269|PubMed:22509010, ECO:0000269|PubMed:2318961, ECO:0000269|PubMed:24529145, ECO:0000269|PubMed:25378237, ECO:0000269|PubMed:25545329, ECO:0000269|PubMed:2569482, ECO:0000269|PubMed:2726768, ECO:0000269|PubMed:3263645, ECO:0000269|PubMed:3955657, ECO:0000269|PubMed:7550239, ECO:0000269|PubMed:7573037, ECO:0000269|PubMed:7583548, ECO:0000269|PubMed:7635461, ECO:0000269|PubMed:7635482, ECO:0000269|PubMed:7649546, ECO:0000269|PubMed:7649549, ECO:0000269|PubMed:8168830, ECO:0000269|PubMed:8347689, ECO:0000269|PubMed:8462973, ECO:0000269|PubMed:8664907, ECO:0000269|PubMed:8740918, ECO:0000269|PubMed:9026534, ECO:0000269|PubMed:9104431, ECO:0000269|PubMed:9143924, ECO:0000269|PubMed:9254862, ECO:0000269|PubMed:9259195, ECO:0000269|PubMed:9452094, ECO:0000269|PubMed:9452095, ECO:0000269|PubMed:9452118, ECO:0000269|PubMed:9654205, ECO:0000269|PubMed:9678702, ECO:0000269|PubMed:9852677, ECO:0000269|Ref.72}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 811;  /note=""K->R: No change. No change; when associated with R-816 and R-830. Insensitive to MYLIP-triggered degradation; when associated with R-816; R-830 and A-839."";  /evidence=""ECO:0000269|PubMed:19520913""; MUTAGEN 816;  /note=""K->R: No change. No change; when associated with R-830. No change; when associated with R-811 and R-830. Insensitive to MYLIP-triggered degradation; when associated with R-830 and A-839. Insensitive to MYLIP-triggered degradation; when associated with R-811; R-830 and A-839."";  /evidence=""ECO:0000269|PubMed:19520913""; MUTAGEN 821;  /note=""I->A: 3-fold decreased affinity for LDLRAP1."";  /evidence=""ECO:0000269|PubMed:22509010""; MUTAGEN 821;  /note=""I->R: 10-fold decreased affinity for LDLRAP1."";  /evidence=""ECO:0000269|PubMed:22509010""; MUTAGEN 828;  /note=""Y->A: Abolishes interaction with ARRB2."";  /evidence=""ECO:0000269|PubMed:12944399""; MUTAGEN 829;  /note=""Q->A: Decreased affinity for LDLRAP1."";  /evidence=""ECO:0000269|PubMed:22509010""; MUTAGEN 830;  /note=""K->R: No change. No change; when associated with R-816. No change; when associated with R-811 and R-816. Insensitive to MYLIP-triggered degradation; when associated with A-839. Insensitive to MYLIP-triggered degradation; when associated with R-816 and A-839. Insensitive to MYLIP-triggered degradation; when associated with R-811; R-816 and A-839."";  /evidence=""ECO:0000269|PubMed:19520913""; MUTAGEN 839;  /note=""C->A: No change. Insensitive to MYLIP-triggered degradation; when associated with R-830. Insensitive to MYLIP-triggered degradation; when associated with R-816 and R-830. Insensitive to MYLIP-triggered degradation; when associated with R-811; R-816 and R-830."";  /evidence=""ECO:0000269|PubMed:19520913""; MUTAGEN 854;  /note=""S->A: No effect on receptor internalization."";  /evidence=""ECO:0000269|PubMed:12944399""; MUTAGEN 854;  /note=""S->D: Enhances interaction with ARRB2 and receptor internalization."";  /evidence=""ECO:0000269|PubMed:12944399"""	P01130;	9606.ENSP00000454071;	1AJJ;1D2J;1F5Y;1F8Z;1HJ7;1HZ8;1I0U;1IJQ;1LDL;1LDR;1LRX;1N7D;1XFE;2FCW;2KRI;2LGP;2M7P;2MG9;2W2M;2W2N;2W2O;2W2P;2W2Q;3BPS;3GCW;3GCX;3M0C;3P5B;3P5C;3SO6;4NE9;5OY9;5OYL;
P10104	WAC_BPT4	reviewed	Fibritin (Collar protein) (Whisker antigen control protein)	wac	Enterobacteria phage T4 (Bacteriophage T4)	487								1AA0;1AVY;1OX3;1RFO;1V1H;1V1I;2BSG;2IBL;2KBL;3A1M;3J2O;4MMQ;4MMR;4MMS;4MMT;4MMU;4MMV;4NCU;4NCV;4NCW;5TDL;6APD;6CNV;6CRV;6CRW;6CRX;6CRZ;6CS0;6CS1;6CS2;6JX7;6OE5;6Z97;6ZGH;6ZHD;7A4N;7L7F;
P72181	NIRS_PARPN	reviewed	Nitrite reductase (EC 1.7.2.1) (Cytochrome cd1) (Cytochrome oxidase) (Hydroxylamine reductase) (EC 1.7.99.1)	nirS	Paracoccus pantotrophus (Thiosphaera pantotropha)	596							935565.JAEM01000004_gene3094;	1AOF;1AOM;1AOQ;1DY7;1E2R;1GQ1;1H9X;1H9Y;1HCM;1HJ3;1HJ4;1HJ5;1QKS;
Q60773	CDN2D_MOUSE	reviewed	Cyclin-dependent kinase 4 inhibitor D (p19-INK4d)	Cdkn2d	Mus musculus (Mouse)	166						Q60773;	10090.ENSMUSP00000083561;	1AP7;1BLX;
P08758	ANXA5_HUMAN	reviewed	Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)	ANXA5 ANX5 ENX2 PP4	Homo sapiens (Human)	320			DISEASE: Pregnancy loss, recurrent, 3 (RPRGL3) [MIM:614391]: A common complication of pregnancy, resulting in spontaneous abortion before the fetus has reached viability. The term includes all miscarriages from the time of conception until 24 weeks of gestation. Recurrent pregnancy loss is defined as 3 or more consecutive spontaneous abortions. {ECO:0000269|PubMed:17339269}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.			P08758;	9606.ENSP00000296511;	1ANW;1ANX;1AVH;1AVR;1HAK;1HVD;1HVE;1HVF;1HVG;1SAV;2XO2;2XO3;6K22;6K25;
Q53654	CNA_STAAU	reviewed	Collagen adhesin	cna	Staphylococcus aureus	1183					"MUTAGEN 175;  /note=""Y->K: More than 90% loss of collagen-binding."";  /evidence=""ECO:0000269|PubMed:16362049"""			1AMX;1D2O;1D2P;2F68;2F6A;
P27485	RET4_PIG	reviewed	Retinol-binding protein 4 (Plasma retinol-binding protein) (PRBP) (RBP)	RBP4	Sus scrofa (Pig)	201							9823.ENSSSCP00000011168;	1AQB;
P50921	TPIS_MORMI	reviewed	Triosephosphate isomerase (TIM) (TPI) (EC 5.3.1.1) (Triose-phosphate isomerase)	tpiA tim tpi	Moritella marina (Vibrio marinus)	256					"MUTAGEN 238;  /note=""A->S: Reduces catalytic efficiency and affinity, but increases thermal stability."";  /evidence=""ECO:0000269|PubMed:9442062"""			1AW1;1AW2;
Q00420	GABP1_MOUSE	reviewed	GA-binding protein subunit beta-1 (GABP subunit beta-1) (GABPB-1) (GABP subunit beta-2) (GABPB-2)	Gabpb1 Gabpb Gabpb2	Mus musculus (Mouse)	383					"MUTAGEN 69;  /note=""K->R: Decreased acetylation; when associated with R-340 and Lys-369."";  /evidence=""ECO:0000269|PubMed:25200183""; MUTAGEN 340;  /note=""K->R: Decreased acetylation; when associated with R-69 and Lys-369."";  /evidence=""ECO:0000269|PubMed:25200183""; MUTAGEN 369;  /note=""K->R: Decreased acetylation; when associated with R-69 and Lys-340."";  /evidence=""ECO:0000269|PubMed:25200183"""		10090.ENSMUSP00000106055;	1AWC;
P02701	AVID_CHICK	reviewed	Avidin	AVD	Gallus gallus (Chicken)	152							9031.ENSGALP00000003846;	1AVD;1AVE;1IJ8;1LDO;1LDQ;1LEL;1NQN;1RAV;1VYO;2A5B;2A5C;2A8G;2AVI;2C4I;2CAM;2JGS;2MF6;3FDC;3MM0;3VGW;3VHH;3VHI;3VHM;4I60;4JHQ;4U46;5CHK;5HLM;5IRU;5IRW;5LUR;5MYQ;6XND;
P01070	ITRA_SOYBN	reviewed	Trypsin inhibitor A (Kunitz-type trypsin inhibitor A)	KTI3	Glycine max (Soybean) (Glycine hispida)	216							3847.GLYMA08G45531.1;	1AVU;1AVW;1AVX;1BA7;6NTT;6O1F;
P12004	PCNA_HUMAN	reviewed	Proliferating cell nuclear antigen (PCNA) (Cyclin)	PCNA	Homo sapiens (Human)	261			DISEASE: Ataxia-telangiectasia-like disorder 2 (ATLD2) [MIM:615919]: A neurodegenerative disorder due to defects in DNA excision repair. ATLD2 is characterized by developmental delay, ataxia, sensorineural hearing loss, short stature, cutaneous and ocular telangiectasia, and photosensitivity. {ECO:0000269|PubMed:24911150}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 13;  /note=""K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-14; R-20; R-77 and R-80."";  /evidence=""ECO:0000269|PubMed:24939902""; MUTAGEN 14;  /note=""K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-13; R-20; R-77 and R-80."";  /evidence=""ECO:0000269|PubMed:24939902""; MUTAGEN 20;  /note=""K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-13; R-14; R-77 and R-80."";  /evidence=""ECO:0000269|PubMed:24939902""; MUTAGEN 40;  /note=""M->A: Complete loss of interaction with UHRF2."";  /evidence=""ECO:0000269|PubMed:11595739""; MUTAGEN 43..45;  /note=""SHV->AAA: No effect on POLD3-binding."";  /evidence=""ECO:0000269|PubMed:11595739""; MUTAGEN 77;  /note=""K->A: Inhibits recruitment to DNA damage sites, but nuclear localization is similar as the wild-type; in association with A-80."";  /evidence=""ECO:0000269|PubMed:24939902""; MUTAGEN 77;  /note=""K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-13; R-14; R-20 and R-80."";  /evidence=""ECO:0000269|PubMed:24939902""; MUTAGEN 80;  /note=""K->A: Inhibits recruitment to DNA damage sites, but nuclear localization is similar as the wild-type; in association with A-77."";  /evidence=""ECO:0000269|PubMed:24939902""; MUTAGEN 80;  /note=""K->R: Inhibits acetylation, recruitment to DNA damage sites, inducible ubiquitination and protein degradation, DNA replication and repair synthesis efficiencies, but homotrimer formation, nuclear recruitment to DNA damage sites, interactions with CREBBP, EP300 and POLD1 are similar as the wild-type; in association with R-13; R-14; R-20 and R-77."";  /evidence=""ECO:0000269|PubMed:24939902""; MUTAGEN 125..128;  /note=""QLGI->AAAA: Strong decrease in POLD3-binding."";  /evidence=""ECO:0000269|PubMed:11595739""; MUTAGEN 128;  /note=""I->A: Complete loss of interaction with UHRF2."";  /evidence=""ECO:0000269|PubMed:11595739""; MUTAGEN 164;  /note=""K->R: Abolishes ubiquitination. No effect on interaction with SHPRH."";  /evidence=""ECO:0000269|PubMed:17108083, ECO:0000269|PubMed:17130289, ECO:0000269|PubMed:18719106, ECO:0000269|PubMed:20129063""; MUTAGEN 188..190;  /note=""VDK->AAA: No effect on POLD3-binding."";  /evidence=""ECO:0000269|PubMed:11595739""; MUTAGEN 211;  /note=""Y->F: Alters chromatin-associated PCNA stability and its function in DNA replication and repair."";  /evidence=""ECO:0000269|PubMed:17115032""; MUTAGEN 250;  /note=""Y->A: Complete loss of interaction with UHRF2."";  /evidence=""ECO:0000269|PubMed:11595739""; MUTAGEN 251..254;  /note=""LAPK->AAAA: Decrease in POLD3-binding."";  /evidence=""ECO:0000269|PubMed:11595739""; MUTAGEN 252;  /note=""A->G: Complete loss of interaction with UHRF2."";  /evidence=""ECO:0000269|PubMed:11595739"""	P12004;	9606.ENSP00000368458;	1AXC;1U76;1U7B;1UL1;1VYJ;1VYM;1W60;2ZVK;2ZVL;2ZVM;3JA9;3P87;3TBL;3VKX;3WGW;4D2G;4RJF;4ZTD;5E0T;5E0U;5E0V;5IY4;5MAV;5MLO;5MLW;5MOM;5YCO;5YD8;6CBI;6EHT;6FCM;6FCN;6GIS;6GWS;6HVO;6K3A;6QC0;6QCG;6S1M;6S1N;6S1O;6TNY;6TNZ;6VVO;7EFA;7KQ0;7KQ1;
P02754	LACB_BOVIN	reviewed	Beta-lactoglobulin (Beta-LG) (allergen Bos d 5)	LGB	Bos taurus (Bovine)	178	ALLERGEN: Causes an allergic reaction in human. Is one of the causes of cow's milk allergy.						9913.ENSBTAP00000019538;	1B0O;1B8E;1BEB;1BSO;1BSQ;1BSY;1CJ5;1DV9;1GX8;1GX9;1GXA;1QG5;1UZ2;1YUP;2AKQ;2BLG;2GJ5;2Q2M;2Q2P;2Q39;2R56;3BLG;3KZA;3NPO;3NQ3;3NQ9;3PH5;3PH6;3UEU;3UEV;3UEW;3UEX;4DQ3;4DQ4;4GNY;4IB6;4IB7;4IB8;4IB9;4IBA;4KII;4LZU;4LZV;4Y0P;4Y0Q;4Y0R;5HTD;5HTE;5IO5;5IO7;5K06;5LKE;5LKF;5NUJ;5NUK;5NUM;5NUN;5Y5C;6FXB;6GE7;6GF9;6GFS;6GHH;6NKQ;6QI6;6QI7;6QPD;6QPE;6RWP;6RWQ;6RWR;6RYT;6T42;6XVE;6ZSQ;6ZSR;7BF7;7BF8;7BF9;7BGA;7BGX;7BGZ;7BH0;7KOT;7KP5;
P06768	RET2_RAT	reviewed	Retinol-binding protein 2 (Cellular retinol-binding protein II) (CRBP-II)	Rbp2 Crbpii	Rattus norvegicus (Rat)	134							10116.ENSRNOP00000018755;	1B4M;1EII;1OPA;1OPB;
P30153	2AAA_HUMAN	reviewed	Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (Medium tumor antigen-associated 61 kDa protein) (PP2A subunit A isoform PR65-alpha) (PP2A subunit A isoform R1-alpha)	PPP2R1A	Homo sapiens (Human)	589			DISEASE: Mental retardation, autosomal dominant 36 (MRD36) [MIM:616362]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. {ECO:0000269|PubMed:25533962, ECO:0000269|PubMed:26168268}. Note=The disease is caused by variants affecting the gene represented in this entry.			P30153;	9606.ENSP00000324804;	1B3U;2IE3;2IE4;2NPP;2NYL;2NYM;2PKG;3C5W;3DW8;3K7V;3K7W;4I5L;4I5N;4LAC;5W0W;6IUR;6NTS;7CUN;7K36;
Q01469	FABP5_HUMAN	reviewed	Fatty acid-binding protein 5 (Epidermal-type fatty acid-binding protein) (E-FABP) (Fatty acid-binding protein, epidermal) (Psoriasis-associated fatty acid-binding protein homolog) (PA-FABP)	FABP5	Homo sapiens (Human)	135					"MUTAGEN 24;  /note=""K->A: Loss of ligand-induced nuclear import; when associated with A-33 and A-34."";  /evidence=""ECO:0000269|PubMed:24692551""; MUTAGEN 33;  /note=""R->A: Loss of ligand-induced nuclear import; when associated with A-24 and A-34."";  /evidence=""ECO:0000269|PubMed:24692551""; MUTAGEN 34;  /note=""K->A: Loss of ligand-induced nuclear import; when associated with A-24 and A-33."";  /evidence=""ECO:0000269|PubMed:24692551"""	Q01469;	9606.ENSP00000297258;	1B56;1JJJ;4AZM;4AZR;4LKP;4LKT;5HZ5;5UR9;
P0AEZ1	METF_ECOLI	reviewed	5,10-methylenetetrahydrofolate reductase (EC 1.5.1.20)	metF b3941 JW3913	Escherichia coli (strain K12)	296					"MUTAGEN 28;  /note=""E->Q: Abolishes enzyme activity."";  /evidence=""ECO:0000269|PubMed:11371182, ECO:0000269|PubMed:16114881""; MUTAGEN 120;  /note=""D->N: Strongly reduces enzyme activity. Strongly reduces affinity for 5-methyltetrahydrofolate."";  /evidence=""ECO:0000269|PubMed:11371182""; MUTAGEN 177;  /note=""A->V: Increases the propensity to lose its essential flavin cofactor."";  /evidence=""ECO:0000269|PubMed:10201405""; MUTAGEN 223;  /note=""F->A: Strongly decreases substrate and NADH binding."";  /evidence=""ECO:0000269|PubMed:19610625""; MUTAGEN 223;  /note=""F->L: Slightly reduced enzyme activity."";  /evidence=""ECO:0000269|PubMed:19610625"""	P0AEZ1;	511145.b3941;	1B5T;1ZP3;1ZP4;1ZPT;1ZRQ;2FMN;2FMO;3FST;3FSU;6PEY;
P02945	BACR_HALSA	reviewed	Bacteriorhodopsin (BR) (Bacterioopsin) (BO)	bop VNG_1467G	Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) (Halobacterium halobium)	262								1AP9;1AT9;1BAC;1BAD;1BCT;1BHA;1BHB;1BM1;1BRD;1BRR;1BRX;1C3W;1C8R;1C8S;1CWQ;1DZE;1E0P;1F4Z;1F50;1FBB;1FBK;1IW6;1IW9;1IXF;1JV6;1JV7;1KG8;1KG9;1KGB;1KME;1L0M;1M0K;1M0L;1M0M;1MGY;1O0A;1P8H;1P8I;1P8U;1PXR;1PXS;1PY6;1Q5I;1Q5J;1QHJ;1QKO;1QKP;1QM8;1R2N;1R84;1S51;1S52;1S53;1S54;1S8J;1S8L;1TN0;1TN5;1UCQ;1VJM;1X0I;1X0K;1X0S;1XJI;2AT9;2BRD;2I1X;2I20;2I21;2NTU;2NTW;2WJK;2WJL;2ZFE;2ZZL;3COC;3COD;3HAN;3HAO;3HAP;3HAQ;3HAR;3HAS;3MBV;3NS0;3NSB;3T45;3UTV;3UTW;3UTX;3UTY;3VHZ;3VI0;4FPD;4HWL;4HYX;4MD1;4MD2;4OV0;4X31;4X32;4XXJ;5A44;5A45;5B34;5B35;5B6V;5B6W;5B6X;5B6Y;5B6Z;5BR2;5BR5;5H2H;5H2I;5H2J;5H2K;5H2L;5H2M;5H2N;5H2O;5H2P;5J7A;5VN7;5VN9;5ZIL;5ZIM;5ZIN;6G7H;6G7I;6G7J;6G7K;6G7L;6GA1;6GA2;6GA3;6GA4;6GA5;6GA6;6GA7;6GA8;6GA9;6GAA;6GAB;6GAC;6GAD;6GAE;6GAF;6GAG;6GAH;6GAI;6RMK;6RNJ;6RPH;6RQO;6RQP;
P03474	NRAM_INBLE	reviewed	Neuraminidase (EC 3.2.1.18)		Influenza B virus (strain B/Lee/1940)	466					"MUTAGEN 117;  /note=""E->G: Reduced substrate binding."";  /evidence=""ECO:0000269|PubMed:9874196""; MUTAGEN 149;  /note=""D->E: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:9874196""; MUTAGEN 150;  /note=""R->K: Reduced substrate binding."";  /evidence=""ECO:0000269|PubMed:9874196""; MUTAGEN 223;  /note=""R->K: Reduced substrate binding."";  /evidence=""ECO:0000269|PubMed:9874196""; MUTAGEN 275;  /note=""E->D: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:9874196""; MUTAGEN 374;  /note=""R->K: 80% loss of catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:9874196""; MUTAGEN 374;  /note=""R->N: 94% loss of catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:9874196""; MUTAGEN 409;  /note=""Y->F: Complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:9874196"""			1B9S;1B9T;1B9V;1INF;1INV;1IVB;1VCJ;
P05230	FGF1_HUMAN	reviewed	Fibroblast growth factor 1 (FGF-1) (Acidic fibroblast growth factor) (aFGF) (Endothelial cell growth factor) (ECGF) (Heparin-binding growth factor 1) (HBGF-1)	FGF1 FGFA	Homo sapiens (Human)	155					"MUTAGEN 24..27;  /note=""KKPK->AAPA: Loss of nuclear import leading to loss of phosphorylation by PKC/PRKCD."";  /evidence=""ECO:0000269|PubMed:22321063""; MUTAGEN 33;  /note=""N->A: No effect on integrin-binding."";  /evidence=""ECO:0000269|PubMed:18441324""; MUTAGEN 50;  /note=""R->E: Dominant-negative mutant. Defective in integrin-binding and in ternary complex formation with integrin and FGFR1. No effect on heparin- and FGFR1-binding. Defective in inducing FGF1 signaling, cell proliferation and cell migration. Defective in inducing angiogenesis, and suppression of angiogenesis in different in vitro and in vivo angiogenesis models."";  /evidence=""ECO:0000269|PubMed:18441324, ECO:0000269|PubMed:20422052, ECO:0000269|PubMed:23469107""; MUTAGEN 102;  /note=""E->A: No effect on integrin-binding. No effect on integrin- and heparin-binding, loss of FGFR1-binding, defective in inducing FGF1 signaling, cell proliferation and cell migration; when associated with A-109 and A-110."";  /evidence=""ECO:0000269|PubMed:18441324""; MUTAGEN 109;  /note=""Y->A: No effect on integrin- and heparin-binding, loss of FGFR1-binding, defective in inducing FGF1 signaling, cell proliferation and cell migration; when associated with A-102 and A-110."";  /evidence=""ECO:0000269|PubMed:18441324""; MUTAGEN 110;  /note=""N->A: No effect on integrin-binding. No effect on integrin- and heparin-binding, loss of FGFR1-binding, defective in inducing FGF1 signaling, cell proliferation and cell migration; when associated with A-102 and A-109."";  /evidence=""ECO:0000269|PubMed:18441324""; MUTAGEN 114;  /note=""S->A: Decrease in LRRC59-binding."";  /evidence=""ECO:0000269|PubMed:11964394""; MUTAGEN 127;  /note=""K->E: Reduced integrin-binding; when associated with E-128. Defective in integrin-, heparin- and FGFR1-binding, and defective in inducing FGF1 signaling, cell proliferation and cell migration; when associated with E-128; E-133 and E-134."";  /evidence=""ECO:0000269|PubMed:18441324""; MUTAGEN 128;  /note=""K->E: Reduced integrin-binding; when associated with E-127. Defective in integrin-, heparin- and FGFR1-binding, and defective in inducing FGF1 signaling, cell proliferation and cell migration; when associated with E-127; E-133 and E-134."";  /evidence=""ECO:0000269|PubMed:18441324""; MUTAGEN 131;  /note=""S->A: Decrease in LRRC59-binding."";  /evidence=""ECO:0000269|PubMed:11964394""; MUTAGEN 131;  /note=""S->E: Decrease in LRRC59-binding."";  /evidence=""ECO:0000269|PubMed:11964394""; MUTAGEN 133;  /note=""K->A: Loss of LRRC59-binding."";  /evidence=""ECO:0000269|PubMed:11964394""; MUTAGEN 133;  /note=""K->E: Loss of CSNK2A-, CSNK2B- and LRRC59-binding. Reduced integrin-binding; when associated with E-134. Defective in integrin-, heparin- and FGFR1-binding, and defective in inducing FGF1 signaling, cell proliferation and cell migration; when associated with E-128; E-133 and E-134."";  /evidence=""ECO:0000269|PubMed:11964394, ECO:0000269|PubMed:18441324""; MUTAGEN 133;  /note=""K->R: No effect on LRRC59-binding."";  /evidence=""ECO:0000269|PubMed:11964394""; MUTAGEN 134;  /note=""R->E: Reduced integrin-binding; when associated with E-133. Defective in integrin-, heparin- and FGFR1-binding, and defective in inducing FGF1 signaling, cell proliferation and cell migration; when associated with E-127; E-128 and E-133."";  /evidence=""ECO:0000269|PubMed:18441324"""	P05230;	9606.ENSP00000480791;	1AXM;1DJS;1DZC;1DZD;1E0O;1EVT;1HKN;1JQZ;1JT3;1JT4;1JT5;1JT7;1JTC;1JY0;1K5U;1K5V;1M16;1NZK;1P63;1PZZ;1Q03;1Q04;1QCT;1RG8;1RML;1RY7;1YTO;1Z2V;1Z4S;2AFG;2AQZ;2AXM;2ERM;2HW9;2HWA;2HWM;2HZ9;2K43;2K4A;2K8R;2KI4;2KI6;2NTD;2Q9X;2RQ9;3B9U;3BA4;3BA5;3BA7;3BAD;3BAG;3BAH;3BAO;3BAQ;3BAU;3BAV;3BB2;3CQA;3CRG;3CRH;3CRI;3CU1;3FGM;3FJ8;3FJ9;3FJA;3FJB;3FJC;3FJD;3FJE;3FJF;3FJH;3FJI;3FJJ;3FJK;3HOM;3JUT;3K1X;3O3Q;3OJ2;3OJM;3OJV;3UD7;3UD8;3UD9;3UDA;4J23;4Q91;4Q9G;4Q9P;4QAL;4QBC;4QBV;4QC4;4QO3;4XKI;4YOL;
P39476	DN7D_SACS2	reviewed	DNA-binding protein 7d (7 kDa DNA-binding protein d) (Sso7d)	sso7d sso7d-1 SSO10610	Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) (Sulfolobus solfataricus)	64							273057.SSO10610;	1BBX;1BNZ;1C8C;1JIC;5B02;5B03;5B0I;5B0J;5B0K;5B0L;5B0M;5GWV;5GWW;5U1C;6J8V;6J8W;6PUT;6PUW;6PUY;6PUZ;6V3K;6VOY;
P17427	AP2A2_MOUSE	reviewed	AP-2 complex subunit alpha-2 (100 kDa coated vesicle protein C) (Adaptor protein complex AP-2 subunit alpha-2) (Adaptor-related protein complex 2 subunit alpha-2) (Alpha-adaptin C) (Alpha2-adaptin) (Clathrin assembly protein complex 2 alpha-C large chain) (Plasma membrane adaptor HA2/AP2 adaptin alpha C subunit)	Ap2a2 Adtab	Mus musculus (Mouse)	938					"MUTAGEN 21;  /note=""R->E: Reduces interaction with CD4 endocytosis signal motif; when associated with AP2S1 S-15."";  /evidence=""ECO:0000269|PubMed:19140243""; MUTAGEN 31;  /note=""K->Q: Reduces phosphatidylinositol binding."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 32;  /note=""R->Q: Reduces phosphatidylinositol binding."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 35;  /note=""K->Q: Reduces phosphatidylinositol binding."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 45;  /note=""K->Q: Reduces phosphatidylinositol binding."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 55;  /note=""K->Q: Strongly reduces phosphatidylinositol binding. Abolishes phosphatidylinositol binding; when associated with Q-56 and Q-57."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 56;  /note=""K->E: Strongly reduces phosphatidylinositol binding."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 56;  /note=""K->Q: Strongly reduces phosphatidylinositol binding. Abolishes phosphatidylinositol binding; when associated with Q-55 and Q-57."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 57;  /note=""K->Q: Strongly reduces phosphatidylinositol binding. Abolishes phosphatidylinositol binding; when associated with Q-55 and Q-56."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 61;  /note=""K->Q: Reduces phosphatidylinositol binding."";  /evidence=""ECO:0000269|PubMed:10459011""; MUTAGEN 727;  /note=""K->A: No effect on DENND1A-,DENND1B- nor DENND1C-binding.""; MUTAGEN 782;  /note=""Q->A: Reduces DENND1A- and DENND1C-binding."";  /evidence=""ECO:0000269|PubMed:20154091""; MUTAGEN 837;  /note=""F->A: Reduces SNAP91, AMPH and BIN1 binding. Abolishes AMPH and SNAP91 binding; when associated with A-916. Abolishes EPN1 and EPS15 binding; when associated with A-905."";  /evidence=""ECO:0000269|PubMed:10380931, ECO:0000269|PubMed:10430869""; MUTAGEN 840;  /note=""W->A: Abolishes AMPH, BIN1, DGKD, EPS15, EPN1, auxilin and SNAP91 binding."";  /evidence=""ECO:0000269|PubMed:10380931, ECO:0000269|PubMed:17880279""; MUTAGEN 849;  /note=""E->A: No effect."";  /evidence=""ECO:0000269|PubMed:10380931""; MUTAGEN 905;  /note=""R->A: Strongly reduces AMPH, SNAP91, auxilin and BIN1 binding. Abolishes EPN1 and EPS15 binding; when associated with A-837."";  /evidence=""ECO:0000269|PubMed:10380931, ECO:0000269|PubMed:10430869""; MUTAGEN 907;  /note=""E->A: Strongly reduces AMPH, SNAP91 and BIN1 binding. Slightly reduces EPS15 and auxilin binding."";  /evidence=""ECO:0000269|PubMed:10380931""; MUTAGEN 916;  /note=""R->A: Strongly reduces AMPH and SNAP91 binding. Abolishes DENND1B-binding; no effect on DENND1A-, nor DENND1C-binding. Abolishes AMPH and SNAP91 binding; when associated with A-837."";  /evidence=""ECO:0000269|PubMed:10430869, ECO:0000269|PubMed:20154091""; MUTAGEN 920;  /note=""R->A: Abolishes AMPH and BIN1 binding. Reduces EPS15, SNAP91 and auxilin binding."";  /evidence=""ECO:0000269|PubMed:10380931"""	P17427;	10090.ENSMUSP00000003038;	1B9K;1KY6;1KY7;1KYD;1KYF;1KYU;1QTP;1QTS;1W80;2JKR;2JKT;2VJ0;3HS8;6OWO;6OXL;
P55273	CDN2D_HUMAN	reviewed	Cyclin-dependent kinase 4 inhibitor D (p19-INK4d)	CDKN2D	Homo sapiens (Human)	166						P55273;	9606.ENSP00000377224;	1BD8;1BI8;
P39767	PORI_RHOBL	reviewed	Porin	opmA	Rhodobacter blasticus (Rhodopseudomonas blastica)	289								1BH3;1H6S;1PRN;2PRN;3PRN;5PRN;6PRN;7PRN;8PRN;
P26509	PGLR2_PECPM	reviewed	Endo-polygalacturonase (EC 3.2.1.15)	pehA W5S_3318	Pectobacterium parmentieri	402							1166016.W5S_3318;	1BHE;
P25033	HEMO_HYACE	reviewed	Hemolin (Hemocyte aggregation inhibitor) (Protein P4)		Hyalophora cecropia (Cecropia moth)	413								1BIH;
Q28133	ALL2_BOVIN	reviewed	Allergen Bos d 2 (Dander major allergen BDA20) (Dermal allergen BDA20) (allergen Bos d 2)		Bos taurus (Bovine)	172	ALLERGEN: Causes an allergic reaction in human. Potent allergen of bovine dander. {ECO:0000269|PubMed:8648026}.						9913.ENSBTAP00000022376;	1BJ7;4WFU;4WFV;
Q51958	Q51958_PSEPU	unreviewed	Muconate lactonizing enzyme	catB	Pseudomonas putida (Arthrobacter siderocapsulatus)	373								1BKH;1F9C;
P24474	NIRS_PSEAE	reviewed	Nitrite reductase (EC 1.7.2.1) (Cytochrome cd1) (Cytochrome oxidase) (Hydroxylamine reductase) (EC 1.7.99.1)	nirS PA0519	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	568								1BL9;1GJQ;1HZU;1HZV;1N15;1N50;1N90;1NIR;1NNO;5GUW;6TPO;6TSI;
P40189	IL6RB_HUMAN	reviewed	Interleukin-6 receptor subunit beta (IL-6 receptor subunit beta) (IL-6R subunit beta) (IL-6R-beta) (IL-6RB) (CDw130) (Interleukin-6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncostatin-M receptor subunit alpha) (CD antigen CD130)	IL6ST	Homo sapiens (Human)	918		BIOTECHNOLOGY: Two extracellular parts of IL6ST/gp130 linked to the Fc-portions of a human IgG1 antibody (sgp130Fc) inhibit IL6 trans-signaling by the IL6:IL6R complex and has no affinity of IL6 or IL6R alone (PubMed:11121117, PubMed:21990364, PubMed:30279168). Also blocks IL11 cluster signaling through IL11R (PubMed:30279168, PubMed:26876177). {ECO:0000269|PubMed:11121117, ECO:0000269|PubMed:21990364, ECO:0000269|PubMed:26876177, ECO:0000269|PubMed:30279168}.	DISEASE: Hyper-IgE recurrent infection syndrome 4, autosomal recessive (HIES4) [MIM:618523]: An immunologic disorder characterized by recurrent infections, mainly affecting the respiratory tract, skin and eye, and skeletal abnormalities including craniosynostosis and scoliosis. Immunologic workup shows increased serum IgE, intermittent eosinophilia, impaired development of certain B- and T-cell populations, as well as impaired acute-phase response. Disease onset is in early childhood. {ECO:0000269|PubMed:28747427, ECO:0000269|PubMed:30309848}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 172;  /note=""C->S: Induces ligand-independent activation."";  /evidence=""ECO:0000269|PubMed:23294003""; MUTAGEN 186..190;  /note=""Missing: Induces ligand-independent activation."";  /evidence=""ECO:0000269|PubMed:23294003""; MUTAGEN 189;  /note=""V->G: Does not induce ligand-independent activation."";  /evidence=""ECO:0000269|PubMed:23294003""; MUTAGEN 190;  /note=""Y->G: Does not induce ligand-independent activation."";  /evidence=""ECO:0000269|PubMed:23294003""; MUTAGEN 215;  /note=""D->G: Induces ligand-independent activation."";  /evidence=""ECO:0000269|PubMed:23294003""; MUTAGEN 252;  /note=""V->G: Induces ligand-independent activation."";  /evidence=""ECO:0000269|PubMed:23294003""; MUTAGEN 759;  /note=""Y->F: Refractory to inhibition by SOCS3."";  /evidence=""ECO:0000269|PubMed:25731159""; MUTAGEN 782;  /note=""S->A: Increases cell surface expression."";  /evidence=""ECO:0000269|PubMed:10811661"""	P40189;	9606.ENSP00000370698;	1BJ8;1BQU;1I1R;1N2Q;1P9M;1PVH;3L5H;3L5I;3L5J;
Q02821	IMA1_YEAST	reviewed	Importin subunit alpha (Karyopherin subunit alpha) (Karyopherin-60) (Serine-rich RNA polymerase I suppressor protein)	SRP1 KAP60 YNL189W N1606	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	542					"MUTAGEN 116;  /note=""S->F: In SRP1-31; temperature-sensitive mutant; reduced growth rate and chromosome loss."";  /evidence=""ECO:0000269|PubMed:8041713""; MUTAGEN 145;  /note=""E->K: In SRP1-49; temperature-sensitive mutant; alteration in nucleolar and microtubule morphology."";  /evidence=""ECO:0000269|PubMed:8041713""; MUTAGEN 219;  /note=""P->Q: In SRP1-1; temperature-sensitive mutant."";  /evidence=""ECO:0000269|PubMed:8041713""; MUTAGEN 286;  /note=""D->N: In SRP1-3; temperature-sensitive mutant."";  /evidence=""ECO:0000269|PubMed:8041713""; MUTAGEN 360;  /note=""E->K: In SRP1-2; temperature-sensitive mutant."";  /evidence=""ECO:0000269|PubMed:8041713""; MUTAGEN 459;  /note=""G->V: In SRP1-54; temperature-sensitive mutant; reduced growth rate."";  /evidence=""ECO:0000269|PubMed:8041713"""	Q02821;	4932.YNL189W;	1BK5;1BK6;1EE4;1EE5;1UN0;1WA5;2C1T;4PVZ;4XZR;5H2W;5H2X;5T94;
P11442	CLH1_RAT	reviewed	Clathrin heavy chain 1	Cltc	Rattus norvegicus (Rat)	1675						P11442;	10116.ENSRNOP00000005987;	1BPO;1C9I;1C9L;
P29373	RABP2_HUMAN	reviewed	Cellular retinoic acid-binding protein 2 (Cellular retinoic acid-binding protein II) (CRABP-II)	CRABP2	Homo sapiens (Human)	138					"MUTAGEN 21;  /note=""K->A: Loss of ligand-induced nuclear import; when associated with A-30 and A-31."";  /evidence=""ECO:0000269|PubMed:15866176""; MUTAGEN 30;  /note=""R->A: Loss of ligand-induced nuclear import; when associated with A-21 and A-31."";  /evidence=""ECO:0000269|PubMed:15866176""; MUTAGEN 31;  /note=""K->A: Loss of ligand-induced nuclear import; when associated with A-21 and A-30."";  /evidence=""ECO:0000269|PubMed:15866176"""	P29373;	9606.ENSP00000482841;	1BLR;1BM5;1CBQ;1CBS;1XCA;2CBS;2FR3;2FRS;2FS6;2FS7;2G78;2G79;2G7B;3CBS;3CR6;3CWK;3D95;3D96;3D97;3F8A;3F9D;3FA6;3FA7;3FA8;3FA9;3FEK;3FEL;3FEN;3FEP;3I17;4I9R;4I9S;4M6S;4M7M;4QGV;4QGW;4QGX;4YBP;4YBU;4YCE;4YCH;4YDA;4YDB;4YFP;4YFQ;4YFR;4YGG;4YGH;4YGZ;4YH0;4YKM;4YKO;5HZQ;5OGB;6HKR;6MOP;6MOQ;6MOR;6MOV;6MOW;6MOX;6MPK;6MQI;6MQJ;6MQW;6MQX;6MQY;6MQZ;6MR0;6NNX;6NNY;6NOE;6Z2U;6Z2Z;7AA0;7AA1;
Q9ZF13	Q9ZF13_THEFU	unreviewed	Beta-mannanase (EC 3.2.1.78) (Fragment)	man	Thermobifida fusca (Thermomonospora fusca)	279								1BQC;2MAN;3MAN;
P02753	RET4_HUMAN	reviewed	Retinol-binding protein 4 (Plasma retinol-binding protein) (PRBP) (RBP) [Cleaved into: Plasma retinol-binding protein(1-182); Plasma retinol-binding protein(1-181); Plasma retinol-binding protein(1-179); Plasma retinol-binding protein(1-176)]	RBP4 PRO2222	Homo sapiens (Human)	201			DISEASE: Retinal dystrophy, iris coloboma, and comedogenic acne syndrome (RDCCAS) [MIM:615147]: A disease characterized by retinal degeneration, ocular colobomas involving both the anterior and posterior segment, impaired night vision and loss of visual acuity. Additional characteristic features include developmental abnormalities and severe acne. {ECO:0000269|PubMed:10232633, ECO:0000269|PubMed:23189188, ECO:0000269|PubMed:9888420}. Note=The disease is caused by variants affecting the gene represented in this entry. Loss of functional RBP4 protein results in serum retinol deficiency. Lack of normal levels of retinol impairs the visual cycle leading to night blindness at early stages; prolonged deficiency may lead to retinal degeneration. Additionally, retinol deficiency may result in dry skin, increased susceptibility to infection and acne (PubMed:23189188). {ECO:0000269|PubMed:23189188}.; DISEASE: Microphthalmia, isolated, with coloboma, 10 (MCOPCB10) [MIM:616428]: A disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues. Ocular abnormalities like opacities of the cornea and lens, scaring of the retina and choroid, and other abnormalities may also be present. Ocular colobomas are a set of malformations resulting from abnormal morphogenesis of the optic cup and stalk, and the fusion of the fetal fissure (optic fissure). {ECO:0000269|PubMed:25910211}. Note=The disease is caused by variants affecting the gene represented in this entry.			P02753;	9606.ENSP00000360522;	1BRP;1BRQ;1JYD;1JYJ;1QAB;1RBP;1RLB;2WQ9;2WQA;2WR6;3BSZ;3FMZ;4O9S;4PSQ;5NTY;5NU2;5NU6;5NU7;5NU8;5NU9;5NUA;5NUB;6QBA;
P02931	OMPF_ECOLI	reviewed	Outer membrane porin F (Outer membrane protein 1A) (Outer membrane protein B) (Outer membrane protein F) (Outer membrane protein IA) (Porin OmpF)	ompF cmlB coa cry tolF b0929 JW0912	Escherichia coli (strain K12)	362				DISRUPTION PHENOTYPE: Leads to decreased susceptibility to a number of hydrophilic antibiotics including ampicillin, cefoxitin and tetracycline (PubMed:19721064). Deletion of ompF confers resistance to colicin E5 (PubMed:27723824). {ECO:0000269|PubMed:19721064, ECO:0000269|PubMed:27723824}.		P02931;	511145.b0929;	1BT9;1GFM;1GFN;1GFO;1GFP;1GFQ;1HXT;1HXU;1HXX;1MPF;1OPF;2OMF;2ZFG;2ZLD;3FYX;3HW9;3HWB;3K19;3K1B;3O0E;3POQ;3POU;3POX;4D5U;4GCP;4GCQ;4GCS;4JFB;4LSE;4LSF;4LSH;4LSI;5NUO;5NUQ;5NUR;6WTZ;6ZHP;6ZHV;
P42773	CDN2C_HUMAN	reviewed	Cyclin-dependent kinase 4 inhibitor C (Cyclin-dependent kinase 6 inhibitor) (p18-INK4c) (p18-INK6)	CDKN2C CDKN6	Homo sapiens (Human)	168						P42773;	9606.ENSP00000262662;	1BU9;1G3N;1IHB;1MX2;1MX4;1MX6;
P01023	A2MG_HUMAN	reviewed	Alpha-2-macroglobulin (Alpha-2-M) (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5)	A2M CPAMD5 FWP007	Homo sapiens (Human)	1474						P01023;	9606.ENSP00000323929;	1BV8;2P9R;4ACQ;6TAV;
P39116	PLY_BACSU	reviewed	Pectate lyase (PL) (EC 4.2.2.2)	pel BSU07560	Bacillus subtilis (strain 168)	420							224308.BSU07560;	1BN8;2BSP;2NZM;2O04;2O0V;2O0W;2O17;2O1D;3KRG;5AMV;5X2I;
P06971	FHUA_ECOLI	reviewed	Ferrichrome outer membrane transporter/phage receptor (Ferric hydroxamate receptor) (Ferric hydroxamate uptake) (Ferrichrome-iron receptor)	fhuA tonA b0150 JW0146	Escherichia coli (strain K12)	747						P06971;	511145.b0150;	1BY3;1BY5;1FCP;1FI1;1QFF;1QFG;1QJQ;1QKC;2FCP;2GRX;4CU4;
P49951	CLH1_BOVIN	reviewed	Clathrin heavy chain 1	CLTC	Bos taurus (Bovine)	1675						P49951;	9913.ENSBTAP00000022210;	1B89;1UTC;1XI4;1XI5;3GC3;3GD1;3IYV;3LVG;3LVH;3QIL;5M5R;5M5S;5M5T;5M5U;5M5V;5M61;6WCJ;
P01024	CO3_HUMAN	reviewed	Complement C3 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1) [Cleaved into: Complement C3 beta chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a anaphylatoxin; Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]	C3 CPAMD1	Homo sapiens (Human)	1663			DISEASE: Complement component 3 deficiency (C3D) [MIM:613779]: A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. {ECO:0000269|PubMed:7961791}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Macular degeneration, age-related, 9 (ARMD9) [MIM:611378]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. {ECO:0000269|PubMed:17634448, ECO:0000269|PubMed:24036952}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; DISEASE: Hemolytic uremic syndrome atypical 5 (AHUS5) [MIM:612925]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. {ECO:0000269|PubMed:18796626, ECO:0000269|PubMed:20513133}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype.; DISEASE: Note=Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage.		"MUTAGEN 1029;  /note=""D->A: Minor effect on binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1030;  /note=""E->A: Impaired binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1032;  /note=""E->A: Impaired binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1035;  /note=""E->A: No effect on binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651""; MUTAGEN 1042;  /note=""R->M: Impaired binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651""; MUTAGEN 1108..1109;  /note=""IL->RR: Impaired binding of C3d to CR2; when associated with A-1163."";  /evidence=""ECO:0000269|PubMed:11387479""; MUTAGEN 1110;  /note=""E->A: No effect on binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20951140""; MUTAGEN 1115;  /note=""D->A: No effect on binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20951140""; MUTAGEN 1121;  /note=""D->A: No effect on binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20951140""; MUTAGEN 1140;  /note=""D->A: No effect on binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1153;  /note=""E->A: Impaired binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1156;  /note=""D->A: Impaired binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1159;  /note=""E->A: Impaired binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1160;  /note=""E->A: Minor effect on binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1163;  /note=""N->A: No effect on binding of C3d to CR2. Impaired binding of C3d to CR2; when associated with 1108-R-R-1109."";  /evidence=""ECO:0000269|PubMed:11387479, ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1163;  /note=""N->R: Impaired binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:11387479, ECO:0000269|PubMed:20083651, ECO:0000269|PubMed:20951140""; MUTAGEN 1284;  /note=""K->A: Impaired binding of C3d to CR2."";  /evidence=""ECO:0000269|PubMed:20083651"""	P01024;	9606.ENSP00000245907;	1C3D;1GHQ;1W2S;2A73;2A74;2GOX;2I07;2ICE;2ICF;2NOJ;2QKI;2WII;2WIN;2WY7;2WY8;2XQW;2XWB;2XWJ;3D5R;3D5S;3G6J;3L3O;3L5N;3NMS;3OED;3OHX;3OXU;3RJ3;3T4A;4HW5;4HWJ;4I6O;4M76;4ONT;4ZH1;5FO7;5FO8;5FO9;5FOA;5FOB;5NBQ;5O32;5O35;6EHG;6RMT;6RMU;6RUR;6RUV;6S0B;6YO6;
P0A855	TOLB_ECOLI	reviewed	Tol-Pal system protein TolB	tolB b0740 JW5100	Escherichia coli (strain K12)	430				DISRUPTION PHENOTYPE: Mutants lacking the tol-pal cluster suffer delayed outer membrane invagination and contain large outer membrane blebs at constriction sites and cell poles (PubMed:17233825). Tol-pal mutants fail to complete division and form cell chains, and fail to process denuded peptidoglycans at the septum (PubMed:32152098). {ECO:0000269|PubMed:17233825, ECO:0000269|PubMed:32152098}.		P0A855;	511145.b0740;	1C5K;1CRZ;2HQS;2IVZ;2W8B;3IAX;
P10790	FABPH_BOVIN	reviewed	Fatty acid-binding protein, heart (Fatty acid-binding protein 3) (Heart-type fatty acid-binding protein) (H-FABP) (Mammary-derived growth inhibitor) (MDGI)	FABP3	Bos taurus (Bovine)	133							9913.ENSBTAP00000022375;	1BWY;
P20333	TNR1B_HUMAN	reviewed	Tumor necrosis factor receptor superfamily member 1B (Tumor necrosis factor receptor 2) (TNF-R2) (Tumor necrosis factor receptor type II) (TNF-RII) (TNFR-II) (p75) (p80 TNF-alpha receptor) (CD antigen CD120b) (Etanercept) [Cleaved into: Tumor necrosis factor receptor superfamily member 1b, membrane form; Tumor necrosis factor-binding protein 2 (TBP-2) (TBPII)]	TNFRSF1B TNFBR TNFR2	Homo sapiens (Human)	461						P20333;	9606.ENSP00000365435;	1CA9;3ALQ;
P32927	IL3RB_HUMAN	reviewed	Cytokine receptor common subunit beta (CDw131) (GM-CSF/IL-3/IL-5 receptor common beta subunit) (CD antigen CD131)	CSF2RB IL3RB IL5RB	Homo sapiens (Human)	897			DISEASE: Pulmonary surfactant metabolism dysfunction 5 (SMDP5) [MIM:614370]: A rare lung disorder due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid-Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress. {ECO:0000269|PubMed:21075760}. Note=The disease is caused by variants affecting the gene represented in this entry.			P32927;	9606.ENSP00000384053;	1C8P;1EGJ;1GH7;2GYS;2NA8;2NA9;4NKQ;5DWU;
P02749	APOH_HUMAN	reviewed	Beta-2-glycoprotein 1 (APC inhibitor) (Activated protein C-binding protein) (Anticardiolipin cofactor) (Apolipoprotein H) (Apo-H) (Beta-2-glycoprotein I) (B2GPI) (Beta(2)GPI)	APOH B2G1	Homo sapiens (Human)	345						P02749;	9606.ENSP00000205948;	1C1Z;1G4F;1G4G;1QUB;2KRI;3OP8;4JHS;6V06;6V08;6V09;
P62965	RABP1_MOUSE	reviewed	Cellular retinoic acid-binding protein 1 (Cellular retinoic acid-binding protein I) (CRABP-I)	Crabp1	Mus musculus (Mouse)	137							10090.ENSMUSP00000034830;	1CBI;1CBR;
P00451	FA8_HUMAN	reviewed	Coagulation factor VIII (Antihemophilic factor) (AHF) (Procoagulant component) [Cleaved into: Factor VIIIa heavy chain, 200 kDa isoform; Factor VIIIa heavy chain, 92 kDa isoform; Factor VIII B chain; Factor VIIIa light chain]	F8 F8C	Homo sapiens (Human)	2351			DISEASE: Hemophilia A (HEMA) [MIM:306700]: A disorder of blood coagulation characterized by a permanent tendency to hemorrhage. About 50% of patients have severe hemophilia resulting in frequent spontaneous bleeding into joints, muscles and internal organs. Less severe forms are characterized by bleeding after trauma or surgery. {ECO:0000269|PubMed:10215414, ECO:0000269|PubMed:10338101, ECO:0000269|PubMed:10404764, ECO:0000269|PubMed:10408784, ECO:0000269|PubMed:10554831, ECO:0000269|PubMed:10612839, ECO:0000269|PubMed:10691849, ECO:0000269|PubMed:10800171, ECO:0000269|PubMed:10886198, ECO:0000269|PubMed:10896236, ECO:0000269|PubMed:10910910, ECO:0000269|PubMed:10910913, ECO:0000269|PubMed:11298607, ECO:0000269|PubMed:11341489, ECO:0000269|PubMed:11410838, ECO:0000269|PubMed:11442643, ECO:0000269|PubMed:11442647, ECO:0000269|PubMed:11554935, ECO:0000269|PubMed:11748850, ECO:0000269|PubMed:11857744, ECO:0000269|PubMed:11858487, ECO:0000269|PubMed:12195713, ECO:0000269|PubMed:12199686, ECO:0000269|PubMed:12203998, ECO:0000269|PubMed:12325022, ECO:0000269|PubMed:12351418, ECO:0000269|PubMed:12406074, ECO:0000269|PubMed:12614369, ECO:0000269|PubMed:12871415, ECO:0000269|PubMed:12930394, ECO:0000269|PubMed:1301194, ECO:0000269|PubMed:1301932, ECO:0000269|PubMed:1301960, ECO:0000269|PubMed:1349567, ECO:0000269|PubMed:1356412, ECO:0000269|PubMed:15682412, ECO:0000269|PubMed:15810915, ECO:0000269|PubMed:1639429, ECO:0000269|PubMed:16805874, ECO:0000269|PubMed:18184865, ECO:0000269|PubMed:1851341, ECO:0000269|PubMed:1908096, ECO:0000269|PubMed:1908817, ECO:0000269|PubMed:1973901, ECO:0000269|PubMed:2104766, ECO:0000269|PubMed:2105106, ECO:0000269|PubMed:2105906, ECO:0000269|PubMed:2106480, ECO:0000269|PubMed:2107542, ECO:0000269|PubMed:21371196, ECO:0000269|PubMed:2495245, ECO:0000269|PubMed:2498882, ECO:0000269|PubMed:2499363, ECO:0000269|PubMed:2506948, ECO:0000269|PubMed:2510835, ECO:0000269|PubMed:25550078, ECO:0000269|PubMed:26278069, ECO:0000269|PubMed:2833855, ECO:0000269|PubMed:2835904, ECO:0000269|PubMed:3012775, ECO:0000269|PubMed:3122181, ECO:0000269|PubMed:7579394, ECO:0000269|PubMed:7759074, ECO:0000269|PubMed:7794769, ECO:0000269|PubMed:8322269, ECO:0000269|PubMed:8449505, ECO:0000269|PubMed:8639447, ECO:0000269|PubMed:8644728, ECO:0000269|PubMed:8759905, ECO:0000269|PubMed:9029040, ECO:0000269|PubMed:9326186, ECO:0000269|PubMed:9341862, ECO:0000269|PubMed:9450898, ECO:0000269|PubMed:9452104, ECO:0000269|PubMed:9569180, ECO:0000269|PubMed:9569189, ECO:0000269|PubMed:9603440, ECO:0000269|PubMed:9792405, ECO:0000269|PubMed:9829908, ECO:0000269|PubMed:9886318}. Note=The disease is caused by variants affecting the gene represented in this entry. Of particular interest for the understanding of the function of F8 is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8 in their plasma (at least 30% of normal), but the protein is non-functional; i.e. the F8 activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.			P00451;	9606.ENSP00000353393;	1CFG;1D7P;1FAC;1IQD;2R7E;3CDZ;3HNB;3HNY;3HOB;3J2Q;3J2S;4BDV;4KI5;4PT6;4XZU;5K8D;6MF2;7KWO;
P52270	TPIS_TRYCR	reviewed	Triosephosphate isomerase, glycosomal (TIM) (Triose-phosphate isomerase) (EC 5.3.1.1)		Trypanosoma cruzi	251								1CI1;1SUX;1TCD;2OMA;2V5B;3Q37;4HHP;
P03069	GCN4_YEAST	reviewed	General control transcription factor GCN4 (Amino acid biosynthesis regulatory protein) (General control protein GCN4)	GCN4 AAS101 AAS3 ARG9 YEL009C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	281				DISRUPTION PHENOTYPE: Abolishes recruitment of the mediator complex to the upstream activating sequence (UAS) of amino-acid starvation responsive genes (PubMed:19940160). Decreases RNA level of genes involved in amino acid biosynthesis and cofactor biosynthesis during amino acid starvation or methyl methanesulfonate stress (PubMed:11390663, PubMed:8336737, PubMed:29628310). Growth dependent on amino acid supplementation (PubMed:10733573). Sensitive to amino acid starvation (PubMed:10549298). Sensitive to purine starvation (PubMed:8336737). Decreases cellular glycogen levels during glucose starvation (PubMed:10733573). {ECO:0000269|PubMed:10549298, ECO:0000269|PubMed:10733573, ECO:0000269|PubMed:11390663, ECO:0000269|PubMed:19940160, ECO:0000269|PubMed:29628310, ECO:0000269|PubMed:8336737}.	"MUTAGEN 97..98;  /note=""FF->AA: Reduces transcriptional activation activity; when associated with A-107; A-110; A-113; A-120; A-123 and A-124."";  /evidence=""ECO:0000269|PubMed:7862116""; MUTAGEN 107;  /note=""M->A: Reduces transcriptional activation activity; when associated with A-97; A-98; A-110; A-113; A-120; A-123 and A-124."";  /evidence=""ECO:0000269|PubMed:7862116""; MUTAGEN 110;  /note=""Y->A: Reduces transcriptional activation activity; when associated with A-97; A-98; A-107; A-113; A-120; A-123 and A-124."";  /evidence=""ECO:0000269|PubMed:7862116""; MUTAGEN 113;  /note=""L->A: Reduces transcriptional activation activity; when associated with A-97; A-98; A-107; A-110; A-120; A-123 and A-124."";  /evidence=""ECO:0000269|PubMed:7862116""; MUTAGEN 120..124;  /note=""WTSLF->ATSAA: Reduces transcriptional activation activity; when associated with A-97; A-98; A-107; A-110 and A-113."";  /evidence=""ECO:0000269|PubMed:7862116"""	P03069;	4932.YEL009C;	1CE9;1DGC;1ENV;1FAV;1FMH;1GCL;1GCM;1GK6;1GZL;1IHQ;1IJ0;1IJ1;1IJ2;1IJ3;1KQL;1LD4;1LLM;1NKN;1PIQ;1RB4;1RB5;1RB6;1SWI;1TMZ;1UNT;1UNU;1UNV;1UNW;1UNX;1UNY;1UNZ;1UO0;1UO1;1UO2;1UO3;1UO4;1UO5;1W5G;1W5H;1W5I;1W5J;1W5K;1W5L;1YSA;1ZII;1ZIJ;1ZIK;1ZIL;1ZIM;1ZTA;2AHP;2B1F;2B22;2BNI;2CCE;2CCF;2CCN;2D3E;2DGC;2EFR;2EFS;2G9J;2HY6;2IPZ;2K8X;2LPB;2N9B;2NRN;2O7H;2OVN;2VKY;2VNL;2WG5;2WG6;2WPY;2WPZ;2WQ0;2WQ1;2WQ2;2WQ3;2YNY;2YNZ;2YO0;2YO1;2YO2;2YO3;2Z5H;2Z5I;2ZTA;3AZD;3BAS;3BAT;3CK4;3CRP;3G9R;3GJP;3I1G;3I5C;3K7Z;3M48;3P8M;3ZMF;4C46;4DMD;4G2K;4HU5;4HU6;4NIZ;4NJ0;4NJ1;4NJ2;4OWI;4TL1;5APP;5APQ;5APS;5APT;5APU;5APV;5APW;5APX;5APY;5APZ;5IEW;5IIR;5IIV;5KHT;6E52;6E95;6H9M;6HN4;6HN5;6O2E;6O2F;6PSA;6UT2;6VWG;6VWH;6VWI;6VWJ;
P12528	FIBER_BPP22	reviewed	Tail spike protein (TSP) (Endo-1,3-alpha-L-rhamnosidase) (EC 3.2.1.-) (Endorhamnosidase) (Gene product 9) (gp9)	9	Salmonella phage P22 (Bacteriophage P22)	667					"MUTAGEN 360;  /note=""E->Q: Complete loss of hydrolysis of O-antigen oligosaccharides."";  /evidence=""ECO:0000269|PubMed:8889178""; MUTAGEN 393;  /note=""D->N: Complete loss of hydrolysis of O-antigen oligosaccharides."";  /evidence=""ECO:0000269|PubMed:8889178""; MUTAGEN 396;  /note=""D->N: Complete loss of hydrolysis of O-antigen oligosaccharides."";  /evidence=""ECO:0000269|PubMed:8889178"""			1CLW;1LKT;1QA1;1QA2;1QA3;1QQ1;1QRB;1QRC;1TSP;1TYU;1TYV;1TYW;1TYX;2VFM;2VFN;2VFO;2VFP;2VFQ;2VKY;2VNL;2XC1;3TH0;5GAI;
P15529	MCP_HUMAN	reviewed	Membrane cofactor protein (TLX) (Trophoblast leukocyte common antigen) (CD antigen CD46)	CD46 MCP MIC10	Homo sapiens (Human)	392			DISEASE: Hemolytic uremic syndrome atypical 2 (AHUS2) [MIM:612922]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. {ECO:0000269|PubMed:14566051, ECO:0000269|PubMed:16386793, ECO:0000269|PubMed:16621965, ECO:0000269|PubMed:20513133}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype. Patients with CD46 mutations seem to have an overall better prognosis compared to patients carrying CFH mutations.		"MUTAGEN 83;  /note=""N->Q: No effect on cytoprotective function. No effect on Neisseria binding. No effect on Measles virus binding."";  /evidence=""ECO:0000269|PubMed:11260136, ECO:0000269|PubMed:8764003, ECO:0000269|PubMed:9759896""; MUTAGEN 114;  /note=""N->Q: Strongly decreases cytoprotective function. Decreases Neisseria binding. Abolishes Measles virus binding."";  /evidence=""ECO:0000269|PubMed:11260136, ECO:0000269|PubMed:8764003, ECO:0000269|PubMed:9759896""; MUTAGEN 273;  /note=""N->Q: Strongly decreases cytoprotective function. Abolishes Neisseria binding. No effect on Measles virus binding."";  /evidence=""ECO:0000269|PubMed:11260136, ECO:0000269|PubMed:8764003, ECO:0000269|PubMed:9759896"""	P15529;	9606.ENSP00000313875;	1CKL;1HR4;2O39;3INB;3L89;3O8E;5FO8;
O66037	PHYT_BACSD	reviewed	3-phytase (EC 3.1.3.8) (Myo-inositol-hexaphosphate 3-phosphohydrolase) (Phytate 3-phosphatase)	phy	Bacillus sp. (strain DS11)	383								1CVM;1H6L;1POO;1QLG;2POO;
P11922	INVA_YERPS	reviewed	Invasin	YPTB1668	Yersinia pseudotuberculosis serotype I (strain IP32953)	985								1CWV;4E1T;
P20701	ITAL_HUMAN	reviewed	Integrin alpha-L (CD11 antigen-like family member A) (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1A) (Leukocyte function-associated molecule 1 alpha chain) (CD antigen CD11a)	ITGAL CD11A	Homo sapiens (Human)	1170					"MUTAGEN 1165;  /note=""S->A: Abolishes phosphorylation and MEM-83-activated T-cell adhesion to ICAM1. Abolishes integrin alpha-L/beta-2 activation by CXCL12 and TERF2IP/RAP1. Does not affect heterodimerization of cell surface expression. Does not affect TCR- or phorbol ester-activated T-cell adhesion to ICAM1."";  /evidence=""ECO:0000269|PubMed:16301335"""	P20701;	9606.ENSP00000349252;	1CQP;1DGQ;1IJ4;1LFA;1MJN;1MQ8;1MQ9;1MQA;1RD4;1T0P;1XDD;1XDG;1XUO;1ZON;1ZOO;1ZOP;2ICA;2K8O;2M3E;2O7N;3BN3;3BQM;3BQN;3E2M;3EOA;3EOB;3F74;3F78;3HI6;3M6F;3TCX;4IXD;5E6R;5E6S;5E6U;6BXB;6BXF;6BXJ;6CKB;
P26214	PGLR2_ASPNA	reviewed	Endopolygalacturonase II (EPG-II) (EC 3.2.1.15) (Pectinase 2) (Polygalacturonase II) (PG-II) (Polygalacturonase X2)	pgaII pg2 ASPNIDRAFT_182156	Aspergillus niger (strain ATCC 1015 / CBS 113.46 / FGSC A1144 / LSHB Ac4 / NCTC 3858a / NRRL 328 / USDA 3528.7)	362					"MUTAGEN 180;  /note=""D->E,N: Reduces activity by 99.9%. No effect on Km for substrate."";  /evidence=""ECO:0000269|PubMed:10521427""; MUTAGEN 201;  /note=""D->E,N: Reduces activity by 99.9%. No effect on Km for substrate."";  /evidence=""ECO:0000269|PubMed:10521427""; MUTAGEN 202;  /note=""D->E: Reduces activity by 99.4%. No effect on Km for substrate."";  /evidence=""ECO:0000269|PubMed:10521427""; MUTAGEN 202;  /note=""D->N: Reduces activity by 99.9%. No effect on Km for substrate."";  /evidence=""ECO:0000269|PubMed:10521427""; MUTAGEN 223;  /note=""H->A: Reduces activity by 99.5%. No effect on Km for substrate."";  /evidence=""ECO:0000269|PubMed:10521427""; MUTAGEN 256;  /note=""R->N: Reduces activity by 86%. Reduces Km for substrate 10-fold."";  /evidence=""ECO:0000269|PubMed:10521427""; MUTAGEN 258;  /note=""K->N: Reduces activity by 99.2%. Reduces Km for substrate 10-fold."";  /evidence=""ECO:0000269|PubMed:10521427"""			1CZF;
P04525	CLAMP_BPT4	reviewed	Sliding clamp (DNA polymerase accessory protein Gp45) (DNA polymerase clamp) (Gene product 45) (gp45) (Sliding clamp Gp45)	45	Enterobacteria phage T4 (Bacteriophage T4)	228								1CZD;3U5Z;3U60;3U61;6DRT;7D7D;
P01031	CO5_HUMAN	reviewed	Complement C5 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4) [Cleaved into: Complement C5 beta chain; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5 alpha' chain]	C5 CPAMD4	Homo sapiens (Human)	1676			DISEASE: Complement component 5 deficiency (C5D) [MIM:609536]: A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Note=An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele. {ECO:0000269|PubMed:15995705}.			P01031;	9606.ENSP00000223642;	1CFA;1KJS;1XWE;3CU7;3HQA;3HQB;3KLS;3KM9;3PRX;3PVM;4A5W;4E0S;4P39;4UU9;5B4P;5B71;5HCC;5HCD;5HCE;5I5K;6H03;6H04;6RPT;7AD6;7AD7;
P05362	ICAM1_HUMAN	reviewed	Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54)	ICAM1	Homo sapiens (Human)	532						P05362;	9606.ENSP00000264832;	1D3E;1D3I;1D3L;1IAM;1IC1;1IJ4;1MQ8;1P53;1Z7Z;2OZ4;3TCX;5MZA;6EIT;6S8U;7BG7;
P25942	TNR5_HUMAN	reviewed	Tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40) (Bp50) (CD40L receptor) (CDw40) (CD antigen CD40)	CD40 TNFRSF5	Homo sapiens (Human)	277			DISEASE: Immunodeficiency with hyper-IgM 3 (HIGM3) [MIM:606843]: A rare immunodeficiency syndrome characterized by normal or elevated serum IgM levels with absence of IgG, IgA, and IgE. It results in a profound susceptibility to bacterial infections. {ECO:0000269|PubMed:11675497, ECO:0000269|PubMed:26545377}. Note=The disease is caused by variants affecting the gene represented in this entry.			P25942;	9606.ENSP00000361359;	1CDF;1CZZ;1D00;1FLL;1LB6;3QD6;5DMI;5DMJ;5IHL;6FAX;6PE8;6PE9;
Q04631	FNTA_RAT	reviewed	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha (EC 2.5.1.58) (EC 2.5.1.59) (CAAX farnesyltransferase subunit alpha) (FTase-alpha) (Ras proteins prenyltransferase subunit alpha) (Type I protein geranyl-geranyltransferase subunit alpha) (GGTase-I-alpha)	Fnta	Rattus norvegicus (Rat)	377						Q04631;	10116.ENSRNOP00000019594;	1D8D;1D8E;1FPP;1FT1;1FT2;1FTI;1HZ7;1JCR;1JCS;1KZO;1KZP;1KZR;1N4P;1N4Q;1N4R;1N4S;1N94;1N95;1N9A;1NI1;1NL4;1O1R;1O1S;1O1T;1O5M;1QBQ;1QE2;1S64;1SA5;1TN7;1TN8;1TNB;1TNO;1TNU;1TNY;1TNZ;1X81;2BED;2FTI;2R2L;2ZIR;2ZIS;3DPY;3E30;3E32;3E33;3E34;3EU5;3EUV;3FTI;3KSL;3KSQ;3PZ4;4GTM;4GTO;4GTP;4GTQ;4GTR;
Q02293	FNTB_RAT	reviewed	Protein farnesyltransferase subunit beta (FTase-beta) (EC 2.5.1.58) (CAAX farnesyltransferase subunit beta) (Ras proteins prenyltransferase subunit beta)	Fntb	Rattus norvegicus (Rat)	437						Q02293;	10116.ENSRNOP00000010588;	1D8D;1D8E;1FPP;1FT1;1FT2;1FTI;1HZ7;1JCR;1JCS;1KZO;1KZP;1KZR;1N94;1N95;1N9A;1NI1;1NL4;1O1R;1O1S;1O1T;1O5M;1QBQ;1QE2;1SA5;1TN7;1TN8;1X81;2BED;2FTI;2R2L;2ZIR;2ZIS;3DPY;3E30;3E32;3E33;3E34;3EU5;3EUV;3FTI;3KSL;3KSQ;4GTM;4GTO;4GTP;4GTQ;4GTR;
Q46079	CSLB_PEDHD	reviewed	Chondroitinase-B (EC 4.2.2.19) (Chondroitin sulfate B lyase) (Chondroitin-B eliminase) (Chondroitin-B lyase)	cslB Phep_0789	Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / CIP 104194 / JCM 7457 / NBRC 12017 / NCIMB 9290 / NRRL B-14731 / HIM 762-3)	506					"MUTAGEN 250;  /note=""K->A: Complete loss of activity."";  /evidence=""ECO:0000269|PubMed:12063249""; MUTAGEN 272;  /note=""H->A: Partial loss of activity."";  /evidence=""ECO:0000269|PubMed:12063249""; MUTAGEN 333;  /note=""E->A: Partial loss of activity."";  /evidence=""ECO:0000269|PubMed:12063249""; MUTAGEN 363;  /note=""R->A: No effect."";  /evidence=""ECO:0000269|PubMed:12063249""; MUTAGEN 364;  /note=""R->A: Partial loss of activity and altered product profile."";  /evidence=""ECO:0000269|PubMed:12063249"""		485917.Phep_0789;	1DBG;1DBO;1OFL;1OFM;
P14283	PERT_BORPE	reviewed	Pertactin autotransporter (P.93) [Cleaved into: Outer membrane protein P.69; Pertactin translocator]	prn omp69A BP1054	Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251)	910							257313.BP1054;	1DAB;
Q08602	PGTA_RAT	reviewed	Geranylgeranyl transferase type-2 subunit alpha (EC 2.5.1.60) (Geranylgeranyl transferase type II subunit alpha) (Rab geranyl-geranyltransferase subunit alpha) (Rab GG transferase alpha) (Rab GGTase alpha) (Rab geranylgeranyltransferase subunit alpha)	Rabggta Ggta	Rattus norvegicus (Rat)	567						Q08602;	10116.ENSRNOP00000049261;	1DCE;1LTX;3C72;3DSS;3DST;3DSU;3DSV;3DSW;3DSX;3HXB;3HXC;3HXD;3HXE;3HXF;3PZ1;3PZ2;3PZ3;4EHM;4GTS;4GTT;4GTV;
P0DQD2	INLB_LISMO	reviewed	Internalin B (InlB) (Invasion protein InlB)	inlB lmo0434	Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e)	630				DISRUPTION PHENOTYPE: Deletion of inlB alone decreases host cell entry; the reduction varies from 99% to 37% depending on the cell line tested. {ECO:0000269|PubMed:11929538}.	"MUTAGEN 95;  /note=""Q->EYLPNLDQLILNNNSIASIVG: Adds LRRb repeat, N-terminal fragment (36-321) binds MET, wild-type phosphorylation of downstream effectors MAPK1/MAPK3, full-length protein induces wild-type cell scattering."";  /evidence=""ECO:0000269|PubMed:22887347""; MUTAGEN 95;  /note=""Q->YLPNLTSLNLSNNQITDISPI: Adds LRRa repeat, N-terminal fragment (36-321) binds MET, slightly reduced phosphorylation of downstream effectors MAPK1/MAPK3."";  /evidence=""ECO:0000269|PubMed:22887347""; MUTAGEN 199..227;  /note=""SDIVPLAGLTKLQNLYLSKNHISDLRALA->RRIVPLARLTKLQNLYLSKNHISDLRALR: A 4 Arg mutant, in vitro wild-type binding of host MET, severely reduced activation of MET and downstream targets."";  /evidence=""ECO:0000269|PubMed:19900460""; MUTAGEN 200..227;  /note=""DIVPLAGLTKLQNLYLSKNHISDLRALA->RIVPLARLTKLQNLYLSKNHISDLRALR: A 3 Arg mutant, in vitro about 100-fold reduced activation of host MET and downstream targets, reduced host cell scattering upon incubation with mutant protein."";  /evidence=""ECO:0000269|PubMed:19900460""; MUTAGEN 206..227;  /note=""GLTKLQNLYLSKNHISDLRALA->CLTKLQNLYLSKNHISDLRALC: A 2 Cys mutant, forms 2 intermolecular disulfide bonds, about 100-fold more potent activator of MET, increased downstream effector phosphorylation."";  /evidence=""ECO:0000269|PubMed:19900460""; MUTAGEN 332;  /note=""T->E: The B-repeat fragment (residues 31-392) no longer scatters host cell colonies, full-length protein reduces MET phosphorylation and downstream activity about 10-fold."";  /evidence=""ECO:0000269|PubMed:27789707""; MUTAGEN 334..336;  /note=""IKT->KKL: The B-repeat fragment (residues 31-392) no longer scatters host cell colonies."";  /evidence=""ECO:0000269|PubMed:27789707""; MUTAGEN 336;  /note=""T->Y: No effect on cell scattering by the B-repeat fragment (residues 31-392)."";  /evidence=""ECO:0000269|PubMed:27789707"""	P0DQD2;		1H6T;2UZX;2UZY;2WQU;2WQV;2WQW;2WQX;2Y5P;2Y5Q;4AW4;4CIL;6DBF;6DBG;
Q7SIG6	ASAP2_MOUSE	reviewed	Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 (Development and differentiation-enhancing factor 2) (Paxillin-associated protein with ARF GAP activity 3) (PAG3) (Pyk2 C-terminus-associated protein) (PAP)	Asap2 Ddef2 Gm1523 Gm592	Mus musculus (Mouse)	958					"MUTAGEN 449;  /note=""W->A: Strongly reduces Arf-GAP mediated stimulation of GTP hydrolysis."";  /evidence=""ECO:0000269|PubMed:10601011""; MUTAGEN 460;  /note=""I->A: Reduces Arf-GAP mediated stimulation of GTP hydrolysis 100-fold and abolishes Arf-GAP mediated stimulation of GTP hydrolysis; when associated with A-306."";  /evidence=""ECO:0000269|PubMed:10601011""; MUTAGEN 467;  /note=""R->A: Abolishes Arf-GAP mediated stimulation of GTP hydrolysis."";  /evidence=""ECO:0000269|PubMed:10601011""; MUTAGEN 467;  /note=""R->K: Reduces Arf-GAP mediated stimulation of GTP hydrolysis more than 10000-fold."";  /evidence=""ECO:0000269|PubMed:10601011""; MUTAGEN 481;  /note=""L->A: Reduces Arf-GAP mediated stimulation of GTP hydrolysis 100-fold and abolishes Arf-GAP mediated stimulation of GTP hydrolysis; when associated with A-285."";  /evidence=""ECO:0000269|PubMed:10601011""; MUTAGEN 482;  /note=""D->A: Reduces Arf-GAP mediated stimulation of GTP hydrolysis 1000-fold."";  /evidence=""ECO:0000269|PubMed:10601011"""	Q7SIG6;	10090.ENSMUSP00000063217;	1DCQ;
P11589	MUP2_MOUSE	reviewed	Major urinary protein 2 (MUP 2)	Mup2	Mus musculus (Mouse)	180							10090.ENSMUSP00000095655;	1DF3;1JV4;1ZND;1ZNE;1ZNG;1ZNH;1ZNK;1ZNL;2DM5;2NND;2NNE;2OZQ;
Q8WZ42	TITIN_HUMAN	reviewed	Titin (EC 2.7.11.1) (Connectin) (Rhabdomyosarcoma antigen MU-RMS-40.14)	TTN	Homo sapiens (Human)	34350			DISEASE: Myopathy, myofibrillar, 9, with early respiratory failure (MFM9) [MIM:603689]: An autosomal dominant myopathy characterized by adulthood onset of weakness in proximal, distal, axial and respiratory muscles. Pelvic girdle weakness, foot drop and neck weakness are the main symptoms at onset, but ultimately the weakness usually involves the proximal compartment of both upper and lower limbs. Additional features include variable degrees of Achilles tendon contractures, spinal rigidity and muscle hypertrophy. Respiratory involvement often leads to requirement for non-invasive ventilation support. {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, familial hypertrophic 9 (CMH9) [MIM:613765]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1G (CMD1G) [MIM:604145]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11788824, ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Tardive tibial muscular dystrophy (TMD) [MIM:600334]: Autosomal dominant, late-onset distal myopathy. Muscle weakness and atrophy are usually confined to the anterior compartment of the lower leg, in particular the tibialis anterior muscle. Clinical symptoms usually occur at age 35-45 years or much later. {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Muscular dystrophy, limb-girdle, autosomal recessive 10 (LGMDR10) [MIM:608807]: An autosomal recessive degenerative myopathy characterized by progressive weakness of the pelvic and shoulder girdle muscles. Severe disability is observed within 20 years of onset. {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Salih myopathy (SALMY) [MIM:611705]: An autosomal recessive, early-onset muscular disorder characterized by dilated cardiomyopathy, delayed motor development with generalized muscle weakness predominantly affecting proximal and distal lower limbs. Skeletal muscle biopsies show minicore-like lesions with mitochondrial depletion and sarcomere disorganization, centralized nuclei, and type 1 fiber predominance. Dystrophic changes become apparent in the second decade. Cardiac muscle biopsies show disruption of myocardial architecture, nuclear hypertrophy, and endomysial fibrosis. Sudden death may occurr due to cardiomyopathy. {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 32207;  /note=""K->A: Disrupts catalytic activity."";  /evidence=""ECO:0000269|PubMed:9804419""; MUTAGEN 32341;  /note=""Y->E: No phosphorylation on tyrosine."";  /evidence=""ECO:0000269|PubMed:9804419"""	Q8WZ42;	9606.ENSP00000467141;	1BPV;1G1C;1NCT;1NCU;1TIT;1TIU;1TKI;1TNM;1TNN;1WAA;1YA5;2A38;2BK8;2F8V;2ILL;2J8H;2J8O;2NZI;2RQ8;2WP3;2WWK;2WWM;2Y9R;3B43;3KNB;3LCY;3LPW;3PUC;3Q5O;3QP3;4C4K;4JNW;4O00;4QEG;4UOW;5BS0;5JDD;5JDE;5JDJ;5JOE;6DL4;6H4L;6HCI;6I0Y;6SDB;6YGN;7AHS;7NIP;
P10775	RINI_PIG	reviewed	Ribonuclease inhibitor (Ribonuclease/angiogenin inhibitor 1)	RNH1 RI RNH	Sus scrofa (Pig)	456						P10775;		1DFJ;2BNH;
P0A6L2	DAPA_ECOLI	reviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA b2478 JW2463	Escherichia coli (strain K12)	292					"MUTAGEN 44;  /note=""T->S: 8% of wild-type activity. 4-fold decrease in affinity for pyruvate, but nearly no change in that for (S)-ASA."";  /evidence=""ECO:0000269|PubMed:15066435, ECO:0000269|PubMed:19505526""; MUTAGEN 44;  /note=""T->V: Reduced kcat by 99.9%."";  /evidence=""ECO:0000269|PubMed:15066435, ECO:0000269|PubMed:19505526""; MUTAGEN 107;  /note=""Y->F: Reduced kcat by 90%."";  /evidence=""ECO:0000269|PubMed:15066435, ECO:0000269|PubMed:18937497""; MUTAGEN 107;  /note=""Y->W: Reduced activity by 95%. Reduced affinity for both substrates. Exists as a mixture of monomer, dimer and tetramer in solution. Has significantly lower thermal stability than the wild-type enzyme."";  /evidence=""ECO:0000269|PubMed:15066435, ECO:0000269|PubMed:18937497""; MUTAGEN 133;  /note=""Y->F: Reduced kcat by 99.7%. Reduced affinity for both substrates."";  /evidence=""ECO:0000269|PubMed:15066435""; MUTAGEN 138;  /note=""R->A,H: Strongly increased KM for L-aspartate 4-semialdehyde. No effect on KM for pyruvate. Reduced activity by 99.7%."";  /evidence=""ECO:0000269|PubMed:16185069""; MUTAGEN 161;  /note=""K->A: 0.1% of wild-type activity. 3-fold decrease in affinity for pyruvate, and 2-fold decrease in that for (S)-ASA."";  /evidence=""ECO:0000269|PubMed:20353808""; MUTAGEN 161;  /note=""K->R: 0.35% of wild-type activity. 3-fold decrease in affinity for pyruvate, but nearly no change in that for (S)-ASA."";  /evidence=""ECO:0000269|PubMed:20353808""; MUTAGEN 197;  /note=""L->Y,D: 1.4 to 2.5% of wild-type activity. Decrease in affinity for pyruvate, but nearly no change in that for (S)-ASA. Exists as a dimer in solution."";  /evidence=""ECO:0000269|PubMed:18556019"""	P0A6L2;	511145.b2478;	1DHP;1S5T;1S5V;1S5W;1YXC;1YXD;2A6L;2A6N;2ATS;2OJP;2PUR;3C0J;3DEN;3DU0;3I7Q;3I7R;3I7S;4EOU;5T25;5T26;
Q56320	TRPF_THEMA	reviewed	N-(5'-phosphoribosyl)anthranilate isomerase (PRAI) (EC 5.3.1.24)	trpF TM_0139	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	205							243274.THEMA_04110;	1DL3;1LBM;1NSJ;
P80188	NGAL_HUMAN	reviewed	Neutrophil gelatinase-associated lipocalin (NGAL) (25 kDa alpha-2-microglobulin-related subunit of MMP-9) (Lipocalin-2) (Oncogene 24p3) (Siderocalin) (p25)	LCN2 HNL NGAL	Homo sapiens (Human)	198					"MUTAGEN 145;  /note=""K->A: Strongly reduced affinity for catecholate-type ferric siderophores; when associated with A-154."";  /evidence=""ECO:0000269|PubMed:20581821""; MUTAGEN 154;  /note=""K->A: Strongly reduced affinity for catecholate-type ferric siderophores; when associated with A-145."";  /evidence=""ECO:0000269|PubMed:20581821"""	P80188;	9606.ENSP00000362108;	1DFV;1L6M;1NGL;1QQS;1X71;1X89;1X8U;3BY0;3CBC;3CMP;3DSZ;3DTQ;3FW4;3FW5;3HWD;3HWE;3HWF;3HWG;3I0A;3K3L;3PEC;3PED;3T1D;3TF6;3TZS;3U0D;4GH7;4IAW;4IAX;4K19;4MVI;4MVK;4MVL;4QAE;4ZFX;4ZHC;4ZHD;4ZHF;4ZHG;4ZHH;5JR8;5KHP;5KIC;5KID;5MHH;5N47;5N48;5NKN;6GQZ;6GR0;6O5D;6QMU;6S8V;6SUA;6Z2C;6Z6Z;
P33038	MURA_ENTCC	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (UDP-N-acetylglucosamine enolpyruvyl transferase) (EPT)	murA murZ ECL_04571	Enterobacter cloacae subsp. cloacae (strain ATCC 13047 / DSM 30054 / NBRC 13535 / NCTC 10005 / WDCM 00083 / NCDC 279-56)	419					"MUTAGEN 115;  /note=""C->D: Significantly lower binding of phosphoenolpyruvate."";  /evidence=""ECO:0000269|PubMed:22378791""; MUTAGEN 115;  /note=""C->S: Loss of activity, but not of substrate binding.""; MUTAGEN 120;  /note=""R->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:22378791"""		716541.ECL_04571;	1DLG;1EJC;1EJD;1EYN;1NAW;1Q3G;1RYW;1YBG;3KQA;3LTH;3SPB;3SU9;3SWA;3SWI;3SWQ;3UPK;3V4T;3V5V;4E7B;4E7C;4E7D;4E7E;4E7F;4E7G;4EII;
P00751	CFAB_HUMAN	reviewed	Complement factor B (EC 3.4.21.47) (C3/C5 convertase) (Glycine-rich beta glycoprotein) (GBG) (PBF2) (Properdin factor B) [Cleaved into: Complement factor B Ba fragment; Complement factor B Bb fragment]	CFB BF BFD	Homo sapiens (Human)	764			DISEASE: Macular degeneration, age-related, 14 (ARMD14) [MIM:615489]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. {ECO:0000269|PubMed:16518403}. Note=Disease susceptibility may be associated with variants affecting the gene represented in this entry. Haplotype analyses have identified a statistically significant common risk haplotype and two protective haplotypes. CFB variant His-9 and C2 variant Asp-318, as well as CFB variant Gln-32 and a variant in intron 10 of C2, confer a significantly reduced risk of AMD. {ECO:0000269|PubMed:16518403}.; DISEASE: Hemolytic uremic syndrome atypical 4 (AHUS4) [MIM:612924]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. {ECO:0000269|PubMed:17182750, ECO:0000269|PubMed:20513133}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.; DISEASE: Complement factor B deficiency (CFBD) [MIM:615561]: An immunologic disorder characterized by increased susceptibility to bacterial infections, particularly Neisseria infections, due to a defect in the alternative complement pathway. {ECO:0000269|PubMed:24152280}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 348..350;  /note=""KLK->AAA: Decreases binding to the pro-C3-convertase complex. Does not affect Complement C3 beta chain binding."";  /evidence=""ECO:0000269|PubMed:31507604"""	P00751;	9606.ENSP00000416561;	1DLE;1Q0P;1RRK;1RS0;1RTK;2OK5;2WIN;2XWB;2XWJ;3HRZ;3HS0;6QSW;6QSX;6RAV;6RUR;6RUV;6T8U;6T8V;6T8W;7JTN;7JTQ;
Q02248	CTNB1_MOUSE	reviewed	Catenin beta-1 (Beta-catenin)	Ctnnb1 Catnb	Mus musculus (Mouse)	781				DISRUPTION PHENOTYPE: Sympathetic ganglia-specific conditional knockout mice lead to a reduction in sympathetic ganglia size and in progenitor cell number, but does not alter sympathetic innervation of peripheral target organs. {ECO:0000269|PubMed:21325504}.	"MUTAGEN 8;  /note=""M->P: Loss of interaction with VCL."";  /evidence=""ECO:0000269|PubMed:20086044""; MUTAGEN 33;  /note=""S->A: Abolished HIPK2-mediated proteasomal degradation."";  /evidence=""ECO:0000269|PubMed:20307497""; MUTAGEN 37;  /note=""S->A: Abolished HIPK2-mediated proteasomal degradation."";  /evidence=""ECO:0000269|PubMed:20307497""; MUTAGEN 552;  /note=""S->A: Abolishes AMPK-mediated phosphorylation."";  /evidence=""ECO:0000269|PubMed:20361929"""	Q02248;	10090.ENSMUSP00000007130;	1DOW;1I7W;1I7X;1JPP;1M1E;1V18;2BCT;3BCT;3OUW;3OUX;4EV8;4EV9;4EVA;4EVP;4EVT;4ONS;
Q9XHH2	DNAL1_CHLRE	reviewed	Dynein axonemal light chain 1 (DNAL1) (Flagellar outer arm dynein light chain 1) (ODA-LC protein LC1)	LC1 CHLREDRAFT_186669	Chlamydomonas reinhardtii (Chlamydomonas smithii)	198					"MUTAGEN 182;  /note=""M->A: Reduces swimming velocity."";  /evidence=""ECO:0000269|PubMed:19620633""; MUTAGEN 182;  /note=""M->G: Reduces swimming velocity."";  /evidence=""ECO:0000269|PubMed:19620633""; MUTAGEN 182;  /note=""M->P: Reduces swimming velocity."";  /evidence=""ECO:0000269|PubMed:19620633""; MUTAGEN 185;  /note=""D->G: Reduces swimming velocity."";  /evidence=""ECO:0000269|PubMed:19620633""; MUTAGEN 185;  /note=""D->P: Reduces swimming velocity and beat frequency."";  /evidence=""ECO:0000269|PubMed:19620633""; MUTAGEN 189;  /note=""R->A: Reduces swimming velocity."";  /evidence=""ECO:0000269|PubMed:19620633""; MUTAGEN 189;  /note=""R->E: Reduces swimming velocity."";  /evidence=""ECO:0000269|PubMed:19620633""; MUTAGEN 196;  /note=""R->A: Reduces swimming velocity."";  /evidence=""ECO:0000269|PubMed:19620633""; MUTAGEN 196;  /note=""R->D: Reduces swimming velocity."";  /evidence=""ECO:0000269|PubMed:19620633"""		3055.EDP06769;	1DS9;1M9L;5YXM;6L4P;
P22629	SAV_STRAV	reviewed	Streptavidin		Streptomyces avidinii	183								1DF8;1HQQ;1HXL;1HXZ;1HY2;1I9H;1KFF;1KL3;1KL4;1KL5;1LCV;1LCW;1LCZ;1LUQ;1MEP;1MK5;1MM9;1MOY;1N43;1N4J;1N7Y;1N9M;1N9Y;1NBX;1NC9;1NDJ;1NQM;1PTS;1RST;1RSU;1RXH;1RXJ;1RXK;1SLD;1SLE;1SLF;1SLG;1SRE;1SRF;1SRG;1SRH;1SRI;1SRJ;1STP;1STR;1STS;1SWA;1SWB;1SWC;1SWD;1SWE;1SWF;1SWG;1SWH;1SWJ;1SWK;1SWL;1SWN;1SWO;1SWP;1SWQ;1SWR;1SWS;1SWT;1SWU;1VWA;1VWB;1VWC;1VWD;1VWE;1VWF;1VWG;1VWH;1VWI;1VWJ;1VWK;1VWL;1VWM;1VWN;1VWO;1VWP;1VWQ;1VWR;2BC3;2F01;2G5L;2GH7;2IZA;2IZB;2IZC;2IZD;2IZE;2IZF;2IZG;2IZH;2IZI;2IZJ;2IZK;2IZL;2QCB;2RTA;2RTB;2RTC;2RTD;2RTE;2RTF;2RTG;2RTH;2RTI;2RTJ;2RTK;2RTL;2RTM;2RTN;2RTO;2RTP;2RTQ;2RTR;2WPU;2Y3E;2Y3F;3MG5;3PK2;3RDM;3RDO;3RDQ;3RDS;3RDU;3RDX;3RE5;3RE6;3RY1;3RY2;3T6F;3T6L;3WYP;3WYQ;3WZN;3WZO;3WZP;3WZQ;3X00;4BX5;4BX6;4BX7;4CPE;4CPF;4CPH;4CPI;4DNE;4EKV;4GD9;4GDA;4GJS;4GJV;4IRW;4JO6;4OKA;4Y59;4Y5D;4YVB;5B5F;5B5G;5CSE;5F2B;5JD2;5K67;5K68;5L3Y;5N7X;5N89;5N8B;5N8E;5N8J;5N8T;5N8W;5N99;5TO2;5VCQ;5VKX;5VL5;5VL8;5WBA;5WBB;5WBC;5WBD;6ANX;6AUC;6AUE;6AUH;6AUL;6AUO;6AVK;6ESS;6ESU;6FH8;6FRY;6GH7;6J6J;6J6K;6LNG;6M9B;6QBB;6QSY;6QW4;6S4Q;6S50;6SOK;6SOS;6T1E;6T1G;6T1K;6T2L;6T2Y;6T2Z;6T30;6T31;6T32;6TIP;6UC3;6UD1;6UD6;6UDB;6UDC;6UI0;6UIU;6UIY;6UIZ;6US6;6VJK;6VJL;6VO9;6VOB;6VOZ;6VP1;6VP2;6VP3;6Y25;6Y2M;6Y2T;6Y33;6Y34;6Y3Q;7DY0;7EFC;7EFD;7KBY;7KBZ;7KNL;
P11444	MANR_PSEPU	reviewed	Mandelate racemase (MR) (EC 5.1.2.2)	mdlA	Pseudomonas putida (Arthrobacter siderocapsulatus)	359					"MUTAGEN 166;  /note=""K->A,M,Q: Loss of activity."";  /evidence=""ECO:0000269|PubMed:7893690""; MUTAGEN 297;  /note=""H->N: Loss of activity."";  /evidence=""ECO:0000269|PubMed:1909893""; MUTAGEN 317;  /note=""E->Q: Reduces activity 10000-fold."";  /evidence=""ECO:0000269|PubMed:7893689"""			1DTN;1MDL;1MDR;1MNS;1MRA;2MNR;3UXK;3UXL;4FP1;4HNC;4M6U;4X2P;6VIM;
P25054	APC_HUMAN	reviewed	Adenomatous polyposis coli protein (Protein APC) (Deleted in polyposis 2.5)	APC DP2.5	Homo sapiens (Human)	2843			DISEASE: Familial adenomatous polyposis 1 (FAP1) [MIM:175100]: A cancer predisposition syndrome characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years. {ECO:0000269|PubMed:10470088, ECO:0000269|PubMed:1316610, ECO:0000269|PubMed:1338691, ECO:0000269|PubMed:1338764, ECO:0000269|PubMed:1338904, ECO:0000269|PubMed:1651563, ECO:0000269|PubMed:21643010, ECO:0000269|PubMed:27217144, ECO:0000269|PubMed:7661930, ECO:0000269|PubMed:7833149, ECO:0000269|PubMed:7833931, ECO:0000269|PubMed:8990002}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Desmoid disease, hereditary (DESMD) [MIM:135290]: An autosomal dominant disease characterized by multifocal fibromatosis of the abdominal wall and mesentery. Desmoid tumors can also affect paraspinal muscles, breast, occiput, arms, and lower ribs. {ECO:0000269|PubMed:10782927, ECO:0000269|PubMed:8940264}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. {ECO:0000269|PubMed:10666372}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Note=The gene represented in this entry may be involved in disease pathogenesis.		"MUTAGEN 516;  /note=""K->E: Impairs interaction with KHDRBS1."";  /evidence=""ECO:0000269|PubMed:22000517""; MUTAGEN 549;  /note=""R->E: Impairs interaction with KHDRBS1."";  /evidence=""ECO:0000269|PubMed:22000517""; MUTAGEN 2841;  /note=""T->L: Loss of interaction with SCRIB."";  /evidence=""ECO:0000269|PubMed:16611247""; MUTAGEN 2843;  /note=""V->Q: Loss of interaction with SCRIB."";  /evidence=""ECO:0000269|PubMed:16611247"""	P25054;	9606.ENSP00000257430;	1DEB;1EMU;1JPP;1M5I;1T08;1TH1;1V18;2RQU;3AU3;3NMW;3NMX;3NMZ;3QHE;3RL7;3RL8;3T7U;4G69;4YJE;4YJL;4YK6;5B6G;5IZ6;5IZ8;5IZ9;5IZA;5Z8H;
P08514	ITA2B_HUMAN	reviewed	Integrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane glycoprotein IIb) (CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb light chain, form 2]	ITGA2B GP2B ITGAB	Homo sapiens (Human)	1039			DISEASE: Glanzmann thrombasthenia (GT) [MIM:273800]: A common inherited disease of platelet aggregation. It is characterized by mucocutaneous bleeding of mild-to-moderate severity. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the GPIIb-IIIa complex at reduced levels, have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. {ECO:0000269|PubMed:10607701, ECO:0000269|PubMed:11798398, ECO:0000269|PubMed:12083483, ECO:0000269|PubMed:12181054, ECO:0000269|PubMed:12424194, ECO:0000269|PubMed:12506038, ECO:0000269|PubMed:15099289, ECO:0000269|PubMed:15219201, ECO:0000269|PubMed:17018384, ECO:0000269|PubMed:20020534, ECO:0000269|PubMed:7508443, ECO:0000269|PubMed:7706461, ECO:0000269|PubMed:8282784, ECO:0000269|PubMed:8704171, ECO:0000269|PubMed:9215749, ECO:0000269|PubMed:9473221, ECO:0000269|PubMed:9722314, ECO:0000269|PubMed:9734640, ECO:0000269|PubMed:9763559, ECO:0000269|PubMed:9920835}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Bleeding disorder, platelet-type, 16 (BDPLT16) [MIM:187800]: An autosomal dominant form of congenital macrothrombocytopenia associated with platelet anisocytosis. It is a disorder of platelet production. Affected individuals may have no or only mildly increased bleeding tendency. In vitro studies show mild platelet functional abnormalities. {ECO:0000269|PubMed:21454453, ECO:0000269|PubMed:9834222}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 1029..1030;  /note=""PP->AA: Imparts constitutive activity (ligand-binding) to alpha-IIb/beta-3."";  /evidence=""ECO:0000269|PubMed:10212286"""	P08514;	9606.ENSP00000262407;	1DPK;1DPQ;1JX5;1KUP;1KUZ;1M8O;1RN0;1S4W;1TYE;1UV9;2K1A;2K9J;2KNC;2MTP;2N9Y;2VC2;2VDK;2VDL;2VDM;2VDN;2VDO;2VDP;2VDQ;2VDR;3FCS;3FCU;3NID;3NIF;3NIG;3T3M;3T3P;3ZDX;3ZDY;3ZDZ;3ZE0;3ZE1;3ZE2;4CAK;4Z7N;4Z7O;4Z7Q;5HDB;6V4P;
P26514	XYNA_STRLI	reviewed	Endo-1,4-beta-xylanase A (Xylanase A) (EC 3.2.1.8) (1,4-beta-D-xylan xylanohydrolase A)	xlnA	Streptomyces lividans	477								1E0V;1E0W;1E0X;1KNL;1KNM;1MC9;1OD8;1V0K;1V0L;1V0M;1V0N;1XAS;
P09465	APHR_CRICR	reviewed	Aphrodisin		Cricetus cricetus (Black-bellied hamster)	167								1E5P;
P23687	PPCE_PIG	reviewed	Prolyl endopeptidase (PE) (EC 3.4.21.26) (Post-proline cleaving enzyme)	PREP	Sus scrofa (Pig)	710							9823.ENSSSCP00000004715;	1E5T;1E8M;1E8N;1H2W;1H2X;1H2Y;1H2Z;1O6F;1O6G;1QFM;1QFS;1UOO;1UOP;1UOQ;1VZ2;1VZ3;2XDW;3EQ7;3EQ8;3EQ9;4AMY;4AMZ;4AN0;4AN1;4AX4;4BCB;4BCC;4BCD;
Q7SIG4	DFPA_LOLVU	reviewed	Diisopropyl-fluorophosphatase (DFPase) (EC 3.1.8.2)		Loligo vulgaris (Common European squid)	314		BIOTECHNOLOGY: Has potential application in bio-remediation by detoxification of organo-phosphates used in insecticides or nerve agents used in chemical warfare such as soman, tabun and sarin. {ECO:0000269|PubMed:11134940}.			"MUTAGEN 21;  /note=""E->Q: 100% decrease in activity. Loss of calcium 1 binding."";  /evidence=""ECO:0000269|PubMed:11435114""; MUTAGEN 37;  /note=""E->Q: 50% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11435114""; MUTAGEN 77;  /note=""Q->F: 100% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 77;  /note=""Q->W: No effect on activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 77;  /note=""Q->Y: 6% increase in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 120;  /note=""N->D: 96% decrease in activity. 100% decrease in activity; when associated with N-229."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 121;  /note=""D->F: 100% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 144;  /note=""Y->S: 8% increase in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 146;  /note=""R->S: 45% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 148;  /note=""M->A: 26% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 173;  /note=""F->A: 84% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 173;  /note=""F->L: 28% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 173;  /note=""F->S: 68% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 173;  /note=""F->V: 46% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 173;  /note=""F->W: 19% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 173;  /note=""F->Y: 53% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 175;  /note=""N->D: 98% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 181;  /note=""H->N: 20% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 195;  /note=""T->A: 60% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 195;  /note=""T->L: 11% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 195;  /note=""T->V: 3% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 219;  /note=""H->N: 3% increase in activity."";  /evidence=""ECO:0000269|PubMed:11295437""; MUTAGEN 224;  /note=""H->N: 14% increase in activity."";  /evidence=""ECO:0000269|PubMed:11295437""; MUTAGEN 229;  /note=""D->N: 100% decrease in activity. Loss of calcium 1 binding. 100% decrease in activity; when associated with D-120."";  /evidence=""ECO:0000269|PubMed:11435114, ECO:0000269|PubMed:15966726""; MUTAGEN 232;  /note=""D->S: 3% increase in activity. 19% decrease in activity; when associated with A-271."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 237;  /note=""N->S: 4% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 244;  /note=""W->F: 44% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11435114""; MUTAGEN 244;  /note=""W->H: 27% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11435114""; MUTAGEN 244;  /note=""W->L: 62% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11435114""; MUTAGEN 244;  /note=""W->Y: No effect on activity."";  /evidence=""ECO:0000269|PubMed:11435114""; MUTAGEN 248;  /note=""H->N: 4% increase in activity."";  /evidence=""ECO:0000269|PubMed:11295437""; MUTAGEN 271;  /note=""S->A: 30% increase in activity. 19% decrease in activity; when associated with S-232."";  /evidence=""ECO:0000269|PubMed:11435114, ECO:0000269|PubMed:15966726""; MUTAGEN 272;  /note=""N->F: 100% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 274;  /note=""H->N: 85% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 287;  /note=""H->A: 90% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 287;  /note=""H->F: 36% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 287;  /note=""H->L: 21% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 287;  /note=""H->N: 97% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 287;  /note=""H->Q: 54% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 287;  /note=""H->W: 44% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 287;  /note=""H->Y: 57% decrease in activity."";  /evidence=""ECO:0000269|PubMed:11295437, ECO:0000269|PubMed:15966726""; MUTAGEN 304;  /note=""Q->F: 50% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 304;  /note=""Q->W: 3% decrease in activity."";  /evidence=""ECO:0000269|PubMed:15966726""; MUTAGEN 314;  /note=""F->A: 3% increase in activity."";  /evidence=""ECO:0000269|PubMed:15966726"""			1E1A;1PJX;2GVU;2GVV;2GVW;2GVX;2IAO;2IAP;2IAQ;2IAR;2IAS;2IAT;2IAU;2IAV;2IAW;2IAX;3BYC;3HLH;3HLI;3I1C;3KGG;3LI3;3LI4;3LI5;3O4P;3U0S;4O5S;4O5T;
P63010	AP2B1_HUMAN	reviewed	AP-2 complex subunit beta (AP105B) (Adaptor protein complex AP-2 subunit beta) (Adaptor-related protein complex 2 subunit beta) (Beta-2-adaptin) (Beta-adaptin) (Clathrin assembly protein complex 2 beta large chain) (Plasma membrane adaptor HA2/AP2 adaptin beta subunit)	AP2B1 ADTB2 CLAPB1	Homo sapiens (Human)	937					"MUTAGEN 815;  /note=""Y->A: Strongly reduces interaction with SNAP91, EPS15, AMPH and BIN1 and clathrin heavy chain."";  /evidence=""ECO:0000269|PubMed:16516836, ECO:0000269|PubMed:16903783""; MUTAGEN 841;  /note=""W->A: Abolishes interaction with LDLRAP1 and ARRB1. Greatly reduces DENND1B-binding."";  /evidence=""ECO:0000269|PubMed:15728179, ECO:0000269|PubMed:16516836, ECO:0000269|PubMed:16903783, ECO:0000269|PubMed:20154091""; MUTAGEN 842;  /note=""K->E: Strongly reduces interaction with ARRB1."";  /evidence=""ECO:0000269|PubMed:16903783""; MUTAGEN 849;  /note=""E->A: Strongly reduces interaction with LDLRAP1, ARRB1 and EPN1. No effect on DENND1B-binding."";  /evidence=""ECO:0000269|PubMed:11777907, ECO:0000269|PubMed:16516836, ECO:0000269|PubMed:20154091""; MUTAGEN 851;  /note=""Q->A: Strongly reduces interaction with ARRB1."";  /evidence=""ECO:0000269|PubMed:16903783""; MUTAGEN 879;  /note=""R->A: No effect on interaction with ARRB1."";  /evidence=""ECO:0000269|PubMed:10944104, ECO:0000269|PubMed:16903783""; MUTAGEN 879;  /note=""R->E: Strongly reduces interaction with EPN1. Reduces interaction with SNAP91 and clathrin. No effect on EPS15 binding."";  /evidence=""ECO:0000269|PubMed:10944104, ECO:0000269|PubMed:16903783""; MUTAGEN 888;  /note=""Y->V: Strongly reduces interaction with SNAP91, EPN1 and clathrin. No effect on EPS15 binding. Abolishes interaction with ARRB1 and with DENND1B."";  /evidence=""ECO:0000269|PubMed:10944104, ECO:0000269|PubMed:15728179, ECO:0000269|PubMed:16516836, ECO:0000269|PubMed:16903783, ECO:0000269|PubMed:20154091""; MUTAGEN 902;  /note=""E->A: Strongly reduces interaction with LDLRAP1 and ARRB1. No effect on DENND1B-binding."";  /evidence=""ECO:0000269|PubMed:11777907, ECO:0000269|PubMed:16516836, ECO:0000269|PubMed:20154091""; MUTAGEN 917;  /note=""K->Q: Strongly reduces interaction with LDLRAP1. SNAP91 and clathrin. Reduces interaction with EPN1. No effect on EPS15 binding."";  /evidence=""ECO:0000269|PubMed:10944104"""	P63010;	9606.ENSP00000482835;	1E42;2G30;2IV8;2IV9;2JKR;2JKT;2VGL;2XA7;4UQI;5M5R;6QH5;6QH6;6QH7;6URI;6YAE;6YAF;6YAH;6YAI;
P19878	NCF2_HUMAN	reviewed	Neutrophil cytosol factor 2 (NCF-2) (67 kDa neutrophil oxidase factor) (NADPH oxidase activator 2) (Neutrophil NADPH oxidase factor 2) (p67-phox)	NCF2 NOXA2 P67PHOX	Homo sapiens (Human)	526			DISEASE: Granulomatous disease, chronic, cytochrome-b-positive 2, autosomal recessive (CGD2) [MIM:233710]: A form of chronic granulomatous disease, a primary immunodeficiency characterized by severe recurrent bacterial and fungal infections, along with manifestations of chronic granulomatous inflammation. It results from an impaired ability of phagocytes to mount a burst of reactive oxygen species in response to pathogens. {ECO:0000269|PubMed:10498624, ECO:0000269|PubMed:10598813, ECO:0000269|PubMed:11112388, ECO:0000269|PubMed:16937026, ECO:0000269|PubMed:18625437, ECO:0000269|PubMed:19624736, ECO:0000269|PubMed:20167518, ECO:0000269|PubMed:23910690, ECO:0000269|PubMed:8286749, ECO:0000269|PubMed:9070911}. Note=The disease is caused by variants affecting the gene represented in this entry.			P19878;	9606.ENSP00000356505;	1E96;1HH8;1K4U;1OEY;1WM5;2DMO;
P02751	FINC_HUMAN	reviewed	Fibronectin (FN) (Cold-insoluble globulin) (CIG) [Cleaved into: Anastellin; Ugl-Y1; Ugl-Y2; Ugl-Y3]	FN1 FN	Homo sapiens (Human)	2477			DISEASE: Glomerulopathy with fibronectin deposits 2 (GFND2) [MIM:601894]: Genetically heterogeneous autosomal dominant disorder characterized clinically by proteinuria, microscopic hematuria, and hypertension that leads to end-stage renal failure in the second to fifth decade of life. {ECO:0000269|PubMed:18268355}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Spondylometaphyseal dysplasia, corner fracture type (SMDCF) [MIM:184255]: An autosomal dominant form of spondylometaphyseal dysplasia, a group of short stature disorders distinguished by abnormalities in the vertebrae and the metaphyses of the tubular bones. SMDCF is characterized by flake-like, triangular, or curvilinear ossification centers at the edges of irregular metaphyses that simulate fractures. These corner fractures involve the distal tibia, the ulnar aspect of the distal radius, the proximal humerus, and the proximal femur. They represent irregular ossification at the growth plates and secondary ossification centers. {ECO:0000269|PubMed:29100092}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 641;  /note=""Y->A: Severely compromised ability to form fibronectin aggregates; when associated with A-681 and A-683."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 642;  /note=""I->A: Little effect on ability to form fibronectin aggregates; when associated with A-682; A-684 and A-692."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 663;  /note=""L->A: No effect on secondary structure nor on fibronectin binding nor on activation of p38 K but abolishes polymerization activity; when associated with A-666."";  /evidence=""ECO:0000269|PubMed:12946358, ECO:0000269|PubMed:19379667""; MUTAGEN 666;  /note=""Y->A: No effect on secondary structure nor on fibronectin binding nor on activation of p38 kinase but abolishes polymerization activity; when associated with A-663."";  /evidence=""ECO:0000269|PubMed:12946358, ECO:0000269|PubMed:19379667""; MUTAGEN 681;  /note=""L->A: Severely compromised ability to form fibronectin aggregates; when associated with A-641 and A-683."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 682;  /note=""I->A: Little effect on ability to form fibronectin aggregates; when associated with A-642; A-684 and A-692."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 683;  /note=""S->A: Severely compromised ability to form fibronectin aggregates; when associated with A-641 and A-681."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 684;  /note=""I->A: Little effect on ability to form fibronectin aggregates; when associated with A-642; A-682 and A-692."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 691;  /note=""E->A: Slightly enhanced ability to form fibronectin aggregates; when associated with A-694 and A-696."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 692;  /note=""V->A: Little effect on ability to form fibronectin aggregates; when associated with A-642; A-682 and A-684."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 694;  /note=""R->A: Slightly enhanced ability to form fibronectin aggregates; when associated with A-691 and A-696."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 695;  /note=""F->A: Loss of ability to form fibronectin aggregates; when associated with A-697."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 696;  /note=""D->A: Slightly enhanced ability to form fibronectin aggregates; when associated with A-691 and A-694."";  /evidence=""ECO:0000269|PubMed:12946358""; MUTAGEN 697;  /note=""F->A: Loss of ability to form fibronectin aggregates; when associated with A-695."";  /evidence=""ECO:0000269|PubMed:12946358"""	P02751;		1E88;1E8B;1FBR;1FNA;1FNF;1FNH;1J8K;1O9A;1OWW;1Q38;1QGB;1QO6;1TTF;1TTG;2CG6;2CG7;2CK2;2CKU;2EC3;2FN2;2FNB;2GEE;2H41;2H45;2HA1;2MNU;2N1K;2OCF;2RKY;2RKZ;2RL0;3CAL;3EJH;3GXE;3M7P;3MQL;3R8Q;3T1W;3ZRZ;4GH7;4JE4;4JEG;4LXO;4MMX;4MMY;4MMZ;4PZ5;5DC0;5DC4;5DC9;5DFT;5J6Z;5J7C;5M0A;5N47;5N48;6HNF;6MFA;6MSV;6NAJ;6XAX;6XAY;7NWL;
P0A6P9	ENO_ECOLI	reviewed	Enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (2-phosphoglycerate dehydratase)	eno b2779 JW2750	Escherichia coli (strain K12)	432					"MUTAGEN 168;  /note=""E->Q: 5% activity; not secreted."";  /evidence=""ECO:0000269|PubMed:15003462""; MUTAGEN 209;  /note=""E->Q: 1% activity; not secreted."";  /evidence=""ECO:0000269|PubMed:15003462""; MUTAGEN 342;  /note=""K->A,Q,R: 1% activity; not secreted."";  /evidence=""ECO:0000269|PubMed:15003462""; MUTAGEN 342;  /note=""K->E: 94% activity; not secreted."";  /evidence=""ECO:0000269|PubMed:15003462"""	P0A6P9;	511145.b2779;	1E9I;2FYM;3H8A;5OHG;6BFY;6BFZ;6D3Q;6NPF;
P10289	FABP6_PIG	reviewed	Gastrotropin (GT) (Fatty acid-binding protein 6) (Ileal lipid-binding protein) (ILBP) (Porcine ileal peptide) (PIP)	FABP6 ILBP ILLBP	Sus scrofa (Pig)	128							9823.ENSSSCP00000018050;	1EAL;1EIO;
Q9RHW0	Q9RHW0_BACSP	unreviewed	Pectate lyase (EC 4.2.2.2)		Bacillus sp.	224								1EE6;
Q05755	GLTB_AZOBR	reviewed	Glutamate synthase [NADPH] large chain (EC 1.4.1.13) (Glutamate synthase subunit alpha) (GLTS alpha chain) (NADPH-GOGAT)	gltB	Azospirillum brasilense	1515								1EA0;2VDC;6S6S;6S6T;6S6U;6S6X;
P52292	IMA1_HUMAN	reviewed	Importin subunit alpha-1 (Karyopherin subunit alpha-2) (RAG cohort protein 1) (SRP1-alpha)	KPNA2 RCH1 SRP1	Homo sapiens (Human)	529					"MUTAGEN 2..80;  /note=""Missing: Complete loss of binding to KPNB1."";  /evidence=""ECO:0000269|PubMed:17596301"""	P52292;	9606.ENSP00000438483;	1EFX;1QGK;1QGR;3FEX;3FEY;3WPT;4E4V;4WV6;5H43;7N8J;
P08244	PYRF_ECOLI	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF b1281 JW1273	Escherichia coli (strain K12)	245						P08244;	511145.b1281;	1EIX;1JJK;1L2U;
O26232	PYRF_METTH	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF MTH_129	Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) (Methanobacterium thermoautotrophicum)	228								1DV7;1DVJ;1KLY;1KLZ;1KM0;1KM1;1KM2;1KM3;1KM4;1KM5;1KM6;1LOL;1LOQ;1LOR;1LOS;1LP6;1X1Z;2E6Y;2ZZ1;2ZZ2;2ZZ3;2ZZ4;2ZZ5;2ZZ6;2ZZ7;3G18;3G1A;3G1D;3G1F;3G1H;3G1S;3G1V;3G1X;3G1Y;3G22;3G24;3LHT;3LHU;3LHV;3LHW;3LHY;3LHZ;3LI0;3LI1;3LLD;3LLF;3LTP;3LTS;3LTY;3LV5;3LV6;3M1Z;3M41;3M43;3M44;3M47;3M5X;3M5Y;3M5Z;3NQ6;3NQ7;3NQA;3NQC;3NQD;3NQE;3NQF;3NQG;3NQM;3P5Y;3P5Z;3P60;3P61;3PBU;3PBV;3PBW;3PBY;3PC0;3QEZ;3QF0;3QMR;3QMS;3QMT;3RLU;3RLV;3SEC;3SGU;3SIZ;3SJ3;3SSJ;3SW6;3SY5;3THQ;3V1P;3W07;3WJW;3WJX;3WJY;3WJZ;3WK0;3WK1;3WK2;3WK3;4FX6;4FX8;4FXR;4GC4;4LC6;4LC8;4LW7;4NT0;4NUW;4NX5;4O11;4O8R;
P31948	STIP1_HUMAN	reviewed	Stress-induced-phosphoprotein 1 (STI1) (Hsc70/Hsp90-organizing protein) (Hop) (Renal carcinoma antigen NY-REN-11) (Transformation-sensitive protein IEF SSP 3521)	STIP1	Homo sapiens (Human)	543						P31948;	9606.ENSP00000351646;	1ELR;1ELW;2LNI;2NC9;3ESK;3FWV;
P06911	LCN5_RAT	reviewed	Epididymal-specific lipocalin-5 (Androgen-dependent epididymal 18.5 kDa protein) (Epididymal retinoic acid-binding protein) (E-RABP) (Epididymal secretory protein I) (ESP-I) [Cleaved into: Epididymal-specific lipocalin-5, B form; Epididymal-specific lipocalin-5, C form]	Lcn5 Erabp	Rattus norvegicus (Rat)	188							10116.ENSRNOP00000058570;	1EPA;1EPB;
P0A6D3	AROA_ECOLI	reviewed	3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19) (5-enolpyruvylshikimate-3-phosphate synthase) (EPSP synthase) (EPSPS)	aroA b0908 JW0891	Escherichia coli (strain K12)	427					"MUTAGEN 96;  /note=""G->A: Insensitive to glyphosate with unaltered affinity for its first substrate S3P, but displays a 30-fold lower affinity for its second substrate PEP."";  /evidence=""ECO:0000269|PubMed:12430021""; MUTAGEN 97;  /note=""T->I: This mutant is sensitive to glyphosate and causes a substantial decrease in the affinity for PEP. Insensitive to glyphosate but maintains high affinity for PEP. It causes a shift of residue G96 toward the glyphosate binding site, impairing efficient binding of glyphosate, while the side chain of I97 points away from the substrate binding site, facilitating PEP utilization; when associated with S-101."";  /evidence=""ECO:0000269|PubMed:19211556""; MUTAGEN 101;  /note=""P->A: Displays a slight decrease of the affinity binding for both S3P and PEP. Decreases the binding affinity of glyphosate, reducing the potency of this inhibitor."";  /evidence=""ECO:0000269|PubMed:17855366, ECO:0000269|PubMed:19211556""; MUTAGEN 101;  /note=""P->G: Displays a slight decrease of the affinity binding for both S3P and PEP. Decreases the binding affinity of glyphosate, reducing the potency of this inhibitor."";  /evidence=""ECO:0000269|PubMed:17855366, ECO:0000269|PubMed:19211556""; MUTAGEN 101;  /note=""P->L: Displays a 2-fold lower affinity binding for both S3P and PEP. Decreases the binding affinity of glyphosate, reducing the potency of this inhibitor."";  /evidence=""ECO:0000269|PubMed:17855366, ECO:0000269|PubMed:19211556""; MUTAGEN 101;  /note=""P->S: Displays a slight decrease of the affinity binding for both S3P and PEP. Decreases the binding affinity of glyphosate, reducing the potency of this inhibitor. Insensitive to glyphosate but maintains high affinity for PEP. It causes a shift of residue G96 toward the glyphosate binding site, impairing efficient binding of glyphosate, while the side chain of I97 points away from the substrate-binding site, facilitating PEP utilization; when associated with I-97."";  /evidence=""ECO:0000269|PubMed:17855366, ECO:0000269|PubMed:19211556""; MUTAGEN 313;  /note=""D->A: The enolpyruvyl transfer reaction is halted after formation of the tetrahedral adduct of the substrates."";  /evidence=""ECO:0000269|PubMed:13129913"""	P0A6D3;	511145.b0908;	1EPS;1G6S;1G6T;1MI4;1P88;1P89;1Q0I;1Q0J;1Q36;1X8R;1X8T;2AA9;2AAY;2PQ9;2QFQ;2QFS;2QFT;2QFU;3FJX;3FJZ;3FK0;3FK1;
P18902	RET4_BOVIN	reviewed	Retinol-binding protein 4 (Plasma retinol-binding protein) (PRBP) (RBP)	RBP4	Bos taurus (Bovine)	183							9913.ENSBTAP00000000566;	1ERB;1FEL;1FEM;1FEN;1HBP;1HBQ;1KT3;1KT4;1KT5;1KT6;1KT7;
P52293	IMA1_MOUSE	reviewed	Importin subunit alpha-1 (Importin alpha P1) (Karyopherin subunit alpha-2) (Pendulin) (Pore targeting complex 58 kDa subunit) (PTAC58) (RAG cohort protein 1) (SRP1-alpha)	Kpna2 Rch1	Mus musculus (Mouse)	529						P52293;	10090.ENSMUSP00000137310;	1EJL;1EJY;1IAL;1IQ1;1PJM;1PJN;1Q1S;1Q1T;1Y2A;2C1M;2YNR;3BTR;3KND;3L3Q;3OQS;3Q5U;3RZ9;3RZX;3TPM;3TPO;3UKW;3UKX;3UKY;3UKZ;3UL0;3UL1;3UVU;3VE6;3ZIN;3ZIO;3ZIP;3ZIQ;3ZIR;4BA3;4HTV;4MZ5;4MZ6;4OIH;4U54;4U58;4U5L;4U5N;4U5O;4U5S;4U5U;4U5V;4UAF;4YI0;4ZDU;5B56;5CTT;5D5K;5E6Q;5EKF;5EKG;5FC8;5GXW;5HHG;5HUW;5HUY;5K9S;5KLR;5KLT;5SVZ;5U5P;5U5R;5UMZ;5V5O;5V5P;5W41;5W4E;5W4F;5W4G;5WUM;5WUN;5X8N;6BVT;6BW0;6BW1;6D7M;6D7N;6IU7;6IUA;6IW8;6IWA;6K06;6MJL;6P6A;6P6E;6WX7;7JJM;7JK7;7JVO;7L04;
P16649	TUP1_YEAST	reviewed	General transcriptional corepressor TUP1 (Flocculation suppressor protein) (Glucose repression regulatory protein TUP1) (Repressor AER2)	TUP1 AAR1 AER2 AMM1 CYC9 FLK1 SFL2 UMR7 YCR084C YCR84C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	713						P16649;	4932.YCR084C;	1ERJ;3VP8;3VP9;
A0A140NB38	A0A140NB38_ECOBD	unreviewed	2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14) (EC 4.1.3.16) (2-keto-3-deoxy-6-phosphogluconate aldolase) (2-keto-4-hydroxyglutarate aldolase) (4-hydroxy-2-oxoglutarate aldolase) (KHG/KDPG aldolase) (Phospho-2-dehydro-3-deoxygluconate aldolase) (Phospho-2-keto-3-deoxygluconate aldolase)	ECBD_1789	Escherichia coli (strain B / BL21-DE3)	213							469008.B21_01809;	1EUA;
P48736	PK3CG_HUMAN	reviewed	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma) (PI3Kgamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.137) (EC 2.7.1.153) (EC 2.7.1.154) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma) (PtdIns-3-kinase subunit p110-gamma) (p110gamma) (Phosphoinositide-3-kinase catalytic gamma polypeptide) (Serine/threonine protein kinase PIK3CG) (EC 2.7.11.1) (p120-PI3K)	PIK3CG	Homo sapiens (Human)	1102					"MUTAGEN 833;  /note=""K->R: Reduced inflammatory reactions but no alterations in cardiac contractility."";  /evidence=""ECO:0000269|PubMed:15294162""; MUTAGEN 947;  /note=""R->P: Abolishes protein and lipid kinase activity. Does not abolishes interaction with GRK2."";  /evidence=""ECO:0000269|PubMed:16094730"""	P48736;	9606.ENSP00000352121;	1E8Y;1E8Z;1HE8;2A4Z;2A5U;2CHW;2CHX;2CHZ;2V4L;3APC;3APD;3APF;3CSF;3CST;3DBS;3DPD;3ENE;3IBE;3L08;3L13;3L16;3L17;3L54;3LJ3;3MJW;3ML8;3ML9;3NZS;3NZU;3OAW;3P2B;3PRE;3PRZ;3PS6;3QAQ;3QAR;3QJZ;3QK0;3R7Q;3R7R;3S2A;3SD5;3T8M;3TJP;3TL5;3ZVV;3ZW3;4ANU;4ANV;4ANW;4ANX;4AOF;4DK5;4EZJ;4EZK;4EZL;4F1S;4FA6;4FAD;4FHJ;4FHK;4FJY;4FJZ;4FLH;4FUL;4G11;4GB9;4HLE;4HVB;4J6I;4KZ0;4KZC;4PS3;4PS7;4PS8;4URK;4WWN;4WWO;4WWP;4XX5;4XZ4;5EDS;5G2N;5G55;5JHA;5JHB;5KAE;5OQ4;5T23;6AUD;6C1S;6FH5;6GQ7;6T3B;6T3C;6XRL;6XRM;7JWE;7JWZ;7JX0;7KKE;
Q9GTP0	Q9GTP0_CHOFU	unreviewed	Thermal hysteresis protein		Choristoneura fumiferana (Spruce budworm moth) (Archips fumiferana)	108								1EWW;1L0S;1N4I;
Q95182	ALL1_HORSE	reviewed	Major allergen Equ c 1 (allergen Equ c 1)		Equus caballus (Horse)	187	ALLERGEN: Causes an allergic reaction in human. Potent allergen responsible for about 80% of anti-horse IgE antibody response in patients who are chronically exposed to horse allergens. {ECO:0000269|PubMed:8955138}.							1EW3;
P19438	TNR1A_HUMAN	reviewed	Tumor necrosis factor receptor superfamily member 1A (Tumor necrosis factor receptor 1) (TNF-R1) (Tumor necrosis factor receptor type I) (TNF-RI) (TNFR-I) (p55) (p60) (CD antigen CD120a) [Cleaved into: Tumor necrosis factor receptor superfamily member 1A, membrane form; Tumor necrosis factor-binding protein 1 (TBPI)]	TNFRSF1A TNFAR TNFR1	Homo sapiens (Human)	455			DISEASE: Periodic fever, familial, autosomal dominant (FPF) [MIM:142680]: A hereditary periodic fever syndrome characterized by recurrent fever, abdominal pain, localized tender skin lesions and myalgia. Reactive amyloidosis is the main complication and occurs in 25% of cases. {ECO:0000269|PubMed:10199409, ECO:0000269|PubMed:10902757, ECO:0000269|PubMed:11443543, ECO:0000269|PubMed:13130484, ECO:0000269|PubMed:14610673}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. {ECO:0000269|PubMed:22801493}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. An intronic mutation affecting alternative splicing and skipping of exon 6 directs increased expression of isoform 4 a transcript encoding a C-terminally truncated protein which is secreted and may function as a TNF antagonist.		"MUTAGEN 376;  /note=""R->A: Abolished GlcNAcylation by E.coli NleB1."";  /evidence=""ECO:0000269|PubMed:30979585"""	P19438;	9606.ENSP00000162749;	1EXT;1FT4;1ICH;1NCF;1TNR;7K7A;7KP7;7KP8;7KPB;
P10822	ICW3_PSOTE	reviewed	Chymotrypsin inhibitor 3 (WCI-3)		Psophocarpus tetragonolobus (Winged bean) (Dolichos tetragonolobus)	207								1EYL;1FMZ;1FN0;1WBC;1XG6;2BEA;2BEB;2ESU;2ET2;2QYI;2WBC;3I29;3I2A;3I2X;3QYD;3VEQ;4H9W;4HA2;4TLP;4WBC;
O16119	ANPY1_TENMO	reviewed	Thermal hysteresis protein YL-1 (THP YL-1) (Beta-helix antifreeze protein 2-14) (THP 2-14)		Tenebrio molitor (Yellow mealworm beetle)	112								1EZG;1L1I;
Q14974	IMB1_HUMAN	reviewed	Importin subunit beta-1 (Importin-90) (Karyopherin subunit beta-1) (Nuclear factor p97) (Pore targeting complex 97 kDa subunit) (PTAC97)	KPNB1 NTF97	Homo sapiens (Human)	876					"MUTAGEN 178;  /note=""I->A: Largely reduced binding to FxFG repeats and reduced nuclear import."";  /evidence=""ECO:0000269|PubMed:10929717""; MUTAGEN 178;  /note=""I->F,D: Loss of binding to FxFG repeats and reduced nuclear import."";  /evidence=""ECO:0000269|PubMed:10929717"""	Q14974;	9606.ENSP00000290158;	1F59;1IBR;1M5N;1O6O;1O6P;1QGK;1QGR;2P8Q;2Q5D;2QNA;3LWW;3W5K;6N88;6N89;
P0A955	ALKH_ECOLI	reviewed	KHG/KDPG aldolase [Includes: 4-hydroxy-2-oxoglutarate aldolase (EC 4.1.3.16) (2-keto-4-hydroxyglutarate aldolase) (KHG-aldolase); 2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14) (2-keto-3-deoxy-6-phosphogluconate aldolase) (KDPG-aldolase) (Phospho-2-dehydro-3-deoxygluconate aldolase) (Phospho-2-keto-3-deoxygluconate aldolase)]	eda hga kdgA b1850 JW1839	Escherichia coli (strain K12)	213				DISRUPTION PHENOTYPE: Cells lacking this gene lose KHG aldolase activity. {ECO:0000269|PubMed:1339418}.	"MUTAGEN 45;  /note=""E->N: 50-fold decrease in catalytic efficiency and 6-fold decrease of binding affinity."";  /evidence=""ECO:0000269|PubMed:16403639, ECO:0000269|PubMed:17981470""; MUTAGEN 133;  /note=""K->Q: Absence of aldolase activity. Shows a markedly altered substrate specificity relative to the wild-type, with an enhanced activity against pyridine carboxaldehyde, benzaldehyde, and alpha-ketobutyrate; when associated with k-161."";  /evidence=""ECO:0000269|PubMed:11342129""; MUTAGEN 161;  /note=""T->K: Shows activity significantly greater than wild-type. Shows a markedly altered substrate specificity relative to the wild-type, with an enhanced activity against pyridine carboxaldehyde, benzaldehyde, and alpha-ketobutyrate; when associated with Q-133."";  /evidence=""ECO:0000269|PubMed:11342129, ECO:0000269|PubMed:17981470""; MUTAGEN 161;  /note=""T->V: Little stereoselectivity, accepting KDPG and KDPGal as substrate with roughly equal efficacy. It strongly diminishes the activity against KDPG and slightly increases activity against KDPGal."";  /evidence=""ECO:0000269|PubMed:11342129, ECO:0000269|PubMed:17981470""; MUTAGEN 168;  /note=""N->S: Shows activity significantly greater than wild-type."";  /evidence=""ECO:0000269|PubMed:11342129"""	P0A955;	511145.b1850;	1EUA;1EUN;1FQ0;1FWR;1WAU;1WBH;2C0A;
O60784	TOM1_HUMAN	reviewed	Target of Myb protein 1	TOM1	Homo sapiens (Human)	492						O60784;	9606.ENSP00000413697;	1ELK;1WRD;2N2N;2N9D;6J56;
P44539	NANA_HAEIN	reviewed	N-acetylneuraminate lyase (NAL) (Neu5Ac lyase) (EC 4.1.3.3) (N-acetylneuraminate pyruvate-lyase) (N-acetylneuraminic acid aldolase) (Sialate lyase) (Sialic acid aldolase) (Sialic acid lyase)	nanA HI_0142	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	293							71421.HI_0142;	1F5Z;1F6K;1F6P;1F73;1F74;1F7B;
O15540	FABP7_HUMAN	reviewed	Fatty acid-binding protein, brain (Brain lipid-binding protein) (BLBP) (Brain-type fatty acid-binding protein) (B-FABP) (Fatty acid-binding protein 7) (Mammary-derived growth inhibitor related)	FABP7 BLBP FABPB MRG	Homo sapiens (Human)	132						O15540;	9606.ENSP00000357429;	1FDQ;1FE3;1JJX;5URA;6L9O;
P50542	PEX5_HUMAN	reviewed	Peroxisomal targeting signal 1 receptor (PTS1 receptor) (PTS1R) (PTS1-BP) (Peroxin-5) (Peroxisomal C-terminal targeting signal import receptor) (Peroxisome receptor 1)	PEX5 PXR1	Homo sapiens (Human)	639			DISEASE: Peroxisome biogenesis disorder 2A (PBD2A) [MIM:214110]: A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and characterized clinically by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life. {ECO:0000269|PubMed:7719337}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Peroxisome biogenesis disorder 2B (PBD2B) [MIM:202370]: A peroxisome biogenesis disorder that includes neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD), two milder manifestations of the Zellweger disease spectrum. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy and vision impairment. Children with the NALD presentation may reach their teens, while patients with the IRD presentation may reach adulthood. The clinical conditions are often slowly progressive in particular with respect to loss of hearing and vision. The biochemical abnormalities include accumulation of phytanic acid, very long chain fatty acids (VLCFA), di- and trihydroxycholestanoic acid and pipecolic acid. {ECO:0000269|PubMed:10462504, ECO:0000269|PubMed:7719337}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Rhizomelic chondrodysplasia punctata 5 (RCDP5) [MIM:616716]: A form of rhizomelic chondrodysplasia punctata, a disease characterized by severely disturbed endochondral bone formation, rhizomelic shortening of femur and humerus, vertebral disorders, dwarfism, cataract, cutaneous lesions, facial dysmorphism, and severe mental retardation with spasticity. {ECO:0000269|PubMed:26220973}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 118;  /note=""W->A: Strongly reduced interaction with PEX14."";  /evidence=""ECO:0000269|PubMed:11438541""; MUTAGEN 122;  /note=""F->A: Strongly reduced interaction with PEX14."";  /evidence=""ECO:0000269|PubMed:11438541"""	P50542;	9606.ENSP00000391601;	1FCH;2C0L;2C0M;2J9Q;2W84;3R9A;4BXU;4KXK;4KYO;
P29208	MENC_ECOLI	reviewed	o-succinylbenzoate synthase (OSB synthase) (OSBS) (EC 4.2.1.113) (4-(2'-carboxyphenyl)-4-oxybutyric acid synthase) (o-succinylbenzoic acid synthase)	menC b2261 JW2256	Escherichia coli (strain K12)	320						P29208;	511145.b2261;	1FHU;1FHV;1R6W;2OFJ;
P0CL66	OSPA_BORBU	reviewed	Outer surface protein A	ospA BB_A15	Borrelia burgdorferi (strain ATCC 35210 / B31 / CIP 102532 / DSM 4680)	273								1FJ1;1OSP;2AF5;2FKG;2FKJ;2G8C;2HKD;2I5V;2I5Z;2OL6;2OL7;2OL8;2OY1;2OY5;2OY7;2OY8;2OYB;2PI3;3AUM;5B2A;6ICS;6IDC;6IEI;6IYS;6J47;6J48;6J49;6J5M;6J5N;6J5O;6J5P;6J5Q;6J5R;6J6B;6J6C;6J6D;6J6E;6KT1;6KWJ;6KWU;6KWV;6LJY;
P0A6L4	NANA_ECOLI	reviewed	N-acetylneuraminate lyase (NAL) (Neu5Ac lyase) (EC 4.1.3.3) (N-acetylneuraminate pyruvate-lyase) (N-acetylneuraminic acid aldolase) (NALase) (Sialate lyase) (Sialic acid aldolase) (Sialic acid lyase)	nanA npl b3225 JW3194	Escherichia coli (strain K12)	297						P0A6L4;	511145.b3225;	1FDY;1FDZ;1HL2;1NAL;2WKJ;2WNN;2WNQ;2WNZ;2WO5;2WPB;2XFW;2YGY;3LBC;3LBM;3LCF;3LCG;3LCH;3LCI;3LCL;3LCW;3LCX;4BWL;4UUI;
P01854	IGHE_HUMAN	reviewed	Immunoglobulin heavy constant epsilon (Ig epsilon chain C region) (Ig epsilon chain C region ND)	IGHE	Homo sapiens (Human)	428								1F6A;1FP5;1G84;1IGE;1O0V;2WQR;2Y7Q;3H9Y;3H9Z;3HA0;4EZM;4GKO;4GRG;4GT7;4J4P;4KI1;5ANM;5HYS;5LGJ;5LGK;5MOI;5MOJ;5MOK;5MOL;5NQW;6EYO;6UQR;
Q9UBU9	NXF1_HUMAN	reviewed	Nuclear RNA export factor 1 (Tip-associated protein) (Tip-associating protein) (mRNA export factor TAP)	NXF1 TAP	Homo sapiens (Human)	619					"MUTAGEN 71;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-78, A-81, A-82, A-89, A-91, A-97, A-98, A-100 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 78;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-81, A-82, A-89, A-91, A-97, A-98, A-100 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 81;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-78, A-82, A-89, A-91, A-97, A-98, A-100 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 82;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-78, A-81, A-89, A-91, A-97, A-98, A-100 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 89;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-78, A-81, A-82, A-91, A-97, A-98, A-100 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 91;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-78, A-81, A-82, A-89, A-97, A-98, A-100 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 97;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-78, A-81, A-82, A-89, A-91, A-98, A-100 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 98;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-78, A-81, A-82, A-89, A-91, A-97, A-100 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 100;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-78, A-81, A-82, A-89, A-91, A-97, A-98 and A-105."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 105;  /note=""R->A: Greatly reduces RNA binding and no effect on interaction with ALYREF/THOC4; when associated with A-71, A-78, A-81, A-82, A-89, A-91, A-97, A-98 and A-100."";  /evidence=""ECO:0000269|PubMed:18364396""; MUTAGEN 306..308;  /note=""ERE->AAA: Decreases the export of mRNAs from the nucleus.""; MUTAGEN 383;  /note=""L->R: Diminishes nuclear rim staining and 80% reduction in mRNA export activity; when associated with R-386. Complete loss of nuclear rim staining and mRNA export activity; when associated with R-386 and A-594."";  /evidence=""ECO:0000269|PubMed:11583626""; MUTAGEN 386;  /note=""L->R: Diminishes nuclear rim staining and 80% reduction in mRNA export activity; when associated with R-383. Complete loss of nuclear rim staining and mRNA export activity; when associated with R-383 and A-594."";  /evidence=""ECO:0000269|PubMed:11583626""; MUTAGEN 399;  /note=""D->A: 60% reduction in mRNA export activity."";  /evidence=""ECO:0000269|PubMed:11583626""; MUTAGEN 450..453;  /note=""LRFR->AAAA: Abolishes interaction with THOC5 and CHTOP."";  /evidence=""ECO:0000269|PubMed:23299939""; MUTAGEN 453;  /note=""R->A: Impairs intramolecular interaction between RBD and NTF2."";  /evidence=""ECO:0000269|PubMed:22893130""; MUTAGEN 456..459;  /note=""KHTR->AAAA: Abolishes interaction with THOC5 and CHTOP, no effect on interaction with NXT1; enhances intramolecular interaction between RBD and NTF2, reduces RNA binding and mRNA export."";  /evidence=""ECO:0000269|PubMed:22893130, ECO:0000269|PubMed:23299939""; MUTAGEN 456;  /note=""K->D: Impairs intramolecular interaction between RBD and NTF2; when associated with D-459.""; MUTAGEN 459;  /note=""R->D: Impairs intramolecular interaction between RBD and NTF2; when associated with D-456.""; MUTAGEN 482;  /note=""D->R: 90% reduction in mRNA export activity."";  /evidence=""ECO:0000269|PubMed:11583626""; MUTAGEN 518;  /note=""I->R: 98% reduction in mRNA export activity."";  /evidence=""ECO:0000269|PubMed:11583626""; MUTAGEN 521;  /note=""P->Q: 35% reduction in mRNA export activity."";  /evidence=""ECO:0000269|PubMed:11583626""; MUTAGEN 594;  /note=""W->A: Suppresses FG-nucleoporin binding. Diminishes nuclear rim staining and 88% reduction in mRNA export activity. Complete loss of nuclear rim staining and mRNA export activity; when associated with R-383 and R-386."";  /evidence=""ECO:0000269|PubMed:11583626""; MUTAGEN 595;  /note=""D->R: Suppresses FG-nucleoporin binding.""; MUTAGEN 617;  /note=""F->A: Suppresses FG-nucleoporin binding."";  /evidence=""ECO:0000269|PubMed:11875519"""	Q9UBU9;	9606.ENSP00000436679;	1FO1;1FT8;1GO5;1JKG;1JN5;1KOH;1KOO;1OAI;2Z5K;2Z5M;3RW6;3RW7;4WYK;6E5U;
Q13309	SKP2_HUMAN	reviewed	S-phase kinase-associated protein 2 (Cyclin-A/CDK2-associated protein p45) (F-box protein Skp2) (F-box/LRR-repeat protein 1) (p45skp2)	SKP2 FBXL1	Homo sapiens (Human)	424						Q13309;	9606.ENSP00000274255;	1FQV;1FS1;1FS2;1LDK;2ASS;2AST;7B5L;7B5M;7B5R;
P0ACC7	GLMU_ECOLI	reviewed	Bifunctional protein GlmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (N-acetylglucosamine-1-phosphate uridyltransferase); Glucosamine-1-phosphate N-acetyltransferase (EC 2.3.1.157)]	glmU yieA b3730 JW3708	Escherichia coli (strain K12)	456					"MUTAGEN 14;  /note=""G->A: 8-fold decrease in uridyltransferase activity. Creates steric conflict and decreases affinity for UTP."";  /evidence=""ECO:0000269|PubMed:10428949""; MUTAGEN 18;  /note=""R->A: Dramatically impairs the uridyltransferase activity."";  /evidence=""ECO:0000269|PubMed:10428949""; MUTAGEN 25;  /note=""K->A: 8-fold decrease in uridyltransferase activity."";  /evidence=""ECO:0000269|PubMed:10428949""; MUTAGEN 296;  /note=""C->A: No effect."";  /evidence=""ECO:0000269|PubMed:9733680""; MUTAGEN 307;  /note=""C->A: 1350-fold decrease in acetyltransferase activity."";  /evidence=""ECO:0000269|PubMed:9733680""; MUTAGEN 324;  /note=""C->A: 8-fold decrease in acetyltransferase activity."";  /evidence=""ECO:0000269|PubMed:9733680""; MUTAGEN 385;  /note=""C->A: No effect."";  /evidence=""ECO:0000269|PubMed:9733680"""	P0ACC7;	511145.b3730;	1FWY;1FXJ;1HV9;2OI5;2OI6;2OI7;3TWD;4AA7;
Q15399	TLR1_HUMAN	reviewed	Toll-like receptor 1 (EC 3.2.2.6) (Toll/interleukin-1 receptor-like protein) (TIL) (CD antigen CD281)	TLR1 KIAA0012	Homo sapiens (Human)	786						Q15399;	9606.ENSP00000354932;	1FYV;2Z7X;6NIH;
O60603	TLR2_HUMAN	reviewed	Toll-like receptor 2 (EC 3.2.2.6) (Toll/interleukin-1 receptor-like protein 4) (CD antigen CD282)	TLR2 TIL4	Homo sapiens (Human)	784					"MUTAGEN 114;  /note=""N->S: Prevents addition of N-glycans. Reduces secretion of the N-terminal ectodomain."";  /evidence=""ECO:0000269|PubMed:15173186""; MUTAGEN 199;  /note=""N->D: Prevents addition of N-glycans. Reduces secretion of the N-terminal ectodomain."";  /evidence=""ECO:0000269|PubMed:15173186""; MUTAGEN 416;  /note=""T->A: Prevents addition of N-glycans. Reduces secretion of the N-terminal ectodomain."";  /evidence=""ECO:0000269|PubMed:15173186""; MUTAGEN 442;  /note=""N->D: Prevents addition of N-glycans. Prevents secretion of the N-terminal ectodomain."";  /evidence=""ECO:0000269|PubMed:15173186""; MUTAGEN 681;  /note=""P->F: Abolishes the interaction with MYD88. No effect on oligomerization or on the structure of the TIR domain."";  /evidence=""ECO:0000269|PubMed:11081518""; MUTAGEN 709;  /note=""K->R: Reduced protein stability."";  /evidence=""ECO:0000269|PubMed:27805901""; MUTAGEN 714;  /note=""K->R: Reduced protein stability."";  /evidence=""ECO:0000269|PubMed:27805901""; MUTAGEN 742..743;  /note=""KK->RR: Reduced protein stability."";  /evidence=""ECO:0000269|PubMed:27805901""; MUTAGEN 751;  /note=""K->R: Reduced protein stability."";  /evidence=""ECO:0000269|PubMed:27805901""; MUTAGEN 754;  /note=""K->R: Loss of PPP1R11-mediated ubiquitination and degradation."";  /evidence=""ECO:0000269|PubMed:27805901"""	O60603;	9606.ENSP00000260010;	1FYW;1FYX;1O77;2Z7X;2Z80;6NIG;
P41496	FABPM_SCHGR	reviewed	Fatty acid-binding protein, muscle (M-FABP)		Schistocerca gregaria (Desert locust) (Gryllus gregarius)	134								1FTP;
P35222	CTNB1_HUMAN	reviewed	Catenin beta-1 (Beta-catenin)	CTNNB1 CTNNB OK/SW-cl.35 PRO2286	Homo sapiens (Human)	781			DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:9065402}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Note=Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life.; DISEASE: Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. {ECO:0000269|PubMed:10192393, ECO:0000269|PubMed:11703283, ECO:0000269|PubMed:12027456}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:10391090}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1.; DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. {ECO:0000269|PubMed:11464291}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Neurodevelopmental disorder with spastic diplegia and visual defects (NEDSDV) [MIM:615075]: An autosomal dominant disorder characterized by global developmental delay, severe intellectual disability with absent or very limited speech, microcephaly, spasticity, and visual abnormalities. {ECO:0000269|PubMed:23033978, ECO:0000269|PubMed:25326669, ECO:0000269|PubMed:28514307}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Vitreoretinopathy, exudative 7 (EVR7) [MIM:617572]: A form of exudative vitreoretinopathy, a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. {ECO:0000269|PubMed:28575650}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 29;  /note=""S->F: No effect."";  /evidence=""ECO:0000269|PubMed:12027456""; MUTAGEN 64;  /note=""Y->F: Abolishes phosphorylation by PTK6."";  /evidence=""ECO:0000269|PubMed:20026641""; MUTAGEN 142;  /note=""Y->E: No effect on interaction with BCL9 and BCL9L."";  /evidence=""ECO:0000269|PubMed:17052462""; MUTAGEN 156;  /note=""L->A: Abolishes interaction with BCL9 but no effect on interaction with CDH3; when associated with A-159."";  /evidence=""ECO:0000269|PubMed:17052462""; MUTAGEN 159;  /note=""L->A: No effect on interaction with BCL9 and CDH3. Abolishes interaction with BCL9 but no effect on interaction with CDH3; when associated with A-156."";  /evidence=""ECO:0000269|PubMed:17052462""; MUTAGEN 178;  /note=""L->A: No effect on interaction with BCL9 and CDH3."";  /evidence=""ECO:0000269|PubMed:17052462""; MUTAGEN 253;  /note=""F->A: Abolishes or strongly reduces AXIN2 binding."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 260;  /note=""H->A: Abolishes or strongly reduces AXIN1 and AXIN2 binding. Strongly reduces phosphorylation and degradation; when associated with A-386 and A-383."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 292;  /note=""K->A: Abolishes or strongly reduces AXIN1 and AXIN2 binding."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 312;  /note=""K->E: Abolishes TCF7L2 binding."";  /evidence=""ECO:0000269|PubMed:11713475""; MUTAGEN 345;  /note=""K->A: Abolishes APC binding."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 383;  /note=""W->A: Abolishes APC binding. Strongly reduces phosphorylation and degradation; when associated with A-260 and A-386."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 386;  /note=""R->A: Strongly reduces APC binding. Strongly reduces phosphorylation and degradation; when associated with A-260 and A-383."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 426;  /note=""N->A: Abolishes TCF7L2 and LEF1 binding."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 435;  /note=""K->A: Strongly reduces or abolishes LEF1 binding."";  /evidence=""ECO:0000269|PubMed:10966653, ECO:0000269|PubMed:11713475""; MUTAGEN 435;  /note=""K->E: Abolishes TCF7L2 binding."";  /evidence=""ECO:0000269|PubMed:10966653, ECO:0000269|PubMed:11713475""; MUTAGEN 469;  /note=""R->A: Abolishes TCF7L2 binding, and strongly reduces or abolishes LEF1 binding."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 470;  /note=""H->A: Abolishes TCF7L2 binding, and strongly reduces or abolishes LEF1 binding."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 508;  /note=""K->A: Abolishes TCF7L2 and LEF1 binding."";  /evidence=""ECO:0000269|PubMed:10966653""; MUTAGEN 660;  /note=""F->A: Abolishes CTNNBIP1 binding; when associated with A-661."";  /evidence=""ECO:0000269|PubMed:12408824""; MUTAGEN 661;  /note=""R->A: Abolishes CTNNBIP1 binding; when associated with A-660."";  /evidence=""ECO:0000269|PubMed:12408824"""	P35222;	9606.ENSP00000344456;	1G3J;1JDH;1JPW;1LUJ;1P22;1QZ7;1T08;1TH1;2G57;2GL7;2Z6H;3DIW;3FQN;3FQR;3SL9;3SLA;3TX7;4DJS;6M90;6M91;6M92;6M93;6M94;6O9B;6O9C;6WLX;6WNX;7AFW;7AR4;
P39594	THIE_BACSU	reviewed	Thiamine-phosphate synthase (TP synthase) (TPS) (EC 2.5.1.3) (Thiamine-phosphate pyrophosphorylase) (TMP pyrophosphorylase) (TMP-PPase)	thiE thiC ywbK BSU38290 ipa-26d	Bacillus subtilis (strain 168)	222					"MUTAGEN 117;  /note=""S->A: 8000-fold reduction in catalytic activity."";  /evidence=""ECO:0000269|PubMed:11513588"""		224308.BSU38290;	1G4E;1G4P;1G4S;1G4T;1G67;1G69;1G6C;2TPS;3O15;3O16;
Q60357	IF6_METJA	reviewed	Translation initiation factor 6 (aIF-6)	eif6 MJ0048	Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) (Methanococcus jannaschii)	228							243232.MJ_0048;	1G61;
P05413	FABPH_HUMAN	reviewed	Fatty acid-binding protein, heart (Fatty acid-binding protein 3) (Heart-type fatty acid-binding protein) (H-FABP) (Mammary-derived growth inhibitor) (MDGI) (Muscle fatty acid-binding protein) (M-FABP)	FABP3 FABP11 MDGI	Homo sapiens (Human)	133						P05413;	9606.ENSP00000362817;	1G5W;1HMR;1HMS;1HMT;2HMB;3RSW;3WBG;3WVM;3WXQ;4TJZ;4TKB;4TKH;4TKJ;4WBK;5B27;5B28;5B29;5CE4;5HZ9;6AQ1;
Q12522	IF6_YEAST	reviewed	Eukaryotic translation initiation factor 6 (eIF-6)	TIF6 CDC95 YPR016C LPZ15C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	245						Q12522;	4932.YPR016C;	1G62;2X7N;3J2I;3JCT;4V7F;5FL8;5H4P;5JCS;5T62;5Z3G;6C0F;6ELZ;6EM1;6EM4;6EM5;6FT6;6M62;6N8J;6N8K;6N8L;6N8M;6N8N;6N8O;6QIK;6QT0;6QTZ;6R84;6R86;6R87;6RI5;6RZZ;6S05;6YLG;6YLH;6YLX;6YLY;7BT6;7BTB;
P38539	DHM1_METME	reviewed	Methanol dehydrogenase [cytochrome c] subunit 1 (EC 1.1.2.7) (MDH large subunit alpha) (MEDH)		Methylophilus methylotrophus (Bacterium W3A1)	573								1G72;2AD6;2AD7;2AD8;4AAH;
P07435	OBP_BOVIN	reviewed	Odorant-binding protein (OBP) (Olfactory mucosa pyrazine-binding protein)		Bos taurus (Bovine)	159							9913.ENSBTAP00000022593;	1G85;1GT1;1GT3;1GT4;1GT5;1HN2;1OBP;1PBO;2HLV;
Q97R46	GLMU_STRPN	reviewed	Bifunctional protein GlmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (N-acetylglucosamine-1-phosphate uridyltransferase); Glucosamine-1-phosphate N-acetyltransferase (EC 2.3.1.157)]	glmU SP_0988	Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)	459							170187.SP_0988;	1G95;1G97;1HM0;1HM8;1HM9;
P17778	YOPM_YERPE	reviewed	Outer membrane protein YopM	yopM yop48 YPCD1.26c y5054 y0059 YP_pCD60	Yersinia pestis	409						P17778;	214092.5832447;	1G9U;1JL5;
P70168	IMB1_MOUSE	reviewed	Importin subunit beta-1 (Karyopherin subunit beta-1) (Nuclear factor p97) (Pore targeting complex 97 kDa subunit) (PTAC97) (SCG)	Kpnb1 Impnb	Mus musculus (Mouse)	876						P70168;	10090.ENSMUSP00000001479;	1GCJ;1UKL;
P06213	INSR_HUMAN	reviewed	Insulin receptor (IR) (EC 2.7.10.1) (CD antigen CD220) [Cleaved into: Insulin receptor subunit alpha; Insulin receptor subunit beta]	INSR	Homo sapiens (Human)	1382			DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin resistance syndrome characterized by insulin-resistant diabetes mellitus with pineal hyperplasia and somatic abnormalities. Typical features include coarse, senile-appearing facies, dental and skin abnormalities, abdominal distension, and phallic enlargement. Inheritance is autosomal recessive. {ECO:0000269|PubMed:10443650, ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:17201797, ECO:0000269|PubMed:2121734, ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:8314008}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most severe form of insulin resistance syndrome, characterized by intrauterine and postnatal growth retardation and death in early infancy. Inheritance is autosomal recessive. {ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:12538626, ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1607067, ECO:0000269|PubMed:1730625, ECO:0000269|PubMed:22768670, ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:24498630, ECO:0000269|PubMed:2479553, ECO:0000269|PubMed:2834824, ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:7538143, ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715, ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945, ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867, ECO:0000269|PubMed:9299395, ECO:0000269|PubMed:9703342}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:1470163, ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Familial hyperinsulinemic hypoglycemia 5 (HHF5) [MIM:609968]: Familial hyperinsulinemic hypoglycemia [MIM:256450], also referred to as congenital hyperinsulinism, nesidioblastosis, or persistent hyperinsulinemic hypoglycemia of infancy (PPHI), is the most common cause of persistent hypoglycemia in infancy and is due to defective negative feedback regulation of insulin secretion by low glucose levels. {ECO:0000269|PubMed:15161766}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Insulin-resistant diabetes mellitus with acanthosis nigricans type A (IRAN type A) [MIM:610549]: Characterized by the association of severe insulin resistance (manifested by marked hyperinsulinemia and a failure to respond to exogenous insulin) with the skin lesion acanthosis nigricans and ovarian hyperandrogenism in adolescent female subjects. Women frequently present with hirsutism, acne, amenorrhea or oligomenorrhea, and virilization. This syndrome is different from the type B that has been demonstrated to be secondary to the presence of circulating autoantibodies against the insulin receptor. {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230, ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473, ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397, ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998, ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:3283938, ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049, ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389, ECO:0000269|PubMed:9175790}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 991;  /note=""L->A: Reduces interaction with IRS1 but has no effect on interaction with SHC1."";  /evidence=""ECO:0000269|PubMed:7559478""; MUTAGEN 992;  /note=""Y->A: Reduces interaction with IRS1 but has no effect on interaction with SHC1."";  /evidence=""ECO:0000269|PubMed:7559478""; MUTAGEN 996..997;  /note=""NP->AA: Abolishes interaction with IRS1. Severely disrupts, but does not abolish interaction with SHC1."";  /evidence=""ECO:0000269|PubMed:7559478""; MUTAGEN 996;  /note=""N->A: Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1."";  /evidence=""ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478""; MUTAGEN 997;  /note=""P->A: Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1."";  /evidence=""ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478""; MUTAGEN 998;  /note=""E->A: Does not affect interaction with IRS1, SHC1 or PIK3R1."";  /evidence=""ECO:0000269|PubMed:7537849""; MUTAGEN 999;  /note=""Y->E: Abolishes interaction with IRS1 and SHC1."";  /evidence=""ECO:0000269|PubMed:2842060, ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:9428692""; MUTAGEN 999;  /note=""Y->F: Has no effect on insulin-stimulated autophosphorylation, but inhibits the biological activity of the receptor. Abolishes interaction with IRS1 and almost completely prevents interaction with SHC1. Has no effect on interaction with PIK3R1. Abolishes interaction with STAT5B."";  /evidence=""ECO:0000269|PubMed:2842060, ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:9428692""; MUTAGEN 1000;  /note=""L->A,R: Severely reduces interaction with SHC1. Has no effect on interaction with IRS1."";  /evidence=""ECO:0000269|PubMed:7559478""; MUTAGEN 1002;  /note=""A->D: Reduces interaction with IRS1 but has no effect on interaction with SHC1."";  /evidence=""ECO:0000269|PubMed:7559478""; MUTAGEN 1011;  /note=""Y->A: Increases kinase activity."";  /evidence=""ECO:0000269|PubMed:12707268""; MUTAGEN 1057;  /note=""K->A: Abolishes the kinase activity and abolishes interaction with IRS1, SHC1, GRB7 and PIK3R1."";  /evidence=""ECO:0000269|PubMed:10803466, ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849""; MUTAGEN 1057;  /note=""K->M,R: Abolishes the kinase activity."";  /evidence=""ECO:0000269|PubMed:10803466, ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849""; MUTAGEN 1159;  /note=""D->N: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:11598120""; MUTAGEN 1163;  /note=""R->Q: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:11598120""; MUTAGEN 1189;  /note=""Y->F: Reduced interaction with GRB7."";  /evidence=""ECO:0000269|PubMed:10803466""; MUTAGEN 1190;  /note=""Y->F: Strongly reduced interaction with GRB7."";  /evidence=""ECO:0000269|PubMed:10803466"""	P06213;	9606.ENSP00000303830;	1GAG;1I44;1IR3;1IRK;1P14;1RQQ;2AUH;2B4S;2HR7;2MFR;2Z8C;3BU3;3BU5;3BU6;3EKK;3EKN;3ETA;3W11;3W12;3W13;4IBM;4OGA;4XLV;4XSS;4XST;4ZXB;5E1S;5HHW;5J3H;5KQV;5U1M;6HN4;6HN5;6PXV;6PXW;6SOF;6VEP;6VEQ;7BW7;7BW8;7BWA;
O73947	PCNA_PYRFU	reviewed	DNA polymerase sliding clamp (Proliferating cell nuclear antigen homolog) (PCNA)	pcn PF0983	Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1)	249					"MUTAGEN 73;  /note=""M->L: No observable effect."";  /evidence=""ECO:0000269|PubMed:11266590""; MUTAGEN 143..147;  /note=""DAVKD->AAVKA: No homotrimer formation. Stimulates ATPase activity of RFC, no stimulation of DNA synthesis by Pol I in presence and absence of RFC. Crystallizes as tail-to-tail homodimers."";  /evidence=""ECO:0000269|PubMed:12649440""; MUTAGEN 143;  /note=""D->A: Small amount of homotrimer in solution. Stimulates ATPase activity of RFC and DNA synthesis by Pol I in presence and absence of RFC. Crystallizes as tail-to-tail homodimers."";  /evidence=""ECO:0000269|PubMed:12649440"""	O73947;	186497.PF0983;	1GE8;1ISQ;1IZ4;1IZ5;3A2F;5AUJ;
P21692	MMP1_PIG	reviewed	Interstitial collagenase (EC 3.4.24.7) (Matrix metalloproteinase-1) (MMP-1) [Cleaved into: 18 kDa interstitial collagenase]	MMP1	Sus scrofa (Pig)	469							9823.ENSSSCP00000015909;	1FBL;
O93627	RBL_THEKO	reviewed	Ribulose bisphosphate carboxylase (RuBisCO) (EC 4.1.1.39)	rbcL rbc TK2290	Thermococcus kodakarensis (strain ATCC BAA-918 / JCM 12380 / KOD1) (Pyrococcus kodakaraensis (strain KOD1))	444				DISRUPTION PHENOTYPE: Cells lacking this gene show a slight decrease in growth as compared to the wild-type when they are grown in nutrient-rich medium. {ECO:0000269|PubMed:17303759}.	"MUTAGEN 63;  /note=""E->S: Decrease in activity and in thermostability. Large decrease in activity; forms dimers; when associated with S-66 and S-69."";  /evidence=""ECO:0000269|PubMed:12070156""; MUTAGEN 66;  /note=""R->S: Large decrease in activity and in thermostability. Large decrease in activity; forms dimers; when associated with S-63 and S-69."";  /evidence=""ECO:0000269|PubMed:12070156""; MUTAGEN 69;  /note=""D->S: Slight decrease in activity; no change in thermostability. Large decrease in activity; forms dimers; when associated with S-63 and S-66."";  /evidence=""ECO:0000269|PubMed:12070156"""	O93627;	69014.TK2290;	1GEH;3A12;3A13;3KDN;3KDO;3WQP;
P82980	RET5_HUMAN	reviewed	Retinol-binding protein 5 (Cellular retinol-binding protein III) (CRBP-III) (HRBPiso)	RBP5	Homo sapiens (Human)	135						P82980;	9606.ENSP00000266560;	1GGL;6E5W;
P18798	MEMB_METCA	reviewed	Methane monooxygenase component A beta chain (EC 1.14.13.25) (Methane hydroxylase)	mmoY MCA1195	Methylococcus capsulatus (strain ATCC 33009 / NCIMB 11132 / Bath)	389						P18798;	243233.MCA1195;	1FYZ;1FZ0;1FZ1;1FZ2;1FZ3;1FZ4;1FZ5;1FZ6;1FZ7;1FZ8;1FZ9;1FZH;1FZI;1MMO;1MTY;1XMF;1XMG;1XMH;1XU3;1XU5;1XVB;1XVC;1XVD;1XVE;1XVF;1XVG;4GAM;
Q8U094	TRPA_PYRFU	reviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA PF1705	Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1)	248							186497.PF1705;	1GEQ;1WDW;2DZP;2DZS;2DZT;2DZU;2DZV;2DZW;2DZX;2E09;5E0K;
P17927	CR1_HUMAN	reviewed	Complement receptor type 1 (C3b/C4b receptor) (CD antigen CD35)	CR1 C3BR	Homo sapiens (Human)	2039						P17927;	9606.ENSP00000356016;	1GKG;1GKN;1GOP;1PPQ;2MCY;2MCZ;2Q7Z;5FO9;
P10493	NID1_MOUSE	reviewed	Nidogen-1 (NID-1) (Entactin)	Nid1 Ent	Mus musculus (Mouse)	1245						P10493;	10090.ENSMUSP00000005532;	1GL4;1H4U;1NPE;
P81608	SAL_PIG	reviewed	Salivary lipocalin (SAL)	SAL1	Sus scrofa (Pig)	191							9823.ENSSSCP00000005870;	1GM6;
P16317	PRTC_DICCH	reviewed	Serralysin C (EC 3.4.24.40) (Secreted protease C) (ProC)	prtC	Dickeya chrysanthemi (Pectobacterium chrysanthemi) (Erwinia chrysanthemi)	479								1GO7;1GO8;1K7G;1K7I;1K7Q;3HB2;3HBU;3HBV;3HDA;
P0CS93	GAOA_GIBZA	reviewed	Galactose oxidase (GAO) (GO) (GOase) (EC 1.1.3.9)	GAOA	Gibberella zeae (Wheat head blight fungus) (Fusarium graminearum)	680					"MUTAGEN 269;  /note=""C->G: Reduces catalytic activity more than 10000-fold.""; MUTAGEN 331;  /note=""W->F: Reduces catalytic efficiency 50-fold and substrate affinity 36-fold.""; MUTAGEN 331;  /note=""W->G: Reduces substrate affinity 20-fold and catalytic activity more than 6000-fold.""; MUTAGEN 331;  /note=""W->H: Reduces catalytic efficiency 1000-fold.""; MUTAGEN 371;  /note=""R->A: Reduces catalytic efficiency 250-fold and substrate affinity 22-fold for D-galactose, but improves catalytic efficiency 1.8-fold towards D-fructose."";  /evidence=""ECO:0000269|PubMed:15239055""; MUTAGEN 371;  /note=""R->K: Reduces catalytic efficiency 45-fold and substrate affinity 8.7-fold for D-galactose, but improves catalytic efficiency 8-fold towards D-fructose."";  /evidence=""ECO:0000269|PubMed:15239055""; MUTAGEN 424;  /note=""C->A: Reduces catalytic efficiency 1.5- to 2-fold towards D-galactose and 1-methyl-alpha-D-galactopyranoside."";  /evidence=""ECO:0000269|PubMed:15047910""; MUTAGEN 424;  /note=""C->S: Improves catalytic efficiency 3- to 4-fold towards D-galactose and 1-methyl-alpha-D-galactopyranoside, mainly by increasing the affinity for the substrates. Improves catalytic efficiency 5.3-fold towards D-galactose; when associated with H-477. Improves catalytic efficiency 4.9-fold towards 1-methyl-alpha-D-galactopyranoside; when associated with A-535. Improves catalytic activity 4.7-fold towards D-galactose, but only 1.8-fold towards 1-methyl-alpha-D-galactopyranoside; when associated with A-477."";  /evidence=""ECO:0000269|PubMed:15047910""; MUTAGEN 477;  /note=""Y->A: No effect. Improves catalytic efficiency 2- to 3-fold towards D-galactose and 1-methyl-alpha-D-galactopyranoside; when associated with A-535. Improves catalytic activity 4.7-fold towards D-galactose, but only 1.8-fold towards 1-methyl-alpha-D-galactopyranoside; when associated with S-424."";  /evidence=""ECO:0000269|PubMed:15047910""; MUTAGEN 477;  /note=""Y->H: No effect. Improves catalytic efficiency 5.3-fold towards D-galactose; when associated with S-424."";  /evidence=""ECO:0000269|PubMed:15047910""; MUTAGEN 505;  /note=""F->A: Reduces catalytic efficiency 166-fold and substrate affinity 9-fold."";  /evidence=""ECO:0000269|PubMed:15239055""; MUTAGEN 535;  /note=""V->A: Improves catalytic efficiency 1.3- to 1.8-fold. Improves catalytic efficiency 2- to 3-fold towards D-galactose and 1-methyl-alpha-D-galactopyranoside; when associated with A-477. Improves catalytic efficiency 4.9-fold towards 1-methyl-alpha-D-galactopyranoside; when associated with S-424."";  /evidence=""ECO:0000269|PubMed:15047910""; MUTAGEN 536;  /note=""Y->F: Reduces catalytic efficiency 1000-fold, but does not reduce substrate affinity."""			1GOF;1GOG;1GOH;1K3I;1T2X;2EIB;2EIC;2EID;2EIE;2JKX;2VZ1;2VZ3;2WQ8;6XLR;6XLS;6XLT;
P83218	PME_DAUCA	reviewed	Pectinesterase (PE) (EC 3.1.1.11) (Pectin methylesterase)		Daucus carota (Wild carrot)	319								1GQ8;
Q9X0C6	HIS6_THEMA	reviewed	Imidazole glycerol phosphate synthase subunit HisF (EC 4.3.2.10) (IGP synthase cyclase subunit) (IGP synthase subunit HisF) (ImGP synthase subunit HisF) (IGPS subunit HisF)	hisF TM_1036	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	253					"MUTAGEN 9;  /note=""C->A: No change in activity."";  /evidence=""ECO:0000269|PubMed:11264293""; MUTAGEN 11;  /note=""D->X: Loss of activity."";  /evidence=""ECO:0000269|PubMed:11264293""; MUTAGEN 19;  /note=""K->S: Decrease in activity."";  /evidence=""ECO:0000269|PubMed:11264293""; MUTAGEN 51;  /note=""D->N: No change in activity."";  /evidence=""ECO:0000269|PubMed:11264293""; MUTAGEN 103;  /note=""N->A: No change in activity."";  /evidence=""ECO:0000269|PubMed:11264293""; MUTAGEN 130;  /note=""D->A,C,F,G,H,I,K,L,M,N,P,Q,R,S,T,V,W,Y: Complete loss of activity."";  /evidence=""ECO:0000269|PubMed:11264293""; MUTAGEN 130;  /note=""D->E: Weak activity."";  /evidence=""ECO:0000269|PubMed:11264293""; MUTAGEN 176;  /note=""D->N: Decrease in activity."";  /evidence=""ECO:0000269|PubMed:11264293""; MUTAGEN 183;  /note=""D->N: No change in activity."";  /evidence=""ECO:0000269|PubMed:11264293"""	Q9X0C6;	243274.THEMA_09180;	1GPW;1THF;1VH7;2A0N;2LLE;2W6R;2WJZ;3CWO;3OG3;3ZR4;4EWN;4FX7;4J9J;5TQL;6RTZ;6RU0;6VDG;6YMU;7AC8;
P00877	RBL_CHLRE	reviewed	Ribulose bisphosphate carboxylase large chain (RuBisCO large subunit) (EC 4.1.1.39)	rbcL	Chlamydomonas reinhardtii (Chlamydomonas smithii)	475							3055.DAA00950;	1GK8;1IR2;1UW9;1UWA;1UZD;1UZH;2V63;2V67;2V68;2V69;2V6A;2VDH;2VDI;5BS2;7JFO;
P06876	MYB_MOUSE	reviewed	Transcriptional activator Myb (Proto-oncogene c-Myb)	Myb	Mus musculus (Mouse)	636						P06876;	10090.ENSMUSP00000020158;	1GUU;1GV2;1GV5;1GVD;1H88;1H89;1IDY;1IDZ;1MBE;1MBF;1MBG;1MBH;1MBJ;1MBK;1MSE;1MSF;1SB0;2AGH;6DMX;6DNQ;
P06653	ALYS_STRPN	reviewed	Autolysin (EC 3.5.1.28) (Cell wall hydrolase) (Mucopeptide aminohydrolase) (Murein hydrolase) (N-acetylmuramoyl-L-alanine amidase)	lytA SP_1937	Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)	318							170187.SP_1937;	1GVM;1H8G;1HCX;2BML;4IVV;4X36;5CTV;
P24670	AROD_SALTI	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD STY1760 t1231	Salmonella typhi	252							220341.16502840;	1GQN;1L9W;1QFE;4CLM;4CNN;4CNO;4CNP;4UIO;6H5C;6H5D;6H5G;6H5J;6SFE;6SFG;
P58989	CRA1_HOMGA	reviewed	Crustacyanin-A1 subunit		Homarus gammarus (European lobster) (Homarus vulgaris)	181								1GKA;1S44;
P07359	GP1BA_HUMAN	reviewed	Platelet glycoprotein Ib alpha chain (GP-Ib alpha) (GPIb-alpha) (GPIbA) (Glycoprotein Ibalpha) (Antigen CD42b-alpha) (CD antigen CD42b) [Cleaved into: Glycocalicin]	GP1BA	Homo sapiens (Human)	652			DISEASE: Non-arteritic anterior ischemic optic neuropathy (NAION) [MIM:258660]: An ocular disease due to ischemic injury to the optic nerve. It usually affects the optic disk and leads to visual loss and optic disk swelling of a pallid nature. Visual loss is usually sudden, or over a few days at most and is usually permanent, with some recovery possibly occurring within the first weeks or months. Patients with small disks having smaller or non-existent cups have an anatomical predisposition for non-arteritic anterior ischemic optic neuropathy. As an ischemic episode evolves, the swelling compromises circulation, with a spiral of ischemia resulting in further neuronal damage. {ECO:0000269|PubMed:14711733}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; DISEASE: Bernard-Soulier syndrome (BSS) [MIM:231200]: A coagulation disorder characterized by a prolonged bleeding time, unusually large platelets, thrombocytopenia, and impaired prothrombin consumption. {ECO:0000269|PubMed:10089893, ECO:0000269|PubMed:1730088, ECO:0000269|PubMed:7690774, ECO:0000269|PubMed:7819107, ECO:0000269|PubMed:7873390, ECO:0000269|PubMed:9639514}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Bernard-Soulier syndrome A2, autosomal dominant (BSSA2) [MIM:153670]: A coagulation disorder characterized by mild to moderate bleeding tendency, thrombocytopenia, and an increased mean platelet volume. Some individuals have no symptoms. Mild bleeding tendencies manifest as epistaxis, gingival bleeding, menorrhagia, easy bruising, or prolonged bleeding after dental surgery. {ECO:0000269|PubMed:11222377}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Pseudo-von Willebrand disease (VWDP) [MIM:177820]: A bleeding disorder characterized by abnormally enhanced binding of von Willebrand factor by the platelet glycoprotein Ib (GP Ib) receptor complex. Hemostatic function is impaired due to the removal of VWF multimers from the circulation. {ECO:0000269|PubMed:14521605, ECO:0000269|PubMed:2052556, ECO:0000269|PubMed:8384898, ECO:0000269|PubMed:8486780}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 249;  /note=""G->A: No change."";  /evidence=""ECO:0000269|PubMed:14521605""; MUTAGEN 249;  /note=""G->K,D: Decreased binding to vWF."";  /evidence=""ECO:0000269|PubMed:14521605""; MUTAGEN 249;  /note=""G->S,V: Increased binding to vWF."";  /evidence=""ECO:0000269|PubMed:14521605"""	P07359;	9606.ENSP00000329380;	1GWB;1K13;1M0Z;1M10;1OOK;1P8V;1P9A;1QYY;1SQ0;1U0N;2BP3;3P72;3PMH;4C2A;4C2B;4CH2;4CH8;4MGX;4YR6;6XFQ;
Q04724	TLE1_HUMAN	reviewed	Transducin-like enhancer protein 1 (E(Sp1) homolog) (Enhancer of split groucho-like protein 1) (ESG1)	TLE1	Homo sapiens (Human)	770					"MUTAGEN 486;  /note=""V->S: Abolishes HESX1 binding."";  /evidence=""ECO:0000269|PubMed:11731482""; MUTAGEN 532;  /note=""Y->H: Abolishes HESX1 binding."";  /evidence=""ECO:0000269|PubMed:11731482""; MUTAGEN 702;  /note=""L->S: Abolishes HESX1 binding."";  /evidence=""ECO:0000269|PubMed:11731482""; MUTAGEN 715;  /note=""S->P: Abolishes HESX1 binding."";  /evidence=""ECO:0000269|PubMed:11731482"""	Q04724;	9606.ENSP00000365682;	1GXR;2CE8;2CE9;4OM2;4OM3;5MWJ;
P95470	ARBA_CELJU	reviewed	Extracellular exo-alpha-(1->5)-L-arabinofuranosidase ArbA (ABF) (EC 3.2.1.55) (Extracellular arabinan exo-alpha-(1->5)-L-arabinosidase ArbA) (Arabinosidase)	arbA	Cellvibrio japonicus (strain Ueda107) (Pseudomonas fluorescens subsp. cellulosa)	347					"MUTAGEN 35;  /note=""D->L: Very slight decrease in exo-arabinofuranosidase activity. Switch from exo to an endo mode of action."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 38;  /note=""D->A: Loss of arabinofuranosidase activity."";  /evidence=""ECO:0000269|PubMed:12198486""; MUTAGEN 38;  /note=""D->E: Strong decrease of binding affinity."";  /evidence=""ECO:0000269|PubMed:12198486""; MUTAGEN 38;  /note=""D->N: Slight decrease of binding affinity."";  /evidence=""ECO:0000269|PubMed:12198486""; MUTAGEN 55;  /note=""P->LTEER: 130-fold less active than wild-type."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 114;  /note=""F->A: Strong decrease of binding affinity."";  /evidence=""ECO:0000269|PubMed:12198486""; MUTAGEN 158;  /note=""D->A: Loss of arabinofuranosidase activity."";  /evidence=""ECO:0000269|PubMed:12198486""; MUTAGEN 158;  /note=""D->N: Loss of arabinofuranosidase activity."";  /evidence=""ECO:0000269|PubMed:12198486""; MUTAGEN 221;  /note=""E->A: Loss of arabinofuranosidase activity."";  /evidence=""ECO:0000269|PubMed:12198486""; MUTAGEN 221;  /note=""E->Q: Loss of arabinofuranosidase activity."";  /evidence=""ECO:0000269|PubMed:12198486""; MUTAGEN 316;  /note=""Q->L: Very slight decrease in arabinofuranosidase activity."";  /evidence=""ECO:0000269|PubMed:15708971"""		498211.CJA_0805;	1GYD;1GYE;1GYH;
P22892	AP1G1_MOUSE	reviewed	AP-1 complex subunit gamma-1 (Adaptor protein complex AP-1 subunit gamma-1) (Adaptor-related protein complex 1 subunit gamma-1) (Clathrin assembly protein complex 1 gamma-1 large chain) (Gamma-adaptin) (Gamma1-adaptin) (Golgi adaptor HA1/AP1 adaptin subunit gamma-1)	Ap1g1 Adtg Clapg1	Mus musculus (Mouse)	822					"MUTAGEN 753;  /note=""A->D: Strongly reduces interaction with EPS15 and SYNRG."";  /evidence=""ECO:0000269|PubMed:12176391""; MUTAGEN 762;  /note=""L->E: Strongly reduces interaction with EPS15 and SYNRG."";  /evidence=""ECO:0000269|PubMed:12176391""; MUTAGEN 765;  /note=""P->N: Reduces interaction with EPS15 and SYNRG."";  /evidence=""ECO:0000269|PubMed:12176391"""	P22892;	10090.ENSMUSP00000090844;	1GYU;1GYV;1GYW;1W63;2A7B;3ZY7;4HMY;4P6Z;6CM9;6CRI;6D83;6D84;6DFF;
Q8TG26	Q8TG26_THEAU	unreviewed	EGI (Endoglucanase) (EC 3.2.1.4)	eg1	Thermoascus aurantiacus	335								1GZJ;1H1N;
P33247	SQHC_ALIAD	reviewed	Squalene--hopene cyclase (EC 4.2.1.129) (EC 5.4.99.17) (Squalene--hopanol cyclase)	shc Aaci_2443	Alicyclobacillus acidocaldarius subsp. acidocaldarius (strain ATCC 27009 / DSM 446 / BCRC 14685 / JCM 5260 / KCTC 1825 / NBRC 15652 / NCIMB 11725 / NRRL B-14509 / 104-IA) (Bacillus acidocaldarius)	631							521098.Aaci_2443;	1GSZ;1H35;1H36;1H37;1H39;1H3A;1H3B;1H3C;1O6H;1O6Q;1O6R;1O79;1SQC;1UMP;2SQC;3SQC;
P24300	XYLA_STRRU	reviewed	Xylose isomerase (EC 5.3.1.5)	xylA	Streptomyces rubiginosus	388								1GW9;1MNZ;1O1H;1OAD;1XIB;1XIC;1XID;1XIE;1XIF;1XIG;1XIH;1XII;1XIJ;1XIS;2G4J;2GLK;2GUB;2GVE;2XIS;3CWH;3GNX;3KBJ;3KBM;3KBN;3KBS;3KBV;3KBW;3KCJ;3KCL;3KCO;3N4A;3QYS;3QZA;3U3H;3XIS;4A8I;4A8L;4A8N;4A8R;4DUO;4DVO;4E3V;4J4K;4LNC;4QDP;4QDW;4QE1;4QE4;4QE5;4QEE;4QEH;4US6;4W4Q;4XIS;4ZB0;4ZB2;4ZB5;4ZBC;5AVH;5AVN;5I7G;5VR0;5Y4I;5Y4J;5ZYC;5ZYD;5ZYE;6IRK;6KCA;6KCC;6KD2;6LL2;6OQZ;6QNC;6QND;6QNH;6QNI;6QNJ;6QRR;6QRS;6QRT;6QRU;6QRV;6QRW;6QRX;6QRY;6QUF;6QUK;6RND;6RNF;6VRS;6YBO;6YBR;7BJZ;7BVL;7BVN;7CK0;7CVK;7CVM;7E03;7NJG;8XIA;9XIA;
P09960	LKHA4_HUMAN	reviewed	Leukotriene A-4 hydrolase (LTA-4 hydrolase) (EC 3.3.2.6) (Leukotriene A(4) hydrolase) (Tripeptide aminopeptidase LTA4H) (EC 3.4.11.4)	LTA4H LTA4	Homo sapiens (Human)	611					"MUTAGEN 135;  /note=""Q->A,L: Srongly increased epoxide hydrolase activity."";  /evidence=""ECO:0000269|PubMed:11917124""; MUTAGEN 135;  /note=""Q->A: Strongly reduced aminopeptidase activity. Strongly decreased affinity for leukotriene. Abolishes epoxide hydrolase activity."";  /evidence=""ECO:0000269|PubMed:11917124""; MUTAGEN 137;  /note=""Q->A: No loss of activity."";  /evidence=""ECO:0000269|PubMed:11675384""; MUTAGEN 137;  /note=""Q->L: Aminopeptidase activity strongly impaired, but keeps LTA4 activity."";  /evidence=""ECO:0000269|PubMed:11675384""; MUTAGEN 137;  /note=""Q->N: Aminopeptidase activity almost absent, but keeps LTA4 activity."";  /evidence=""ECO:0000269|PubMed:11675384""; MUTAGEN 140;  /note=""H->Q: Aminopeptidase activity almost absent, but keeps LTA4 activity."";  /evidence=""ECO:0000269|PubMed:11917124""; MUTAGEN 269;  /note=""G->A: No loss of activity."";  /evidence=""ECO:0000269|PubMed:1881903""; MUTAGEN 270;  /note=""G->A: No loss of activity."";  /evidence=""ECO:0000269|PubMed:11675384""; MUTAGEN 271;  /note=""M->L: No loss of activity."";  /evidence=""ECO:0000269|PubMed:11675384""; MUTAGEN 272;  /note=""E->A,D: Complete loss of epoxide hydrolase activity and aminopeptidase activity."";  /evidence=""ECO:0000269|PubMed:11675384""; MUTAGEN 272;  /note=""E->Q: Loss of LTA4 hydrolase activity, and aminopeptidase activity strongly impaired."";  /evidence=""ECO:0000269|PubMed:11675384""; MUTAGEN 273;  /note=""N->A: No loss of epoxide hydrolase activity and aminopeptidase activity."";  /evidence=""ECO:0000269|PubMed:11675384""; MUTAGEN 296;  /note=""H->Y: Complete loss of LTA4 hydrolase and peptidase enzyme activities."";  /evidence=""ECO:0000269|PubMed:1881903""; MUTAGEN 297;  /note=""E->A: Loss of epoxide hydrolase and aminopeptidase activities."";  /evidence=""ECO:0000269|PubMed:1357660, ECO:0000269|PubMed:1516710, ECO:0000269|PubMed:18804029""; MUTAGEN 297;  /note=""E->K: Loss of epoxide hydrolase and aminopeptidase activities."";  /evidence=""ECO:0000269|PubMed:1357660, ECO:0000269|PubMed:1516710, ECO:0000269|PubMed:18804029""; MUTAGEN 297;  /note=""E->Q: Loss of aminopeptidase activity, but keeps LTA4 hydrolase activity."";  /evidence=""ECO:0000269|PubMed:1357660, ECO:0000269|PubMed:1516710, ECO:0000269|PubMed:18804029""; MUTAGEN 300;  /note=""H->L: Complete loss of LTA4 hydrolase and peptidase enzyme activities."";  /evidence=""ECO:0000269|PubMed:1881903""; MUTAGEN 319;  /note=""E->A: Complete loss of LTA4 hydrolase and peptidase enzyme activities."";  /evidence=""ECO:0000269|PubMed:1881903""; MUTAGEN 372;  /note=""D->N: No loss of activity."";  /evidence=""ECO:0000269|PubMed:11917124""; MUTAGEN 374;  /note=""D->N: No loss of activity."";  /evidence=""ECO:0000269|PubMed:11917124""; MUTAGEN 376;  /note=""D->A: Strongly reduced hydrolysis of peptides starting with Arg. Small effect on hydrolysis of peptides starting with Ala. Abolishes epoxide hydrolase activity."";  /evidence=""ECO:0000269|PubMed:11917124, ECO:0000269|PubMed:18804029""; MUTAGEN 376;  /note=""D->E: Strongly reduced aminopeptidase activity. Abolishes epoxide hydrolase activity."";  /evidence=""ECO:0000269|PubMed:11917124, ECO:0000269|PubMed:18804029""; MUTAGEN 376;  /note=""D->N: Abolishes aminopeptidase activity. Decreased epoxide hydrolase activity."";  /evidence=""ECO:0000269|PubMed:11917124, ECO:0000269|PubMed:18804029""; MUTAGEN 385;  /note=""E->Q: Reduced aminopeptidase activity. Minor effect on epoxide hydrolase activity."";  /evidence=""ECO:0000269|PubMed:11917124""; MUTAGEN 564;  /note=""R->A,K,M: Abolishes epoxide hydrolase activity. Reduced aminopeptidase activity."";  /evidence=""ECO:0000269|PubMed:15078870""; MUTAGEN 566;  /note=""K->A,M: Strongly reduced affinity for peptide substrates. Reduced epoxide hydrolase and aminopeptidase activity."";  /evidence=""ECO:0000269|PubMed:15078870""; MUTAGEN 566;  /note=""K->R: No effect on epoxide hydrolase and aminopeptidase activity."";  /evidence=""ECO:0000269|PubMed:15078870"""	P09960;	9606.ENSP00000228740;	1GW6;1H19;1HS6;1SQM;2R59;2VJ8;3B7R;3B7S;3B7T;3B7U;3CHO;3CHP;3CHQ;3CHR;3CHS;3FH5;3FH7;3FH8;3FHE;3FTS;3FTU;3FTV;3FTW;3FTX;3FTY;3FTZ;3FU0;3FU3;3FU5;3FU6;3FUD;3FUE;3FUF;3FUH;3FUI;3FUJ;3FUK;3FUL;3FUM;3FUN;3U9W;4DPR;4L2L;4MKT;4MS6;4R7L;4RSY;4RVB;5AEN;5BPP;5FWQ;5N3W;5NI2;5NI4;5NI6;5NIA;5NID;5NIE;6ENB;6ENC;6END;6O5H;7AUZ;7AV0;7AV1;7AV2;
P08174	DAF_HUMAN	reviewed	Complement decay-accelerating factor (CD antigen CD55)	CD55 CR DAF	Homo sapiens (Human)	381			DISEASE: Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) [MIM:226300]: An autosomal recessive disease characterized by abdominal pain and diarrhea, primary intestinal lymphangiectasia, edema due to hypoproteinemia, malabsorption, and less frequently, bowel inflammation, recurrent infections, and angiopathic thromboembolic disease. Patients' T lymphocytes show increased complement activation causing surface deposition of complement and the generation of soluble C5a. {ECO:0000269|PubMed:28657829, ECO:0000269|PubMed:28657861}. Note=The disease is caused by variants affecting the gene represented in this entry. CHAPLE is caused by biallelic mutations in the CD55 gene.			P08174;	9606.ENSP00000356030;	1H03;1H04;1H2P;1H2Q;1M11;1NWV;1OJV;1OJW;1OJY;1OK1;1OK2;1OK3;1OK9;1UOT;1UPN;2C8I;2QZD;2QZF;2QZH;3IYP;3J24;5FOA;6ILJ;6ILK;6LA5;7C9W;
Q9SE42	RPE1_ORYSJ	reviewed	Ribulose-phosphate 3-epimerase, cytoplasmic isoform (EC 5.1.3.1) (Cyt-RPEase) (Pentose-5-phosphate 3-epimerase) (PPE) (RPEcyt) (Ribulose-5-phosphate-epimerase)	Os09g0505700 LOC_Os09g32810	Oryza sativa subsp. japonica (Rice)	228							4530.OS09T0505700-02;	1H1Y;1H1Z;
P16027	DHM1_METEA	reviewed	Methanol dehydrogenase [cytochrome c] subunit 1 (EC 1.1.2.7) (MDH large subunit alpha) (MEDH)	moxF mxaF MexAM1_META1p4538	Methylorubrum extorquens (strain ATCC 14718 / DSM 1338 / JCM 2805 / NCIMB 9133 / AM1) (Methylobacterium extorquens)	626					"MUTAGEN 130;  /note=""C->S: Inactive."";  /evidence=""ECO:0000269|PubMed:11502173""; MUTAGEN 131;  /note=""C->S: Inactive."";  /evidence=""ECO:0000269|PubMed:11502173""; MUTAGEN 330;  /note=""D->E: Lower affinity for methanol."";  /evidence=""ECO:0000269|PubMed:11502173"""		272630.MexAM1_META1p4538;	1H4I;1H4J;1W6S;
Q8WTS6	SETD7_HUMAN	reviewed	Histone-lysine N-methyltransferase SETD7 (EC 2.1.1.364) (Histone H3-K4 methyltransferase SETD7) (H3-K4-HMTase SETD7) (Lysine N-methyltransferase 7) (SET domain-containing protein 7) (SET7/9)	SETD7 KIAA1717 KMT7 SET7 SET9	Homo sapiens (Human)	366					"MUTAGEN 220;  /note=""E->A: Increases near-attack conformations."";  /evidence=""ECO:0000269|PubMed:16433545""; MUTAGEN 228;  /note=""E->A: Increases near-attack conformations."";  /evidence=""ECO:0000269|PubMed:16433545""; MUTAGEN 245;  /note=""Y->A: Significantly reduces the monomethyltransferase activity but increases the dimethyltransferase activity."";  /evidence=""ECO:0000269|PubMed:12540855, ECO:0000269|PubMed:16433545""; MUTAGEN 294;  /note=""K->A: Significantly reduces the catalytic activity."";  /evidence=""ECO:0000269|PubMed:16433545""; MUTAGEN 297;  /note=""H->A,G: Abolishes methyltransferase activity."";  /evidence=""ECO:0000269|PubMed:11779497, ECO:0000269|PubMed:11850410, ECO:0000269|PubMed:15099517, ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16141209""; MUTAGEN 317;  /note=""K->A: Induces a reduction in methyltransferase activity toward TAF10 but an increased methyltransferase activity for H3 and p53/TP53."";  /evidence=""ECO:0000269|PubMed:16415881"""	Q8WTS6;	9606.ENSP00000274031;	1H3I;1MT6;1MUF;1N6A;1N6C;1O9S;1XQH;2F69;3CBM;3CBO;3CBP;3M53;3M54;3M55;3M56;3M57;3M58;3M59;3M5A;3OS5;3VUZ;3VV0;4E47;4J7F;4J7I;4J83;4J8O;4JDS;4JLG;5AYF;5EG2;5YLT;
Q9ZEY1	Q9ZEY1_LISMN	unreviewed	Class 1 internalin InlH (Internalin H) (Internalin H protein)	inlH FR217_07310	Listeria monocytogenes	548								1H6U;
Q9F5I8	CGIA_ALTMA	reviewed	Iota-carrageenase (EC 3.2.1.157)	cgiA	Alteromonas macleodii (Pseudoalteromonas macleodii)	491								1H80;1KTW;3LMW;
P09619	PGFRB_HUMAN	reviewed	Platelet-derived growth factor receptor beta (PDGF-R-beta) (PDGFR-beta) (EC 2.7.10.1) (Beta platelet-derived growth factor receptor) (Beta-type platelet-derived growth factor receptor) (CD140 antigen-like family member B) (Platelet-derived growth factor receptor 1) (PDGFR-1) (CD antigen CD140b)	PDGFRB PDGFR PDGFR1	Homo sapiens (Human)	1106			DISEASE: Note=A chromosomal aberration involving PDGFRB is found in a form of chronic myelomonocytic leukemia (CMML). Translocation t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML).; DISEASE: Myeloproliferative disorder chronic with eosinophilia (MPE) [MIM:131440]: A hematologic disorder characterized by malignant eosinophils proliferation. Note=The gene represented in this entry may be involved in disease pathogenesis. Chromosomal aberrations involving PDGFRB have been found in many instances of chronic myeloproliferative disorder with eosinophilia. Translocation t(5;12) with ETV6 on chromosome 12 creating an PDGFRB-ETV6 fusion protein (PubMed:12181402). Translocation t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 fusion protein (PubMed:15492236). Translocation t(1;5)(q23;q33) that forms a PDE4DIP-PDGFRB fusion protein (PubMed:12907457). Translocation t(5;6)(q33-34;q23) with CEP85L that fuses the 5'-end of CEP85L (isoform 4) to the 3'-end of PDGFRB (PubMed:21938754). {ECO:0000269|PubMed:12181402, ECO:0000269|PubMed:12907457, ECO:0000269|PubMed:15492236, ECO:0000269|PubMed:21938754}.; DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. Note=The gene represented in this entry may be involved in disease pathogenesis. A chromosomal aberration involving PDGFRB has been found in a patient with AML. Translocation t(5;14)(q33;q32) with TRIP11 (PubMed:9373237). {ECO:0000269|PubMed:9373237}.; DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. Note=The gene represented in this entry may be involved in disease pathogenesis. A chromosomal aberration involving PDGFRB has been found in a patient with JMML. Translocation t(5;17)(q33;p11.2) with SPECC1 (PubMed:15087372). {ECO:0000269|PubMed:15087372}.; DISEASE: Basal ganglia calcification, idiopathic, 4 (IBGC4) [MIM:615007]: A form of basal ganglia calcification, an autosomal dominant condition characterized by symmetric calcification in the basal ganglia and other brain regions. Affected individuals can either be asymptomatic or show a wide spectrum of neuropsychiatric symptoms, including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, seizures, and chronic headache. Serum levels of calcium, phosphate, alkaline phosphatase and parathyroid hormone are normal. The neuropathological hallmark of the disease is vascular and pericapillary calcification, mainly of calcium phosphate, in the affected brain areas. {ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Myofibromatosis, infantile 1 (IMF1) [MIM:228550]: A rare mesenchymal disorder characterized by the development of benign tumors in the skin, striated muscles, bones, and, more rarely, visceral organs. Subcutaneous or soft tissue nodules commonly involve the skin of the head, neck, and trunk. Skeletal and muscular lesions occur in about half of the patients. Lesions may be solitary or multicentric, and they may be present at birth or become apparent in early infancy or occasionally in adult life. Visceral lesions are associated with high morbidity and mortality. {ECO:0000269|PubMed:23731537, ECO:0000269|PubMed:23731542}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Kosaki overgrowth syndrome (KOGS) [MIM:616592]: A syndrome characterized by somatic overgrowth, distinctive facial features, hyperelastic and fragile skin, and progressive neurologic deterioration with white matter lesions on brain imaging. {ECO:0000269|PubMed:25454926}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Premature aging syndrome, Penttinen type (PENTT) [MIM:601812]: A syndrome characterized by a prematurely aged appearance with lipoatrophy, epidermal and dermal atrophy along with hypertrophic lesions that resemble scars, thin hair, proptosis, underdeveloped cheekbones, and marked acro-osteolysis. {ECO:0000269|PubMed:26279204}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 579;  /note=""Y->F: Loss of kinase activity; when associated with F-581. Strongly reduces interaction with SRC family kinases. No effect on interaction with GRB10."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:7685273""; MUTAGEN 581;  /note=""Y->F: Loss of kinase activity; when associated with F-579. No effect on interaction with GRB10."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:7685273""; MUTAGEN 634;  /note=""K->A,R: Loss of kinase activity. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity."";  /evidence=""ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825""; MUTAGEN 716;  /note=""Y->F: No effect neither on interaction with GRB10 and RASA1 nor on phosphatidylinositol 3-kinase activity."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164""; MUTAGEN 740;  /note=""Y->F: Strongly reduces up-regulation of cell proliferation; when associated with F-751. Strongly decreases phosphatidylinositol 3-kinase activity. No effect on interaction with GRB10 and RASA1."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:21679854""; MUTAGEN 751;  /note=""Y->F: Strongly reduces up-regulation of cell proliferation; when associated with F-740. Abolishes phosphatidylinositol 3-kinase activity and interaction with NCK1, and slightly reduces interaction with RASA1. No effect on interaction with GRB10."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:7692233""; MUTAGEN 763;  /note=""Y->F: No effect on interaction with RASA1 and on phosphatidylinositol 3-kinase activity."";  /evidence=""ECO:0000269|PubMed:1314164""; MUTAGEN 771;  /note=""Y->F: Loss of interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321""; MUTAGEN 775;  /note=""Y->F: No effect on interaction with RASA1 and on phosphatidylinositol 3-kinase activity."";  /evidence=""ECO:0000269|PubMed:1314164""; MUTAGEN 778;  /note=""Y->F: Strongly reduces expression levels."";  /evidence=""ECO:0000269|PubMed:1314164""; MUTAGEN 857;  /note=""Y->F: Reduces kinase activity. No effect on interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:20494825""; MUTAGEN 1009;  /note=""Y->F: No effect on interaction with GRB10. Abolishes interaction with PLCG1; when associated with F-1021."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:7691811""; MUTAGEN 1021;  /note=""Y->F: Strongly reduces up-regulation of cell proliferation. Abolishes interaction with PLCG1; when associated with F-1009. No effect on interaction with GRB10."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:17620338, ECO:0000269|PubMed:21679854"""	P09619;	9606.ENSP00000261799;	1GQ5;1H9O;1LWP;1SHA;2IUI;2L6W;2PLD;2PLE;3MJG;
P08603	CFAH_HUMAN	reviewed	Complement factor H (H factor 1)	CFH HF HF1 HF2	Homo sapiens (Human)	1231			DISEASE: Basal laminar drusen (BLD) [MIM:126700]: Drusen are extracellular deposits that accumulate below the retinal pigment epithelium on Bruch membrane. Basal laminar drusen refers to an early adult-onset drusen phenotype that shows a pattern of uniform small, slightly raised yellow subretinal nodules randomly scattered in the macula. In later stages, these drusen often become more numerous, with clustered groups of drusen scattered throughout the retina. In time these small basal laminar drusen may expand and ultimately lead to a serous pigment epithelial detachment of the macula that may result in vision loss. {ECO:0000269|PubMed:18252232}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Complement factor H deficiency (CFHD) [MIM:609814]: A disorder that can manifest as several different phenotypes, including asymptomatic, recurrent bacterial infections, and renal failure. Laboratory features usually include decreased serum levels of factor H, complement component C3, and a decrease in other terminal complement components, indicating activation of the alternative complement pathway. It is associated with a number of renal diseases with variable clinical presentation and progression, including membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome. {ECO:0000269|PubMed:10803850, ECO:0000269|PubMed:11158219, ECO:0000269|PubMed:11170895, ECO:0000269|PubMed:11170896, ECO:0000269|PubMed:12020532, ECO:0000269|PubMed:14978182, ECO:0000269|PubMed:16612335, ECO:0000269|PubMed:9312129}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Hemolytic uremic syndrome atypical 1 (AHUS1) [MIM:235400]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. {ECO:0000269|PubMed:10577907, ECO:0000269|PubMed:10762557, ECO:0000269|PubMed:11851332, ECO:0000269|PubMed:12960213, ECO:0000269|PubMed:14583443, ECO:0000269|PubMed:14978182, ECO:0000269|PubMed:20513133, ECO:0000269|PubMed:9551389}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype.; DISEASE: Macular degeneration, age-related, 4 (ARMD4) [MIM:610698]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. {ECO:0000269|PubMed:22019782}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.		"MUTAGEN 337;  /note=""H->A: About 10% loss of heparin-binding."";  /evidence=""ECO:0000269|PubMed:17893204""; MUTAGEN 341;  /note=""R->A: About 20% loss of heparin-binding."";  /evidence=""ECO:0000269|PubMed:17893204""; MUTAGEN 1182;  /note=""R->A: About 50% loss of C3b binding."";  /evidence=""ECO:0000269|PubMed:16601698""; MUTAGEN 1183;  /note=""W->L: About 40% loss of C3b binding."";  /evidence=""ECO:0000269|PubMed:16601698""; MUTAGEN 1186;  /note=""K->A: About 20% loss of C3b binding."";  /evidence=""ECO:0000269|PubMed:16601698""; MUTAGEN 1188;  /note=""K->A: About 50% loss of C3b binding."";  /evidence=""ECO:0000269|PubMed:16601698""; MUTAGEN 1198;  /note=""E->A: About 30% loss of C3b binding."";  /evidence=""ECO:0000269|PubMed:16601698"""	P08603;	9606.ENSP00000356399;	1FHC;1HAQ;1HCC;1HFH;1HFI;1KOV;2BZM;2G7I;2IC4;2JGW;2JGX;2KMS;2QFG;2QFH;2RLP;2RLQ;2UWN;2V8E;2W80;2W81;2WII;2XQW;3GAU;3GAV;3GAW;3KXV;3KZJ;3OXU;3R62;3RJ3;3SW0;4AYD;4AYE;4AYI;4AYM;4B2R;4B2S;4J38;4K12;4ONT;4ZH1;5NBQ;5O32;5O35;5WTB;6ATG;
Q9X0D7	MINC_THEMA	reviewed	Probable septum site-determining protein MinC	minC TM_1047	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	210							243274.THEMA_09125;	1HF2;
Q07181	PGLR_GIBFU	reviewed	Polygalacturonase (PG) (EC 3.2.1.15) (FmPG) (Pectinase)	PGA	Gibberella fujikuroi (Bakanae and foot rot disease fungus) (Fusarium fujikuroi)	373					"MUTAGEN 188;  /note=""H->P: Reduces activity by 98.2%. Lowers affinity for substrate 50-fold."";  /evidence=""ECO:0000269|PubMed:11687632""; MUTAGEN 191;  /note=""D->A: Loss of activity. No effect on Km for substrate."";  /evidence=""ECO:0000269|PubMed:11687632""; MUTAGEN 212..213;  /note=""DD->EE: Loss of activity. No effect on Km for substrate."";  /evidence=""ECO:0000269|PubMed:11687632""; MUTAGEN 212..213;  /note=""DD->NN: Loss of activity. No effect on Km for substrate."";  /evidence=""ECO:0000269|PubMed:11687632""; MUTAGEN 267;  /note=""R->A: Loss of activity. Lowers affinity for substrate over 10-fold."";  /evidence=""ECO:0000269|PubMed:11687632""; MUTAGEN 269;  /note=""K->E: Reduces activity by 99.87%. Lowers affinity for substrate over 10-fold."";  /evidence=""ECO:0000269|PubMed:11687632"""		5127.CCT72952;	1HG8;
P0A794	PDXJ_ECOLI	reviewed	Pyridoxine 5'-phosphate synthase (PNP synthase) (EC 2.6.99.2)	pdxJ b2564 JW2548	Escherichia coli (strain K12)	243						P0A794;	511145.b2564;	1HO1;1HO4;1IXN;1IXO;1IXP;1IXQ;1M5W;6RG0;
Q09161	NCBP1_HUMAN	reviewed	Nuclear cap-binding protein subunit 1 (80 kDa nuclear cap-binding protein) (CBP80) (NCBP 80 kDa subunit)	NCBP1 CBP80 NCBP	Homo sapiens (Human)	790					"MUTAGEN 7;  /note=""S->A: Reduced phosphorylation by RPS6KB1. Abolishes phosphorylation by RPS6KB1; when associated with 21-A-A-22."";  /evidence=""ECO:0000269|PubMed:10973943""; MUTAGEN 17..18;  /note=""KR->AA: Abolishes nuclear localization and phosphorylation by RPS6KB1."";  /evidence=""ECO:0000269|PubMed:10973943""; MUTAGEN 21..22;  /note=""TS->A: Reduced phosphorylation by RPS6KB1. Abolishes phosphorylation by RPS6KB1; when associated with A-7."";  /evidence=""ECO:0000269|PubMed:10973943"""	Q09161;	9606.ENSP00000364289;	1H2T;1H2U;1H2V;1H6K;1N52;1N54;3FEX;3FEY;5OO6;5OOB;6D0Y;7ABG;
P41807	VATH_YEAST	reviewed	V-type proton ATPase subunit H (V-ATPase subunit H) (V-ATPase 54 kDa subunit) (Vacuolar proton pump subunit H)	VMA13 CLS11 YPR036W YP3085.02	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	478						P41807;	4932.YPR036W;	1HO8;3J9T;3J9U;3J9V;5BW9;5D80;5VOX;5VOY;5VOZ;6O7V;6O7W;6O7X;
P60174	TPIS_HUMAN	reviewed	Triosephosphate isomerase (TIM) (EC 5.3.1.1) (Methylglyoxal synthase) (EC 4.2.3.3) (Triose-phosphate isomerase)	TPI1 TPI	Homo sapiens (Human)	249			DISEASE: Triosephosphate isomerase deficiency (TPID) [MIM:615512]: An autosomal recessive multisystem disorder characterized by congenital hemolytic anemia, progressive neuromuscular dysfunction, susceptibility to bacterial infection, and cardiomyopathy. {ECO:0000269|PubMed:2876430, ECO:0000269|PubMed:8503454, ECO:0000269|PubMed:8571957, ECO:0000269|PubMed:9338582, ECO:0000269|Ref.37}. Note=The disease is caused by variants affecting the gene represented in this entry.			P60174;	9606.ENSP00000229270;	1HTI;1KLG;1KLU;1WYI;2IAM;2IAN;2JK2;2VOM;4BR1;4E41;4POC;4POD;4UNK;4UNL;4ZVJ;6C2G;6D43;6NLH;6UP1;6UP5;6UP8;6UPF;
O43432	IF4G3_HUMAN	reviewed	Eukaryotic translation initiation factor 4 gamma 3 (eIF-4-gamma 3) (eIF-4G 3) (eIF4G 3) (eIF-4-gamma II) (eIF4GII)	EIF4G3	Homo sapiens (Human)	1585					"MUTAGEN 756;  /note=""R->D: Reduces binding to EIF4A; when associated with D-759 and D-764."";  /evidence=""ECO:0000269|PubMed:11172724""; MUTAGEN 759;  /note=""R->D: Reduces binding to EIF4A; when associated with D-756 and D-764."";  /evidence=""ECO:0000269|PubMed:11172724""; MUTAGEN 764;  /note=""K->D: Reduces binding to EIF4A; when associated with D-756 and D-759."";  /evidence=""ECO:0000269|PubMed:11172724""; MUTAGEN 814;  /note=""R->D: Reduces binding to EIF4A; when associated with D-820."";  /evidence=""ECO:0000269|PubMed:11172724""; MUTAGEN 820;  /note=""K->D: Reduces binding to EIF4A; when associated with D-814."";  /evidence=""ECO:0000269|PubMed:11172724""; MUTAGEN 834..835;  /note=""RK->DD: Reduces binding to IRES."";  /evidence=""ECO:0000269|PubMed:11172724"""	O43432;	9606.ENSP00000383274;	1HU3;
Q9U7C3	Q9U7C3_9TRYP	unreviewed	Peroxisome targeting signal 1 receptor PEX5		Trypanosoma brucei	655								1HXI;3CVL;3CVN;
P20058	HEMO_RABIT	reviewed	Hemopexin	HPX	Oryctolagus cuniculus (Rabbit)	460							9986.ENSOCUP00000021163;	1HXN;1QHU;1QJS;4RT6;
P15057	LYS_BPCP1	reviewed	Lysozyme (EC 3.2.1.17) (CP-1 lysin) (Endolysin) (Muramidase)	CPL1 22	Streptococcus phage Cp-1 (Bacteriophage Cp-1)	339					"MUTAGEN 10;  /note=""D->A,E,H,K,N: Almost complete loss of activity."";  /evidence=""ECO:0000269|PubMed:1390634""; MUTAGEN 37;  /note=""E->A: 95% loss of activity."";  /evidence=""ECO:0000269|PubMed:1390634""; MUTAGEN 37;  /note=""E->D: 63% loss of activity."";  /evidence=""ECO:0000269|PubMed:1390634""; MUTAGEN 37;  /note=""E->K: Almost complete loss of activity."";  /evidence=""ECO:0000269|PubMed:1390634""; MUTAGEN 37;  /note=""E->Q: 13% loss of activity."";  /evidence=""ECO:0000269|PubMed:1390634""; MUTAGEN 92;  /note=""D->A: Almost complete loss of activity."";  /evidence=""ECO:0000269|PubMed:14527392""; MUTAGEN 94;  /note=""E->A,Q: Almost complete loss of activity."";  /evidence=""ECO:0000269|PubMed:14527392""; MUTAGEN 182;  /note=""D->A: Almost complete loss of activity."";  /evidence=""ECO:0000269|PubMed:14527392"""	P15057;		1H09;1OBA;2IXU;2IXV;2J8F;2J8G;
O74213	PGLR1_ASPAC	reviewed	Endopolygalacturonase I (EC 3.2.1.15) (Pectinase 1) (Polygalacturonase I) (PG-I)	pgaI pg1 pga1	Aspergillus aculeatus	378								1IA5;1IB4;
P00942	TPIS_YEAST	reviewed	Triosephosphate isomerase (TIM) (EC 5.3.1.1) (Triose-phosphate isomerase)	TPI1 YDR050C YD9609.05C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	248						P00942;	4932.YDR050C;	1I45;1NEY;1NF0;1YPI;2YPI;3YPI;4FF7;7TIM;
Q56319	TRPC_THEMA	reviewed	Indole-3-glycerol phosphate synthase (IGPS) (EC 4.1.1.48)	trpC TM_0140	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	252							243274.THEMA_04105;	1I4N;1J5T;
Q01172	PELA_ASPNG	reviewed	Pectin lyase A (PLA) (EC 4.2.2.10) (Pectin lyase II) (PLII)	pelA	Aspergillus niger	379							5061.CADANGAP00011153;	1IDJ;1IDK;
P04629	NTRK1_HUMAN	reviewed	High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (Tropomyosin-related kinase A) (Tyrosine kinase receptor) (Tyrosine kinase receptor A) (Trk-A) (gp140trk) (p140-TrkA)	NTRK1 MTC TRK TRKA	Homo sapiens (Human)	796			DISEASE: Congenital insensitivity to pain with anhidrosis (CIPA) [MIM:256800]: Characterized by a congenital insensitivity to pain, anhidrosis (absence of sweating), absence of reaction to noxious stimuli, self-mutilating behavior, and mental retardation. This rare autosomal recessive disorder is also known as congenital sensory neuropathy with anhidrosis or hereditary sensory and autonomic neuropathy type IV or familial dysautonomia type II. {ECO:0000269|PubMed:10090906, ECO:0000269|PubMed:10233776, ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:10567924, ECO:0000269|PubMed:10861667, ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:11310631, ECO:0000269|PubMed:18077166, ECO:0000269|PubMed:22302274, ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:28177573, ECO:0000269|PubMed:28328124, ECO:0000269|PubMed:8696348}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Note=Chromosomal aberrations involving NTRK1 are found in papillary thyroid carcinomas (PTCs) (PubMed:2869410, PubMed:7565764, PubMed:1532241). Translocation t(1;3)(q21;q11) with TFG generates the TRKT3 (TRK-T3) transcript by fusing TFG to the 3'-end of NTRK1 (PubMed:7565764). A rearrangement with TPM3 generates the TRK transcript by fusing TPM3 to the 3'-end of NTRK1 (PubMed:2869410). An intrachromosomal rearrangement that links the protein kinase domain of NTRK1 to the 5'-end of the TPR gene forms the fusion protein TRK-T1. TRK-T1 is a 55 kDa protein reacting with antibodies against the C-terminus of the NTRK1 protein (PubMed:1532241). {ECO:0000269|PubMed:1532241, ECO:0000269|PubMed:2869410, ECO:0000269|PubMed:7565764}.		"MUTAGEN 496;  /note=""Y->F: Loss of interaction with SHC1 and altered phosphorylation of SHC1. Altered neurite outgrowth and altered activation of the MAPK pathway; when associated with F-791."";  /evidence=""ECO:0000269|PubMed:8155326""; MUTAGEN 540..541;  /note=""LV->AA: Abolishes interaction with GGA3."";  /evidence=""ECO:0000269|PubMed:26446845""; MUTAGEN 544;  /note=""K->A: No effect on interaction with GGA3."";  /evidence=""ECO:0000269|PubMed:26446845""; MUTAGEN 544;  /note=""K->N: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:8155326""; MUTAGEN 610..611;  /note=""LL->AA: No effect on interaction with GGA3."";  /evidence=""ECO:0000269|PubMed:26446845""; MUTAGEN 791;  /note=""Y->F: Loss of interaction with PLCG1 and altered phosphorylation of PLCG1. Altered neurite outgrowth and altered activation of the MAPK pathway; when associated with F-496."";  /evidence=""ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326"""	P04629;	9606.ENSP00000431418;	1HE7;1SHC;1WWA;1WWW;2IFG;2N90;4AOJ;4CRP;4F0I;4GT5;4PMM;4PMP;4PMS;4PMT;4YNE;4YPS;5H3Q;5I8A;5JFS;5JFV;5JFW;5JFX;5KMI;5KMJ;5KMK;5KML;5KMM;5KMN;5KMO;5KVT;5WR7;6D1Y;6D1Z;6D20;6D22;6DKB;6DKG;6DKI;6DKW;6IQN;6J5L;6NPT;6NSP;6NSS;6PL1;6PL2;6PL3;6PL4;6PMA;6PMB;6PMC;6PME;
P63104	1433Z_HUMAN	reviewed	14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1)	YWHAZ	Homo sapiens (Human)	245					"MUTAGEN 49;  /note=""K->E: Loss of interaction with NOXA1."";  /evidence=""ECO:0000269|PubMed:17913709""; MUTAGEN 56..60;  /note=""RSSWR->ASSWA: Abolishes lamellipodia formation and induces filopodia formation."";  /evidence=""ECO:0000269|PubMed:16959763""; MUTAGEN 58;  /note=""S->A: Loss of sphingosine-activated PKA phosphorylation. Promotes homodimerization and heterodimerization with YWHAE. Enhanced transcriptional activity of P53."";  /evidence=""ECO:0000269|PubMed:15883165, ECO:0000269|PubMed:16376338""; MUTAGEN 58;  /note=""S->E: Loss of homodimerization. Reduced dimerization with YWHAE. Significantly reduced interaction with P53. No enhancement of P53 transcriptional activity."";  /evidence=""ECO:0000269|PubMed:15883165, ECO:0000269|PubMed:16376338""; MUTAGEN 184;  /note=""S->A: On DNA damage, loss of MAPK8-mediated phosphorylation. Loss of binding ABL1. Attenuates ABL1-mediated apoptosis. No loss of interaction with BAX under stress conditions. Inhibits translocation of BAX to mitochondria."";  /evidence=""ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:15696159""; MUTAGEN 232;  /note=""T->A: Loss of phosphorylation by CK1."";  /evidence=""ECO:0000269|PubMed:31024343"""	P63104;	9606.ENSP00000379287;	1IB1;1QJA;1QJB;2C1J;2C1N;2O02;2WH0;3CU8;3NKX;3RDH;4BG6;4FJ3;4HKC;4IHL;4N7G;4N7Y;4N84;4WRQ;4ZDR;5D2D;5D3F;5EWZ;5EXA;5J31;5JM4;5M35;5M36;5M37;5NAS;5ULO;5WXN;5XY9;6EF5;6EJL;6EWW;6F08;6F09;6FN9;6FNA;6FNB;6FNC;6Q0K;6RLZ;6U2H;6XAG;6YMO;6YO8;6YOS;6ZFD;6ZFG;7D8H;7D8P;7D9V;
Q14671	PUM1_HUMAN	reviewed	Pumilio homolog 1 (HsPUM) (Pumilio-1)	PUM1 KIAA0099 PUMH1	Homo sapiens (Human)	1186			DISEASE: Spinocerebellar ataxia 47 (SCA47) [MIM:617931]: A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA47 is an autosomal dominant disease with a highly variable phenotype and incomplete penetrance. Clinical features include developmental disability, ataxia, and seizures. {ECO:0000269|PubMed:29474920}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 209;  /note=""S->A: Does not affect RNA-binding activity."";  /evidence=""ECO:0000269|PubMed:20818387""; MUTAGEN 714;  /note=""S->A: Decreased RNA-binding activity."";  /evidence=""ECO:0000269|PubMed:20818387""; MUTAGEN 714;  /note=""S->E: Phospho-mimic mutant; persistent RNA-binding activity in quiescent cells."";  /evidence=""ECO:0000269|PubMed:20818387""; MUTAGEN 863..867;  /note=""SRFIQ->GRFIR: B and inds cytosine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 899..903;  /note=""NYVIQ->GYVIR: Specifically binds cytosine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 935..939;  /note=""CRVIQ->GRVIR: Specifically binds cytosine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 971..975;  /note=""NHVVQ->GHVVR: Specifically binds cytosine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 1007..1011;  /note=""CRVIQ->GRVIR,ARVIR,SRVIR,TRVIR,CRVIR: Specifically binds cytosine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 1007..1011;  /note=""CRVIQ->SRVIE: Specifically binds guanine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 1007;  /note=""C->N: Specifically binds uracil-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 1043..1047;  /note=""NYVIQ->GYVIR: Specifically binds cytosine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 1043..1044;  /note=""NY->SN: Changes the specificity for RNA; when associated with E-1047."";  /evidence=""ECO:0000269|PubMed:12202039""; MUTAGEN 1047;  /note=""Q->E: Changes the specificity for RNA; when associated with 1043-SN-1044."";  /evidence=""ECO:0000269|PubMed:12202039""; MUTAGEN 1079..1083;  /note=""SNVVE->GNVVR: Specifically binds cytosine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425""; MUTAGEN 1122..1126;  /note=""NYVVQ->GYVVR: Specifically binds cytosine-nucleotide in RNA target."";  /evidence=""ECO:0000269|PubMed:21572425"""	Q14671;	9606.ENSP00000391723;	1IB2;1M8W;1M8X;1M8Y;1M8Z;2YJY;3BSB;3BSX;3Q0L;3Q0M;3Q0N;3Q0O;3Q0P;5YKH;5YKI;
Q9DEA6	Q9DEA6_CHICK	unreviewed	Tropomodulin (Fragment)	E-Tmod	Gallus gallus (Chicken)	345								1IO0;
P06820	NRAM_I67A0	reviewed	Neuraminidase (EC 3.2.1.18)		Influenza A virus (strain A/Tokyo/3/1967 H2N2)	469								1ING;1INH;1INW;1INX;1IVC;1IVD;1IVE;1IVF;1IVG;1NN2;2BAT;
Q7SI98	Q7SI98_STROI	unreviewed	Beta-xylanase (EC 3.2.1.8)		Streptomyces olivaceoviridis (Streptomyces corchorusii)	436								1ISV;1ISW;1ISX;1ISY;1ISZ;1IT0;1V6U;1V6V;1V6W;1V6X;1V6Y;1XYF;2D1Z;2D20;2D22;2D23;2D24;2G3I;2G3J;2G4F;5GQD;5GQE;
P08069	IGF1R_HUMAN	reviewed	Insulin-like growth factor 1 receptor (EC 2.7.10.1) (Insulin-like growth factor I receptor) (IGF-I receptor) (CD antigen CD221) [Cleaved into: Insulin-like growth factor 1 receptor alpha chain; Insulin-like growth factor 1 receptor beta chain]	IGF1R	Homo sapiens (Human)	1367			DISEASE: Insulin-like growth factor 1 resistance (IGF1RES) [MIM:270450]: A disorder characterized by intrauterine growth retardation, poor postnatal growth and increased plasma IGF1 levels. {ECO:0000269|PubMed:14657428, ECO:0000269|PubMed:15928254, ECO:0000269|PubMed:25040157}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 980;  /note=""Y->F: Reduces tyrosine phosphorylation. Abolishes interaction with IRS1 and SHC1. Does not abolish interaction with PIK3R1, nor with GRB10."";  /evidence=""ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:7541045""; MUTAGEN 1033;  /note=""K->A: Kinase inactive. Abolishes tyrosine phosphorylation and abolishes interaction with IRS1, SHC1 and PIK3R1."";  /evidence=""ECO:0000269|PubMed:7541045""; MUTAGEN 1280;  /note=""Y->F: No effect on GRB10-binding."";  /evidence=""ECO:0000269|PubMed:10454568""; MUTAGEN 1281;  /note=""Y->F: No effect on GRB10-binding."";  /evidence=""ECO:0000269|PubMed:10454568""; MUTAGEN 1346;  /note=""Y->F: Loss of GRB10-binding."";  /evidence=""ECO:0000269|PubMed:10454568"""	P08069;	9606.ENSP00000268035;	1IGR;1JQH;1K3A;1M7N;1P4O;2OJ9;2ZM3;3D94;3F5P;3I81;3LVP;3LW0;3NW5;3NW6;3NW7;3O23;3QQU;4D2R;4XSS;5FXQ;5FXR;5FXS;5HZN;5U8Q;5U8R;6JK8;6VWG;6VWH;6VWI;6VWJ;
P07360	CO8G_HUMAN	reviewed	Complement component C8 gamma chain	C8G	Homo sapiens (Human)	202						P07360;	9606.ENSP00000224181;	1IW2;1LF7;2OVA;2OVD;2OVE;2QOS;2RD7;3OJY;6H03;6H04;
P50086	PSD10_YEAST	reviewed	Probable 26S proteasome regulatory subunit p28 (Proteasome non-ATPase subunit 6)	NAS6 YGR232W G8564	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	228						P50086;	4932.YGR232W;	1IXV;1WG0;2DZN;2DZO;
P25963	IKBA_HUMAN	reviewed	NF-kappa-B inhibitor alpha (I-kappa-B-alpha) (IkB-alpha) (IkappaBalpha) (Major histocompatibility complex enhancer-binding protein MAD3)	NFKBIA IKBA MAD3 NFKBI	Homo sapiens (Human)	317			DISEASE: Ectodermal dysplasia and immunodeficiency 2 (EDAID2) [MIM:612132]: A form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. This form of ectodermal dysplasia is associated with decreased production of pro-inflammatory cytokines and certain interferons, rendering patients susceptible to infection. EDAID2 inheritance is autosomal dominant. {ECO:0000269|PubMed:14523047, ECO:0000269|PubMed:18412279}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 21;  /note=""K->R: Little change in Tax-stimulated transactivation. No sumoylation. Greatly reduced Tax- or cytokine-stimulated transactivation and decrease in ubiquitination and degradation; when associated with R-22."";  /evidence=""ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:7479976, ECO:0000269|PubMed:8657102""; MUTAGEN 22;  /note=""K->R: Little change in Tax-stimulated transactivation. No sumoylation. Greatly reduced Tax- or cytokine-stimulated transactivation and decrease in ubiquitination and degradation; when associated with R-21."";  /evidence=""ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:17956732, ECO:0000269|PubMed:7479976, ECO:0000269|PubMed:8657102""; MUTAGEN 31;  /note=""D->A: Loss of phosphorylation; when associated with A-35."";  /evidence=""ECO:0000269|PubMed:8657102""; MUTAGEN 32;  /note=""S->A: Loss of phosphorylation, ubiquitination and degradation; when associated with A-36."";  /evidence=""ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:8657102""; MUTAGEN 32;  /note=""S->T: Decrease in phosphorylation and degradation; when associated with T-36."";  /evidence=""ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:8657102""; MUTAGEN 35;  /note=""D->A: Loss in phosphorylation; when associated with A-31."";  /evidence=""ECO:0000269|PubMed:8657102""; MUTAGEN 35;  /note=""D->G: No change neither in phosphorylation, nor on degradation."";  /evidence=""ECO:0000269|PubMed:8657102""; MUTAGEN 36;  /note=""S->A: Loss of phosphorylation, ubiquitination, and degradation; when associated with A-32."";  /evidence=""ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:8657102""; MUTAGEN 36;  /note=""S->T: Decrease in phosphorylation and degradation; when associated with T-32."";  /evidence=""ECO:0000269|PubMed:10329681, ECO:0000269|PubMed:8657102""; MUTAGEN 38;  /note=""K->R: No change in Tax-stimulated transactivation. No change in Tax-stimulated transactivation; when associated with R-47."";  /evidence=""ECO:0000269|PubMed:7479976""; MUTAGEN 42;  /note=""Y->F: No phosphorylation."";  /evidence=""ECO:0000269|PubMed:8797825""; MUTAGEN 45..52;  /note=""MVKELQEI->AAKEAQEA: No nuclear export."";  /evidence=""ECO:0000269|PubMed:10655476""; MUTAGEN 47;  /note=""K->R: Little change in Tax-stimulated transactivation. No change in Tax-stimulated transactivation; when associated with R-38."";  /evidence=""ECO:0000269|PubMed:7479976""; MUTAGEN 115..120;  /note=""LHLAVI->AHAAVA: Greatly reduced nuclear localization. Great reduction in its ability to inhibit DNA binding of RELA."";  /evidence=""ECO:0000269|PubMed:9566872""; MUTAGEN 210;  /note=""N->A: Almost abolished ability to inhibit NF-kappa-B DNA-binding activity; when associated with A-244."";  /evidence=""ECO:0000269|PubMed:17003112""; MUTAGEN 234;  /note=""S->A: No inducible ubiquitination nor protein degradation."";  /evidence=""ECO:0000269|PubMed:8657102""; MUTAGEN 244;  /note=""N->A: Almost abolished ability to inhibit NF-kappa-B DNA-binding activity; when associated with A-210."";  /evidence=""ECO:0000269|PubMed:17003112""; MUTAGEN 262;  /note=""S->A: No inducible ubiquitination nor protein degradation."";  /evidence=""ECO:0000269|PubMed:8657102""; MUTAGEN 263;  /note=""T->A: No inducible ubiquitination nor protein degradation."";  /evidence=""ECO:0000269|PubMed:8657102"""	P25963;	9606.ENSP00000216797;	1IKN;1NFI;6TTU;6Y1J;
P18891	LECF_ALEAU	reviewed	Fucose-specific lectin (Aleuria aurantia lectin) (AAL)		Aleuria aurantia (Orange peel mushroom)	313		BIOTECHNOLOGY: AAL's binding activity could be used to identify secreted fucosylated glycoproteins that may represent candidate biomarkers for cancer since fucosylation of N-linked glycans has been associated with several types of cancer such as liver cancer (PubMed:22789673, PubMed:24027776, PubMed:27650323). Identified as one of the several suitable fluorescently labeled lectins that can be used in a combination for the visualization and quantification of extracellular glycoconjugates in dental supragingival biofilms grown for 48 hours in situ in the absence of dietary carbohydrates (PubMed:28748044). {ECO:0000269|PubMed:22789673, ECO:0000269|PubMed:24027776, ECO:0000269|PubMed:27650323, ECO:0000269|PubMed:28748044}.			"MUTAGEN 7;  /note=""Y->R: Impairs homodimerization."";  /evidence=""ECO:0000269|PubMed:20798114""; MUTAGEN 225;  /note=""N->Q: Leads to increased binding to fucosylated glycans."";  /evidence=""ECO:0000269|PubMed:21945439, ECO:0000269|PubMed:27650323""; MUTAGEN 284;  /note=""S->D: Impairs homodimerization."";  /evidence=""ECO:0000269|PubMed:20798114"""			1IUB;1IUC;1OFZ;5MXC;6GKE;
Q5SJ28	DEOC_THET8	reviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC TTHA1186	Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)	220							300852.55772568;	1J2W;1UB3;
O25927	LPXA_HELPY	reviewed	Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase (UDP-N-acetylglucosamine acyltransferase) (EC 2.3.1.129)	lpxA HP_1375	Helicobacter pylori (strain ATCC 700392 / 26695) (Campylobacter pylori)	270							85962.C694_07095;	1J2Z;
Q9WZD5	Q9WZD5_THEMA	unreviewed	Uncharacterized protein	TM_0667	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	256								1J6O;
Q7M1T4	Q7M1T4_ARTIN	unreviewed	Mannose-specific lectin KM+		Artocarpus integer (Jack fruit) (Artocarpus integrifolia)	149								1J4S;1J4T;1J4U;1VBO;1VBP;4AKD;
P18670	LECA_ARTIN	reviewed	Agglutinin alpha chain (Jacalin alpha chain)		Artocarpus integer (Jack fruit) (Artocarpus integrifolia)	133								1JAC;1KU8;1KUJ;1M26;1PXD;1TOQ;1TP8;1UGW;1UGX;1UGY;1UH0;1UH1;1WS4;1WS5;4AK4;4AKB;4AKC;4R6N;4R6O;4R6P;4R6Q;4R6R;5J4T;5J4X;5J50;5J51;5JM1;
P00909	TRPC_ECOLI	reviewed	Tryptophan biosynthesis protein TrpCF [Includes: Indole-3-glycerol phosphate synthase (IGPS) (EC 4.1.1.48); N-(5'-phospho-ribosyl)anthranilate isomerase (PRAI) (EC 5.3.1.24)]	trpC trpF b1262 JW1254	Escherichia coli (strain K12)	453						P00909;	511145.b1262;	1JCM;1PII;2KZH;
P49354	FNTA_HUMAN	reviewed	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha (EC 2.5.1.58) (EC 2.5.1.59) (CAAX farnesyltransferase subunit alpha) (FTase-alpha) (Ras proteins prenyltransferase subunit alpha) (Type I protein geranyl-geranyltransferase subunit alpha) (GGTase-I-alpha)	FNTA	Homo sapiens (Human)	379					"MUTAGEN 164;  /note=""K->N: Reduced activity."";  /evidence=""ECO:0000269|PubMed:8419339""; MUTAGEN 199;  /note=""N->K: Reduced catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:8494894"""	P49354;	9606.ENSP00000303423;	1JCQ;1LD7;1LD8;1MZC;1S63;1SA4;1TN6;2F0Y;2H6F;2H6G;2H6H;2H6I;2IEJ;3E37;
Q9H074	PAIP1_HUMAN	reviewed	Polyadenylate-binding protein-interacting protein 1 (PABP-interacting protein 1) (PAIP-1) (Poly(A)-binding protein-interacting protein 1)	PAIP1	Homo sapiens (Human)	479						Q9H074;	9606.ENSP00000302768;	1JH4;3NTW;3RK6;6YXJ;
Q8VUT0	Q8VUT0_PARDE	unreviewed	Quinohemoprotein amine dehydrogenase 60 kDa subunit		Paracoccus denitrificans	512								1JJU;1PBY;
Q8VUS7	Q8VUS7_PARDE	unreviewed	Quinohemoprotein amine dehydrogenase 40 kDa subunit		Paracoccus denitrificans	358								1JJU;1PBY;
Q8VW82	Q8VW82_PSEPU	unreviewed	Quinohemoprotein amine dehydrogenase 40 kDa subunit		Pseudomonas putida (Arthrobacter siderocapsulatus)	379								1JMX;1JMZ;
P0A6L0	DEOC_ECOLI	reviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC dra thyR b4381 JW4344	Escherichia coli (strain K12)	259					"MUTAGEN 47;  /note=""C->A,S: 3-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 102;  /note=""D->E: 44-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 102;  /note=""D->L: 2000-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 102;  /note=""D->N: 1500-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 137;  /note=""K->L: 20-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 167;  /note=""K->L: 1000-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 167;  /note=""K->R: 20-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 201;  /note=""K->L: 1500-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 201;  /note=""K->R: 1000-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300""; MUTAGEN 259;  /note=""Y->F: 200-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:11598300"""	P0A6L0;	511145.b4381;	1JCJ;1JCL;1KTN;1P1X;5EKY;5EL1;5EMU;
P38677	CMLE_NEUCR	reviewed	Carboxy-cis,cis-muconate cyclase (EC 5.5.1.5) (3-carboxy-cis,cis-muconate lactonizing enzyme) (CMLE)	NCU04071	Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987)	366								1JOF;
Q9NZ52	GGA3_HUMAN	reviewed	ADP-ribosylation factor-binding protein GGA3 (Golgi-localized, gamma ear-containing, ARF-binding protein 3)	GGA3 KIAA0154	Homo sapiens (Human)	723					"MUTAGEN 91;  /note=""N->A: No effect on regulation of BACE1 degradation."";  /evidence=""ECO:0000269|PubMed:20484053""; MUTAGEN 194;  /note=""N->A: Loss of interaction with ARF1 and Golgi localization."";  /evidence=""ECO:0000269|PubMed:11301005""; MUTAGEN 199;  /note=""S->P: Loss of interaction with ARF1 and Golgi localization."";  /evidence=""ECO:0000269|PubMed:11301005""; MUTAGEN 217;  /note=""T->P: Loss of interaction with ARF1 and Golgi localization."";  /evidence=""ECO:0000269|PubMed:11301005""; MUTAGEN 247;  /note=""L->P: Loss of UBC-binding and ubiquitination."";  /evidence=""ECO:0000269|PubMed:14660606""; MUTAGEN 258;  /note=""K->M: No effect. Confers an affinity to RABEP1 identical to GGA1; when associated with N-283."";  /evidence=""ECO:0000269|PubMed:15143060""; MUTAGEN 262;  /note=""L->S: Loss of UBC-binding and ubiquitination."";  /evidence=""ECO:0000269|PubMed:14660606""; MUTAGEN 276;  /note=""L->A: Loss of UBC-binding and ubiquitination. Abolishes binding to ubiquitin. Abolishes regulation of BACE1 degradation. No effect on interaction with NTRK1."";  /evidence=""ECO:0000269|PubMed:14660606, ECO:0000269|PubMed:15039775, ECO:0000269|PubMed:20484053, ECO:0000269|PubMed:26446845""; MUTAGEN 276;  /note=""L->S: Loss of UBC-binding and ubiquitination."";  /evidence=""ECO:0000269|PubMed:14660606, ECO:0000269|PubMed:15039775""; MUTAGEN 280;  /note=""L->R: Loss of UBC-binding and ubiquitination."";  /evidence=""ECO:0000269|PubMed:14660606""; MUTAGEN 283;  /note=""S->N: Can bind RABEP1. Confers an affinity to RABEP1 identical to GGA1; when associated with M-258."";  /evidence=""ECO:0000269|PubMed:15143060""; MUTAGEN 284;  /note=""D->G: Loss of UBC-binding and ubiquitination."";  /evidence=""ECO:0000269|PubMed:14660606""; MUTAGEN 293;  /note=""Y->H: Loss of UBC-binding and ubiquitination."";  /evidence=""ECO:0000269|PubMed:14660606""; MUTAGEN 313;  /note=""D->A: Acts as dominant negatif. Prevents proteolytic cleavage by CASP3; when associated with A-328, A-333 and A-428."";  /evidence=""ECO:0000269|PubMed:17553422""; MUTAGEN 328;  /note=""D->A: Prevents proteolytic cleavage by CASP3; when associated with A-313, A-333 and A-428."";  /evidence=""ECO:0000269|PubMed:17553422""; MUTAGEN 333;  /note=""D->A: Prevents proteolytic cleavage by CASP3; when associated with A-313, A-328 and A-428."";  /evidence=""ECO:0000269|PubMed:17553422""; MUTAGEN 391..395;  /note=""DEELL->AAAAA: Increased binding to IGF2R."";  /evidence=""ECO:0000269|PubMed:12060753""; MUTAGEN 428;  /note=""D->A: Prevents proteolytic cleavage by CASP3; when associated with A-313, A-328 and A-333."";  /evidence=""ECO:0000269|PubMed:17553422"""	Q9NZ52;	9606.ENSP00000438085;	1JPL;1JUQ;1LF8;1P4U;1WR6;1YD8;
O34508	AEEP_BACSU	reviewed	L-Ala-D/L-Glu epimerase (AE epimerase) (AEE) (EC 5.1.1.20)	ykfB BSU12980	Bacillus subtilis (strain 168)	366							224308.BSU12980;	1JPM;1TKK;
P0C1A2	PLYA_DICCH	reviewed	Pectate lyase A (EC 4.2.2.2)	pelA	Dickeya chrysanthemi (Pectobacterium chrysanthemi) (Erwinia chrysanthemi)	393								1JRG;1JTA;1OOC;1PE9;
O87916	O87916_STREX	unreviewed	Beta-lactamase inhibitory protein II	bliB	Streptomyces exfoliatus (Streptomyces hydrogenans)	311								1JTD;3QHY;3QI0;
P0A988	DPO3B_ECOLI	reviewed	Beta sliding clamp (Beta clamp) (Sliding clamp) (Beta-clamp processivity factor) (DNA polymerase III beta sliding clamp subunit)	dnaN b3701 JW3678	Escherichia coli (strain K12)	366		BIOTECHNOLOGY: Small molecules can bind to the hydrophobic cleft and inhibit binding of various protein factors, suggesting this may make and attractive antibiotic target (PubMed:18678908). {ECO:0000269|PubMed:18678908}.			"MUTAGEN 24;  /note=""R->A: Mild defect in DNA replication, impaired loading of clamp on DNA, polymerase speed is wild-type. More severe replication defect and very poor clamp loading; when associated with A-149."";  /evidence=""ECO:0000269|PubMed:18191219""; MUTAGEN 66;  /note=""G->E: In dnaN159; a temperature- and UV-sensitive mutation, displays altered DNA polymerase usage, chronically induced SOS response; when associated with A-174."";  /evidence=""ECO:0000269|PubMed:15466025""; MUTAGEN 133;  /note=""A->T: Reduction of synthesis of beta*, probably due to mutation of its promoter."";  /evidence=""ECO:0000269|PubMed:8576211""; MUTAGEN 135;  /note=""M->L: 3-fold reduction of synthesis of beta*, probably due to loss of its start codon."";  /evidence=""ECO:0000269|PubMed:8576211""; MUTAGEN 146;  /note=""M->L: No effect on synthesis of beta*."";  /evidence=""ECO:0000269|PubMed:8576211""; MUTAGEN 149;  /note=""Q->A: Mild defect in DNA replication, impaired loading of clamp on DNA, polymerase speed is wild-type. More severe replication defect and very poor clamp loading; when associated with A-24."";  /evidence=""ECO:0000269|PubMed:18191219""; MUTAGEN 153..154;  /note=""YY->SS: Very poor loading of clamp on DNA, polymerase speed is wild-type."";  /evidence=""ECO:0000269|PubMed:18191219""; MUTAGEN 174;  /note=""G->A: In dnaN159; a temperature- and UV-sensitive mutation, displays altered DNA polymerase usage, chronically induced SOS response; when associated with A-66."";  /evidence=""ECO:0000269|PubMed:15466025""; MUTAGEN 272..273;  /note=""IL->AA: Monomeric in solution, binds very tightly to subunit delta (holA). The monomer binds tightly to linear and circular DNA. Cannot bind both Pol III and IV simultaneously."";  /evidence=""ECO:0000269|PubMed:11525728, ECO:0000269|PubMed:16168375, ECO:0000269|PubMed:18191219"""	P0A988;	511145.b3701;	1JQJ;1JQL;1MMI;1OK7;1UNN;1WAI;2POL;2XUR;3BEP;3D1E;3D1F;3D1G;3F1V;3PWE;3Q4J;3Q4K;3Q4L;3QSB;4K3K;4K3L;4K3M;4K3O;4K3P;4K3Q;4K3R;4K3S;4MJP;4MJQ;4MJR;4N94;4N95;4N96;4N97;4N98;4N99;4N9A;5FKU;5FKV;5FKW;5M1S;6E8E;6FVL;
P00533	EGFR_HUMAN	reviewed	Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)	EGFR ERBB ERBB1 HER1	Homo sapiens (Human)	1210			DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16672372}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Inflammatory skin and bowel disease, neonatal, 2 (NISBD2) [MIM:616069]: A disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized. {ECO:0000269|PubMed:24691054}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 275;  /note=""Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309."";  /evidence=""ECO:0000269|PubMed:12297050""; MUTAGEN 287;  /note=""F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309."";  /evidence=""ECO:0000269|PubMed:12297050""; MUTAGEN 309;  /note=""R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287."";  /evidence=""ECO:0000269|PubMed:12297050""; MUTAGEN 429;  /note=""R->E: Abolishes autophosphorylation and activation of downstream kinases."";  /evidence=""ECO:0000269|PubMed:12297050""; MUTAGEN 525..1210;  /note=""Missing: Increased EGF binding."";  /evidence=""ECO:0000269|PubMed:19718021""; MUTAGEN 587..590;  /note=""DGPH->AGPA: Decreases intramolecular interactions and facilitates EGF binding."";  /evidence=""ECO:0000269|PubMed:12620237""; MUTAGEN 587;  /note=""D->A: Increased EGF binding; when associated with A-590 and A-609."";  /evidence=""ECO:0000269|PubMed:19718021""; MUTAGEN 590;  /note=""H->A: Increased EGF binding; when associated with A-587; A-590 and A-609."";  /evidence=""ECO:0000269|PubMed:19718021""; MUTAGEN 609;  /note=""K->A: Decreases intramolecular interactions and facilitates EGF binding. Increased EGF binding; when associated with A-587; A-590 and A-609."";  /evidence=""ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:19718021""; MUTAGEN 688;  /note=""L->A: Strongly reduced phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760""; MUTAGEN 689;  /note=""V->A: Reduced autophosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 689;  /note=""V->M: Constitutively activated kinase."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 690;  /note=""E->A: Reduced phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760""; MUTAGEN 692;  /note=""L->A,P: Strongly reduced phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760""; MUTAGEN 693;  /note=""T->A: Increased phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 693;  /note=""T->D: Strongly reduced phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 694;  /note=""P->A: Strongly reduced phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 699;  /note=""P->A: Reduced phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 700;  /note=""N->A: Abolishes phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 704;  /note=""L->A: Abolishes phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 705;  /note=""R->A: Abolishes phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 706;  /note=""I->A: Abolishes phosphorylation."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 745;  /note=""K->A,M: Abolishes kinase activity."";  /evidence=""ECO:0000269|PubMed:19560417""; MUTAGEN 974;  /note=""D->A: Strongly reduced phosphorylation.""; MUTAGEN 977;  /note=""R->A: Reduced phosphorylation."";  /evidence=""ECO:0000269|PubMed:19563760""; MUTAGEN 1005..1006;  /note=""ED->RK: Constitutively activated kinase."";  /evidence=""ECO:0000269|PubMed:19563760""; MUTAGEN 1016;  /note=""Y->F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092."";  /evidence=""ECO:0000269|PubMed:10805725""; MUTAGEN 1048..1210;  /note=""Missing: Abolishes palmitoylation."";  /evidence=""ECO:0000269|PubMed:27153536""; MUTAGEN 1049;  /note=""C->A: Decreased palmitoylation."";  /evidence=""ECO:0000269|PubMed:27153536""; MUTAGEN 1067;  /note=""Q->G: No effect on interaction with CBLC."";  /evidence=""ECO:0000269|PubMed:22888118""; MUTAGEN 1068;  /note=""R->G: Strongly decreases interaction with CBLC."";  /evidence=""ECO:0000269|PubMed:22888118""; MUTAGEN 1069;  /note=""Y->F: Abolishes interaction with CBLC."";  /evidence=""ECO:0000269|PubMed:22888118""; MUTAGEN 1092;  /note=""Y->F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016."";  /evidence=""ECO:0000269|PubMed:10805725""; MUTAGEN 1110;  /note=""Y->F: No change in interaction with PIK3C2B."";  /evidence=""ECO:0000269|PubMed:10805725""; MUTAGEN 1146;  /note=""C->A: Decreased palmitoylation."";  /evidence=""ECO:0000269|PubMed:27153536""; MUTAGEN 1172;  /note=""Y->F: No change in interaction with PIK3C2B."";  /evidence=""ECO:0000269|PubMed:10805725""; MUTAGEN 1197;  /note=""Y->F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016."";  /evidence=""ECO:0000269|PubMed:10805725"""	P00533;	9606.ENSP00000275493;	1DNQ;1DNR;1IVO;1M14;1M17;1MOX;1NQL;1XKK;1YY9;1Z9I;2EB2;2EB3;2EXP;2EXQ;2GS2;2GS6;2GS7;2ITN;2ITO;2ITP;2ITQ;2ITT;2ITU;2ITV;2ITW;2ITX;2ITY;2ITZ;2J5E;2J5F;2J6M;2JIT;2JIU;2JIV;2KS1;2M0B;2M20;2N5S;2RF9;2RFD;2RFE;2RGP;3B2U;3B2V;3BEL;3BUO;3C09;3G5V;3G5Y;3GOP;3GT8;3IKA;3LZB;3NJP;3OB2;3OP0;3P0Y;3PFV;3POZ;3QWQ;3UG1;3UG2;3VJN;3VJO;3VRP;3VRR;3W2O;3W2P;3W2Q;3W2R;3W2S;3W32;3W33;4G5J;4G5P;4HJO;4I1Z;4I20;4I21;4I22;4I23;4I24;4JQ7;4JQ8;4JR3;4JRV;4KRL;4KRM;4KRO;4KRP;4LI5;4LL0;4LQM;4LRM;4R3P;4R3R;4R5S;4RIW;4RIX;4RIY;4RJ4;4RJ5;4RJ6;4RJ7;4RJ8;4TKS;4UIP;4UV7;4WD5;4WKQ;4WRG;4ZAU;4ZJV;4ZSE;5C8K;5C8M;5C8N;5CAL;5CAN;5CAO;5CAP;5CAQ;5CAS;5CAU;5CAV;5CNN;5CNO;5CZH;5CZI;5D41;5EDP;5EDQ;5EDR;5EM5;5EM6;5EM7;5EM8;5FED;5FEE;5FEQ;5GMP;5GNK;5GTY;5GTZ;5HCX;5HCY;5HCZ;5HG5;5HG7;5HG8;5HG9;5HIB;5HIC;5J9Y;5J9Z;5JEB;5LV6;5SX4;5SX5;5U8L;5UG8;5UG9;5UGA;5UGB;5UGC;5UWD;5WB7;5WB8;5X26;5X27;5X28;5X2A;5X2C;5X2F;5X2K;5XDK;5XDL;5XGM;5XGN;5XWD;5Y25;5Y9T;5YU9;5ZTO;5ZWJ;6ARU;6B3S;6D8E;6DUK;6JRJ;6JRK;6JRX;6JWL;6JX0;6JX4;6JXT;6JZ0;6LUB;6LUD;6P1D;6P1L;6P8Q;6S89;6S8A;6S9B;6S9C;6S9D;6TFU;6TFV;6TFW;6TFY;6TFZ;6TG0;6TG1;6V5N;6V5P;6V66;6V6K;6V6O;6VH4;6VHN;6VHP;6WA2;6WAK;6WXN;6XL4;6Z4B;6Z4D;7A2A;7AEI;7AEM;
P20749	BCL3_HUMAN	reviewed	B-cell lymphoma 3 protein (BCL-3) (Proto-oncogene BCL3)	BCL3 BCL4 D19S37	Homo sapiens (Human)	454			DISEASE: Note=A chromosomal aberration involving BCL3 may be a cause of B-cell chronic lymphocytic leukemia (B-CLL). Translocation t(14;19)(q32;q13.1) with immunoglobulin gene regions. {ECO:0000269|PubMed:2180580, ECO:0000269|PubMed:7896265}.			P20749;	9606.ENSP00000164227;	1K1A;1K1B;
P17172	BP27_BPT4	reviewed	Baseplate central spike complex protein gp27 (Gene product 27) (gp27) (Hub protein 27)	27	Enterobacteria phage T4 (Bacteriophage T4)	391						P17172;		1K28;1PDJ;1WTH;2Z6B;5IV5;
P16009	NEEDL_BPT4	reviewed	Pre-baseplate central spike protein Gp5 (Pre-Gp5) (Peptidoglycan hydrolase gp5) (EC 3.2.1.17) [Cleaved into: Baseplate central spike protein Gp5* (Mature Gp5); Gp5C]	5	Enterobacteria phage T4 (Bacteriophage T4)	575					"MUTAGEN 351;  /note=""S->A,H: Reduced proteolytic cleavage of the pre-baseplate central spike protein Gp5."";  /evidence=""ECO:0000269|PubMed:15701513""; MUTAGEN 351;  /note=""S->K,Q,T,Y: Complete loss of proteolytic cleavage of the Pre-baseplate central spike protein Gp5."";  /evidence=""ECO:0000269|PubMed:15701513""; MUTAGEN 351;  /note=""S->L: Complete loss of proteolytic cleavage of the Pre-baseplate central spike protein Gp5. 90% loss of lysozyme activity."";  /evidence=""ECO:0000269|PubMed:15701513"""	P16009;		1K28;1PDL;1WTH;2Z6B;3A1M;4JIV;4JIW;4JJ2;4KU0;4OSD;5IV5;6P1Z;6P20;6P22;6P2A;6XC0;6XC1;7CN7;
P06756	ITAV_HUMAN	reviewed	Integrin alpha-V (Vitronectin receptor) (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain]	ITGAV MSK8 VNRA VTNR	Homo sapiens (Human)	1048						P06756;	9606.ENSP00000261023;	1JV2;1L5G;1M1X;1U8C;3IJE;4G1E;4G1M;4MMX;4MMY;4MMZ;4O02;4UM8;4UM9;5FFG;5FFO;5NEM;5NER;5NET;5NEU;6AVQ;6AVR;6AVU;6DJP;6MK0;6MSL;6MSU;6NAJ;6OM1;6OM2;6UJA;6UJB;6UJC;
Q60778	IKBB_MOUSE	reviewed	NF-kappa-B inhibitor beta (NF-kappa-BIB) (I-kappa-B-beta) (IkB-B) (IkB-beta) (IkappaBbeta)	Nfkbib Ikbb	Mus musculus (Mouse)	359						Q60778;	10090.ENSMUSP00000032815;	1K3Z;1OY3;
P79074	P79074_9AGAR	unreviewed	Endopolygalacturonase (EC 3.2.1.15)	cppg1	Chondrostereum purpureum	403								1K5C;1KCC;1KCD;
P41391	RNA1_SCHPO	reviewed	Ran GTPase-activating protein 1 (Protein rna1)	rna1 SPAC22E12.07	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	386						P41391;	4896.SPAC22E12.07.1;	1K5D;1K5G;1YRG;2CA6;
P10969	AGI3_WHEAT	reviewed	Agglutinin isolectin 3 (WGA3) (Fragment)		Triticum aestivum (Wheat)	186								1K7T;1K7U;1K7V;1WGT;2X52;
P96086	TRI_THEAC	reviewed	Tricorn protease (EC 3.4.21.-)	tri Ta1490	Thermoplasma acidophilum (strain ATCC 25905 / DSM 1728 / JCM 9062 / NBRC 15155 / AMRC-C165)	1071					"MUTAGEN 131..132;  /note=""RR->EE: Decreased catalytic activity towards protein substrates. Retains 10% of wild-type activity towards casein and about 30% towards oxidized insulin beta chain. However, there is no change in the activity for a tripeptide substrate."";  /evidence=""ECO:0000269|PubMed:11719810, ECO:0000269|PubMed:12470958""; MUTAGEN 184;  /note=""L->C: Both peptidolytic and proteolytic activities doubled, probably due to the increase of the diameter of the channel for product exit. Retains less than 50% of wild-type activity after modification of the thiol group by maleimide, which decreases the diameter of the exit channel and impairs product exit from the catalytic chamber."";  /evidence=""ECO:0000269|PubMed:11719810, ECO:0000269|PubMed:12470958""; MUTAGEN 414;  /note=""R->C: Retains 50% of wild-type activity after modification of the thiol group by maleimide, which decreases the diameter of the access channel and impairs substrate access to the active site. Decreased catalytic activity towards fluorogenic substrate and insulin beta chain prior to any modification or oxidation, probably due to the decrease of the diameter of the substrate access channel. Further decreased catalytic activity towards these substrates after modification with fluorescein-5-maleimide or oxidation by oxidized glutathione; when associated with C-643."";  /evidence=""ECO:0000269|PubMed:11719810, ECO:0000269|PubMed:12470958""; MUTAGEN 643;  /note=""A->C: Decreased catalytic activity towards fluorogenic substrate and insulin beta chain prior to any modification or oxidation. Further decreased catalytic activity towards these substrates after modification with fluorescein-5-maleimide or oxidation by oxidized glutathione; when associated with C-414."";  /evidence=""ECO:0000269|PubMed:12470958""; MUTAGEN 746;  /note=""H->A: Loss of catalytic activity."";  /evidence=""ECO:0000269|PubMed:11719810""; MUTAGEN 965;  /note=""S->A: Loss of catalytic activity."";  /evidence=""ECO:0000269|PubMed:11719810"""		273075.Ta1490;	1K32;1N6D;1N6E;1N6F;
P27487	DPP4_HUMAN	reviewed	Dipeptidyl peptidase 4 (EC 3.4.14.5) (ADABP) (Adenosine deaminase complexing protein 2) (ADCP-2) (Dipeptidyl peptidase IV) (DPP IV) (T-cell activation antigen CD26) (TP103) (CD antigen CD26) [Cleaved into: Dipeptidyl peptidase 4 membrane form (Dipeptidyl peptidase IV membrane form); Dipeptidyl peptidase 4 soluble form (Dipeptidyl peptidase IV soluble form)]	DPP4 ADCP2 CD26	Homo sapiens (Human)	766					"MUTAGEN 85;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 92;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 150;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 205;  /note=""E->K: Inhibits dipeptidyl peptidase activity."";  /evidence=""ECO:0000269|PubMed:10570924""; MUTAGEN 206;  /note=""E->L: Inhibits dipeptidyl peptidase activity."";  /evidence=""ECO:0000269|PubMed:10570924""; MUTAGEN 219;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 229;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 281;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 321;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 520;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 685;  /note=""N->A: Does not inhibit dipeptidyl peptidase activity, interaction with ADA and homodimer formation."";  /evidence=""ECO:0000269|PubMed:14691230""; MUTAGEN 750;  /note=""H->A: Inhibits weakly homodimerization and dipeptidyl peptidase activity."";  /evidence=""ECO:0000269|PubMed:15448155, ECO:0000269|PubMed:17287217""; MUTAGEN 750;  /note=""H->E: Inhibits strongly homodimerization, dipeptidyl peptidase activity, interaction with CARD11 and T-cell costimulation activity."";  /evidence=""ECO:0000269|PubMed:15448155, ECO:0000269|PubMed:17287217"""	P27487;	9606.ENSP00000353731;	1J2E;1N1M;1NU6;1NU8;1PFQ;1R9M;1R9N;1RWQ;1TK3;1TKR;1U8E;1W1I;1WCY;1X70;2AJL;2BGN;2BGR;2BUB;2FJP;2G5P;2G5T;2G63;2HHA;2I03;2I78;2IIT;2IIV;2JID;2OAG;2OGZ;2OLE;2ONC;2OPH;2OQI;2OQV;2P8S;2QJR;2QKY;2QOE;2QT9;2QTB;2RGU;2RIP;3BJM;3C43;3C45;3CCB;3CCC;3D4L;3EIO;3F8S;3G0B;3G0C;3G0D;3G0G;3H0C;3HAB;3HAC;3KWF;3KWJ;3NOX;3O95;3O9V;3OC0;3OPM;3Q0T;3Q8W;3QBJ;3SWW;3SX4;3VJK;3VJL;3VJM;3W2T;3WQH;4A5S;4DSA;4DSZ;4DTC;4G1F;4J3J;4JH0;4KR0;4L72;4LKO;4N8D;4N8E;4PNZ;4PV7;4QZV;5I7U;5ISM;5J3J;5KBY;5T4B;5T4E;5T4F;5T4H;5Y7H;5Y7J;5Y7K;5ZID;6B1E;6B1O;
P56220	DAPD_UNKP	reviewed	2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase (EC 2.3.1.117) (Tetrahydrodipicolinate N-succinyltransferase) (THDP succinyltransferase) (THP succinyltransferase) (Tetrahydropicolinate succinylase)	dapD	Unknown prokaryotic organism	274								1KGQ;1KGT;1TDT;2TDT;3TDT;
Q01518	CAP1_HUMAN	reviewed	Adenylyl cyclase-associated protein 1 (CAP 1)	CAP1 CAP	Homo sapiens (Human)	475						Q01518;	9606.ENSP00000361883;	1K8F;
P50870	VATD_ENTFC	reviewed	Streptogramin A acetyltransferase (EC 2.3.1.-) (Virginiamycin acetyltransferase D) (Vat(D))	vatD satA	Enterococcus faecium (Streptococcus faecium)	209					"MUTAGEN 82;  /note=""H->A: 105-fold decrease in activity."";  /evidence=""ECO:0000269|PubMed:12771141"""			1KHR;1KK4;1KK5;1KK6;1MR7;1MR9;1MRL;3DHO;
P03528	SIGM1_REOVD	reviewed	Outer capsid protein sigma-1 (Sigma1) (Cell attachment protein) (Hemagglutinin)	S1	Reovirus type 3 (strain Dearing) (T3D) (Mammalian orthoreovirus 3)	455								1KKE;2OJ5;2OJ6;3EOY;3S6X;3S6Y;3S6Z;6GAP;
P13036	FECA_ECOLI	reviewed	Fe(3+) dicitrate transport protein FecA (Iron(III) dicitrate transport protein FecA)	fecA b4291 JW4251	Escherichia coli (strain K12)	774						P13036;	511145.b4291;	1KMO;1KMP;1PNZ;1PO0;1PO3;1ZZV;2D1U;
P02468	LAMC1_MOUSE	reviewed	Laminin subunit gamma-1 (Laminin B2 chain) (Laminin-1 subunit gamma) (Laminin-10 subunit gamma) (Laminin-11 subunit gamma) (Laminin-2 subunit gamma) (Laminin-3 subunit gamma) (Laminin-4 subunit gamma) (Laminin-6 subunit gamma) (Laminin-7 subunit gamma) (Laminin-8 subunit gamma) (Laminin-9 subunit gamma) (S-laminin subunit gamma) (S-LAM gamma)	Lamc1 Lamb-2 Lamc-1	Mus musculus (Mouse)	1607						P02468;	10090.ENSMUSP00000027752;	1KLO;1NPE;1TLE;4AQT;5MC9;
P07464	THGA_ECOLI	reviewed	Galactoside O-acetyltransferase (GAT) (EC 2.3.1.18) (Acetyl-CoA:galactoside 6-O-acetyltransferase) (Thiogalactoside acetyltransferase) (Thiogalactoside transacetylase)	lacA b0342 JW0333	Escherichia coli (strain K12)	203					"MUTAGEN 115;  /note=""H->A: Results in an 1800-fold decrease in catalytic activity."";  /evidence=""ECO:0000269|PubMed:7592843"""	P07464;	511145.b0342;	1KQA;1KRR;1KRU;1KRV;
P39304	ULAD_ECOLI	reviewed	3-keto-L-gulonate-6-phosphate decarboxylase UlaD (EC 4.1.1.85) (3-dehydro-L-gulonate-6-phosphate decarboxylase) (KGPDC) (L-ascorbate utilization protein D)	ulaD sgaH yjfV b4196 JW4154	Escherichia coli (strain K12)	216					"MUTAGEN 33;  /note=""E->K: Loss of activity."";  /evidence=""ECO:0000269|PubMed:15157077""; MUTAGEN 64;  /note=""K->A: 16% of wild-type activity."";  /evidence=""ECO:0000269|PubMed:15157077""; MUTAGEN 67;  /note=""D->A: 5% of wild-type activity."";  /evidence=""ECO:0000269|PubMed:15157077""; MUTAGEN 112;  /note=""E->A: 0.5% of wild-type activity."";  /evidence=""ECO:0000269|PubMed:15157077""; MUTAGEN 136;  /note=""H->A: 5% of wild-type activity."";  /evidence=""ECO:0000269|PubMed:15157077""; MUTAGEN 139;  /note=""R->V: 17% of wild-type activity."";  /evidence=""ECO:0000269|PubMed:15157077"""	P39304;	511145.b4196;	1KV8;1KW1;1Q6L;1Q6O;1Q6Q;1Q6R;1SO3;1SO4;1SO5;1SO6;1XBV;1XBX;1XBY;1XBZ;
P17555	CAP_YEAST	reviewed	Adenylyl cyclase-associated protein (CAP)	SRV2 CAP1 YNL138W N1210 N1838	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	526						P17555;	4932.YNL138W;	1K4Z;1KQ5;
P33148	CADHF_XENLA	reviewed	EP-cadherin (C-cadherin)		Xenopus laevis (African clawed frog)	880						P33148;		1L3W;
Q50245	Q50245_METMZ	unreviewed	ORF492		Methanosarcina mazei (Methanosarcina frisia)	491								1L0Q;
Q58CQ2	ARC1B_BOVIN	reviewed	Actin-related protein 2/3 complex subunit 1B (Arp2/3 complex 41 kDa subunit) (p41-ARC)	ARPC1B	Bos taurus (Bovine)	372						Q58CQ2;	9913.ENSBTAP00000056302;	1K8K;1TYQ;1U2V;2P9I;2P9K;2P9L;2P9N;2P9P;2P9S;2P9U;3DXK;3DXM;3RSE;3UKR;3UKU;3ULE;4JD2;4XEI;4XF2;6DEC;
Q13616	CUL1_HUMAN	reviewed	Cullin-1 (CUL-1)	CUL1	Homo sapiens (Human)	776						Q13616;	9606.ENSP00000326804;	1LDJ;1LDK;1U6G;3RTR;3TDU;3TDZ;4F52;4P5O;5V89;6TTU;6WCQ;7B5L;7B5M;7B5N;7B5R;7B5S;
Q59232	Q59232_BACSP	unreviewed	Cellulase (EC 3.2.1.4)		Bacillus sp.	389								1LF1;
Q44534	Q44534_AZOVI	unreviewed	ORF 2		Azotobacter vinelandii	244								1LRV;
P55038	GLTS_SYNY3	reviewed	Ferredoxin-dependent glutamate synthase 2 (EC 1.4.7.1) (FD-GOGAT)	gltS sll1499	Synechocystis sp. (strain PCC 6803 / Kazusa)	1556						P55038;	1148.1653782;	1LLW;1LLZ;1LM1;1OFD;1OFE;
Q46455	SELB_MOOTH	reviewed	Selenocysteine-specific elongation factor (SelB translation factor)	selB	Moorella thermoacetica (Clostridium thermoaceticum)	634								1LVA;1WSU;2PLY;2UWM;2V9V;
P0A722	LPXA_ECOLI	reviewed	Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase (UDP-N-acetylglucosamine acyltransferase) (EC 2.3.1.129)	lpxA b0181 JW0176	Escherichia coli (strain K12)	262						P0A722;	511145.b0181;	1LXA;2AQ9;2JF2;2JF3;2QIA;2QIV;4J09;6HY2;6P9P;6P9Q;6P9R;6P9S;6P9T;
P04115	FIBG_PETMA	reviewed	Fibrinogen gamma chain	FGG	Petromyzon marinus (Sea lamprey)	432								1LWU;1N73;
P13466	GELA_DICDI	reviewed	Gelation factor (Actin-binding protein 120) (ABP-120)	abpC DDB_G0269100	Dictyostelium discoideum (Slime mold)	857							44689.DDB0201554;	1KSR;1QFH;1WLH;2N62;6G4A;
P21860	ERBB3_HUMAN	reviewed	Receptor tyrosine-protein kinase erbB-3 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-3) (Tyrosine kinase-type cell surface receptor HER3)	ERBB3 HER3	Homo sapiens (Human)	1342			DISEASE: Lethal congenital contracture syndrome 2 (LCCS2) [MIM:607598]: A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy, and congenital non-progressive joint contractures (arthrogryposis). The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS2 patients manifest craniofacial/ocular findings, lack of hydrops, multiple pterygia, and fractures, as well as a normal duration of pregnancy and a unique feature of a markedly distended urinary bladder (neurogenic bladder defect). The phenotype suggests a spinal cord neuropathic etiology. {ECO:0000269|PubMed:17701904}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Erythroleukemia, familial (FERLK) [MIM:133180]: An autosomal dominant myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Disease penetrance is incomplete. {ECO:0000269|PubMed:27416908}. Note=Disease susceptibility may be associated with variants affecting the gene represented in this entry.		"MUTAGEN 742;  /note=""K->M: Strongly reduced autophosphorylation."";  /evidence=""ECO:0000269|PubMed:20351256""; MUTAGEN 868;  /note=""Y->E: Strongly reduced tyrosine phosphorylation."";  /evidence=""ECO:0000269|PubMed:20351256"""	P21860;	9606.ENSP00000267101;	1M6B;2L9U;3KEX;3LMG;3P11;4LEO;4P59;4RIW;4RIX;4RIY;5CUS;5O4O;5O7P;6KBI;6OP9;7D85;
O02611	TPIS_ENTHI	reviewed	Triosephosphate isomerase (TIM) (EC 5.3.1.1) (Triose-phosphate isomerase)	TPI	Entamoeba histolytica	261							5759.rna_EHI_056480-1;	1M6J;
Q9GSA6	Q9GSA6_CHOFU	unreviewed	Antifreeze protein isoform 501		Choristoneura fumiferana (Spruce budworm moth) (Archips fumiferana)	138								1M8N;1Z2F;
Q07412	TPIS_PLAFA	reviewed	Triosephosphate isomerase (TIM) (EC 5.3.1.1) (Triose-phosphate isomerase)	TPI	Plasmodium falciparum	248								1LYX;1LZO;1M7O;1M7P;1O5X;1VGA;1WOA;1WOB;1YDV;2FI6;2VFD;2VFE;2VFF;2VFG;2VFH;2VFI;3PSV;3PSW;3PVF;3PWA;3PY2;4YWI;4YXG;4Z0J;4Z0S;4ZZ9;5BMW;5BMX;5BNK;5BRB;5GV4;5GZP;
P23006	DHMH_PARVE	reviewed	Methylamine dehydrogenase heavy chain (MADH) (EC 1.4.9.1) (Methylamine dehydrogenase (amicyanin))	mauB madA	Paracoccus versutus (Thiobacillus versutus)	426							34007.IT40_03135;	1MAE;1MAF;2MAD;3C75;
P04626	ERBB2_HUMAN	reviewed	Receptor tyrosine-protein kinase erbB-2 (EC 2.7.10.1) (Metastatic lymph node gene 19 protein) (MLN 19) (Proto-oncogene Neu) (Proto-oncogene c-ErbB-2) (Tyrosine kinase-type cell surface receptor HER2) (p185erbB2) (CD antigen CD340)	ERBB2 HER2 MLN19 NEU NGL	Homo sapiens (Human)	1255			DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15457249}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:15457249, ECO:0000269|PubMed:17344846}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:15457249}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. {ECO:0000269|PubMed:15457249, ECO:0000269|PubMed:17344846}. Note=The protein represented in this entry is involved in disease pathogenesis.; DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2. {ECO:0000269|PubMed:21097718}.		"MUTAGEN 317..318;  /note=""LH->AA: Reduces dimerization with ERBB3."";  /evidence=""ECO:0000269|PubMed:15093539""; MUTAGEN 611;  /note=""M->A: Prevents synthesis of isoform 2."";  /evidence=""ECO:0000269|PubMed:16794579""; MUTAGEN 687;  /note=""M->A: Prevents synthesis of isoform 3."";  /evidence=""ECO:0000269|PubMed:16794579""; MUTAGEN 706;  /note=""M->A: No effect on isoform production."";  /evidence=""ECO:0000269|PubMed:16794579""; MUTAGEN 712;  /note=""M->A: No effect on isoform production."";  /evidence=""ECO:0000269|PubMed:16794579"""	P04626;	9606.ENSP00000269571;	1MFG;1MFL;1MW4;1N8Z;1OVC;1QR1;1S78;2A91;2JWA;2KS1;2L4K;2N2A;3BE1;3H3B;3MZW;3N85;3PP0;3RCD;3WLW;3WSQ;4GFU;4HRL;4HRM;4HRN;5K33;5KWG;5MY6;5O4G;5OB4;5TQS;6ATT;6BGT;6J71;6LBX;6OGE;
Q10657	TPIS_CAEEL	reviewed	Triosephosphate isomerase (TIM) (EC 5.3.1.1) (Methylglyoxal synthase) (EC 4.2.3.3) (Triose-phosphate isomerase)	tpi-1 Y17G7B.7	Caenorhabditis elegans	247							6239.Y17G7B.7;	1MO0;
P00885	ALKD_PSEPU	reviewed	2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14) (KDPG-aldolase) (Phospho-2-dehydro-3-deoxygluconate aldolase) (Phospho-2-keto-3-deoxygluconate aldolase)	eda	Pseudomonas putida (Arthrobacter siderocapsulatus)	226							1240350.AMZE01000025_gene1661;	1MXS;
P29894	DHMH_PARDE	reviewed	Methylamine dehydrogenase heavy chain (MADH) (EC 1.4.9.1) (Methylamine dehydrogenase (amicyanin))	mauB	Paracoccus denitrificans	417						P29894;		1MG2;1MG3;2BBK;2GC4;2GC7;2J55;2J56;2J57;2MTA;
O66540	DEOC_AQUAE	reviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC aq_148	Aquifex aeolicus (strain VF5)	219							224324.aq_148;	1MZH;
P08133	ANXA6_HUMAN	reviewed	Annexin A6 (67 kDa calelectrin) (Annexin VI) (Annexin-6) (Calphobindin-II) (CPB-II) (Chromobindin-20) (Lipocortin VI) (Protein III) (p68) (p70)	ANXA6 ANX6	Homo sapiens (Human)	673						P08133;	9606.ENSP00000346550;	1M9I;
Q46857	DKGA_ECOLI	reviewed	2,5-diketo-D-gluconic acid reductase A (2,5-DKG reductase A) (2,5-DKGR A) (25DKGR-A) (EC 1.1.1.274) (AKR5C)	dkgA yqhE b3012 JW5499	Escherichia coli (strain K12)	275							511145.b3012;	1MZR;
P62775	MTPN_RAT	reviewed	Myotrophin (Granule cell differentiation protein) (Protein V-1)	Mtpn Gcdp	Rattus norvegicus (Rat)	118					"MUTAGEN 33;  /note=""E->A: Reduced interaction with RELA. Reduced translocation to the nucleus. Reduced activation of NF-kappa-B transcription factor activity."";  /evidence=""ECO:0000269|PubMed:18693253"""	P62775;	10116.ENSRNOP00000015808;	1MYO;2MYO;
P16157	ANK1_HUMAN	reviewed	Ankyrin-1 (ANK-1) (Ankyrin-R) (Erythrocyte ankyrin)	ANK1 ANK	Homo sapiens (Human)	1881			DISEASE: Spherocytosis 1 (SPH1) [MIM:182900]: A form of spherocytosis, a hematologic disorder leading to chronic hemolytic anemia and characterized by numerous abnormally shaped erythrocytes which are generally spheroidal. SPH1 is characterized by severe hemolytic anemia. Inheritance can be autosomal dominant or autosomal recessive. Patients with homozygous mutations have a more severe disorder. {ECO:0000269|PubMed:11102985, ECO:0000269|PubMed:8640229}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 1824;  /note=""T->P: Abolishes interaction with OBSCN (in isoform Mu17)."";  /evidence=""ECO:0000269|PubMed:12527750""; MUTAGEN 1826;  /note=""K->E: Abolishes interaction with OBSCN (in isoform Mu17)."";  /evidence=""ECO:0000269|PubMed:12527750""; MUTAGEN 1829;  /note=""R->G: Abolishes interaction with OBSCN (in isoform Mu17)."";  /evidence=""ECO:0000269|PubMed:12527750""; MUTAGEN 1830;  /note=""K->E: Abolishes interaction with OBSCN (in isoform Mu17)."";  /evidence=""ECO:0000269|PubMed:12527750"""	P16157;	9606.ENSP00000265709;	1N11;2YQF;2YVI;3F59;3KBT;3KBU;3UD1;3UD2;
Q9Y948	DEOC_AERPE	reviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC APE_2437.1	Aeropyrum pernix (strain ATCC 700893 / DSM 11879 / JCM 9820 / NBRC 100138 / K1)	235		BIOTECHNOLOGY: Its high stability makes the enzyme a potential candidate to be used as a synthetic catalyst in practical application. {ECO:0000269|PubMed:12529358}.					272557.APE_2437.1;	1N7K;
P27378	P2_BPPRD	reviewed	Adsorption protein P2 (Protein P2)	II	Enterobacteria phage PRD1 (Bacteriophage PRD1)	591								1N7U;1N7V;
P20702	ITAX_HUMAN	reviewed	Integrin alpha-X (CD11 antigen-like family member C) (Leu M5) (Leukocyte adhesion glycoprotein p150,95 alpha chain) (Leukocyte adhesion receptor p150,95) (CD antigen CD11c)	ITGAX CD11C	Homo sapiens (Human)	1163						P20702;	9606.ENSP00000454623;	1N3Y;2LUV;3K6S;3K71;3K72;4NEH;4NEN;5ES4;
P32523	PRP19_YEAST	reviewed	Pre-mRNA-processing factor 19 (EC 2.3.2.27) (RING-type E3 ubiquitin transferase PRP19)	PRP19 PSO4 YLL036C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	503						P32523;	4932.YLL036C;	1N87;2BAY;3LRV;4ZB4;5GM6;5GMK;5LJ5;5M8C;5MQ0;5WSG;5Y88;5YLZ;6BK8;6EXN;6J6G;6J6H;6J6N;6J6Q;
P78055	FSAA_ECOLI	reviewed	Fructose-6-phosphate aldolase 1 (EC 4.1.2.-) (Fructose-6-phosphate aldolase A) (FSAA)	fsaA fsa mipB ybiZ b0825 JW5109	Escherichia coli (strain K12)	220		BIOTECHNOLOGY: Is an interesting tool in chemoenzymatic synthesis for the construction of chiral complex polyhydroxylated sugar-type structures. The use of hydroxyacetone (acetol) as a donor compound allows access to various 1-deoxysugars. Can also be used for the synthesis of a broad range of iminocyclitols, that are potent glycosidase and glycosyltransferase inhibitors, from dihydroxyacetone, hydroxyacetone or 1-hydroxy-butan-2-one as donor substrate, and a range of acceptor substrates. {ECO:0000269|PubMed:17985886, ECO:0000269|PubMed:19554584, ECO:0000269|Ref.6}.			"MUTAGEN 85;  /note=""K->R: Loss of activity."";  /evidence=""ECO:0000269|PubMed:11120740"""	P78055;	511145.b0825;	1L6W;4RXF;4RXG;4RZ4;4S1F;5ZOL;
P07834	CDC4_YEAST	reviewed	Cell division control protein 4 (E3 ubiquitin ligase complex SCF subunit CDC4) (F-box protein CDC4)	CDC4 YFL009W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	779					"MUTAGEN 82;  /note=""K->A: Prevents nuclear localization; when associated with A-83 and A-85.""; MUTAGEN 83;  /note=""R->A: Prevents nuclear localization; when associated with A-82 and A-85.""; MUTAGEN 83;  /note=""R->G: Prevents nuclear localization.""; MUTAGEN 85;  /note=""K->A: Prevents nuclear localization; when associated with A-82 and A-83."";  /evidence=""ECO:0000269|PubMed:11080155"""	P07834;	4932.YFL009W;	1NEX;2P63;3MKS;3V7D;
P26213	PGLR1_ASPNG	reviewed	Endopolygalacturonase I (EC 3.2.1.15) (Pectinase 1) (Polygalacturonase I) (PG-I)	pgaI pg1 pga1	Aspergillus niger	368							5061.CADANGAP00001113;	1NHC;
P06129	BTUB_ECOLI	reviewed	Vitamin B12 transporter BtuB (Cobalamin receptor) (Outer membrane cobalamin translocator)	btuB bfe cer dcrC b3966 JW3938	Escherichia coli (strain K12)	614					"MUTAGEN 28;  /note=""L->P: Inactivates uptake."";  /evidence=""ECO:0000269|PubMed:11705387""; MUTAGEN 30;  /note=""V->G,P: Inactivates uptake."";  /evidence=""ECO:0000269|PubMed:11705387"""	P06129;	511145.b3966;	1NQE;1NQF;1NQG;1NQH;1UJW;2GSK;2GUF;2YSU;3M8B;3M8D;3RGM;3RGN;
P51016	HOA_PSEUF	reviewed	4-hydroxy-2-oxovalerate aldolase (HOA) (EC 4.1.3.39) (4-hydroxy-2-keto-pentanoic acid aldolase) (4-hydroxy-2-oxopentanoate aldolase)	dmpG	Pseudomonas sp. (strain CF600)	345						P51016;		1NVM;
Q11176	WDR1_CAEEL	reviewed	Actin-interacting protein 1 (AIP1) (Uncoordinated protein 78)	unc-78 C04F6.4	Caenorhabditis elegans	611							6239.C04F6.4a.1;	1NR0;1PEV;
Q9Y3D6	FIS1_HUMAN	reviewed	Mitochondrial fission 1 protein (FIS1 homolog) (hFis1) (Tetratricopeptide repeat protein 11) (TPR repeat protein 11)	FIS1 TTC11 CGI-135	Homo sapiens (Human)	152					"MUTAGEN 14;  /note=""L->P: Approximately 40% of cells display fragmented mitochondria."";  /evidence=""ECO:0000269|PubMed:16118244""; MUTAGEN 42;  /note=""L->P: Less than 15% of cells display fragmented mitochondria."";  /evidence=""ECO:0000269|PubMed:16118244""; MUTAGEN 58;  /note=""L->P: Less than 15% of cells display fragmented mitochondria."";  /evidence=""ECO:0000269|PubMed:16118244""; MUTAGEN 77;  /note=""L->P: Less than 15% of cells display fragmented mitochondria. Shows greatly reduced binding to DNM1L."";  /evidence=""ECO:0000269|PubMed:16118244""; MUTAGEN 91;  /note=""L->P: Less than 15% of cells display fragmented mitochondria. Shows greatly reduced binding to DNM1L."";  /evidence=""ECO:0000269|PubMed:16118244""; MUTAGEN 110;  /note=""L->P: Approximately 40% of cells display fragmented mitochondria. No change in binding to DNM1L."";  /evidence=""ECO:0000269|PubMed:16118244""; MUTAGEN 149;  /note=""K->A: Protein localizes to both mitochondrion and endoplasmic reticulum. Protein localizes to endoplasmic reticulum only; when associated with A-151."";  /evidence=""ECO:0000269|PubMed:14996942""; MUTAGEN 151;  /note=""K->A: Protein localizes to both mitochondrion and endoplasmic reticulum. Protein localizes to endoplasmic reticulum only; when associated with A-149."";  /evidence=""ECO:0000269|PubMed:14996942"""	Q9Y3D6;	9606.ENSP00000223136;	1NZN;1PC2;
Q63135	CR1L_RAT	reviewed	Complement component receptor 1-like protein (Antigen 5I2) (Complement regulatory protein Crry)	Cr1l Crry	Rattus norvegicus (Rat)	559							10116.ENSRNOP00000010798;	1NTJ;2XRB;2XRD;
Q02790	FKBP4_HUMAN	reviewed	Peptidyl-prolyl cis-trans isomerase FKBP4 (PPIase FKBP4) (EC 5.2.1.8) (51 kDa FK506-binding protein) (FKBP51) (52 kDa FK506-binding protein) (52 kDa FKBP) (FKBP-52) (59 kDa immunophilin) (p59) (FK506-binding protein 4) (FKBP-4) (FKBP59) (HSP-binding immunophilin) (HBI) (Immunophilin FKBP52) (Rotamase) [Cleaved into: Peptidyl-prolyl cis-trans isomerase FKBP4, N-terminally processed]	FKBP4 FKBP52	Homo sapiens (Human)	459					"MUTAGEN 67..68;  /note=""FD->DV: Decreased catalytic activity toward TRPC1."";  /evidence=""ECO:0000269|PubMed:19945390"""	Q02790;	9606.ENSP00000001008;	1N1A;1P5Q;1Q1C;1QZ2;4DRJ;4LAV;4LAW;4LAX;4LAY;4TW8;6RCY;
Q9X1K9	DAPA_THEMA	reviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA TM_1521	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	294					"MUTAGEN 166..168;  /note=""DID->AAA: Exists as a monomer in solution. Decreased activity and substrate affinity. Reduced thermal stability."";  /evidence=""ECO:0000269|PubMed:21803176"""		243274.THEMA_06695;	1O5K;3PB0;3PB2;
P77791	MAA_ECOLI	reviewed	Maltose O-acetyltransferase (MAT) (EC 2.3.1.79) (Maltose transacetylase)	maa ylaD b0459 JW0448	Escherichia coli (strain K12)	183						P77791;	511145.b0459;	1OCX;6AG8;
P0DJM0	INLA_LISMO	reviewed	Internalin A	inlA lmo0433	Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e)	800				DISRUPTION PHENOTYPE: Deletion of both inlA and inlB prevents bacterial uptake by human enterocyte-like cell line Caco-2 (PubMed:1905979). Deletion of inlA alone decreases host cell entry; the reduction varies from 98% to none depending on the cell line tested (PubMed:11929538, PubMed:8601315, PubMed:10406800). {ECO:0000269|PubMed:10406800, ECO:0000269|PubMed:11929538, ECO:0000269|PubMed:1905979, ECO:0000269|PubMed:8601315}.	"MUTAGEN 150;  /note=""F->A: No longer binds human cadherin-1 (CDH1) domain 1."";  /evidence=""ECO:0000269|PubMed:12526809""; MUTAGEN 192;  /note=""S->N: 40-fold increased affinity for human CDH1 domain 1. 6700-fold increased affinity for CDH1, better adhesion to human Caco cells, 1000-fold more virulent in mice; when associated with S-369."";  /evidence=""ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:17715295""; MUTAGEN 194;  /note=""G->SS: Increased affinity for human CDH1 domain 1."";  /evidence=""ECO:0000269|PubMed:17715295""; MUTAGEN 343;  /note=""Y->A: No longer binds human CDH1 domain 1."";  /evidence=""ECO:0000269|PubMed:12526809""; MUTAGEN 347;  /note=""Y->A: Decreased affinity for human CDH1 domain 1."";  /evidence=""ECO:0000269|PubMed:12526809""; MUTAGEN 367;  /note=""F->A: No longer binds human CDH1 domain 1."";  /evidence=""ECO:0000269|PubMed:12526809""; MUTAGEN 369;  /note=""Y->A: Increased affinity for human CDH1 domain 1."";  /evidence=""ECO:0000269|PubMed:12526809, ECO:0000269|PubMed:17715295""; MUTAGEN 369;  /note=""Y->S: 170-fold increased affinity for human CDH1 domain 1. 6700-fold increased affinity for CDH1, better adhesion to human Caco cells, 1000-fold more virulent in mice; when associated with N-192."";  /evidence=""ECO:0000269|PubMed:17540170, ECO:0000269|PubMed:17715295""; MUTAGEN 387;  /note=""W->A: No longer binds human CDH1 domain 1."";  /evidence=""ECO:0000269|PubMed:12526809"""	P0DJM0;	169963.lmo0433;	1O6S;1O6T;1O6V;2OMT;2OMU;2OMV;2OMW;2OMX;2OMY;2OMZ;
Q08638	BGLA_THEMA	reviewed	Beta-glucosidase A (EC 3.2.1.21) (Beta-D-glucoside glucohydrolase) (Cellobiase) (Gentiobiase)	bglA	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	446							243274.THEMA_04935;	1OD0;1OIF;1OIM;1OIN;1UZ1;1W3J;2CBU;2CBV;2CES;2CET;2J75;2J77;2J78;2J79;2J7B;2J7C;2J7D;2J7E;2J7F;2J7G;2J7H;2JAL;2VRJ;2WBG;2WC3;2WC4;4GXP;5N6S;5N6T;5OSS;
P58822	PGIP2_PHAVU	reviewed	Polygalacturonase inhibitor 2 (Polygalacturonase-inhibiting protein 2) (PGIP-2)	PGIP2	Phaseolus vulgaris (Kidney bean) (French bean)	342					"MUTAGEN 89;  /note=""L->H: No effect."";  /evidence=""ECO:0000269|PubMed:10228150""; MUTAGEN 181;  /note=""V->G: No effect. Loss of activity; when associated with K-253. No effect; when associated with S-326."";  /evidence=""ECO:0000269|PubMed:10228150""; MUTAGEN 207;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:10228150""; MUTAGEN 253;  /note=""Q->K: 70% decrease of activity. Loss of activity; when associated with G-181 or S-326."";  /evidence=""ECO:0000269|PubMed:10228150""; MUTAGEN 300;  /note=""H->Q: No effect."";  /evidence=""ECO:0000269|PubMed:10228150""; MUTAGEN 320;  /note=""Q->K: No effect."";  /evidence=""ECO:0000269|PubMed:10228150""; MUTAGEN 326;  /note=""A->S: No effect. No effect; when associated with G-181. Loss of activity; when associated with K-253."";  /evidence=""ECO:0000269|PubMed:10228150""; MUTAGEN 340;  /note=""A->S: No effect."";  /evidence=""ECO:0000269|PubMed:10228150"""		3885.XP_007159022.1;	1OGQ;
P48845	DEXT_TALMI	reviewed	Dextranase (EC 3.2.1.11) (Alpha-1,6-glucan-6-glucanohydrolase)	DEX	Talaromyces minioluteus (Filamentous fungus) (Penicillium minioluteum)	608								1OGM;1OGO;
P58315	ALF1_THETK	reviewed	Fructose-bisphosphate aldolase class 1 (EC 4.1.2.13) (Fructose-bisphosphate aldolase class I) (FBP aldolase) (FBPA)	fba TTX_1278	Thermoproteus tenax (strain ATCC 35583 / DSM 2078 / JCM 9277 / NBRC 100435 / Kra 1)	263					"MUTAGEN 144;  /note=""W->E: Loss of FBP aldolase activity; when associated with F-146."";  /evidence=""ECO:0000269|PubMed:15766250""; MUTAGEN 146;  /note=""Y->F: The catalytic activity is at least 3-fold lower than for the wild-type. Loss of FBP aldolase activity; when associated with E-144."";  /evidence=""ECO:0000269|PubMed:15766250"""		768679.TTX_1278;	1OJX;1OK4;1OK6;1W8S;2YCE;
P0A917	OMPX_ECOLI	reviewed	Outer membrane protein X	ompX ybiG b0814 JW0799	Escherichia coli (strain K12)	171						P0A917;	511145.b0814;	1ORM;1Q9F;1Q9G;1QJ8;1QJ9;2M06;2M07;2MNH;
P22411	DPP4_PIG	reviewed	Dipeptidyl peptidase 4 (EC 3.4.14.5) (Dipeptidyl peptidase IV) (DPP IV) (T-cell activation antigen CD26) (CD antigen CD26) [Cleaved into: Dipeptidyl peptidase 4 membrane form (Dipeptidyl peptidase IV membrane form); Dipeptidyl peptidase 4 soluble form (Dipeptidyl peptidase IV soluble form)]	DPP4 CD26	Sus scrofa (Pig)	766							9823.ENSSSCP00000028692;	1ORV;1ORW;2AJ8;2AJB;2AJC;2AJD;2BUA;2BUC;5LLS;
O25728	HCPC_HELPY	reviewed	Putative beta-lactamase HcpC (EC 3.5.2.6) (Cysteine-rich protein C)	hcpC HP_1098	Helicobacter pylori (strain ATCC 700392 / 26695) (Campylobacter pylori)	290						O25728;	85962.C694_05665;	1OUV;
P93114	LECC_CALSE	reviewed	Jacalin-related lectin Calsepa (Agglutinin) (Mannose/maltose-specific lectin)		Calystegia sepium (Hedge bindweed) (Convolvulus sepium)	153		BIOTECHNOLOGY: Can be used for the isolation of glycoproteins from humans, plants and fungi. Is a powerful T-cell mitogen in the mouse, and can thus be used as an alternative to concanavalin A for the mitogenic proliferation of murine lymphocytes (PubMed:9111143). Identified as one of the several suitable fluorescently labeled lectins that can be used in a combination for the visualization and quantification of extracellular glycoconjugates in dental supragingival biofilms grown for 48 hours in situ in the absence of dietary carbohydrates (PubMed:28748044). Used in lectin-based microarrays to detect altered glycosylation in cancer tissue (PubMed:32143591). {ECO:0000269|PubMed:28748044, ECO:0000269|PubMed:32143591, ECO:0000269|PubMed:9111143}.						1OUW;5AV7;5XFI;
P0ADK6	YIBA_ECOLI	reviewed	Protein YibA	yibA b3594 JW3568	Escherichia coli (strain K12)	280						P0ADK6;	511145.b3594;	1OYZ;
Q9BZR6	RTN4R_HUMAN	reviewed	Reticulon-4 receptor (Nogo receptor) (NgR) (Nogo-66 receptor)	RTN4R NOGOR UNQ330/PRO526	Homo sapiens (Human)	473			DISEASE: Schizophrenia (SCZD) [MIM:181500]: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder. {ECO:0000269|PubMed:15532024, ECO:0000269|PubMed:19052207, ECO:0000269|PubMed:28892071}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.		"MUTAGEN 151;  /note=""R->E: Impaired ganglioside binding."";  /evidence=""ECO:0000269|PubMed:18411262""; MUTAGEN 199;  /note=""R->E: Impaired ganglioside binding."";  /evidence=""ECO:0000269|PubMed:18411262""; MUTAGEN 277;  /note=""K->A: No effect on interaction with MAG."";  /evidence=""ECO:0000269|PubMed:18411262""; MUTAGEN 277;  /note=""K->D: Decreases interaction with MAG; when associated with D-279."";  /evidence=""ECO:0000269|PubMed:18411262""; MUTAGEN 279;  /note=""R->A: Mildly decreases interaction with MAG."";  /evidence=""ECO:0000269|PubMed:18411262""; MUTAGEN 279;  /note=""R->D: Decreases interaction with MAG; when associated with D-277."";  /evidence=""ECO:0000269|PubMed:18411262""; MUTAGEN 279;  /note=""R->E: Impaired ganglioside binding."";  /evidence=""ECO:0000269|PubMed:18411262"""	Q9BZR6;	9606.ENSP00000043402;	1OZN;1P8T;
P31489	YADA1_YEREN	reviewed	Adhesin YadA (Type 5 secretion system autotransporter YadA)	yadA invA yop1 yopA	Yersinia enterocolitica	455					"MUTAGEN 73..75;  /note=""IAI->EDE: 8% of wild-type collagen-binding activity."";  /evidence=""ECO:0000269|PubMed:10931316""; MUTAGEN 101..103;  /note=""VAI->DDE: 3% of wild-type collagen-binding activity."";  /evidence=""ECO:0000269|PubMed:10931316""; MUTAGEN 155..157;  /note=""VAI->DDE: Loss of collagen-binding activity."";  /evidence=""ECO:0000269|PubMed:10931316""; MUTAGEN 155..157;  /note=""VAI->QST: Less than 0.5% of wild-type collagen-binding activity."";  /evidence=""ECO:0000269|PubMed:10931316""; MUTAGEN 155;  /note=""V->D: Less than 1% of wild-type collagen-binding activity."";  /evidence=""ECO:0000269|PubMed:10931316""; MUTAGEN 156;  /note=""A->D: Loss of collagen-binding activity."";  /evidence=""ECO:0000269|PubMed:10931316""; MUTAGEN 171..173;  /note=""IAI->EDE: Loss of collagen-binding activity."";  /evidence=""ECO:0000269|PubMed:10931316""; MUTAGEN 185..187;  /note=""VSI->DDE: Loss of collagen-binding activity."";  /evidence=""ECO:0000269|PubMed:10931316"""			1P9H;
P14925	AMD_RAT	reviewed	Peptidylglycine alpha-amidating monooxygenase (PAM) [Includes: Peptidylglycine alpha-hydroxylating monooxygenase (PHM) (EC 1.14.17.3); Peptidyl-alpha-hydroxyglycine alpha-amidating lyase (EC 4.3.2.5) (Peptidylamidoglycolate lyase) (PAL)]	Pam	Rattus norvegicus (Rat)	976					"MUTAGEN 533;  /note=""R->A: Abolishes peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity."";  /evidence=""ECO:0000269|PubMed:19604476""; MUTAGEN 533;  /note=""R->Q: Abolishes peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity."";  /evidence=""ECO:0000269|PubMed:19604476""; MUTAGEN 706;  /note=""R->A: Abolishes peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity."";  /evidence=""ECO:0000269|PubMed:19604476""; MUTAGEN 706;  /note=""R->Q: Reduces peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity."";  /evidence=""ECO:0000269|PubMed:19604476""; MUTAGEN 784;  /note=""M->A: Abolishes peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity."";  /evidence=""ECO:0000269|PubMed:19604476""; MUTAGEN 784;  /note=""M->Q: Abolishes peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity."";  /evidence=""ECO:0000269|PubMed:19604476""; MUTAGEN 787;  /note=""D->A: Reduces peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity."";  /evidence=""ECO:0000269|PubMed:19604476"""	P14925;	10116.ENSRNOP00000046774;	1OPM;1PHM;1SDW;1YI9;1YIP;1YJK;1YJL;3FVZ;3FW0;3MIB;3MIC;3MID;3MIE;3MIF;3MIG;3MIH;3MLJ;3MLK;3MLL;3PHM;4E4Z;5WJA;5WKW;5WM0;6ALA;6ALV;6AMP;6AN3;6AO6;6AY0;6NCK;
Q9Y297	FBW1A_HUMAN	reviewed	F-box/WD repeat-containing protein 1A (E3RSIkappaB) (Epididymis tissue protein Li 2a) (F-box and WD repeats protein beta-TrCP) (pIkappaBalpha-E3 receptor subunit)	BTRC BTRCP FBW1A FBXW1A	Homo sapiens (Human)	605						Q9Y297;	9606.ENSP00000359206;	1P22;2P64;6M90;6M91;6M92;6M93;6M94;6TTU;
P07207	NOTCH_DROME	reviewed	Neurogenic locus Notch protein [Cleaved into: Processed neurogenic locus Notch protein]	N CG3936	Drosophila melanogaster (Fruit fly)	2703				DISRUPTION PHENOTYPE: RNAi-mediated knockdown in the larval brain neuroblasts abolishes the expression of pnt, induces the ectopic expression of erm, results in the ectopic expression of Ase in type II neuroblasts (NBs) and their premature loss (PubMed:18342578, PubMed:23056424, PubMed:27151950). Simultaneous RNAi-mediated knockdown of pnt partially restores normal neuroblast numbers and inhibits ectopic erm expression (PubMed:27151950). {ECO:0000269|PubMed:18342578, ECO:0000269|PubMed:23056424, ECO:0000269|PubMed:27151950}.	"MUTAGEN 739;  /note=""C->Y: In mcd5; induces loss of microchaetae sensory precursors.""; MUTAGEN 2060;  /note=""A->V: In su42c; deltex-like mutation that induces outstreched wings and variability-fused ocelli.""; MUTAGEN 2328;  /note=""Y->F: Abolishes interaction with Nedd4 and reduces ubiquitination."";  /evidence=""ECO:0000269|PubMed:15620649"""	P07207;	7227.FBpp0070483;	1OT8;2JMF;
O01479	TMOD_CAEEL	reviewed	Tropomodulin (Tmod-like protein) (cTmd1) (Uncoordinated protein 94)	unc-94 tmd-1 C06A5.7	Caenorhabditis elegans	392							6239.C06A5.7b;	1PGV;
P46680	AIP1_YEAST	reviewed	Actin-interacting protein 1	AIP1 YMR092C YM9582.17C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	615						P46680;	4932.YMR092C;	1PGU;1PI6;
P81294	PLY1_JUNAS	reviewed	Pectate lyase 1 (EC 4.2.2.2) (Major pollen allergen Jun a 1) (allergen Jun a 1)		Juniperus ashei (Ozark white cedar)	367	ALLERGEN: Causes an allergic reaction in human. Binds to IgE of patients allergic to mountain cedar (PubMed:10482836, PubMed:10482835, PubMed:14563374, PubMed:16423400). Binds to IgE in 71% of the 14 patients tested allergic to mountain cedar. Binds to IgE in 40% of the 35 patients tested allergic to Japanese cedar (PubMed:10482835). IgE-binding is significantly reduced by heat denaturation (75 degrees Celsius), chemical denaturation (guanidine treatment) and reductive alkylation in guanidine, but not by reductive alkylation alone, indicating the presence of conformational epitopes. On the other hand, heat and guanidine-induced denaturation increases binding to a mouse monoclonal antibody KW-S91, indicative of enhanced display of the linear epitope by these treatments (PubMed:16423400). Causes proliferation of the peripheral blood mononuclear cells (PBMCs) in patients allergic to mountain cedar (PubMed:10482835). Causes seasonal allergic rhinitis in North America (PubMed:10482836, PubMed:10482835, PubMed:14563374, PubMed:16423400). {ECO:0000269|PubMed:10482835, ECO:0000269|PubMed:10482836, ECO:0000269|PubMed:14563374, ECO:0000269|PubMed:16423400}.				"MUTAGEN 224;  /note=""H->A: Reduced pectate lyase activity."";  /evidence=""ECO:0000269|PubMed:20559000"""			1PXZ;
P53620	COPG1_BOVIN	reviewed	Coatomer subunit gamma-1 (Gamma-1-coat protein) (Gamma-1-COP)	COPG1 COPG	Bos taurus (Bovine)	874						P53620;	9913.ENSBTAP00000017588;	1PZD;3TJZ;
P10721	KIT_HUMAN	reviewed	Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Piebald trait protein) (PBT) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (p145 c-kit) (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (CD antigen CD117)	KIT SCFR	Homo sapiens (Human)	976			DISEASE: Piebald trait (PBT) [MIM:172800]: Autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes. {ECO:0000269|PubMed:11074500, ECO:0000269|PubMed:1370874, ECO:0000269|PubMed:1376329, ECO:0000269|PubMed:1717985, ECO:0000269|PubMed:7687267, ECO:0000269|PubMed:8680409, ECO:0000269|PubMed:9450866, ECO:0000269|PubMed:9699740}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Gastrointestinal stromal tumor (GIST) [MIM:606764]: Common mesenchymal neoplasms arising in the gastrointestinal tract, most often in the stomach. They are histologically, immunohistochemically, and genetically different from typical leiomyomas, leiomyosarcomas, and schwannomas. Most GISTs are composed of a fairly uniform population of spindle-shaped cells. Some tumors are dominated by epithelioid cells or contain a mixture of spindle and epithelioid morphologies. Primary GISTs in the gastrointestinal tract commonly metastasize in the omentum and mesenteries, often as multiple nodules. However, primary tumors may also occur outside of the gastrointestinal tract, in other intra-abdominal locations, especially in the omentum and mesentery. {ECO:0000269|PubMed:11505412, ECO:0000269|PubMed:15824741, ECO:0000269|PubMed:9438854, ECO:0000269|PubMed:9697690}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. Note=The gene represented in this entry is involved in disease pathogenesis. Somatic mutations that lead to constitutive activation of KIT are detected in AML patients. These mutations fall into two classes, the most common being in-frame internal tandem duplications of variable length in the juxtamembrane region that disrupt the normal regulation of the kinase activity. Likewise, point mutations in the kinase domain can result in a constitutively activated kinase.; DISEASE: Mastocytosis, cutaneous (MASTC) [MIM:154800]: A form of mastocytosis, a heterogeneous group of disorders associated with abnormal proliferation and accumulation of mast cells in various tissues, especially in the skin and hematopoietic organs. MASTC is an autosomal dominant form characterized by macules, papules, nodules, or diffuse infiltration of the skin, often associated with localized hyperpigmentation. Gentle rubbing of the lesions induces histamine release from mechanically activated mast cells, causing local wheals, erythema, and often pruritus, a phenomenon termed Darier sign. {ECO:0000269|PubMed:15173254, ECO:0000269|PubMed:19865100, ECO:0000269|PubMed:21689725, ECO:0000269|PubMed:24289326, ECO:0000269|PubMed:9990072}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Mastocytosis, systemic (MASTSYS) [MIM:154800]: A severe form of mastocytosis characterized by abnormal proliferation and accumulation of mast cells in several organs, resulting in a systemic disease that may affect bone, gastrointestinal tract, lymphatics, spleen, and liver. In some cases, it is associated with a clonal hematologic non-mast-cell lineage disease, such as a myelodysplastic or myeloproliferative disorder. It can also lead to mast cell leukemia, which carries a high risk of mortality. {ECO:0000269|PubMed:9990072}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 381;  /note=""R->A: Reduces autophosphorylation in response to KITLG/SCF."";  /evidence=""ECO:0000269|PubMed:17662946""; MUTAGEN 386;  /note=""E->A: Reduces autophosphorylation in response to KITLG/SCF."";  /evidence=""ECO:0000269|PubMed:17662946""; MUTAGEN 571;  /note=""I->A: Reduction in SH2B2/APS binding. Abolishes SH2B2/APS binding; when associated with A-939."";  /evidence=""ECO:0000269|PubMed:12444928""; MUTAGEN 623;  /note=""K->M: Stronger interaction with MPDZ."";  /evidence=""ECO:0000269|PubMed:11018522""; MUTAGEN 741;  /note=""S->A: Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation; when associated with A-746."";  /evidence=""ECO:0000269|PubMed:7539802""; MUTAGEN 746;  /note=""S->A: Abolishes down-regulation of kinase activity by PKC/PRKCA-mediated phosphorylation; when associated with A-741."";  /evidence=""ECO:0000269|PubMed:7539802""; MUTAGEN 823;  /note=""Y->F: No decrease in activity. Leads to autophosphorylation at Tyr-900."";  /evidence=""ECO:0000269|PubMed:20147452""; MUTAGEN 939;  /note=""L->A: Reduction in SH2B2/APS binding. Abolishes SH2B2/APS binding; when associated with A-571."";  /evidence=""ECO:0000269|PubMed:12444928"""	P10721;	9606.ENSP00000288135;	1PKG;1QZJ;1QZK;1R01;1T45;1T46;2E9W;2EC8;2IUH;2VIF;3G0E;3G0F;4HVS;4K94;4K9E;4PGZ;4U0I;6GQJ;6GQK;6GQL;6GQM;6HH1;6ITT;6ITV;6KLA;6MOB;6XV9;6XVA;6XVB;
Q8MQJ9	BRAT_DROME	reviewed	Brain tumor protein	brat CG10719	Drosophila melanogaster (Fruit fly)	1037				DISRUPTION PHENOTYPE: In larval brain, results in deregulated cell cycle and defective differentiation of immature intermediate neuroblast progenitors ultimately leading to overgrowth and proliferation (PubMed:16564014, PubMed:18342578). RNAi-mediated knockdown in the larval brain results in overproliferation of type II neuroblast cells on the dorsal side of the larval brains but had no effect in the type I neuroblast lineage in the ventral nerve cord (PubMed:22143802, PubMed:18342578). {ECO:0000269|PubMed:16564014, ECO:0000269|PubMed:18342578, ECO:0000269|PubMed:22143802}.	"MUTAGEN 802;  /note=""H->L: In bratfs3; induces production of tumor-like neoplasms in the larval brain. Disrupts interaction with nos and pum.""; MUTAGEN 829;  /note=""Y->A: Disrupts recruitment by pum."";  /evidence=""ECO:0000269|PubMed:14561773""; MUTAGEN 847;  /note=""R->A: Disrupts recruitment by pum."";  /evidence=""ECO:0000269|PubMed:14561773""; MUTAGEN 859;  /note=""Y->A: Does not affect recruitment by pum."";  /evidence=""ECO:0000269|PubMed:14561773""; MUTAGEN 860;  /note=""G->D: In bratts1; induces production of tumor-like neoplasms in the larval brain. Disrupts interaction with nos and pum.""; MUTAGEN 875;  /note=""R->A: Disrupts recruitment by pum."";  /evidence=""ECO:0000269|PubMed:14561773""; MUTAGEN 970;  /note=""E->A: Does not affect recruitment by pum."";  /evidence=""ECO:0000269|PubMed:14561773""; MUTAGEN 1012;  /note=""D->A: Does not affect recruitment by pum."";  /evidence=""ECO:0000269|PubMed:14561773"""	Q8MQJ9;	7227.FBpp0293081;	1Q7F;4ZLR;5EX7;6J9R;
Q00205	PELB_ASPNG	reviewed	Pectin lyase B (PLB) (EC 4.2.2.10)	pelB	Aspergillus niger	378							5061.CADANGAP00002970;	1QCX;
P03275	SPIKE_ADE02	reviewed	Fiber protein (SPIKE) (Protein IV)	L5	Human adenovirus C serotype 2 (HAdV-2) (Human adenovirus 2)	582								1QHV;1QIU;1V1H;1V1I;1X9T;2C9F;4AR2;4V4U;
Q92973	TNPO1_HUMAN	reviewed	Transportin-1 (Importin beta-2) (Karyopherin beta-2) (M9 region interaction protein) (MIP)	TNPO1 KPNB2 MIP1 TRN	Homo sapiens (Human)	898					"MUTAGEN 468;  /note=""W->A: Abolishes interaction with the ADAR nuclear localization signal. Abolishes ADAR nuclear import."";  /evidence=""ECO:0000269|PubMed:24753571""; MUTAGEN 738;  /note=""W->A: Abolishes interaction with the ADAR nuclear localization signal. Abolishes ADAR nuclear import."";  /evidence=""ECO:0000269|PubMed:24753571"""	Q92973;	9606.ENSP00000336712;	1QBK;2H4M;2OT8;2QMR;2Z5J;2Z5K;2Z5M;2Z5N;2Z5O;4FDD;4FQ3;4JLQ;4OO6;5J3V;5TQC;5YVG;5YVH;5YVI;7CYL;
P0C1A8	PMEA_DICCH	reviewed	Pectinesterase A (PE A) (EC 3.1.1.11) (Pectin methylesterase A)	pemA pem	Dickeya chrysanthemi (Pectobacterium chrysanthemi) (Erwinia chrysanthemi)	366								1QJV;
Q9X0C7	HIS4_THEMA	reviewed	1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase (EC 5.3.1.16) (Phosphoribosylformimino-5-aminoimidazole carboxamide ribotide isomerase)	hisA TM_1037	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	241					"MUTAGEN 8;  /note=""D->N: Loss of activity."";  /evidence=""ECO:0000269|PubMed:12356303""; MUTAGEN 48;  /note=""H->A: Decrease in activity."";  /evidence=""ECO:0000269|PubMed:12356303""; MUTAGEN 51;  /note=""D->N: Decrease in activity."";  /evidence=""ECO:0000269|PubMed:12356303""; MUTAGEN 83;  /note=""R->N: Decrease in activity."";  /evidence=""ECO:0000269|PubMed:12356303""; MUTAGEN 127;  /note=""D->N: Almost no activity."";  /evidence=""ECO:0000269|PubMed:12356303""; MUTAGEN 164;  /note=""T->A: Strong decrease in activity."";  /evidence=""ECO:0000269|PubMed:12356303"""		243274.THEMA_09175;	1QO2;2CFF;2W79;
Q7SIA3	Q7SIA3_MARHY	unreviewed	Oxidoreductase		Marinobacter hydrocarbonoclasticus (Pseudomonas nautica)	581								1QNI;
P32602	SEC17_YEAST	reviewed	Alpha-soluble NSF attachment protein (SNAP-alpha) (N-ethylmaleimide-sensitive factor attachment protein alpha) (Vesicular-fusion protein SEC17) (alpha-SNAP chaperone)	SEC17 YBL050W YBL0505 YBL0517	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	292						P32602;	4932.YBL050W;	1QQE;
P40881	CAH_METTE	reviewed	Carbonic anhydrase (EC 4.2.1.1)		Methanosarcina thermophila	247								1QQ0;1QRE;1QRF;1QRG;1QRL;1QRM;1THJ;3OTM;3OTZ;3OU9;3OUP;3OW5;
P0AGC3	SLT_ECOLI	reviewed	Soluble lytic murein transglycosylase (EC 4.2.2.n1) (Exomuramidase) (Peptidoglycan lytic exotransglycosylase) (Slt70)	slt sltY b4392 JW4355	Escherichia coli (strain K12)	645					"MUTAGEN 505;  /note=""E->Q: Inactivates the enzyme."""	P0AGC3;	511145.b4392;	1QSA;1QTE;1SLY;
P46531	NOTC1_HUMAN	reviewed	Neurogenic locus notch homolog protein 1 (Notch 1) (hN1) (Translocation-associated notch protein TAN-1) [Cleaved into: Notch 1 extracellular truncation (NEXT); Notch 1 intracellular domain (NICD)]	NOTCH1 TAN1	Homo sapiens (Human)	2555			DISEASE: Aortic valve disease 1 (AOVD1) [MIM:109730]: A common defect in the aortic valve in which two rather than three leaflets are present. It is often associated with aortic valve calcification, stenosis and insufficiency. In extreme cases, the blood flow may be so restricted that the left ventricle fails to grow, resulting in hypoplastic left heart syndrome. {ECO:0000269|PubMed:16025100}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Adams-Oliver syndrome 5 (AOS5) [MIM:616028]: A form of Adams-Oliver syndrome, a disorder characterized by the congenital absence of skin (aplasia cutis congenita) in combination with transverse limb defects. Aplasia cutis congenita can be located anywhere on the body, but in the vast majority of the cases, it is present on the posterior parietal region where it is often associated with an underlying defect of the parietal bones. Limb abnormalities are typically limb truncation defects affecting the distal phalanges or entire digits (true ectrodactyly). Only rarely, metatarsals/metacarpals or more proximal limb structures are also affected. Apart from transverse limb defects, syndactyly, most commonly of second and third toes, can also be observed. The clinical features are highly variable and can also include cardiovascular malformations, brain abnormalities and vascular defects such as cutis marmorata and dilated scalp veins. {ECO:0000269|PubMed:25132448}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 1728;  /note=""P->C: Formation of an artifactual disulfide bond with PSEN1."";  /evidence=""ECO:0000269|PubMed:30598546""; MUTAGEN 1755..1761;  /note=""Missing: Loss of proteolytic cleavage by gamma-secretase."";  /evidence=""ECO:0000269|PubMed:30598546"""	P46531;	9606.ENSP00000277541;	1PB5;1TOZ;1YYH;2F8X;2F8Y;2HE0;2VJ3;3ETO;3I08;3L95;3NBN;3V79;4CUD;4CUE;4CUF;4D0E;4D0F;5FM9;5FMA;5KZO;5L0R;5UB5;6IDF;6PY8;
Q57703	PSLS_METJA	reviewed	Phosphosulfolactate synthase (EC 4.4.1.19) ((2R)-phospho-3-sulfolactate synthase) (PSL synthase)	comA MJ0255	Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) (Methanococcus jannaschii)	251					"MUTAGEN 137;  /note=""K->N: Loss of function."";  /evidence=""ECO:0000269|PubMed:11830598"""		243232.MJ_0255;	1QWG;
P38262	SIF2_YEAST	reviewed	SIR4-interacting protein SIF2	SIF2 EMB1 YBR103W YBR0832	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	535						P38262;	4932.YBR103W;	1R5M;
P42390	TRPA_MAIZE	reviewed	Indole-3-glycerol phosphate lyase, chloroplastic (EC 4.1.2.8) (Benzoxazineless 1) (Indole synthase) (Tryptophan synthase alpha chain) (EC 4.2.1.20)	BX1	Zea mays (Maize)	347							4577.GRMZM2G085381_P03;	1RD5;1TJR;
Q9S400	AROA_STRPN	reviewed	3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19) (5-enolpyruvylshikimate-3-phosphate synthase) (EPSP synthase) (EPSPS)	aroA SP_1371	Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)	427						Q9S400;	170187.SP_1371;	1RF4;1RF5;1RF6;
P52697	6PGL_ECOLI	reviewed	6-phosphogluconolactonase (6-P-gluconolactonase) (Pgl) (EC 3.1.1.31)	pgl ybhE b0767 JW0750	Escherichia coli (strain K12)	331						P52697;	511145.b0767;	1RI6;
P36888	FLT3_HUMAN	reviewed	Receptor-type tyrosine-protein kinase FLT3 (EC 2.7.10.1) (FL cytokine receptor) (Fetal liver kinase-2) (FLK-2) (Fms-like tyrosine kinase 3) (FLT-3) (Stem cell tyrosine kinase 1) (STK-1) (CD antigen CD135)	FLT3 CD135 FLK2 STK1	Homo sapiens (Human)	993			DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. {ECO:0000269|PubMed:11090077, ECO:0000269|PubMed:11290608, ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097, ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:18305215, ECO:0000269|PubMed:8946930, ECO:0000269|PubMed:9737679}. Note=The gene represented in this entry may be involved in disease pathogenesis. Somatic mutations that lead to constitutive activation of FLT3 are frequent in AML patients. These mutations fall into two classes, the most common being in-frame internal tandem duplications of variable length in the juxtamembrane region that disrupt the normal regulation of the kinase activity. Likewise, point mutations in the activation loop of the kinase domain can result in a constitutively activated kinase.		"MUTAGEN 589;  /note=""Y->F: Reduced phosphorylation of the wild-type kinase in response to ligand binding. No effect on the phosphorylation of the constitutively activated mutant kinase variants. Abolishes activation of STAT5A."";  /evidence=""ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:16684964, ECO:0000269|PubMed:9737679""; MUTAGEN 591;  /note=""Y->F: No significant effect on tyrosine phosphorylation. Abolishes activation of STAT5A."";  /evidence=""ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:9737679""; MUTAGEN 599;  /note=""Y->F: Abolishes interaction with PTPN11/SHP2 and phosphorylation of PTPN11/SHP2."";  /evidence=""ECO:0000269|PubMed:16684964""; MUTAGEN 644;  /note=""K->A: Abolishes kinase activity."";  /evidence=""ECO:0000269|PubMed:15831474"""	P36888;	9606.ENSP00000241453;	1RJB;3QS7;3QS9;4RT7;4XUF;5X02;6IL3;6JQR;
P15873	PCNA_YEAST	reviewed	Proliferating cell nuclear antigen (PCNA)	POL30 YBR088C YBR0811	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	258						P15873;	4932.YBR088C;	1PLQ;1PLR;1SXJ;2OD8;3F1W;3GPM;3GPN;3L0W;3L0X;3L10;3PGE;3V60;3V61;3V62;4L60;4L6P;4YHR;5JNE;5T9D;5V7K;5V7L;5V7M;5ZUT;6CX2;6CX3;6CX4;6D0Q;6D0R;6E49;6W9W;6WAC;
Q43843	RPE_SOLTU	reviewed	Ribulose-phosphate 3-epimerase, chloroplastic (EC 5.1.3.1) (Pentose-5-phosphate 3-epimerase) (PPE) (R5P3E) (RPE) (Fragment)		Solanum tuberosum (Potato)	280							4113.PGSC0003DMT400050256;	1RPX;
Q9RYA6	Q9RYA6_DEIRA	unreviewed	o-succinylbenzoate synthase (OSB synthase) (OSBS) (EC 4.2.1.113) (4-(2'-carboxyphenyl)-4-oxybutyric acid synthase) (o-succinylbenzoic acid synthase)	menC DR_0044	Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)	375							243230.DR_0044;	1R0M;1XPY;1XS2;2FKP;2GGG;2GGH;2GGI;2GGJ;
O75832	PSD10_HUMAN	reviewed	26S proteasome non-ATPase regulatory subunit 10 (26S proteasome regulatory subunit p28) (Gankyrin) (p28(GANK))	PSMD10	Homo sapiens (Human)	226					"MUTAGEN 182;  /note=""E->A: Abolishes interaction with RB1."";  /evidence=""ECO:0000269|PubMed:10613832"""	O75832;	9606.ENSP00000217958;	1QYM;1TR4;1UOH;4NIK;5VHF;5VHH;5VHI;5VHJ;5VHM;5VHN;5VHO;5VHP;5VHQ;5VHR;
Q00001	RHGA_ASPAC	reviewed	Rhamnogalacturonase A (RGase A) (RHG A) (EC 3.2.1.171) (Rhamnogalacturonan hydrolase A)	rhgA	Aspergillus aculeatus	440								1RMG;
P0C1A7	PLYL_DICD3	reviewed	Pectate lyase L (EC 4.2.2.2) (Pectate transeliminase) (Pel9A)	pelL Dda3937_02794	Dickeya dadantii (strain 3937) (Erwinia chrysanthemi (strain 3937))	425				DISRUPTION PHENOTYPE: The pelL mutant displays a reduced virulence on potato tubers and Saintpaulia ionantha plants. {ECO:0000269|PubMed:8577252}.	"MUTAGEN 273;  /note=""K->A: Loss of catalytic activity."";  /evidence=""ECO:0000269|PubMed:14670977"""		198628.Dda3937_02794;	1RU4;
P12255	FHAB_BORPE	reviewed	Filamentous hemagglutinin	fhaB BP1879	Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251)	3590						P12255;	257313.BP1879;	1RWR;
O29912	PCNA_ARCFU	reviewed	DNA polymerase sliding clamp (Proliferating cell nuclear antigen homolog) (PCNA)	pcn AF_0335	Archaeoglobus fulgidus (strain ATCC 49558 / DSM 4304 / JCM 9628 / NBRC 100126 / VC-16)	245							224325.AF_0335;	1RWZ;1RXM;1RXZ;3P83;
P9WI79	PKND_MYCTU	reviewed	Serine/threonine-protein kinase PknD (EC 2.7.11.1)	pknD Rv0931c MTCY08C9.08	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	664				DISRUPTION PHENOTYPE: No growth phenotype in phosphate-rich medium (3.6 mM Pi), in restricted medium (Sauton) grows better than wild-type but in phosphate-free Sauton medium dies faster than wild-type when pre-exposed to starvation. {ECO:0000269|PubMed:20933472}.	"MUTAGEN 79;  /note=""H->A: Lack of activity."";  /evidence=""ECO:0000269|PubMed:17242402""; MUTAGEN 81;  /note=""Y->A: Decreases activity and alters substrate specificity."";  /evidence=""ECO:0000269|PubMed:17242402""; MUTAGEN 138;  /note=""D->N: 2600-fold decrease in activity."";  /evidence=""ECO:0000269|PubMed:17411339"""	P9WI79;	83332.Rv0931c;	1RWI;1RWL;
Q9UBQ5	EIF3K_HUMAN	reviewed	Eukaryotic translation initiation factor 3 subunit K (eIF3k) (Eukaryotic translation initiation factor 3 subunit 12) (Muscle-specific gene M9 protein) (PLAC-24) (eIF-3 p25) (eIF-3 p28)	EIF3K EIF3S12 ARG134 HSPC029 MSTP001 PTD001	Homo sapiens (Human)	218						Q9UBQ5;	9606.ENSP00000248342;	1RZ4;3J8B;3J8C;6FEC;6YBD;6ZMW;6ZON;6ZP4;6ZVJ;7A09;
Q8WVQ1	CANT1_HUMAN	reviewed	Soluble calcium-activated nucleotidase 1 (SCAN-1) (EC 3.6.1.6) (Apyrase homolog) (Putative MAPK-activating protein PM09) (Putative NF-kappa-B-activating protein 107)	CANT1 SHAPY	Homo sapiens (Human)	401			DISEASE: Desbuquois dysplasia 1 (DBQD1) [MIM:251450]: A chondrodysplasia characterized by severe prenatal and postnatal growth retardation (less than -5 SD), joint laxity, short extremities, progressive scoliosis, round face, midface hypoplasia, prominent bulging eyes. The main radiologic features are short long bones with metaphyseal splay, a 'Swedish key' appearance of the proximal femur (exaggerated trochanter), and advance carpal and tarsal bone age. Two forms of Desbuquois dysplasia are distinguished on the basis of the presence or absence of characteristic hand anomalies: an extra ossification center distal to the second metacarpal, delta phalanx, bifid distal thumb phalanx, and phalangeal dislocations. {ECO:0000269|PubMed:19853239, ECO:0000269|PubMed:20425819, ECO:0000269|PubMed:21037275, ECO:0000269|PubMed:21412251, ECO:0000269|PubMed:21654728, ECO:0000269|PubMed:22539336}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Epiphyseal dysplasia, multiple, 7 (EDM7) [MIM:617719]: A form of multiple epiphyseal dysplasia, a generalized skeletal dysplasia associated with significant morbidity. Joint pain, joint deformity, waddling gait, and short stature are the main clinical signs and symptoms. Radiological examination of the skeleton shows delayed, irregular mineralization of the epiphyseal ossification centers and of the centers of the carpal and tarsal bones. Multiple epiphyseal dysplasia is broadly categorized into the more severe Fairbank and the milder Ribbing types. The Fairbank type is characterized by shortness of stature, short and stubby fingers, small epiphyses in several joints, including the knee, ankle, hand, and hip. The Ribbing type is confined predominantly to the hip joints and is characterized by hands that are normal and stature that is normal or near-normal. EDM7 inheritance is autosomal recessive. {ECO:0000269|PubMed:28742282}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 60;  /note=""C->S: Loss of dimer formation."";  /evidence=""ECO:0000269|PubMed:16835225""; MUTAGEN 112;  /note=""D->A: Reduces activity by 99%."";  /evidence=""ECO:0000269|PubMed:15006348""; MUTAGEN 114;  /note=""D->A: Reduces activity by 99%."";  /evidence=""ECO:0000269|PubMed:15006348, ECO:0000269|PubMed:15248776""; MUTAGEN 139;  /note=""S->C: Reduces GDPase and ADPase activities 1.7-fold. Severe loss of dimer formation; when associated with S-287."";  /evidence=""ECO:0000269|PubMed:16835225""; MUTAGEN 152;  /note=""G->E: Slightly reduced activity."";  /evidence=""ECO:0000269|PubMed:15248776""; MUTAGEN 160;  /note=""E->Y: Increases GDPase activity 2-fold and ADPase activity 5-fold. Forms dimer even at suboptimal Ca(2+) concentrations."";  /evidence=""ECO:0000269|PubMed:15248776, ECO:0000269|PubMed:16835225""; MUTAGEN 163;  /note=""R->A: Reduces activity by 98%."";  /evidence=""ECO:0000269|PubMed:15248776""; MUTAGEN 166;  /note=""E->Q: Reduces activity by 95%."";  /evidence=""ECO:0000269|PubMed:15006348""; MUTAGEN 168;  /note=""S->A: Reduces activity by over 99.9%."";  /evidence=""ECO:0000269|PubMed:15006348""; MUTAGEN 169;  /note=""D->N: Reduces activity by 96%."";  /evidence=""ECO:0000269|PubMed:15006348""; MUTAGEN 181;  /note=""D->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:15248776""; MUTAGEN 182;  /note=""D->N: Reduces activity by over 99.9%."";  /evidence=""ECO:0000269|PubMed:15006348""; MUTAGEN 200;  /note=""I->C: Reduces GDPase activity 2-fold and ADPase activity 2.5-fold. No effect on dimer formation; when associated with S-287."";  /evidence=""ECO:0000269|PubMed:16835225""; MUTAGEN 202;  /note=""S->C: Reduces GDPase activity 1.7-fold and ADPase activity 1.5-fold. No effect on dimer formation; when associated with S-287."";  /evidence=""ECO:0000269|PubMed:16835225""; MUTAGEN 205;  /note=""D->A: Slightly reduced activity."";  /evidence=""ECO:0000269|PubMed:15248776""; MUTAGEN 215;  /note=""E->Q: Reduces activity by 99%."";  /evidence=""ECO:0000269|PubMed:15006348""; MUTAGEN 246;  /note=""E->M: Increases activity 5-fold."";  /evidence=""ECO:0000269|PubMed:15006348""; MUTAGEN 256;  /note=""S->C: No effect on GDPase and ADPase activities. No effect on dimer formation; when associated with S-287."";  /evidence=""ECO:0000269|PubMed:16835225""; MUTAGEN 287;  /note=""C->S: Reduces GDPase and ADPase activities 1.3-fold."";  /evidence=""ECO:0000269|PubMed:16835225""; MUTAGEN 301;  /note=""R->A: Reduces activity by 99%."";  /evidence=""ECO:0000269|PubMed:15006348, ECO:0000269|PubMed:15248776""; MUTAGEN 308;  /note=""S->C: Reduces GDPase activity 1.3-fold and ADPase activity 2-fold. Severe loss of dimer formation; when associated with S-287."";  /evidence=""ECO:0000269|PubMed:16835225""; MUTAGEN 317;  /note=""A->C: Reduces GDPase activity 1.7-fold and ADPase activity 1.5-fold. Severe loss of dimer formation; when associated with S-287."";  /evidence=""ECO:0000269|PubMed:16835225"""	Q8WVQ1;	9606.ENSP00000307674;	1S18;1S1D;2H2N;2H2U;
Q9WYH8	AROF_THEMA	reviewed	Phospho-2-dehydro-3-deoxyheptonate aldolase (EC 2.5.1.54) (3-deoxy-D-arabino-heptulosonate 7-phosphate synthase) (DAHP synthase) (Phospho-2-keto-3-deoxyheptonate aldolase)	aroF TM_0343	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	338							243274.THEMA_03000;	1RZM;1VR6;3PG8;3PG9;4GRS;
P42330	AK1C3_HUMAN	reviewed	Aldo-keto reductase family 1 member C3 (EC 1.1.1.-) (EC 1.1.1.210) (EC 1.1.1.53) (EC 1.1.1.62) (17-beta-hydroxysteroid dehydrogenase type 5) (17-beta-HSD 5) (3-alpha-HSD type II, brain) (3-alpha-hydroxysteroid dehydrogenase type 2) (3-alpha-HSD type 2) (EC 1.1.1.357) (Chlordecone reductase homolog HAKRb) (Dihydrodiol dehydrogenase 3) (DD-3) (DD3) (Dihydrodiol dehydrogenase type I) (HA1753) (Prostaglandin F synthase) (PGFS) (EC 1.1.1.188) (Testosterone 17-beta-dehydrogenase 5) (EC 1.1.1.239) (EC 1.1.1.64)	AKR1C3 DDH1 HSD17B5 KIAA0119 PGFS	Homo sapiens (Human)	323					"MUTAGEN 75;  /note=""K->E: No effect on 17beta-HSD activity."";  /evidence=""ECO:0000269|PubMed:9927279""; MUTAGEN 226;  /note=""R->P: Decreases in the retinaldehyde reductase activity. 3-fold decrease in the kcat value, whereas the KM value does not vary."";  /evidence=""ECO:0000269|PubMed:21851338""; MUTAGEN 226;  /note=""R->Q: Decrease in the retinaldehyde reductase activity. Exhibits changes in both KM and kcat values."";  /evidence=""ECO:0000269|PubMed:21851338"""	P42330;	9606.ENSP00000369927;	1RY0;1RY8;1S1P;1S1R;1S2A;1S2C;1XF0;1ZQ5;2F38;2FGB;3R43;3R58;3R6I;3R7M;3R8G;3R8H;3R94;3UFY;3UG8;3UGR;3UWE;4DBS;4DBU;4DBW;4DZ5;4FA3;4FAL;4FAM;4H7C;4HMN;4WDT;4WDU;4WDW;4WDX;4WRH;4XVD;4XVE;4YVV;4YVX;4ZFC;5HNT;5HNU;6A7B;6F2U;6F78;6GXK;7C7F;7C7G;7C7H;
Q02793	SKI8_YEAST	reviewed	Antiviral protein SKI8 (Superkiller protein 8)	SKI8 REC103 YGL213C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	397						Q02793;	4932.YGL213C;	1S4U;1SQ9;4BUJ;5MC6;
Q90623	MYPT1_CHICK	reviewed	Protein phosphatase 1 regulatory subunit 12A (130 kDa myosin-binding subunit of smooth muscle myosin phosphatase) (Myosin phosphatase-targeting subunit 1) (Myosin phosphatase target subunit 1) (PP1M subunit M110) (Protein phosphatase myosin-binding subunit)	PPP1R12A MBS MYPT1	Gallus gallus (Chicken)	1004					"MUTAGEN 695;  /note=""T->A: Reduces phosphorylation. Reduces phosphorylation on serine and threonine residues by 80%; when associated with A-850."";  /evidence=""ECO:0000269|PubMed:10601309""; MUTAGEN 850;  /note=""T->A: Reduces phosphorylation. Reduces phosphorylation on serine and threonine residues by 80%; when associated with A-695."";  /evidence=""ECO:0000269|PubMed:10601309"""	Q90623;	9031.ENSGALP00000016789;	1S70;
P49792	RBP2_HUMAN	reviewed	E3 SUMO-protein ligase RanBP2 (EC 2.3.2.-) (358 kDa nucleoporin) (Nuclear pore complex protein Nup358) (Nucleoporin Nup358) (Ran-binding protein 2) (RanBP2) (p270)	RANBP2 NUP358	Homo sapiens (Human)	3224			DISEASE: Encephalopathy, acute, infection-induced, 3 (IIAE3) [MIM:608033]: A rapidly progressive encephalopathy manifesting in susceptible individuals with seizures and coma. It can occur within days in otherwise healthy children after common viral infections such as influenza and parainfluenza, without evidence of viral infection of the brain or inflammatory cell infiltration. Brain T2-weighted magnetic resonance imaging reveals characteristic symmetric lesions present in the thalami, pons and brainstem. {ECO:0000269|PubMed:19118815}. Note=The disease is caused by variants affecting the gene represented in this entry. Mutations in the RANBP2 gene predispose to IIAE3, but by themselves are insufficient to make the phenotype fully penetrant; additional genetic and environmental factors are required (PubMed:19118815). {ECO:0000269|PubMed:19118815}.; DISEASE: Note=A chromosomal aberration involving RANBP2 is a cause of chromosome 8p11 myeloproliferative syndrome. Translocation t(2;8)(q12;p11) with FGFR1. Chromosome 8p11 myeloproliferative syndrome is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. {ECO:0000269|PubMed:23041776}.		"MUTAGEN 2632;  /note=""V->K: Abolishes interaction with sumoylated RANGAP1."";  /evidence=""ECO:0000269|PubMed:15388847""; MUTAGEN 2634;  /note=""I->K: Abolishes interaction with sumoylated RANGAP1."";  /evidence=""ECO:0000269|PubMed:15388847""; MUTAGEN 2635;  /note=""V->K: Abolishes interaction with sumoylated RANGAP1."";  /evidence=""ECO:0000269|PubMed:15388847""; MUTAGEN 2640;  /note=""P->A: No effect on SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2645;  /note=""K->A: No effect on SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2651;  /note=""L->A: Abolishes binding to UBE2I and SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2652;  /note=""K->A: No effect on SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2653;  /note=""L->A: Abolishes binding to UBE2I and SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2654;  /note=""P->A: Impairs SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2655;  /note=""P->A: No effect on SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2656;  /note=""T->A: Impairs SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2657;  /note=""F->A: Abolishes binding to UBE2I and SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2658;  /note=""F->A: Abolishes binding to UBE2I and SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2659;  /note=""C->S,A: Impairs SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2676;  /note=""D->A: Impairs SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2677;  /note=""F->A: Impairs SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033""; MUTAGEN 2689;  /note=""Y->A: Impairs SUMO E3 ligase activity."";  /evidence=""ECO:0000269|PubMed:15378033"""	P49792;	9606.ENSP00000283195;	1RRP;1XKE;1Z5S;2LAS;3UIN;3UIO;3UIP;4GA0;4I9Y;4L6E;4LQW;5CLL;5CLQ;
P43886	CYSE_HAEIN	reviewed	Serine acetyltransferase (SAT) (EC 2.3.1.30)	cysE HI_0606	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	267							71421.HI_0606;	1S80;1SSM;1SSQ;1SST;1Y7L;
Q6GII7	AROD_STAAR	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD SAR0860	Staphylococcus aureus (strain MRSA252)	238								1SFJ;1SFL;
Q44244	Q44244_9PSEU	unreviewed	o-succinylbenzoate synthase (OSB synthase) (OSBS) (EC 4.2.1.113) (4-(2'-carboxyphenyl)-4-oxybutyric acid synthase) (o-succinylbenzoic acid synthase)	Aaar menC	Amycolatopsis sp.	368								1SJA;1SJB;1SJC;1SJD;4A6G;5FJO;5FJP;5FJR;5FJT;5FJU;
P63043	STMN4_RAT	reviewed	Stathmin-4 (Stathmin-like protein B3) (RB3)	Stmn4	Rattus norvegicus (Rat)	189						P63043;		1SA0;1SA1;1Z2B;3DU7;3E22;3HKB;3HKC;3HKD;3HKE;3N2G;3N2K;3RYC;3RYF;3RYH;3RYI;3UT5;4EB6;4I4T;4I50;4I55;4IHJ;4IIJ;4O2A;4O2B;4O4H;4O4I;4O4J;4O4L;4TUY;4TV8;4TV9;4X1I;4X1K;4X1Y;4X20;4YJ2;4YJ3;4ZHQ;4ZI7;4ZOL;5BMV;5C8Y;5CA0;5CA1;5CB4;5EZY;5FNV;5GON;5H74;5H7O;5IYZ;5J2T;5J2U;5JH7;5JQG;5JVD;5KX5;5LA6;5LOV;5LP6;5LXS;5LXT;5LYJ;5M7E;5M7G;5M8D;5M8G;5MF4;5NFZ;5NG1;5NJH;5O7A;5OSK;5OV7;5S4L;5S4M;5S4N;5S4O;5S4P;5S4Q;5S4R;5S4S;5S4T;5S4U;5S4V;5S4W;5S4X;5S4Y;5S4Z;5S50;5S51;5S52;5S53;5S54;5S55;5S56;5S57;5S58;5S59;5S5A;5S5B;5S5C;5S5D;5S5E;5S5F;5S5G;5S5H;5S5I;5S5J;5S5K;5S5L;5S5M;5S5N;5S5O;5S5P;5S5Q;5S5R;5S5S;5S5T;5S5U;5S5V;5S5W;5S5X;5S5Y;5S5Z;5S60;5S61;5S62;5S63;5S64;5S65;5S66;5S67;5XAF;5XAG;5XHC;5XI5;5XI7;5XIW;5XKE;5XKF;5XKG;5XKH;5XLT;5XLZ;5XP3;5YL2;5YL4;5YLJ;5YLS;5YZ3;5Z4P;5Z4U;5ZXH;6AGK;6BS2;6D88;6EG5;6F7C;6FII;6FJF;6FJM;6FKJ;6FKL;6GF3;6GJ4;6GZE;6H9B;6HX8;6I5C;6JCJ;6K9V;6KNZ;6N47;6QQN;6QTN;6S9E;6SES;6TDE;6TIS;6TIU;6TIY;6TIZ;6Y4M;6Y4N;6Y6D;7CBZ;7CDA;7CE6;7CE8;7CEK;7JFR;
P0A431	PSBO_THEEB	reviewed	Photosystem II manganese-stabilizing polypeptide (MSP)	psbO tll0444	Thermosynechococcus elongatus (strain BP-1)	272						P0A431;	197221.22294165;	1S5L;2AXT;3KZI;4FBY;4IXQ;4IXR;4PBU;4PJ0;4RVY;4TNH;4TNI;4TNJ;4TNK;4V62;4V82;5E79;5E7C;5H2F;5KAF;5KAI;5MX2;5TIS;5ZZN;6DHE;6DHF;6DHG;6DHH;6DHO;6DHP;6W1O;6W1P;6W1Q;6W1R;6W1T;6W1U;6W1V;
Q48152	Q48152_HAEIF	unreviewed	Adhesin (Hia)	hia	Haemophilus influenzae	1098								1S7M;2GR7;2GR8;3EMF;3EMI;3EMO;
O06522	CDTA_HAEDU	reviewed	Cytolethal distending toxin subunit A (CDT A)	cdtA HD_0902	Haemophilus ducreyi (strain 35000HP / ATCC 700724)	223					"MUTAGEN 91;  /note=""W->G: Abolishes toxicity towards intact cells; when associated with G-98; G-100 and G-102."";  /evidence=""ECO:0000269|PubMed:15164065""; MUTAGEN 98;  /note=""W->G: Abolishes toxicity towards intact cells; when associated with G-91; G-100 and G-102."";  /evidence=""ECO:0000269|PubMed:15164065""; MUTAGEN 100;  /note=""W->G: Abolishes toxicity towards intact cells; when associated with G-91; G-98 and G-102."";  /evidence=""ECO:0000269|PubMed:15164065""; MUTAGEN 102;  /note=""Y->G: Abolishes toxicity towards intact cells; when associated with G-91; G-98 and G-100."";  /evidence=""ECO:0000269|PubMed:15164065"""		233412.HD_0902;	1SR4;
Q93X60	Q93X60_CICIN	unreviewed	Fructan 1-exohydrolase IIa (EC 3.2.1.80)	1-feh IIa	Cichorium intybus (Chicory)	581								1ST8;2ADD;2ADE;2AEY;2AEZ;
P09959	SWI6_YEAST	reviewed	Regulatory protein SWI6 (Cell-cycle box factor subunit SWI6) (MBF subunit P90) (Trans-acting activator of HO endonuclease gene)	SWI6 YLR182W L9470.8	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	803						P09959;	4932.YLR182W;	1SW6;2XFV;5XW5;
Q8J0D2	CBHRE_GEOS1	reviewed	Oligoxyloglucan reducing end-specific cellobiohydrolase (OXG-RCBH) (EC 3.2.1.150)		Geotrichum sp. (strain M128)	812					"MUTAGEN 58;  /note=""D->N: No catalytic activity."";  /evidence=""ECO:0000269|PubMed:15242597""; MUTAGEN 467;  /note=""E->Q: No effect on catalytic activity."";  /evidence=""ECO:0000269|PubMed:15242597""; MUTAGEN 488;  /note=""D->N: No catalytic activity."";  /evidence=""ECO:0000269|PubMed:15242597""; MUTAGEN 513;  /note=""D->N: No effect on catalytic activity."";  /evidence=""ECO:0000269|PubMed:15242597"""			1SQJ;2EBS;
P39081	PCF11_YEAST	reviewed	Protein PCF11 (protein 1 of CF I)	PCF11 YDR228C YD9934.13C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	626					"MUTAGEN 66;  /note=""A->D: Loss of interaction with RBP1 CTD."";  /evidence=""ECO:0000269|PubMed:12727883""; MUTAGEN 68..70;  /note=""DSI->AAA: Loss of interaction with RBP1 CTD."";  /evidence=""ECO:0000269|PubMed:12727883"""	P39081;	4932.YDR228C;	1SZ9;1SZA;2BF0;2NAX;2NPI;4C0B;4C0H;4OI4;5M9Z;
P0A9D4	CYSE_ECOLI	reviewed	Serine acetyltransferase (SAT) (EC 2.3.1.30)	cysE b3607 JW3582	Escherichia coli (strain K12)	273						P0A9D4;	511145.b3607;	1T3D;
P00940	TPIS_CHICK	reviewed	Triosephosphate isomerase (TIM) (EC 5.3.1.1) (Methylglyoxal synthase) (EC 4.2.3.3) (Triose-phosphate isomerase)	TPI1	Gallus gallus (Chicken)	248					"MUTAGEN 95;  /note=""H->N: Reduces activity 5000-fold."";  /evidence=""ECO:0000269|PubMed:2361134""; MUTAGEN 165;  /note=""E->D: Reduces activity 300-fold."";  /evidence=""ECO:0000269|PubMed:2361134"""	P00940;	9031.ENSGALP00000023396;	1SPQ;1SQ7;1SSD;1SSG;1SU5;1SW0;1SW3;1SW7;1TIM;1TPB;1TPC;1TPH;1TPU;1TPV;1TPW;4P61;8TIM;
P55196	AFAD_HUMAN	reviewed	Afadin (ALL1-fused gene from chromosome 6 protein) (Protein AF-6) (Afadin adherens junction formation factor)	AFDN AF6 MLLT4	Homo sapiens (Human)	1824			DISEASE: Note=A chromosomal aberration involving AFDN is associated with acute leukemias. Translocation t(6;11)(q27;q23) with KMT2A/MLL1. The result is a rogue activator protein.			P55196;	9606.ENSP00000375960;	1T2M;1XZ9;2AIN;2EXG;5A6C;
Q05546	TENR_RAT	reviewed	Tenascin-R (TN-R) (Janusin) (Neural recognition molecule J1-160/180) (Restrictin)	Tnr	Rattus norvegicus (Rat)	1356						Q05546;	10116.ENSRNOP00000068101;	1TDQ;
Q9Y3R4	NEUR2_HUMAN	reviewed	Sialidase-2 (EC 3.2.1.18) (Cytosolic sialidase) (N-acetyl-alpha-neuraminidase 2)	NEU2	Homo sapiens (Human)	380					"MUTAGEN 46;  /note=""D->A: Loss of enzyme activity."";  /evidence=""ECO:0000269|PubMed:22228546""; MUTAGEN 218;  /note=""E->A,Q: Loss of enzyme activity."";  /evidence=""ECO:0000269|PubMed:22228546""; MUTAGEN 270;  /note=""Q->E: No effect on enzyme activity."";  /evidence=""ECO:0000269|PubMed:22228546"""	Q9Y3R4;	9606.ENSP00000233840;	1SNT;1SO7;1VCU;2F0Z;2F10;2F11;2F12;2F13;2F24;2F25;2F26;2F27;2F28;2F29;4NC5;4NCS;
P09943	IDE3_ERYCA	reviewed	Trypsin inhibitor DE-3		Erythrina caffra (Kaffir tree) (Coastal coral tree)	172								1TIE;
Q27084	TAL2_TACTR	reviewed	Tachylectin-2 (Lectin L10c)		Tachypleus tridentatus (Japanese horseshoe crab)	255								1TL2;3KIF;3KIH;
Q56312	CHEY_THEMA	reviewed	Chemotaxis protein CheY	cheY TM_0700	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	120						Q56312;	243274.THEMA_01165;	1TMY;1U0S;2LLE;2TMY;3TMY;4IGA;4QWV;4QYW;4TMY;6C40;
P74061	RPE_SYNY3	reviewed	Ribulose-phosphate 3-epimerase (EC 5.1.3.1)	rpe sll0807	Synechocystis sp. (strain PCC 6803 / Kazusa)	230						P74061;	1148.1653221;	1TQJ;
Q8I5L3	Q8I5L3_PLAF7	unreviewed	Ribulose-phosphate 3-epimerase (EC 5.1.3.1)	PF3D7_1219900	Plasmodium falciparum (isolate 3D7)	227								1TQX;
P15090	FABP4_HUMAN	reviewed	Fatty acid-binding protein, adipocyte (Adipocyte lipid-binding protein) (ALBP) (Adipocyte-type fatty acid-binding protein) (A-FABP) (AFABP) (Fatty acid-binding protein 4)	FABP4	Homo sapiens (Human)	132						P15090;	9606.ENSP00000256104;	1TOU;1TOW;2HNX;2NNQ;3FR2;3FR4;3FR5;3P6C;3P6D;3P6E;3P6F;3P6G;3P6H;3Q6L;3RZY;4NNS;4NNT;5D45;5D47;5D48;5D4A;5EDB;5EDC;5HZ6;5HZ8;5Y0F;5Y0G;5Y0X;5Y12;5Y13;6AYL;6LJS;6LJT;6LJU;6LJV;6LJW;6LJX;
P67825	CUTC_SHIFL	reviewed	Copper homeostasis protein CutC	cutC SF1915 S2005	Shigella flexneri	248								1TWD;1X7I;1X8C;
P13674	P4HA1_HUMAN	reviewed	Prolyl 4-hydroxylase subunit alpha-1 (4-PH alpha-1) (EC 1.14.11.2) (Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1)	P4HA1 P4HA	Homo sapiens (Human)	534					"MUTAGEN 210;  /note=""Y->A: Strongly reduced affinity for peptide substrate."";  /evidence=""ECO:0000269|PubMed:15456751""; MUTAGEN 213;  /note=""Y->A: Strongly reduced affinity for peptide substrate."";  /evidence=""ECO:0000269|PubMed:15456751""; MUTAGEN 247;  /note=""Y->A: Strongly reduced affinity for peptide substrate."";  /evidence=""ECO:0000269|PubMed:15456751"""	P13674;	9606.ENSP00000263556;	1TJC;2V5F;2YQ8;4BT8;4BT9;4BTA;4BTB;
O31618	THIG_BACSU	reviewed	Thiazole synthase (EC 2.8.1.10)	thiG yjbT BSU11690	Bacillus subtilis (strain 168)	256					"MUTAGEN 98;  /note=""K->A: No activity; no imine formation with DXP."";  /evidence=""ECO:0000269|PubMed:15012138""; MUTAGEN 100;  /note=""E->A: Activity reduced 38-fold."";  /evidence=""ECO:0000269|PubMed:15362849""; MUTAGEN 184;  /note=""D->A: No activity."";  /evidence=""ECO:0000269|PubMed:15362849"""	O31618;	224308.BSU11690;	1TYG;1XM3;
Q89FH0	TARD_BRADU	reviewed	D(-)-tartrate dehydratase (EC 4.2.1.81)	tarD bll6730	Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110)	389					"MUTAGEN 102;  /note=""K->A,M: Loss of dehydration activity."";  /evidence=""ECO:0000269|PubMed:17144653""; MUTAGEN 184;  /note=""K->A: Loss of dehydration activity."";  /evidence=""ECO:0000269|PubMed:17144653""; MUTAGEN 184;  /note=""K->R: Reduced dehydration activity."";  /evidence=""ECO:0000269|PubMed:17144653""; MUTAGEN 322;  /note=""H->N: Decreased but measurable dehydration activity."";  /evidence=""ECO:0000269|PubMed:17144653"""		224911.27355010;	1TZZ;2DW6;2DW7;
Q81VW8	Q81VW8_BACAN	unreviewed	Dihydropteroate synthase (DHPS) (EC 2.5.1.15) (Dihydropteroate pyrophosphorylase)	folP GBAA_0071	Bacillus anthracis	280								1TWS;1TWW;1TWZ;1TX0;1TX2;3H21;3H22;3H23;3H24;3H26;3H2A;3H2C;3H2E;3H2F;3H2M;3H2N;3H2O;3TYA;3TYB;3TYC;3TYD;3TYE;4D8A;4D8Z;4D9P;4DAF;4DAI;4DB7;4NHV;4NIL;4NIR;4NL1;
P26449	BUB3_YEAST	reviewed	Cell cycle arrest protein BUB3	BUB3 YOR026W OR26.16	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	341					"MUTAGEN 2;  /note=""Q->L: Abolishes checkpoint function. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 31;  /note=""W->G: Abolishes checkpoint function and interaction with MAD2, MAD3 and CDC20. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:11726501""; MUTAGEN 120;  /note=""W->G: Abolishes checkpoint function and interaction with MAD2, MAD3 and CDC20. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:11726501""; MUTAGEN 188;  /note=""E->V: Abolishes checkpoint function. No effect on interaction with BUB1 and MAD3. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 191;  /note=""G->R: Abolishes checkpoint function. No effect on interaction with BUB1 and MAD3. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 192;  /note=""L->E: Abolishes checkpoint function. No effect on interaction with BUB1 and MAD3. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 193;  /note=""K->T: Abolishes checkpoint function. No effect on interaction with BUB1 and MAD3. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 217;  /note=""R->E: Abolishes checkpoint function. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 226;  /note=""Q->L: Abolishes checkpoint function. No effect on interaction with BUB1 and MAD3. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 242;  /note=""R->E: Abolishes checkpoint function. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 276;  /note=""S->P: Abolishes checkpoint function. Lowers interaction with BUB1 and MAD3. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329""; MUTAGEN 278;  /note=""W->R: Abolishes checkpoint function. No effect on interaction with BUB1. Lowers interaction with MAD3. Benomyl-sensitive phenotype."";  /evidence=""ECO:0000269|PubMed:15644329"""	P26449;	4932.YOR026W;	1U4C;1YFQ;2I3S;2I3T;4BL0;
P9WPE1	CITEL_MYCTU	reviewed	Citrate lyase subunit beta-like protein (EC 4.1.-.-)	citE Rv2498c	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	273							83332.Rv2498c;	1U5H;1U5V;1Z6K;6AQ4;
Q86VP6	CAND1_HUMAN	reviewed	Cullin-associated NEDD8-dissociated protein 1 (Cullin-associated and neddylation-dissociated protein 1) (TBP-interacting protein of 120 kDa A) (TBP-interacting protein 120A) (p120 CAND1)	CAND1 KIAA0829 TIP120 TIP120A	Homo sapiens (Human)	1230						Q86VP6;	9606.ENSP00000442318;	1U6G;4A0C;
P03001	TF3A_XENLA	reviewed	Transcription factor IIIA (TFIIIA) (S-TFIIIA/O-TFIIIA)	gtf3a	Xenopus laevis (African clawed frog)	366					"MUTAGEN 38;  /note=""S->E,A: Abolishes phosphorylation by CK2."";  /evidence=""ECO:0000269|PubMed:11853545""; MUTAGEN 42;  /note=""C->S: Loss of DNA binding."";  /evidence=""ECO:0000269|PubMed:1762917""; MUTAGEN 55;  /note=""H->L: Inhibition of specific DNA binding."";  /evidence=""ECO:0000269|PubMed:1762917""; MUTAGEN 91;  /note=""G->S: Loss of DNA binding."";  /evidence=""ECO:0000269|PubMed:1762917""; MUTAGEN 93;  /note=""K->E: Loss of DNA binding."";  /evidence=""ECO:0000269|PubMed:1762917""; MUTAGEN 134;  /note=""C->S: No effect."";  /evidence=""ECO:0000269|PubMed:1762917""; MUTAGEN 186;  /note=""C->S: No effect."";  /evidence=""ECO:0000269|PubMed:1762917""; MUTAGEN 336;  /note=""S->E,A: Slightly decreases phosphorylation by CK2."";  /evidence=""ECO:0000269|PubMed:11853545""; MUTAGEN 350;  /note=""S->E,A: No effect on phosphorylation by CK2."";  /evidence=""ECO:0000269|PubMed:11853545"""			1TF3;1TF6;1UN6;2HGH;2J7J;
O06739	PSLS_BACSU	reviewed	Phosphosulfolactate synthase (EC 4.4.1.19) ((2R)-phospho-3-sulfolactate synthase) (PSL synthase)	yitD BSU10950	Bacillus subtilis (strain 168)	252							224308.BSU10950;	1U83;
Q14145	KEAP1_HUMAN	reviewed	Kelch-like ECH-associated protein 1 (Cytosolic inhibitor of Nrf2) (INrf2) (Kelch-like protein 19)	KEAP1 INRF2 KIAA0132 KLHL19	Homo sapiens (Human)	624					"MUTAGEN 15;  /note=""R->A: Reduced formation of a high-molecular mass KEAP1 molecule when methylglyoxal accumulates."";  /evidence=""ECO:0000269|PubMed:30323285""; MUTAGEN 123..127;  /note=""VSIEG->ASAEA: Abolished interaction with NFE2L2/NRF2; when associated with 161-A-A-162."";  /evidence=""ECO:0000269|PubMed:15601839""; MUTAGEN 125..127;  /note=""IEG->AAA: Increases ubiquitination and proteolytic degradation."";  /evidence=""ECO:0000269|PubMed:15572695""; MUTAGEN 135;  /note=""R->A: Reduced formation of a high-molecular mass KEAP1 molecule when methylglyoxal accumulates."";  /evidence=""ECO:0000269|PubMed:30323285""; MUTAGEN 151;  /note=""C->S,N,D,L: Substitution with a small side chain that prevents covalent modification by an electrophile; promotes constitutive ubiquitination of NFE2L2/NRF2 and subsequent repression of phase 2 detoxifying enzymes. Resistance of ubiquitination of PGAM5 to inhibition by oxidative stress and sulforaphane. Impaired interaction with CUL3. Reduced formation of a high-molecular mass KEAP1 molecule when methylglyoxal accumulates."";  /evidence=""ECO:0000269|PubMed:14585973, ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285""; MUTAGEN 151;  /note=""C->W,Y: Substitution with a bulky side chain that mimicks covalent modification by an electrophile; prevents ubiquitination and degradation of NFE2L2/NRF2, leading to constitutive activation of NFE2L2/NRF2 and subsequent expression of phase 2 detoxifying enzymes."";  /evidence=""ECO:0000269|PubMed:19489739, ECO:0000269|PubMed:24896564""; MUTAGEN 161..162;  /note=""MY->AA: Abolished interaction with NFE2L2/NRF2; when associated with 123-A--A-127."";  /evidence=""ECO:0000269|PubMed:15601839""; MUTAGEN 162..164;  /note=""YQI->AAA: Increases ubiquitination and proteolytic degradation."";  /evidence=""ECO:0000269|PubMed:15572695""; MUTAGEN 273;  /note=""C->S: Abolishes repression of NFE2L2/NRF2-dependent gene expression. Slows down degradation of NFE2L2/NRF2."";  /evidence=""ECO:0000269|PubMed:14585973""; MUTAGEN 288;  /note=""C->S: Abolishes repression of NFE2L2/NRF2-dependent gene expression. Slows down degradation of NFE2L2/NRF2."";  /evidence=""ECO:0000269|PubMed:14585973""; MUTAGEN 308;  /note=""L->A: Loss of export from nucleus; when associated with A-310."";  /evidence=""ECO:0000269|PubMed:15657435""; MUTAGEN 310;  /note=""L->A: Loss of export from nucleus; when associated with A-308."";  /evidence=""ECO:0000269|PubMed:15657435""; MUTAGEN 334;  /note=""Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5."";  /evidence=""ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:17046835""; MUTAGEN 380;  /note=""R->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:20452972""; MUTAGEN 382;  /note=""N->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:20452972""; MUTAGEN 415;  /note=""R->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Does not affect interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972""; MUTAGEN 436;  /note=""H->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Does not affect interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:20452972""; MUTAGEN 478;  /note=""F->A: Abolishes repression of NFE2L2/NRF2-dependent gene expression."";  /evidence=""ECO:0000269|PubMed:16888629""; MUTAGEN 483;  /note=""R->A: Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Does not affect interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972""; MUTAGEN 525;  /note=""Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Abolishes interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:20452972""; MUTAGEN 572;  /note=""Y->A: Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Abolishes interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972"""	Q14145;	9606.ENSP00000171111;	1U6D;1ZGK;2FLU;3VNG;3VNH;3ZGC;3ZGD;4CXI;4CXJ;4CXT;4IFJ;4IFL;4IFN;4IN4;4IQK;4L7B;4L7C;4L7D;4N1B;4XMB;5DAD;5DAF;5F72;5GIT;5NLB;5WFL;5WFV;5WG1;5WHL;5WHO;5WIY;5X54;6FFM;6FMP;6FMQ;6HWS;6LRZ;6ROG;6SP1;6SP4;6T7V;6T7Z;6TG8;6TYM;6TYP;6UF0;6V6Z;6W66;6W67;6W68;6W69;6WCQ;6Z6A;7K28;7K29;7K2A;7K2B;7K2C;7K2D;7K2E;7K2F;7K2G;7K2H;7K2I;7K2J;7K2K;7K2L;7K2M;7K2N;7K2O;7K2P;7K2Q;7K2R;7K2S;
Q975N2	PCNA1_SULTO	reviewed	DNA polymerase sliding clamp 1 (Proliferating cell nuclear antigen homolog 1) (PCNA1)	pcn1 pcnA STK_03870	Sulfurisphaera tokodaii (strain DSM 16993 / JCM 10545 / NBRC 100140 / 7) (Sulfolobus tokodaii)	245							273063.STK_03870;	1UD9;
P16608	TRPA_THET2	reviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA TT_C0729	Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27)	271							262724.TT_C0729;	1UJP;1WXJ;
P94522	EABN1_BACSU	reviewed	Extracellular endo-alpha-(1->5)-L-arabinanase 1 (ABN) (EC 3.2.1.99) (Endo-1,5-alpha-L-arabinanase)	abnA BSU28810	Bacillus subtilis (strain 168)	323				DISRUPTION PHENOTYPE: Cells lacking this gene retains about 40% of the capacity to hydrolyze linear arabinan compared to the wild-type. {ECO:0000269|PubMed:14973026, ECO:0000269|PubMed:15556708}.	"MUTAGEN 43;  /note=""H->A: Decrease in binding affinity."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 44;  /note=""D->A: Loss of arabinanase activity."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 104;  /note=""W->A: Significantly less active (10000-fold) than the wild-type arabinanase against both linear arabinan and arabinooligosaccharides."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 124;  /note=""F->A: Increase in binding affinity."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 163;  /note=""D->A: Loss of arabinanase activity."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 181;  /note=""F->A: Significantly less active than the wild-type arabinanase against both linear arabinan (50-fold) and the arabinooligosaccharides (1000-fold)."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 182;  /note=""W->A: Same binding affinity as wild-type."";  /evidence=""ECO:0000269|PubMed:15708971""; MUTAGEN 215;  /note=""E->A: Loss of arabinanase activity."";  /evidence=""ECO:0000269|PubMed:15556708, ECO:0000269|PubMed:15708971"""		224308.BSU28810;	1UV4;
Q9Y376	CAB39_HUMAN	reviewed	Calcium-binding protein 39 (MO25alpha) (Protein Mo25)	CAB39 MO25 CGI-66	Homo sapiens (Human)	341					"MUTAGEN 240;  /note=""R->A: Abolishes activation of STK11/LKB1; when associated with A-243."";  /evidence=""ECO:0000269|PubMed:19892943""; MUTAGEN 243;  /note=""F->A: Abolishes activation of STK11/LKB1; when associated with A-240."";  /evidence=""ECO:0000269|PubMed:19892943"""	Q9Y376;	9606.ENSP00000258418;	1UPK;1UPL;2WTK;3GNI;4FZA;4FZD;4FZF;4NZW;4O27;
P63005	LIS1_MOUSE	reviewed	Platelet-activating factor acetylhydrolase IB subunit beta (Lissencephaly-1 protein) (LIS-1) (PAF acetylhydrolase 45 kDa subunit) (PAF-AH 45 kDa subunit) (PAF-AH alpha) (PAFAH alpha)	Pafah1b1 Lis-1 Lis1 Pafaha	Mus musculus (Mouse)	410				DISRUPTION PHENOTYPE: Double heterozygous PAFAH1B1 and homozygous VLDLR knockout mice present no obvious cortical layering defects (PubMed:17330141). Double heterozygous PAFAH1B1 and homozygous LRP8 knockout mice display a reeler-like phenotype in the forebrain consisting of the inversion of cortical layers and hippocampal disorganization (PubMed:17330141). {ECO:0000269|PubMed:17330141}.	"MUTAGEN 15;  /note=""I->R: Impairs self-association and reduces protein stability."";  /evidence=""ECO:0000269|PubMed:16258276""; MUTAGEN 19;  /note=""L->R: Impairs self-association, reduces protein stability and promotes localization to actin fibers."";  /evidence=""ECO:0000269|PubMed:16258276""; MUTAGEN 31;  /note=""F->S: Abrogates interaction with NDLE1, NUDC, PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability."";  /evidence=""ECO:0000269|PubMed:12885786""; MUTAGEN 149;  /note=""H->R: Abrogates self-association and interaction with DAB1, dynein, NDEL1, PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability."";  /evidence=""ECO:0000269|PubMed:11163259, ECO:0000269|PubMed:11231056, ECO:0000269|PubMed:12885786, ECO:0000269|PubMed:14578885""; MUTAGEN 152;  /note=""S->W: Abrogates interaction with NDEL1."";  /evidence=""ECO:0000269|PubMed:11231056""; MUTAGEN 162;  /note=""G->S: Abrogates interaction with PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability."";  /evidence=""ECO:0000269|PubMed:12885786""; MUTAGEN 169;  /note=""S->P: Abrogates interaction with NDEL1, PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability."";  /evidence=""ECO:0000269|PubMed:11231056, ECO:0000269|PubMed:12885786""; MUTAGEN 238;  /note=""R->A: Abrogates interaction with PAFAH1B2."";  /evidence=""ECO:0000269|PubMed:15572112""; MUTAGEN 317;  /note=""D->H: Abrogates interaction with NDEL1, PAFAH1B3 and RSN. Also impairs localization to centrosomes and microtubule plus ends. Reduces protein stability."";  /evidence=""ECO:0000269|PubMed:12885786"""	P63005;	10090.ENSMUSP00000021091;	1UUJ;1VYH;
Q9HAU5	RENT2_HUMAN	reviewed	Regulator of nonsense transcripts 2 (Nonsense mRNA reducing factor 2) (Up-frameshift suppressor 2 homolog) (hUpf2)	UPF2 KIAA1408 RENT2	Homo sapiens (Human)	1272					"MUTAGEN 796..797;  /note=""RK->EE: Strongly impairs RNA-binding."";  /evidence=""ECO:0000269|PubMed:15004547""; MUTAGEN 847;  /note=""D->K: Does not abolish interaction with UPF3B."";  /evidence=""ECO:0000269|PubMed:15004547""; MUTAGEN 851..852;  /note=""ED->KR: Does not abolish interaction with UPF3B. Does not abolish interaction with UPF3B; when associated with D-854."";  /evidence=""ECO:0000269|PubMed:15004547""; MUTAGEN 854;  /note=""R->D: Does not abolish interaction with UPF3B; when associated with K-851 and R-852."";  /evidence=""ECO:0000269|PubMed:15004547""; MUTAGEN 858;  /note=""E->R: Abolishes interaction with UPF3B and association with SMG1 and RBM8A; reduces phosphorylation of UPF1."";  /evidence=""ECO:0000269|PubMed:15004547, ECO:0000269|PubMed:16452507""; MUTAGEN 894;  /note=""Y->A: Does not impair RNA-binding; when associated with A-932."";  /evidence=""ECO:0000269|PubMed:15004547""; MUTAGEN 932;  /note=""Y->A: Does not impair RNA-binding; when associated with A-894."";  /evidence=""ECO:0000269|PubMed:15004547""; MUTAGEN 1113;  /note=""F->E: Abolishes interaction with UPF1.""; MUTAGEN 1120;  /note=""M->E: Decreases interaction with UPF1; does not reduce NMD efficiency."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1121;  /note=""M->E: Decreases interaction with UPF1; does not reduce NMD efficiency."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1123;  /note=""E->R: Decreases interaction with UPF1."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1169;  /note=""M->E: Decreases interaction with UPF1."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1171;  /note=""F->E: Abolishes interaction with UPF1; reduces NMD efficiency."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1171;  /note=""F->E: Greatly reduces NMD efficiency; when associated with E-1173 and E-1174."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1173;  /note=""M->E: Abolishes interaction with UPF1."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1173;  /note=""M->E: Greatly reduces NMD efficiency; when associated with E-1171 and E-1174."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1174;  /note=""L->E: Abolishes interaction with UPF1; reduces NMD efficiency."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1174;  /note=""L->E: Greatly reduces NMD efficiency; when associated with E-1171 and E-1173."";  /evidence=""ECO:0000269|PubMed:19556969""; MUTAGEN 1176;  /note=""R->E: Decreases interaction with UPF1."";  /evidence=""ECO:0000269|PubMed:19556969"""	Q9HAU5;	9606.ENSP00000348708;	1UW4;2WJV;4CEK;4CEM;
O33833	BFRA_THEMA	reviewed	Beta-fructosidase (EC 3.2.1.26) (Invertase) (Sucrase)	bfrA TM_1414	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	432					"MUTAGEN 190;  /note=""E->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:16411890""; MUTAGEN 190;  /note=""E->D: Reduced activity."";  /evidence=""ECO:0000269|PubMed:16411890"""		243274.THEMA_07250;	1UYP;1W2T;
Q04830	FIBER_BPK1F	reviewed	Tail spike protein (TSP) (Endo-N-acetylneuraminidase) (Endo-N) (EC 3.2.1.129) (Endo-alpha-sialidase) (EndoNF) (G102) [Cleaved into: C-terminal chaperone protein]		Escherichia phage K1F (Bacteriophage K1F)	1064					"MUTAGEN 328;  /note=""W->R: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:20096705""; MUTAGEN 350;  /note=""H->A,N,Q: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:20096705""; MUTAGEN 410;  /note=""K->A: 80% loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:20096705""; MUTAGEN 542;  /note=""H->A: 60% loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:20096705""; MUTAGEN 549;  /note=""R->A: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:20096705""; MUTAGEN 581;  /note=""E->A: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:15608653, ECO:0000269|PubMed:20096705""; MUTAGEN 596;  /note=""R->A: Complete loss of enzymatic activity; when associated with A-581. Complete loss of enzymatic activity; when associated with A-647."";  /evidence=""ECO:0000269|PubMed:15608653""; MUTAGEN 647;  /note=""R->A: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:15608653, ECO:0000269|PubMed:20096705""; MUTAGEN 911;  /note=""S->A: Complete loss of proteolytic processing. 190-fold reduced enzymatic activity."";  /evidence=""ECO:0000269|PubMed:19189967"""			1V0E;1V0F;3GVJ;3GVK;3GVL;3GW6;3JU4;
Q6XV27	NRAM_I56A2	reviewed	Neuraminidase (EC 3.2.1.18)		Influenza A virus (strain A/Duck/England/1/1956 H11N6)	470								1V0Z;1W1X;1W20;1W21;2CML;6HFY;6HG5;6HGB;
P38011	GBLP_YEAST	reviewed	Guanine nucleotide-binding protein subunit beta-like protein (Receptor for activated C kinase) (Receptor of activated protein kinase C 1) (RACK1) (Small ribosomal subunit protein RACK1)	ASC1 CPC2 YMR116C YM9718.15C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	319				DISRUPTION PHENOTYPE: Defective activation of the ribosome quality control (RQC) pathway. {ECO:0000269|PubMed:28223409}.		P38011;	4932.YMR116C;	1TRJ;3FRX;3J6X;3J6Y;3J77;3J78;3RFG;3RFH;4U3M;4U3N;4U3U;4U4N;4U4O;4U4Q;4U4R;4U4U;4U4Y;4U4Z;4U50;4U51;4U52;4U53;4U55;4U56;4U6F;4V6I;4V7R;4V88;4V8Y;4V8Z;4V92;5DAT;5DC3;5DGE;5DGF;5DGV;5FCI;5FCJ;5I4L;5JUO;5JUP;5JUS;5JUT;5JUU;5LYB;5M1J;5MC6;5MEI;5NDG;5NDV;5NDW;5OBM;5ON6;5TBW;5TGA;5TGM;6FAI;6GQ1;6GQB;6GQV;6HHQ;6I7O;6Q8Y;6RBE;6S47;6SNT;6SV4;6T4Q;6T7I;6T7T;6T83;6TB3;6TNU;6WDR;6WOO;6XIQ;6XIR;6Z6J;6Z6K;6ZCE;6ZU9;6ZVI;7A1G;7B7D;7NRC;7NRD;
O59257	O59257_PYRHO	unreviewed	173aa long hypothetical ferripyochelin binding protein	PH1591	Pyrococcus horikoshii (strain ATCC 700860 / DSM 12428 / JCM 9974 / NBRC 100139 / OT-3)	173							70601.3258020;	1V3W;1V67;2FKO;
Q6WJ03	Q6WJ03_9MONO	unreviewed	Hemagglutinin-neuraminidase glycoprotein	HN	Human respirovirus 3	572								1V2I;1V3B;1V3C;1V3D;1V3E;4WEF;
P0A877	TRPA_ECOLI	reviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA b1260 JW1252	Escherichia coli (strain K12)	268						P0A877;	511145.b1260;	1V7Y;1WQ5;1XC4;1XCF;
Q9AJM4	Q9AJM4_9BACI	unreviewed	Pectate lyase 47	pl47	Bacillus sp. TS-47	441								1VBL;
Q868M7	Q868M7_CUCEC	unreviewed	Hemolytic lectin CEL-III	cel3	Cucumaria echinata (Sea cucumber)	442								1VCL;2Z48;2Z49;3W9T;
Q8ZXK7	DEOC_PYRAE	reviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC PAE1231	Pyrobaculum aerophilum (strain ATCC 51768 / DSM 7523 / JCM 9630 / CIP 104966 / NBRC 100827 / IM2)	226							178306.PAE1231;	1VCV;
O08808	DIAP1_MOUSE	reviewed	Protein diaphanous homolog 1 (Diaphanous-related formin-1) (DRF1) (p140mDIA) (mDIA1)	Diaph1 Diap1	Mus musculus (Mouse)	1255				DISRUPTION PHENOTYPE: Knockout mice show normal organization of the cerebral cortex with no significant differences in cortical white matter or callosal thickness (PubMed:24781755). Histological analysis of coronal brain sections at early and postnatal stages shows unilateral ventricular enlargement (PubMed:24781755). {ECO:0000269|PubMed:24781755}.		O08808;	10090.ENSMUSP00000025337;	1V9D;1Z2C;2BAP;2BNX;2F31;2V8F;3EG5;3O4X;3OBV;4UWX;
P83825	P83825_THETH	unreviewed	N-(5'-phosphoribosyl)anthranilate isomerase (PRAI) (EC 5.3.1.24)	trpF TthHB5018_03080	Thermus thermophilus	203								1V5X;
P77689	SUFD_ECOLI	reviewed	FeS cluster assembly protein SufD	sufD ynhC b1681 JW1671	Escherichia coli (strain K12)	423						P77689;	511145.b1681;	1VH4;2ZU0;5AWF;5AWG;
P44480	ALKH_HAEIN	reviewed	Putative KHG/KDPG aldolase [Includes: 4-hydroxy-2-oxoglutarate aldolase (EC 4.1.3.16) (2-keto-4-hydroxyglutarate aldolase) (KHG-aldolase); 2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14) (2-keto-3-deoxy-6-phosphogluconate aldolase) (KDPG-aldolase) (Phospho-2-dehydro-3-deoxygluconate aldolase) (Phospho-2-keto-3-deoxygluconate aldolase)]	eda HI_0047	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	212							71421.HI_0047;	1VHC;
O59543	RNP3_PYRHO	reviewed	Ribonuclease P protein component 3 (RNase P component 3) (EC 3.1.26.5) (Rpp30)	rnp3 PH1877	Pyrococcus horikoshii (strain ATCC 700860 / DSM 12428 / JCM 9974 / NBRC 100139 / OT-3)	212					"MUTAGEN 42;  /note=""K->A: Fully reconstitutes RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 68;  /note=""R->A: 75% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 87;  /note=""R->A: Fully reconstitutes RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 90;  /note=""R->A: 45% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 98;  /note=""D->A: 80% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 107;  /note=""R->A: 45% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 114;  /note=""H->A: 75% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 123;  /note=""K->A: 45% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 158;  /note=""K->A: 75% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 176;  /note=""R->A: 45% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 180;  /note=""D->A: 50% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052""; MUTAGEN 196;  /note=""K->A: 45% reconstituted RNase P activity."";  /evidence=""ECO:0000269|PubMed:15184052"""	O59543;	70601.3258316;	1V77;2CZV;
O34790	PCRB_BACSU	reviewed	Heptaprenylglyceryl phosphate synthase (HepGP synthase) (EC 2.5.1.n9) (Glycerol-1-phosphate heptaprenyltransferase)	pcrB yerE BSU06600	Bacillus subtilis (strain 168)	228				DISRUPTION PHENOTYPE: Cells lacking this gene show a cloggy growth and do not produce the dephosphorylated and acetylated derivatives of HepGP. {ECO:0000269|PubMed:21761520}.			224308.BSU06600;	1VIZ;3VZX;3VZY;3VZZ;3W00;
Q9YBQ2	APEH_AERPE	reviewed	Acylamino-acid-releasing enzyme (AARE) (EC 3.4.19.1) (Acyl-peptide hydrolase) (APH) (Acylaminoacyl-peptidase)	APE_1547.1	Aeropyrum pernix (strain ATCC 700893 / DSM 11879 / JCM 9820 / NBRC 100138 / K1)	582							272557.APE_1547.1;	1VE6;1VE7;2HU5;2HU7;2HU8;2QR5;2QZP;3O4G;3O4H;3O4I;3O4J;4RE5;4RE6;
P41366	VMO1_CHICK	reviewed	Vitelline membrane outer layer protein 1 (VMO-1) (VMO-I) (VMOI)	VMO1	Gallus gallus (Chicken)	183							9031.ENSGALP00000029440;	1VMO;
Q9X1F0	Q9X1F0_THEMA	unreviewed	Glycerol uptake operon antiterminator-related protein	TM_1436	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	176								1VKF;
Q9WYA0	Q9WYA0_THEMA	unreviewed	Beta sliding clamp	TM_0262	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	366								1VPK;
Q9WYG7	PYRF_THEMA	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF TM_0332	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	201							243274.THEMA_03060;	1VQT;
Q9WYD1	TAL_THEMA	reviewed	Transaldolase (EC 2.2.1.2)	tal TM_0295	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	218							243274.THEMA_03250;	1VPX;
P29498	FABP_SCHMA	reviewed	14 kDa fatty acid-binding protein (Sm14)		Schistosoma mansoni (Blood fluke)	133							6183.Smp_095360.1;	1VYF;1VYG;2POA;
P68638	VCP_VACCW	reviewed	Complement control protein C3 (28 kDa protein) (Secretory protein 35) (Protein C3) (VCP)	VACWR025 C3L	Vaccinia virus (strain Western Reserve) (VACV) (Vaccinia virus (strain WR))	263						P68638;		1VVC;1VVD;1VVE;
Q9X0V2	Q9X0V2_THEMA	unreviewed	Uncharacterized protein	TM_1225	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	326								1VKD;
Q9WXS1	Q9WXS1_THEMA	unreviewed	2-dehydro-3-deoxyphosphogluconate aldolase/4-hydroxy-2-oxoglutarate aldolase	TM_0066	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	205								1VLW;1WA3;5KP9;7B3Y;
P16250	HIS4_STRCO	reviewed	Phosphoribosyl isomerase A (1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase) (EC 5.3.1.16) (N-(5'-phosphoribosyl)anthranilate isomerase) (PRAI) (EC 5.3.1.24) (Phosphoribosylformimino-5-aminoimidazole carboxamide ribotide isomerase)	priA hisA SCO2050 SC4G6.19c	Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145)	240					"MUTAGEN 11;  /note=""D->A: No activity."";  /evidence=""ECO:0000269|PubMed:17967415""; MUTAGEN 19;  /note=""R->A: No effect on activity toward PRA. No activity toward ProFAR."";  /evidence=""ECO:0000269|PubMed:17967415""; MUTAGEN 81;  /note=""S->T: No activity toward PRA. Almost no effect on activity toward ProFAR."";  /evidence=""ECO:0000269|PubMed:17967415""; MUTAGEN 130;  /note=""D->A: Very low activity toward PRA. No activity toward ProFAR."";  /evidence=""ECO:0000269|PubMed:17967415""; MUTAGEN 130;  /note=""D->Q: No activity."";  /evidence=""ECO:0000269|PubMed:17967415""; MUTAGEN 166;  /note=""T->A: No activity."";  /evidence=""ECO:0000269|PubMed:17967415""; MUTAGEN 171;  /note=""D->A: Low activity toward PRA. No activity toward ProFAR."";  /evidence=""ECO:0000269|PubMed:17967415"""		100226.SCO2050;	1VZW;2VEP;2X30;5DN1;
P48449	LSS_HUMAN	reviewed	Lanosterol synthase (EC 5.4.99.7) (2,3-epoxysqualene--lanosterol cyclase) (Oxidosqualene--lanosterol cyclase) (OSC) (hOSC)	LSS OSC	Homo sapiens (Human)	732			DISEASE: Cataract 44 (CTRCT44) [MIM:616509]: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. {ECO:0000269|PubMed:26200341, ECO:0000269|PubMed:29016354}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Hypotrichosis 14 (HYPT14) [MIM:618275]: A form of hypotrichosis, a condition characterized by the presence of less than the normal amount of hair and abnormal hair follicles and shafts, which are thin and atrophic. The extent of scalp and body hair involvement can be very variable, within as well as between families. HYPT14 is an autosomal recessive form characterized by sparse to absent lanugo-like scalp hair, sparse and brittle eyebrows, and sparse eyelashes and body hair. {ECO:0000269|PubMed:30401459}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Alopecia-mental retardation syndrome 4 (APMR4) [MIM:618840]: An autosomal recessive disorder characterized by alopecia universalis, scaly skin, mild to severe intellectual disability, delayed or absent speech, and motor delay. {ECO:0000269|PubMed:30401459, ECO:0000269|PubMed:30723320}. Note=The disease is caused by variants affecting the gene represented in this entry.			P48449;	9606.ENSP00000380837;	1W6J;1W6K;
P52303	AP1B1_RAT	reviewed	AP-1 complex subunit beta-1 (Adaptor protein complex AP-1 subunit beta-1) (Adaptor-related protein complex 1 subunit beta-1) (Beta-1-adaptin) (Beta-adaptin 1) (Clathrin assembly protein complex 1 beta large chain) (Golgi adaptor HA1/AP1 adaptin beta subunit)	Ap1b1 Adtb1	Rattus norvegicus (Rat)	949						P52303;	10116.ENSRNOP00000054218;	1W63;
O14980	XPO1_HUMAN	reviewed	Exportin-1 (Exp1) (Chromosome region maintenance 1 protein homolog)	XPO1 CRM1	Homo sapiens (Human)	1071					"MUTAGEN 191;  /note=""S->A: Does not abolish Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 284;  /note=""V->E: Does not abolish Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 334;  /note=""D->G: Does not abolish Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 337;  /note=""I->L: Does not abolish Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 346;  /note=""T->A: Does not abolish Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 402;  /note=""V->I: Does not abolish Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 411;  /note=""P->T: Strongly abolishes interaction with Rex and RANBP3, abolishes Rex-mediated mRNA export. Does not abolish interaction with RANBP3; when associated with S-414. Abolishes Rex multimerization; when associated with S-414."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 412;  /note=""M->V: Does not abolish interaction with Rex and RANBP3, and Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 414;  /note=""F->S: Strongly abolishes interaction with Rex and RANBP3, abolishes Rex-mediated mRNA export. Does not abolish interaction with RANBP3; when associated with T-411. Abolishes Rex multimerization; when associated with T-411."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 428..447;  /note=""EEVLVVENDQGEVVREFMKD->QQVLVVQNNQGQVVRQFMKN: Abolishes Ran binding activity in absence of cargo and abolishes partially Ran binding activity in presence of cargo."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 430..446;  /note=""VLVVENDQGEVVREFMK->DEDEENDQGEDEEEDDD: Partially restores Ran binding activity in presence of cargo."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 430..433;  /note=""VLVV->DEDE: Abolishes Ran binding activity both in absence or presence of cargo."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 454;  /note=""Y->A: Does not abolish Ran binding activity and nuclear export complex formation."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 474;  /note=""R->I: Strongly abolishes interaction with Rex and RANBP3, abolishes Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 481;  /note=""H->Q: Strongly abolishes interaction with Rex and RANBP3, abolishes Rex-mediated mRNA export."";  /evidence=""ECO:0000269|PubMed:14612415""; MUTAGEN 513;  /note=""E->A: Abolishes Ran binding activity and nuclear export complex formation. Abolishes Ran binding activity and nuclear export complex formation; when associated with A-553 and A-554."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 525;  /note=""L->A: Enhances Ran binding activity and does not abolish nuclear export complex formation. Does not abolish Ran binding activity and partially abolish nuclear export complex formation; when associated with A-561. Does not abolish Ran binding activity and partially abolish nuclear export complex formation; when associated with A-568 and A-572."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 550;  /note=""Q->A: Enhances Ran binding activity and does not abolish nuclear export complex formation; when associated with A-553 and A-590."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 553;  /note=""R->A: Enhances Ran binding activity and does not abolish nuclear export complex formation; when associated with A-550 and A-590. Abolishes Ran binding activity and nuclear export complex formation; when associated with A-513 and A-554."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 554;  /note=""F->A: Partially abolishes Ran binding activity and does not abolish nuclear export complex formation. Abolishes Ran binding activity and nuclear export complex formation; when associated with A-561. Abolishes Ran binding activity and nuclear export complex formation; when associated with A-553 and A-513."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 561;  /note=""F->A: Abolishes Ran binding activity and nuclear export complex formation. Abolishes Ran binding activity and nuclear export complex formation; when associated with A-554. Does not abolish Ran binding activity and partially abolish nuclear export complex formation; when associated with A-525."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 568;  /note=""K->A: Does not abolish Ran binding activity and partially abolish nuclear export complex formation; when associated with A-525 and A-572."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 572;  /note=""F->A: Does not abolish Ran binding activity and partially abolish nuclear export complex formation; when associated with A-525 and A-568."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 583;  /note=""M->A: Enhances Ran binding activity; when associated with A-590."";  /evidence=""ECO:0000269|PubMed:15574331""; MUTAGEN 590;  /note=""K->A: Enhances Ran binding activity and does not abolish nuclear export complex formation. Enhances Ran binding activity and does not abolish nuclear export complex formation; when associated with A-583. Enhances Ran binding activity and does not abolish nuclear export complex formation; when associated with A-550 and A-553."";  /evidence=""ECO:0000269|PubMed:15574331"""	O14980;	9606.ENSP00000384863;	1W9C;2L1L;3GB8;4BSM;4BSN;5DIS;6TVO;7B51;
P33307	CSE1_YEAST	reviewed	Importin alpha re-exporter (Chromosome segregation protein CSE1)	CSE1 YGL238W HRC135	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	960						P33307;	4932.YGL238W;	1WA5;1Z3H;
P24014	SLIT_DROME	reviewed	Protein slit (dSlit) [Cleaved into: Protein slit N-product; Protein slit C-product]	sli CG43758	Drosophila melanogaster (Fruit fly)	1504				DISRUPTION PHENOTYPE: Flies lacking sli exhibit disruption of the developing midline cells and the commissural axon pathways. {ECO:0000269|PubMed:3144436}.		P24014;	7227.FBpp0303575;	1W8A;
P56732	AVR2_CHICK	reviewed	Avidin-related protein 2	AVR2	Gallus gallus (Chicken)	150							9031.ENSGALP00000038525;	1WBI;
Q8NK89	ABFB_ASPKW	reviewed	Alpha-L-arabinofuranosidase B (ABF B) (Arabinosidase B) (EC 3.2.1.55)	abfB AKAW_08685	Aspergillus kawachii (strain NBRC 4308) (White koji mold) (Aspergillus awamori var. kawachi)	499		BIOTECHNOLOGY: Contribute to an increase in cereal utilization and formation of aroma in shochu brewing. {ECO:0000269|PubMed:16233515}.			"MUTAGEN 176..177;  /note=""CC->AA: Decreases the affinity toward the substrate."";  /evidence=""ECO:0000269|PubMed:15292273""; MUTAGEN 204;  /note=""T->A: Reduces thermostability and catalytic activity."";  /evidence=""ECO:0000269|PubMed:15292273""; MUTAGEN 221;  /note=""E->A: Impairs catalytic activity."";  /evidence=""ECO:0000269|PubMed:15292273""; MUTAGEN 297;  /note=""D->A: Impairs catalytic activity."";  /evidence=""ECO:0000269|PubMed:15292273"""		40384.Q8NK89;	1WD3;1WD4;2D43;2D44;6SXR;6SXS;6SXT;
O54288	KDGA_SACSO	reviewed	2-dehydro-3-deoxy-phosphogluconate/2-dehydro-3-deoxy-6-phosphogalactonate aldolase (EC 4.1.2.55)		Saccharolobus solfataricus (Sulfolobus solfataricus)	294								1W37;1W3I;1W3N;1W3T;2YDA;6G3Z;6GSO;6GT8;6GV2;6H2R;6H2S;6H7R;6H7S;
O15294	OGT1_HUMAN	reviewed	UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit (EC 2.4.1.255) (O-GlcNAc transferase subunit p110) (O-linked N-acetylglucosamine transferase 110 kDa subunit) (OGT)	OGT	Homo sapiens (Human)	1046			DISEASE: Note=Regulation of OGT activity and altered O-GlcNAcylations are implicated in diabetes and Alzheimer disease. O-GlcNAcylation of AKT1 affects insulin signaling and, possibly diabetes. Reduced O-GlcNAcylations and resulting increased phosphorylations of MAPT/TAU are observed in Alzheimer disease (AD) brain cerebrum.; DISEASE: Mental retardation, X-linked 106 (MRX106) [MIM:300997]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. {ECO:0000269|PubMed:26273451, ECO:0000269|PubMed:28302723, ECO:0000269|PubMed:28584052}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 208;  /note=""W->E: Abolishes homodimerization of the TPR domain. Slightly reduced enzyme activity; when associated with D-211."";  /evidence=""ECO:0000269|PubMed:15361863""; MUTAGEN 211;  /note=""I->D: Abolishes homodimerization of the TPR domain. Slightly reduced enzyme activity; when associated with E-208."";  /evidence=""ECO:0000269|PubMed:15361863""; MUTAGEN 508;  /note=""H->A: Loss of enzyme activity. Moderate increase in KMT2E ubiquitination. Moderate increase in KMT2E ubiquitination; when associated with A-508."";  /evidence=""ECO:0000269|PubMed:21240259, ECO:0000269|PubMed:26678539""; MUTAGEN 568;  /note=""H->A: Reduces enzyme activity by about 95%. Moderate increase in KMT2E ubiquitination; when associated with A-508."";  /evidence=""ECO:0000269|PubMed:21240259, ECO:0000269|PubMed:26678539""; MUTAGEN 911;  /note=""H->A: Reduces enzyme activity by over 90%."";  /evidence=""ECO:0000269|PubMed:21240259"""	O15294;	9606.ENSP00000362824;	1W3B;3PE3;3PE4;3TAX;4AY5;4AY6;4CDR;4GYW;4GYY;4GZ3;4GZ5;4GZ6;4N39;4N3A;4N3B;4N3C;4XI9;4XIF;5BNW;5C1D;5HGV;5LVV;5LWV;5NPR;5NPS;5VIE;5VIF;6E37;6EOU;6IBO;6MA1;6MA2;6MA3;6MA4;6MA5;6Q4M;6TKA;
Q92547	TOPB1_HUMAN	reviewed	DNA topoisomerase 2-binding protein 1 (DNA topoisomerase II-beta-binding protein 1) (TopBP1) (DNA topoisomerase II-binding protein 1)	TOPBP1 KIAA0259	Homo sapiens (Human)	1522						Q92547;	9606.ENSP00000260810;	1WF6;2XNH;2XNK;3AL2;3AL3;3JVE;3OLC;3PD7;3UEN;3UEO;6RML;6RMM;7CMZ;
Q05823	RN5A_HUMAN	reviewed	2-5A-dependent ribonuclease (2-5A-dependent RNase) (EC 3.1.26.-) (Ribonuclease 4) (Ribonuclease L) (RNase L)	RNASEL RNS4	Homo sapiens (Human)	741			DISEASE: Prostate cancer, hereditary, 1 (HPC1) [MIM:601518]: A condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000305|PubMed:11799394, ECO:0000305|PubMed:11941539, ECO:0000305|PubMed:12415269, ECO:0000305|PubMed:17344846}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.		"MUTAGEN 240;  /note=""K->N: Reduced 2-5A binding activity; almost complete loss of 2-5A binding activity; when associated with N-274."";  /evidence=""ECO:0000269|PubMed:7680958""; MUTAGEN 274;  /note=""K->N: Reduced 2-5A binding activity; almost complete loss of 2-5A binding activity; when associated with N-240."";  /evidence=""ECO:0000269|PubMed:7680958""; MUTAGEN 392;  /note=""K->R: Complete loss of enzymatic activity and enzyme dimerization. No change in binding to 2-5A and RNA."";  /evidence=""ECO:0000269|PubMed:9862963""; MUTAGEN 583;  /note=""H->A: No change in enzymatic activity."";  /evidence=""ECO:0000269|PubMed:11333017""; MUTAGEN 584;  /note=""P->A: No change in enzymatic activity."";  /evidence=""ECO:0000269|PubMed:11333017""; MUTAGEN 632;  /note=""W->A: No change in enzymatic activity."";  /evidence=""ECO:0000269|PubMed:11333017""; MUTAGEN 661;  /note=""D->A: Complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:11333017""; MUTAGEN 667;  /note=""R->A: Complete loss of enzymatic activity. No change in 2-5A binding and enzyme dimerization."";  /evidence=""ECO:0000269|PubMed:11333017""; MUTAGEN 672;  /note=""H->A: Complete loss of enzymatic activity. No change in 2-5A binding activity and enzyme dimerization."";  /evidence=""ECO:0000269|PubMed:11333017"""	Q05823;	9606.ENSP00000356530;	1WDY;4G8K;4G8L;4OAU;4OAV;
P10810	CD14_MOUSE	reviewed	Monocyte differentiation antigen CD14 (Myeloid cell-specific leucine-rich glycoprotein) (CD antigen CD14)	Cd14	Mus musculus (Mouse)	366				DISRUPTION PHENOTYPE: No visible phenotype. Mice are fertile and appear healthy when kept in a clean, microbe-free environment. Mice do not respond to bacterial smooth lipopolysaccharide (LPS). Contrary to wild-type, they do not develop toxic shock or secrete TNF in response to LPS. Surprisingly, they have fewer live bacteria in their lungs and bloodstream after inoculation with bacteria and are not killed by an inoculum that is lethal to wild-type; they are killed when the inoculum is further increased. {ECO:0000269|PubMed:8612135}.			10090.ENSMUSP00000056669;	1WWL;
Q970G9	Q970G9_SULTO	unreviewed	Uncharacterized protein	ST1625 STK_16250	Sulfurisphaera tokodaii (strain DSM 16993 / JCM 10545 / NBRC 100140 / 7) (Sulfolobus tokodaii)	173							273063.STK_16250;	1WY6;
Q8L5H4	Q8L5H4_MUSAC	unreviewed	Lectin		Musa acuminata (Banana) (Musa cavendishii)	141								1X1V;3MIT;3MIU;3MIV;
Q9Z2X8	KEAP1_MOUSE	reviewed	Kelch-like ECH-associated protein 1 (Cytosolic inhibitor of Nrf2) (INrf2)	Keap1 Inrf2 Kiaa0132	Mus musculus (Mouse)	624				DISRUPTION PHENOTYPE: Early postnatal lethality caused by abnormal cornification (PubMed:14517554). Mice survive until weaning and probably die from malnutrition resulting from hyperkeratosis in the esophagus and forestomach that cause gastric obstruction (PubMed:14517554). Defects are caused by constitutive activation Nfe2l2/Nrf2, leading to constitutive expression of phase 2 detoxifying enzymes (PubMed:14517554). Mice lacking both Nfe2l2/Nrf2 and Keap1 reverse the hyperkeratosis phenotype and are healthy and viable in normal conditions (PubMed:14517554). {ECO:0000269|PubMed:14517554}.	"MUTAGEN 71;  /note=""R->G: Abolished ability to ubiquitinate NFE2L2/NRF2 without affecting homodimerization."";  /evidence=""ECO:0000269|PubMed:16790436""; MUTAGEN 151;  /note=""C->S: Substitution with a small side chain that prevents covalent modification by an electrophile; promotes constitutive ubiquitination of NFE2L2/NRF2 and subsequent repression of phase 2 detoxifying enzymes. Knockin mice are healthy and viable in normal conditions but do not activate NFE2L2/NRF2 in response to oxidative stress."";  /evidence=""ECO:0000269|PubMed:18268004, ECO:0000269|PubMed:20956331""; MUTAGEN 273;  /note=""C->A: Abolishes repression of NFE2L2/NRF2-dependent gene expression. Knockin mice die approximately three weeks after birth because of impaired ability of the BCR(KEAP1) complex to ubiquitinate NFE2L2/NRF2; when associated with A-288."";  /evidence=""ECO:0000269|PubMed:14764894""; MUTAGEN 273;  /note=""C->W,M: Retains ability to degrade NFE2L2/NRF2; when associated with E-288."";  /evidence=""ECO:0000269|PubMed:26527616""; MUTAGEN 288;  /note=""C->A: Abolishes repression of NFE2L2/NRF2-dependent gene expression. Slows down degradation of NFE2L2/NRF2. Knockin mice die approximately three weeks after birth because of impaired ability of the BCR(KEAP1) complex to ubiquitinate NFE2L2/NRF2; when associated with A-273."";  /evidence=""ECO:0000269|PubMed:14764894""; MUTAGEN 288;  /note=""C->E,N,R: Retains ability to degrade NFE2L2/NRF2; when associated with W-273. Abolishes ability to be activated by 15-deoxy-delta(12,14)-prostaglandin J2."";  /evidence=""ECO:0000269|PubMed:26527616""; MUTAGEN 334;  /note=""Y->A: Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:20173742""; MUTAGEN 363;  /note=""S->A: Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:20173742""; MUTAGEN 380;  /note=""R->A: Impaired interaction with SQSTM1/p62. Abolished interaction with SQSTM1/p62; when associated with A-415 and A-483."";  /evidence=""ECO:0000269|PubMed:20173742, ECO:0000269|PubMed:20421418""; MUTAGEN 380;  /note=""R->M: Impaired interaction with NFE2L2/NRF2."";  /evidence=""ECO:0000269|PubMed:16790436""; MUTAGEN 382;  /note=""N->A: Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:20173742""; MUTAGEN 415;  /note=""R->A: Impaired interaction with SQSTM1/p62. Abolished interaction with SQSTM1/p62; when associated with A-380 and A-483."";  /evidence=""ECO:0000269|PubMed:20173742, ECO:0000269|PubMed:20421418""; MUTAGEN 415;  /note=""R->M: Impaired interaction with NFE2L2/NRF2."";  /evidence=""ECO:0000269|PubMed:16790436""; MUTAGEN 483;  /note=""R->A: Does not affect interaction with SQSTM1/p62. Abolished interaction with SQSTM1/p62; when associated with A-380 and A-415."";  /evidence=""ECO:0000269|PubMed:20173742, ECO:0000269|PubMed:20421418""; MUTAGEN 483;  /note=""R->M: Impaired interaction with NFE2L2/NRF2."";  /evidence=""ECO:0000269|PubMed:16790436""; MUTAGEN 508;  /note=""S->A: Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:20173742""; MUTAGEN 530;  /note=""Q->A: Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:20173742""; MUTAGEN 555;  /note=""S->A: Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:20173742""; MUTAGEN 599..601;  /note=""SGR->AAA: Decreases repression of NFE2L2/NRF2-dependent gene expression."";  /evidence=""ECO:0000269|PubMed:16507366""; MUTAGEN 602..604;  /note=""SGV->AAA: Abolishes repression of NFE2L2/NRF2-dependent gene expression."";  /evidence=""ECO:0000269|PubMed:16507366""; MUTAGEN 602;  /note=""S->A: Impaired interaction with SQSTM1/p62."";  /evidence=""ECO:0000269|PubMed:20173742""; MUTAGEN 605..608;  /note=""GVAV->AAAA: Decreases repression of NFE2L2/NRF2-dependent gene expression."";  /evidence=""ECO:0000269|PubMed:16507366"""	Q9Z2X8;	10090.ENSMUSP00000131029;	1X2J;1X2R;2DYH;2Z32;3ADE;3WDZ;3WN7;4ZY3;5CGJ;5FNQ;5FNR;5FNS;5FNT;5FNU;5FZJ;5FZN;6QMC;6QMD;6QME;6QMJ;6QMK;6ZEW;6ZEX;6ZEY;6ZEZ;6ZF0;6ZF1;6ZF2;6ZF3;6ZF4;6ZF5;6ZF6;6ZF7;6ZF8;7C5E;7C60;
Q8DQ62	Q8DQ62_STRR6	unreviewed	Teichoic acid phosphorylcholine esterase/choline binding protein E (CbpE)	lytD spr0831	Streptococcus pneumoniae (strain ATCC BAA-255 / R6)	627							171101.spr0831;	1WRA;2BIB;
Q92882	OSTF1_HUMAN	reviewed	Osteoclast-stimulating factor 1	OSTF1	Homo sapiens (Human)	214						Q92882;	9606.ENSP00000340836;	1X2K;1ZLM;3EHQ;3EHR;
O22265	SR43C_ARATH	reviewed	Signal recognition particle 43 kDa protein, chloroplastic (Chromo protein SRP43) (CpSRP43)	CAO CPSRP43 At2g47450 T30B22.25	Arabidopsis thaliana (Mouse-ear cress)	373				DISRUPTION PHENOTYPE: Plants show a reduced level of the major light-harvesting chlorophyll a/b-binding proteins (LHCPs). {ECO:0000269|PubMed:9878634}.	"MUTAGEN 161;  /note=""R->A: Decreased interaction with LHCP."";  /evidence=""ECO:0000269|PubMed:18621669""; MUTAGEN 192;  /note=""R->A: Decreased interaction with LHCP."";  /evidence=""ECO:0000269|PubMed:18621669""; MUTAGEN 204;  /note=""Y->A: Loss of interaction with LHCP."";  /evidence=""ECO:0000269|PubMed:18621669""; MUTAGEN 226;  /note=""R->A: Decreased interaction with LHCP."";  /evidence=""ECO:0000269|PubMed:18621669""; MUTAGEN 269;  /note=""Y->A: Decreased interaction with ALB3."";  /evidence=""ECO:0000269|PubMed:20018841""; MUTAGEN 291;  /note=""W->A: Decreased interaction with ALB3."";  /evidence=""ECO:0000269|PubMed:20018841""; MUTAGEN 293;  /note=""D->A: Decreased interaction with ALB3."";  /evidence=""ECO:0000269|PubMed:20018841"""	O22265;	3702.AT2G47450.1;	1X32;1X3P;1X3Q;2HUG;2N88;3DEO;3DEP;3UI2;5E4W;5E4X;
Q81HJ5	Q81HJ5_BACCR	unreviewed	Outer surface protein	BC_0811	Bacillus cereus (strain ATCC 14579 / DSM 31 / CCUG 7414 / JCM 2152 / NBRC 15305 / NCIMB 9373 / NCTC 2599 / NRRL B-3711)	361								1X7F;
P21793	PGS2_BOVIN	reviewed	Decorin (Bone proteoglycan II) (PG-S2)	DCN	Bos taurus (Bovine)	360						P21793;	9913.ENSBTAP00000004562;	1XCD;1XEC;1XKU;
P71451	INLC_LISMG	reviewed	Internalin C (InlC) (Internalin-related protein A)	inlC irpA	Listeria monocytogenes serotype 1/2a (strain EGD / Mackaness)	297				DISRUPTION PHENOTYPE: Significant reduction in virulence when injected intravenously into C57BL/6 mice; no effect on intracellular growth of bacteria in infected cell lines (PubMed:8878044, PubMed:20855622, PubMed:23403554). Slightly reduced virulence when injected intravenously into BALB/c mice; no effect on intracellular growth of bacteria in infected cell lines (PubMed:8975898). Decreased bacterial spreading in polarized epithelial cells (human Caco-2 BBE1 cell line), decreased formation of host cell plasma membrane protusions, host cell junctions are not perturbed by bacteria (PubMed:19767742). Significantly increased production of cytokines, significantly increased recruitment of neutrophils to the peritoneum, after intraperitoneal injection into BALB/c mice (PubMed:20855622). {ECO:0000269|PubMed:19767742, ECO:0000269|PubMed:20855622, ECO:0000269|PubMed:23403554, ECO:0000269|PubMed:8878044, ECO:0000269|PubMed:8975898}.	"MUTAGEN 146;  /note=""F->A: Reduced binding to the SH3 6 domain of human DNMBP (Tuba), decreased bacterial spreading in an infected polarized enterocyte cell line, host cell junctions are no longer perturbed."";  /evidence=""ECO:0000269|PubMed:24332715""; MUTAGEN 173;  /note=""K->A: Reduced binding to the SH3 6 domain of human DNMBP (Tuba); conflicting results are also found. Host NF-kappa-B is still not translocated into the nucleus, decreased virulence in C57BL/6 mice, bacteria replicate less well in mouse liver."";  /evidence=""ECO:0000269|PubMed:19767742, ECO:0000269|PubMed:23403554, ECO:0000269|PubMed:24332715""; MUTAGEN 246..247;  /note=""YY->AA: Prevents InlC-only crystals."";  /evidence=""ECO:0000269|PubMed:24332715"""	P71451;		1XEU;4CC4;
O88689	PCDA4_MOUSE	reviewed	Protocadherin alpha-4 (PCDH-alpha-4)	Pcdha4 Cnr1	Mus musculus (Mouse)	947						O88689;		1WUZ;5DZW;
P42658	DPP6_HUMAN	reviewed	Dipeptidyl aminopeptidase-like protein 6 (DPPX) (Dipeptidyl aminopeptidase-related protein) (Dipeptidyl peptidase 6) (Dipeptidyl peptidase IV-like protein) (Dipeptidyl peptidase VI) (DPP VI)	DPP6	Homo sapiens (Human)	865			DISEASE: Familial paroxysmal ventricular fibrillation 2 (VF2) [MIM:612956]: A cardiac arrhythmia marked by fibrillary contractions of the ventricular muscle due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricle and by absence of atrial activity. {ECO:0000269|PubMed:19285295}. Note=The disease is caused by variants affecting the gene represented in this entry. A genetic variation 340 bases upstream from the ATG start site of the DPP6 gene is the cause of familial paroxysmal ventricular fibrillation type 2.; DISEASE: Mental retardation, autosomal dominant 33 (MRD33) [MIM:616311]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD33 patients manifest microcephaly and intellectual disability. {ECO:0000269|PubMed:23832105}. Note=The disease is caused by variants affecting the gene represented in this entry.			P42658;	9606.ENSP00000367001;	1XFD;
P14280	PME1_SOLLC	reviewed	Pectinesterase 1 (PE 1) (EC 3.1.1.11) (Pectin methylesterase 1)	PME1.9	Solanum lycopersicum (Tomato) (Lycopersicon esculentum)	546							4081.Solyc07g064170.2.1;	1XG2;
Q816R4	Q816R4_BACCR	unreviewed	Putative acetyltransferase/acyltransferase	BC_4754	Bacillus cereus (strain ATCC 14579 / DSM 31 / CCUG 7414 / JCM 2152 / NBRC 15305 / NCIMB 9373 / NCTC 2599 / NRRL B-3711)	170								1XHD;
P23468	PTPRD_HUMAN	reviewed	Receptor-type tyrosine-protein phosphatase delta (Protein-tyrosine phosphatase delta) (R-PTP-delta) (EC 3.1.3.48)	PTPRD	Homo sapiens (Human)	1912					"MUTAGEN 1178;  /note=""R->A: 2.5-fold reduction in cleavage. 10-fold reduction in cleavage; when associated with A-1181."";  /evidence=""ECO:0000269|PubMed:7896816""; MUTAGEN 1181;  /note=""R->A: No reduction in cleavage. 10-fold reduction in cleavage; when associated with A-1178."";  /evidence=""ECO:0000269|PubMed:7896816"""	P23468;	9606.ENSP00000370593;	1X5Z;2DLH;2YD6;2YD7;4RCA;5WY8;5XNP;6X3A;
P19544	WT1_HUMAN	reviewed	Wilms tumor protein (WT33)	WT1	Homo sapiens (Human)	449			DISEASE: Frasier syndrome (FS) [MIM:136680]: Characterized by a slowly progressing nephropathy leading to renal failure in adolescence or early adulthood, male pseudohermaphroditism, and no Wilms tumor. As for histological findings of the kidneys, focal glomerular sclerosis is often observed. There is phenotypic overlap with Denys-Drash syndrome. Inheritance is autosomal dominant. {ECO:0000269|PubMed:10571943}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Wilms tumor 1 (WT1) [MIM:194070]: Embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms. {ECO:0000269|PubMed:1317572, ECO:0000269|PubMed:15150775, ECO:0000269|PubMed:9108089, ECO:0000269|PubMed:9529364}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Denys-Drash syndrome (DDS) [MIM:194080]: Typical nephropathy characterized by diffuse mesangial sclerosis, genital abnormalities, and/or Wilms tumor. There is phenotypic overlap with WAGR syndrome and Frasier syndrome. Inheritance is autosomal dominant, but most cases are sporadic. {ECO:0000269|PubMed:10738002, ECO:0000269|PubMed:10799199, ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:11519891, ECO:0000269|PubMed:1302008, ECO:0000269|PubMed:1338906, ECO:0000269|PubMed:15349765, ECO:0000269|PubMed:1655284, ECO:0000269|PubMed:8111391, ECO:0000269|PubMed:8112732, ECO:0000269|PubMed:8295405, ECO:0000269|PubMed:8388765, ECO:0000269|PubMed:8411073, ECO:0000269|PubMed:8741319, ECO:0000269|PubMed:8956030, ECO:0000269|PubMed:9475094, ECO:0000269|PubMed:9529364}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Nephrotic syndrome 4 (NPHS4) [MIM:256370]: A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. Some affected individuals have an inherited steroid-resistant form and progress to end-stage renal failure. Most patients with NPHS4 show diffuse mesangial sclerosis on renal biopsy, which is a pathologic entity characterized by mesangial matrix expansion with no mesangial hypercellularity, hypertrophy of the podocytes, vacuolized podocytes, thickened basement membranes, and diminished patency of the capillary lumen. {ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:15253707, ECO:0000269|PubMed:20798252, ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Meacham syndrome (MEACHS) [MIM:608978]: Rare sporadically occurring multiple malformation syndrome characterized by male pseudohermaphroditism with abnormal internal female genitalia comprising a uterus and double or septate vagina, complex congenital heart defect and diaphragmatic abnormalities. {ECO:0000269|PubMed:17853480}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving WT1 may be a cause of desmoplastic small round cell tumor (DSRCT). Translocation t(11;22)(p13;q12) with EWSR1.; DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. {ECO:0000269|PubMed:8401592}. Note=The disease may be caused by variants affecting the gene represented in this entry.		"MUTAGEN 73;  /note=""K->R: Abolishes sumoylation; when associated with R-177."";  /evidence=""ECO:0000269|PubMed:15520190""; MUTAGEN 177;  /note=""K->R: Abolishes sumoylation; when associated with R-77."";  /evidence=""ECO:0000269|PubMed:15520190""; MUTAGEN 343;  /note=""H->A: Reduced RNA binding."";  /evidence=""ECO:0000269|PubMed:19123921""; MUTAGEN 366;  /note=""R->A: Strongly reduced binding of DNA and RNA."";  /evidence=""ECO:0000269|PubMed:19123921""; MUTAGEN 372;  /note=""R->A: Strongly reduced binding of DNA and RNA."";  /evidence=""ECO:0000269|PubMed:19123921""; MUTAGEN 394;  /note=""R->A,S: Strongly reduced binding of DNA and RNA."";  /evidence=""ECO:0000269|PubMed:19123921""; MUTAGEN 434;  /note=""H->A: Reduced RNA binding."";  /evidence=""ECO:0000269|PubMed:19123921"""	P19544;	9606.ENSP00000331327;	1LU6;1XF7;2G7T;2G7V;2G7W;2G7X;2JP9;2JPA;2PRT;3HPJ;3MYJ;4R2E;4R2P;4R2Q;4R2R;4R2S;4WUU;5KL2;5KL3;5KL4;5KL5;5KL6;5KL7;6B0O;6B0P;6B0Q;6B0R;6BLW;6RSY;6WLH;
O00105	IPUA_ASPNG	reviewed	Isopullulanase (EC 3.2.1.57)	ipuA	Aspergillus niger	564								1WMR;1X0C;2Z8G;3WWG;
Q8U192	THIE_PYRFU	reviewed	Thiamine-phosphate synthase (TP synthase) (TPS) (EC 2.5.1.3) (Thiamine-phosphate pyrophosphorylase) (TMP pyrophosphorylase) (TMP-PPase)	thiE PF1334	Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1)	207							186497.PF1334;	1XI3;
P40477	NU159_YEAST	reviewed	Nucleoporin NUP159 (Nuclear pore protein NUP159)	NUP159 NUP158 RAT7 YIL115C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1460						P40477;	4932.YIL115C;	1XIP;3PBP;3RRM;3TKN;4DS1;
A0A6L7H340	A0A6L7H340_BACAN	unreviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA2 dapA GBAA_3935	Bacillus anthracis	292							198094.BA_3935;	1XKY;1XL9;3HIJ;
Q13835	PKP1_HUMAN	reviewed	Plakophilin-1 (Band 6 protein) (B6P)	PKP1	Homo sapiens (Human)	747			DISEASE: Ectodermal dysplasia-skin fragility syndrome (EDSFS) [MIM:604536]: A form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Characterized by features of both cutaneous fragility and congenital ectodermal dysplasia affecting skin, hair and nails. There is no evidence of significant abnormalities in other epithelia or tissues. Desmosomes in the skin are small and poorly formed with widening of keratinocyte intercellular spaces and perturbed desmosome/keratin intermediate filament interactions. Note=The disease is caused by variants affecting the gene represented in this entry.			Q13835;	9606.ENSP00000263946;	1XM9;
P0AFB1	NLPI_ECOLI	reviewed	Lipoprotein NlpI	nlpI yhbM b3163 JW3132	Escherichia coli (strain K12)	294				DISRUPTION PHENOTYPE: Highly sensitive to osmotic conditions in low-salt medium and also thermosensitive under low-salt conditions. Shows pronounced filamentation at 42 degree Celsius under low osmolarity, but not at 30 or 37 degrees. Growth in low-salt medium is severely restricted at 30 degrees and no growth is observed at 37 and 42 degree Celsius. Shows increased eDNA production. Produces 100-fold more outer-membrane vesicles making the organism more resistant to toxins, and enhancing survival under stress. Higher sensitivity to ultra high pressure than wild-type counterparts (PubMed:16597971). Strongly represses cell swarming but no effect on cell swimming (PubMed:17122336). {ECO:0000269|PubMed:10400590, ECO:0000269|PubMed:15047720, ECO:0000269|PubMed:16597971, ECO:0000269|PubMed:16855227, ECO:0000269|PubMed:17122336, ECO:0000269|PubMed:17163978, ECO:0000269|PubMed:20833130}.	"MUTAGEN 103;  /note=""G->D: Loss of interaction with Prc and IbpB leading to thermosensitivity."";  /evidence=""ECO:0000269|PubMed:15047720""; MUTAGEN 282..294;  /note=""Missing: Loss of activity leading to thermosensitivity."";  /evidence=""ECO:0000269|PubMed:15047720""; MUTAGEN 283..294;  /note=""Missing: No phenotype."";  /evidence=""ECO:0000269|PubMed:15047720""; MUTAGEN 284..294;  /note=""Missing: No phenotype."";  /evidence=""ECO:0000269|PubMed:15047720"""	P0AFB1;	511145.b3163;	1XNF;5WQL;6IQQ;6IQS;6IQU;
Q9NZL4	HPBP1_HUMAN	reviewed	Hsp70-binding protein 1 (HspBP1) (Heat shock protein-binding protein 1) (Hsp70-binding protein 2) (HspBP2) (Hsp70-interacting protein 1) (Hsp70-interacting protein 2)	HSPBP1 HSPBP PP1845	Homo sapiens (Human)	359						Q9NZL4;	9606.ENSP00000255631;	1XQR;1XQS;
Q57265	Q57265_NEIME	unreviewed	Capsule biosynthesis protein (Polyhydroxyalkanoate biosynthesis repressor PhaR) (Polysialic acid capsule biosynthesis protein SiaC) (SiaC)	synC siaC A6J53_03590 B1A92_03300 CNQ34_04405 NCTC8249_00031 NCTC8554_01562	Neisseria meningitidis	349								1XUU;1XUZ;4IPI;4IPJ;
P23945	FSHR_HUMAN	reviewed	Follicle-stimulating hormone receptor (FSH-R) (Follitropin receptor)	FSHR LGR1	Homo sapiens (Human)	695			DISEASE: Ovarian dysgenesis 1 (ODG1) [MIM:233300]: An autosomal recessive disease characterized by primary amenorrhea, variable development of secondary sex characteristics, poorly developed streak ovaries, and high serum levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). {ECO:0000269|PubMed:10551778, ECO:0000269|PubMed:11889179, ECO:0000269|PubMed:12571157, ECO:0000269|PubMed:12915623, ECO:0000269|PubMed:7553856, ECO:0000269|PubMed:9769327, ECO:0000269|PubMed:9851774}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Ovarian hyperstimulation syndrome (OHSS) [MIM:608115]: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis. {ECO:0000269|PubMed:12930927, ECO:0000269|PubMed:12930928, ECO:0000269|PubMed:15080154, ECO:0000269|PubMed:16278261, ECO:0000269|PubMed:17721928, ECO:0000269|PubMed:24058690, ECO:0000269|PubMed:25581598}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 330;  /note=""Y->F: No change in intracellular cAMP accumulation."";  /evidence=""ECO:0000269|PubMed:11847099""; MUTAGEN 335;  /note=""Y->F: Reduces intracellular cAMP accumulation."";  /evidence=""ECO:0000269|PubMed:11847099"""	P23945;	9606.ENSP00000384708;	1XUN;1XWD;4AY9;4MQW;
P48632	FPVA_PSEAE	reviewed	Ferripyoverdine receptor	fpvA PA2398	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	815								1XKH;2IAH;2O5P;2W16;2W6T;2W6U;2W75;2W76;2W77;2W78;5ODW;
P25053	TENI_BACSU	reviewed	Thiazole tautomerase (EC 5.3.99.10)	tenI BSU11660	Bacillus subtilis (strain 168)	205				DISRUPTION PHENOTYPE: Inactivation of this gene causes a delay in sporulation, but does not affect cell growth and the production of extracellular enzymes. {ECO:0000269|PubMed:1898926}.	"MUTAGEN 122;  /note=""H->Q,A: Loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:21534620"""		224308.BSU11660;	1YAD;3QH2;
Q45871	Q45871_CLOBO	unreviewed	HA-33 (HA-33 protein) (HA33) (HA34) (Non-toxin haemagglutinin HA34)	HA-33 HA ha33 ha34	Clostridium botulinum	293								1YBI;4LO0;4LO1;4LO2;4LO3;4LO7;5BP5;5BQU;
P56734	AVR4_CHICK	reviewed	Avidin-related protein 4/5	AVR4; AVR5	Gallus gallus (Chicken)	150							9031.ENSGALP00000033787;	1Y52;1Y53;1Y55;2FHL;2FHN;2MF6;2OF8;2OF9;2OFA;2OFB;3MM0;4BCS;
Q8YEF2	Q8YEF2_BRUME	unreviewed	Hydroxymethylglutaryl-CoA lyase (EC 4.1.3.4)	BMEI1926	Brucella melitensis biotype 1 (strain 16M / ATCC 23456 / NCTC 10094)	287							224914.BMEI1926;	1YDN;
P27859	TATD_ECOLI	reviewed	3'-5' ssDNA/RNA exonuclease TatD (EC 3.1.11.-) (EC 3.1.13.-) (DNase TatD)	tatD mttC yigW yigX b4483 JW5931	Escherichia coli (strain K12)	260				DISRUPTION PHENOTYPE: Knockout cells are less resistant to the DNA damaging agent H(2)O(2). {ECO:0000269|PubMed:25114049}.	"MUTAGEN 62;  /note=""H->A: Significant decrease in nuclease activity."";  /evidence=""ECO:0000269|PubMed:25114049""; MUTAGEN 64;  /note=""H->A: No change in nuclease activity."";  /evidence=""ECO:0000269|PubMed:25114049""; MUTAGEN 91;  /note=""E->A: Lack of nuclease activity."";  /evidence=""ECO:0000269|PubMed:25114049""; MUTAGEN 127;  /note=""H->A: No change in nuclease activity."";  /evidence=""ECO:0000269|PubMed:25114049""; MUTAGEN 152;  /note=""H->A: No change in nuclease activity."";  /evidence=""ECO:0000269|PubMed:25114049""; MUTAGEN 201;  /note=""E->A: Lack of nuclease activity."";  /evidence=""ECO:0000269|PubMed:25114049""; MUTAGEN 203;  /note=""D->A: Lack of nuclease activity."";  /evidence=""ECO:0000269|PubMed:25114049"""		511145.b4483;	1XWY;4P5U;4PE8;
Q8WUM0	NU133_HUMAN	reviewed	Nuclear pore complex protein Nup133 (133 kDa nucleoporin) (Nucleoporin Nup133)	NUP133	Homo sapiens (Human)	1156			DISEASE: Nephrotic syndrome 18 (NPHS18) [MIM:618177]: A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. Some affected individuals have an inherited steroid-resistant form that progresses to end-stage renal failure. NPHS18 is an autosomal recessive, steroid-resistant progressive form with onset in the first decade of life. {ECO:0000269|PubMed:30179222}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Galloway-Mowat syndrome 8 (GAMOS8) [MIM:618349]: A form of Galloway-Mowat syndrome, a severe renal-neurological disease characterized by early-onset nephrotic syndrome associated with microcephaly, central nervous system abnormalities, developmental delays, and a propensity for seizures. Brain anomalies include gyration defects ranging from lissencephaly to pachygyria and polymicrogyria, and cerebellar hypoplasia. Most patients show facial dysmorphism characterized by a small, narrow forehead, large/floppy ears, deep-set eyes, hypertelorism and micrognathia. Additional variable features are visual impairment and arachnodactyly. Most patients die in early childhood. GAMOS8 inheritance is autosomal recessive. {ECO:0000269|PubMed:30427554}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q8WUM0;	9606.ENSP00000261396;	1XKS;3CQC;3CQG;3I4R;5A9Q;
Q4W6G0	QGDA_PSEPU	reviewed	Quinohemoprotein alcohol dehydrogenase ADH-IIG (ADH IIG) (EC 1.1.9.1) (Alcohol dehydrogenase (azurin))	qgdA	Pseudomonas putida (Arthrobacter siderocapsulatus)	718								1YIQ;
P08575	PTPRC_HUMAN	reviewed	Receptor-type tyrosine-protein phosphatase C (EC 3.1.3.48) (Leukocyte common antigen) (L-CA) (T200) (CD antigen CD45)	PTPRC CD45	Homo sapiens (Human)	1306			DISEASE: Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]: A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. {ECO:0000269|PubMed:11145714}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Multiple sclerosis (MS) [MIM:126200]: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. {ECO:0000269|PubMed:11101853}. Note=Disease susceptibility may be associated with variants affecting the gene represented in this entry.		"MUTAGEN 853;  /note=""C->S: Loss of activity. Abolishes interaction with SKAP1."";  /evidence=""ECO:0000269|PubMed:11909961"""	P08575;	9606.ENSP00000411355;	1YGR;1YGU;5FMV;5FN6;5FN7;
P23509	GLGS_SOLTU	reviewed	Glucose-1-phosphate adenylyltransferase small subunit, chloroplastic/amyloplastic (EC 2.7.7.27) (ADP-glucose pyrophosphorylase) (ADP-glucose synthase) (AGPase B) (Alpha-D-glucose-1-phosphate adenyl transferase)		Solanum tuberosum (Potato)	521						P23509;	4113.PGSC0003DMT400079823;	1YP2;1YP3;1YP4;
P94489	XYNB_BACSU	reviewed	Beta-xylosidase (EC 3.2.1.37) (1,4-beta-D-xylan xylohydrolase) (Xylan 1,4-beta-xylosidase)	xynB BSU17580	Bacillus subtilis (strain 168)	533							224308.BSU17580;	1YIF;
Q9K6P5	Q9K6P5_ALKHC	unreviewed	Xylan beta-1,4-xylosidase (EC 3.2.1.37)	xynB	Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) (Bacillus halodurans)	528							272558.10176307;	1YRZ;
Q3E840	DPH3_YEAST	reviewed	Diphthamide biosynthesis protein 3 (Kluyveromyces lactis toxin-insensitive protein 11)	KTI11 DPH3 YBL071W-A	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	82					"MUTAGEN 4;  /note=""Y->A: Impaired interaction with ATS1/KTI13."";  /evidence=""ECO:0000269|PubMed:25543256""; MUTAGEN 5;  /note=""D->A: Impaired interaction with ATS1/KTI13."";  /evidence=""ECO:0000269|PubMed:25543256""; MUTAGEN 8;  /note=""E->A: Little or no effect on interaction with ATS1/KTI13."";  /evidence=""ECO:0000269|PubMed:25543256"""	Q3E840;	4932.YBL071W-A;	1YOP;1YWS;4D4O;4D4P;4X33;5AX2;
Q9I1L3	Q9I1L3_PSEAE	unreviewed	Uncharacterized protein	PA2260	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	260								1YX1;
P65522	NANE_STRP1	reviewed	Putative N-acetylmannosamine-6-phosphate 2-epimerase (EC 5.1.3.9) (ManNAc-6-P epimerase)	nanE SPy_0251 M5005_Spy0212	Streptococcus pyogenes serotype M1	234								1YXY;
O93655	TRF3_THEAC	reviewed	Tricorn protease-interacting factor F3 (EC 3.4.11.-)	trf3 Ta0815	Thermoplasma acidophilum (strain ATCC 25905 / DSM 1728 / JCM 9062 / NBRC 15155 / AMRC-C165)	780							273075.Ta0815;	1Z1W;1Z5H;3Q7J;
P04850	HN_PIV5	reviewed	Hemagglutinin-neuraminidase (EC 3.2.1.18)	HN	Parainfluenza virus 5 (strain W3) (PIV5) (Simian virus 5)	565								1Z4V;1Z4W;1Z4X;1Z4Y;1Z4Z;1Z50;3TSI;4JF7;
Q12884	SEPR_HUMAN	reviewed	Prolyl endopeptidase FAP (EC 3.4.21.26) (170 kDa melanoma membrane-bound gelatinase) (Dipeptidyl peptidase FAP) (EC 3.4.14.5) (Fibroblast activation protein alpha) (FAPalpha) (Gelatine degradation protease FAP) (EC 3.4.21.-) (Integral membrane serine protease) (Post-proline cleaving enzyme) (Serine integral membrane protease) (SIMP) (Surface-expressed protease) (Seprase) [Cleaved into: Antiplasmin-cleaving enzyme FAP, soluble form (APCE) (EC 3.4.14.5) (EC 3.4.21.-) (EC 3.4.21.26)]	FAP	Homo sapiens (Human)	760					"MUTAGEN 123;  /note=""R->A,M,E: Reduces dipeptidyl peptidase and endopeptidase activities."";  /evidence=""ECO:0000269|PubMed:17381073""; MUTAGEN 203;  /note=""E->A,D,Q: Reduces dipeptidyl peptidase and endopeptidase activities. Does not inhibit cell adhesion, migration and invasion. Inhibits dipeptidyl peptidase and endopeptidase activities; when associated with A-204."";  /evidence=""ECO:0000269|PubMed:16175601, ECO:0000269|PubMed:17381073""; MUTAGEN 204;  /note=""E->A,D,Q: Reduces dipeptidyl peptidase and endopeptidase activities. Does not inhibit cell adhesion, migration and invasion. Inhibits dipeptidyl peptidase and endopeptidase activities; when associated with A-203."";  /evidence=""ECO:0000269|PubMed:16175601, ECO:0000269|PubMed:17381073""; MUTAGEN 624;  /note=""S->A: Reduces dipeptidyl peptidase and gelatinolytic activities. Does not inhibit cell adhesion, migration and invasion."";  /evidence=""ECO:0000269|PubMed:10593948, ECO:0000269|PubMed:16175601""; MUTAGEN 656;  /note=""Y->F: Reduces dipeptidyl peptidase and endopeptidase activities."";  /evidence=""ECO:0000269|PubMed:17381073""; MUTAGEN 657;  /note=""A->D,N: Inhibits endopeptidase activity. Increases dipeptidyl peptidase activity."";  /evidence=""ECO:0000269|PubMed:17381073""; MUTAGEN 657;  /note=""A->F,V: Reduces dipeptidyl peptidase and endopeptidase activities."";  /evidence=""ECO:0000269|PubMed:17381073""; MUTAGEN 657;  /note=""A->Q: Inhibits endopeptidase activity. No change in dipeptidyl peptidase activity."";  /evidence=""ECO:0000269|PubMed:17381073""; MUTAGEN 657;  /note=""A->S,T: Reduces strongly endopeptidase activity. No change in dipeptidyl peptidase activity."";  /evidence=""ECO:0000269|PubMed:17381073""; MUTAGEN 704;  /note=""N->A: Reduces dipeptidyl peptidase and endopeptidase activities."";  /evidence=""ECO:0000269|PubMed:17381073"""	Q12884;	9606.ENSP00000188790;	1Z68;6Y0F;
Q4R2T2	Q4R2T2_STRC1	unreviewed	Prenyltransferase		Streptomyces sp. (strain CL190)	307								1ZB6;1ZCW;1ZDW;1ZDY;
A9CG82	A9CG82_AGRFC	unreviewed	Glycerophosphodiester phosphodiesterase	ugpQ Atu4212	Agrobacterium fabrum (strain C58 / ATCC 33970) (Agrobacterium tumefaciens (strain C58))	248							176299.Atu4212;	1ZCC;
Q8U0A9	Q8U0A9_PYRFU	unreviewed	2-dehydro-3-deoxyphosphoheptonate aldolase (EC 2.5.1.54)	PF1690	Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1)	262							186497.PF1690;	1ZCO;4C1K;4C1L;4GRS;
P30130	FIMD_ECOLI	reviewed	Outer membrane usher protein FimD	fimD b4317 JW5780	Escherichia coli (strain K12)	878						P30130;	511145.b4317;	1ZDV;1ZDX;1ZE3;3BWU;3OHN;3RFZ;4J3O;6E14;6E15;
P35844	KES1_YEAST	reviewed	Oxysterol-binding protein homolog 4 (Protein KES1)	KES1 OSH4 YPL145C LPI3C P2614	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	434					"MUTAGEN 97;  /note=""Y->F: Abolishes both cholesterol binding and biological function."";  /evidence=""ECO:0000269|PubMed:16136145""; MUTAGEN 109;  /note=""K->A: Strong reduction in cholesterol transport. Abolishes binding to phosphatidylinositol 4-phosphate."";  /evidence=""ECO:0000269|PubMed:16136145, ECO:0000269|PubMed:22162133""; MUTAGEN 111;  /note=""L->D: Abolishes both cholesterol binding and biological function."";  /evidence=""ECO:0000269|PubMed:16136145""; MUTAGEN 112;  /note=""N->E: Abolishes binding to phosphatidylinositol 4-phosphate."";  /evidence=""ECO:0000269|PubMed:22162133""; MUTAGEN 117;  /note=""E->A: Abolishes both cholesterol binding and biological function."";  /evidence=""ECO:0000269|PubMed:16136145""; MUTAGEN 143..144;  /note=""HH->AA: Reduction in cholesterol transport. Abolishes binding to phosphatidylinositol 4-phosphate."";  /evidence=""ECO:0000269|PubMed:16136145, ECO:0000269|PubMed:22162133, ECO:0000269|PubMed:26206936""; MUTAGEN 168;  /note=""K->A: Slight reduction in cholesterol transport."";  /evidence=""ECO:0000269|PubMed:16136145""; MUTAGEN 168;  /note=""K->A: Strong reduction in cholesterol transport."";  /evidence=""ECO:0000269|PubMed:16136145""; MUTAGEN 202..204;  /note=""HIE->AIA: Strong reduction in cholesterol binding without affecting phosphatidylinositol 4-phosphate binding."";  /evidence=""ECO:0000269|PubMed:22162133""; MUTAGEN 336;  /note=""K->A: Strong reduction in cholesterol transport. Abolishes binding to phosphatidylinositol 4-phosphate."";  /evidence=""ECO:0000269|PubMed:16136145, ECO:0000269|PubMed:22162133""; MUTAGEN 340;  /note=""E->A: Abolishes binding to phosphatidylinositol 4-phosphate."";  /evidence=""ECO:0000269|PubMed:22162133""; MUTAGEN 344;  /note=""R->A: Slight reduction in cholesterol transport. Abolishes binding to phosphatidylinositol 4-phosphate."";  /evidence=""ECO:0000269|PubMed:16136145, ECO:0000269|PubMed:22162133"""	P35844;	4932.YPL145C;	1ZHT;1ZHW;1ZHX;1ZHY;1ZHZ;1ZI7;3SPW;4F4B;4FES;4JCH;
O15455	TLR3_HUMAN	reviewed	Toll-like receptor 3 (CD antigen CD283)	TLR3	Homo sapiens (Human)	904			DISEASE: Encephalopathy, acute, infection-induced, Herpes-specific, 2 (IIAE2) [MIM:613002]: A rare complication of human herpesvirus 1 (HHV-1) infection, occurring in only a small minority of HHV-1 infected individuals. It is characterized by hemorrhagic necrosis of parts of the temporal and frontal lobes. Onset is over several days and involves fever, headache, seizures, stupor, and often coma, frequently with a fatal outcome. {ECO:0000269|PubMed:17872438}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. TLR3 mutations predispose otherwise healthy individuals to isolated herpes simplex encephalitis through a mechanism that involves impaired IFNs production and reduced immune defense against viral infection in the central nervous system.		"MUTAGEN 95;  /note=""C->A: Reduced response to ds-RNA."";  /evidence=""ECO:0000269|PubMed:16144834""; MUTAGEN 122;  /note=""C->A: Reduced response to ds-RNA."";  /evidence=""ECO:0000269|PubMed:16144834""; MUTAGEN 196;  /note=""N->G: Reduced expression levels; when associated with R-247."";  /evidence=""ECO:0000269|PubMed:16144834""; MUTAGEN 247;  /note=""N->R: Reduced response to ds-RNA. Reduced expression levels; when associated with G-196."";  /evidence=""ECO:0000269|PubMed:16144834""; MUTAGEN 539;  /note=""H->A: No effect."";  /evidence=""ECO:0000269|PubMed:16720699""; MUTAGEN 539;  /note=""H->E: Loss of RNA binding. Constitutive activation of NF-kappa-B."";  /evidence=""ECO:0000269|PubMed:16720699""; MUTAGEN 541;  /note=""N->A: Loss of RNA binding. Abolishes activation of NF-kappa-B."";  /evidence=""ECO:0000269|PubMed:16720699""; MUTAGEN 759;  /note=""Y->F: Reduced activation of NF-kappa-B in response to ds-RNA. Reduced induction of IL-8 in response to ds-RNA. Loss of interaction with WDFY1."";  /evidence=""ECO:0000269|PubMed:17178723, ECO:0000269|PubMed:25736436""; MUTAGEN 858;  /note=""Y->F: Loss of interaction with WDFY1."";  /evidence=""ECO:0000269|PubMed:25736436"""	O15455;	9606.ENSP00000296795;	1ZIW;2A0Z;2MK9;2MKA;3ULU;3ULV;5GS0;7C76;
Q5L3Y2	PDXS_GEOKA	reviewed	Pyridoxal 5'-phosphate synthase subunit PdxS (PLP synthase subunit PdxS) (EC 4.3.3.6) (Pdx1)	pdxS GK0011	Geobacillus kaustophilus (strain HTA426)	294							235909.GK0011;	1ZNN;4WXY;4WXZ;4WY0;
Q7RMC9	Q7RMC9_PLAYO	unreviewed	2-deoxy-D-ribose 5-phosphate aldolase (EC 4.1.2.4) (Phosphodeoxyriboaldolase)	PY02252	Plasmodium yoelii yoelii	262								2A4A;
Q01705	NOTC1_MOUSE	reviewed	Neurogenic locus notch homolog protein 1 (Notch 1) (Motch A) (mT14) (p300) [Cleaved into: Notch 1 extracellular truncation (NEXT); Notch 1 intracellular domain (NICD)]	Notch1 Motch	Mus musculus (Mouse)	2531					"MUTAGEN 65;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 146;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 232;  /note=""T->V: No significant effect on its binding and activation by DLL1 or JAG1. No significant effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. Decrease in LFNG- and MFNG-mediated inhibition of its activation by JAG1. Significant decrease in LFNG- and MFNG-mediated inhibition of its activation by JAG1; when associated with V-1402."";  /evidence=""ECO:0000269|PubMed:28089369""; MUTAGEN 311;  /note=""T->V: Significant loss of binding and activation by DLL1 or JAG1. Decrease in RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. Decrease in LFNG-mediated inhibition of its activation by JAG1. Significant loss of binding and activation by DLL1 or JAG1 and complete loss of RFNG- and LFNG-mediated enhancement of its activation by DLL1; when associated with V-466. Decreased localization to the plasma membrane; when associated with A-435."";  /evidence=""ECO:0000269|PubMed:28089369, ECO:0000269|PubMed:30127001""; MUTAGEN 341;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 349;  /note=""T->V: Reduced binding and activation by JAG1 but not DLL1. Decrease in MFNG-mediated enhancement of its activation by DLL1."";  /evidence=""ECO:0000269|PubMed:28089369""; MUTAGEN 378;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 435;  /note=""S->A: No effect on localization to the plasma membrane. No effect on binding and activation by DLL1. Decreased localization to the plasma membrane; when associated with V-311."";  /evidence=""ECO:0000269|PubMed:30127001""; MUTAGEN 458;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 466;  /note=""T->V: Reduced binding and activation by DLL1 but not JAG1. Decrease in RFNG- and LFNG-mediated enhancement of its activation by DLL1. Loss of RFNG-mediated enhancement of its activation by JAG1. Significant loss of binding and activation by DLL1 or JAG1 and complete loss of RFNG- and LFNG-mediated enhancement of its activation by DLL1; when associated with V-311."";  /evidence=""ECO:0000269|PubMed:28089369""; MUTAGEN 496;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 534;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 609;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 647;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 722;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 759;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 797;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 951;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 997;  /note=""T->V: Reduced binding and activation by DLL1 but not JAG1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. No effect on LFNG- and MFNG-mediated inhibition of its activation by JAG1."";  /evidence=""ECO:0000269|PubMed:28089369""; MUTAGEN 1027;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 1035;  /note=""T->V: Reduced binding and activation by JAG1 but not DLL1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. No effect on LFNG- and MFNG-mediated inhibition of its activation by JAG1."";  /evidence=""ECO:0000269|PubMed:28089369""; MUTAGEN 1065;  /note=""S->A: Reduced activity."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 1159;  /note=""T->V: No significant effect on its binding and activation by DLL1 or JAG1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. No effect on LFNG- and MFNG-mediated inhibition of its activation by JAG1."";  /evidence=""ECO:0000269|PubMed:28089369""; MUTAGEN 1189;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 1273;  /note=""S->A: No effect."";  /evidence=""ECO:0000269|PubMed:21757702""; MUTAGEN 1362;  /note=""T->V: No significant effect on its binding and activation by DLL1 or JAG1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. No effect on LFNG- and MFNG-mediated inhibition of its activation by JAG1."";  /evidence=""ECO:0000269|PubMed:28089369""; MUTAGEN 1402;  /note=""T->V: No significant effect on its binding and activation by DLL1 or JAG1. No effect on RFNG-, LFNG- and MFNG-mediated enhancement of its activation by DLL1. Decrease in LFNG- and MFNG-mediated inhibition of its activation by JAG1. Significant decrease in LFNG- and MFNG-mediated inhibition of its activation by JAG1; when associated with V-232."";  /evidence=""ECO:0000269|PubMed:28089369""; MUTAGEN 1651..1654;  /note=""RQRR->AAAA: Processing by furin-like convertase abolished."";  /evidence=""ECO:0000269|PubMed:9653148""; MUTAGEN 1675;  /note=""C->S: Produces an activated, ligand-independent molecule; when associated with S-1682."";  /evidence=""ECO:0000269|PubMed:10882062""; MUTAGEN 1682;  /note=""C->S: Produces an activated, ligand-independent molecule; when associated with S-1675."";  /evidence=""ECO:0000269|PubMed:10882062""; MUTAGEN 1744;  /note=""V->L: NICD processing severely reduced.""; MUTAGEN 1945;  /note=""N->A: Reduced ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation and greatly reduced transactivation capacity. Abolished ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation; when associated with G-2012. Almost abolished transactivation capacity; when associated with A-2012."";  /evidence=""ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:18299578""; MUTAGEN 2012;  /note=""N->A: Slightly reduced ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation. Abolished ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation and almost abolished transactivation capacity; when associated with A-1945."";  /evidence=""ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:18299578""; MUTAGEN 2012;  /note=""N->G: Reduced ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation. Abolished ability to promote HIF1AN-dependent 2-oxoglutarate decarboxylation; when associated with A-1945."";  /evidence=""ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:18299578"""	Q01705;	10090.ENSMUSP00000028288;	1YMP;2QC9;2RQZ;2RR0;2RR2;3P3N;3P3P;5KY0;5KY4;5KY8;5KY9;
Q9DL16	Q9DL16_9INFA	unreviewed	Neuraminidase (EC 3.2.1.18) (Fragment)		Influenza A virus (A/Greece/109/99 (H3N2))	461								2AEP;
Q43866	INV1_ARATH	reviewed	Beta-fructofuranosidase, insoluble isoenzyme CWINV1 (EC 3.2.1.26) (Cell wall beta-fructosidase 1) (AtbetaFRUCT1) (Cell wall invertase 1) (AtcwINV1) (Sucrose hydrolase 1)	CWINV1 BFRUCT1 At3g13790 MMM17.26	Arabidopsis thaliana (Mouse-ear cress)	584					"MUTAGEN 63;  /note=""W->L: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17873089""; MUTAGEN 66;  /note=""D->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17873089, ECO:0000269|PubMed:18258263""; MUTAGEN 90;  /note=""W->L: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17873089""; MUTAGEN 125;  /note=""W->L: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17873089""; MUTAGEN 246;  /note=""E->A,Q: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17873089, ECO:0000269|PubMed:17963237, ECO:0000269|PubMed:18258263""; MUTAGEN 282;  /note=""D->A: Impaired beta-fructofuranosidase activity but enhanced 1-fructan exohydrolase activity."";  /evidence=""ECO:0000269|PubMed:17873089, ECO:0000269|PubMed:18258263""; MUTAGEN 282;  /note=""D->F: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17873089, ECO:0000269|PubMed:18258263""; MUTAGEN 282;  /note=""D->N: Normal activity."";  /evidence=""ECO:0000269|PubMed:17873089, ECO:0000269|PubMed:18258263""; MUTAGEN 285;  /note=""K->L: Slightly reduced activity."";  /evidence=""ECO:0000269|PubMed:17873089""; MUTAGEN 342;  /note=""N->D: Reduced activity and glycosylation."";  /evidence=""ECO:0000269|PubMed:17139091, ECO:0000269|PubMed:17888113"""	Q43866;	3702.AT3G13790.1;	2AC1;2OXB;2QQU;2QQV;2QQW;2XQR;
P42700	RO60_XENLA	reviewed	60 kDa SS-A/Ro ribonucleoprotein (60 kDa Ro protein) (60 kDa ribonucleoprotein Ro) (Ro60) (RoRNP) (TROVE domain family member 2)	ro60 trove2	Xenopus laevis (African clawed frog)	538								1YVP;1YVR;2I91;
Q5ZSV0	Q5ZSV0_LEGPH	unreviewed	Ankyrin repeat family protein	legA1 lpg2416	Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC 33152 / DSM 7513)	368							272624.lpg2416;	2AJA;
Q44493	ALGE4_AZOVI	reviewed	Mannuronan C5-epimerase AlgE4 (EC 5.1.3.37) (Poly(beta-D-mannuronate) C5 epimerase 4)	algE4	Azotobacter vinelandii	553								2AGM;2PYG;2PYH;
P84888	AAUB_ALCFA	reviewed	Aralkylamine dehydrogenase heavy chain (EC 1.4.9.2) (Aromatic amine dehydrogenase) (AADH)	aauB	Alcaligenes faecalis	390							511.JT27_04295;	2AGL;2AGW;2AGX;2AGY;2AGZ;2AH0;2AH1;2H3X;2H47;2HJ4;2HJB;2HKM;2HKR;2HXC;2I0R;2I0S;2I0T;2IAA;2IUP;2IUQ;2IUR;2IUV;2OIZ;2OJY;2OK4;2OK6;2Q7Q;
P31947	1433S_HUMAN	reviewed	14-3-3 protein sigma (Epithelial cell marker protein 1) (Stratifin)	SFN HME1	Homo sapiens (Human)	248						P31947;	9606.ENSP00000340989;	1YWT;1YZ5;3IQJ;3IQU;3IQV;3LW1;3MHR;3O8I;3P1N;3P1O;3P1P;3P1Q;3P1R;3P1S;3SMK;3SML;3SMM;3SMN;3SMO;3SP5;3SPR;3T0L;3T0M;3U9X;3UX0;4DAT;4DAU;4DHM;4DHN;4DHO;4DHP;4DHQ;4DHR;4DHS;4DHT;4DHU;4FL5;4FR3;4IEA;4JC3;4JDD;4QLI;4Y32;4Y3B;4Y5I;5BTV;5HF3;5LTW;5LU1;5LU2;5MHC;5MOC;5MXO;5MY9;5MYC;5N5R;5N5T;5N5W;5N75;5OEG;5OEH;5OK9;5OKF;5OM0;5OMA;6FAU;6FAV;6FAW;6FBB;6FBW;6FBY;6FCP;6FI4;6FI5;6G6X;6G8I;6G8J;6G8K;6G8L;6G8P;6G8Q;6GHP;6HHP;6HKB;6HKF;6HMT;6HMU;6HN2;6NV2;6QDR;6QDS;6QDT;6QDU;6QHL;6QHM;6QIU;6QZR;6QZS;6R5L;6RHC;6RJL;6RJQ;6RJZ;6RK8;6RKI;6RKK;6RKM;6RL3;6RL4;6RL6;6RM5;6RM7;6RP6;6RWH;6RWI;6RWS;6RWU;6RX2;6S39;6S3C;6S40;6S9Q;6SIN;6SIO;6SIP;6SIQ;6SLV;6SLW;6SLX;6T5F;6T5H;6T80;6TCH;6TJM;6TL3;6TLF;6TLG;6TM7;6TWZ;6W0L;6XWD;6XXC;6XY5;6Y18;6Y1D;6Y1J;6Y3M;6Y3O;6Y3R;6Y3S;6Y3V;6Y3W;6Y40;6Y44;6Y58;6Y7T;6Y8A;6Y8B;6Y8D;6Y8E;6YE9;6YIA;6YIB;6YIC;6YLU;6YOW;6YOX;6YOY;6YP2;6YP3;6YP8;6YPL;6YPY;6YQ2;6ZCJ;7AEW;7AOG;7AXN;7AYF;7AZ1;7AZ2;7BDP;7BDT;7BDY;7BFW;7BG3;7BGQ;7BGR;7BGV;7BGW;7BI3;7BIQ;7BIY;7BJF;7BJL;7BJW;7BKH;7NFW;7NIF;7NIG;7NIX;7NJ6;7NJ8;7NJ9;7NJA;7NJB;7NK3;7NK5;7NLA;7NLE;7NM1;7NM3;7NM9;7NQP;7NR7;7NRK;7NRL;7NSV;7NV4;7NVI;7NWS;7NXS;7NXT;7NXW;7NXY;7NY4;7NYE;7NYF;7NYG;7NZ6;7NZG;7NZK;7NZV;7O34;7O3A;7O3F;7O3P;7O3Q;7O3R;7O3S;7O57;7O59;7O5A;7O5C;7O5D;7O5F;7O5G;7O5O;7O5P;7O5S;7O5U;7O5X;7O6F;7O6G;7O6I;7O6J;7O6K;7O6M;7O6O;
O89053	COR1A_MOUSE	reviewed	Coronin-1A (Coronin-like protein A) (Clipin-A) (Coronin-like protein p57) (Tryptophan aspartate-containing coat protein) (TACO)	Coro1a Coro1	Mus musculus (Mouse)	461						O89053;	10090.ENSMUSP00000032949;	2AKF;2AQ5;2B4E;
Q5CS32	Q5CS32_CRYPI	unreviewed	Protein with 2 CAP (CARP) domains, possible adenyl cyclase-associated protein (Fragment)	cgd5_440	Cryptosporidium parvum (strain Iowa II)	183								2B0R;
Q04114	Q04114_ENTFL	unreviewed	Helix-turn-helix domain-containing protein (Helix-turn-helix transcriptional regulator) (Pheromone cCF10 receptor) (PrgX)	prgX GTI81_15620 H7D67_14785	Enterococcus faecalis (Streptococcus faecalis)	317								2AW6;2AWI;2AXU;2AXV;2AXZ;2GRL;
P19658	EXO70_YEAST	reviewed	Exocyst complex component EXO70 (Exocyst complex protein of 70 kDa)	EXO70 YJL085W J0932	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	623						P19658;	4932.YJL085W;	2B1E;2B7M;2PFV;5YFP;6VKL;
Q9XSC9	TCO2_BOVIN	reviewed	Transcobalamin-2 (TC-2) (Transcobalamin II) (TC II) (TCII)	TCN2	Bos taurus (Bovine)	432							9913.ENSBTAP00000029446;	2BB6;2BBC;2V3N;2V3P;
Q82ZI8	Q82ZI8_ENTFA	unreviewed	Uncharacterized protein	EF_3068	Enterococcus faecalis (strain ATCC 700802 / V583)	217							226185.EF_3068;	2B6C;
Q8DYB9	Q8DYB9_STRA5	unreviewed	Copper homeostasis protein CutC	cutC SAG1569	Streptococcus agalactiae serotype V (strain ATCC BAA-611 / 2603 V/R)	211								2BDQ;
Q59310	Q59310_CLOPF	unreviewed	Exo-alpha-sialidase (EC 3.2.1.18)	nanH	Clostridium perfringens	694								2BF6;2VK5;2VK6;2VK7;
P9WPY5	AROA_MYCTU	reviewed	3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19) (5-enolpyruvylshikimate-3-phosphate synthase) (EPSP synthase) (EPSPS)	aroA Rv3227	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	450							83332.Rv3227;	2BJB;2O0B;2O0D;2O0E;2O0X;2O0Z;2O15;
Q06142	IMB1_YEAST	reviewed	Importin subunit beta-1 (Importin-95) (Karyopherin subunit beta-1) (Karyopherin-95)	KAP95 YLR347C L8300.15	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	861						Q06142;	4932.YLR347C;	2BKU;3EA5;3ND2;5OWU;
Q2UVX4	CO3_BOVIN	reviewed	Complement C3 [Cleaved into: Complement C3 beta chain; Complement C3 alpha chain; C3a anaphylatoxin; C3-beta-c (C3bc); Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]	C3	Bos taurus (Bovine)	1661							9913.ENSBTAP00000022979;	2B39;
P74334	ACOX_SYNY3	reviewed	Apocarotenoid-15,15'-oxygenase (ACO) (8'-apo-beta-carotenal 15,15'-oxygenase) (EC 1.13.11.75) (Diox1)	sll1541	Synechocystis sp. (strain PCC 6803 / Kazusa)	490						P74334;	1148.1653515;	2BIW;2BIX;4OU8;4OU9;5KJA;5KJB;5KJD;5KK0;6BIG;6C7K;6C7O;6C7P;
O22321	O22321_MUSAC	unreviewed	Ripening-associated protein		Musa acuminata (Banana) (Musa cavendishii)	141								2BMY;2BMZ;2BN0;4PIF;4PIK;4PIT;4PIU;5EXG;
Q16531	DDB1_HUMAN	reviewed	DNA damage-binding protein 1 (DDB p127 subunit) (DNA damage-binding protein a) (DDBa) (Damage-specific DNA-binding protein 1) (HBV X-associated protein 1) (XAP-1) (UV-damaged DNA-binding factor) (UV-damaged DNA-binding protein 1) (UV-DDB 1) (XPE-binding factor) (XPE-BF) (Xeroderma pigmentosum group E-complementing protein) (XPCe)	DDB1 XAP1	Homo sapiens (Human)	1140					"MUTAGEN 316..319;  /note=""YLDN->ALAA: Impairs interaction with DDA1."";  /evidence=""ECO:0000269|PubMed:16949367""; MUTAGEN 537;  /note=""E->A: Slightly impairs interaction with CUL4A."";  /evidence=""ECO:0000269|PubMed:16413485""; MUTAGEN 561;  /note=""W->A: Strongly impairs interaction with CUL4A."";  /evidence=""ECO:0000269|PubMed:16413485""; MUTAGEN 840..842;  /note=""EAE->AAA: Impairs interaction with AMBRA1, DTL, DET1, DCAF1, DCAF5, DCAF11 and DCAF8."";  /evidence=""ECO:0000269|PubMed:16949367""; MUTAGEN 910..913;  /note=""MALY->AAAA: Impairs interaction with AMBRA1, DTL and DCAF5."";  /evidence=""ECO:0000269|PubMed:16949367""; MUTAGEN 953;  /note=""W->A: Impairs interaction with AMBRA1, ERCC8, DCAF5 and DCAF11."";  /evidence=""ECO:0000269|PubMed:16949367"""	Q16531;	9606.ENSP00000301764;	2B5L;2B5M;2B5N;2HYE;3E0C;3EI1;3EI2;3EI3;3EI4;3I7H;3I7K;3I7L;3I7N;3I7O;3I7P;3I89;3I8C;3I8E;4A08;4A09;4A0A;4A0B;4A0K;4A0L;4A11;4CI1;4CI2;4CI3;4E54;4E5Z;4TZ4;5FQD;5HXB;5JK7;5V3O;6BN7;6BN8;6BN9;6BNB;6BOY;6DSZ;6FCV;6H0F;6H0G;6PAI;6Q0R;6Q0V;6Q0W;6R8Y;6R8Z;6R90;6R91;6R92;6SJ7;6TD3;6UD7;6UE5;6UML;6XK9;7LPS;
Q309D1	Q309D1_9AGAR	unreviewed	Lectin PVL (Fragment)	pvl	Lacrymaria velutina	395								2BWM;2BWR;2C25;2C4D;4UP4;
P18177	TCDB_CLODI	reviewed	Toxin B (EC 3.4.22.-) [Cleaved into: Glucosyltransferase TcdB (EC 2.4.1.-)]	tcdB toxB	Clostridioides difficile (Peptoclostridium difficile)	2366				DISRUPTION PHENOTYPE: Cells lacking tcdB display virulence and cytotoxicity, because of the presence of TcdA (PubMed:20844489). Cells lacking both tcdA and tcdB display a strongly reduced virulence (PubMed:20844489). {ECO:0000269|PubMed:20844489}.	"MUTAGEN 102;  /note=""W->A: Abolished glucosyltransferase activity and ability to induce the host inflammatory and innate immune responses; when associated with N-288."";  /evidence=""ECO:0000269|PubMed:24919149""; MUTAGEN 270;  /note=""D->A: Does not affect ability to form a pore in the membrane of host endosomes at low pH to translocate the GT44 and peptidase C80 domains across the endosomal membrane. Strongly reduced glucosyltransferase activity."";  /evidence=""ECO:0000269|PubMed:17901056, ECO:0000269|PubMed:24567384""; MUTAGEN 273;  /note=""R->A: Strongly reduced glucosyltransferase activity."";  /evidence=""ECO:0000269|PubMed:17901056""; MUTAGEN 284;  /note=""Y->A: Strongly reduced glucosyltransferase activity."";  /evidence=""ECO:0000269|PubMed:17901056""; MUTAGEN 288;  /note=""D->N: Abolished glucosyltransferase activity and ability to induce the host inflammatory and innate immune responses; when associated with A-102."";  /evidence=""ECO:0000269|PubMed:24919149""; MUTAGEN 383..385;  /note=""INQ->SNN: Changes substrate preference and promotes N-acetylglucosaminyltransferase activity instead of glucosyltransferase activity."";  /evidence=""ECO:0000269|PubMed:16157585""; MUTAGEN 384;  /note=""N->A: Strongly reduced glucosyltransferase activity."";  /evidence=""ECO:0000269|PubMed:17901056""; MUTAGEN 455;  /note=""R->E: Impaired ability to recognize RhoA substrate."";  /evidence=""ECO:0000269|PubMed:17901056""; MUTAGEN 461;  /note=""D->R: Impaired ability to recognize RhoA substrate."";  /evidence=""ECO:0000269|PubMed:17901056""; MUTAGEN 463;  /note=""K->E: Impaired ability to recognize RhoA substrate."";  /evidence=""ECO:0000269|PubMed:17901056""; MUTAGEN 472;  /note=""E->R: Impaired ability to recognize RhoA substrate."";  /evidence=""ECO:0000269|PubMed:17901056""; MUTAGEN 520;  /note=""W->A: Strongly reduced glucosyltransferase activity."";  /evidence=""ECO:0000269|PubMed:17901056""; MUTAGEN 653;  /note=""H->A: Abolished protease activity and autoprocessing."";  /evidence=""ECO:0000269|PubMed:27571750""; MUTAGEN 698;  /note=""C->A: Abolished protease activity and autoprocessing."";  /evidence=""ECO:0000269|PubMed:27571750""; MUTAGEN 757;  /note=""H->A: Abolished autoprocessing."";  /evidence=""ECO:0000269|PubMed:27571750""; MUTAGEN 1035;  /note=""I->C,K: Reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1037;  /note=""D->K: Slightly reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1038;  /note=""G->K: Slightly reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1041;  /note=""L->K: Reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1095;  /note=""P->K: Reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1098;  /note=""G->K: Reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1099;  /note=""I->K: Reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1106;  /note=""L->C: Reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1106;  /note=""L->K: Strongly reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1107;  /note=""V->K: Reduced ability to form a pore in the membrane of host endosomes to translocate the GT44 and peptidase C80 domains across the endosomal membrane."";  /evidence=""ECO:0000269|PubMed:24567384""; MUTAGEN 1433..1437;  /note=""LKILM->DKILD: Abolished interaction with host FZD2; when associated with A-1493."";  /evidence=""ECO:0000269|PubMed:29748286""; MUTAGEN 1437;  /note=""M->D: Abolished interaction with host FZD2; when associated with A-1493."";  /evidence=""ECO:0000269|PubMed:29748286""; MUTAGEN 1493;  /note=""L->A: Abolished interaction with host FZD2; when associated with D-1437 or 1433-D--D-1437."";  /evidence=""ECO:0000269|PubMed:29748286""; MUTAGEN 1501;  /note=""D->A: Strongly reduced interaction with host FZD2."";  /evidence=""ECO:0000269|PubMed:29748286""; MUTAGEN 1509..1511;  /note=""YSN->ASA: Strongly reduced interaction with host FZD2."";  /evidence=""ECO:0000269|PubMed:29748286""; MUTAGEN 1509;  /note=""Y->A: Strongly reduced interaction with host FZD2; when associated with A-1599."";  /evidence=""ECO:0000269|PubMed:29748286""; MUTAGEN 1597;  /note=""F->D: Abolished interaction with host FZD2."";  /evidence=""ECO:0000269|PubMed:29748286""; MUTAGEN 1597;  /note=""F->G,D: Abolished interaction with host FZD2."";  /evidence=""ECO:0000269|PubMed:29748286""; MUTAGEN 1599;  /note=""Q->A: Strongly reduced interaction with host FZD2; when associated with A-1509."";  /evidence=""ECO:0000269|PubMed:29748286"""	P18177;		2BVL;2BVM;4NC2;4NP4;5UQM;5UQN;5UQT;6AR6;6C0B;6OQ5;6OQ6;6OQ7;6OQ8;7ML7;
O75695	XRP2_HUMAN	reviewed	Protein XRP2	RP2	Homo sapiens (Human)	350			DISEASE: Retinitis pigmentosa 2 (RP2) [MIM:312600]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10090907, ECO:0000269|PubMed:10520237, ECO:0000269|PubMed:10634633, ECO:0000269|PubMed:10937588, ECO:0000269|PubMed:10942419, ECO:0000269|PubMed:11462235, ECO:0000269|PubMed:11847227, ECO:0000269|PubMed:11992260, ECO:0000269|PubMed:12657579, ECO:0000269|PubMed:14564670, ECO:0000269|PubMed:16472755, ECO:0000269|PubMed:22334370, ECO:0000269|PubMed:9697692}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 2;  /note=""G->A: Loss of membrane association."";  /evidence=""ECO:0000269|PubMed:10942419""; MUTAGEN 3;  /note=""C->S: Targeting to internal membranes. Loss of targeting to the plasma membrane."";  /evidence=""ECO:0000269|PubMed:10942419""; MUTAGEN 28;  /note=""S->A: Reduces affinity for mouse ARL3; when associated with A-29."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 29;  /note=""W->A: Reduces affinity for mouse ARL3; when associated with A-28."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 31;  /note=""Q->A: Does not reduce affinity for mouse ARL3; when associated with A-32."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 32;  /note=""R->A: Does not reduce affinity for mouse ARL3; when associated with A-31."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 101;  /note=""F->A: Reduces affinity for mouse ARL3."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 115;  /note=""Q->A: Reduces affinity for mouse ARL3."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 116;  /note=""Q->A: Reduces affinity and GTP-hydrolysis rate for mouse ARL3."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 118;  /note=""R->A: Reduces affinity and GTP-hydrolysis rate for mouse ARL3."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 120;  /note=""R->H: Reduces affinity for mouse ARL3; when associated with S-121."";  /evidence=""ECO:0000269|PubMed:18376416""; MUTAGEN 121;  /note=""D->S: Reduces affinity for mouse ARL3; when associated with H-120.""; MUTAGEN 177;  /note=""F->A: Reduces affinity and GTP-hydrolysis rate for mouse ARL3."";  /evidence=""ECO:0000269|PubMed:18376416"""	O75695;	9606.ENSP00000218340;	2BX6;3BH6;3BH7;
Q8CG76	ARK72_MOUSE	reviewed	Aflatoxin B1 aldehyde reductase member 2 (EC 1.1.1.n11) (Succinic semialdehyde reductase) (SSA reductase)	Akr7a2 Afar Akr7a5	Mus musculus (Mouse)	367						Q8CG76;	10090.ENSMUSP00000073459;	2C91;
Q9WUD1	CHIP_MOUSE	reviewed	E3 ubiquitin-protein ligase CHIP (EC 2.3.2.27) (Carboxy terminus of Hsp70-interacting protein) (RING-type E3 ubiquitin transferase CHIP) (STIP1 homology and U box-containing protein 1)	Stub1 Chip	Mus musculus (Mouse)	304					"MUTAGEN 2;  /note=""K->R: Impaired interaction with ATXN3; when associated with R-4 and R-7."";  /evidence=""ECO:0000269|PubMed:21855799""; MUTAGEN 4;  /note=""K->R: Impaired interaction with ATXN3; when associated with R-2 and R-7."";  /evidence=""ECO:0000269|PubMed:21855799""; MUTAGEN 7;  /note=""K->R: Impaired interaction with ATXN3; when associated with R-2 and R-4."";  /evidence=""ECO:0000269|PubMed:21855799""; MUTAGEN 261;  /note=""H->A: Loss of E3 ubiquitin protein ligase activity."";  /evidence=""ECO:0000269|PubMed:11435423""; MUTAGEN 270;  /note=""P->A: Loss of E3 ubiquitin protein ligase activity."";  /evidence=""ECO:0000269|PubMed:11435423"""	Q9WUD1;	10090.ENSMUSP00000040431;	2C2L;2C2V;3Q47;3Q49;3Q4A;
O50390	O50390_MYCTO	unreviewed	Pentapeptide repeat family protein	MT3469	Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh)	183								2BM4;2BM5;2BM6;2BM7;
P36959	GMPR1_HUMAN	reviewed	GMP reductase 1 (GMPR 1) (EC 1.7.1.7) (Guanosine 5'-monophosphate oxidoreductase 1) (Guanosine monophosphate reductase 1)	GMPR GMPR1	Homo sapiens (Human)	345						P36959;	9606.ENSP00000259727;	2BLE;2BWG;
Q03988	Q03988_LYSSH	unreviewed	Mosquitocidal toxin	mtx1	Lysinibacillus sphaericus (Bacillus sphaericus)	870								2CB4;2CB6;2VSA;2VSE;
Q89ZI2	OGA_BACTN	reviewed	O-GlcNAcase BT_4395 (EC 3.2.1.169) (Beta-N-acetylglucosaminidase) (Beta-N-acetylhexosaminidase) (Beta-hexosaminidase) (Hexosaminidase B) (N-acetyl-beta-glucosaminidase)	BT_4395	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	737					"MUTAGEN 158;  /note=""Y->F: 99% decrease in activity for pNP-O-GlcNAc."";  /evidence=""ECO:0000269|PubMed:16565725""; MUTAGEN 263;  /note=""D->A: 99% decrease in activity for pNP-O-GlcNAc."";  /evidence=""ECO:0000269|PubMed:16565725""; MUTAGEN 263;  /note=""D->N: 99% decrease in activity for pNP-O-GlcNAc."";  /evidence=""ECO:0000269|PubMed:16565725""; MUTAGEN 264;  /note=""D->A: 99% decrease in activity for pNP-O-GlcNAc."";  /evidence=""ECO:0000269|PubMed:16565725""; MUTAGEN 264;  /note=""D->N: 99% decrease in activity for pNP-O-GlcNAc."";  /evidence=""ECO:0000269|PubMed:16565725""; MUTAGEN 303;  /note=""Y->F: 113% increase in activity for pNP-O-GlcNAc."";  /evidence=""ECO:0000269|PubMed:16565725""; MUTAGEN 393;  /note=""N->A: 95% decrease in activity for pNP-O-GlcNAc."";  /evidence=""ECO:0000269|PubMed:16565725"""		226186.BT_4395;	2CHN;2CHO;2J47;2J4G;2JIW;2VVN;2VVS;2W4X;2W66;2W67;2WCA;2WZH;2WZI;2X0H;2XJ7;2XM1;2XM2;4AIS;4AIU;4UR9;5ABE;5ABF;5ABG;5ABH;5FKY;5FL0;5FL1;5MI4;5MI5;5MI6;5MI7;7K41;
O58462	PYRF_PYRHO	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF PH0731	Pyrococcus horikoshii (strain ATCC 700860 / DSM 12428 / JCM 9974 / NBRC 100139 / OT-3)	208							70601.3257139;	2CZ5;2CZD;2CZE;2CZF;
P38261	EXO84_YEAST	reviewed	Exocyst complex component EXO84 (Exocyst complex protein of 84 kDa) (U1 SNP1-associating protein 3)	EXO84 USA3 YBR102C YBR0831	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	753						P38261;	4932.YBR102C;	2D2S;5YFP;6VKL;
P61964	WDR5_HUMAN	reviewed	WD repeat-containing protein 5 (BMP2-induced 3-kb gene protein)	WDR5 BIG3	Homo sapiens (Human)	334					"MUTAGEN 47;  /note=""A->E: Strongly reduced affinity for histone H3."";  /evidence=""ECO:0000269|PubMed:16600877""; MUTAGEN 91;  /note=""S->F: Strongly reduced affinity for histone H3."";  /evidence=""ECO:0000269|PubMed:16600877""; MUTAGEN 107;  /note=""D->A: Strongly reduced affinity for histone H3. Significant decrease in interaction with KMT2A."";  /evidence=""ECO:0000269|PubMed:16600877, ECO:0000269|PubMed:16829960, ECO:0000269|PubMed:18840606""; MUTAGEN 107;  /note=""D->N: Strongly reduced affinity for histone H3."";  /evidence=""ECO:0000269|PubMed:16829960""; MUTAGEN 133;  /note=""F->A: Strongly reduced affinity for histone H3. Significant decrease in interaction with KMT2A."";  /evidence=""ECO:0000269|PubMed:16829960, ECO:0000269|PubMed:18840606""; MUTAGEN 133;  /note=""F->D: Strongly reduced affinity for histone H3."";  /evidence=""ECO:0000269|PubMed:16600877""; MUTAGEN 133;  /note=""F->L: Strongly reduced affinity for histone H3."";  /evidence=""ECO:0000269|PubMed:16829960""; MUTAGEN 149;  /note=""F->A: Significant decrease in interaction with KMT2A."";  /evidence=""ECO:0000269|PubMed:18840606""; MUTAGEN 225;  /note=""N->A: Loss of interaction with RBBP5 and reduced ability to stimulate KMT2A methyltransferase activity in association with RBBP5 and ASH2L."";  /evidence=""ECO:0000269|PubMed:21220120""; MUTAGEN 240;  /note=""L->K: Loss of interaction with RBBP5 and reduced ability to stimulate KMT2A methyltransferase activity in association with RBBP5 and ASH2L."";  /evidence=""ECO:0000269|PubMed:21220120""; MUTAGEN 263;  /note=""F->A: Strongly reduced affinity for histone H3. Significant decrease in interaction with KMT2A."";  /evidence=""ECO:0000269|PubMed:16829960, ECO:0000269|PubMed:18840606""; MUTAGEN 263;  /note=""F->W: Strongly reduced affinity for histone H3."";  /evidence=""ECO:0000269|PubMed:16829960""; MUTAGEN 289;  /note=""Q->A: Reduced interaction with RBBP5 and reduced ability to stimulate KMT2A methyltransferase activity in association with RBBP5 and ASH2L."";  /evidence=""ECO:0000269|PubMed:21220120""; MUTAGEN 321;  /note=""L->A: Abolishes histone H3 binding."";  /evidence=""ECO:0000269|PubMed:16829960""; MUTAGEN 322;  /note=""E->A: Strongly reduced affinity for histone H3. No effect on interaction with KMT2A."";  /evidence=""ECO:0000269|PubMed:16600877, ECO:0000269|PubMed:18840606"""	P61964;	9606.ENSP00000351446;	2CNX;2CO0;2G99;2G9A;2GNQ;2H13;2H14;2H68;2H6K;2H6N;2H6Q;2H9L;2H9M;2H9N;2H9P;2O9K;3EG6;3EMH;3MXX;3N0D;3N0E;3P4F;3PSL;3SMR;3UR4;3UVK;3UVL;3UVM;3UVN;3UVO;4A7J;4CY1;4CY2;4ERQ;4ERY;4ERZ;4ES0;4ESG;4EWR;4GM3;4GM8;4GM9;4GMB;4IA9;4O45;4QL1;4Y7R;5EAL;5EAM;5EAP;5EAR;5M23;5M25;5SXM;5VFC;6BYN;6D9X;6DAI;6DAK;6DAR;6DAS;6DY7;6DYA;6E1Y;6E1Z;6E22;6E23;6IAM;6KIU;6KIV;6KIW;6KIX;6KIZ;6OFZ;6OI0;6OI1;6OI2;6OI3;6PG3;6PG4;6PG5;6PG6;6PG7;6PG8;6PG9;6PGA;6PGB;6PGC;6PGD;6PGE;6PGF;6PWV;6PWW;6U5M;6U5Y;6U6W;6U80;6U8B;6U8L;6U8O;6UCS;6UFX;6UHY;6UHZ;6UIF;6UIK;6UJ4;6UJH;6UJJ;6UJL;6UOZ;6W5I;6W5M;6W5N;6WJQ;7DNO;
Q99062	CSF3R_HUMAN	reviewed	Granulocyte colony-stimulating factor receptor (G-CSF receptor) (G-CSF-R) (CD antigen CD114)	CSF3R GCSFR	Homo sapiens (Human)	836			DISEASE: Hereditary neutrophilia (NEUTROPHILIA) [MIM:162830]: A form of lifelong, persistent neutrophilia, a condition characterized by an increase in the number of neutrophils in the blood. {ECO:0000269|PubMed:19620628}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Neutropenia, severe congenital 7, autosomal recessive (SCN7) [MIM:617014]: A form of severe congenital neutropenia, a disorder of hematopoiesis characterized by maturation arrest of granulopoiesis at the level of promyelocytes with peripheral blood absolute neutrophil counts below 0.5 x 10(9)/l and early onset of severe bacterial infections. {ECO:0000269|PubMed:24753537, ECO:0000269|PubMed:26324699}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q99062;	9606.ENSP00000362195;	1AZ7;2D9Q;
O58277	O58277_PYRHO	unreviewed	Uncharacterized protein	PH0542	Pyrococcus horikoshii (strain ATCC 700860 / DSM 12428 / JCM 9974 / NBRC 100139 / OT-3)	253						O58277;		2DB0;
Q7MUW6	PTP_PORGI	reviewed	Prolyl tripeptidyl peptidase (PTP) (EC 3.4.14.12) (Prolyl tripeptidyl peptidase 81.8 kDa form) (Prolyl tripeptidyl peptidase A) [Cleaved into: Prolyl tripeptidyl peptidase 75.8 kDa form]	ptpA PG_1361	Porphyromonas gingivalis (strain ATCC BAA-308 / W83)	732					"MUTAGEN 205;  /note=""E->Q: Inactive."";  /evidence=""ECO:0000269|PubMed:18042490""; MUTAGEN 636;  /note=""E->A: Reduced activity."";  /evidence=""ECO:0000269|PubMed:18042490"""		242619.PG_1361;	2D5L;2DCM;2EEP;2Z3W;2Z3Z;
Q99QV3	DRP35_STAAM	reviewed	Lactonase drp35 (EC 3.1.1.-)	drp35 SAV2688	Staphylococcus aureus (strain Mu50 / ATCC 700699)	324					"MUTAGEN 47;  /note=""E->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 47;  /note=""E->Q: Loss of activity due to inability to bind calcium ion."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 47;  /note=""E->S: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 63;  /note=""F->A: 2.5-fold increase in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 92;  /note=""K->A: Increase in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 137;  /note=""D->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 137;  /note=""D->N: Loss of activity but still able to bind calcium ion."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 137;  /note=""D->S: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 138;  /note=""D->A: Decrease in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 151;  /note=""D->A: Decrease in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 184;  /note=""N->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 184;  /note=""N->D: Decrease in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 184;  /note=""N->S: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 185;  /note=""G->A: Decrease in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 235;  /note=""D->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 235;  /note=""D->N: Loss of activity due to inability to bind calcium ion."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 235;  /note=""D->S: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 236;  /note=""S->A: Decrease in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 237;  /note=""C->A: Increase in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 280;  /note=""R->A: Increase in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853""; MUTAGEN 301;  /note=""E->A: Increase in lactonase activity."";  /evidence=""ECO:0000269|PubMed:17166853"""			2DG0;2DG1;2DSO;
Q70DK5	XG74_ACETH	reviewed	Xyloglucanase Xgh74A (EC 3.2.1.-)	xghA	Acetivibrio thermocellus (Hungateiclostridium thermocellum)	842					"MUTAGEN 70;  /note=""D->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:16772298""; MUTAGEN 480;  /note=""D->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:16772298"""	Q70DK5;		2CN2;2CN3;
O95154	ARK73_HUMAN	reviewed	Aflatoxin B1 aldehyde reductase member 3 (EC 1.-.-.-) (AFB1 aldehyde reductase 2) (AFB1-AR 2)	AKR7A3 AFAR2	Homo sapiens (Human)	331						O95154;	9606.ENSP00000355377;	2CLP;
O75369	FLNB_HUMAN	reviewed	Filamin-B (FLN-B) (ABP-278) (ABP-280 homolog) (Actin-binding-like protein) (Beta-filamin) (Filamin homolog 1) (Fh1) (Filamin-3) (Thyroid autoantigen) (Truncated actin-binding protein) (Truncated ABP)	FLNB FLN1L FLN3 TABP TAP	Homo sapiens (Human)	2602			DISEASE: Note=Interaction with FLNA may compensate for dysfunctional FLNA homodimer in the periventricular nodular heterotopia (PVNH) disorder.; DISEASE: Atelosteogenesis 1 (AO1) [MIM:108720]: A lethal chondrodysplasia characterized by distal hypoplasia of the humeri and femurs, hypoplasia of the mid-thoracic spine, occasionally complete lack of ossification of single hand bones, and the finding in cartilage of multiple degenerated chondrocytes which are encapsulated in fibrous tissue. {ECO:0000269|PubMed:14991055}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Atelosteogenesis 3 (AO3) [MIM:108721]: A short-limb lethal skeletal dysplasia with vertebral abnormalities, disharmonious skeletal maturation, poorly modeled long bones and joint dislocations. Recurrent respiratory insufficiency and/or infections usually result in early death. {ECO:0000269|PubMed:14991055}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Boomerang dysplasia (BOOMD) [MIM:112310]: A perinatal lethal osteochondrodysplasia characterized by absence or underossification of the limb bones and vertebrae. Patients manifest dwarfism with short, bowed, rigid limbs and characteristic facies. Boomerang dysplasia is distinguished from atelosteogenesis on the basis of a more severe defect in mineralization, with complete absence of ossification in some limb elements and vertebral segments. {ECO:0000269|PubMed:15994868}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Larsen syndrome (LRS) [MIM:150250]: An osteochondrodysplasia characterized by large-joint dislocations and characteristic craniofacial abnormalities. The cardinal features of the condition are dislocations of the hip, knee and elbow joints, with equinovarus or equinovalgus foot deformities. Spatula-shaped fingers, most marked in the thumb, are also present. Craniofacial anomalies include hypertelorism, prominence of the forehead, a depressed nasal bridge, and a flattened midface. Cleft palate and short stature are often associated features. Spinal anomalies include scoliosis and cervical kyphosis. Hearing loss is a well-recognized complication. {ECO:0000269|PubMed:14991055, ECO:0000269|PubMed:16801345}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Spondylocarpotarsal synostosis syndrome (SCT) [MIM:272460]: Disorder characterized by short stature and vertebral, carpal and tarsal fusions. {ECO:0000269|PubMed:14991055}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 2468;  /note=""K->R: Cytoplasmic localization."";  /evidence=""ECO:0000269|PubMed:19270716"""	O75369;	9606.ENSP00000420213;	2DI8;2DI9;2DIA;2DIB;2DIC;2DJ4;2DLG;2DMB;2DMC;2E9I;2E9J;2EE6;2EE9;2EEA;2EEB;2EEC;2EED;2WA5;2WA6;2WA7;3FER;4B7L;5DCP;
Q92673	SORL_HUMAN	reviewed	Sortilin-related receptor (Low-density lipoprotein receptor relative with 11 ligand-binding repeats) (LDLR relative with 11 ligand-binding repeats) (LR11) (SorLA-1) (Sorting protein-related receptor containing LDLR class A repeats) (SorLA)	SORL1 C11orf32	Homo sapiens (Human)	2214			DISEASE: Alzheimer disease (AD) [MIM:104300]: Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. {ECO:0000269|PubMed:21220680, ECO:0000269|PubMed:22472873, ECO:0000269|PubMed:23565137, ECO:0000269|PubMed:24523320}. Note=The gene represented in this entry may be involved in disease pathogenesis.		"MUTAGEN 78..81;  /note=""RRKR->GRKG: Loss of propeptide cleavage."";  /evidence=""ECO:0000269|PubMed:11294867""; MUTAGEN 2163..2164;  /note=""RR->AA: Affects the nuclear location of the C-terminal fragment generated by PSEN1."";  /evidence=""ECO:0000269|PubMed:16531402""; MUTAGEN 2172..2177;  /note=""FANSHY->AAASHA: No effect on endocytosis."";  /evidence=""ECO:0000269|PubMed:17646382""; MUTAGEN 2190..2214;  /note=""Missing: Strong reduction in Golgi apparatus - endosome sorting. Loss of interaction with AP-1 complex."";  /evidence=""ECO:0000269|PubMed:17646382""; MUTAGEN 2190..2198;  /note=""DDLGEDDED->AALGAAAAA: Loss of interaction with GGA1 and PACS1. No effect on interaction with APP. Affects subcellular location, increasing localization at the cell surface, possibly due to drastically decreased endocytosis. Impaired Golgi apparatus - endosome sorting. Increased amyloidogenic APP processing by beta-secretase, resulting in increased levels of soluble APP-beta and amyloid-beta protein 40 and 42. Loss of APOA5 internalization."";  /evidence=""ECO:0000269|PubMed:17646382, ECO:0000269|PubMed:17855360, ECO:0000269|PubMed:18603531""; MUTAGEN 2190..2191;  /note=""DD->AA: No effect on the interaction with HSPA12A."";  /evidence=""ECO:0000269|PubMed:30679749""; MUTAGEN 2194..2198;  /note=""EDDED->AAAAA: Strong decrease in interaction with HSPA12A."";  /evidence=""ECO:0000269|PubMed:30679749""; MUTAGEN 2201..2202;  /note=""MI->AA: No effect on endocytosis. Decreased Golgi apparatus - endosome sorting."";  /evidence=""ECO:0000269|PubMed:17646382""; MUTAGEN 2203..2204;  /note=""TG->AA: No effect on the interaction with HSPA12A."";  /evidence=""ECO:0000269|PubMed:30679749""; MUTAGEN 2205..2206;  /note=""FS->AA: No effect on the interaction with HSPA12A."";  /evidence=""ECO:0000269|PubMed:30679749""; MUTAGEN 2207..2208;  /note=""DD->AA: Strong decrease in interaction with HSPA12A."";  /evidence=""ECO:0000269|PubMed:30679749""; MUTAGEN 2208..2211;  /note=""DVPM->AVPA: Loss of interaction with GGA1 and PACS1. No effect on interaction with APP. Affects subcellular location, by causing increased localization to recycling endosomes. Increased APP processing by alpha-secretase, resulting in increased levels of soluble APP-alpha and C83 APP fragments. Decreased APP processing by beta-secretase, resulting in reduced levels of C99 APP fragment."";  /evidence=""ECO:0000269|PubMed:17855360""; MUTAGEN 2209..2210;  /note=""VP->AA: No effect on the interaction with HSPA12A."";  /evidence=""ECO:0000269|PubMed:30679749""; MUTAGEN 2211..2214;  /note=""Missing: No effect on endocytosis. Affects LPL sorting to endosomes."";  /evidence=""ECO:0000269|PubMed:17646382, ECO:0000269|PubMed:21385844"""	Q92673;	9606.ENSP00000260197;	2DM4;3G2S;3G2T;3WSX;3WSY;3WSZ;
Q15020	SART3_HUMAN	reviewed	Squamous cell carcinoma antigen recognized by T-cells 3 (SART-3) (Tat-interacting protein of 110 kDa) (Tip110) (p110 nuclear RNA-binding protein)	SART3 KIAA0156 TIP110	Homo sapiens (Human)	963						Q15020;	9606.ENSP00000228284;	2DO4;5CTQ;5CTR;5CTT;5JJW;5JJX;5JPZ;
Q4D3W2	PYRD_TRYCC	reviewed	Dihydroorotate dehydrogenase (fumarate) (DHOD) (DHODase) (DHOdehase) (EC 1.3.98.1) (Dihydroorotate oxidase)	pyr4 tcdhod2 Tc00.1047053508375.50	Trypanosoma cruzi (strain CL Brener)	314							5693.XP_809064.1;	2DJL;2DJX;2E68;2E6A;2E6D;2E6F;3C3N;3W1A;3W1L;3W1M;3W1N;3W1P;3W1Q;3W1R;3W1T;3W1U;3W1X;3W22;3W23;3W2J;3W2K;3W2L;3W2M;3W2N;3W2U;3W3O;3W6Y;3W70;3W71;3W72;3W73;3W74;3W75;3W76;3W7C;3W7D;3W7E;3W7G;3W7H;3W7I;3W7J;3W7K;3W7L;3W7M;3W7N;3W7O;3W7P;3W7Q;3W83;3W84;3W85;3W86;3W87;3W88;4JD4;4JDB;5E93;5EA9;
P04825	AMPN_ECOLI	reviewed	Aminopeptidase N (EC 3.4.11.2) (Alpha-aminoacylpeptide hydrolase)	pepN b0932 JW0915	Escherichia coli (strain K12)	870				DISRUPTION PHENOTYPE: A quadruple peptidase disruption (pepA, pepB, pepD and pepN) does not grow in M9 minimal medium, does grow better when supplemented with casamino acids (PubMed:20067529). {ECO:0000269|PubMed:20067529}.		P04825;	511145.b0932;	2DQ6;2DQM;2HPO;2HPT;2ZXG;3B2P;3B2X;3B34;3B37;3B3B;3KED;3PUU;3QJX;4Q4E;4Q4I;4XMT;4XMU;4XMV;4XMW;4XMX;4XMZ;4XN1;4XN2;4XN4;4XN5;4XN7;4XN8;4XN9;4XNA;4XNB;4XND;4XO3;4XO4;4XO5;5MFR;5MFS;5MFT;5YO1;5YQ1;5YQ2;5YQB;6G8B;
Q9CR50	ZN363_MOUSE	reviewed	RING finger and CHY zinc finger domain-containing protein 1 (EC 2.3.2.27) (Androgen receptor N-terminal-interacting protein) (CH-rich-interacting match with PLAG1) (E3 ubiquitin-protein ligase Pirh2) (RING-type E3 ubiquitin transferase RCHY1) (Zinc finger protein 363)	Rchy1 Arnip Chimp Zfp363 Znf363	Mus musculus (Mouse)	261							10090.ENSMUSP00000031345;	2DKT;2ECM;
Q9HBW1	LRRC4_HUMAN	reviewed	Leucine-rich repeat-containing protein 4 (Brain tumor-associated protein BAG) (Nasopharyngeal carcinoma-associated gene 14 protein) (Netrin-G2 ligand) (NGL-2)	LRRC4 BAG NAG14 UNQ554/PRO1111	Homo sapiens (Human)	653						Q9HBW1;	9606.ENSP00000249363;	2DL9;3ZYI;
Q9Z2X2	PSD10_MOUSE	reviewed	26S proteasome non-ATPase regulatory subunit 10 (26S proteasome regulatory subunit p28) (Gankyrin)	Psmd10	Mus musculus (Mouse)	231						Q9Z2X2;	10090.ENSMUSP00000033805;	2DVW;2DWZ;3AJI;
P17065	SEC2_YEAST	reviewed	Rab guanine nucleotide exchange factor SEC2 (GDP-GTP exchange factor SEC2)	SEC2 YNL272C N0641	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	759					"MUTAGEN 483;  /note=""C->Y: In SEC2-78; temperature-sensitive; causes mislocalization of the protein, displaying many cytoplasmic punctae."";  /evidence=""ECO:0000269|PubMed:10747090"""	P17065;	4932.YNL272C;	2E7S;2EQB;2OCY;4ZDW;
Q15109	RAGE_HUMAN	reviewed	Advanced glycosylation end product-specific receptor (Receptor for advanced glycosylation end products)	AGER RAGE	Homo sapiens (Human)	404						Q15109;	9606.ENSP00000364210;	1PWI;2BJP;2E5E;2ENS;2L7U;2LE9;2LMB;2M1K;2MJW;2MOV;3CJJ;3O3U;4LP4;4LP5;4OF5;4OFV;4OI7;4OI8;4P2Y;4XYN;4YBH;5D7F;6VXG;
P95782	P95782_STEMA	unreviewed	Dipeptidyl peptidase IV		Stenotrophomonas maltophilia (Pseudomonas maltophilia) (Xanthomonas maltophilia)	741								2ECF;
O66440	AROD_AQUAE	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD aq_021	Aquifex aeolicus (strain VF5)	219							224324.aq_021;	2EGZ;2YSW;
O67502	TRPA_AQUAE	reviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA aq_1548	Aquifex aeolicus (strain VF5)	262							224324.aq_1548;	2EKC;
Q09LX0	Q09LX0_GEOSE	unreviewed	Beta-xylosidase	xynB3	Geobacillus stearothermophilus (Bacillus stearothermophilus)	535								2EXH;2EXI;2EXJ;2EXK;
P11172	UMPS_HUMAN	reviewed	Uridine 5'-monophosphate synthase (UMP synthase) [Includes: Orotate phosphoribosyltransferase (OPRT) (OPRTase) (EC 2.4.2.10); Orotidine 5'-phosphate decarboxylase (ODC) (EC 4.1.1.23) (OMPdecase)]	UMPS OK/SW-cl.21	Homo sapiens (Human)	480			DISEASE: Orotic aciduria 1 (ORAC1) [MIM:258900]: A disorder of pyrimidine metabolism resulting in megaloblastic anemia and orotic acid crystalluria that is frequently associated with some degree of physical and mental retardation. A minority of cases have additional features, particularly congenital malformations and immune deficiencies. {ECO:0000269|PubMed:9042911}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 312;  /note=""D->N: Loss of OMPdecase activity."";  /evidence=""ECO:0000269|PubMed:18184586"""	P11172;	9606.ENSP00000232607;	2EAW;2JGY;2P1F;2QCC;2QCD;2QCE;2QCF;2QCG;2QCH;2QCL;2QCM;2QCN;2V30;2WNS;3BGG;3BGJ;3BK0;3BVJ;3DBP;3EWU;3EWW;3EWX;3EWY;3EWZ;3EX1;3EX2;3EX3;3EX4;3EX6;3G3D;3G3M;3L0K;3L0N;3MI2;3MO7;3MW7;4HIB;4HKP;
P76045	OMPG_ECOLI	reviewed	Outer membrane porin G (Outer membrane protein G)	ompG b1319 JW1312	Escherichia coli (strain K12)	301						P76045;	511145.b1319;	2F1C;2IWV;2IWW;2JQY;2WVP;2X9K;4CTD;5MWV;6OQH;
O15394	NCAM2_HUMAN	reviewed	Neural cell adhesion molecule 2 (N-CAM-2) (NCAM-2)	NCAM2 NCAM21	Homo sapiens (Human)	837						O15394;	9606.ENSP00000383392;	2DOC;2JLL;2KBG;2V5T;2VAJ;2WIM;2XY1;2XY2;2XYC;
A0A0H2WQ05	A0A0H2WQ05_SALPA	unreviewed	Putative transferase	ydcK SPA1259 GNB70_000877	Salmonella paratyphi A (strain ATCC 9150 / SARB42)	326								2F9C;2PIG;
O81226	O81226_CARPA	unreviewed	Glutamine cyclotransferase (EC 2.3.2.5)		Carica papaya (Papaya)	288								2FAW;2IWA;
P16154	TCDA_CLODI	reviewed	Toxin A (EC 3.4.22.-) [Cleaved into: Glucosyltransferase TcdA (EC 2.4.1.-)]	tcdA toxA	Clostridioides difficile (Peptoclostridium difficile)	2710				DISRUPTION PHENOTYPE: Cells lacking tcdA display virulence and cytotoxity, because of the presence of TcdB (PubMed:20844489). Cells lacking both tcdA and tcdB display a strongly reduced virulence (PubMed:20844489). {ECO:0000269|PubMed:20844489}.	"MUTAGEN 542;  /note=""L->A: Abolished cleavage."";  /evidence=""ECO:0000269|PubMed:19553670""; MUTAGEN 589;  /note=""D->N: Abolished protease activity and autoprocessing."";  /evidence=""ECO:0000269|PubMed:19553670""; MUTAGEN 590;  /note=""D->N: Does not affect protease activity and autoprocessing."";  /evidence=""ECO:0000269|PubMed:19553670""; MUTAGEN 655;  /note=""H->A: Abolished protease activity and autoprocessing."";  /evidence=""ECO:0000269|PubMed:19553670, ECO:0000269|PubMed:27571750""; MUTAGEN 700;  /note=""C->A,S: Abolished protease activity and autoprocessing."";  /evidence=""ECO:0000269|PubMed:19553670, ECO:0000269|PubMed:27571750""; MUTAGEN 759;  /note=""H->A: Abolished autoprocessing."";  /evidence=""ECO:0000269|PubMed:27571750"""			2F6E;2G7C;2QJ6;3HO6;3SRZ;3SS1;4DMV;4DMW;4NBX;4NBZ;4R04;5UMI;5UQK;5UQL;
Q8I4V8	FKB35_PLAF7	reviewed	Peptidyl-prolyl cis-trans isomerase FKBP35 (EC 5.2.1.8) (PfFKBP35)	FKBP35 PF3D7_1247400	Plasmodium falciparum (isolate 3D7)	304					"MUTAGEN 148;  /note=""K->A: Severe loss of binding to a HSP90 C-terminus peptide (MEEVD)."";  /evidence=""ECO:0000269|PubMed:19691130""; MUTAGEN 152;  /note=""N->A: Severe loss of binding to a HSP90 C-terminus peptide (MEEVD)."";  /evidence=""ECO:0000269|PubMed:19691130""; MUTAGEN 199;  /note=""N->A: Severe loss of binding to a HSP90 C-terminus peptide (MEEVD)."";  /evidence=""ECO:0000269|PubMed:19691130""; MUTAGEN 229;  /note=""K->A: Severe loss of binding to a HSP90 C-terminus peptide (MEEVD)."";  /evidence=""ECO:0000269|PubMed:19691130""; MUTAGEN 233;  /note=""K->A: Severe loss of binding to a HSP90 C-terminus peptide (MEEVD)."";  /evidence=""ECO:0000269|PubMed:19691130"""			2FBN;2OFN;2VN1;4J4N;4QT2;4QT3;
B1WVN5	RFR32_CROS5	reviewed	Pentapeptide repeat protein Rfr32	rfr32 cce_1272	Crocosphaera subtropica (strain ATCC 51142 / BH68) (Cyanothece sp. (strain ATCC 51142))	179							43989.cce_1272;	2F3L;2G0Y;
Q13332	PTPRS_HUMAN	reviewed	Receptor-type tyrosine-protein phosphatase S (R-PTP-S) (EC 3.1.3.48) (Receptor-type tyrosine-protein phosphatase sigma) (R-PTP-sigma)	PTPRS	Homo sapiens (Human)	1948					"MUTAGEN 97;  /note=""R->A: Abolishes interaction with NTRK3; when associated with A-100."";  /evidence=""ECO:0000269|PubMed:25385546""; MUTAGEN 100;  /note=""R->A: Abolishes interaction with NTRK3; when associated with A-97."";  /evidence=""ECO:0000269|PubMed:25385546""; MUTAGEN 233;  /note=""Y->S: Abolishes interaction with NTRK3."";  /evidence=""ECO:0000269|PubMed:25385546""; MUTAGEN 241..242;  /note=""RR->AA: Decreases interaction with NTRK3."";  /evidence=""ECO:0000269|PubMed:25385546"""	Q13332;	9606.ENSP00000349932;	2FH7;2YD2;2YD3;2YD9;4BPC;4PBX;
Q9HXJ2	PILF_PSEAE	reviewed	Type IV pilus assembly protein PilF	pilF PA3805	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	252				DISRUPTION PHENOTYPE: Mutant shows an impaired export/assembly of the fimbrial subunit PilA, and accumulates this protein in the membrane fraction (PubMed:8973346). In addition, loss of PilF expression abolishes multimerization of PilQ (PubMed:18776008). {ECO:0000269|PubMed:18776008, ECO:0000269|PubMed:8973346}.	"MUTAGEN 18;  /note=""C->G: Loss of association with the outer membrane. PilQ multimers were detected not only in the outer membrane but also in the inner membrane and the soluble lysate."";  /evidence=""ECO:0000269|PubMed:18776008"""			2FI7;2HO1;
Q9A1H8	Q9A1H8_STRP1	unreviewed	Ribulose-phosphate 3-epimerase (EC 5.1.3.1)	rpe SPy_0264	Streptococcus pyogenes serotype M1	220								2FLI;
P43490	NAMPT_HUMAN	reviewed	Nicotinamide phosphoribosyltransferase (NAmPRTase) (Nampt) (EC 2.4.2.12) (Pre-B-cell colony-enhancing factor 1) (Pre-B cell-enhancing factor) (Visfatin)	NAMPT PBEF PBEF1	Homo sapiens (Human)	491					"MUTAGEN 219;  /note=""D->N,S: No effect on activity towards nicotinamide. Alters specificity, so that the enzyme acquires activity towards nicotinic acid."";  /evidence=""ECO:0000269|PubMed:16783377""; MUTAGEN 247;  /note=""H->A: Reduces activity towards nicotinamide."";  /evidence=""ECO:0000269|PubMed:16783377""; MUTAGEN 311;  /note=""R->D: Reduces activity towards nicotinamide."";  /evidence=""ECO:0000269|PubMed:16783377"""	P43490;	9606.ENSP00000222553;	2E5B;2E5C;2E5D;2GVG;2GVJ;3DGR;3DHD;3DHF;3DKJ;3DKL;4JNM;4JR5;4KFN;4KFO;4KFP;4L4L;4L4M;4LTS;4LV9;4LVA;4LVB;4LVD;4LVF;4LVG;4LWW;4M6P;4M6Q;4N9B;4N9C;4N9D;4N9E;4O0Z;4O10;4O12;4O13;4O14;4O15;4O16;4O17;4O18;4O19;4O1A;4O1B;4O1C;4O1D;4O28;4WQ6;5KIT;5LX3;5LX5;5NSD;5U2M;5U2N;5UPE;5UPF;5WI0;5WI1;6ATB;6AZJ;6B75;6B76;6E68;6PEB;6TA0;6TA2;6TAC;
P68175	STSY_RAUSE	reviewed	Strictosidine synthase (EC 4.3.3.2)	STR1	Rauvolfia serpentina (Serpentine wood) (Ophioxylon serpentinum)	344								2FP8;2FP9;2FPB;2FPC;2V91;2VAQ;3V1S;4IMB;4IYG;6N5V;
P14585	LIN12_CAEEL	reviewed	Protein lin-12 (Abnormal cell lineage protein 12) (Notch-like protein lin-12) [Cleaved into: lin-12/Notch intracellular domain]	lin-12 R107.8	Caenorhabditis elegans	1429				DISRUPTION PHENOTYPE: RNAi-mediated knockdown in cells of the pi uterine cell lineage results in impaired basement membrane mobility (PubMed:27661254). Knockdown on a glp-1 mutant background impairs octanol response when animals are shifted to the restrictive temperature (PubMed:21549604). {ECO:0000269|PubMed:21549604, ECO:0000269|PubMed:27661254}.	"MUTAGEN 400..1429;  /note=""Missing: In n941; Increased total quiescence versus control animals. Affects cell fates of ventral, but not dorsal, postembryonic mesodermal lineage (M lineage). Similar, but enhanced phenotype seen when combined with RNAi-mediated knockdown of lag-2. On a sma-9 mutant background, reverses the dorsoventral polarity of the M lineage. Normal octanol response, but dramatically impaired when combined with RNAi-mediated knockdown of glp-1/Notch receptor."";  /evidence=""ECO:0000269|PubMed:18036582, ECO:0000269|PubMed:21549604"""	P14585;	6239.R107.8;	2FO1;3BRD;3BRF;
O06741	YITF_BACSU	reviewed	Putative isomerase YitF (EC 5.-.-.-)	yitF BSU10970	Bacillus subtilis (strain 168)	371							224308.BSU10970;	2GDQ;2GGE;
P14740	DPP4_RAT	reviewed	Dipeptidyl peptidase 4 (EC 3.4.14.5) (Bile canaliculus domain-specific membrane glycoprotein) (Dipeptidyl peptidase IV) (DPP IV) (GP110 glycoprotein) (T-cell activation antigen CD26) (CD antigen CD26) [Cleaved into: Dipeptidyl peptidase 4 membrane form (Dipeptidyl peptidase IV membrane form); Dipeptidyl peptidase 4 soluble form (Dipeptidyl peptidase IV soluble form); Dipeptidyl peptidase 4 60 kDa soluble form (Dipeptidyl peptidase IV 60 kDa soluble form)]	Dpp4 Cd26	Rattus norvegicus (Rat)	767					"MUTAGEN 629;  /note=""G->A: Reduced activity."";  /evidence=""ECO:0000269|PubMed:7905271""; MUTAGEN 629;  /note=""G->R: Reduced activity."";  /evidence=""ECO:0000269|PubMed:7905271""; MUTAGEN 630;  /note=""W->E: No effect on activity."";  /evidence=""ECO:0000269|PubMed:7905271""; MUTAGEN 631;  /note=""S->A: Reduced activity."";  /evidence=""ECO:0000269|PubMed:7905271""; MUTAGEN 632;  /note=""Y->F: No effect on activity."";  /evidence=""ECO:0000269|PubMed:7905271""; MUTAGEN 632;  /note=""Y->G: Reduced activity."";  /evidence=""ECO:0000269|PubMed:7905271""; MUTAGEN 632;  /note=""Y->L: Reduced activity."";  /evidence=""ECO:0000269|PubMed:7905271""; MUTAGEN 633;  /note=""G->A: Reduced activity."";  /evidence=""ECO:0000269|PubMed:7905271""; MUTAGEN 633;  /note=""G->S: Reduced activity."";  /evidence=""ECO:0000269|PubMed:7905271"""	P14740;	10116.ENSRNOP00000045536;	2GBC;2GBF;2GBG;2GBI;2I3Z;2OAE;4FFV;4FFW;5VTA;
P21809	PGS1_BOVIN	reviewed	Biglycan (Bone/cartilage proteoglycan I) (Leucine-rich PG I) (PG-S1)	BGN	Bos taurus (Bovine)	369						P21809;	9913.ENSBTAP00000044462;	2FT3;
Q975F9	S1PNA_SULTO	reviewed	Bifunctional sugar-1-phosphate nucleotidylyltransferase/acetyltransferase [Includes: Sugar-1-phosphate nucleotidylyltransferase (Sugar-1-P NTase) (Glucose-1-phosphate thymidylyltransferase) (EC 2.7.7.24) (Glucose-1-phosphate uridylyltransferase) (Glc-1-P UTase) (EC 2.7.7.9) (N-acetylgalactosamine-1-phosphate uridyltransferase) (GalNAc-1-P UTase) (EC 2.7.7.83) (N-acetylglucosamine-1-phosphate uridyltransferase) (GlcNAc-1-P UTase) (EC 2.7.7.23); Sugar-1-phosphate acetyltransferase (Galactosamine-1-phosphate N-acetyltransferase) (GalN-1-P AcTase) (GalN-1-P acetyltransferase) (EC 2.3.1.276) (Glucosamine-1-phosphate N-acetyltransferase) (GlcN-1-P AcTase) (GlcN-1-P acetyltransferase) (EC 2.3.1.157)]	STK_04520 ST0452	Sulfurisphaera tokodaii (strain DSM 16993 / JCM 10545 / NBRC 100140 / 7) (Sulfolobus tokodaii)	401					"MUTAGEN 80;  /note=""T->A,G,Q: Increases both GlcNAc-1-P UTase and Glc-1-P UTase activities."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 80;  /note=""T->D,H: Decrease in GlcNAc-1-P UTase activity but increase in Glc-1-P UTase activity."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 80;  /note=""T->E,K,L,M,R,W,Y: Strong decrease in GlcNAc-1-P UTase activity and loss of Glc-1-P UTase activity."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 80;  /note=""T->F,I: Loss of both GlcNAc-1-P UTase and Glc-1-P UTase activities."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 80;  /note=""T->N,S: Strong increase in GlcNAc-1-P UTase activity and decrease in Glc-1-P UTase activity."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 80;  /note=""T->N: Loss of GlcNAc-1-P UTase activity; when associated with V-97."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 97;  /note=""Y->A,D,F,G,I,K,T,V: Increases GlcNAc-1-P UTase activity. Decreases Glc-1-P UTase activity."";  /evidence=""ECO:0000269|PubMed:27864169""; MUTAGEN 97;  /note=""Y->C,E,P,R,W: Decreases GlcNAc-1-P UTase and Glc-1-P UTase activities."";  /evidence=""ECO:0000269|PubMed:27864169""; MUTAGEN 97;  /note=""Y->H,L,M,N,Q,S: Increases GlcNAc-1-P UTase and Glc-1-P UTase activities."";  /evidence=""ECO:0000269|PubMed:27864169""; MUTAGEN 97;  /note=""Y->V: Loss of GlcNAc-1-P UTase activity; when associated with N-80."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 146;  /note=""E->A,C,F,G,I,K,L,M,P,Q,R,V,W,Y: Loss of both GlcNAc-1-P UTase and Glc-1-P UTase activities."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 146;  /note=""E->D,N: Decrease in GlcNAc-1-P UTase and Glc-1-P UTase activities."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 146;  /note=""E->H,S,T: Decrease in GlcNAc-1-P UTase activity and loss of Glc-1-P UTase activity."";  /evidence=""ECO:0000269|PubMed:30291121""; MUTAGEN 308;  /note=""H->A: Strong decrease in GalN-1-P AcTase activity and almost loss of GlcN-1-P AcTase activity."";  /evidence=""ECO:0000269|PubMed:25567746""; MUTAGEN 311;  /note=""Y->A: Strong decrease in GalN-1-P AcTase activity and increase in GlcN-1-P AcTase activity."";  /evidence=""ECO:0000269|PubMed:25567746""; MUTAGEN 331;  /note=""N->A: Strong decrease in GalN-1-P AcTase activity and decrease in GlcN-1-P AcTase activity."";  /evidence=""ECO:0000269|PubMed:25567746""; MUTAGEN 337;  /note=""K->A: Slight decrease in GalN-1-P AcTase activity and increase in GlcN-1-P AcTase activity."";  /evidence=""ECO:0000269|PubMed:25567746""; MUTAGEN 340;  /note=""K->A: Decrease in GalN-1-P AcTase activity and increase in GlcN-1-P AcTase activity."";  /evidence=""ECO:0000269|PubMed:25567746""; MUTAGEN 391..401;  /note=""Missing: No change in GlcNAc-1-P UTase activity. Shows 38% less GalN-1-P AcTase activity than the wild-type, but increases GlcN-1-P AcTase activity 16.8 times. Significantly affects the thermostability of the entire protein."";  /evidence=""ECO:0000269|PubMed:25567746""; MUTAGEN 397..401;  /note=""Missing: No change in GlcNAc-1-P UTase activity. Shows 20% less GalN-1-P AcTase activity than the wild-type, but increases GlcN-1-P AcTase activity 4.8 times. Does not affect thermostability."";  /evidence=""ECO:0000269|PubMed:25567746"""		273063.STK_04520;	2GGO;2GGQ;5Z09;5Z0A;
Q7D0W3	Q7D0W3_AGRFC	unreviewed	Calcium-binding protein, regucalcin	Atu0702	Agrobacterium fabrum (strain C58 / ATCC 33970) (Agrobacterium tumefaciens (strain C58))	295							176299.Atu0702;	2GHS;
Q6VEQ7	Q6VEQ7_BAUBA	unreviewed	Kunitz-type inihibitor		Bauhinia bauhinioides (Perlebia bauhinoides)	193								2GO2;6DWF;6DWH;6DWU;
Q8U3Y3	Q8U3Y3_PYRFU	unreviewed	Acylaminoacyl-peptidase-like protein	PF0318	Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1)	620							186497.PF0318;	2GOP;
Q9SQT8	DHQSD_ARATH	reviewed	Bifunctional 3-dehydroquinate dehydratase/shikimate dehydrogenase, chloroplastic (DHQ-SDH protein) (DHQase-SORase) (Protein EMBRYO DEFECTIVE 3004) [Includes: Dehydroquinate dehydratase (DHQ) (EC 4.2.1.10); Shikimate dehydrogenase (SDH) (EC 1.1.1.25)]	EMB3004 At3g06350 F24P17.18	Arabidopsis thaliana (Mouse-ear cress)	603					"MUTAGEN 336;  /note=""S->A: 13-fold decrease in substrate affinity but almost no change in activity."";  /evidence=""ECO:0000269|PubMed:16784230""; MUTAGEN 338;  /note=""S->A: 10-fold decrease in activity, and 9-fold decrease in substrate affinity."";  /evidence=""ECO:0000269|PubMed:16784230""; MUTAGEN 385;  /note=""K->A: Strongly reduced shikimate dehydrogenase activity, but minor change in substrate affinity."";  /evidence=""ECO:0000269|PubMed:16784230""; MUTAGEN 385;  /note=""K->N: Strongly reduced shikimate dehydrogenase activity, but no change in substrate affinity."";  /evidence=""ECO:0000269|PubMed:16784230""; MUTAGEN 423;  /note=""D->A: Loss of shikimate dehydrogenase activity."";  /evidence=""ECO:0000269|PubMed:16784230""; MUTAGEN 423;  /note=""D->N: Reduced shikimate dehydrogenase activity, but no change in substrate affinity."";  /evidence=""ECO:0000269|PubMed:16784230""; MUTAGEN 550;  /note=""Y->F,A: 100-fold decrease in activity, and 2-fold decrease in substrate affinity."";  /evidence=""ECO:0000269|PubMed:16784230"""		3702.AT3G06350.1;	2GPT;2O7Q;2O7S;6BMB;6BMQ;
Q9R4E4	AROA_AGRSC	reviewed	3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19) (5-enolpyruvylshikimate-3-phosphate synthase) (EPSP synthase) (EPSPS)	aroA	Agrobacterium sp. (strain CP4)	455		BIOTECHNOLOGY: Introduced by genetic manipulation and expressed in glyphosate-tolerant soybean, canola, cotton and maize by Monsanto. Developed to provide new weed-control options for farmers. Expression of this protein in plants imparts high levels of glyphosate tolerance. {ECO:0000305}.			"MUTAGEN 100;  /note=""A->G: Confers resistance to glyphosate."";  /evidence=""ECO:0000269|PubMed:16916934"""			2GG4;2GG6;2GGA;2GGD;2PQB;2PQC;2PQD;
Q92600	CNOT9_HUMAN	reviewed	CCR4-NOT transcription complex subunit 9 (Cell differentiation protein RQCD1 homolog) (Rcd-1)	CNOT9 RCD1 RQCD1	Homo sapiens (Human)	299					"MUTAGEN 227;  /note=""R->E: Loss of DNA binding."";  /evidence=""ECO:0000269|PubMed:17189474"""	Q92600;	9606.ENSP00000273064;	2FV2;4CRU;4CRV;4CT6;4CT7;5LSW;5ONA;5ONB;6HOM;6HON;
Q53EL6	PDCD4_HUMAN	reviewed	Programmed cell death protein 4 (Neoplastic transformation inhibitor protein) (Nuclear antigen H731-like) (Protein 197/15a)	PDCD4 H731	Homo sapiens (Human)	469					"MUTAGEN 67;  /note=""S->A: Loss of phosphorylation site. Reduces interaction with BTRC. Abolishes phosphorylation by PKB; when associated with A-457."";  /evidence=""ECO:0000269|PubMed:16357133, ECO:0000269|PubMed:17053147""; MUTAGEN 71;  /note=""S->A: Strongly reduced interaction with BTRC. Strongly reduced ubiquitination."";  /evidence=""ECO:0000269|PubMed:17053147""; MUTAGEN 76;  /note=""S->A: Strongly reduced interaction with BTRC. Strongly reduced ubiquitination."";  /evidence=""ECO:0000269|PubMed:17053147""; MUTAGEN 174;  /note=""E->A: Reduced inhibition of EIF4A1 helicase activity."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 210;  /note=""E->A: Reduced inhibition of EIF4A1 helicase activity. Strongly reduced inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 249;  /note=""E->A: Reduced interaction with EIF4A1."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 252;  /note=""L->A: Strongly reduced interaction with EIF4A1. Reduced inhibition of EIF4A1 helicase activity. Strongly reduced inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 253;  /note=""D->A: Strongly reduced interaction with EIF4A1. Strongly reduced inhibition of translation. Reduced inhibition of EIF4A1 helicase activity."";  /evidence=""ECO:0000269|PubMed:19153607, ECO:0000269|PubMed:19204291""; MUTAGEN 255;  /note=""P->A: Reduced inhibition of EIF4A1 helicase activity. Strongly reduced inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 333;  /note=""M->A: No effect on inhibition of EIF4A1 and on inhibition of translation; when associated with A-340."";  /evidence=""ECO:0000269|PubMed:19204291""; MUTAGEN 337;  /note=""E->A: No effect on inhibition of EIF4A1 and on inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19204291""; MUTAGEN 340;  /note=""L->A: No effect on inhibition of EIF4A1 and on inhibition of translation; when associated with A-333."";  /evidence=""ECO:0000269|PubMed:19204291""; MUTAGEN 358;  /note=""H->A: Strongly reduced interaction with EIF4A1."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 359;  /note=""F->A: Strongly reduced inhibition of EIF4A1. Strongly reduced inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19204291""; MUTAGEN 361;  /note=""H->A: Strongly reduced inhibition of EIF4A1. Strongly reduced inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19204291""; MUTAGEN 414;  /note=""D->A: Strongly reduced interaction with EIF4A1. Strongly reduced inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 418;  /note=""D->A: Reduced interaction with EIF4A1. Strongly reduced inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 420;  /note=""P->A: Strongly reduced interaction with EIF4A1. Strongly reduced inhibition of translation."";  /evidence=""ECO:0000269|PubMed:19153607""; MUTAGEN 457;  /note=""S->A: Loss of phosphorylation site, and loss of nuclear accumulation. Abolishes phosphorylation by PKB; when associated with A-67."";  /evidence=""ECO:0000269|PubMed:16357133"""	Q53EL6;	9606.ENSP00000280154;	2GGF;2KZT;2RG8;2ZU6;3EIJ;
P07213	TOM70_YEAST	reviewed	Mitochondrial import receptor subunit TOM70 (70 kDa mitochondrial outer membrane protein) (Translocase of outer membrane 70 kDa subunit)	TOM70 MAS70 OMP1 YNL121C N1905	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	617						P07213;	4932.YNL121C;	2GW1;
P83051	BBCI_BAUBA	reviewed	Kunitz-type proteinase inhibitor BbCI		Bauhinia bauhinioides (Perlebia bauhinoides)	164								2GZB;
A0A0H3JV42	A0A0H3JV42_STAAW	unreviewed	Uncharacterized protein	MW0446	Staphylococcus aureus (strain MW2)	257								2GZX;
P17315	CIRA_ECOLI	reviewed	Colicin I receptor	cirA cir feuA b2155 JW2142	Escherichia coli (strain K12)	663						P17315;	511145.b2155;	2HDF;2HDI;
Q05583	CIAO1_YEAST	reviewed	Cytosolic iron-sulfur protein assembly protein 1	CIA1 YDR267C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	330					"MUTAGEN 127;  /note=""R->E: Impaired in cytosolic Fe/S protein assembly."";  /evidence=""ECO:0000269|PubMed:17937914"""	Q05583;	4932.YDR267C;	2HES;
Q97Z84	PCNA2_SACS2	reviewed	DNA polymerase sliding clamp 2 (Proliferating cell nuclear antigen homolog 2) (PCNA2)	pcn2 pcnA-2 SSO1047	Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) (Sulfolobus solfataricus)	245					"MUTAGEN 146..149;  /note=""LSDL->KLSK: Loss of interaction with PCNA3, no change with PCNA1."";  /evidence=""ECO:0000269|PubMed:16945955"""		273057.SSO1047;	2HII;2HIK;2IO4;2IX2;2IZO;2NTI;3FDS;
P57765	PCNA3_SACS2	reviewed	DNA polymerase sliding clamp 3 (Proliferating cell nuclear antigen homolog 3) (PCNA3)	pcn3 pcnA-1 SSO0405 C41_016	Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) (Sulfolobus solfataricus)	244							273057.SSO0405;	2HII;2HIK;2IJX;2IX2;2NTI;
D0VWW2	D0VWW2_DISSP	unreviewed	mOrange		Discosoma sp. (Sea anemone)	236								2H5O;4Q7R;4Q7T;4Q7U;5FHV;5H88;
Q58923	TPIS_METJA	reviewed	Triosephosphate isomerase (TIM) (TPI) (EC 5.3.1.1) (Triose-phosphate isomerase)	tpiA MJ1528	Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) (Methanococcus jannaschii)	219							243232.MJ_1528;	2H6R;
Q5TLG6	Q5TLG6_9CNID	unreviewed	Fluorescent protein Dronpa	Dronpa	Echinophyllia sp. SC22	224								2GX0;2GX2;2IE2;2IOV;2POX;2Z1O;2Z6X;2Z6Y;2Z6Z;3ZUF;3ZUJ;3ZUL;4EMQ;4HQ8;4HQ9;4HQC;4IZN;4UTS;5HZS;5HZT;5HZU;6D38;6D39;6MXW;6MYB;6MYC;6NQJ;6NQK;6NQL;6NQN;6NQO;6NQP;6NQQ;6NQR;6NQS;6NQV;
P07333	CSF1R_HUMAN	reviewed	Macrophage colony-stimulating factor 1 receptor (CSF-1 receptor) (CSF-1-R) (CSF-1R) (M-CSF-R) (EC 2.7.10.1) (Proto-oncogene c-Fms) (CD antigen CD115)	CSF1R FMS	Homo sapiens (Human)	972			DISEASE: Note=Aberrant expression of CSF1 or CSF1R can promote cancer cell proliferation, invasion and formation of metastases. Overexpression of CSF1 or CSF1R is observed in a significant percentage of breast, ovarian, prostate, and endometrial cancers.; DISEASE: Note=Aberrant expression of CSF1 or CSF1R may play a role in inflammatory diseases, such as rheumatoid arthritis, glomerulonephritis, atherosclerosis, and allograft rejection.; DISEASE: Leukoencephalopathy, diffuse hereditary, with spheroids (HDLS) [MIM:221820]: An autosomal dominant adult-onset rapidly progressive neurodegenerative disorder characterized by variable behavioral, cognitive, and motor changes. Patients often die of dementia within 6 years of onset. Brain imaging shows patchy abnormalities in the cerebral white matter, predominantly affecting the frontal and parietal lobes. {ECO:0000269|PubMed:22197934, ECO:0000269|PubMed:23408870, ECO:0000269|PubMed:24336230, ECO:0000269|PubMed:24532199}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Brain abnormalities, neurodegeneration, and dysosteosclerosis (BANDDOS) [MIM:618476]: An autosomal recessive disease with variable manifestations. Main features are brain malformations with calcifying leukoencephalopathy, progressive neurodegeneration, and bone sclerotic features. The age at onset ranges from infancy to early adulthood. Neurologic features include loss of previous motor and language skills, cognitive impairment, spasticity, and focal seizures. Brain imaging shows periventricular white matter abnormalities and calcifications, large cisterna magna or Dandy-Walker malformation, and sometimes agenesis of the corpus callosum. {ECO:0000269|PubMed:30982608, ECO:0000269|PubMed:30982609}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 301;  /note=""L->S: Constitutive kinase activity."";  /evidence=""ECO:0000269|PubMed:15117969""; MUTAGEN 708;  /note=""Y->F: Impairs degradation of activated CSF1R."";  /evidence=""ECO:0000269|PubMed:10340379""; MUTAGEN 802;  /note=""D->V: Constitutive kinase activity. Loss of inhibition by imatinib."";  /evidence=""ECO:0000269|PubMed:10340379, ECO:0000269|PubMed:16170366""; MUTAGEN 809;  /note=""Y->F: Reduced kinase activity. Reduced interaction with SRC, FYN and YES1."";  /evidence=""ECO:0000269|PubMed:7681396""; MUTAGEN 969;  /note=""Y->F: Abolishes down-regulation of activated CSF1R."";  /evidence=""ECO:0000269|PubMed:15117969"""	P07333;	9606.ENSP00000286301;	2I0V;2I0Y;2I1M;2OGV;3BEA;3DPK;3KRJ;3KRL;3LCD;3LCO;4DKD;4HW7;4LIQ;4R7H;4R7I;4WRL;4WRM;6IG8;6N33;6T2W;6WXJ;
Q07230	ZSCA2_MOUSE	reviewed	Zinc finger and SCAN domain-containing protein 2 (Zinc finger protein 29) (Zfp-29)	Zscan2 Zfp-29 Zfp29	Mus musculus (Mouse)	614						Q07230;	10090.ENSMUSP00000042321;	2I13;
Q5EAQ1	M4GDB_DANRE	reviewed	MIF4G domain-containing protein B	mif4gdb zgc:110826	Danio rerio (Zebrafish) (Brachydanio rerio)	222						Q5EAQ1;	7955.ENSDARP00000124808;	2I2O;4JHJ;4JHK;
Q13619	CUL4A_HUMAN	reviewed	Cullin-4A (CUL-4A)	CUL4A	Homo sapiens (Human)	759					"MUTAGEN 86..90;  /note=""LYQAV->AAAAA: Largely reduces interaction with DDB1; abolishes interaction with DDB2."";  /evidence=""ECO:0000269|PubMed:16482215, ECO:0000269|PubMed:17079684""; MUTAGEN 139..142;  /note=""WQDH->AADA: Largely reduces interaction with DDB1; abolishes interaction with DDB2."";  /evidence=""ECO:0000269|PubMed:16482215, ECO:0000269|PubMed:17079684"""	Q13619;	9606.ENSP00000364589;	2HYE;4A0K;
Q76MZ3	2AAA_MOUSE	reviewed	Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PP2A subunit A isoform PR65-alpha) (PP2A subunit A isoform R1-alpha)	Ppp2r1a	Mus musculus (Mouse)	589						Q76MZ3;	10090.ENSMUSP00000007708;	2IAE;2PF4;3FGA;6EF4;
Q13362	2A5G_HUMAN	reviewed	Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform (PP2A B subunit isoform B'-gamma) (PP2A B subunit isoform B56-gamma) (PP2A B subunit isoform PR61-gamma) (PP2A B subunit isoform R5-gamma) (Renal carcinoma antigen NY-REN-29)	PPP2R5C KIAA0044	Homo sapiens (Human)	524						Q13362;	9606.ENSP00000412324;	2IAE;2JAK;2NPP;2NYL;2NYM;3FGA;5JJA;5K6S;5SW9;5SWF;6OYL;6TOQ;6VOY;6VRO;6Z2Y;
Q75TD0	Q75TD0_GEOKU	unreviewed	Maltose transacetylase (EC 2.3.1.79)	GKB08 GKB08	Geobacillus kaustophilus	185								2IC7;2P2O;
Q5BJK3	Q5BJK3_DANRE	unreviewed	Zgc:110177 (Zgc:110177 protein)	napga napgl zgc:110177	Danio rerio (Zebrafish) (Brachydanio rerio)	305								2IFU;
D0VWU8	D0VWU8_BORBG	unreviewed	Outer Surface Protein A		Borrelia burgdorferi (Lyme disease spirochete) (Borreliella burgdorferi)	320								2HKD;2OY8;3CKA;3EC5;5YS7;5Z1O;6KK9;
Q8X123	Q8X123_9AGAR	unreviewed	Agglutinin		Marasmius oreades	293								2IHO;3EF2;5D61;5D62;5D63;5MU9;6TSL;6TSM;6TSN;6TSO;6TSP;6TSQ;6TSR;6YH0;
Q9H9B1	EHMT1_HUMAN	reviewed	Histone-lysine N-methyltransferase EHMT1 (EC 2.1.1.-) (Euchromatic histone-lysine N-methyltransferase 1) (Eu-HMTase1) (G9a-like protein 1) (GLP) (GLP1) (Histone H3-K9 methyltransferase 5) (H3-K9-HMTase 5) (Lysine N-methyltransferase 1D)	EHMT1 EUHMTASE1 GLP KIAA1876 KMT1D	Homo sapiens (Human)	1298			DISEASE: Kleefstra syndrome 1 (KLEFS1) [MIM:610253]: A form of Kleefstra syndrome, an autosomal dominant disease characterized by variable mental retardation, psychomotor developmental delay, seizures, behavioral abnormalities, and facial dysmorphisms. KLEFS1 patients additionally manifest brachy(micro)cephaly, congenital heart defects, and urogenital defects. {ECO:0000269|PubMed:16826528, ECO:0000269|PubMed:19264732}. Note=The disease is caused by variants affecting the gene represented in this entry. The syndrome can be either caused by intragenic EHMT1 mutations leading to haploinsufficiency of the EHMT1 gene or by a submicroscopic 9q34.3 deletion. Although it is not known if and to what extent other genes in the 9q34.3 region contribute to the syndrome observed in deletion cases, EHMT1 seems to be the major determinant of the core disease phenotype (PubMed:19264732). {ECO:0000269|PubMed:16826528, ECO:0000269|PubMed:19264732}.		"MUTAGEN 874;  /note=""W->A: Abolishes binding to methylated RELA K310me1, histone H3K9me1 and H3K9me2."";  /evidence=""ECO:0000269|PubMed:21515635""; MUTAGEN 882;  /note=""E->A: Abolishes binding to methylated RELA K310me1, histone H3K9me1 and H3K9me2."";  /evidence=""ECO:0000269|PubMed:21515635""; MUTAGEN 905;  /note=""E->A: Abolishes binding to histone H3K9me."";  /evidence=""ECO:0000269|PubMed:18264113""; MUTAGEN 912;  /note=""W->A: Abolishes binding to methylated RELA K310me1, histone H3K9me1 and H3K9me2."";  /evidence=""ECO:0000269|PubMed:21515635"""	Q9H9B1;	9606.ENSP00000417980;	2IGQ;2RFI;3B7B;3B95;3FPD;3HNA;3MO0;3MO2;3MO5;3SW9;3SWC;4I51;5TTG;5TUZ;5V9J;5VSD;5VSF;6BY9;6MBO;6MBP;
Q4VPP2	Q4VPP2_GIAIN	unreviewed	Alpha-11 giardin		Giardia intestinalis (Giardia lamblia)	307								2II2;2IIC;
Q9HB96	FANCE_HUMAN	reviewed	Fanconi anemia group E protein (Protein FACE)	FANCE FACE	Homo sapiens (Human)	536			DISEASE: Fanconi anemia complementation group E (FANCE) [MIM:600901]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:11001585, ECO:0000269|PubMed:17924555}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 346;  /note=""T->A: Non-phosphorylatable by CHEK1, not polyubiquitinated and unable to complement the mitomycin C hypersensitivity of cells lacking FANCE; when associated with A-374."";  /evidence=""ECO:0000269|PubMed:17296736""; MUTAGEN 374;  /note=""S->A: Non-phosphorylatable by CHEK1, not polyubiquitinated and unable to complement the mitomycin C hypersensitivity of cells lacking FANCE; when associated with A-346."";  /evidence=""ECO:0000269|PubMed:17296736"""	Q9HB96;	9606.ENSP00000229769;	2ILR;7KZP;7KZQ;7KZR;7KZS;7KZT;7KZV;
Q3SAG3	Q3SAG3_9BACI	unreviewed	Inulin fructotransferase	ift	Bacillus sp. snu-7	450								2INU;2INV;
Q8KAL8	Q8KAL8_CHLTE	unreviewed	DUF3856 domain-containing protein	CT2138	Chlorobaculum tepidum (strain ATCC 49652 / DSM 12025 / NBRC 103806 / TLS) (Chlorobium tepidum)	174							194439.CT2138;	2HR2;
A1E266	A1E266_9PEZI	unreviewed	Endopolygalacturonase (EC 3.2.1.15)	Pg1	Colletotrichum lupini var. setosum (nom. inval.)	362								2IQ7;
P0CD76	LPXD_CHLTR	reviewed	UDP-3-O-acylglucosamine N-acyltransferase (EC 2.3.1.191)	lpxD CT_243	Chlamydia trachomatis (strain D/UW-3/Cx)	354								2IU8;2IU9;2IUA;
Q12395	DCN1_YEAST	reviewed	Defective in cullin neddylation protein 1	DCN1 YLR128W L3111	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	269						Q12395;	4932.YLR128W;	2IS9;2L4E;2L4F;3BQ3;3O2P;3O6B;3TDI;
Q12308	TFC8_YEAST	reviewed	Transcription factor tau 60 kDa subunit (TFIIIC 60 kDa subunit) (Transcription factor C subunit 8)	TFC8 YPL007C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	588						Q12308;	4932.YPL007C;	2J04;
P52294	IMA5_HUMAN	reviewed	Importin subunit alpha-5 (Karyopherin subunit alpha-1) (Nucleoprotein interactor 1) (NPI-1) (RAG cohort protein 2) (SRP1-beta) [Cleaved into: Importin subunit alpha-5, N-terminally processed]	KPNA1 RCH2	Homo sapiens (Human)	538						P52294;	9606.ENSP00000343701;	2JDQ;3TJ3;4B18;6WX9;
Q3YE50	Q3YE50_BORBO	unreviewed	Pertactin (Fragment)		Bordetella bronchiseptica (Alcaligenes bronchisepticus)	678								2IOU;
Q15274	NADC_HUMAN	reviewed	Nicotinate-nucleotide pyrophosphorylase [carboxylating] (EC 2.4.2.19) (Quinolinate phosphoribosyltransferase [decarboxylating]) (QAPRTase) (QPRTase)	QPRT	Homo sapiens (Human)	297					"MUTAGEN 1..12;  /note=""Missing: Forms dimers instead of hexamers."";  /evidence=""ECO:0000269|PubMed:26805589""; MUTAGEN 1..10;  /note=""Missing: Forms dimers instead of hexamers."";  /evidence=""ECO:0000269|PubMed:26805589""; MUTAGEN 1..9;  /note=""Missing: Forms dimers instead of hexamers."";  /evidence=""ECO:0000269|PubMed:26805589""; MUTAGEN 1..8;  /note=""Missing: Forms dimers instead of hexamers."";  /evidence=""ECO:0000269|PubMed:26805589""; MUTAGEN 1..4;  /note=""Missing: No effect on hexamer formation."";  /evidence=""ECO:0000269|PubMed:26805589""; MUTAGEN 102;  /note=""R->A,Q: Reduced activity."";  /evidence=""ECO:0000269|PubMed:17868694""; MUTAGEN 138;  /note=""R->Q: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17868694""; MUTAGEN 139;  /note=""K->A,S: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17868694""; MUTAGEN 161;  /note=""R->A: Reduced activity."";  /evidence=""ECO:0000269|PubMed:17868694""; MUTAGEN 161;  /note=""R->Q: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17868694""; MUTAGEN 171;  /note=""K->A,S: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17868694"""	Q15274;	9606.ENSP00000378782;	2JBM;4KWV;4KWW;5AYX;5AYY;5AYZ;
Q96FE5	LIGO1_HUMAN	reviewed	Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 (Leucine-rich repeat and immunoglobulin domain-containing protein 1) (Leucine-rich repeat neuronal protein 1) (Leucine-rich repeat neuronal protein 6A)	LINGO1 LERN1 LRRN6A UNQ201/PRO227	Homo sapiens (Human)	620			DISEASE: Mental retardation, autosomal recessive 64 (MRT64) [MIM:618103]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT64 patients have moderate to severe intellectual disability, delayed motor development, aggressive behavior, and slurred or absent speech. {ECO:0000269|PubMed:28837161}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q96FE5;	9606.ENSP00000347451;	2ID5;4OQT;
P21796	VDAC1_HUMAN	reviewed	Voltage-dependent anion-selective channel protein 1 (VDAC-1) (hVDAC1) (Outer mitochondrial membrane protein porin 1) (Plasmalemmal porin) (Porin 31HL) (Porin 31HM)	VDAC1 VDAC	Homo sapiens (Human)	283					"MUTAGEN 12;  /note=""K->R: PRKN-dependent polybiquitination is decreased, whereas PRKN-dependent monoubiquitination, mitochondrial calcium uptake and apoptosis are unaffected; when associated with R-20; R-53 and 109-R-R-110."";  /evidence=""ECO:0000269|PubMed:32047033""; MUTAGEN 20;  /note=""K->R: PRKN-dependent polybiquitination is decreased, whereas PRKN-dependent monoubiquitination, mitochondrial calcium uptake and apoptosis are unaffected; when associated with R-12; R-53 and 109-R-R-110."";  /evidence=""ECO:0000269|PubMed:32047033""; MUTAGEN 53;  /note=""K->R: PRKN-dependent polybiquitination is decreased, whereas PRKN-dependent monoubiquitination, mitochondrial calcium uptake and apoptosis are unaffected; when associated with R-12; R-20 and 109-R-R-110."";  /evidence=""ECO:0000269|PubMed:32047033""; MUTAGEN 73;  /note=""E->Q: Abolishes ceramide and phosphatidylcholine binding."";  /evidence=""ECO:0000269|PubMed:31015432""; MUTAGEN 109..110;  /note=""KK->RR: PRKN-dependent polybiquitination is decreased, whereas PRKN-dependent monoubiquitination, mitochondrial calcium uptake and apoptosis are unaffected; when associated with R-12; R-20 and R-53."";  /evidence=""ECO:0000269|PubMed:32047033""; MUTAGEN 193;  /note=""S->A: Conformation remains open and constitutively allows cytochrome c efflux."";  /evidence=""ECO:0000269|PubMed:20230784""; MUTAGEN 193;  /note=""S->E: Conformation remains closed and prevents cytochrome c leakage."";  /evidence=""ECO:0000269|PubMed:20230784""; MUTAGEN 274;  /note=""K->R: Loss of PRKN-dependent monoubiquitination increases mitochondria calcium uptake, and ultimately increased apoptosis. Consequently, mitochondria are swelled with defective cristae structures. PRKN-dependent polyubiquitination is unaffected."";  /evidence=""ECO:0000269|PubMed:32047033"""		9606.ENSP00000265333;	2JK4;2K4T;5JDP;5XDN;5XDO;6G6U;6G73;6TIQ;6TIR;
P78324	SHPS1_HUMAN	reviewed	Tyrosine-protein phosphatase non-receptor type substrate 1 (SHP substrate 1) (SHPS-1) (Brain Ig-like molecule with tyrosine-based activation motifs) (Bit) (CD172 antigen-like family member A) (Inhibitory receptor SHPS-1) (Macrophage fusion receptor) (MyD-1 antigen) (Signal-regulatory protein alpha-1) (Sirp-alpha-1) (Signal-regulatory protein alpha-2) (Sirp-alpha-2) (Signal-regulatory protein alpha-3) (Sirp-alpha-3) (p84) (CD antigen CD172a)	SIRPA BIT MFR MYD1 PTPNS1 SHPS1 SIRP	Homo sapiens (Human)	504						P78324;	9606.ENSP00000382941;	2JJS;2JJT;2UV3;2WNG;4CMM;6BIT;6NMR;6NMS;6NMT;6NMU;6NMV;7KPG;
O35381	AN32A_MOUSE	reviewed	Acidic leucine-rich nuclear phosphoprotein 32 family member A (Acidic nuclear phosphoprotein pp32) (Leucine-rich acidic nuclear protein) (LANP) (Potent heat-stable protein phosphatase 2A inhibitor I1PP2A)	Anp32a Anp32 Lanp	Mus musculus (Mouse)	247				DISRUPTION PHENOTYPE: Mice are viable and fertile. They have no derangements in any of the major organ systems, including the nervous systems. Moreover, bone marrow cells from mutant mice only show mild decrease of colony-forming unit(CFU)-myeloid. {ECO:0000269|PubMed:15060138, ECO:0000269|PubMed:29467488}.		O35381;	10090.ENSMUSP00000082652;	2JQD;
Q96PM5	ZN363_HUMAN	reviewed	RING finger and CHY zinc finger domain-containing protein 1 (EC 2.3.2.27) (Androgen receptor N-terminal-interacting protein) (CH-rich-interacting match with PLAG1) (E3 ubiquitin-protein ligase Pirh2) (RING finger protein 199) (RING-type E3 ubiquitin transferase RCHY1) (Zinc finger protein 363) (p53-induced RING-H2 protein) (hPirh2)	RCHY1 ARNIP CHIMP PIRH2 RNF199 ZNF363	Homo sapiens (Human)	261					"MUTAGEN 176;  /note=""M->E: Abolishes E3 ubiquitin-protein ligase activity."";  /evidence=""ECO:0000269|PubMed:19043414""; MUTAGEN 186;  /note=""C->A: Abolishes E3 ubiquitin-protein ligase activity."";  /evidence=""ECO:0000269|PubMed:19043414"""	Q96PM5;	9606.ENSP00000321239;	2JRJ;2K2C;2K2D;
Q54727	NANB_STRPN	reviewed	Sialidase B (EC 3.2.1.18) (Neuraminidase B)	nanB SP_1687	Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)	697							170187.SP_1687;	2JKB;2VW0;2VW1;2VW2;4FOQ;4FOV;4FOW;4FOY;4FP2;4FP3;4FPC;4FPE;4FPF;4FPG;4FPH;4FPJ;4FPK;4FPL;4FPO;4FPY;4FQ4;4XE9;4XHB;4XHX;4XIK;4XIL;4XIO;4XJ8;4XJ9;4XJA;4XJU;4XJW;4XJZ;4XMA;4XMI;4XOG;4XYX;
Q9Y263	PLAP_HUMAN	reviewed	Phospholipase A-2-activating protein (PLA2P) (PLAP)	PLAA PLAP	Homo sapiens (Human)	795			DISEASE: Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies (NDMSBA) [MIM:617527]: An autosomal recessive neurodevelopmental disorder characterized by progressive microcephaly, spastic quadriparesis, global developmental delay, profound mental retardation and severely impaired or absent motor function. More variable features include seizures and optic atrophy. {ECO:0000269|PubMed:28007986, ECO:0000269|PubMed:28413018}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q9Y263;	9606.ENSP00000380460;	2K89;2K8A;2K8B;2K8C;3EBB;
Q13418	ILK_HUMAN	reviewed	Integrin-linked protein kinase (EC 2.7.11.1) (59 kDa serine/threonine-protein kinase) (Beta-integrin-linked kinase) (ILK-1) (ILK-2) (p59ILK)	ILK ILK1 ILK2	Homo sapiens (Human)	452					"MUTAGEN 99;  /note=""H->D: Alters interaction with LIMS1."";  /evidence=""ECO:0000269|PubMed:19074270""; MUTAGEN 359;  /note=""E->K: Inactivation of ILK."";  /evidence=""ECO:0000269|PubMed:9736715"""	Q13418;	9606.ENSP00000379975;	2KBX;3F6Q;3IXE;3KMU;3KMW;3REP;4HI8;4HI9;6MIB;
P39687	AN32A_HUMAN	reviewed	Acidic leucine-rich nuclear phosphoprotein 32 family member A (Acidic nuclear phosphoprotein pp32) (pp32) (Leucine-rich acidic nuclear protein) (LANP) (Mapmodulin) (Potent heat-stable protein phosphatase 2A inhibitor I1PP2A) (Putative HLA-DR-associated protein I) (PHAPI)	ANP32A C15orf1 LANP MAPM PHAP1	Homo sapiens (Human)	249					"MUTAGEN 158;  /note=""S->A: Complete loss of phosphorylation; when associated with A-204."";  /evidence=""ECO:0000269|PubMed:15287743""; MUTAGEN 158;  /note=""S->A: No loss of phosphorylation."";  /evidence=""ECO:0000269|PubMed:15287743""; MUTAGEN 189;  /note=""E->A: Loss of interaction with influenza virus A PB2."";  /evidence=""ECO:0000269|PubMed:30666459""; MUTAGEN 196;  /note=""E->A: Loss of interaction with influenza virus A PB2."";  /evidence=""ECO:0000269|PubMed:30666459""; MUTAGEN 204;  /note=""S->A: Complete loss of phosphorylation; when associated with A-158."";  /evidence=""ECO:0000269|PubMed:15287743""; MUTAGEN 204;  /note=""S->A: No loss of phosphorylation."""	P39687;	9606.ENSP00000417864;	2JE0;2JE1;4XOS;6XZQ;
P21784	RAG2_MOUSE	reviewed	V(D)J recombination-activating protein 2 (RAG-2)	Rag2 Rag-2	Mus musculus (Mouse)	527				DISRUPTION PHENOTYPE: Mice are viable but fail to produce mature B or T-lymphocytes. Very immature lymphoid cells are present in primary lymphoid organs. These cells do not rearrange their immunoglobulin or T-cell receptor loci. Double knockout with TREX1 does not show a visible phenotype. {ECO:0000269|PubMed:1547487, ECO:0000269|PubMed:18724932}.	"MUTAGEN 128;  /note=""D->N: Does not affect the endonuclease activity of the RAG complex."";  /evidence=""ECO:0000269|PubMed:10601032""; MUTAGEN 199;  /note=""E->Q: Does not affect the endonuclease activity of the RAG complex."";  /evidence=""ECO:0000269|PubMed:10601032""; MUTAGEN 202;  /note=""D->N: Does not affect the endonuclease activity of the RAG complex."";  /evidence=""ECO:0000269|PubMed:10601032""; MUTAGEN 280;  /note=""E->Q: Does not affect the endonuclease activity of the RAG complex."";  /evidence=""ECO:0000269|PubMed:10601032""; MUTAGEN 310;  /note=""D->N: Does not affect the endonuclease activity of the RAG complex."";  /evidence=""ECO:0000269|PubMed:10601032""; MUTAGEN 358;  /note=""D->N: Does not affect the endonuclease activity of the RAG complex."";  /evidence=""ECO:0000269|PubMed:10601032""; MUTAGEN 374;  /note=""D->N: Does not affect the endonuclease activity of the RAG complex."";  /evidence=""ECO:0000269|PubMed:10601032""; MUTAGEN 402;  /note=""Y->A: Reduced interaction with histones."";  /evidence=""ECO:0000269|PubMed:16111638""; MUTAGEN 403;  /note=""N->A: Reduced interaction with histones."";  /evidence=""ECO:0000269|PubMed:16111638""; MUTAGEN 406;  /note=""D->A: Reduced interaction with histones."";  /evidence=""ECO:0000269|PubMed:16111638""; MUTAGEN 407;  /note=""E->A: Reduced interaction with histones."";  /evidence=""ECO:0000269|PubMed:16111638""; MUTAGEN 408;  /note=""D->A: Induces a slight reduction in V(D)J recombination without affecting interaction with histones.""; MUTAGEN 415;  /note=""Y->A: Abolishes binding to H3K4me3 without affecting phosphoinositide-binding."";  /evidence=""ECO:0000269|PubMed:18033247""; MUTAGEN 440;  /note=""K->A: Binds PtdIns(4,5)P2 at wild-type level."";  /evidence=""ECO:0000269|PubMed:15964836""; MUTAGEN 443;  /note=""M->A: Abolishes binding to H3K4me3 without affecting phosphoinositide-binding."";  /evidence=""ECO:0000269|PubMed:18033247""; MUTAGEN 445;  /note=""Y->A,D: Still binds H3K4me3 and H3R2me2 but with reduced affinity."";  /evidence=""ECO:0000269|PubMed:18025461""; MUTAGEN 453;  /note=""W->R: Abolishes binding to H3K4me3 without affecting phosphoinositide-binding. Impairs enzymatic activity of the RAG complex."";  /evidence=""ECO:0000269|PubMed:18033247, ECO:0000269|PubMed:19524534""; MUTAGEN 464;  /note=""R->A: Leads to a strong reduction in PtdIns(4,5)P2-binding."";  /evidence=""ECO:0000269|PubMed:15964836""; MUTAGEN 468;  /note=""H->A: Leads to a strong reduction in PtdIns(4,5)P2-binding."";  /evidence=""ECO:0000269|PubMed:15964836"""	P21784;	10090.ENSMUSP00000038204;	2JWO;2V83;2V85;2V86;2V87;2V88;2V89;4WWX;5ZDZ;5ZE0;5ZE1;5ZE2;6CG0;6CIJ;6CIK;6CIL;6CIM;6OEM;6OEN;6OEO;6OEP;6OEQ;6OER;6OES;6OET;6V0V;6XNX;6XNY;6XNZ;
P07110	PAPC_ECOLX	reviewed	Outer membrane usher protein PapC	papC	Escherichia coli	836								2KT6;2VQI;3FIP;6CD2;
Q6VRY4	Q6VRY4_NEIME	unreviewed	Factor H binding protein variant B01_001 (Fragment)	fhbp	Neisseria meningitidis	260								2KDY;
P62774	MTPN_MOUSE	reviewed	Myotrophin (Granule cell differentiation protein) (Protein V-1)	Mtpn Gcdp	Mus musculus (Mouse)	118						P62774;	10090.ENSMUSP00000031866;	2KXP;
Q15814	TBCC_HUMAN	reviewed	Tubulin-specific chaperone C (Tubulin-folding cofactor C) (CFC)	TBCC	Homo sapiens (Human)	346					"MUTAGEN 262;  /note=""R->A: Inhibits stimulation of tubulin GTPase activity."";  /evidence=""ECO:0000269|PubMed:11847227"""	Q15814;	9606.ENSP00000361967;	2L3L;2YUH;
P10475	GUN2_BACSU	reviewed	Endoglucanase (EC 3.2.1.4) (Carboxymethyl-cellulase) (CMCase) (Cellulase) (Endo-1,4-beta-glucanase)	eglS bglC gld BSU18130	Bacillus subtilis (strain 168)	499							224308.BSU18130;	2L8A;3PZT;3PZU;3PZV;6UFV;6UFW;
Q9JPP1	Q9JPP1_NEIME	unreviewed	Gna2132 (Heparin binding protein) (Neisserial heparin binding antigen) (Putative lipoprotein GNA2132)	gna2132 nhba	Neisseria meningitidis	427								2LFU;5O1R;6CUJ;
O43683	BUB1_HUMAN	reviewed	Mitotic checkpoint serine/threonine-protein kinase BUB1 (hBUB1) (EC 2.7.11.1) (BUB1A)	BUB1 BUB1L	Homo sapiens (Human)	1085					"MUTAGEN 106;  /note=""A->D,W: Loss of interaction with KNL1."";  /evidence=""ECO:0000269|PubMed:17981135""; MUTAGEN 122;  /note=""L->G: Loss of interaction with KNL1."";  /evidence=""ECO:0000269|PubMed:17981135""; MUTAGEN 130;  /note=""A->S: Partial rescue of the spindle-assembly checkpoint activity. Increased rate of chromosome congression errors. Impaired localization to kinetochores and loss of kinetochore binding of CENPF, SGO1 and BUBR1 but not of MCAK, MAD1L1 or MAD2L1."";  /evidence=""ECO:0000269|PubMed:19487456""; MUTAGEN 535;  /note=""K->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-536 and A-537."";  /evidence=""ECO:0000269|PubMed:17158872""; MUTAGEN 536;  /note=""E->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-535 and A-537."";  /evidence=""ECO:0000269|PubMed:17158872""; MUTAGEN 537;  /note=""N->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-535 and A-536."";  /evidence=""ECO:0000269|PubMed:17158872""; MUTAGEN 609;  /note=""T->A: Diminished interaction with PLK1."";  /evidence=""ECO:0000269|PubMed:16760428""; MUTAGEN 625;  /note=""K->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-626 and A-627."";  /evidence=""ECO:0000269|PubMed:17158872""; MUTAGEN 626;  /note=""E->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-625 and A-627."";  /evidence=""ECO:0000269|PubMed:17158872""; MUTAGEN 627;  /note=""N->A: Loss of ubiquitination and CDH1-dependent degradation; when associated with A-625 and A-626."";  /evidence=""ECO:0000269|PubMed:17158872""; MUTAGEN 821;  /note=""K->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:10198256"""	O43683;	9606.ENSP00000302530;	2LAH;4A1G;4QPM;4R8Q;5DMZ;6F7B;7B1F;7B1H;7B1J;
P15705	STI1_YEAST	reviewed	Heat shock protein STI1	STI1 YOR027W OR26.17	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	589						P15705;	4932.YOR027W;	2LLV;2LLW;3UPV;3UQ3;
P55884	EIF3B_HUMAN	reviewed	Eukaryotic translation initiation factor 3 subunit B (eIF3b) (Eukaryotic translation initiation factor 3 subunit 9) (Prt1 homolog) (hPrt1) (eIF-3-eta) (eIF3 p110) (eIF3 p116)	EIF3B EIF3S9	Homo sapiens (Human)	814						P55884;	9606.ENSP00000354125;	2KRB;2NLW;5K1H;6YBT;6ZMW;6ZON;6ZP4;6ZVJ;7A09;
Q6QCC2	Q6QCC2_NEIME	unreviewed	Factor H-binding protein (Lipoprotein) (Lipoprotein GNA1870)	gna1870 fhbp	Neisseria meningitidis	274								2KC0;3KVD;6TIK;
P45464	LPOA_ECOLI	reviewed	Penicillin-binding protein activator LpoA (PBP activator LpoA) (Lipoprotein activator of PBP from the outer membrane A)	lpoA yraM b3147 JW3116	Escherichia coli (strain K12)	678				DISRUPTION PHENOTYPE: Absence of both LpoA and LpoB leads to a decrease in peptide cross-linking and to cell lysis. {ECO:0000269|PubMed:21183074}.		P45464;	511145.b3147;	2MHK;6DR3;
Q0P9D1	PGLD_CAMJE	reviewed	UDP-N-acetylbacillosamine N-acetyltransferase (EC 2.3.1.203) (Protein glycosylation D) (UDP-4-amino-4,6-dideoxy-N-acetyl-alpha-D-glucosamine N-acetyltransferase)	pglD Cj1123c	Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168)	195					"MUTAGEN 15;  /note=""H->A: Induces a higher KM and approximate 3-fold decrease in the turnover number."";  /evidence=""ECO:0000269|PubMed:18667421""; MUTAGEN 118;  /note=""N->A: Reduction in catalytic activity."";  /evidence=""ECO:0000269|PubMed:18198901""; MUTAGEN 124;  /note=""E->A: Reduction in catalytic activity."";  /evidence=""ECO:0000269|PubMed:18198901""; MUTAGEN 125;  /note=""H->A: Strong reduction in catalytic activity."";  /evidence=""ECO:0000269|PubMed:18198901, ECO:0000269|PubMed:18667421""; MUTAGEN 134;  /note=""H->A: Slight reduction in catalytic activity."";  /evidence=""ECO:0000269|PubMed:18198901, ECO:0000269|PubMed:18667421"""	Q0P9D1;	192222.Cj1123c;	2NPO;2VHE;3BFP;3BSS;3BSW;3BSY;5T2Y;5TYH;
P0C1A9	PMEA_DICD3	reviewed	Pectinesterase A (PE A) (EC 3.1.1.11) (Pectin methylesterase A)	pemA pem Dda3937_03374	Dickeya dadantii (strain 3937) (Erwinia chrysanthemi (strain 3937))	366					"MUTAGEN 153;  /note=""Q->A: Strong decrease in affinity for substrate."";  /evidence=""ECO:0000269|PubMed:17717531""; MUTAGEN 177;  /note=""Q->A: Strong decrease in catalytic activity."";  /evidence=""ECO:0000269|PubMed:17717531""; MUTAGEN 178;  /note=""D->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17717531""; MUTAGEN 198;  /note=""V->A: Strong decrease in catalytic activity."";  /evidence=""ECO:0000269|PubMed:17717531""; MUTAGEN 199;  /note=""D->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17717531""; MUTAGEN 267;  /note=""R->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17717531""; MUTAGEN 269;  /note=""W->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17717531""; MUTAGEN 272;  /note=""T->A: Decreases affinity for substrate."";  /evidence=""ECO:0000269|PubMed:17717531""; MUTAGEN 306;  /note=""M->A: Strong decrease in catalytic activity. Decreases affinity for substrate."";  /evidence=""ECO:0000269|PubMed:17717531"""		198628.Dda3937_03374;	2NSP;2NST;2NT6;2NT9;2NTB;2NTP;2NTQ;
Q4JC35	KDGA_SULAC	reviewed	2-dehydro-3-deoxy-phosphogluconate/2-dehydro-3-deoxy-6-phosphogalactonate aldolase (EC 4.1.2.55)	Saci_0225	Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770)	288							330779.Saci_0225;	2NUW;2NUX;2NUY;
P38764	RPN1_YEAST	reviewed	26S proteasome regulatory subunit RPN1 (HMG-CoA reductase degradation protein 2) (Proteasome non-ATPase subunit 1)	RPN1 HRD2 NAS1 RPD1 YHR027C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	993						P38764;	4932.YHR027C;	2N3T;2N3U;2N3V;2N3W;2NBW;3JCO;3JCP;4CR2;4CR3;4CR4;5A5B;5MPB;5MPC;5MPD;5MPE;5WVI;5WVK;6FVT;6FVU;6FVV;6FVW;6FVX;6FVY;6J2C;6J2N;6J2Q;6J2X;6J30;
Q9A753	Q9A753_CAUVC	unreviewed	Bactofilin A	bacA CC_1873	Caulobacter vibrioides (strain ATCC 19089 / CB15) (Caulobacter crescentus)	161						Q9A753;	190650.CC_1873;	2N3D;
Q79AD2	Q79AD2_SERMA	unreviewed	HasR protein	hasR	Serratia marcescens	899						Q79AD2;		2M5J;3CSL;3CSN;3DDR;5C58;
Q84527	Q84527_PBCV1	unreviewed	Arginine/Ornithine decarboxylase	A207R	Paramecium bursaria Chlorella virus 1 (PBCV-1)	372								2NV9;2NVA;
P05695	PORP_PSEAE	reviewed	Porin P (Outer membrane protein D1)	oprP PA3279	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	440								2O4V;
Q8ZKY6	Q8ZKY6_SALTY	unreviewed	Putative mandelate racemase	STM3833	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	397								2O56;
Q32R26	Q32R26_EPTBU	unreviewed	Variable lymphocyte receptor A	VLRA	Eptatretus burgeri (Inshore hagfish)	371								2O6Q;
Q4G1L2	Q4G1L2_EPTBU	unreviewed	Variable lymphocyte receptor B	VLRB	Eptatretus burgeri (Inshore hagfish)	273								2O6R;2Z62;2Z63;2Z65;2Z66;3A79;3A7B;3A7C;3UL7;3UL8;3UL9;3ULA;3V44;3V47;4ARN;4ARR;4BV4;4QDH;4QXE;4QXF;5GY2;5IJB;5IJC;5IJD;6BXA;6BXC;
Q4G1L3	Q4G1L3_EPTBU	unreviewed	Variable lymphocyte receptor B	VLRB	Eptatretus burgeri (Inshore hagfish)	305								2O6S;3A79;4J4L;4UIP;
D0VWX3	D0VWX3_9CYAN	unreviewed	Repeat Five Residue (Rfr) protein or pentapeptide repeat protein	Rfr23	Cyanothece	150								2O6W;
Q12038	SRO7_YEAST	reviewed	Lethal(2) giant larvae protein homolog SRO7 (Polarity protein SRO7) (Sodium protection protein 1) (Suppressor of RHO3 protein 7)	SRO7 SNI1 SOP1 YPR032W YP9367.12	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1033						Q12038;	4932.YPR032W;	2OAJ;
P63590	AROD_STRP1	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD SPy_0809 M5005_Spy0624	Streptococcus pyogenes serotype M1	228								2OCZ;
Q48031	Q48031_HAEIF	unreviewed	Adhesin	hmw1A	Haemophilus influenzae	1536								2ODL;
Q5L1E2	MTNW_GEOKA	reviewed	2,3-diketo-5-methylthiopentyl-1-phosphate enolase (DK-MTP-1-P enolase) (EC 5.3.2.5) (RuBisCO-like protein) (RLP)	mtnW GK0953	Geobacillus kaustophilus (strain HTA426)	413					"MUTAGEN 98;  /note=""K->A: Loss of enolase activity."";  /evidence=""ECO:0000269|PubMed:17352497""; MUTAGEN 147;  /note=""K->A: Same activity as the wild-type."";  /evidence=""ECO:0000269|PubMed:17352497""; MUTAGEN 173;  /note=""K->A: Same activity as the wild-type."";  /evidence=""ECO:0000269|PubMed:17352497"""		235909.GK0953;	2OEJ;2OEK;2OEL;2OEM;
P37527	PDXS_BACSU	reviewed	Pyridoxal 5'-phosphate synthase subunit PdxS (PLP synthase subunit PdxS) (EC 4.3.3.6) (Pdx1) (Superoxide-inducible protein 7) (SOI7)	pdxS yaaD BSU00110	Bacillus subtilis (strain 168)	294					"MUTAGEN 18;  /note=""K->A: Almost no effect on activity."";  /evidence=""ECO:0000269|PubMed:19152323""; MUTAGEN 75;  /note=""S->A: Almost no effect on activity."";  /evidence=""ECO:0000269|PubMed:19152323""; MUTAGEN 81;  /note=""K->A,R: No activity, does not form covalent adduct with ribose-5-phosphate."";  /evidence=""ECO:0000269|PubMed:17189272""; MUTAGEN 99;  /note=""D->A: Results in 20-fold reduction of activity."";  /evidence=""ECO:0000269|PubMed:19152323""; MUTAGEN 149;  /note=""K->A: No activity, does not form covalent adduct with ribose-5-phosphate or ribulose 5-phosphate."";  /evidence=""ECO:0000269|PubMed:15771487, ECO:0000269|PubMed:17189272""; MUTAGEN 149;  /note=""K->R: No activity, but can, as the wild-type, form covalent adduct with ribose-5-phosphate."";  /evidence=""ECO:0000269|PubMed:17189272"""	P37527;	224308.BSU00110;	2NV1;2NV2;
G5EEM5	ZYG9_CAEEL	reviewed	Zygote defective protein 9	zyg-9 F22B5.7	Caenorhabditis elegans	1415				DISRUPTION PHENOTYPE: Maternal-effect embryonic lethal with meiotic and mitotic spindle positioning defects in one-cell stage embryos. RNAi-mediated knockdown results in meiosis and mitosis defects in embryos whereby embryos have one or both polar bodies absent, more than one female pronucleus and display irregular female pronuclear migration, which leads to delayed association with the male pronucleus (PubMed:16971515). RNAi-mediated knockdown results in defective mitotic spindle positioning and rotation in which spindles are established in the posterior side of the embryo and on the wrong axis (PubMed:16971515). RNAi-mediated knockdown results in a decrease in length of astral microtubules in embryos, with fewer microtubules extending from their centrosomes during cold conditions (PubMed:16971515). RNAi-mediated knockdown in a let-711 heteroallelic s2587 and it150 mutant background results in inviable embryos which do not hatch, however the astral microtubule length, polar body, female pronuclear migration and mitotic spindle defects of the single zyg-9 RNAi mutant are partially suppressed (PubMed:16971515). {ECO:0000269|PubMed:12885567, ECO:0000269|PubMed:12956952, ECO:0000269|PubMed:15866166, ECO:0000269|PubMed:16054029, ECO:0000269|PubMed:1614224, ECO:0000269|PubMed:16971515, ECO:0000269|PubMed:17666432, ECO:0000269|PubMed:2249759, ECO:0000269|PubMed:3949074, ECO:0000269|PubMed:6684994, ECO:0000269|PubMed:7371984, ECO:0000269|PubMed:9606208}.	"MUTAGEN 203;  /note=""G->E: In or628; decrease in abundance at centromeres."";  /evidence=""ECO:0000269|PubMed:17666432""; MUTAGEN 488;  /note=""G->E: In or593; decrease in abundance at centromeres."";  /evidence=""ECO:0000269|PubMed:17666432""; MUTAGEN 862;  /note=""I->K: In or635; reduction in tac-1 binding."";  /evidence=""ECO:0000269|PubMed:17666432""; MUTAGEN 1317;  /note=""E->K: In or643; decrease in abundance at centromeres and in the cytoplasm and reduction in tac-1 binding."";  /evidence=""ECO:0000269|PubMed:17666432"""	G5EEM5;	6239.F22B5.7;	2OF3;
Q12GE3	Q12GE3_POLSJ	unreviewed	Galactarate dehydratase / L-talarate dehydratase (EC 4.2.1.-) (EC 4.2.1.42)	Bpro_0435	Polaromonas sp. (strain JS666 / ATCC BAA-500)	383							296591.Bpro_0435;	2OG9;3CB3;
P35658	NU214_HUMAN	reviewed	Nuclear pore complex protein Nup214 (214 kDa nucleoporin) (Nucleoporin Nup214) (Protein CAN)	NUP214 CAIN CAN KIAA0023	Homo sapiens (Human)	2090			DISEASE: Note=A chromosomal aberration involving NUP214 is found in a subset of acute myeloid leukemia (AML); also known as acute non-lymphocytic leukemia. Translocation t(6;9)(p23;q34) with DEK. It results in the formation of a DEK-CAN fusion gene. {ECO:0000269|PubMed:1549122}.; DISEASE: Note=A chromosomal aberration involving NUP214 is found in some cases of acute undifferentiated leukemia (AUL). Translocation t(6;9)(q21;q34.1) with SET. {ECO:0000269|PubMed:1630450}.; DISEASE: Encephalopathy, acute, infection-induced, 9 (IIAE9) [MIM:618426]: An autosomal recessive disorder characterized by infancy-onset of episodic neurodevelopmental regression in association with infection-induced febrile illness. Clinical features include poor overall growth, seizures, myoclonic jerks, microcephaly, ataxia, and cerebellar atrophy. {ECO:0000269|PubMed:30758658, ECO:0000269|PubMed:31178128}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; DISEASE: Note=Chromosomal aberrations involving NUP214 are found in acute lymphoblastic leukemia (PubMed:20851865, PubMed:15361874). Translocation t(9;9)(q34;q34) with ABL1 (PubMed:15361874). Translocation t(5;9)(q35;q34) with SQSTM1 (PubMed:20851865). {ECO:0000269|PubMed:15361874, ECO:0000269|PubMed:20851865}.		"MUTAGEN 353;  /note=""V->A: Reduced binding to DDX19B."";  /evidence=""ECO:0000269|PubMed:19219046""; MUTAGEN 359;  /note=""D->R: Impairs interaction with DDX19B."";  /evidence=""ECO:0000269|PubMed:19219046"""	P35658;	9606.ENSP00000352400;	2OIT;3FHC;3FMO;3FMP;5DIS;
O35433	TRPV1_RAT	reviewed	Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Capsaicin receptor) (Osm-9-like TRP channel 1) (OTRPC1) (Vanilloid receptor 1) (Vanilloid receptor type 1-like)	Trpv1 Vr1 Vr1l	Rattus norvegicus (Rat)	838					"MUTAGEN 114;  /note=""R->E: Abolishes capsaicin-evoked current and binding to resiniferatoxin."";  /evidence=""ECO:0000269|PubMed:12228246""; MUTAGEN 114;  /note=""Missing: Abolishes sensitivity to acid."";  /evidence=""ECO:0000269|PubMed:12228246""; MUTAGEN 115;  /note=""R->D: Abolishes capsaicin-evoked current and binding to resiniferatoxin."";  /evidence=""ECO:0000269|PubMed:12228246""; MUTAGEN 116;  /note=""S->A: Abolishes phosphorylation by PKCM and enhances channel response to capsaicin by PKCM."";  /evidence=""ECO:0000269|PubMed:15471852""; MUTAGEN 155;  /note=""K->A: Abolishes ATP binding. Abolishes CALM binding. Impairs normal desensitization by repeated exposure to capsaicin."";  /evidence=""ECO:0000269|PubMed:17582331, ECO:0000269|PubMed:23109716""; MUTAGEN 160;  /note=""K->A: Abolishes ATP binding. Abolishes CALM binding."";  /evidence=""ECO:0000269|PubMed:17582331""; MUTAGEN 199;  /note=""Y->A: Strongly reduces affinity for ATP; when associated with A-202."";  /evidence=""ECO:0000269|PubMed:17582331""; MUTAGEN 202;  /note=""Q->A: Strongly reduces affinity for ATP; when associated with A-199."";  /evidence=""ECO:0000269|PubMed:17582331""; MUTAGEN 502;  /note=""S->A: Largely reduces PMA enhancement of capsaicin-evoked currents, but no effect on direct activation by PMA. Loss of activation by capsaicin and loss of vanilloid binding; when associated with I-704."";  /evidence=""ECO:0000269|PubMed:11884385, ECO:0000269|PubMed:14523239, ECO:0000269|PubMed:14630912""; MUTAGEN 511;  /note=""Y->A: Loss of sensitivity to capsaicin."";  /evidence=""ECO:0000269|PubMed:14996838""; MUTAGEN 547;  /note=""M->L: Reduces binding to resiniferatoxin."";  /evidence=""ECO:0000269|PubMed:14996838""; MUTAGEN 550;  /note=""T->I: Reduces sensitivity to capsaicin 10-fold; no effect on sensitivity to resiniferatoxin. Reduces binding to resiniferatoxin."";  /evidence=""ECO:0000269|PubMed:14996838""; MUTAGEN 636;  /note=""E->K: Abolishes channel activity. Restored channel activity; when associated with E-639."";  /evidence=""ECO:0000269|PubMed:10931826""; MUTAGEN 636;  /note=""E->Q: Slight modification of pore attributes."";  /evidence=""ECO:0000269|PubMed:10931826""; MUTAGEN 639;  /note=""K->E: Restored channel activity; when associated with K-636."";  /evidence=""ECO:0000269|PubMed:10931826""; MUTAGEN 644;  /note=""M->Y: Slightly modifies channel permeability."";  /evidence=""ECO:0000269|PubMed:10931826""; MUTAGEN 646;  /note=""D->N: Strongly reduces the affinity for pore blocker ruthenium red and lowered channel permeability for Mg(2+)."";  /evidence=""ECO:0000269|PubMed:10931826""; MUTAGEN 648;  /note=""E->Q: Minor modification of pore attributes."";  /evidence=""ECO:0000269|PubMed:10931826""; MUTAGEN 651;  /note=""E->Q: Minor modification of pore attributes."";  /evidence=""ECO:0000269|PubMed:10931826""; MUTAGEN 704;  /note=""T->A: No effect on PMA-induced enhancement of capsaicin-evoked currents but reduces direct activation by PMA."";  /evidence=""ECO:0000269|PubMed:14523239, ECO:0000269|PubMed:14630912""; MUTAGEN 704;  /note=""T->I: Loss of activation by capsaicin and loss of vanilloid binding; when associated with A-502."";  /evidence=""ECO:0000269|PubMed:14523239, ECO:0000269|PubMed:14630912""; MUTAGEN 761;  /note=""E->K,Q: Abolishes capsaiin-evoked current and binding to resiniferatoxin."";  /evidence=""ECO:0000269|PubMed:12228246""; MUTAGEN 761;  /note=""Missing: Abolishes sensitivity to acid."";  /evidence=""ECO:0000269|PubMed:12228246""; MUTAGEN 785;  /note=""R->Q: Strongly reduces CALM-binding and abolishes PLC-mediated channel activity; when associated with Q-788."";  /evidence=""ECO:0000269|PubMed:12764195, ECO:0000269|PubMed:23109716""; MUTAGEN 787;  /note=""W->R: Reduces CALM-binding. Reduces desensitization by repeated exposure to capsaicin."";  /evidence=""ECO:0000269|PubMed:23109716""; MUTAGEN 788;  /note=""K->Q: Strongly reduces CALM-binding and abolishes PLC-mediated channel activity; when associated with Q-785 or Q-797."";  /evidence=""ECO:0000269|PubMed:12764195, ECO:0000269|PubMed:23109716""; MUTAGEN 797;  /note=""R->Q: Abolishes PLC-mediated channel activity; when associated with Q-788."";  /evidence=""ECO:0000269|PubMed:12764195""; MUTAGEN 800;  /note=""S->A: Largely reduces direct activation of by PMA and PMA-induced currents; no effect on receptor kinase-induced currents."";  /evidence=""ECO:0000269|PubMed:11884385, ECO:0000269|PubMed:12764195, ECO:0000269|PubMed:14523239"""	O35433;	10116.ENSRNOP00000026493;	2NYJ;2PNN;3J5P;3J5Q;3J5R;3J9J;3SUI;5IRX;5IRZ;5IS0;
Q45040	Q45040_BORBG	unreviewed	Outer surface protein A	ospA	Borrelia burgdorferi (Lyme disease spirochete) (Borreliella burgdorferi)	273								2OL6;2PI3;3CKF;3CKG;
A4GWM6	A4GWM6_LISMN	unreviewed	Class 1 internalin InlA (InlA) (Internalin A) (Fragment)	inlA D6P18_08105	Listeria monocytogenes	800								2OMT;
A4GWL5	A4GWL5_LISMN	unreviewed	InlA (Internalin A) (Fragment)	inlA	Listeria monocytogenes	800								2OMX;
Q99LI7	CSTF3_MOUSE	reviewed	Cleavage stimulation factor subunit 3 (CF-1 77 kDa subunit) (Cleavage stimulation factor 77 kDa subunit) (CSTF 77 kDa subunit) (CstF-77)	Cstf3	Mus musculus (Mouse)	717							10090.ENSMUSP00000028599;	2OND;2OOE;
A0A0H3K7S1	A0A0H3K7S1_STAAE	unreviewed	Glycerophosphodiester phosphodiesterase (Glycerophosphoryl diester phosphodiesterase)	glpQ NWMN_0830 CNH35_04790	Staphylococcus aureus (strain Newman)	309								2OOG;
Q9F3A5	Q9F3A5_STRCO	unreviewed	Putative isomerase	SCO7570	Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145)	375							100226.SCO7570;	2OQH;4DYE;
Q8EMJ9	GALRD_OCEIH	reviewed	Galactarate dehydratase (D-threo-forming) (GalrD) (EC 4.2.1.158) (GalrD-II)	OB2843	Oceanobacillus iheyensis (strain DSM 14371 / CIP 107618 / JCM 11309 / KCTC 3954 / HTE831)	391					"MUTAGEN 45;  /note=""H->Q: Loss of activity."";  /evidence=""ECO:0000269|PubMed:19883118""; MUTAGEN 90;  /note=""Y->F: 3550-fold reduction in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:19883118""; MUTAGEN 162;  /note=""R->N: 17000-fold reduction in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:19883118""; MUTAGEN 164;  /note=""Y->F: Loss of activity."";  /evidence=""ECO:0000269|PubMed:19883118"""		221109.22778530;	2OQY;3ES7;3ES8;3FYY;3GD6;3HPF;
A0A0H2V2B5	A0A0H2V2B5_SHIFL	unreviewed	Glycerophosphodiester phosphodiesterase	ugpQ SF3466	Shigella flexneri	247								2OTD;
O50580	DT3E_PSECI	reviewed	D-tagatose 3-epimerase (DTE) (EC 5.1.3.31) (D-ribulose 3-epimerase) (Ketose 3-epimerase)		Pseudomonas cichorii	290					"MUTAGEN 37;  /note=""S->N: Moderate increase in catalytic efficiency for D-fructose."";  /evidence=""ECO:0000269|PubMed:25655925""; MUTAGEN 183;  /note=""Q->H: Shows a pronounced increase in catalytic efficiency for L-sorbose. It seems that this mutation switches the substrate preference from hexoses with a 4S,5R configuration to those with a 4R,5S configuration."";  /evidence=""ECO:0000269|PubMed:25655925"""			2OU4;2QUL;2QUM;2QUN;4PFH;4PGL;4XSL;4XSM;4YTQ;4YTR;4YTS;4YTT;4YTU;5J8L;
Q9RKF7	Q9RKF7_STRCO	unreviewed	Putative racemase	SCO3480	Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145)	361							100226.SCO3480;	2OVL;3CK5;
Q8UEU8	Y1656_AGRFC	reviewed	Uncharacterized protein Atu1656	Atu1656 AGR_C_3050	Agrobacterium fabrum (strain C58 / ATCC 33970) (Agrobacterium tumefaciens (strain C58))	293							176299.Atu1656;	2OJH;
O30011	AROD_ARCFU	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD AF_0228	Archaeoglobus fulgidus (strain ATCC 49558 / DSM 4304 / JCM 9628 / NBRC 100126 / VC-16)	196							224325.AF_0228;	2OX1;
P05532	KIT_MOUSE	reviewed	Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (CD antigen CD117)	Kit Sl	Mus musculus (Mouse)	979			DISEASE: Note=Defects in Kit are the cause of the white-spotting phenotype (W). White-spotting variants induces severe effects on pigmentation, gametogenesis and hematopoiesis. Mice homozygous for W42 die perinatally of macrocytic anemia.		"MUTAGEN 571;  /note=""Y->F: Abolishes interaction with PTPN11/SHP-2."";  /evidence=""ECO:0000269|PubMed:9528781""; MUTAGEN 573;  /note=""Y->F: Abolishes interaction with PTPN6/SHP-1."";  /evidence=""ECO:0000269|PubMed:9528781""; MUTAGEN 573;  /note=""Missing: Abolishes interaction with PTPN6/SHP-1."";  /evidence=""ECO:0000269|PubMed:9528781""; MUTAGEN 723;  /note=""Y->F: Abolishes interaction with PIK3R1."";  /evidence=""ECO:0000269|PubMed:7527401""; MUTAGEN 860;  /note=""F->S: Mice display white fur, hearing loss, anemia and mast cell deficiency, plus sterility in both males and females."";  /evidence=""ECO:0000269|PubMed:15731517"""	P05532;	10090.ENSMUSP00000005815;	2O26;
A0A0H2WWB5	A0A0H2WWB5_STAAC	unreviewed	o-succinylbenzoate synthase (OSB synthase) (OSBS) (EC 4.2.1.113) (4-(2'-carboxyphenyl)-4-oxybutyric acid synthase) (o-succinylbenzoic acid synthase)	menC SACOL1843	Staphylococcus aureus (strain COL)	333								2OKT;
B2J846	B2J846_NOSP7	unreviewed	Uncharacterized protein	Npun_F0524	Nostoc punctiforme (strain ATCC 29133 / PCC 73102)	305							63737.Npun_F0524;	2P4O;
A0A0H3JTK7	A0A0H3JTK7_STAAN	unreviewed	Glycerophosphoryl diester phosphodiesterase	glpQ	Staphylococcus aureus (strain N315)	309								2P76;
Q81IL5	NSAR_BACCR	reviewed	N-succinyl-L-Arg/Lys racemase (EC 5.1.1.-) (N-succinyl amino acid racemase) (NSAR)	BC_0371	Bacillus cereus (strain ATCC 14579 / DSM 31 / CCUG 7414 / JCM 2152 / NBRC 15305 / NCIMB 9373 / NCTC 2599 / NRRL B-3711)	369								2P88;2P8B;2P8C;
P62881	GNB5_MOUSE	reviewed	Guanine nucleotide-binding protein subunit beta-5 (Gbeta5) (Transducin beta chain 5)	Gnb5	Mus musculus (Mouse)	395						P62881;	10090.ENSMUSP00000076155;	2PBI;6N9G;
A3SNG0	A3SNG0_ROSNI	unreviewed	Mandelate racemase/muconate lactonizing enzyme, putative	ISM_14080	Roseovarius nubinhibens (strain ATCC BAA-591 / DSM 15170 / ISM)	376							89187.ISM_14080;	2PCE;3FV9;
O35250	EXOC7_MOUSE	reviewed	Exocyst complex component 7 (Exocyst complex component Exo70)	Exoc7 Exo70	Mus musculus (Mouse)	697						O35250;	10090.ENSMUSP00000021147;	2PFT;
Q6ARP5	Q6ARP5_DESPS	unreviewed	Related to N-acylamino acid racemase (MenC)	DP0251	Desulfotalea psychrophila (strain LSv54 / DSM 12343)	368							177439.DP0251;	2PGE;
Q570C0	TIR1_ARATH	reviewed	Protein TRANSPORT INHIBITOR RESPONSE 1 (Weak ethylene-insensitive protein 1)	TIR1 FBL1 WEI1 At3g62980 T20O10.80	Arabidopsis thaliana (Mouse-ear cress)	594				DISRUPTION PHENOTYPE: Plant are deficient in a variety of auxin-regulated growth processes including lateral root formation, and hypocotyl and cell elongation. {ECO:0000269|PubMed:9436980}.	"MUTAGEN 10;  /note=""P->A: Abolishes SCF(TIR1) complex formation, altered auxin-mediated response and reduced affinity for auxin."";  /evidence=""ECO:0000269|PubMed:10398681, ECO:0000269|PubMed:15917798""; MUTAGEN 33;  /note=""V->A: No affinity for auxin."";  /evidence=""ECO:0000269|PubMed:15917798""; MUTAGEN 35;  /note=""K->A: No affinity for auxin."";  /evidence=""ECO:0000269|PubMed:15917798""; MUTAGEN 147;  /note=""G->D: In tir1-1; insensitive to auxin ubiquitously and to ethylene in roots only."";  /evidence=""ECO:0000269|PubMed:9436980""; MUTAGEN 441;  /note=""G->D: In tir1-2; insensitive to auxin."";  /evidence=""ECO:0000269|PubMed:9436980""; MUTAGEN 574..594;  /note=""Missing: In tir1-101/wei1; insensitive to auxin ubiquitously and to ethylene in roots only."";  /evidence=""ECO:0000269|PubMed:12606727"""	Q570C0;	3702.AT3G62980.1;	2P1M;2P1N;2P1O;2P1P;2P1Q;3C6N;3C6O;3C6P;
C1DMY1	C1DMY1_AZOVD	unreviewed	L-rhamnonate dehydratase (RhamD) (EC 4.2.1.90)	rhmD Avin_09220	Azotobacter vinelandii (strain DJ / ATCC BAA-1303)	394							322710.Avin_09220;	2OZ3;3EKG;
Q72L02	Q72L02_THET2	unreviewed	Hypothetical conserved protein	TT_C0263	Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27)	355							262724.TT_C0263;	2PL2;
P38968	SEC31_YEAST	reviewed	Protein transport protein SEC31 (Protein WEB1)	SEC31 WEB1 YDL195W D1229	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1273						P38968;	4932.YDL195W;	2PM6;2PM7;2PM9;2QTV;3MZL;4BZJ;4BZK;6ZG5;6ZG6;6ZL0;
Q04491	SEC13_YEAST	reviewed	Protein transport protein SEC13	SEC13 ANU3 YLR208W L8167.4	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	297					"MUTAGEN 176;  /note=""G->R: Leads to mislocalization of NPCs and overproliferation of the nuclear and ER membranes at 34 degree Celsius."";  /evidence=""ECO:0000269|PubMed:12215173""; MUTAGEN 224;  /note=""S->K: Growth inhibited above 30 degrees Celsius."";  /evidence=""ECO:0000269|PubMed:8432727""; MUTAGEN 262;  /note=""W->R: Growth inhibited above 30 degrees Celsius."";  /evidence=""ECO:0000269|PubMed:8432727""; MUTAGEN 266;  /note=""G->D: Growth inhibited above 34 degrees Celsius."";  /evidence=""ECO:0000269|PubMed:8432727"""	Q04491;	4932.YLR208W;	2PM6;2PM7;2PM9;3IKO;3JRO;3JRP;3MZK;3MZL;4BZJ;4BZK;4XMM;4XMN;6ZG5;6ZG6;6ZL0;
Q0FPQ4	HPBD_SALBH	reviewed	4-hydroxyproline betaine 2-epimerase (Hyp-B 2-epimerase) (EC 5.1.1.22) ((4R)-4-hydroxyproline betaine 2-epimerase)	hpbD R2601_01638	Salipiger bermudensis (strain DSM 26914 / JCM 13377 / KCTC 12554 / HTCC2601) (Pelagibaca bermudensis)	367							314265.R2601_01638;	2PMQ;4H2H;
Q38PT6	Q38PT6_9HEXA	unreviewed	6.5 kDa glycine-rich antifreeze protein		Hypogastrura harveyi	103								2PNE;3BOG;3BOI;
Q8ZL58	TAGAD_SALTY	reviewed	L-talarate/galactarate dehydratase (TalrD/GalrD) (EC 4.2.1.156) (EC 4.2.1.42) (StTGD)	STM3697	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	398				DISRUPTION PHENOTYPE: Cells lacking this gene lose the ability to grow on L-talarate as carbon source, and are impaired in the ability to utilize galactarate as carbon source. {ECO:0000269|PubMed:17649980}.	"MUTAGEN 197;  /note=""K->A: Loss of dehydration activity on both L-talarate and galactarate and loss of epimerization activity."";  /evidence=""ECO:0000269|PubMed:17649980""; MUTAGEN 328;  /note=""H->N,A: Loss of dehydration activity on both L-talarate and galactarate and loss of epimerization activity."";  /evidence=""ECO:0000269|PubMed:17649980"""			2PP0;2PP1;2PP3;
Q9GYW4	Q9GYW4_ANOGA	unreviewed	Thioester-containing protein I	TEP-I	Anopheles gambiae (African malaria mosquito)	1340						Q9GYW4;		2PN5;4LNV;
Q2U1E8	Q2U1E8_ASPOR	unreviewed	MR_MLE domain-containing protein	AO090011000058	Aspergillus oryzae (strain ATCC 42149 / RIB 40) (Yellow koji mold)	371								2PS2;
Q92ZS5	Q92ZS5_RHIME	unreviewed	Enolase	SMa0708	Rhizobium meliloti (strain 1021) (Ensifer meliloti) (Sinorhizobium meliloti)	389								2PPG;4H1Z;
Q8RB32	Q8RB32_CALS4	unreviewed	Glycerophosphoryl diester phosphodiesterase	UgpQ TTE0993	Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) (Thermoanaerobacter tengcongensis)	243							273068.TTE0993;	2PZ0;
O34452	YRRB_BACSU	reviewed	TPR repeat-containing protein YrrB	yrrB BSU27490	Bacillus subtilis (strain 168)	206							224308.BSU27490;	2Q7F;
O87275	O87275_9STAP	unreviewed	Virginiamycin B lyase (EC 4.2.99.-) (Streptogramin B lyase)	vgbB	Staphylococcus cohnii	295								2QC5;
P42703	LIFR_MOUSE	reviewed	Leukemia inhibitory factor receptor (LIF receptor) (LIF-R) (D-factor/LIF receptor) (CD antigen CD118)	Lifr	Mus musculus (Mouse)	1092						P42703;	10090.ENSMUSP00000126137;	2Q7N;
Q5P025	Q5P025_AROAE	unreviewed	Mandelate racemase/muconate lactonizing enzyme family protein	ebA5637 ebA5652	Aromatoleum aromaticum (strain EbN1) (Azoarcus sp. (strain EbN1))	387							76114.ebA5652;	2QDE;
Q3M5E0	Q3M5E0_TRIV2	unreviewed	Uncharacterized protein	Ava_4197	Trichormus variabilis (strain ATCC 29413 / PCC 7937) (Anabaena variabilis)	342							240292.Ava_4197;	2QE8;
Q3EZ40	Q3EZ40_BACTI	unreviewed	Transcriptional activator plcR	RBTH_02551	Bacillus thuringiensis serovar israelensis ATCC 35646	285								2QFC;
Q969H0	FBXW7_HUMAN	reviewed	F-box/WD repeat-containing protein 7 (Archipelago homolog) (hAgo) (F-box and WD-40 domain-containing protein 7) (F-box protein FBX30) (SEL-10) (hCdc4)	FBXW7 FBW7 FBX30 SEL10	Homo sapiens (Human)	707					"MUTAGEN 26;  /note=""S->A: Abolished phosphorylation by ATM."";  /evidence=""ECO:0000269|PubMed:26774286""; MUTAGEN 72;  /note=""S->A: Does not affect phosphorylation by ATM."";  /evidence=""ECO:0000269|PubMed:26774286""; MUTAGEN 159;  /note=""S->A: Does not affect interaction with PIN1."";  /evidence=""ECO:0000269|PubMed:22608923""; MUTAGEN 205;  /note=""T->A: Impaired interaction with PIN1."";  /evidence=""ECO:0000269|PubMed:22608923""; MUTAGEN 252..257;  /note=""ALDELI->DDDEDD: Prevents homodimerization."";  /evidence=""ECO:0000269|PubMed:17434132""; MUTAGEN 349;  /note=""S->A: Does not affect interaction with PIN1."";  /evidence=""ECO:0000269|PubMed:22608923""; MUTAGEN 372;  /note=""S->A: Does not affect interaction with PIN1."";  /evidence=""ECO:0000269|PubMed:22608923"""	Q969H0;	9606.ENSP00000281708;	2OVP;2OVQ;2OVR;5IBK;5V4B;
P46675	STU2_YEAST	reviewed	Protein STU2 (Suppressor of tubulin 2)	STU2 YLR045C L2108	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	888					"MUTAGEN 23;  /note=""W->A: Disrupts interaction with tubulin heterodimer. Impairs polymerase activity under microtubule stress."";  /evidence=""ECO:0000269|PubMed:17355870, ECO:0000269|PubMed:22904013""; MUTAGEN 69;  /note=""V->D: Impairs polymerase activity under microtubule stress."";  /evidence=""ECO:0000269|PubMed:22904013""; MUTAGEN 116;  /note=""R->A: Decreases interaction with tubulin heterodimer."";  /evidence=""ECO:0000269|PubMed:17355870""; MUTAGEN 151;  /note=""K->A: Disrupts interaction with tubulin heterodimer."";  /evidence=""ECO:0000269|PubMed:17355870""; MUTAGEN 200;  /note=""R->A: No effect on polymerase activity under normal conditions but impairs polymerase activity under microtubule stress."";  /evidence=""ECO:0000269|PubMed:22904013, ECO:0000269|PubMed:25097237""; MUTAGEN 341;  /note=""W->A: Disrupts interaction with tubulin heterodimer. Impairs polymerase activity under microtubule stress."";  /evidence=""ECO:0000269|PubMed:22904013, ECO:0000269|PubMed:25097237""; MUTAGEN 519;  /note=""R->A: Disrupts interaction with tubulin heterodimer. No effect on polymerase activity under normal conditions but impairs polymerase activity under microtubule stress."";  /evidence=""ECO:0000269|PubMed:22904013, ECO:0000269|PubMed:25097237"""	P46675;	4932.YLR045C;	2QK1;4FFB;4U3J;6BL7;7KDF;
Q92YR6	Q92YR6_RHIME	unreviewed	Mandelate racemase/muconate lactonizing enzyme family protein (EC 5.5.1.1)	SMa1461	Rhizobium meliloti (strain 1021) (Ensifer meliloti) (Sinorhizobium meliloti)	374								2PGW;
Q57843	ADHS_METJA	reviewed	2-amino-3,7-dideoxy-D-threo-hept-6-ulosonate synthase (ADH synthase) (ADHS) (ADTH synthase) (EC 2.2.1.10) (Transaldolase-like ADHS)	aroA' MJ0400	Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) (Methanococcus jannaschii)	273							243232.MJ_0400;	2QJG;2QJH;2QJI;
P0A940	BAMA_ECOLI	reviewed	Outer membrane protein assembly factor BamA (Omp85)	bamA yaeT yzzN yzzY b0177 JW0172	Escherichia coli (strain K12)	810				DISRUPTION PHENOTYPE: Deletion is lethal. Depletion results in the accumulation of incorrectly assembled outer membrane proteins, including TolC, OmpF, OmpC and OmpA (PubMed:15851030, PubMed:16102012). Decreased expression leads to decreased susceptibility to contact-dependent growth inhibition (CDI), and decreased expression of outer membrane proteins (including in this study LamB) as well as up-regulation of periplasmic protease DegP (PubMed:18761695, PubMed:23469034). {ECO:0000269|PubMed:15851030, ECO:0000269|PubMed:16102012, ECO:0000269|PubMed:18761695, ECO:0000269|PubMed:23469034}.	"MUTAGEN 181;  /note=""N->A: Lethal, protein does not accumulate."";  /evidence=""ECO:0000269|PubMed:26900875""; MUTAGEN 251;  /note=""K->A: Lethal, protein does not accumulate."";  /evidence=""ECO:0000269|PubMed:26900875""; MUTAGEN 259;  /note=""N->A: Lethal, protein does not accumulate."";  /evidence=""ECO:0000269|PubMed:26900875""; MUTAGEN 351..353;  /note=""KIR->PIP: Lethal, wild-type protein levels."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 351;  /note=""K->P: Reduces cell growth, wild-type protein levels."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 366;  /note=""R->E: Severely impairs cell growth, wild-type protein levels."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 373;  /note=""E->K: Lethal, wild-type protein levels."";  /evidence=""ECO:0000269|PubMed:26900875, ECO:0000269|PubMed:26901871""; MUTAGEN 393;  /note=""G->C: No effect. Lethal; when associated with C-584, probably locks protein in a single conformation that prevents movement, growth restored by strong reducing agent."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 415..419;  /note=""VYKVK->PYKVP: Lethal, wild-type protein levels."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 415..417;  /note=""VYK->PYP: Lethal, wild-type protein levels."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 417..419;  /note=""KVK->PVP: Lethal, wild-type protein levels."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 429;  /note=""G->P: Lethal, wild-type protein levels."";  /evidence=""ECO:0000269|PubMed:26900875""; MUTAGEN 430;  /note=""I->C: Reduced folding of OmpT; when associated with C-808, traps protein in lateral closed conformation, growth restored by reducing agent."";  /evidence=""ECO:0000269|PubMed:27686148""; MUTAGEN 435;  /note=""E->C: No effect. Lethal; when associated with C-658 or C-665, probably locks protein in a single conformation that prevents movement, growth restored by strong reducing agent."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 435;  /note=""E->L: Very minor growth defect. Lethal; when associated with L-800."";  /evidence=""ECO:0000269|PubMed:24619089""; MUTAGEN 464;  /note=""D->L: Very minor growth defect."";  /evidence=""ECO:0000269|PubMed:24619089""; MUTAGEN 500;  /note=""D->L: Very minor growth defect."";  /evidence=""ECO:0000269|PubMed:24619089""; MUTAGEN 547;  /note=""R->A: Lethal."";  /evidence=""ECO:0000269|PubMed:24619089""; MUTAGEN 554..562;  /note=""EHPSTSDQD->VDYPYDVPDYA: Loop 4 to HA epitope; still susceptible to CdiA-EC93."";  /evidence=""ECO:0000269|PubMed:23882017""; MUTAGEN 556..563;  /note=""PSTSDQDN->G: Delta loop 4; slight increase in resistance to CdiA-EC93, forms aggregates with CdiA-EC93 cells."";  /evidence=""ECO:0000269|PubMed:23882017""; MUTAGEN 584;  /note=""G->C: No effect. Lethal; when associated with C-393, probably locks protein in a single conformation that prevents movement, growth restored by strong reducing agent."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 658;  /note=""S->C: No effect. Lethal; when associated with C-435, probably locks protein in a single conformation that prevents movement, growth restored by strong reducing agent."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 661;  /note=""R->A: Slow growth on solid and liquid media, less protein accumulates which is more proteinase sensitive."";  /evidence=""ECO:0000269|PubMed:24619089""; MUTAGEN 665;  /note=""S->C: No effect. Lethal; when associated with C-435, probably locks protein in a single conformation that prevents movement, growth restored by strong reducing agent."";  /evidence=""ECO:0000269|PubMed:26901871""; MUTAGEN 673..702;  /note=""Missing: Lethal."";  /evidence=""ECO:0000269|PubMed:24619089""; MUTAGEN 675..701;  /note=""FPHQASNYDPDYDYECATQDGAKDLCK->G: Delta loop 6; fully resistant to CdiA-EC93, does not form aggregates with CdiA-EC93 cells."";  /evidence=""ECO:0000269|PubMed:23882017""; MUTAGEN 677..685;  /note=""HQASNYDPD->VDYPYDVPDYA: Loop 6 to HA epitope; still susceptible to CdiA-EC93."";  /evidence=""ECO:0000269|PubMed:23882017""; MUTAGEN 740;  /note=""D->A: Slow growth on solid and liquid media, less protein accumulates which is more proteinase sensitive."";  /evidence=""ECO:0000269|PubMed:24619089""; MUTAGEN 754..755;  /note=""YS->VDYPYDVPDYA: Loop 7 to HA epitope; fully resistant to CdiA-EC93, does not form aggregates with CdiA-EC93 cells."";  /evidence=""ECO:0000269|PubMed:23882017""; MUTAGEN 800;  /note=""E->L: Very minor growth defect. Lethal; when associated with L-435."";  /evidence=""ECO:0000269|PubMed:24619089""; MUTAGEN 808;  /note=""K->C: Reduced folding of OmpT; when associated with C-430, traps protein in lateral closed conformation, growth restored by reducing agent."";  /evidence=""ECO:0000269|PubMed:27686148"""	P0A940;	511145.b0177;	2QCZ;2QDF;2V9H;3EFC;3OG5;3Q6B;4C4V;4N75;4PK1;4XGA;5AYW;5D0O;5D0Q;5EKQ;5LJO;6LYQ;6LYR;6LYS;6LYU;6SN9;6SOB;6SOJ;6T1W;6V05;7BNQ;7NBX;7NCS;7ND0;7NRI;
Q48245	VACA2_HELPX	reviewed	Vacuolating cytotoxin autotransporter [Cleaved into: Vacuolating cytotoxin; Vacuolating cytotoxin translocator]	vacA	Helicobacter pylori (Campylobacter pylori)	1287								1SEW;2QV3;6NYF;6NYG;6NYJ;6NYL;6NYM;6NYN;6ODY;
Q8P6Z9	Q8P6Z9_XANCP	unreviewed	Pectate lyase II	pelB XCC2815	Xanthomonas campestris pv. campestris (strain ATCC 33913 / DSM 3586 / NCPPB 528 / LMG 568 / P 25)	353							340.xcc-b100_1345;	2QX3;2QXZ;2QY1;
P34077	NIC96_YEAST	reviewed	Nucleoporin NIC96 (96 kDa nucleoporin-interacting component) (Nuclear pore protein NIC96)	NIC96 YFR002W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	839						P34077;	4932.YFR002W;	2QX5;2RFO;6X07;
Q921E6	EED_MOUSE	reviewed	Polycomb protein EED	Eed	Mus musculus (Mouse)	441					"MUTAGEN 193;  /note=""I->N: Hypomorphic allele. Abrogates interaction with EZH2 and impairs transcriptional repression."";  /evidence=""ECO:0000269|PubMed:9234727, ECO:0000269|PubMed:9742080""; MUTAGEN 196;  /note=""L->P: Null allele. Abrogates interaction with EZH2 and impairs transcriptional repression."";  /evidence=""ECO:0000269|PubMed:17259173, ECO:0000269|PubMed:9234727, ECO:0000269|PubMed:9742080""; MUTAGEN 246;  /note=""L->E: Abrogates interaction with EZH2."";  /evidence=""ECO:0000269|PubMed:17937919""; MUTAGEN 315;  /note=""L->E: Impairs interaction with EZH2."";  /evidence=""ECO:0000269|PubMed:17937919""; MUTAGEN 316;  /note=""G->A: Impairs interaction with EZH2."";  /evidence=""ECO:0000269|PubMed:17937919"""	Q921E6;	10090.ENSMUSP00000102853;	2QXV;
Q6ND47	RBLL2_RHOPA	reviewed	Ribulose bisphosphate carboxylase-like protein 2 (RuBisCO-like protein)	rlp2 RPA0262	Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009)	432							258594.RPA0262;	2QYG;
Q8ZNR3	SOPA_SALTY	reviewed	E3 ubiquitin-protein ligase SopA (EC 2.3.2.26) (HECT-type E3 ubiquitin transferase SopA) (Salmonella outer protein A) (Secreted effector protein SopA)	sopA STM2066	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	782					"MUTAGEN 747;  /note=""L->A: Slight decrease in activity."";  /evidence=""ECO:0000269|PubMed:18066077""; MUTAGEN 752;  /note=""T->A: Strong decrease in activity."";  /evidence=""ECO:0000269|PubMed:18066077""; MUTAGEN 753;  /note=""C->S: Loss of ubiquitin ligase activity. No thioester formation."";  /evidence=""ECO:0000269|PubMed:17076670"""	Q8ZNR3;		2QYU;2QZA;3SY2;5JW7;
P9WMN3	GLMU_MYCTU	reviewed	Bifunctional protein GlmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (N-acetylglucosamine-1-phosphate uridyltransferase); Glucosamine-1-phosphate N-acetyltransferase (EC 2.3.1.157)]	glmU Rv1018c	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	495						P9WMN3;	83332.Rv1018c;	2QKX;3D8V;3D98;3DJ4;3FOQ;3SPT;3ST8;4G3P;4G3Q;4G3S;4G87;4HCQ;
Q96QK1	VPS35_HUMAN	reviewed	Vacuolar protein sorting-associated protein 35 (hVPS35) (Maternal-embryonic 3) (Vesicle protein sorting 35)	VPS35 MEM3 TCCCTA00141	Homo sapiens (Human)	796			DISEASE: Parkinson disease 17 (PARK17) [MIM:614203]: An autosomal dominant, adult-onset form of Parkinson disease. Parkinson disease is a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. {ECO:0000269|PubMed:21763482, ECO:0000269|PubMed:21763483, ECO:0000269|PubMed:22517097, ECO:0000269|PubMed:23395371, ECO:0000269|PubMed:24819384, ECO:0000269|PubMed:24980502}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 108;  /note=""L->P: Disrupts interaction with VPS26; no effect on interaction with VPS29."";  /evidence=""ECO:0000269|PubMed:23331060""; MUTAGEN 675;  /note=""H->R: Disrupts interaction with VPS29. Does not effect interaction with VPS26."";  /evidence=""ECO:0000269|PubMed:23331060"""	Q96QK1;	9606.ENSP00000299138;	2R17;5F0J;5F0K;5F0L;5F0M;5F0P;5OSH;5OSI;7BLN;7BLO;
P0ADV1	LPTA_ECOLI	reviewed	Lipopolysaccharide export system protein LptA	lptA yhbN b3200 JW3167	Escherichia coli (strain K12)	185				DISRUPTION PHENOTYPE: Results in an earlier growth arrest and onset of cell lethality. {ECO:0000269|PubMed:16765569}.	"MUTAGEN 36;  /note=""I->D,E: No change in activity."";  /evidence=""ECO:0000269|PubMed:18534617""; MUTAGEN 38;  /note=""I->D: Decrease in activity."";  /evidence=""ECO:0000269|PubMed:18534617""; MUTAGEN 38;  /note=""I->E: No change in activity."";  /evidence=""ECO:0000269|PubMed:18534617""; MUTAGEN 76;  /note=""R->D,E: No change in activity."";  /evidence=""ECO:0000269|PubMed:18534617""; MUTAGEN 95;  /note=""F->A: No change in activity."";  /evidence=""ECO:0000269|PubMed:18534617"""	P0ADV1;	511145.b3200;	2R19;2R1A;6GD5;
Q7D0E8	Q7D0E8_AGRFC	unreviewed	Dihydrodipicolinate synthase	dapA Atu0899	Agrobacterium fabrum (strain C58 / ATCC 33970) (Agrobacterium tumefaciens (strain C58))	302							176299.Atu0899;	2R8W;
Q704D1	KDGA_THETE	reviewed	2-dehydro-3-deoxy-D-gluconate/2-dehydro-3-deoxy-phosphogluconate aldolase (KD(P)G aldolase) (EC 4.1.2.14) (EC 4.1.2.51)	kdgA	Thermoproteus tenax	306								2R91;2R94;
Q6E4B4	Q6E4B4_PETMA	unreviewed	Variable lymphocyte receptor		Petromyzon marinus (Sea lamprey)	273								2R9U;
Q64V53	Q64V53_BACFR	unreviewed	WGR domain-containing protein	BF1877	Bacteroides fragilis (strain YCH46)	354								2RA8;
Q9HUR5	Q9HUR5_PSEAE	unreviewed	Vanillate porin OpdK	opdK PA4898	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	417								2QTK;2Y2X;3SYS;
Q91WD2	TRPV6_MOUSE	reviewed	Transient receptor potential cation channel subfamily V member 6 (TrpV6) (Calcium transport protein 1) (CaT1) (Epithelial calcium channel 2) (ECaC2)	Trpv6	Mus musculus (Mouse)	767				DISRUPTION PHENOTYPE: Mutant mice have lower body weight than their littermates throughout their lifespan and low fertility, due to impaired calcium homeostasis. Mutant mice display strongly impaired intestinal Ca(2+) uptake and increased urinary Ca(2+) levels (PubMed:17129178). Still, their serum Ca(2+) levels are normal, probably due to compensation by another calcium channel (PubMed:17129178, PubMed:20399919). In spite of this, mutant mice display decreased femoral mineral density; also when they are fed a high-calcium diet (PubMed:17129178). In contrast, no difference in bone density was observed in another study; mutant and wild-type mice displayed similar values when fed a normal diet, and a similar reduction in bone mass when fed a low-calcium diet (PubMed:20399919). Besides, the majority of mutant mice display alopecia and develop dermatitis (PubMed:17129178). {ECO:0000269|PubMed:17129178, ECO:0000269|PubMed:20399919}.	"MUTAGEN 577;  /note=""L->C: Abolishes channel activity."";  /evidence=""ECO:0000269|PubMed:14736889""; MUTAGEN 581;  /note=""D->A: Abolishes binding of Mg(2+) and increases pore diameter. Impairs intestinal Ca(2+) uptake."";  /evidence=""ECO:0000269|PubMed:12601087, ECO:0000269|PubMed:14736889, ECO:0000269|PubMed:22878123""; MUTAGEN 581;  /note=""D->C: Abolishes channel activity."";  /evidence=""ECO:0000269|PubMed:12601087, ECO:0000269|PubMed:14736889""; MUTAGEN 581;  /note=""D->G: Increases pore diameter."";  /evidence=""ECO:0000269|PubMed:12601087, ECO:0000269|PubMed:14736889""; MUTAGEN 586;  /note=""Y->C: Abolishes channel activity."";  /evidence=""ECO:0000269|PubMed:14736889""; MUTAGEN 639;  /note=""T->A: Abolishes plasma membrane localization and channel activity."";  /evidence=""ECO:0000269|PubMed:12660155"""		10090.ENSMUSP00000031902;	2RFA;
Q978J0	Y1425_THEVO	reviewed	Putative ankyrin repeat protein TV1425	TV1425 TVG1472127	Thermoplasma volcanium (strain ATCC 51530 / DSM 4299 / JCM 9571 / NBRC 15438 / GSS1)	189							273116.14325664;	2RFM;
Q0P823	DAPD_CAMJE	reviewed	2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase (EC 2.3.1.117) (Tetrahydrodipicolinate N-succinyltransferase) (THDP succinyltransferase) (THP succinyltransferase) (Tetrahydropicolinate succinylase)	dapD Cj1605c	Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168)	386						Q0P823;	192222.Cj1605c;	2RIJ;
P08362	HEMA_MEASE	reviewed	Hemagglutinin glycoprotein	H	Measles virus (strain Edmonston) (MeV) (Subacute sclerose panencephalitis virus)	617						P08362;		2RKC;2ZB5;2ZB6;3ALW;3ALX;3ALZ;3INB;
P45025	MURA_HAEIN	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (UDP-N-acetylglucosamine enolpyruvyl transferase) (EPT)	murA murZ HI_1081	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	424							71421.HI_1081;	2RL1;2RL2;3SWE;
O68975	O68975_YEREN	unreviewed	Exopolygalacturonase		Yersinia enterocolitica	601								2UVE;2UVF;
P39371	NANM_ECOLI	reviewed	N-acetylneuraminate epimerase (EC 5.1.3.24) (N-acetylneuraminate anomerase NanM) (N-acetylneuraminate mutarotase) (Neu5Ac mutarotase) (Sialic acid epimerase)	nanM yjhT b4310 JW5777	Escherichia coli (strain K12)	368					"MUTAGEN 30;  /note=""K->A: No effect on catalytic activity."";  /evidence=""ECO:0000269|PubMed:18063573""; MUTAGEN 228;  /note=""E->A: Great decrease in catalytic activity."";  /evidence=""ECO:0000269|PubMed:18063573""; MUTAGEN 234;  /note=""R->A: Decrease in catalytic activity."";  /evidence=""ECO:0000269|PubMed:18063573""; MUTAGEN 297;  /note=""H->A: No effect on catalytic activity."";  /evidence=""ECO:0000269|PubMed:18063573""; MUTAGEN 302;  /note=""K->A: No effect on catalytic activity."";  /evidence=""ECO:0000269|PubMed:18063573""; MUTAGEN 328;  /note=""Y->A: No effect on catalytic activity."";  /evidence=""ECO:0000269|PubMed:18063573""; MUTAGEN 344;  /note=""E->A: No effect on catalytic activity."";  /evidence=""ECO:0000269|PubMed:18063573"""	P39371;	511145.b4310;	2UVK;
Q9VEZ3	MSPS_DROME	reviewed	Protein mini spindles	msps CG5000	Drosophila melanogaster (Fruit fly)	2042					"MUTAGEN 21;  /note=""W->E: Impairs microtubule polymerization. Disrupts tubulin binding; when associated with E-292."";  /evidence=""ECO:0000269|PubMed:17889670, ECO:0000269|PubMed:24966168""; MUTAGEN 292;  /note=""W->E: Impairs microtubule polymerization. Disrupts tubulin binding; when associated with E-21."";  /evidence=""ECO:0000269|PubMed:17889670, ECO:0000269|PubMed:24966168""; MUTAGEN 546..549;  /note=""KVLK->EAAE: Disrupts microtubule lattice binding."";  /evidence=""ECO:0000269|PubMed:21965297""; MUTAGEN 606;  /note=""W->E: Impairs microtubule polymerization, decreases microtubule lattice localization."";  /evidence=""ECO:0000269|PubMed:24966168""; MUTAGEN 874;  /note=""W->E: Impairs microtubule polymerization, decreases microtubule lattice localization."";  /evidence=""ECO:0000269|PubMed:24966168""; MUTAGEN 1102..1107;  /note=""KLKTVR->ELEAAA: Disrupts microtubule lattice binding."";  /evidence=""ECO:0000269|PubMed:21965297"""	Q9VEZ3;	7227.FBpp0293341;	2QK2;4QMH;4Y5J;5VJC;
P95435	PSCG_PSEAE	reviewed	Type III export protein PscG (Pseudomonas secretion protein G)	pscG PA1720	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	115				DISRUPTION PHENOTYPE: Deletion mutant looses the capacity to lyse macrophages, indicating the absence of a functional T3SS. {ECO:0000269|PubMed:20494986}.	"MUTAGEN 5;  /note=""L->S: About 20% loss of cytotoxicity; in association with S-9."";  /evidence=""ECO:0000269|PubMed:20494986""; MUTAGEN 9;  /note=""L->S: About 20% loss of cytotoxicity; in association with S-5."";  /evidence=""ECO:0000269|PubMed:20494986"""	P95435;		2UWJ;
Q8SWC5	Q8SWC5_ENCCU	unreviewed	Similarity to SUPPRESSOR OF FORKED PROTEIN(mRNA stability)	ECU02_0930	Encephalitozoon cuniculi (strain GB-M1) (Microsporidian parasite)	493								2UY1;
Q2RFK4	Q2RFK4_MOOTA	unreviewed	SelB translation factor (Selenocysteine-specific elongation factor)	Moth_2503	Moorella thermoacetica (strain ATCC 39073 / JCM 9320)	634							264732.Moth_2503;	2UWM;
A7YYL1	A7YYL1_XENTR	unreviewed	Avd protein	avd	Xenopus tropicalis (Western clawed frog) (Silurana tropicalis)	148								2UYW;2UZ2;
P43889	GLMU_HAEIN	reviewed	Bifunctional protein GlmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (N-acetylglucosamine-1-phosphate uridyltransferase); Glucosamine-1-phosphate N-acetyltransferase (EC 2.3.1.157)]	glmU HI_0642	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)	456					"MUTAGEN 25;  /note=""K->A: No pyrophosphorylase activity."";  /evidence=""ECO:0000269|PubMed:18029420""; MUTAGEN 76;  /note=""Q->A: No pyrophosphorylase activity."";  /evidence=""ECO:0000269|PubMed:18029420""; MUTAGEN 103;  /note=""Y->A: Reduces the pyrophosphorylase activity."";  /evidence=""ECO:0000269|PubMed:18029420""; MUTAGEN 105;  /note=""D->A: No pyrophosphorylase activity."";  /evidence=""ECO:0000269|PubMed:18029420""; MUTAGEN 223;  /note=""V->A: Reduces slightly the pyrophosphorylase activity."";  /evidence=""ECO:0000269|PubMed:18029420""; MUTAGEN 224;  /note=""E->A: Reduces the pyrophosphorylase activity."";  /evidence=""ECO:0000269|PubMed:18029420"""		71421.HI_0642;	2V0H;2V0I;2V0J;2V0K;2V0L;2VD4;2W0V;2W0W;4E1K;4KNR;4KNX;4KPX;4KPZ;4KQL;
P02461	CO3A1_HUMAN	reviewed	Collagen alpha-1(III) chain	COL3A1	Homo sapiens (Human)	1466			DISEASE: Ehlers-Danlos syndrome, vascular type (EDSVASC) [MIM:130050]: A severe form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. EDSVASC is an autosomal dominant disease characterized by joint and dermal manifestations as in other forms of the syndrome, and by proneness to spontaneous rupture of bowel and large arteries. The vascular complications may affect all anatomical areas. {ECO:0000269|PubMed:10706896, ECO:0000269|PubMed:10923041, ECO:0000269|PubMed:11168790, ECO:0000269|PubMed:12694234, ECO:0000269|PubMed:12786757, ECO:0000269|PubMed:1352273, ECO:0000269|PubMed:1357232, ECO:0000269|PubMed:1370809, ECO:0000269|PubMed:1496983, ECO:0000269|PubMed:1895316, ECO:0000269|PubMed:2243125, ECO:0000269|PubMed:2349939, ECO:0000269|PubMed:2492273, ECO:0000269|PubMed:2808425, ECO:0000269|PubMed:7749417, ECO:0000269|PubMed:7833919, ECO:0000269|PubMed:7912131, ECO:0000269|PubMed:8019562, ECO:0000269|PubMed:8098182, ECO:0000269|PubMed:8411057, ECO:0000269|PubMed:8514866, ECO:0000269|PubMed:8664902, ECO:0000269|PubMed:8680408, ECO:0000269|PubMed:8884076, ECO:0000269|PubMed:8990011, ECO:0000269|PubMed:9036918, ECO:0000269|PubMed:9147870, ECO:0000269|PubMed:9452103, ECO:0000269|Ref.50, ECO:0000269|Ref.55}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Polymicrogyria with or without vascular-type Ehlers-Danlos syndrome (PMGEDSV) [MIM:618343]: An autosomal recessive disorder with a highly variable phenotype and onset in early childhood. Disease features include cobblestone-like malformation of the cortex, polymicrogyria, intellectual and motor developmental delay, small joint hypermobility, vascular fragility, aneurysms, thin translucent skin and easy bruising, congenital heart defects, and foot deformities. Early death due to vascular dissection may occur. {ECO:0000269|PubMed:19455184, ECO:0000269|PubMed:25205403, ECO:0000269|PubMed:28258187, ECO:0000269|PubMed:28742248}. Note=The disease is caused by variants affecting the gene represented in this entry.			P02461;	9606.ENSP00000304408;	2V53;3DMW;4AE2;4AEJ;4AK3;4GYX;6FZV;6FZW;
Q62667	MVP_RAT	reviewed	Major vault protein (MVP)	Mvp	Rattus norvegicus (Rat)	861						Q62667;	10116.ENSRNOP00000027360;	2QZV;4HL8;4V60;6BP7;6BP8;
Q9NBA1	Q9NBA1_DROME	unreviewed	Dscam	Dscam1 Dscam CG17800	Drosophila melanogaster (Fruit fly)	2016								2V5M;2V5S;4XHQ;
Q0E9K4	Q0E9K4_DROME	unreviewed	Down syndrome cell adhesion molecule 1, isoform BE	Dscam1 43Bc CT39257 Dm_2R:13579 Dm_2R:13612 DmDscam Dmel\CG17800 DSCAM DScam DsCam Dscam dScam dscam Dscam-hv dscam1 Dsm l(2)05518 l(2)43Bc Neu1 p270 CG17800 Dmel_CG17800	Drosophila melanogaster (Fruit fly)	2031								2V5R;4X9F;
Q8DR52	Q8DR52_STRR6	unreviewed	Choline-binding protein F	cbpF spr0337	Streptococcus pneumoniae (strain ATCC BAA-255 / R6)	338							171101.spr0337;	2V04;2V05;2VYU;2X8M;2X8O;2X8P;
Q6BF16	DGOA_ECOLI	reviewed	2-dehydro-3-deoxy-6-phosphogalactonate aldolase (EC 4.1.2.21) (2-oxo-3-deoxygalactonate 6-phosphate aldolase) (6-phospho-2-dehydro-3-deoxygalactonate aldolase) (6-phospho-2-keto-3-deoxygalactonate aldolase) (KDPGal)	dgoA yidU b4477 JW5628	Escherichia coli (strain K12)	205					"MUTAGEN 37;  /note=""E->N: 50-fold decrease in catalytic efficiency and 6-fold decrease of binding affinity."";  /evidence=""ECO:0000269|PubMed:17981470""; MUTAGEN 154;  /note=""V->T: Little stereoselectivity, accepting KDPG and KDPGal as substrate with roughly equal efficacy. Reduced the preference for KDPGal. It diminishes the activity against KDPGal and increases activity against KDPG."";  /evidence=""ECO:0000269|PubMed:17981470"""		511145.b4477;	2V81;2V82;4QCC;
P75682	YAGE_ECOLI	reviewed	Putative 2-dehydro-3-deoxy-D-gluconate aldolase YagE (KDG aldolase YagE) (EC 4.1.2.51) (Putative 2-dehydro-3-deoxy-D-pentonate aldolase YagE) (EC 4.1.2.28)	yagE b0268 JW0261	Escherichia coli (strain K12)	302				DISRUPTION PHENOTYPE: Disruption mutant has reduced ability to catabolize D-xylonic acid. YjhH-yagE double mutant cannot use D-xylonate as the sole source of carbon. {ECO:0000269|PubMed:23233208}.		P75682;	511145.b0268;	2V8Z;2V9D;3N2X;3NEV;4OE7;4ONV;4PTN;4U4M;
Q07607	DAPA_RHIML	reviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7) (Protein MosA)	dapA mosA	Rhizobium meliloti (Ensifer meliloti) (Sinorhizobium meliloti)	292								2VC6;
Q03774	TRM82_YEAST	reviewed	tRNA (guanine-N(7)-)-methyltransferase non-catalytic subunit TRM82 (Transfer RNA methyltransferase 82)	TRM82 YDR165W YD8358.19	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	444					"MUTAGEN 223;  /note=""K->L: Decreased tRNA methylation."";  /evidence=""ECO:0000269|PubMed:26416026"""	Q03774;	4932.YDR165W;	2VDU;
P18484	AP2A2_RAT	reviewed	AP-2 complex subunit alpha-2 (100 kDa coated vesicle protein C) (Adaptor protein complex AP-2 subunit alpha-2) (Adaptor-related protein complex 2 subunit alpha-2) (Alpha-adaptin C) (Alpha2-adaptin) (Clathrin assembly protein complex 2 alpha-C large chain) (Plasma membrane adaptor HA2/AP2 adaptin alpha C subunit)	Ap2a2 Adtab	Rattus norvegicus (Rat)	938						P18484;	10116.ENSRNOP00000060992;	2VGL;2XA7;4NEE;4UQI;6OWT;6QH5;6QH6;6QH7;6URI;6YAE;6YAF;6YAH;
O87496	O87496_YEREN	unreviewed	Chaperone SycD	sycD	Yersinia enterocolitica W22703	168						O87496;		2VGX;2VGY;4AM9;
Q9AYY6	Q9AYY6_BPHK6	unreviewed	Tail spike protein	9	Enterobacteria phage HK620 (Bacteriophage HK620)	710								2VJI;2VJJ;2X6W;2X6X;2X6Y;2X85;4AVZ;4XKV;4XKW;4XL9;4XLA;4XLC;4XLE;4XLF;4XLH;4XM3;4XMY;4XN0;4XN3;4XNF;4XON;4XOP;4XOR;4XOT;4XQF;4XR6;4YEJ;4YEL;6G0X;6GVP;6GVR;
P50120	RET2_HUMAN	reviewed	Retinol-binding protein 2 (Cellular retinol-binding protein II) (CRBP-II)	RBP2 CRBP2	Homo sapiens (Human)	134						P50120;	9606.ENSP00000232217;	2RCQ;2RCT;4EDE;4EEJ;4EFG;4EXZ;4GKC;4QYN;4QYP;4QZT;4QZU;4RUU;4ZCB;4ZGU;4ZH6;4ZH9;4ZJ0;4ZR2;5DG4;5DPQ;5F58;5F6B;5F7G;5FAZ;5FEN;5FFH;5U6G;6BTH;6BTI;6C7Z;6E50;6E51;6E5E;6E5Q;6E5R;6E5S;6E6L;6E7M;6MCU;6MCV;6MKV;6MLB;6ON5;6ON7;6ON8;6VID;6VIS;6VIT;6WNF;6WNJ;6WP0;6WP1;6WP2;7JVG;7JVY;7JWD;7JWR;7JX2;7JZ5;7K3I;7LHJ;7LHM;7LHN;7LHO;
Q9XJP3	FIBER_BPSFV	reviewed	Tail spike protein (TSP) (Endo-1,3-alpha-L-rhamnosidase) (EC 3.2.1.-) (Endorhamnosidase)		Shigella phage Sf6 (Shigella flexneri bacteriophage VI) (Bacteriophage SfVI)	623					"MUTAGEN 248;  /note=""D->N: 98.5% loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:18462681""; MUTAGEN 294;  /note=""E->Q: 87% loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:18462681""; MUTAGEN 367;  /note=""E->Q: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:18462681""; MUTAGEN 400;  /note=""D->N: Almost complete loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:18462681"""			2VBE;2VBK;2VBM;4URR;
O94813	SLIT2_HUMAN	reviewed	Slit homolog 2 protein (Slit-2) [Cleaved into: Slit homolog 2 protein N-product; Slit homolog 2 protein C-product]	SLIT2 SLIL3	Homo sapiens (Human)	1529						O94813;	9606.ENSP00000422591;	2V70;2V9S;2V9T;2WFH;
Q9JZ41	Q9JZ41_NEIMB	unreviewed	Putative fimbrial biogenesis and twitching motility protein	NMB1309	Neisseria meningitidis serogroup B (strain MC58)	253								2VQ2;
P62575	NANA_STREE	reviewed	Sialidase A (EC 3.2.1.18) (Neuraminidase A)	nanA	Streptococcus pneumoniae	1035								2VVZ;2YA4;2YA5;2YA6;2YA7;2YA8;4C1X;4ZXK;5KKY;7A54;7A5X;
O43765	SGTA_HUMAN	reviewed	Small glutamine-rich tetratricopeptide repeat-containing protein alpha (Alpha-SGT) (Vpu-binding protein) (UBP)	SGTA SGT SGT1	Homo sapiens (Human)	313					"MUTAGEN 38;  /note=""C->A: Reduces tail-anchored proteins transfer."";  /evidence=""ECO:0000269|PubMed:25535373"""	O43765;	9606.ENSP00000221566;	2VYI;4CPG;4GOD;4GOE;4GOF;
Q86YC2	PALB2_HUMAN	reviewed	Partner and localizer of BRCA2	PALB2 FANCN	Homo sapiens (Human)	1186			DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. {ECO:0000269|PubMed:17287723, ECO:0000269|PubMed:22241545, ECO:0000269|PubMed:28319063}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry. Breast cancer susceptibility is strongly associated with PALB2 truncating mutations. Conversely, rare missense mutations do not strongly influence breast cancer risk (PubMed:22241545). {ECO:0000269|PubMed:22241545}.; DISEASE: Fanconi anemia complementation group N (FANCN) [MIM:610832]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:17200672}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Pancreatic cancer 3 (PNCA3) [MIM:613348]: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. {ECO:0000269|PubMed:19264984}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 14;  /note=""K->A: Loss of interaction with BRCA1 but no effect on interaction with BRCA2."";  /evidence=""ECO:0000269|PubMed:19369211""; MUTAGEN 21;  /note=""L->A: Loss of interaction with BRCA1 but no effect on interaction with BRCA2."";  /evidence=""ECO:0000269|PubMed:19369211""; MUTAGEN 28;  /note=""Y->A: Loss of interaction with BRCA1 but no effect on interaction with BRCA2."";  /evidence=""ECO:0000269|PubMed:19369211""; MUTAGEN 35;  /note=""L->A: Loss of interaction with BRCA1 but no effect on interaction with BRCA2."";  /evidence=""ECO:0000269|PubMed:19369211""; MUTAGEN 42;  /note=""E->A: Loss of interaction with BRCA1 but no effect on interaction with BRCA2."";  /evidence=""ECO:0000269|PubMed:19369211""; MUTAGEN 1030;  /note=""T->I: Unstable and promotes protein degradation; reduces interaction with RAD51C and RAD51."";  /evidence=""ECO:0000269|PubMed:24141787"""	Q86YC2;	9606.ENSP00000261584;	2W18;3EU7;
Q8T6U0	Q8T6U0_9CNID	unreviewed	Green fluorescent protein		Dendronephthya sp. SSAL-2002	225								2VZX;5EXB;5EXC;
P62576	NANA_STRR6	reviewed	Sialidase A (EC 3.2.1.18) (Neuraminidase A)	nanA spr1536	Streptococcus pneumoniae (strain ATCC BAA-255 / R6)	1035							171101.spr1536;	2W20;3H71;3H72;3H73;
Q9L6G4	Q9L6G4_PSEAI	unreviewed	Exo-alpha-sialidase (Sialidase)	DT376_07370 ECC04_003015 IPC116_12015	Pseudomonas aeruginosa	438								2W38;3H6J;
Q9IH62	GLYCP_NIPAV	reviewed	Glycoprotein G	G	Nipah virus	602						Q9IH62;		2VSM;2VWD;3D11;3D12;6VY5;
O60763	USO1_HUMAN	reviewed	General vesicular transport factor p115 (Protein USO1 homolog) (Transcytosis-associated protein) (TAP) (Vesicle-docking protein)	USO1 VDP	Homo sapiens (Human)	962					"MUTAGEN 942;  /note=""S->A: Loss of phosphorylation. Promotes association with Golgi membranes."";  /evidence=""ECO:0000269|PubMed:9478999""; MUTAGEN 942;  /note=""S->D: Decreased association with Golgi membranes."";  /evidence=""ECO:0000269|PubMed:9478999"""	O60763;	9606.ENSP00000444850;	2W3C;
I1RH17	I1RH17_GIBZE	unreviewed	Uncharacterized protein	FG03054.1 FGRAMPH1_01T11943	Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) (Wheat head blight fungus) (Fusarium graminearum)	381								2W5N;
Q837D8	Q837D8_ENTFA	unreviewed	Pentapeptide repeat family protein	EF_0905	Enterococcus faecalis (strain ATCC 700802 / V583)	211							226185.EF_0905;	2W7Z;
Q9JXV4	Q9JXV4_NEIMB	unreviewed	Lipoprot_C domain-containing protein	NMB1870	Neisseria meningitidis serogroup B (strain MC58)	320						Q9JXV4;		2W80;2W81;2Y7S;2YPV;4AYD;4AYE;5NQX;5NQZ;5O14;5T5F;6XZW;
Q96QV1	HHIP_HUMAN	reviewed	Hedgehog-interacting protein (HHIP) (HIP)	HHIP HIP UNQ5825/PRO19644	Homo sapiens (Human)	700					"MUTAGEN 380;  /note=""E->A: Abolishes SHH binding."";  /evidence=""ECO:0000269|PubMed:19561609""; MUTAGEN 382;  /note=""M->A: Abolishes SHH binding."";  /evidence=""ECO:0000269|PubMed:19561609""; MUTAGEN 383;  /note=""D->A,R: Abolishes SHH binding."";  /evidence=""ECO:0000269|PubMed:19561609, ECO:0000269|PubMed:19561611""; MUTAGEN 387;  /note=""D->A: Abolishes SHH binding."";  /evidence=""ECO:0000269|PubMed:19561609"""	Q96QV1;	9606.ENSP00000296575;	2WFT;2WFX;2WG3;2WG4;3HO3;3HO4;3HO5;
Q09065	UREF_HELPY	reviewed	Urease accessory protein UreF	ureF HP_0069	Helicobacter pylori (strain ATCC 700392 / 26695) (Campylobacter pylori)	254				DISRUPTION PHENOTYPE: Cells do not express urease. {ECO:0000269|PubMed:1313413}.		Q09065;	85962.C694_00330;	2WGL;3CXN;3O1Q;3SF5;4HI0;
G1K3N4	MAN5_SALAG	reviewed	Mannan endo-1,4-beta-mannosidase (EC 3.2.1.78) (Mannanase 5A) (Man5A) (Mannanase A) (ManA)		Salipaludibacillus agaradhaerens (Bacillus agaradhaerens)	308								2WHJ;
Q5YEX6	Q5YEX6_9BACI	unreviewed	Beta-mannanase (EC 3.2.1.78) (Endo-1,4-beta-mannosidase)	manA	Bacillus sp. N16-5	493								2WHL;3JUG;
Q93S40	OATWY_NEIME	reviewed	Polysialic acid O-acetyltransferase (EC 2.3.1.-) (Polysialyltransferase) (PST)	oatWY siaD	Neisseria meningitidis	215					"MUTAGEN 121;  /note=""H->A: Reduces activity 50-fold."";  /evidence=""ECO:0000269|PubMed:19525232""; MUTAGEN 145;  /note=""W->A: Reduces activity 56-fold."";  /evidence=""ECO:0000269|PubMed:19525232""; MUTAGEN 171;  /note=""Y->A: Reduces activity 48-fold."";  /evidence=""ECO:0000269|PubMed:19525232"""			2WLC;2WLD;2WLE;2WLF;2WLG;
Q9ER30	KLH41_RAT	reviewed	Kelch-like protein 41 (Kel-like protein 23) (Kelch repeat and BTB domain-containing protein 10) (Kelch-related protein 1) (Sarcosin)	Klhl41 Kbtbd10 Krp1	Rattus norvegicus (Rat)	606						Q9ER30;	10116.ENSRNOP00000009969;	2WOZ;
Q53G59	KLH12_HUMAN	reviewed	Kelch-like protein 12 (CUL3-interacting protein 1) (DKIR homolog) (hDKIR)	KLHL12 C3IP1	Homo sapiens (Human)	568					"MUTAGEN 15;  /note=""H->A: Abolished ubiquitination by the SCF(FBXL17) complex."";  /evidence=""ECO:0000269|PubMed:30190310""; MUTAGEN 34;  /note=""D->A: Abolished ubiquitination by the SCF(FBXL17) complex."";  /evidence=""ECO:0000269|PubMed:30190310""; MUTAGEN 50;  /note=""V->A: Increased recognition and ubiquitination by the SCF(FBXL17) complex."";  /evidence=""ECO:0000269|PubMed:30190310""; MUTAGEN 60;  /note=""A->E,K: Abolished ubiquitination by the SCF(FBXL17) complex."";  /evidence=""ECO:0000269|PubMed:30190310""; MUTAGEN 289..290;  /note=""FG->AA: Abolishes interaction with SEC31A and subsequent monoubiquitination of SEC31A. Abolishes ubiquitination of PEF1."";  /evidence=""ECO:0000269|PubMed:22358839, ECO:0000269|Ref.3"""	Q53G59;	9606.ENSP00000356230;	2VPJ;6TTK;6V7O;
Q8ZL64	SADA_SALTY	reviewed	Autotransporter adhesin SadA (Salmonella adhesin A) (Type 5 secretion system autotransporter SadA)	sadA STM3691	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	1461				DISRUPTION PHENOTYPE: In vitro, loss of sadA does not affect cell aggregation, biofilm formation and adhesion to epithelial cells. Disruption does not affect the course of infection. {ECO:0000269|PubMed:21859856}.				2WPQ;2WPR;2WPS;2YNY;2YNZ;2YO0;2YO1;2YO2;2YO3;3ZMF;
Q7DDU0	Q7DDU0_NEIMB	unreviewed	Polysialic acid capsule biosynthesis protein SiaC	siaC NMB0068	Neisseria meningitidis serogroup B (strain MC58)	349								2WQP;
Q8DP07	Q8DP07_STRR6	unreviewed	1,4-beta-N-acetylmuramidase (EC 3.2.1.17)	lytC spr1431	Streptococcus pneumoniae (strain ATCC BAA-255 / R6)	501							171101.spr1431;	2WW5;2WWC;2WWD;
A0QV09	Y2407_MYCS2	reviewed	Uncharacterized oxidoreductase MSMEG_2407/MSMEI_2346 (EC 1.-.-.-)	MSMEG_2407 MSMEI_2346	Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) (Mycobacterium smegmatis)	283							246196.MSMEI_2346;	2WZM;2WZT;
Q9VEC5	Q9VEC5_DROME	unreviewed	Importin-13	cdm 3R23 Cdm CG 7212 Dmel\CG7212 Imp13 imp13 sd-5 CG7212 Dmel_CG7212	Drosophila melanogaster (Fruit fly)	971							7227.FBpp0083039;	2X1G;3ZKV;
O94829	IPO13_HUMAN	reviewed	Importin-13 (Imp13) (Karyopherin-13) (Kap13) (Ran-binding protein 13) (RanBP13)	IPO13 KIAA0724 RANBP13	Homo sapiens (Human)	963						O94829;	9606.ENSP00000361418;	2X19;2XWU;3ZJY;
O09496	O09496_9CAUD	unreviewed	K5 lyase		Escherichia virus K5	632								2X3H;
Q12125	GET4_YEAST	reviewed	Golgi to ER traffic protein 4 (Guided entry of tail-anchored proteins 4)	GET4 YOR164C O3580	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	312						Q12125;	4932.YOR164C;	2WPV;3LKU;4PWX;5BW8;5BWK;
Q9I325	Q9I325_PSEAE	unreviewed	Regulatory protein PcrH	pcrH PA1707	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	167								2XCB;2XCC;
Q4QHU7	Q4QHU7_LEIMA	unreviewed	Prolyl endopeptidase (EC 3.4.21.-)	OPB LMJF_09_0770	Leishmania major	731							5664.LmjF.09.0770;	2XE4;
P33981	TTK_HUMAN	reviewed	Dual specificity protein kinase TTK (EC 2.7.12.1) (Phosphotyrosine picked threonine-protein kinase) (PYT)	TTK MPS1 MPS1L1	Homo sapiens (Human)	857					"MUTAGEN 664;  /note=""D->A: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:18243099, ECO:0000269|PubMed:18480048""; MUTAGEN 686;  /note=""T->A: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:18480048"""	P33981;	9606.ENSP00000358813;	2X9E;2ZMC;2ZMD;3CEK;3DBQ;3GFW;3H9F;3HMN;3HMO;3HMP;3VQU;3W1F;3WYX;3WYY;3WZJ;3WZK;4B94;4BHZ;4BI0;4BI1;4BI2;4C4E;4C4F;4C4G;4C4H;4C4I;4C4J;4CV8;4CV9;4CVA;4D2S;4H7X;4H7Y;4JS8;4JT3;4O6L;4ZEG;5AP0;5AP1;5AP2;5AP3;5AP4;5AP5;5AP6;5AP7;5EH0;5EHL;5EHO;5EHY;5EI2;5EI6;5EI8;5LJJ;5MRB;5N7V;5N84;5N87;5N93;5N9S;5NA0;5NAD;5NTT;5O91;6B4W;6GVJ;6H3K;6N6O;6TN9;6TNB;6TNC;6TND;7CHM;7CHN;7CHT;7CIL;7CJA;7CLH;
Q86TB9	PATL1_HUMAN	reviewed	Protein PAT1 homolog 1 (PAT1-like protein 1) (Protein PAT1 homolog b) (Pat1b) (hPat1b)	PATL1 OK/KNS-cl.5	Homo sapiens (Human)	770					"MUTAGEN 86;  /note=""L->A: Loss of nuclear export; when associated with A-90, A-93 and A-95."";  /evidence=""ECO:0000269|PubMed:22090346""; MUTAGEN 90;  /note=""L->A: Loss of nuclear export; when associated with A-86, A-93 and A-95."";  /evidence=""ECO:0000269|PubMed:22090346""; MUTAGEN 93;  /note=""M->A: Loss of nuclear export; when associated with A-86, A-90 and A-95."";  /evidence=""ECO:0000269|PubMed:22090346""; MUTAGEN 95;  /note=""I->A: Loss of nuclear export; when associated with A-86, A-90 and A-93."";  /evidence=""ECO:0000269|PubMed:22090346""; MUTAGEN 519;  /note=""R->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-520; A-591; A-595; A-625 and A-626."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 520;  /note=""R->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-591; A-595; A-625 and A-626."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 523;  /note=""L->A: In mut2; Abolishes interaction with the decapping machinery and localization to P-body; when associated with A-527; A-530 and S-534."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 527;  /note=""E->A: In mut2; Abolishes interaction with the decapping machinery and localization to P-body; when associated with S-523; A-530 and S-534."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 530;  /note=""Y->A: In mut2; Abolishes interaction with the decapping machinery and localization to P-body; when associated with S-523; A-527 and S-534."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 534;  /note=""L->S: In mut2; Abolishes interaction with the decapping machinery and localization to P-body; when associated with S-523; A-527 and A-530."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 539..557;  /note=""YERRYLLSLEEERPALMDD->GSGSGSG: In mut3; does not affect neither RNA-binding,interaction with the decapping machinery, nor localization to P-body."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 591;  /note=""R->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-520; A-595; A-625 and A-626."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 595;  /note=""R->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-520; A-591; A-625 and A-626."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 625;  /note=""K->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-520; A-591; A-595 and A-626."";  /evidence=""ECO:0000269|PubMed:20543818""; MUTAGEN 626;  /note=""K->A: In mut1; Abolishes RNA-binding, localization to P-body and interaction with the decapping machinery; when associated with A-519; A-520; A-591; A-595 and A-625."";  /evidence=""ECO:0000269|PubMed:20543818"""	Q86TB9;	9606.ENSP00000300146;	2XEQ;2XER;2XES;
Q8P6F4	Q8P6F4_XANCP	unreviewed	Cell division coordinator CpoB	cpoB XCC3016	Xanthomonas campestris pv. campestris (strain ATCC 33913 / DSM 3586 / NCPPB 528 / LMG 568 / P 25)	272							340.xcc-b100_1181;	2XEV;
P61965	WDR5_MOUSE	reviewed	WD repeat-containing protein 5 (BMP2-induced 3-kb gene protein) (WD repeat-containing protein BIG-3)	Wdr5 Big Big3	Mus musculus (Mouse)	334						P61965;	10090.ENSMUSP00000109585;	2XL2;2XL3;
Q8DI95	YC48L_THEEB	reviewed	Ycf48-like protein	tll1695	Thermosynechococcus elongatus (strain BP-1)	347							197221.22295420;	2XBG;5OJ5;
O60566	BUB1B_HUMAN	reviewed	Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (EC 2.7.11.1) (MAD3/BUB1-related protein kinase) (hBUBR1) (Mitotic checkpoint kinase MAD3L) (Protein SSK1)	BUB1B BUBR1 MAD3L SSK1	Homo sapiens (Human)	1050			DISEASE: Note=Defects in BUB1B are associated with tumor formation.; DISEASE: Premature chromatid separation trait (PCS) [MIM:176430]: Consists of separate and splayed chromatids with discernible centromeres and involves all or most chromosomes of a metaphase. It is found in up to 2% of metaphases in cultured lymphocytes from approximately 40% of normal individuals. When PCS is present in 5% or more of cells, it is known as the heterozygous PCS trait and has no obvious phenotypic effect, although some have reported decreased fertility. Inheritance is autosomal dominant. {ECO:0000269|PubMed:16411201}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Mosaic variegated aneuploidy syndrome 1 (MVA1) [MIM:257300]: A severe developmental disorder characterized by mosaic aneuploidies, predominantly trisomies and monosomies, involving multiple different chromosomes and tissues. Affected individuals typically present with severe intrauterine growth retardation and microcephaly. Eye anomalies, mild dysmorphism, variable developmental delay, and a broad spectrum of additional congenital abnormalities and medical conditions may also occur. The risk of malignancy is high, with rhabdomyosarcoma, Wilms tumor and leukemia reported in several cases. {ECO:0000269|PubMed:15475955}. Note=The disease is caused by variants affecting the gene represented in this entry. MVA1 is caused by biallelic mutations in the BUB1B gene.		"MUTAGEN 159;  /note=""A->W: Loss of interaction with KNL1."";  /evidence=""ECO:0000269|PubMed:17981135""; MUTAGEN 175;  /note=""F->A: Loss of interaction with KNL1."";  /evidence=""ECO:0000269|PubMed:17981135""; MUTAGEN 579;  /note=""D->E: Abolishes the cleavage by caspase-3."";  /evidence=""ECO:0000269|PubMed:16227576""; MUTAGEN 610;  /note=""D->E: Abolishes the cleavage by caspase-3."";  /evidence=""ECO:0000269|PubMed:16227576""; MUTAGEN 620;  /note=""T->A: Induces chromosome congression defects and mitotic delay."";  /evidence=""ECO:0000269|PubMed:17785528""; MUTAGEN 795;  /note=""K->A: Does not abolish the capacity to inhibit APC/CDC20."";  /evidence=""ECO:0000269|PubMed:11702782, ECO:0000269|PubMed:12925705""; MUTAGEN 795;  /note=""K->R: Inhibits kinase activity."";  /evidence=""ECO:0000269|PubMed:11702782, ECO:0000269|PubMed:12925705"""	O60566;	9606.ENSP00000287598;	2WVI;3SI5;4GGD;5JJA;5K6S;5KHU;5LCW;5SWF;6TLJ;
P41889	CUT9_SCHPO	reviewed	Anaphase-promoting complex subunit cut9 (20S cyclosome/APC complex protein cut9) (Cell untimely torn protein 9)	cut9 dre1 SPAC6F12.15c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	671					"MUTAGEN 412;  /note=""G->D: In cut9-T98; temperature-sensitive."";  /evidence=""ECO:0000269|PubMed:7798319""; MUTAGEN 535;  /note=""A->T: In cut9-665; temperature-sensitive."";  /evidence=""ECO:0000269|PubMed:7798319"""	P41889;	4896.SPAC6F12.15c.1;	2XPI;
Q80ZD8	AMGO1_MOUSE	reviewed	Amphoterin-induced protein 1 (AMIGO-1) (Alivin-2)	Amigo1 Ali2 Amigo Kiaa1163	Mus musculus (Mouse)	492					"MUTAGEN 348;  /note=""N->A: Prevents from leaving the ER."";  /evidence=""ECO:0000269|PubMed:21983541"""	Q80ZD8;	10090.ENSMUSP00000102267;	2XOT;
Q9MCI8	EIBD_ECOLX	reviewed	Immunoglobulin-binding protein EibD (Trimeric autotransporter adhesin EibD) (TAA EibD) (Type 5 secretion system autotransporter EibD)	eibD	Escherichia coli	511					"MUTAGEN 332..334;  /note=""KKY->AAA: Loss of IgA binding by fragment 161-418, no change in IgG binding."";  /evidence=""ECO:0000269|PubMed:21742268""; MUTAGEN 387..388;  /note=""DY->AA: 2-fold decreased affinity for IgA, at least 5-fold decreased affinity for IgG by fragment 161-418."";  /evidence=""ECO:0000269|PubMed:21742268""; MUTAGEN 415..417;  /note=""TRT->AAA: 5-fold decreased affinity for IgA, 4-fold decreased affinity for IgG by fragment 161-418."";  /evidence=""ECO:0000269|PubMed:21742268"""			2XQH;2XZR;
Q70C34	Q70C34_XANAL	unreviewed	Chain B (McbG-like protein)	albXIX XaFJ1_GM001502	Xanthomonas albilineans	200								2XT2;2XT4;
O95198	KLHL2_HUMAN	reviewed	Kelch-like protein 2 (Actin-binding protein Mayven)	KLHL2	Homo sapiens (Human)	593						O95198;	9606.ENSP00000424198;	2XN4;4CHB;
P16473	TSHR_HUMAN	reviewed	Thyrotropin receptor (Thyroid-stimulating hormone receptor) (TSH-R)	TSHR LGR3	Homo sapiens (Human)	764			DISEASE: Note=Defects in TSHR are found in patients affected by hyperthyroidism with different etiologies. Somatic, constitutively activating TSHR mutations and/or constitutively activating G(s)alpha mutations have been identified in toxic thyroid nodules (TTNs) that are the predominant cause of hyperthyroidism in iodine deficient areas. These mutations lead to TSH independent activation of the cAMP cascade resulting in thyroid growth and hormone production. TSHR mutations are found in autonomously functioning thyroid nodules (AFTN), toxic multinodular goiter (TMNG) and hyperfunctioning thyroid adenomas (HTA). TMNG encompasses a spectrum of different clinical entities, ranging from a single hyperfunctioning nodule within an enlarged thyroid, to multiple hyperfunctioning areas scattered throughout the gland. HTA are discrete encapsulated neoplasms characterized by TSH-independent autonomous growth, hypersecretion of thyroid hormones, and TSH suppression. Defects in TSHR are also a cause of thyroid neoplasms (papillary and follicular cancers).; DISEASE: Note=Autoantibodies against TSHR are directly responsible for the pathogenesis and hyperthyroidism of Graves disease. Antibody interaction with TSHR results in an uncontrolled receptor stimulation.; DISEASE: Hypothyroidism, congenital, non-goitrous, 1 (CHNG1) [MIM:275200]: A non-autoimmune condition characterized by resistance to thyroid-stimulating hormone (TSH) leading to increased levels of plasma TSH and low levels of thyroid hormone. It presents variable severity depending on the completeness of the defect. Most patients are euthyroid and asymptomatic, with a normal sized thyroid gland. Only a subset of patients develop hypothyroidism and present a hypoplastic thyroid gland. {ECO:0000269|PubMed:10720030, ECO:0000269|PubMed:11095460, ECO:0000269|PubMed:11442002, ECO:0000269|PubMed:12050212, ECO:0000269|PubMed:14725684, ECO:0000269|PubMed:15531543, ECO:0000269|PubMed:25978107, ECO:0000269|PubMed:7528344, ECO:0000269|PubMed:8954020, ECO:0000269|PubMed:9100579, ECO:0000269|PubMed:9185526, ECO:0000269|PubMed:9329388}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Familial gestational hyperthyroidism (HTFG) [MIM:603373]: A condition characterized by abnormally high levels of serum thyroid hormones occurring during early pregnancy. {ECO:0000269|PubMed:9854118}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Hyperthyroidism, non-autoimmune (HTNA) [MIM:609152]: A condition characterized by abnormally high levels of serum thyroid hormones, thyroid hyperplasia, goiter and lack of anti-thyroid antibodies. Typical features of Graves disease such as exophthalmia, myxedema, antibodies anti-TSH receptor and lymphocytic infiltration of the thyroid gland are absent. {ECO:0000269|PubMed:10199795, ECO:0000269|PubMed:10852462, ECO:0000269|PubMed:11081252, ECO:0000269|PubMed:11127522, ECO:0000269|PubMed:11201847, ECO:0000269|PubMed:11517004, ECO:0000269|PubMed:11549687, ECO:0000269|PubMed:15163335, ECO:0000269|PubMed:7800007, ECO:0000269|PubMed:7920658, ECO:0000269|PubMed:8636266, ECO:0000269|PubMed:8964822, ECO:0000269|PubMed:9349581, ECO:0000269|PubMed:9360555, ECO:0000269|PubMed:9398746, ECO:0000269|PubMed:9589634}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 283;  /note=""C->S: Abolishes cell surface expression."";  /evidence=""ECO:0000269|PubMed:11847099""; MUTAGEN 385..387;  /note=""YDY->EDE: Inhibits intracellular cAMP accumulation."";  /evidence=""ECO:0000269|PubMed:11847099""; MUTAGEN 385..387;  /note=""YDY->FDF: Abolishes sulfation. Inhibits intracellular cAMP accumulation."";  /evidence=""ECO:0000269|PubMed:11847099""; MUTAGEN 385;  /note=""Y->E: Reduces binding with thyrotropin. Inhibits intracellular cAMP accumulation."";  /evidence=""ECO:0000269|PubMed:11847099, ECO:0000305|PubMed:11847099""; MUTAGEN 385;  /note=""Y->F: Reduces sulfation. Reduces binding with thyrotropin. Inhibits intracellular cAMP accumulation."";  /evidence=""ECO:0000269|PubMed:11847099, ECO:0000305|PubMed:11847099""; MUTAGEN 387;  /note=""Y->E: No change in intracellular cAMP accumulation."";  /evidence=""ECO:0000269|PubMed:11847099""; MUTAGEN 387;  /note=""Y->F: Reduces sulfation. No change in intracellular cAMP accumulation."";  /evidence=""ECO:0000269|PubMed:11847099"""	P16473;	9606.ENSP00000441235;	1XUM;2XWT;3G04;
Q9HWP4	Q9HWP4_PSEAE	unreviewed	Probable porin	PA4137	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	418								2Y0H;3T0S;
Q2I1Y8	Q2I1Y8_KLEPN	unreviewed	QnrB1 (Quinolone resistance pentapeptide repeat protein QnrB1)	qnrB1 G5637_27160	Klebsiella pneumoniae	214								2XTW;2XTX;2XTY;
Q00610	CLH1_HUMAN	reviewed	Clathrin heavy chain 1 (Clathrin heavy chain on chromosome 17) (CLH-17)	CLTC CLH17 CLTCL2 KIAA0034	Homo sapiens (Human)	1675			DISEASE: Mental retardation, autosomal dominant 56 (MRD56) [MIM:617854]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. {ECO:0000269|PubMed:26822784, ECO:0000269|PubMed:29100083}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 65;  /note=""P->N: Disrupts spindle localization."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 67;  /note=""S->G: Disrupts spindle localization."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 87;  /note=""T->A: Disrupts spindle localization."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 89;  /note=""Q->A: Disrupts spindle localization."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 96;  /note=""K->E: Disrupts spindle localization."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 98;  /note=""K->E: Disrupts spindle localization."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 444;  /note=""R->E: Disrupts spindle localization; when associated with E-445, E-500 E-506 and E-507."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 445;  /note=""K->E: Disrupts spindle localization; when associated with E-444, E-500, E-506 and E-507."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 480..484;  /note=""LRANV->ERGQC: Disrupts spindle localization and interaction with TACC3."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 481;  /note=""R->E: Disrupts spindle localization; when associated with E-487, E-500, E-506 and E-507."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 487;  /note=""K->E: Disrupts spindle localization; when associated with E-481, E-500, E-506 and E-507."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 500;  /note=""K->E: Disrupts spindle localization; when associated with E-444, E-445, E-506 and E-507."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 500;  /note=""K->E: Disrupts spindle localization; when associated with E-481, E-487, E-506 and E-507."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 506;  /note=""K->E: Disrupts spindle localization; when associated with E-444, E-445, E-500 and E-507."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 506;  /note=""K->E: Disrupts spindle localization; when associated with E-481, E-487, E-500 and E-507."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 507;  /note=""K->E: Disrupts spindle localization; when associated with E-444, E-445, E-500 and E-506."";  /evidence=""ECO:0000269|PubMed:23918938""; MUTAGEN 507;  /note=""K->E: Disrupts spindle localization; when associated with E-481, E-487, E-500 and E-506."";  /evidence=""ECO:0000269|PubMed:23918938"""	Q00610;	9606.ENSP00000479606;	2XZG;4G55;6E4L;6QNN;6QNP;
B0VHH0	KCE_CLOAI	reviewed	3-keto-5-aminohexanoate cleavage enzyme (EC 2.3.1.247)	kce CLOAM0912	Cloacimonas acidaminovorans (strain Evry)	276					"MUTAGEN 82;  /note=""S->G: Reduced catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:21632536""; MUTAGEN 143;  /note=""E->G,Q: Reduced catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:21632536""; MUTAGEN 226;  /note=""R->G: Loss of catalytic activity."";  /evidence=""ECO:0000269|PubMed:21632536""; MUTAGEN 231;  /note=""D->G: Loss of catalytic activity."";  /evidence=""ECO:0000269|PubMed:21632536"""		459349.CLOAM0912;	2Y7D;2Y7E;2Y7F;2Y7G;
Q89IH6	Q89IH6_BRADU	unreviewed	Blr5658 protein	blr5658	Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110)	163							224911.27353934;	2Y32;4BBO;
B8ZY56	B8ZY56_GIBZA	unreviewed	Exo-1,5-alpha-L-arabinofuranobiosidase (EC 3.2.1.55) (Fragment)	arb93a	Gibberella zeae (Wheat head blight fungus) (Fusarium graminearum)	365								2YDP;2YDT;5M1Z;
P77774	BAMB_ECOLI	reviewed	Outer membrane protein assembly factor BamB	bamB yfgL b2512 JW2496	Escherichia coli (strain K12)	392						P77774;	511145.b2512;	2YH3;2YMS;3P1L;3PRW;3Q7M;3Q7N;3Q7O;4PK1;4XGA;5AYW;5D0O;5LJO;6LYQ;6LYR;6LYS;6LYU;6SN9;6SOB;6SOJ;6V05;7BNQ;7NBX;7NCS;7ND0;7NRI;
P0AC02	BAMD_ECOLI	reviewed	Outer membrane protein assembly factor BamD	bamD yfiO b2595 JW2577	Escherichia coli (strain K12)	245				DISRUPTION PHENOTYPE: Depletion decreases the density of outer membrane proteins, but does not significantly affect transport of lipopolysaccharides to the outer membrane. {ECO:0000269|PubMed:16824102}.		P0AC02;	511145.b2595;	2YHC;3Q5M;3TGO;5AYW;5D0O;5D0Q;5EKQ;5LJO;6LYQ;6LYR;6LYS;6LYU;6SN9;6SOB;6SOJ;6V05;7BNQ;7NBX;7NCS;7ND0;7NRI;
B2J0I0	B2J0I0_NOSP7	unreviewed	WD-40 repeat protein	Npun_R6612	Nostoc punctiforme (strain ATCC 29133 / PCC 73102)	1229							63737.Npun_R6612;	2YMU;6R5X;6R5Y;6R5Z;6R60;
Q8ZKG6	Q8ZKG6_SALTY	unreviewed	Putative inner membrane protein	STM4261	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	5559								2YN3;2YN5;
Q09028	RBBP4_HUMAN	reviewed	Histone-binding protein RBBP4 (Chromatin assembly factor 1 subunit C) (CAF-1 subunit C) (Chromatin assembly factor I p48 subunit) (CAF-I 48 kDa subunit) (CAF-I p48) (Nucleosome-remodeling factor subunit RBAP48) (Retinoblastoma-binding protein 4) (RBBP-4) (Retinoblastoma-binding protein p48)	RBBP4 RBAP48	Homo sapiens (Human)	425						Q09028;	9606.ENSP00000362592;	2XU7;3GFC;4PBY;4PBZ;4PC0;4R7A;5FXY;5VTB;5WAI;5WAK;5XWR;5XXQ;5Y1U;6BW3;6BW4;6C23;6C24;6G16;6NQ3;6WKR;6ZRC;6ZRD;7AOA;7KSO;7KSR;7KTP;7M40;
A4IKE6	A4IKE6_GEOTN	unreviewed	Uncharacterized protein	GTNG_0418	Geobacillus thermodenitrificans (strain NG80-2)	428							420246.GTNG_0418;	2YNQ;4ANO;
P41811	COPB2_YEAST	reviewed	Coatomer subunit beta' (Beta'-coat protein) (Beta'-COP)	SEC27 YGL137W G2827	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	889						P41811;	4932.YGL137W;	2YNN;2YNO;2YNP;4J73;4J77;4J78;4J79;4J81;4J82;4J84;4J86;
Q9H2K2	TNKS2_HUMAN	reviewed	Poly [ADP-ribose] polymerase tankyrase-2 (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 6) (ARTD6) (Poly [ADP-ribose] polymerase 5B) (Protein poly-ADP-ribosyltransferase tankyrase-2) (EC 2.4.2.-) (TNKS-2) (TRF1-interacting ankyrin-related ADP-ribose polymerase 2) (Tankyrase II) (Tankyrase-2) (TANK2) (Tankyrase-like protein) (Tankyrase-related protein)	TNKS2 PARP5B TANK2 TNKL	Homo sapiens (Human)	1166					"MUTAGEN 553;  /note=""H->D: Enhanced hydroxylation by HIF1AN."";  /evidence=""ECO:0000269|PubMed:21251231""; MUTAGEN 553;  /note=""H->N: Enhanced hydroxylation by HIF1AN."";  /evidence=""ECO:0000269|PubMed:21251231""; MUTAGEN 1054;  /note=""M->V: Loss of activity."";  /evidence=""ECO:0000269|PubMed:19759537"""	Q9H2K2;	9606.ENSP00000360689;	2Y0I;3KR7;3KR8;3MHJ;3MHK;3P0N;3P0P;3P0Q;3TWQ;3TWR;3TWS;3TWT;3TWU;3TWV;3TWW;3TWX;3U9H;3U9Y;3UA9;3W51;4AVU;4AVW;4BFP;4BJ9;4BJB;4BJC;4BS4;4BU3;4BU5;4BU6;4BU7;4BU8;4BU9;4BUA;4BUD;4BUE;4BUF;4BUI;4BUS;4BUT;4BUU;4BUV;4BUW;4BUX;4BUY;4HKI;4HKK;4HKN;4HL5;4HLF;4HLG;4HLH;4HLK;4HLM;4HMH;4HYF;4IUE;4J1Z;4J21;4J22;4J3L;4J3M;4KZL;4KZQ;4KZU;4L09;4L0B;4L0I;4L0S;4L0T;4L0V;4L10;4L2F;4L2G;4L2K;4L31;4L32;4L33;4L34;4M7B;4PML;4PNL;4PNM;4PNN;4PNQ;4PNR;4PNS;4PNT;4TJU;4TJW;4TJY;4TK0;4TK5;4TKF;4TKG;4TKI;4UFU;4UFY;4UHG;4UI3;4UI4;4UI5;4UI6;4UI7;4UI8;4UVL;4UVN;4UVO;4UVP;4UVS;4UVT;4UVU;4UVV;4UVW;4UVX;4UVY;4UVZ;4UX4;4W5I;4Z68;5ADQ;5ADR;5ADS;5ADT;5AEH;5AKU;5AKW;5AL1;5AL2;5AL3;5AL4;5AL5;5BXO;5BXU;5C5P;5C5Q;5C5R;5DCZ;5FPF;5FPG;5JRT;5NOB;5NSP;5NUT;5OWS;5OWT;6TG4;6TKM;6TKN;6TKP;6TKQ;6TKR;6TKS;
Q5KY94	AROD_GEOKA	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD GK2057	Geobacillus kaustophilus (strain HTA426)	257							235909.GK2057;	2YR1;
O67315	MURA_AQUAE	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (UDP-N-acetylglucosamine enolpyruvyl transferase) (EPT)	murA aq_1281	Aquifex aeolicus (strain VF5)	425							224324.aq_1281;	2YVW;3SWG;
Q53W90	Q53W90_THET8	unreviewed	2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14)	TTHB072	Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)	207								2YW3;2YW4;
Q57695	DAPA_METJA	reviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA MJ0244	Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) (Methanococcus jannaschii)	289							243232.MJ_0244;	2YXG;
Q3ZD73	Q3ZD73_XANCA	unreviewed	Hax2	hax2	Xanthomonas campestris pv. armoraciae	1321								2YPF;
Q71VM4	IMA1A_ORYSJ	reviewed	Importin subunit alpha-1a	Os01g0253300 LOC_Os01g14950	Oryza sativa subsp. japonica (Rice)	526						Q71VM4;	4530.OS01T0253300-01;	2YNS;4B8J;4B8O;4B8P;4BPL;4BQK;
Q9QUK6	TLR4_MOUSE	reviewed	Toll-like receptor 4 (EC 3.2.2.6) (CD antigen CD284)	Tlr4 Lps	Mus musculus (Mouse)	835			DISEASE: Note=The protein is encoded by the Lps locus, an important susceptibility locus, influencing the propensity to develop a disseminated Gram-negative infection. {ECO:0000269|PubMed:9851930, ECO:0000269|PubMed:9989976}.	DISRUPTION PHENOTYPE: Animals with a double knockout of APOE and TLR4, fed a Western diet for 12 weeks, have less aortic plaque formation than single APOE knockout mice. They also show lower serum concentrations of IL1A, ILB and IL18. {ECO:0000269|PubMed:23812099}.		Q9QUK6;	10090.ENSMUSP00000045770;	2Z64;3VQ1;3VQ2;5IJB;5IJC;5IJD;
P41783	PRGH_SALTY	reviewed	Protein PrgH	prgH STM2874	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	392						P41783;		2Y9J;3GR0;3GR1;3J1W;3J1X;3J6D;4G1I;4G2S;5TCP;5TCR;6DUZ;6PEM;6PEP;6Q14;6Q15;6Q16;6UOT;6UOV;7AH9;7AHI;
O00206	TLR4_HUMAN	reviewed	Toll-like receptor 4 (EC 3.2.2.6) (hToll) (CD antigen CD284)	TLR4	Homo sapiens (Human)	839					"MUTAGEN 431;  /note=""H->A: Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-456 or A-458."";  /evidence=""ECO:0000269|PubMed:20711192""; MUTAGEN 456;  /note=""H->A: Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-431. Suppresses NF-kappa-B activation induced by Ni(2+); when associated with A-458."";  /evidence=""ECO:0000269|PubMed:20711192""; MUTAGEN 458;  /note=""H->A: Partially diminishes NF-kappa-B activation induced by Ni(2+). Strongly reduces NF-kappa-B activation induced by Ni(2+); when associated with A-431. Suppresses NF-kappa-B activation induced by Ni(2+); when associated with A-456."";  /evidence=""ECO:0000269|PubMed:20711192""; MUTAGEN 526;  /note=""N->A: Abolishes LPS-response and prevents the cell surface expression."";  /evidence=""ECO:0000269|PubMed:11706042""; MUTAGEN 575;  /note=""N->A: Abolishes LPS-response and prevents the cell surface expression."";  /evidence=""ECO:0000269|PubMed:11706042""; MUTAGEN 697;  /note=""E->R: Abolishes LPS-response."";  /evidence=""ECO:0000269|PubMed:11081518""; MUTAGEN 710;  /note=""R->E: Abolishes LPS-response."";  /evidence=""ECO:0000269|PubMed:11081518""; MUTAGEN 711;  /note=""D->K: Abolishes LPS-response."";  /evidence=""ECO:0000269|PubMed:11081518""; MUTAGEN 714;  /note=""P->H,R,E: Abolishes MYD88-binding and LPS-response."";  /evidence=""ECO:0000269|PubMed:11081518"""	O00206;	9606.ENSP00000363089;	2Z62;2Z63;2Z65;2Z66;3FXI;3UL7;3UL8;3UL9;3ULA;4G8A;5NAM;5NAO;
F1QGH7	CTNB1_DANRE	reviewed	Catenin beta-1 (Beta-catenin)	ctnnb1	Danio rerio (Zebrafish) (Brachydanio rerio)	780							7955.ENSDARP00000032935;	2Z6G;
Q9QUN7	TLR2_MOUSE	reviewed	Toll-like receptor 2 (EC 3.2.2.6) (CD antigen CD282)	Tlr2	Mus musculus (Mouse)	784				DISRUPTION PHENOTYPE: Mutants succumb to Staphylococcus aureus infection within 5 days. {ECO:0000269|PubMed:15690042}.	"MUTAGEN 681;  /note=""P->H: Abolishes MYD88-binding and response to microbial cell wall components."";  /evidence=""ECO:0000269|PubMed:10548109"""	Q9QUN7;	10090.ENSMUSP00000029623;	2Z81;2Z82;3A79;3A7B;3A7C;5D3I;
P17978	VGB_STAAU	reviewed	Virginiamycin B lyase (EC 4.2.99.-) (Streptogramin B lyase)	vgb vgh	Staphylococcus aureus	299					"MUTAGEN 18;  /note=""Y->F: 600-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:17563376""; MUTAGEN 228;  /note=""H->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17563376""; MUTAGEN 268;  /note=""E->Q: 56-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:17563376""; MUTAGEN 270;  /note=""H->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17563376""; MUTAGEN 284;  /note=""E->Q: 137-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:17563376"""			2Z2N;2Z2O;2Z2P;
Q5L0U0	PYRF_GEOKA	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF GK1155	Geobacillus kaustophilus (strain HTA426)	244							235909.GK1155;	2YYT;2YYU;
O31526	YESW_BACSU	reviewed	Rhamnogalacturonan endolyase YesW (EC 4.2.2.23)	yesW BSU07050	Bacillus subtilis (strain 168)	620					"MUTAGEN 363;  /note=""H->A: Strongly reduced catalytic activity."";  /evidence=""ECO:0000269|PubMed:17947240""; MUTAGEN 399;  /note=""H->A: Strongly reduced catalytic activity."";  /evidence=""ECO:0000269|PubMed:17947240""; MUTAGEN 401;  /note=""D->N: Strongly reduced catalytic activity."";  /evidence=""ECO:0000269|PubMed:17947240""; MUTAGEN 422;  /note=""E->Q: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17947240""; MUTAGEN 452;  /note=""R->A: Strongly reduced catalytic activity and reduced affinity for substrate."";  /evidence=""ECO:0000269|PubMed:17947240""; MUTAGEN 535;  /note=""K->A: Strongly reduced catalytic activity and reduced affinity for substrate."";  /evidence=""ECO:0000269|PubMed:17947240""; MUTAGEN 595;  /note=""Y->F: Strongly reduced catalytic activity."";  /evidence=""ECO:0000269|PubMed:17947240"""		224308.BSU07050;	2Z8R;2Z8S;2ZUX;
O87198	HOSA_THET2	reviewed	Homocitrate synthase (HCS) (EC 2.3.3.14)	lys20 TT_C1550	Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27)	376				DISRUPTION PHENOTYPE: Cells lacking this gene show lysine auxotrophy, which can be complemented with alpha-aminoadipate but not with diaminopimelate. {ECO:0000269|PubMed:9868782}.	"MUTAGEN 72;  /note=""H->L: Significant decrease in sensitivity to lysine inhibition. Large decrease in affinity for 2-oxoglutarate. Almost no effect on affinity for acetyl-CoA and on turnover number."";  /evidence=""ECO:0000269|PubMed:19996101"""		262724.TT_C1550;	2ZTJ;2ZTK;2ZYF;3A9I;
B9A0T7	B9A0T7_PLECO	unreviewed	Tamavidin2	tam2	Pleurotus cornucopiae (Cornucopia mushroom)	141								2ZSC;
O31666	MTNW_BACSU	reviewed	2,3-diketo-5-methylthiopentyl-1-phosphate enolase (DK-MTP-1-P enolase) (EC 5.3.2.5) (RuBisCO-like protein) (RLP)	mtnW ykrW BSU13590	Bacillus subtilis (strain 168)	405						O31666;	224308.BSU13590;	2ZVI;
Q5SJX8	Q5SJX8_THET8	unreviewed	o-succinylbenzoate synthase (OSB synthase) (OSBS) (EC 4.2.1.113) (4-(2'-carboxyphenyl)-4-oxybutyric acid synthase) (o-succinylbenzoic acid synthase)	menC TTHA0874	Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)	369							300852.55772256;	2ZC8;
Q9WXM1	AEEP_THEMA	reviewed	L-Ala-D/L-Glu epimerase (AE epimerase) (AEE) (EC 5.1.1.20)	TM_0006	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	345							243274.THEMA_04770;	2ZAD;3DEQ;3DER;3DES;3DFY;
Q08282	TYW4_YEAST	reviewed	tRNA wybutosine-synthesizing protein 4 (tRNA yW-synthesizing protein 4) (EC 2.1.1.290) (EC 2.3.1.231) (tRNA(Phe) (7-(3-amino-3-(methoxycarbonyl)propyl)wyosine(37)-N)-methoxycarbonyltransferase) (tRNA(Phe) (7-(3-amino-3-carboxypropyl)wyosine(37)-O)-methyltransferase)	PPM2 TYW4 YOL141W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	695					"MUTAGEN 88;  /note=""R->A: Loss of function."";  /evidence=""ECO:0000269|PubMed:19287006"""	Q08282;	4932.YOL141W;	2ZW9;2ZWA;2ZZK;
Q764N8	Q764N8_GEOS1	unreviewed	Xyloglucanase		Geotrichum sp. (strain M128)	776								3A0F;
D0VWR2	PSBO_THEVL	reviewed	Photosystem II manganese-stabilizing polypeptide (MSP)	psbO	Thermosynechococcus vulcanus (Synechococcus vulcanus)	244						D0VWR2;		3A0B;3A0H;3WU2;4IL6;4UB6;4UB8;5B5E;5B66;5GTH;5GTI;5V2C;5WS5;5WS6;6JLJ;6JLK;6JLL;6JLM;6JLN;6JLO;6JLP;7CJI;7CJJ;7COU;7D1T;7D1U;
O60921	HUS1_HUMAN	reviewed	Checkpoint protein HUS1 (hHUS1)	HUS1	Homo sapiens (Human)	280						O60921;	9606.ENSP00000258774;	3A1J;3G65;3GGR;6J8Y;
Q7ZA77	Q7ZA77_PENCH	unreviewed	Exo-arabinanase	abnx	Penicillium chrysogenum (Penicillium notatum)	378								3A71;3A72;
P0A6N4	EFP_ECOLI	reviewed	Elongation factor P (EF-P)	efp b4147 JW4107	Escherichia coli (strain K12)	188				DISRUPTION PHENOTYPE: Disruption of this gene leads to lethality (PubMed:9405429) or to a very slow growth phenotype (PubMed:20729861). Required for the expression of poly-Pro-containing proteins. {ECO:0000269|PubMed:20729861, ECO:0000269|PubMed:23239623, ECO:0000269|PubMed:9405429}.	"MUTAGEN 31;  /note=""K->A: No lysylation."";  /evidence=""ECO:0000269|PubMed:20729861""; MUTAGEN 33;  /note=""G->K: No lysylation. Loss of in vivo EF-P function for cell growth."";  /evidence=""ECO:0000269|PubMed:20729861""; MUTAGEN 34;  /note=""K->A: No lysylation and loss of EF-P activity. No facilitation of translation of poly-Pro stretches."";  /evidence=""ECO:0000269|PubMed:20729861, ECO:0000269|PubMed:22128152, ECO:0000269|PubMed:23239623"""	P0A6N4;	511145.b4147;	3A5Z;6ENJ;6ENU;
P58546	MTPN_HUMAN	reviewed	Myotrophin (Protein V-1)	MTPN	Homo sapiens (Human)	118						P58546;	9606.ENSP00000376800;	3AAA;7DF7;7DSA;7DSB;
P0AEJ6	EUTB_ECOLI	reviewed	Ethanolamine ammonia-lyase large subunit (EAL large subunit) (EC 4.3.1.7) (Ethanolamine ammonia-lyase alpha subunit) (Ethanolamine ammonia-lyase heavy chain) (Ethanolamine deaminase large subunit)	eutB b2441 JW2434	Escherichia coli (strain K12)	453						P0AEJ6;	511145.b2441;	3ABO;3ABQ;3ABR;3ABS;3ANY;3AO0;5YSN;5YSR;
O60671	RAD1_HUMAN	reviewed	Cell cycle checkpoint protein RAD1 (hRAD1) (EC 3.1.11.2) (DNA repair exonuclease rad1 homolog) (Rad1-like DNA damage checkpoint protein)	RAD1 REC1	Homo sapiens (Human)	282					"MUTAGEN 226..233;  /note=""SLLKPSTK->AAAAAAAA: Abolishes association of the 9-1-1 complex with RAD17."";  /evidence=""ECO:0000269|PubMed:10884395"""	O60671;	9606.ENSP00000371469;	3A1J;3G65;3GGR;6J8Y;
P53196	RPN14_YEAST	reviewed	26S proteasome regulatory subunit RPN14 (Proteasome non-ATPase subunit 14)	RPN14 YGL004C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	417						P53196;	4932.YGL004C;	3ACP;3VL1;
O31097	PHYC_BACIU	reviewed	3-phytase (EC 3.1.3.8) (Myo-inositol-hexaphosphate 3-phosphohydrolase) (Phytate 3-phosphatase)	phyC phyB13	Bacillus subtilis	383								3AMR;3AMS;
O60844	ZG16_HUMAN	reviewed	Zymogen granule membrane protein 16 (Zymogen granule protein 16) (hZG16) (Secretory lectin ZG16)	ZG16	Homo sapiens (Human)	167						O60844;	9606.ENSP00000383563;	3APA;3VY6;3VY7;3VZE;3VZF;3VZG;7O3I;7O4P;7O88;
Q82L26	Q82L26_STRAW	unreviewed	Alpha-galactosidase (EC 3.2.1.22) (Melibiase)	agaA2 SAVERM_2186	Streptomyces avermitilis (strain ATCC 31267 / DSM 46492 / JCM 5070 / NBRC 14893 / NCIMB 12804 / NRRL 8165 / MA-4680)	658							227882.SAV_2186;	3A21;3A22;3A23;
P31340	SPIKE_BPP2	reviewed	Spike protein (Baseplate assembly protein gpV) (Gene V protein) (GpV)	V	Escherichia phage P2 (Bacteriophage P2)	211								3AQJ;3QR7;3QR8;
Q93DY9	MAMA_MAGGM	reviewed	Magnetosome protein MamA (MM24.3)	mamA MGMSRv2__2371 mgI495 MGR_4099	Magnetospirillum gryphiswaldense (strain DSM 6361 / JCM 21280 / NBRC 15271 / MSR-1)	217				DISRUPTION PHENOTYPE: Normal magnetic response, many fewer magnetosomes. MamC is mislocalized in punctate spots throughout the cell (PubMed:24816605). Deletion of approximately 80 kb of DNA, including this operon, leads to cells that are non-magnetic, lack internal membrane systems, grow poorly, have reduced mobility and take-up and accumulate iron poorly (PubMed:13129949). {ECO:0000269|PubMed:13129949, ECO:0000269|PubMed:24816605}.	"MUTAGEN 1..41;  /note=""Missing: No longer forms homooligomeric complexes."";  /evidence=""ECO:0000269|PubMed:21784982""; MUTAGEN 1..26;  /note=""Missing: Forms asymmetric and broken homooligomeric complexes."";  /evidence=""ECO:0000269|PubMed:21784982"""			3AS8;3ASF;
Q2W8Q0	MAMA_MAGSA	reviewed	Magnetosome protein MamA	mamA mms24 amb0971	Magnetospirillum magneticum (strain AMB-1 / ATCC 700264)	217				DISRUPTION PHENOTYPE: Takes up less Fe(3+) than wild-type cells, is less responsive to magnetic field, cells have 1-5 magnetosomes (compared to 8-14 in wild-type). Cells have chains of empty vesicles (PubMed:15004275). Magnetosomes are slightly further apart than in wild-type (PubMed:20439702). Deletion of genes mamH to mamV (amb0961 to amb0978) gives cells with no magnetosomes and no magnetic response (PubMed:20212111). {ECO:0000269|PubMed:15004275, ECO:0000269|PubMed:20212111, ECO:0000269|PubMed:20439702}.	"MUTAGEN 1..41;  /note=""Missing: No longer forms homooligomeric complexes, no longer associates with magnetosomes."";  /evidence=""ECO:0000269|PubMed:21784982""; MUTAGEN 1..26;  /note=""Missing: No longer associates with magnetosomes, protein is unstable."";  /evidence=""ECO:0000269|PubMed:21784982""; MUTAGEN 50;  /note=""R->E: Protein no longer associates with magnetosomes, no longer forms homooligomeric complexes, a crystal of 41-217 has a large rotation of the NTD."";  /evidence=""ECO:0000269|PubMed:21784982"""			3AS4;3AS5;3ASD;3ASG;3ASH;
Q99467	CD180_HUMAN	reviewed	CD180 antigen (Lymphocyte antigen 64) (Radioprotective 105 kDa protein) (CD antigen CD180)	CD180 LY64 RP105	Homo sapiens (Human)	661						Q99467;	9606.ENSP00000256447;	3B2D;
Q9LBW4	HPS_MYCGS	reviewed	3-hexulose-6-phosphate synthase (HPS) (EC 4.1.2.43) (D-arabino-3-hexulose-6-phosphate formaldehyde lyase)	rmpA	Mycobacterium gastri	207								3AJX;
O34678	YTBE_BACSU	reviewed	Uncharacterized oxidoreductase YtbE (EC 1.-.-.-)	ytbE BSU29050	Bacillus subtilis (strain 168)	280							224308.BSU29050;	3B3D;
Q46R99	Q46R99_CUPPJ	unreviewed	Glycosyl hydrolase, BNR repeat protein	Reut_B4987	Cupriavidus pinatubonensis (strain JMP 134 / LMG 1197) (Cupriavidus necator (strain JMP 134))	393							264198.Reut_B4987;	3B7F;
D0VWS0	D0VWS0_RABIT	unreviewed	Titin (EC 2.7.11.1)		Oryctolagus cuniculus (Rabbit)	570								3B43;
O50325	O50325_DICCH	unreviewed	Pectate lyase (EC 4.2.2.2)	pelI	Dickeya chrysanthemi (Pectobacterium chrysanthemi) (Erwinia chrysanthemi)	344								3B4N;3B8Y;3B90;
P49687	NU145_YEAST	reviewed	Nucleoporin NUP145 (EC 3.4.21.-) (Nuclear pore protein NUP145) [Cleaved into: Nucleoporin NUP145N (N-NUP145); Nucleoporin NUP145C (C-NUP145)]	NUP145 RAT10 YGL092W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1317					"MUTAGEN 604;  /note=""H->P: Loss of autocatalytic cleavage; when associated with L-608."";  /evidence=""ECO:0000269|PubMed:9305650""; MUTAGEN 605;  /note=""F->S: Loss of autocatalytic cleavage; when associated with R-608."";  /evidence=""ECO:0000269|PubMed:9305650""; MUTAGEN 606;  /note=""S->A: Loss of autocatalytic cleavage."";  /evidence=""ECO:0000269|PubMed:10542288""; MUTAGEN 608;  /note=""W->L: Loss of autocatalytic cleavage; when associated with P-604."";  /evidence=""ECO:0000269|PubMed:9305650""; MUTAGEN 608;  /note=""W->R: Loss of autocatalytic cleavage; when associated with F-605."";  /evidence=""ECO:0000269|PubMed:9305650"""	P49687;	4932.YGL092W;	3BG0;3BG1;3IKO;3JRO;3JRP;3KEP;3KES;4XMM;4XMN;
P55735	SEC13_HUMAN	reviewed	Protein SEC13 homolog (GATOR complex protein SEC13) (SEC13-like protein 1) (SEC13-related protein)	SEC13 D3S1231E SEC13A SEC13L1 SEC13R	Homo sapiens (Human)	322						P55735;	9606.ENSP00000373312;	3BG0;3BG1;5A9Q;
Q120Q7	Q120Q7_POLSJ	unreviewed	Mandelate racemase/muconate lactonizing enzyme	Bpro_5118	Polaromonas sp. (strain JS666 / ATCC BAA-500)	382								3BJS;
Q8F3Q1	CIMA_LEPIN	reviewed	(R)-citramalate synthase CimA (EC 2.3.1.182) (LiCMS)	cimA LA_2350	Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601)	516					"MUTAGEN 16;  /note=""R->K,Q: Loss of activity."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 17;  /note=""D->A: 34-fold increase in Km for pyruvate and 315-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 17;  /note=""D->N: 4.4-fold increase in Km for pyruvate and 480-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 81;  /note=""L->A: 4.7-fold increase in Km for pyruvate and 15.7-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 81;  /note=""L->V: 3.3-fold increase in Km for pyruvate and 10.1-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 83;  /note=""F->A: 5-fold increase in Km for acetyl-CoA and 120-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 104;  /note=""L->V: 1.8-fold increase in Km for pyruvate and 3.4-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 144;  /note=""Y->L: 259-fold increase in Km for pyruvate and 76-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 144;  /note=""Y->V: 114-fold increase in Km for pyruvate and 5.3-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 146;  /note=""E->D,Q: Minor effects on the binding of acetyl-CoA, but causes a strong decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 179;  /note=""T->A: 16.4-fold increase in Km for pyruvate and 186-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 302;  /note=""H->A,N: Loss of activity."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 304;  /note=""D->A: 5.2-fold increase in Km for acetyl-CoA and 16.6-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 310;  /note=""N->A: 2.2-fold increase in Km for acetyl-CoA and 1.7-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 311;  /note=""L->A: 8-fold increase in Km for acetyl-CoA and 6-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 312;  /note=""Y->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:18498255""; MUTAGEN 430;  /note=""Y->L: No change in Km for acetyl-CoA and 2.3-fold decrease in kcat. Severely impairs inhibition by isoleucine."";  /evidence=""ECO:0000269|PubMed:19351325""; MUTAGEN 431;  /note=""D->A: 1.8-fold decrease in Km for acetyl-CoA and 5-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:19351325""; MUTAGEN 451;  /note=""L->V: 1.5-fold increase in Km for acetyl-CoA and 4.3 decrease in kcat."";  /evidence=""ECO:0000269|PubMed:19351325""; MUTAGEN 454;  /note=""Y->A: 1.4 decrease in Km for acetyl-CoA and 17-fold decrease in kcat. Still inhibited by isoleucine and weakly inhibited by leucine."";  /evidence=""ECO:0000269|PubMed:19351325""; MUTAGEN 458;  /note=""I->A: 1.3-fold decrease in Km for acetyl-CoA and 14-fold decrease in kcat. Abolishes inhibition by isoleucine."";  /evidence=""ECO:0000269|PubMed:19351325""; MUTAGEN 464;  /note=""T->A: 1.8-fold decrease in Km for acetyl-CoA and 4.3-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:19351325""; MUTAGEN 468;  /note=""V->A: No change in Km for acetyl-CoA and 2-fold decrease in kcat. Increases inhibition by isoleucine and leucine becomes an effective inhibitor."";  /evidence=""ECO:0000269|PubMed:19351325""; MUTAGEN 493;  /note=""P->A: 1.5-fold decrease in Km for acetyl-CoA and 2.6-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:19351325""; MUTAGEN 495;  /note=""Q->A: 1.6-fold decrease in Km for acetyl-CoA and 2.8-fold decrease in kcat."";  /evidence=""ECO:0000269|PubMed:19351325"""			3BLE;3BLF;3BLI;3F6G;3F6H;
Q72U69	LP49_LEPIC	reviewed	Antigen Lp49 (Leptospiral 49 kilodalton protein) (Lp49)	orfC LIC_10793	Leptospira interrogans serogroup Icterohaemorrhagiae serovar copenhageni (strain Fiocruz L1-130)	456		BIOTECHNOLOGY: May be useful for detecting a broad spectrum of Leptospira infection in humans and animals due to its presence in several pathogenic serovars of L.interrogans including copenhageni, canicola, hardjo, icterohaemorrhagiae and pomona, and also in L.borgpetersenii hardjo. May be used for serodiagnosis of both early and convalescent phases of leptospirosis infectious disease. {ECO:0000269|PubMed:17609931}.						3BWS;
P78552	I13R1_HUMAN	reviewed	Interleukin-13 receptor subunit alpha-1 (IL-13 receptor subunit alpha-1) (IL-13R subunit alpha-1) (IL-13R-alpha-1) (IL-13RA1) (Cancer/testis antigen 19) (CT19) (CD antigen CD213a1)	IL13RA1 IL13R IL13RA	Homo sapiens (Human)	427						P78552;	9606.ENSP00000360730;	3BPN;3BPO;4HWB;5E4E;
Q816E8	Q816E8_BACCR	unreviewed	Uncharacterized protein	BC_4913	Bacillus cereus (strain ATCC 14579 / DSM 31 / CCUG 7414 / JCM 2152 / NBRC 15305 / NCIMB 9373 / NCTC 2599 / NRRL B-3711)	237								3BVS;3JX7;3JXY;3JXZ;3JY1;5CL3;5CL4;5CL5;5CL6;5CL7;5CL8;5CL9;5CLA;5CLB;5CLC;5CLD;5CLE;5KUB;5UUF;5UUG;5UUH;
P25339	PUF4_YEAST	reviewed	Pumilio homology domain family member 4	PUF4 YGL014W YGL023	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	888						P25339;	4932.YGL014W;	3BWT;3BX2;3BX3;4DZS;
Q8X8Y7	DAPD_ECO57	reviewed	2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase (EC 2.3.1.117) (Tetrahydrodipicolinate N-succinyltransferase) (THDP succinyltransferase) (THP succinyltransferase) (Tetrahydropicolinate succinylase)	dapD Z0176 ECs0168	Escherichia coli O157:H7	274							155864.EDL933_0169;	3BXY;
Q8Y3L4	INLJ_LISMO	reviewed	Internalin J	inlJ lmo2821	Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e)	851				DISRUPTION PHENOTYPE: No visible effect on colonization of host tissue culture cells; decreased organ colonization in mice. {ECO:0000269|PubMed:16177371, ECO:0000269|PubMed:18227172}.			169963.lmo2821;	3BZ5;
Q87K10	Q87K10_VIBPA	unreviewed	Oligogalacturonate lyase	VPA0088	Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633)	388							223926.28808226;	3C5M;
Q9XVI2	Q9XVI2_CAEEL	unreviewed	SYmmetrical Sister cell hermaphrodite gonad defect	sys-1 CELE_T23D8.9 T23D8.9	Caenorhabditis elegans	811						Q9XVI2;	6239.T23D8.9a;	3C2G;3C2H;
Q6MQC7	Q6MQC7_BDEBA	unreviewed	Uncharacterized protein	Bd0547	Bdellovibrio bacteriovorus (strain ATCC 15356 / DSM 50701 / NCIMB 9529 / HD100)	330							264462.Bd0547;	3CAW;
P61167	Y1785_RHOPA	reviewed	UPF0311 protein RPA1785	RPA1785	Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009)	153							258594.RPA1785;	3C5O;
Q9H0B6	KLC2_HUMAN	reviewed	Kinesin light chain 2 (KLC 2)	KLC2	Homo sapiens (Human)	622			DISEASE: Spastic paraplegia, optic atrophy, and neuropathy (SPOAN) [MIM:609541]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPOAN is characterized by spastic paraplegia with progressive joint contractures and spine deformities, loss of independent ambulation by age 10 years, sub-normal vision secondary to congenital optic atrophy, and neuropathy. Inheritance is autosomal recessive. {ECO:0000269|PubMed:26385635}. Note=The gene represented in this entry is involved in disease pathogenesis. The disease is caused by a homozygous deletion in the non-coding region of the KLC2 gene. {ECO:0000269|PubMed:26385635}.			Q9H0B6;	9606.ENSP00000399403;	3CEQ;3EDT;
Q16576	RBBP7_HUMAN	reviewed	Histone-binding protein RBBP7 (Histone acetyltransferase type B subunit 2) (Nucleosome-remodeling factor subunit RBAP46) (Retinoblastoma-binding protein 7) (RBBP-7) (Retinoblastoma-binding protein p46)	RBBP7 RBAP46	Homo sapiens (Human)	425						Q16576;	9606.ENSP00000369424;	3CFS;3CFV;7M3X;
Q97DY3	Q97DY3_CLOAB	unreviewed	Predicted amidohodrolase (Dihydroorotase family)	CA_C3337	Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787)	262							272562.CA_C3337;	3CJP;
Q30V63	Q30V63_DESAG	unreviewed	Hexapeptide repeat-containing transferase	Dde_3640	Desulfovibrio alaskensis (strain ATCC BAA 1058 / DSM 17464 / G20) (Desulfovibrio desulfuricans (strain G20))	477							207559.Dde_3640;	3C8V;
P32719	ALSE_ECOLI	reviewed	D-allulose-6-phosphate 3-epimerase (EC 5.1.3.-)	alsE yjcU b4085 JW4046	Escherichia coli (strain K12)	231					"MUTAGEN 196;  /note=""Missing: Shortens the substrate-binding pocket. Slightly lower activity towards allulose 6-phosphate and increased activity towards ribulose 5-phosphate."";  /evidence=""ECO:0000269|PubMed:18700786""; MUTAGEN 197;  /note=""Missing: Shortens the substrate-binding pocket. Slightly lower activity towards allulose 6-phosphate and increased activity towards ribulose 5-phosphate."";  /evidence=""ECO:0000269|PubMed:18700786""; MUTAGEN 198;  /note=""Missing: Shortens the substrate-binding pocket. Slightly lower activity towards allulose 6-phosphate and increased activity towards ribulose 5-phosphate."";  /evidence=""ECO:0000269|PubMed:18700786"""	P32719;	511145.b4085;	3CT7;3CTL;
B3EYM8	IABN_GEOSE	reviewed	Intracellular endo-alpha-(1->5)-L-arabinanase (ABN) (EC 3.2.1.99) (Endo-1,5-alpha-L-arabinanase)	abnB	Geobacillus stearothermophilus (Bacillus stearothermophilus)	315								3CU9;3D5Y;3D5Z;3D60;3D61;6F1G;
Q8EMJ7	Q8EMJ7_OCEIH	unreviewed	Dihydrodipicolinate synthase (EC 4.3.3.7)	OB2845	Oceanobacillus iheyensis (strain DSM 14371 / CIP 107618 / JCM 11309 / KCTC 3954 / HTE831)	304							221109.22778532;	3D0C;
Q57W55	Q57W55_TRYB2	unreviewed	Peroxisome targeting signal 1 receptor	Tb927.5.1100	Trypanosoma brucei brucei (strain 927/4 GUTat10.1)	655						Q57W55;	5691.AAZ11225;	3CV0;3CVP;3CVQ;
P78344	IF4G2_HUMAN	reviewed	Eukaryotic translation initiation factor 4 gamma 2 (eIF-4-gamma 2) (eIF-4G 2) (eIF4G 2) (Death-associated protein 5) (DAP-5) (p97)	EIF4G2 DAP5 OK/SW-cl.75	Homo sapiens (Human)	907						P78344;	9606.ENSP00000433664;	3D3M;3L6A;4IUL;
Q2HXD9	Q2HXD9_STRMO	unreviewed	Aminopeptidase (S9 family peptidase)	HG542_00635	Streptomyces morookaense (Streptoverticillium morookaense)	662								3AZO;3AZP;3AZQ;
Q9Y613	FHOD1_HUMAN	reviewed	FH1/FH2 domain-containing protein 1 (Formin homolog overexpressed in spleen 1) (FHOS) (Formin homology 2 domain-containing protein 1)	FHOD1 FHOS FHOS1	Homo sapiens (Human)	1164						Q9Y613;	9606.ENSP00000258201;	3DAD;6XF1;6XF2;
A0A0H3LM82	A0A0H3LM82_BORBR	unreviewed	Putative mandelate racemase/muconate lactonizing enzyme	BB2459	Bordetella bronchiseptica (strain ATCC BAA-588 / NCTC 13252 / RB50) (Alcaligenes bronchisepticus)	382							257310.BB2459;	3DDM;
A5KUH4	IMAND_VIBBS	reviewed	D-galactonate dehydratase family member VSWAT3_13707	VSWAT3_13707	Vibrionales bacterium (strain SWAT-3)	399								3DFH;3R25;3SBF;
Q5HG25	DAPA_STAAC	reviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA SACOL1430	Staphylococcus aureus (strain COL)	295								3DI0;3DI1;
A5U161	GLMU_MYCTA	reviewed	Bifunctional protein GlmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (N-acetylglucosamine-1-phosphate uridyltransferase); Glucosamine-1-phosphate N-acetyltransferase (EC 2.3.1.157)]	glmU MRA_1026	Mycobacterium tuberculosis (strain ATCC 25177 / H37Ra)	495							419947.MRA_1026;	3DK5;
O24456	GBLPA_ARATH	reviewed	Receptor for activated C kinase 1A (Guanine nucleotide-binding protein subunit beta-like protein A) (WD-40 repeat auxin-dependent protein ARCA)	RACK1A ARCA At1g18080 T10F20.9 T10O22.6	Arabidopsis thaliana (Mouse-ear cress)	327				DISRUPTION PHENOTYPE: Shorter hypocotyls in etiolated seedlings, epinastic cotyledons, reduced rosette leaf production by half and late flowering under short-day conditions. Reduced sensitivity to gibberellin and brassinosteroid in seed germination, hypersensitivity to abscisic acid in seed germination and early seedling development, and hyposensitivity to auxin in adventitious and lateral root formation. Plants show a significant resistance to water stress conditions by limiting water loss through the guard cells. {ECO:0000269|PubMed:16829549, ECO:0000269|PubMed:18715992, ECO:0000269|PubMed:18947417}.		O24456;	3702.AT1G18080.1;	3DM0;
Q0E9I4	Q0E9I4_DROME	unreviewed	Down syndrome cell adhesion molecule 1, isoform O	Dscam1 43Bc CT39257 Dm_2R:13579 Dm_2R:13612 DmDscam Dmel\CG17800 DSCAM DScam DsCam Dscam dScam dscam Dscam-hv dscam1 Dsm l(2)05518 l(2)43Bc Neu1 p270 CG17800 Dmel_CG17800	Drosophila melanogaster (Fruit fly)	2031								3DMK;
Q8KC98	Q8KC98_CHLTE	unreviewed	Rab family protein	CT1526	Chlorobaculum tepidum (strain ATCC 49652 / DSM 12025 / NBRC 103806 / TLS) (Chlorobium tepidum)	1102							194439.CT1526;	3DPT;3DPU;5IL7;6HLU;
Q5MWV9	BADA_BARHN	reviewed	Autotransporter adhesin BadA (Bartonella adhesin A) (BadA) (Non-fimbrial adhesin A) (Type 5 secretion system autotransporter BadA) (Type IV pilus)	badA	Bartonella henselae (Rochalimaea henselae)	3082		BIOTECHNOLOGY: Antisera to this protein are frequently present in humans and animals infected by B.henselae, suggesting it might be useful as a marker for B.henselae infection. {ECO:0000305|PubMed:15534369}.		DISRUPTION PHENOTYPE: No longer binds to host cells or host extracellular matrix proteins, loss of bacterial 'type IV-like pili'. Bacteria are more frequently phagocytosed by murine J774 macrophages. Infected HeLa cells no longer secrete proangiogenic factors such as VEGFA, ADM, IGFBP3 or IL-8 (PubMed:15534369). Decreased binding to host epithelial cells and to host extracellular matrix components vitronectin, hyaluronate, fibronectin, laminin, collagens I, III and IV under static and dynamic flow conditions (PubMed:21536788). {ECO:0000269|PubMed:15534369, ECO:0000269|PubMed:21536788}.				3D9X;
Q9Y765	FNTA_CANAX	reviewed	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha (EC 2.5.1.58) (EC 2.5.1.59) (CAAX farnesyltransferase subunit alpha) (FTase-alpha) (Ras proteins prenyltransferase subunit alpha) (Type I protein geranyl-geranyltransferase subunit alpha) (GGTase-I-alpha)	RAM2	Candida albicans (Yeast)	306								3DRA;4YDO;
A7V5N4	A7V5N4_BACUC	unreviewed	Uncharacterized protein	BACUNI_02894	Bacteroides uniformis (strain ATCC 8492 / DSM 6597 / CCUG 4942 / CIP 103695 / JCM 5828 / KCTC 5204 / NCTC 13054 / VPI 0061)	334							411479.BACUNI_02894;	3DSM;
Q8YQS9	Q8YQS9_NOSS1	unreviewed	All3740 protein	all3740	Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576)	237							103690.17132874;	3DU1;
Q96DX5	ASB9_HUMAN	reviewed	Ankyrin repeat and SOCS box protein 9 (ASB-9)	ASB9	Homo sapiens (Human)	294						Q96DX5;	9606.ENSP00000369855;	3D9H;3ZKJ;3ZNG;6V9H;
P78774	ARPC1_SCHPO	reviewed	Actin-related protein 2/3 complex subunit 1 (Arp2/3 complex 41 kDa subunit) (p41-ARC)	arc1 sop2 SPBC14C8.06	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	377						P78774;	4896.SPBC14C8.06.1;	3DWL;6W17;6W18;
P22027	ATP5S_BOVIN	reviewed	ATP synthase subunit s, mitochondrial (ATP synthase-coupling factor B) (FB) (Distal membrane arm assembly complex 2-like protein) (Mitochondrial ATP synthase regulatory component factor B)	DMAC2L ATP5S ATPW	Bos taurus (Bovine)	200							9913.ENSBTAP00000020228;	3DZE;3E2J;3E3Z;3E4G;
P42702	LIFR_HUMAN	reviewed	Leukemia inhibitory factor receptor (LIF receptor) (LIF-R) (CD antigen CD118)	LIFR	Homo sapiens (Human)	1097			DISEASE: Stueve-Wiedemann syndrome (STWS) [MIM:601559]: Severe autosomal recessive condition and belongs to the group of the bent-bone dysplasias. SWS is characterized by bowing of the lower limbs, with internal cortical thickening, wide metaphyses with abnormal trabecular pattern, and camptodactyly. Additional features include feeding and swallowing difficulties, as well as respiratory distress and hyperthermic episodes, which cause death in the first months of life. The rare survivors develop progressive scoliosis, spontaneous fractures, bowing of the lower limbs, with prominent joints and dysautonomia symptoms, including temperature instability, absent corneal and patellar reflexes, and smooth tongue. {ECO:0000269|PubMed:14740318}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving LIFR is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(5;8)(p13;q12) with PLAG1.			P42702;	9606.ENSP00000263409;	3E0G;
Q99MB1	TLR3_MOUSE	reviewed	Toll-like receptor 3 (CD antigen CD283)	Tlr3	Mus musculus (Mouse)	905						Q99MB1;	10090.ENSMUSP00000034056;	3CIG;3CIY;7C77;
Q9RXN3	Q9RXN3_DEIRA	unreviewed	Gluconolactonase, putative	DR_0277	Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)	288							243230.DR_0277;	3E5Z;
Q5LKY7	Q5LKY7_RUEPO	unreviewed	Transcriptional regulator, LacI family	SPOA0242	Ruegeria pomeroyi (strain ATCC 700808 / DSM 15171 / DSS-3) (Silicibacter pomeroyi)	346							246200.SPOA0242;	3E3M;
Q2VGE8	Q2VGE8_PETMA	unreviewed	Variable lymphocyte receptor diversity region (Fragment)	VLR	Petromyzon marinus (Sea lamprey)	194								3E6J;
Q6N9H8	Q6N9H8_RHOPA	unreviewed	Putative dihydrodipicolinate synthetase (EC 4.2.1.52)	dapA1 RPA1571	Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009)	292							258594.RPA1571;	3EB2;
Q9KLB0	Q9KLB0_VIBCH	unreviewed	Hexapeptide-repeat containing-acetyltransferase	VC_A0836	Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)	192							243277.VC_A0836;	3ECT;3NZ2;
Q5LT20	Q5LT20_RUEPO	unreviewed	Mandelate racemase/muconate lactonizing enzyme, putative	SPO1594	Ruegeria pomeroyi (strain ATCC 700808 / DSM 15171 / DSS-3) (Silicibacter pomeroyi)	368							246200.SPO1594;	3EEZ;
Q8FV25	DAPD_BRUSU	reviewed	2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase (EC 2.3.1.117) (Tetrahydrodipicolinate N-succinyltransferase) (THDP succinyltransferase) (THP succinyltransferase) (Tetrahydropicolinate succinylase)	dapD BRA1028 BS1330_II1020	Brucella suis biovar 1 (strain 1330)	284								3EG4;
A6L3P9	A6L3P9_PHOV8	unreviewed	Putative aldolase	BVU_2661	Phocaeicola vulgatus (strain ATCC 8482 / DSM 1447 / JCM 5826 / CCUG 4940 / NBRC 14291 / NCTC 11154) (Bacteroides vulgatus)	510							435590.BVU_2661;	3DXI;
Q92466	DDB2_HUMAN	reviewed	DNA damage-binding protein 2 (DDB p48 subunit) (DDBb) (Damage-specific DNA-binding protein 2) (UV-damaged DNA-binding protein 2) (UV-DDB 2)	DDB2	Homo sapiens (Human)	427			DISEASE: Xeroderma pigmentosum complementation group E (XP-E) [MIM:278740]: An autosomal recessive pigmentary skin disorder characterized by solar hypersensitivity of the skin, high predisposition for developing cancers on areas exposed to sunlight and, in some cases, neurological abnormalities. The skin develops marked freckling and other pigmentation abnormalities. XP-E patients show a mild phenotype with minimal or no neurologic features. {ECO:0000269|PubMed:8798680}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 258;  /note=""L->A: Impairs interaction with DDB1."";  /evidence=""ECO:0000269|PubMed:17079684""; MUTAGEN 262;  /note=""S->A: Impairs interaction with DDB1."";  /evidence=""ECO:0000269|PubMed:17079684""; MUTAGEN 264;  /note=""D->A: Impairs interaction with DDB1."";  /evidence=""ECO:0000269|PubMed:17079684""; MUTAGEN 269;  /note=""I->A: Impairs interaction with DDB1."";  /evidence=""ECO:0000269|PubMed:17079684""; MUTAGEN 270;  /note=""W->A: Impairs interaction with DDB1."";  /evidence=""ECO:0000269|PubMed:17079684""; MUTAGEN 272;  /note=""L->A: Impairs interaction with DDB1."";  /evidence=""ECO:0000269|PubMed:17079684""; MUTAGEN 273;  /note=""R->A: Impairs interaction with DDB1."";  /evidence=""ECO:0000269|PubMed:17079684""; MUTAGEN 350;  /note=""L->P: Impairs interaction with DDB1."";  /evidence=""ECO:0000269|PubMed:16949367"""	Q92466;	9606.ENSP00000256996;	3EI4;3I7L;4E54;4E5Z;6R8Y;6R8Z;6R90;6R91;6R92;
P21645	LPXD_ECOLI	reviewed	UDP-3-O-(3-hydroxymyristoyl)glucosamine N-acyltransferase (UDP-3-O-(3-OHC14)-GlcN N-acyltransferase) (EC 2.3.1.191) (Protein FirA) (Rifampicin resistance protein) (UDP-3-O-(3-hydroxytetradecanoyl)glucosamine N-acyltransferase)	lpxD firA omsA b0179 JW0174	Escherichia coli (strain K12)	341					"MUTAGEN 41;  /note=""F->A: 30-fold decrease in affinity for UDP-3-O-((3R)-hydroxytetradecanoyl)-GlcN and 5-fold decrease in catalytic activity."";  /evidence=""ECO:0000269|PubMed:18422345""; MUTAGEN 165;  /note=""Q->R: In firA200; confers temperature sensitivity and reverses the rifampicin resistance of rpoB mutants."";  /evidence=""ECO:0000269|PubMed:1987124""; MUTAGEN 172;  /note=""I->F: In firA201; confers temperature sensitivity.""; MUTAGEN 228;  /note=""G->D: In firA200 and firA201; confers temperature sensitivity."";  /evidence=""ECO:0000269|PubMed:1987124""; MUTAGEN 239;  /note=""H->A: 1000-fold reduction in catalytic activity with very little effect on substrate affinity."";  /evidence=""ECO:0000269|PubMed:18422345""; MUTAGEN 252;  /note=""G->S: In firA200 and firA201; confers temperature sensitivity."";  /evidence=""ECO:0000269|PubMed:1987124""; MUTAGEN 271;  /note=""S->N: In omsA; confers temperature sensitivity."";  /evidence=""ECO:0000269|PubMed:1429432""; MUTAGEN 276;  /note=""H->A: 30-fold reduction in catalytic activity."";  /evidence=""ECO:0000269|PubMed:18422345""; MUTAGEN 290;  /note=""M->A: Change in the acyl donor selectivity, showing a preference for 3-hydroxypalmitoyl-ACP over 3-hydroxytetradecanoyl-ACP as substrate. Produces a lipid A with longer acyl chains."";  /evidence=""ECO:0000269|PubMed:19655786""; MUTAGEN 292;  /note=""M->A: No change in the acyl donor selectivity."";  /evidence=""ECO:0000269|PubMed:19655786"""	P21645;	511145.b0179;	3EH0;4IHF;4IHG;4IHH;6P83;6P84;6P85;6P86;6P87;6P88;6P89;6P8A;6P8B;
Q60932	VDAC1_MOUSE	reviewed	Voltage-dependent anion-selective channel protein 1 (VDAC-1) (mVDAC1) (Outer mitochondrial membrane protein porin 1) (Plasmalemmal porin) (Voltage-dependent anion-selective channel protein 5) (VDAC-5) (mVDAC5)	Vdac1 Vdac5	Mus musculus (Mouse)	296					"MUTAGEN 25;  /note=""K->R: Decreased localization of SQSTM1/p62 to damaged mitochondria; when associated with R-33; R-66 and 122-R-R-123."";  /evidence=""ECO:0000269|PubMed:32047033""; MUTAGEN 33;  /note=""K->R: Decreased localization of SQSTM1/p62 to damaged mitochondria; when associated with R-25; R-66 and 122-R-R-123."";  /evidence=""ECO:0000269|PubMed:32047033""; MUTAGEN 66;  /note=""K->R: Decreased localization of SQSTM1/p62 to damaged mitochondria; when associated with R-25; R-33 and 122-R-R-123."";  /evidence=""ECO:0000269|PubMed:32047033""; MUTAGEN 122..123;  /note=""KK->RR: Decreased localization of SQSTM1/p62 to damaged mitochondria; when associated with R-25; R-33 and R-66."";  /evidence=""ECO:0000269|PubMed:32047033""; MUTAGEN 287;  /note=""K->R: No effect on localization of SQSTM1/p62 to damaged mitochondria."";  /evidence=""ECO:0000269|PubMed:32047033"""	Q60932;	10090.ENSMUSP00000099819;	3EMN;4C69;7KUH;
Q2Z1W1	Q2Z1W1_PHACH	unreviewed	Glucan 1,3-beta-glucosidase (EC 3.2.1.58)	lam55A	Phanerodontia chrysosporium (White-rot fungus) (Sporotrichum pruinosum)	778								3EQN;3EQO;
A6ZUJ9	A6ZUJ9_YEAS7	unreviewed	Budding uninhibited by benzimidazole-related protein	BUB1 SCY_2082	Saccharomyces cerevisiae (strain YJM789) (Baker's yeast)	1021								3ESL;
Q8KKW2	Q8KKW2_RHIEC	unreviewed	Hypothetical conserved protein	RHE_PD00032	Rhizobium etli (strain CFN 42 / ATCC 51251)	155								3EW1;3EW2;
Q8IUH5	ZDH17_HUMAN	reviewed	Palmitoyltransferase ZDHHC17 (EC 2.3.1.225) (Acyltransferase ZDHHC17) (EC 2.3.1.-) (DHHC domain-containing cysteine-rich protein 17) (DHHC17) (Huntingtin yeast partner H) (Huntingtin-interacting protein 14) (HIP-14) (Huntingtin-interacting protein 3) (HIP-3) (Huntingtin-interacting protein H) (Putative MAPK-activating protein PM11) (Putative NF-kappa-B-activating protein 205) (Zinc finger DHHC domain-containing protein 17)	ZDHHC17 HIP14 HIP3 HYPH KIAA0946 HSPC294	Homo sapiens (Human)	632					"MUTAGEN 67;  /note=""Y->A: Decreased binding affinity for SNAP25."";  /evidence=""ECO:0000269|PubMed:28757145""; MUTAGEN 89;  /note=""E->A: No effect on SNAP25 binding."";  /evidence=""ECO:0000269|PubMed:28757145""; MUTAGEN 100;  /note=""N->A: Abolishes SNAP25 binding."";  /evidence=""ECO:0000269|PubMed:28757145""; MUTAGEN 122;  /note=""D->A: Mildly decreased binding affinity for SNAP25."";  /evidence=""ECO:0000269|PubMed:28757145""; MUTAGEN 130;  /note=""W->A: Abolishes SNAP25 and HTT binding."";  /evidence=""ECO:0000269|PubMed:28757145""; MUTAGEN 467;  /note=""C->S: Abolishes palmitoyltransferase activity."";  /evidence=""ECO:0000269|PubMed:15489887, ECO:0000269|PubMed:28757145"""	Q8IUH5;	9606.ENSP00000403397;	3EU9;5W7I;5W7J;
Q2YDS1	DDB2_DANRE	reviewed	DNA damage-binding protein 2 (Damage-specific DNA-binding protein 2)	ddb2 si:dkey-45f10.3	Danio rerio (Zebrafish) (Brachydanio rerio)	496						Q2YDS1;	7955.ENSDARP00000091438;	3EI1;3EI2;3EI3;4A08;4A09;4A0A;4A0B;4A0K;4A0L;
A6KZB9	A6KZB9_PHOV8	unreviewed	Serine O-acetyltransferase (EC 2.3.1.30)	BVU_1092	Phocaeicola vulgatus (strain ATCC 8482 / DSM 1447 / JCM 5826 / CCUG 4940 / NBRC 14291 / NCTC 11154) (Bacteroides vulgatus)	302							435590.BVU_1092;	3F1X;
Q8ZCP4	PDXJ_YERPE	reviewed	Pyridoxine 5'-phosphate synthase (PNP synthase) (EC 2.6.99.2)	pdxJ YPO2930 y1300 YP_2525	Yersinia pestis	243						Q8ZCP4;	214092.YPO2930;	3F4N;
Q8ZMP9	Q8ZMP9_SALTY	unreviewed	3-hexulose-6-phosphate synthase (EC 4.1.2.43)	STM2755	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	211								3F4W;
Q99523	SORT_HUMAN	reviewed	Sortilin (100 kDa NT receptor) (Glycoprotein 95) (Gp95) (Neurotensin receptor 3) (NT3) (NTR3)	SORT1	Homo sapiens (Human)	831			DISEASE: Note=A common polymorphism located in a non-coding region between CELSR2 and PSRC1 alters a CEBP transcription factor binding site and is responsible for changes in hepatic expression of SORT1. Altered SORT1 expression in liver affects low density lipoprotein cholesterol levels in plasma and is associated with susceptibility to myocardial infarction. {ECO:0000269|PubMed:20686566}.		"MUTAGEN 74..77;  /note=""RWRR->GWRA: Abrogates propeptide cleavage."";  /evidence=""ECO:0000269|PubMed:9927419""; MUTAGEN 76..77;  /note=""RR->GG: Abrogates propeptide cleavage."";  /evidence=""ECO:0000269|PubMed:9927419""; MUTAGEN 783;  /note=""C->S: Loss of palmitoylation. Decreased recycling from endosomes to the Golgi apparatus. Increased lysosomal degradation."";  /evidence=""ECO:0000269|PubMed:18817523""; MUTAGEN 792;  /note=""Y->A: Reduces endocytosis and Golgi to endosome sorting; when associated with A-795."";  /evidence=""ECO:0000269|PubMed:11331584""; MUTAGEN 795;  /note=""L->A: Reduces endocytosis and Golgi to endosome sorting; when associated with A-792."";  /evidence=""ECO:0000269|PubMed:11331584""; MUTAGEN 823..824;  /note=""DD->NN: Reduces interaction with GGA1."";  /evidence=""ECO:0000269|PubMed:11390366""; MUTAGEN 825;  /note=""S->A: Reduces interaction with GGA1."";  /evidence=""ECO:0000269|PubMed:11390366""; MUTAGEN 826..828;  /note=""DED->NQN: Abrogates interaction with GGA1 and impairs localization to the Golgi."";  /evidence=""ECO:0000269|PubMed:11390366""; MUTAGEN 829..830;  /note=""LL->AA: Abrogates interaction with GGA1 and impairs localization to the Golgi."";  /evidence=""ECO:0000269|PubMed:11331584, ECO:0000269|PubMed:11390366""; MUTAGEN 829..830;  /note=""Missing: Abrogates interaction with GGA2. Reduces endocytosis and Golgi to endosome sorting; when associated with A-792 and A-795."";  /evidence=""ECO:0000269|PubMed:11331584, ECO:0000269|PubMed:11390366"""	Q99523;	9606.ENSP00000256637;	3F6K;3G2U;3G2V;4MSL;4N7E;4PO7;5MRH;5MRI;6EHO;6X3L;6X48;6X4H;
P35729	NU120_YEAST	reviewed	Nucleoporin NUP120 (Nuclear pore protein NUP120)	NUP120 RAT2 YKL057C YKL313 YKL314	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1037						P35729;	4932.YKL057C;	3F7F;3H7N;3HXR;4XMM;4XMN;6X06;
Q93DA8	Q93DA8_STRMG	unreviewed	RmpD	rmpD	Streptococcus mutans	221								3EXR;3EXS;3EXT;
Q89ZH8	Q89ZH8_BACTN	unreviewed	Uncharacterized protein	BT_4399	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	383								3FGB;
P53011	SEH1_YEAST	reviewed	Nucleoporin SEH1 (Nuclear pore protein SEH1) (SEC13 homolog 1)	SEH1 YGL100W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	349						P53011;	4932.YGL100W;	3EWE;3F3F;3F3G;3F3P;4XMM;6X08;
Q9JZR4	DAPA_NEIMB	reviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA NMB0929	Neisseria meningitidis serogroup B (strain MC58)	291								3FLU;
Q9UJX3	APC7_HUMAN	reviewed	Anaphase-promoting complex subunit 7 (APC7) (Cyclosome subunit 7)	ANAPC7 APC7	Homo sapiens (Human)	599					"MUTAGEN 56;  /note=""L->R: Loss of homodimerization; when associated with K-60."";  /evidence=""ECO:0000269|PubMed:19091741""; MUTAGEN 60;  /note=""L->K: Loss of homodimerization; when associated with R-56."";  /evidence=""ECO:0000269|PubMed:19091741"""	Q9UJX3;	9606.ENSP00000394394;	3FFL;4UI9;5A31;5G04;5G05;5KHR;5KHU;5L9T;5L9U;5LCW;6Q6G;6Q6H;6TLJ;6TM5;6TNT;
P38825	TOM71_YEAST	reviewed	Protein TOM71 (71 kDa mitochondrial outer membrane protein)	TOM71 TOM72 YHR117W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	639						P38825;	4932.YHR117W;	3FP2;3FP3;3FP4;3LCA;
Q8YHF1	KDSA_BRUME	reviewed	2-dehydro-3-deoxyphosphooctonate aldolase (EC 2.5.1.55) (3-deoxy-D-manno-octulosonic acid 8-phosphate synthase) (KDO-8-phosphate synthase) (KDO 8-P synthase) (KDOPS) (Phospho-2-dehydro-3-deoxyoctonate aldolase)	kdsA BMEI0850	Brucella melitensis biotype 1 (strain 16M / ATCC 23456 / NCTC 10094)	277							224914.BMEI0850;	3FS2;
O76071	CIAO1_HUMAN	reviewed	Probable cytosolic iron-sulfur protein assembly protein CIAO1 (WD repeat-containing protein 39)	CIAO1 CIA1 WDR39	Homo sapiens (Human)	339					"MUTAGEN 87..89;  /note=""IWK->AAA: Does not affect binding to HSC20."";  /evidence=""ECO:0000269|PubMed:29309586""; MUTAGEN 176..178;  /note=""LYR->AAA: Abolishes binding to HSC20."";  /evidence=""ECO:0000269|PubMed:29309586"""	O76071;	9606.ENSP00000418287;	3FM0;
B0RN69	B0RN69_XANCB	unreviewed	Gluconolactonase (EC 3.1.1.17)	gnl1 XCCB100_0569	Xanthomonas campestris pv. campestris (strain B100)	305								3DR2;
Q5HCZ5	ATRF2_STAAC	reviewed	Putative acetyltransferase SACOL2570 (EC 2.3.1.-)	SACOL2570	Staphylococcus aureus (strain COL)	199								3FTT;3V4E;4DCL;4EGG;5U2K;5V0Z;
D0VX18	D0VX18_PETMA	unreviewed	Variable lymphocyte receptor VLRB.2D	vlr	Petromyzon marinus (Sea lamprey)	178								3G3A;
P16466	HLYA_PROMI	reviewed	Hemolysin	hpmA	Proteus mirabilis	1577								3FY3;4W8Q;4W8R;4W8S;4W8T;5KDK;5KEH;5KF3;5KKD;5SZ8;6PYK;6PZL;6Q0P;
D0VX19	D0VX19_PETMA	unreviewed	Variable lymphocyte receptor VLRB.2D	vlr	Petromyzon marinus (Sea lamprey)	170								3G3B;
Q97DZ9	Y3321_CLOAB	reviewed	UPF0311 protein CA_C3321	CA_C3321	Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787)	158							272562.CA_C3321;	3G7G;
Q15493	RGN_HUMAN	reviewed	Regucalcin (RC) (Gluconolactonase) (GNL) (EC 3.1.1.17) (Senescence marker protein 30) (SMP-30)	RGN SMP30	Homo sapiens (Human)	299					"MUTAGEN 18;  /note=""E->A: Reduces enzyme activity by about 90%."";  /evidence=""ECO:0000269|PubMed:20329768""; MUTAGEN 103;  /note=""N->A: Reduces enzyme activity by about 95%."";  /evidence=""ECO:0000269|PubMed:20329768""; MUTAGEN 154;  /note=""N->A: Reduces enzyme activity by about 95%."";  /evidence=""ECO:0000269|PubMed:20329768""; MUTAGEN 204;  /note=""D->A: Reduces enzyme activity by over 98%."";  /evidence=""ECO:0000269|PubMed:20329768"""	Q15493;	9606.ENSP00000380365;	3G4E;3G4H;4GNB;4GNC;
Q6TFC6	Q6TFC6_THETR	unreviewed	QdtC	qdtC	Thermoanaerobacterium thermosaccharolyticum (Clostridium thermosaccharolyticum)	265								3FS8;3FSB;3FSC;
Q28175	RPE65_BOVIN	reviewed	Retinoid isomerohydrolase (EC 3.1.1.64) (All-trans-retinyl-palmitate hydrolase) (Lutein isomerase) (Meso-zeaxanthin isomerase) (EC 5.3.3.22) (Retinal pigment epithelium-specific 65 kDa protein) (Retinol isomerase)	RPE65	Bos taurus (Bovine)	533							9913.ENSBTAP00000041254;	3FSN;3KVC;4F2Z;4F30;4F3A;4F3D;4RSC;4RSE;4RYX;4RYY;4RYZ;4ZHK;5UL5;5ULG;7K88;7K89;7K8G;7L0E;
P36037	DOA1_YEAST	reviewed	Protein DOA1 (Degradation of alpha protein 1) (Ubiquitin fusion degradation protein 3)	DOA1 UFD3 ZZZ4 YKL213C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	715				DISRUPTION PHENOTYPE: Severely reduces cell growth in response to misfolded protein, translation inhibition-induced, heat or mitochondrial oxidative stresses but not in response to ER stress (PubMed:16427015, PubMed:18508771, PubMed:16428438, PubMed:27044889). {ECO:0000269|PubMed:16427015, ECO:0000269|PubMed:16428438, ECO:0000269|PubMed:18508771, ECO:0000269|PubMed:27044889}.	"MUTAGEN 2..425;  /note=""Missing: No binding to ubiquitin but does not affect the interaction with CDC48."";  /evidence=""ECO:0000269|PubMed:16427015""; MUTAGEN 2..359;  /note=""Missing: No binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:16427015""; MUTAGEN 2..353;  /note=""Missing: No binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:16428438""; MUTAGEN 2..330;  /note=""Missing: Does not affect binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:16428438""; MUTAGEN 2..287;  /note=""Missing: No binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:16427015""; MUTAGEN 5;  /note=""L->S: No binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:21070969""; MUTAGEN 15;  /note=""D->S: No binding to ubiquitin. Reduces cell growth at high temperatures (37 degrees Celsius). Inhibits cell growth at high temperatures and prevents the degradation of mitochondrial proteins FZO1, MDM34 and MSP1 without affecting the interaction with CDC48 and UFD1; when associated with A-222 and A-265."";  /evidence=""ECO:0000269|PubMed:21070969, ECO:0000269|PubMed:27044889""; MUTAGEN 158;  /note=""A->E: No binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:21070969""; MUTAGEN 222;  /note=""F->A: No binding to ubiquitin. Inhibits cell growth at high temperatures and prevents the degradation of mitochondrial proteins FZO1, MDM34 and MSP1 without affecting the interaction with CDC48 and UFD1; when associated with S-15 and A-265."";  /evidence=""ECO:0000269|PubMed:21070969, ECO:0000269|PubMed:27044889""; MUTAGEN 237;  /note=""C->Y: In ufd3-2; severe reduction in the degradation of short-lived ubiquitin-fusion proteins. No defect in the interaction with CDC48."";  /evidence=""ECO:0000269|PubMed:8890162""; MUTAGEN 265;  /note=""W->A: No binding to ubiquitin. Inhibits cell growth at high temperatures and prevents the degradation of mitochondrial proteins FZO1, MDM34 and MSP1 without affecting the interaction with CDC48 and UFD1; when associated with S-15 and A-222."";  /evidence=""ECO:0000269|PubMed:21070969, ECO:0000269|PubMed:27044889""; MUTAGEN 281;  /note=""D->S: No binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:21070969""; MUTAGEN 289..715;  /note=""Missing: No binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:16427015""; MUTAGEN 417;  /note=""F->D: Prevents binding to mono-ubiquitin, reduces levels of free ubiquitin, prevents the degradation of mitochondrial proteins FZO1, MDM34 and MSP1 and is partially sensitive to misfolded protein or translation inhibition-induced stresses; when associated with D-434."";  /evidence=""ECO:0000269|PubMed:16428438, ECO:0000269|PubMed:27044889""; MUTAGEN 426..715;  /note=""Missing: No binding to ubiquitin and no interaction with CDC48."";  /evidence=""ECO:0000269|PubMed:16427015, ECO:0000269|PubMed:16428438""; MUTAGEN 434..443;  /note=""Missing: Loss of interaction with HSE1 and ubiquitin without affecting general ubquitination levels. Prevents protease CSP1 sorting into the vacuole."";  /evidence=""ECO:0000269|PubMed:18508771""; MUTAGEN 434..440;  /note=""FILKNTN->AAAKAAA: Loss of interaction with HSE1 without affecting binding to ubiquitin or general ubquitination levels. Prevents protease CSP1 sorting into the vacuole."";  /evidence=""ECO:0000269|PubMed:18508771""; MUTAGEN 434;  /note=""F->D: Prevents binding to mono-ubiquitin, reduces levels of free ubiquitin, prevents the degradation of mitochondrial proteins FZO1, MDM34 and MSP1 and is partially sensitive to misfolded protein or translation inhibition-induced stresses; when associated with D-417."";  /evidence=""ECO:0000269|PubMed:16428438, ECO:0000269|PubMed:27044889""; MUTAGEN 451..715;  /note=""Missing: Does not affect binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:16428438""; MUTAGEN 495..715;  /note=""Missing: Loss of interaction with CDC48 without affecting binding to ubiquitin."";  /evidence=""ECO:0000269|PubMed:16427015""; MUTAGEN 541;  /note=""R->A: Depletion of cellular ubiquitin pools and reduced activity of the ubiquitin fusion degradation pathway. Prevents the interaction with CDC48 and UFD1 and thus the degradation of mitochondrial proteins FZO1, MDM34 and MSP1; when associated with A-669."";  /evidence=""ECO:0000269|PubMed:19805280, ECO:0000269|PubMed:27044889""; MUTAGEN 669;  /note=""R->A: Depletion of cellular ubiquitin pools and reduced activity of the ubiquitin fusion degradation pathway. Prevents the interaction with CDC48 and UFD1 and thus the degradation of mitochondrial proteins FZO1, MDM34 and MSP1; when associated with A-541."";  /evidence=""ECO:0000269|PubMed:19805280, ECO:0000269|PubMed:27044889"""	P36037;	4932.YKL213C;	3GAE;3L3F;3ODT;3PSP;3PST;
Q9RZH8	Q9RZH8_DEIRA	unreviewed	Uncharacterized protein	DR_C0006	Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)	244								3GG7;
Q5ZSW6	Q5ZSW6_LEGPH	unreviewed	Leucine-rich repeat-containing protein	legL7 lpg2400	Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC 33152 / DSM 7513)	354							272624.lpg2400;	3GOZ;
Q6P5F9	XPO1_MOUSE	reviewed	Exportin-1 (Exp1) (Chromosome region maintenance 1 protein homolog)	Xpo1 Crm1	Mus musculus (Mouse)	1071						Q6P5F9;	10090.ENSMUSP00000099933;	3GJX;3NBY;3NBZ;3NC0;3NC1;
P41541	USO1_BOVIN	reviewed	General vesicular transport factor p115 (Protein USO1 homolog) (Transcytosis-associated protein) (TAP) (Vesicle-docking protein)	USO1 VDP	Bos taurus (Bovine)	961							9913.ENSBTAP00000022642;	3GQ2;3GRL;
Q8MSU4	SYMPK_DROME	reviewed	Symplekin	Sym CG2097	Drosophila melanogaster (Fruit fly)	1165						Q8MSU4;	7227.FBpp0078372;	3GS3;4IMI;4IMJ;4YGX;6NPW;
Q9RRX4	Q9RRX4_DEIRA	unreviewed	Uncharacterized protein	DR_2358	Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)	211							243230.DR_2358;	3GW4;
P76143	LSRF_ECOLI	reviewed	3-hydroxy-5-phosphonooxypentane-2,4-dione thiolase (EC 2.3.1.245)	lsrF yneB b1517 JW1510	Escherichia coli (strain K12)	291					"MUTAGEN 57;  /note=""D->A: No activity."";  /evidence=""ECO:0000269|PubMed:25225400""; MUTAGEN 203;  /note=""K->A: No activity."";  /evidence=""ECO:0000269|PubMed:25225400""; MUTAGEN 251;  /note=""D->A: No activity."";  /evidence=""ECO:0000269|PubMed:25225400"""	P76143;	511145.b1517;	3GKF;3GLC;3GND;4P2V;
Q80U58	PUM2_MOUSE	reviewed	Pumilio homolog 2	Pum2 Kiaa0235	Mus musculus (Mouse)	1066						Q80U58;	10090.ENSMUSP00000131074;	3GVO;3GVT;
Q9EQK5	MVP_MOUSE	reviewed	Major vault protein (MVP)	Mvp	Mus musculus (Mouse)	861							10090.ENSMUSP00000127250;	3GF5;3GNF;3GNG;
F9UQE3	F9UQE3_LACPL	unreviewed	6-phosphogluconolactonase (EC 3.1.1.31)	lp_2219	Lactobacillus plantarum (strain ATCC BAA-793 / NCIMB 8826 / WCFS1)	339							220668.lp_2219;	3HFQ;
A0A6L7H2S4	A0A6L7H2S4_BACAN	unreviewed	Maltose O-acetyltransferase (EC 2.3.1.79)	maa GBAA_3402	Bacillus anthracis	187								3HJJ;3IGJ;
Q44124	Q44124_ACTPL	unreviewed	Transferrin-binding protein B	tbpB	Actinobacillus pleuropneumoniae (Haemophilus pleuropneumoniae)	547								3HOE;3HOL;
Q838Q8	Q838Q8_ENTFA	unreviewed	Ankyrin repeat family protein	EF_0377	Enterococcus faecalis (strain ATCC 700802 / V583)	201							226185.EF_0377;	3HRA;
P62944	AP2B1_RAT	reviewed	AP-2 complex subunit beta (AP105B) (Adaptor protein complex AP-2 subunit beta) (Adaptor-related protein complex 2 subunit beta) (Beta-2-adaptin) (Beta-adaptin) (Clathrin assembly protein complex 2 beta large chain) (Plasma membrane adaptor HA2/AP2 adaptin beta subunit)	Ap2b1 Clapb1	Rattus norvegicus (Rat)	937					"MUTAGEN 756;  /note=""Q->A: Abolishes interaction with PIP5K1C."";  /evidence=""ECO:0000269|PubMed:19287005""; MUTAGEN 804;  /note=""Q->A: Abolishes interaction with PIP5K1C."";  /evidence=""ECO:0000269|PubMed:19287005""; MUTAGEN 806;  /note=""A->F: Abolishes interaction with PIP5K1C."";  /evidence=""ECO:0000269|PubMed:19287005""; MUTAGEN 808;  /note=""K->E: Abolishes interaction with PIP5K1C."";  /evidence=""ECO:0000269|PubMed:19287005""; MUTAGEN 815;  /note=""Y->A: Abolishes interaction with PIP5K1C."";  /evidence=""ECO:0000269|PubMed:19287005"""	P62944;	10116.ENSRNOP00000068516;	3H1Z;3HS9;6OWT;
Q8A1I2	Q8A1I2_BACTN	unreviewed	IPT/TIG domain-containing protein	BT_3679	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	430							226186.BT_3679;	3HRP;
A6VIT4	A6VIT4_METM7	unreviewed	Pyrrolo-quinoline quinone	MmarC7_1297	Methanococcus maripaludis (strain C7 / ATCC BAA-1331)	322							426368.MmarC7_1297;	3HXJ;
P0A2U4	IPGC_SHIFL	reviewed	Chaperone protein IpgC	ipgC ippI CP0129	Shigella flexneri	155						P0A2U4;		3GYZ;3GZ1;3GZ2;3KS2;6SCB;
Q5SBN3	Q5SBN3_LACRE	unreviewed	Dextransucrase (EC 2.4.1.5) (Sucrose 6-glucosyltransferase)		Lactobacillus reuteri	1772								3HZ3;3KLK;3KLL;4AYG;
P38181	NU170_YEAST	reviewed	Nucleoporin NUP170 (Nuclear pore protein NUP170)	NUP170 NLE3 YBL079W YBL0725	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1502						P38181;	4932.YBL079W;	3I5P;3I5Q;
Q96MX6	DAA10_HUMAN	reviewed	Dynein axonemal assembly factor 10 (WD repeat-containing protein 92) (WD repeat-containing protein Monad)	DNAAF10 WDR92	Homo sapiens (Human)	357						Q96MX6;	9606.ENSP00000477980;	3I2N;
O94258	XPOT_SCHPO	reviewed	Exportin-T (Exportin(tRNA)) (Karyopherin-beta) (tRNA exportin)	los1 SPBP8B7.09c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	978						O94258;	4896.SPBP8B7.09c.1;	3IBV;3ICQ;
Q5LM96	Q5LM96_RUEPO	unreviewed	Muconate cycloisomerase I (EC 5.5.1.1)	catB SPO3667	Ruegeria pomeroyi (strain ATCC 700808 / DSM 15171 / DSS-3) (Silicibacter pomeroyi)	376							246200.SPO3667;	3I6E;
Q9KMS8	Q9KMS8_VIBCH	unreviewed	Hexulose-6-phosphate synthase SgbH, putative	VC_A0242	Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)	215							243277.VC_A0242;	3IEB;3JR2;
P25822	PUM_DROME	reviewed	Maternal protein pumilio	pum CG9755	Drosophila melanogaster (Fruit fly)	1533				DISRUPTION PHENOTYPE: Flies display defective abdomen pattern formation and are embryonic lethal. {ECO:0000269|PubMed:1459455}.	"MUTAGEN 1127;  /note=""R->A: Disrupts RNA-binding."";  /evidence=""ECO:0000269|PubMed:11336677""; MUTAGEN 1167;  /note=""K->A: Disrupts RNA-binding."";  /evidence=""ECO:0000269|PubMed:11336677""; MUTAGEN 1199;  /note=""R->A: Disrupts RNA-binding."";  /evidence=""ECO:0000269|PubMed:11336677""; MUTAGEN 1235;  /note=""H->A: Disrupts RNA-binding."";  /evidence=""ECO:0000269|PubMed:11336677""; MUTAGEN 1330;  /note=""G->D: In Pum680; abolishes interaction with brat and translational repression activity but not RNA-binding activity."";  /evidence=""ECO:0000269|PubMed:11336677, ECO:0000269|PubMed:9660969""; MUTAGEN 1346;  /note=""E->K: Disrupts RNA-binding."";  /evidence=""ECO:0000269|PubMed:11336677""; MUTAGEN 1365;  /note=""C->R: Abolishes interaction with brat."";  /evidence=""ECO:0000269|PubMed:11336677""; MUTAGEN 1366;  /note=""T->D: Abolishes interaction with brat."";  /evidence=""ECO:0000269|PubMed:11336677""; MUTAGEN 1367;  /note=""F->S: Abolishes interaction with nos."";  /evidence=""ECO:0000269|PubMed:11336677""; MUTAGEN 1368;  /note=""N->S: Abolishes interaction with brat."";  /evidence=""ECO:0000269|PubMed:11336677"""	P25822;	7227.FBpp0305823;	3H3D;5KL1;5KL8;5KLA;
Q8ZLQ7	NANE2_SALTY	reviewed	Putative N-acetylmannosamine-6-phosphate 2-epimerase 2 (EC 5.1.3.9) (ManNAc-6-P epimerase 2)	nanE2 STM3337	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	229								3IGS;
Q13042	CDC16_HUMAN	reviewed	Cell division cycle protein 16 homolog (Anaphase-promoting complex subunit 6) (APC6) (CDC16 homolog) (CDC16Hs) (Cyclosome subunit 6)	CDC16 ANAPC6	Homo sapiens (Human)	620						Q13042;	9606.ENSP00000353549;	3HYM;4UI9;5A31;5G04;5G05;5KHR;5KHU;5L9T;5L9U;5LCW;6Q6G;6Q6H;6TLJ;6TM5;6TNT;
Q8IXQ5	KLHL7_HUMAN	reviewed	Kelch-like protein 7	KLHL7	Homo sapiens (Human)	586			DISEASE: Perching syndrome (PERCHING) [MIM:617055]: An autosomal recessive multisystem disorder characterized by global developmental delay, dysmorphic facial features, feeding and respiratory difficulties with poor overall growth, axial hypotonia, and joint contractures. The features are variable, even within families, and may also include retinitis pigmentosa, cardiac or genitourinary anomalies, and abnormal sweating. {ECO:0000269|PubMed:27392078}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Retinitis pigmentosa 42 (RP42) [MIM:612943]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:19520207, ECO:0000269|PubMed:20547956, ECO:0000269|PubMed:21828050, ECO:0000269|PubMed:22084217}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q8IXQ5;	9606.ENSP00000343273;	3II7;
P14923	PLAK_HUMAN	reviewed	Junction plakoglobin (Catenin gamma) (Desmoplakin III) (Desmoplakin-3)	JUP CTNNG DP3	Homo sapiens (Human)	745			DISEASE: Naxos disease (NXD) [MIM:601214]: An autosomal recessive disorder characterized by the association of diffuse non-epidermolytic palmoplantar keratoderma with woolly hair and cardiac abnormalities such as dilated cardiomyopathy and arrhythmogenic right ventricular dysplasia. {ECO:0000269|PubMed:10902626}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Arrhythmogenic right ventricular dysplasia, familial, 12 (ARVD12) [MIM:611528]: A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias. {ECO:0000269|PubMed:17924338, ECO:0000269|PubMed:20031617}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 14;  /note=""T->A: Abolishes glycosylation. Does not affect binding to CDH1, DSC1 or DSG1."";  /evidence=""ECO:0000269|PubMed:12847106""; MUTAGEN 19;  /note=""T->A: Reduces glycosylation."";  /evidence=""ECO:0000269|PubMed:12847106""; MUTAGEN 21;  /note=""T->A: Does not affect glycosylation."";  /evidence=""ECO:0000269|PubMed:12847106""; MUTAGEN 24;  /note=""S->A: Does not affect glycosylation."";  /evidence=""ECO:0000269|PubMed:12847106""; MUTAGEN 28;  /note=""S->A: Does not affect glycosylation."";  /evidence=""ECO:0000269|PubMed:12847106""; MUTAGEN 32;  /note=""T->A: Does not affect glycosylation."";  /evidence=""ECO:0000269|PubMed:12847106"""	P14923;	9606.ENSP00000377508;	3IFQ;
Q8A861	AEEP_BACTN	reviewed	L-Ala-D/L-Glu epimerase (AE epimerase) (AEE) (EC 5.1.1.20)	BT_1313	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	383							226186.BT_1313;	3IJI;3IJL;3IJQ;
Q5NGP6	Q5NGP6_FRATT	unreviewed	Ribulose-phosphate 3-epimerase (EC 5.1.3.1)	rpe FTT_0789	Francisella tularensis subsp. tularensis (strain SCHU S4 / Schu 4)	222								3INP;
A9B055	AREP_HERA2	reviewed	Aromatic dipeptide epimerase (EC 5.1.1.-)	Haur_1114	Herpetosiphon aurantiacus (strain ATCC 23779 / DSM 785 / 114-95)	356							316274.Haur_1114;	3IK4;
Q9X6R4	Q9X6R4_AERCA	unreviewed	Prolyl endopeptidase		Aeromonas caviae (Aeromonas punctata)	690								3IUJ;3IUL;3IUM;3IUN;3IUQ;3IUR;3IVM;3MUN;3MUO;
Q9Y823	HOSM_SCHPO	reviewed	Homocitrate synthase, mitochondrial (HCS) (EC 2.3.3.14)	lys4 SPBC1105.02c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	418							4896.SPBC1105.02c.1;	3IVS;3IVT;3IVU;3MI3;
O75530	EED_HUMAN	reviewed	Polycomb protein EED (hEED) (Embryonic ectoderm development protein) (WD protein associating with integrin cytoplasmic tails 1) (WAIT-1)	EED	Homo sapiens (Human)	441			DISEASE: Cohen-Gibson syndrome (COGIS) [MIM:617561]: An autosomal dominant overgrowth disorder characterized by accelerated osseous maturation, advanced bone age, skeletal abnormalities including flaring of the metaphyses of the long bones, large hands with long fingers and camptodactyly, scoliosis, cervical spine anomalies, dysmorphic facial features, and variable intellectual disability. {ECO:0000269|PubMed:25787343, ECO:0000269|PubMed:27193220, ECO:0000269|PubMed:27868325, ECO:0000269|PubMed:28229514, ECO:0000269|PubMed:28475857}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 97;  /note=""F->A: Abolishes binding to H3K27me3."";  /evidence=""ECO:0000269|PubMed:20974918""; MUTAGEN 148;  /note=""Y->A: Abolishes binding to H3K27me3."";  /evidence=""ECO:0000269|PubMed:20974918""; MUTAGEN 193;  /note=""I->N: Impairs interaction with EZH2."";  /evidence=""ECO:0000269|PubMed:9584199""; MUTAGEN 196;  /note=""L->P: Impairs interaction with EZH2."";  /evidence=""ECO:0000269|PubMed:9584199""; MUTAGEN 300..301;  /note=""ST->AA: Impairs interaction with the matrix protein MA of HIV-1."";  /evidence=""ECO:0000269|PubMed:9880543""; MUTAGEN 305..308;  /note=""HRNY->AAAA: Impairs interaction with the matrix protein MA of HIV-1."";  /evidence=""ECO:0000269|PubMed:9880543""; MUTAGEN 364;  /note=""W->A: Abolishes binding to H3K27me3."";  /evidence=""ECO:0000269|PubMed:20974918""; MUTAGEN 364;  /note=""W->L: Abolishes binding to H3K27me3."";  /evidence=""ECO:0000269|PubMed:20974918""; MUTAGEN 365;  /note=""Y->A: Abolishes binding to H3K27me3."";  /evidence=""ECO:0000269|PubMed:20974918"""	O75530;	9606.ENSP00000263360;	3IIW;3IIY;3IJ0;3IJ1;3IJC;3JPX;3JZG;3JZH;3JZN;3K26;3K27;4W2R;4X3E;5GSA;5H13;5H14;5H15;5H17;5H19;5H24;5H25;5HYN;5IJ7;5IJ8;5K0M;5LS6;5TTW;5U5H;5U5K;5U5T;5U62;5U69;5U6D;5U8A;5U8F;5WG6;5WP3;5WUK;6B3W;6C23;6C24;6SFB;6SFC;6U4Y;6V3X;6V3Y;6W7F;6W7G;6WKR;6YVI;6YVJ;7KSO;7KSR;7KTP;7KXT;
Q12250	RPN5_YEAST	reviewed	26S proteasome regulatory subunit RPN5 (Proteasome non-ATPase subunit 5)	RPN5 NAS5 YDL147W D1572	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	445						Q12250;	4932.YDL147W;	3J47;3JCK;3JCO;3JCP;4CR2;4CR3;4CR4;5A5B;5MPB;5MPC;5MPD;5MPE;5WVI;5WVK;5ZMR;6FVT;6FVU;6FVV;6FVW;6FVX;6FVY;6J2C;6J2N;6J2Q;6J2X;6J30;
Q12377	RPN6_YEAST	reviewed	26S proteasome regulatory subunit RPN6 (Proteasome non-ATPase subunit 4)	RPN6 NAS4 YDL097C D2381	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	434					"MUTAGEN 132;  /note=""F->L: In rpn6-2; temperature-sensitive mutant that shows defects in proteasome assembly when incubated at 37 degrees Celsius; when associated with P-377."";  /evidence=""ECO:0000269|PubMed:15611133""; MUTAGEN 377;  /note=""L->P: In rpn6-2; temperature-sensitive mutant that shows defects in proteasome assembly when incubated at 37 degrees Celsius; when associated with L-132."";  /evidence=""ECO:0000269|PubMed:15611133"""	Q12377;	4932.YDL097C;	3J47;3JCK;3JCO;3JCP;4CR2;4CR3;4CR4;5A5B;5MPB;5MPC;5MPD;5MPE;5WVI;5WVK;6FVT;6FVU;6FVV;6FVW;6FVX;6FVY;6J2C;6J2N;6J2Q;6J2X;6J30;
Q6CNI7	Q6CNI7_KLULA	unreviewed	KLLA0E12277p	KLLA0_E12277g	Kluyveromyces lactis (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-1140 / WM37) (Yeast) (Candida sphaerica)	326							28985.XP_454502.1;	3J80;3J81;3JAM;3JAP;3JAQ;5IT7;5IT9;6FYX;6FYY;6GSM;6GSN;6UZ7;
Q9NTM9	CUTC_HUMAN	reviewed	Copper homeostasis protein cutC homolog	CUTC CGI-32	Homo sapiens (Human)	273					"MUTAGEN 31;  /note=""C->A: Reduces copper binding. Reduces copper binding by 75%; when associated with A-52."";  /evidence=""ECO:0000269|PubMed:19878721""; MUTAGEN 52;  /note=""C->A: Reduces copper binding. Reduces copper binding by 75%; when associated with A-31."";  /evidence=""ECO:0000269|PubMed:19878721"""	Q9NTM9;	9606.ENSP00000359507;	3IWP;
Q91YW3	DNJC3_MOUSE	reviewed	DnaJ homolog subfamily C member 3 (Interferon-induced, double-stranded RNA-activated protein kinase inhibitor) (Protein kinase inhibitor of 58 kDa) (Protein kinase inhibitor p58)	Dnajc3 P58ipk	Mus musculus (Mouse)	504					"MUTAGEN 48;  /note=""L->D: Reduces binding affinity for misfolded proteins by 40%."";  /evidence=""ECO:0000269|PubMed:20184891""; MUTAGEN 71;  /note=""Y->A: Reduces binding affinity for misfolded proteins by 40%."";  /evidence=""ECO:0000269|PubMed:20184891""; MUTAGEN 75;  /note=""Y->H: Reduces binding affinity for misfolded proteins by 40%."";  /evidence=""ECO:0000269|PubMed:20184891""; MUTAGEN 104;  /note=""F->A: Reduces binding affinity for misfolded proteins by 40%."";  /evidence=""ECO:0000269|PubMed:20184891""; MUTAGEN 186;  /note=""W->A: Doesn't affect binding of misfolded proteins."";  /evidence=""ECO:0000269|PubMed:20184891"""	Q91YW3;	10090.ENSMUSP00000022734;	3IEG;
O60602	TLR5_HUMAN	reviewed	Toll-like receptor 5 (Toll/interleukin-1 receptor-like protein 3)	TLR5 TIL3	Homo sapiens (Human)	858			DISEASE: Systemic lupus erythematosus 1 (SLEB1) [MIM:601744]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.			O60602;	9606.ENSP00000440643;	1P95;3J0A;
P54921	SNAA_RAT	reviewed	Alpha-soluble NSF attachment protein (SNAP-alpha) (N-ethylmaleimide-sensitive factor attachment protein alpha)	Napa Snap Snapa	Rattus norvegicus (Rat)	295						P54921;	10116.ENSRNOP00000002044;	3J96;3J97;3J98;3J99;6MDM;6MDN;
P06103	EIF3B_YEAST	reviewed	Eukaryotic translation initiation factor 3 subunit B (eIF3b) (Cell cycle regulation and translation initiation protein) (Eukaryotic translation initiation factor 3 90 kDa subunit) (eIF3 p90) (Translation initiation factor eIF3 p90 subunit)	PRT1 CDC63 YOR361C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	763					"MUTAGEN 124..130;  /note=""KGFLFVE->AAAAAAA: Impairs interaction with HCR1 and TIF32, impairs interaction of the eIF-3 complex with eIF-1, eIF-2 and the 40S ribosome, and impairs initiation of translation."";  /evidence=""ECO:0000269|PubMed:16581774"""	P06103;	4932.YOR361C;	3JAP;3JAQ;3NS5;3NS6;3ZWL;4U1E;4U1F;6FYX;6FYY;6GSM;6GSN;6ZCE;6ZU9;
P40217	EIF3I_YEAST	reviewed	Eukaryotic translation initiation factor 3 subunit I (eIF3i) (Eukaryotic translation initiation factor 3 39 kDa subunit) (eIF-3 39 kDa subunit) (eIF3 p39)	TIF34 YMR146C YM9375.16C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	347						P40217;	4932.YMR146C;	3JAP;3JAQ;3ZWL;5A5U;6FYX;6FYY;6GSM;6GSN;6ZCE;6ZU9;
O13615	PRP46_SCHPO	reviewed	Pre-mRNA-splicing factor prp5 (Complexed with cdc5 protein 1) (Pre-mRNA-processing protein 5)	prp5 cwf1 pi024 SPBP22H7.07	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	473						O13615;	4896.SPBP22H7.07.1;	3JB9;
O94620	CWF17_SCHPO	reviewed	Pre-mRNA-splicing factor cwf17 (Complexed with cdc5 protein 17)	cwf17 SPBC1289.11	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	340						O94620;	4896.SPBC1289.11.1;	3JB9;
Q9USX8	RU2A_SCHPO	reviewed	U2 small nuclear ribonucleoprotein A' (U2 snRNP A')	lea1 SPBC1861.08c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	239						Q9USX8;	4896.SPBC1861.08c.1;	3JB9;
O14011	PRP19_SCHPO	reviewed	Pre-mRNA-processing factor 19 (EC 2.3.2.27) (Complexed with cdc5 protein 8) (RING-type E3 ubiquitin transferase PRP19)	prp19 cwf8 SPAC29A4.08c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	488						O14011;	4896.SPAC29A4.08c.1;	3JB9;
Q3UP24	NLRC4_MOUSE	reviewed	NLR family CARD domain-containing protein 4 (Caspase recruitment domain-containing protein 12) (Ice protease-activating factor) (Ipaf)	Nlrc4 Card12 Ipaf	Mus musculus (Mouse)	1024				DISRUPTION PHENOTYPE: Mice show defects in inflammasome function in response to S.typhimurium (Salmonella) infection. Differences are however observed depending on the strain background: in a C57BL/6J strain background, no striking differences are observed compared to wild-type mice following Salmonella infection. While in a BALB/c strain background, mice are highly susceptible to orogastric but not intraperitoneal infection with Salmonella: enhanced lethality is preceded by impaired expression of endothelial adhesion molecules, lower neutrophil recruitment and poor intestinal pathogen clearance. {ECO:0000269|PubMed:15190255, ECO:0000269|PubMed:16717117, ECO:0000269|PubMed:22484733}.	"MUTAGEN 443;  /note=""H->L: Constitutively active."";  /evidence=""ECO:0000269|PubMed:23765277""; MUTAGEN 533;  /note=""S->A: Abolishes phosphorylation and prevents activation of caspase-1 and pyroptosis in response to S.typhimurium."";  /evidence=""ECO:0000269|PubMed:22885697""; MUTAGEN 533;  /note=""S->D: Mimics phosphorylation; causes rapid macrophage pyroptosis without infection."";  /evidence=""ECO:0000269|PubMed:22885697"""	Q3UP24;	10090.ENSMUSP00000059637;	3JBL;4KXF;5AJ2;6B5B;
P20053	PRP4_YEAST	reviewed	U4/U6 small nuclear ribonucleoprotein PRP4 (Pre-mRNA-processing protein 4)	PRP4 RNA4 YPR178W P9705.6	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	465						P20053;	4932.YPR178W;	3JCM;5GAN;5GAP;5NRL;5ZWM;5ZWO;
O13034	RAG2_DANRE	reviewed	V(D)J recombination-activating protein 2 (RAG-2)	rag2 rag-2	Danio rerio (Zebrafish) (Brachydanio rerio)	530							7955.ENSDARP00000068402;	3JBW;3JBX;3JBY;6DBI;6DBJ;6DBL;6DBO;6DBQ;6DBR;6DBT;6DBU;6DBV;6DBW;6DBX;
P19735	PRP6_YEAST	reviewed	Pre-mRNA-splicing factor 6	PRP6 RNA6 YBR055C YBR0508	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	899						P19735;	4932.YBR055C;	3JCM;5GAN;5GAP;5NRL;5ZWM;5ZWO;
P32565	RPN2_YEAST	reviewed	26S proteasome regulatory subunit RPN2	RPN2 SEN3 YIL075C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	945						P32565;	4932.YIL075C;	3JCO;3JCP;4ADY;4CR2;4CR3;4CR4;5A5B;5MPB;5MPC;5MPD;5MPE;5WVI;5WVK;6FVT;6FVU;6FVV;6FVW;6FVX;6FVY;6J2C;6J2N;6J2Q;6J2X;6J30;
P25382	NLE1_YEAST	reviewed	Ribosome assembly protein 4 (Notchless protein homolog 1) (Ribosome biogenesis factor RSA4)	RSA4 YCR072C YCR72C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	515					"MUTAGEN 114;  /note=""E->A: Impairs interaction with MDN1."";  /evidence=""ECO:0000269|PubMed:19737519""; MUTAGEN 114;  /note=""E->D: Impairs interaction with MDN1. Blocks progression of the nascent pre-60S subunit and subsequent export to the cytoplasm."";  /evidence=""ECO:0000269|PubMed:19737519""; MUTAGEN 448;  /note=""Y->E: Impairs interaction with NSA2."";  /evidence=""ECO:0000269|PubMed:25404745"""	P25382;	4932.YCR072C;	3JCT;4V7F;4WJU;4WJV;5FL8;5JCS;6FT6;6M62;6YLF;6YLG;6YLH;7BT6;7BTB;
P12359	PSBO_SPIOL	reviewed	Oxygen-evolving enhancer protein 1, chloroplastic (OEE1) (33 kDa subunit of oxygen evolving system of photosystem II) (33 kDa thylakoid membrane protein) (OEC 33 kDa subunit)	PSBO	Spinacia oleracea (Spinach)	332						P12359;		3JCU;
O75762	TRPA1_HUMAN	reviewed	Transient receptor potential cation channel subfamily A member 1 (Ankyrin-like with transmembrane domains protein 1) (Transformation-sensitive protein p120) (Wasabi receptor)	TRPA1 ANKTM1	Homo sapiens (Human)	1119			DISEASE: Episodic pain syndrome, familial, 1 (FEPS1) [MIM:615040]: An autosomal dominant neurologic disorder characterized by onset in infancy of episodic debilitating upper body pain triggered by fasting, cold, and physical stress. The period of intense pain is accompanied by breathing difficulties, tachycardia, sweating, generalized pallor, peribuccal cyanosis, and stiffness of the abdominal wall. Affected individuals do not manifest altered pain sensitivity outside the episodes. {ECO:0000269|PubMed:20547126}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 173;  /note=""C->S: Decrease in activation by hyperoxia and diallyl disulfide."";  /evidence=""ECO:0000269|PubMed:21873995""; MUTAGEN 192;  /note=""C->S: Decrease in activation by hyperoxia and diallyl disulfide."";  /evidence=""ECO:0000269|PubMed:21873995""; MUTAGEN 394;  /note=""P->A: Loss of answer to hypoxia and hydroxylase inhibitor DMOG, but not to AITC and hyperoxia."";  /evidence=""ECO:0000269|PubMed:21873995""; MUTAGEN 620;  /note=""K->A: Important decrease in electrophile-evoked response."";  /evidence=""ECO:0000269|PubMed:27241698""; MUTAGEN 621;  /note=""C->A,S: Decrease in electrophile-evoked response. No change in answer to hyperoxia and diallyl disulfide. In TRPA1-3C-K708R/Q; loss in irritant-evoked response."";  /evidence=""ECO:0000269|PubMed:17164327, ECO:0000269|PubMed:21873995, ECO:0000269|PubMed:27241698, ECO:0000269|PubMed:30878828""; MUTAGEN 622;  /note=""P->A: Loss of activation by the scorpion wasabi receptor toxin."";  /evidence=""ECO:0000269|PubMed:31447178""; MUTAGEN 633;  /note=""C->S: Decrease in activation by hyperoxia and diallyl disulfide. Important decrease in activation by hyperoxia and diallyl disulfide; when associated with S-856."";  /evidence=""ECO:0000269|PubMed:21873995""; MUTAGEN 634;  /note=""M->L: Loss of activation by the scorpion wasabi receptor toxin."";  /evidence=""ECO:0000269|PubMed:31447178""; MUTAGEN 641;  /note=""C->A,S: Decrease in electrophile-evoked and hyperoxia response. In TRPA1-3C-K708R/Q; loss in irritant-evoked response."";  /evidence=""ECO:0000269|PubMed:17164327, ECO:0000269|PubMed:21873995""; MUTAGEN 646;  /note=""T->P: Loss of activation by the scorpion wasabi receptor toxin."";  /evidence=""ECO:0000269|PubMed:31447178""; MUTAGEN 665;  /note=""C->A,L,S: Decrease in electrophile-evoked and hyperoxia response. In TRPA1-3C-K708R/Q; loss in irritant-evoked response."";  /evidence=""ECO:0000269|PubMed:17164327, ECO:0000269|PubMed:21873995, ECO:0000269|PubMed:27241698""; MUTAGEN 710;  /note=""K->R,Q: No change in electrophile sensitivity. In TRPA1-3C-K708R/Q; loss in irritant-evoked response.""; MUTAGEN 856;  /note=""C->S: Decrease in activation by hyperoxia and diallyl disulfide. Important decrease in activation by hyperoxia and diallyl disulfide; when associated with S-633."";  /evidence=""ECO:0000269|PubMed:21873995""; MUTAGEN 909;  /note=""F->A,T: Loss of inhibition by A-967079, AP-18, and ASD. Increase in activation by cinnamaldehyde, AITC and acrolein."";  /evidence=""ECO:0000269|PubMed:25855297, ECO:0000269|PubMed:30878828""; MUTAGEN 944;  /note=""F->A: Loss of inhibition by A-967079, AP-18, and ASD. Weak or no change in activation by cinnamaldehyde, AITC and acrolein."";  /evidence=""ECO:0000269|PubMed:30878828"""	O75762;	9606.ENSP00000262209;	3J9P;6HC8;6PQO;6PQP;6PQQ;6V9V;6V9W;6V9X;6V9Y;6WJ5;6X2J;7JUP;
A1ADJ6	NEUO_ECOK1	reviewed	Polysialic acid O-acetyltransferase (EC 2.3.1.136) (Capsule O-acetyl transferase)	neuO APECO1_4217	Escherichia coli O1:K1 / APEC	307					"MUTAGEN 210;  /note=""H->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17519228""; MUTAGEN 234;  /note=""W->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:17519228"""			3JQY;
Q186A6	AROD_CLOD6	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD CD630_22170	Clostridioides difficile (strain 630) (Peptoclostridium difficile)	255							272563.CD630_22170;	3JS3;4H3D;
Q9WYR8	Q9WYR8_THEMA	unreviewed	Exo-poly-alpha-D-galacturonosidase, putative	TM_0437	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	448								3JUR;
A6LGH9	A6LGH9_PARD8	unreviewed	Putative lipoprotein	BDI_3087	Parabacteroides distasonis (strain ATCC 8503 / DSM 20701 / CIP 104284 / JCM 5825 / NCTC 11152)	269							435591.BDI_3087;	3JX8;
Q97IW1	Q97IW1_CLOAB	unreviewed	Beta-xylosidase, family 43 glycosyl hydrolase	CA_C1529	Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787)	327							272562.CA_C1529;	3K1U;
Q834W6	HYEP_ENTFA	reviewed	Hydrophobic dipeptide epimerase (EC 5.1.1.-)	EF_1511 I574_01909 OO5_01959	Enterococcus faecalis (strain ATCC 700802 / V583)	354							226185.EF_1511;	3JVA;3JW7;3JZU;3K1G;3KUM;
A0A1D5PXA5	TRPV4_CHICK	reviewed	Transient receptor potential cation channel subfamily V member 4 (TrpV4) (Vanilloid receptor-related osmotically activated channel) (VR-OAC)	TRPV4	Gallus gallus (Chicken)	852					"MUTAGEN 178;  /note=""K->A: Strongly decreased affinity for ATP and Ca(2+)-calmodulin. Abolishes ATP-mediated increase in channel sensitivity to agonists."";  /evidence=""ECO:0000269|PubMed:19864432""; MUTAGEN 183;  /note=""K->A: Strongly decreased affinity for ATP and slightly decreased affinity for Ca(2+)-calmodulin."";  /evidence=""ECO:0000269|PubMed:19864432""; MUTAGEN 205;  /note=""K->A: No significant effect on affinity for ATP and Ca(2+)-calmodulin."";  /evidence=""ECO:0000269|PubMed:19864432"""		9031.ENSGALP00000008256;	3JXI;3JXJ;3W9F;3W9G;6F55;
Q07807	PUF3_YEAST	reviewed	mRNA-binding protein PUF3 (Pumilio homology domain family member 3)	PUF3 YLL013C L1325	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	879					"MUTAGEN 553;  /note=""S->C: Prevents binding to COX17 mRNA and its rapid decay and increases affinity to HO mRNA, a PUF5 target."";  /evidence=""ECO:0000269|PubMed:16244132"""	Q07807;	4932.YLL013C;	3K49;3K4E;
Q09312	FBF2_CAEEL	reviewed	Fem-3 mRNA-binding factor 2	fbf-2 F21H12.5	Caenorhabditis elegans	632					"MUTAGEN 28;  /note=""P->A: Abolishes interaction with dlc-1."";  /evidence=""ECO:0000269|PubMed:27864381""; MUTAGEN 136;  /note=""S->A,D: Abolishes interaction with dlc-1."";  /evidence=""ECO:0000269|PubMed:27864381""; MUTAGEN 137;  /note=""K->A,D: Abolishes interaction with dlc-1."";  /evidence=""ECO:0000269|PubMed:27864381""; MUTAGEN 139..140;  /note=""Missing: Abolishes interaction with dlc-1."";  /evidence=""ECO:0000269|PubMed:27864381""; MUTAGEN 607..632;  /note=""Missing: Abolishes interaction with dlc-1."";  /evidence=""ECO:0000269|PubMed:27864381"""	Q09312;	6239.F21H12.5;	3K5Q;3K5Y;3K5Z;3K61;3K62;3K64;3QG9;3QGB;3QGC;3V6Y;3V74;6NOC;6NOF;6NOH;6PUN;
Q12745	SEC39_YEAST	reviewed	Protein transport protein SEC39 (Dependent on SLY1-20 protein 3)	SEC39 DSL3 YLR440C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	709						Q12745;	4932.YLR440C;	3K8P;
Q9KFK0	Q9KFK0_ALKHC	unreviewed	BH0479 protein	BH0479	Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) (Bacillus halodurans)	164							272558.10173092;	3K9I;
Q8SQV4	Q8SQV4_ENCCU	unreviewed	POSSIBLE PROTEIN OF NUCLEAR SCAFFOLD	ECU11_1160	Encephalitozoon cuniculi (strain GB-M1) (Microsporidian parasite)	475								3KAE;
Q6IV60	Q6IV60_9POXV	unreviewed	K1L	K1L	Vaccinia virus	284								3KEA;
Q3S340	Q3S340_9INFB	unreviewed	Neuraminidase (EC 3.2.1.18)		Influenza B virus (B/Perth/211/2001)	466								3K36;3K37;3K38;3K39;3K3A;
Q5CPK7	Q5CPK7_CRYPI	unreviewed	Inosine-5-monophosphate dehydrogenase (EC 1.1.1.205) (Fragment)	cgd6_20	Cryptosporidium parvum (strain Iowa II)	402								3KHJ;
Q99M75	RTN4R_RAT	reviewed	Reticulon-4 receptor (Nogo receptor) (NgR) (Nogo-66 receptor)	Rtn4r Nogor	Rattus norvegicus (Rat)	473						Q99M75;	10116.ENSRNOP00000041517;	3KJ4;
Q8DKB5	CCMM_THEEB	reviewed	Carboxysome assembly protein CcmM (CcmM70) (M70) (Carbon dioxide concentrating mechanism protein CcmM) (Carbonic anhydrase) (EC 4.2.1.1)	ccmM tll0944	Thermosynechococcus elongatus (strain BP-1)	652					"MUTAGEN 174..197;  /note=""DIHFAQHVVGINEALLSGYQCAEN->AYSHTNEAVVYVNVHLAEGYKETS: About 50% activity (in the CcmM 1-209 construct), not inhibited by reducing agents."";  /evidence=""ECO:0000269|PubMed:20133749""; MUTAGEN 200;  /note=""C->S: Loss of CA activity (in the CcmM 1-209 construct)."";  /evidence=""ECO:0000269|PubMed:20133749"""	Q8DKB5;	197221.22294667;	3KWC;3KWD;3KWE;6MR1;
Q8L1Z5	TPIS_BARHE	reviewed	Triosephosphate isomerase (TIM) (TPI) (EC 5.3.1.1) (Triose-phosphate isomerase)	tpiA BH05680	Bartonella henselae (strain ATCC 49882 / DSM 28221 / Houston 1) (Rochalimaea henselae)	254							283166.BH05680;	3KXQ;
O60486	PLXC1_HUMAN	reviewed	Plexin-C1 (Virus-encoded semaphorin protein receptor) (CD antigen CD232)	PLXNC1 VESPR	Homo sapiens (Human)	1568						O60486;	9606.ENSP00000258526;	3KUZ;3NVN;3NVQ;6VXK;
G1SJB4	G1SJB4_RABIT	unreviewed	Uncharacterized protein		Oryctolagus cuniculus (Rabbit)	424								3JAG;3JAH;3JAI;4D5L;4D61;4KZX;4KZY;4KZZ;5K0Y;5LZS;5LZT;5LZU;5LZV;5LZW;5LZX;5LZY;5LZZ;6D90;6D9J;6GZ3;6HCF;6HCJ;6HCM;6HCQ;6MTB;6MTC;6MTD;6MTE;6P4G;6P4H;6P5I;6P5J;6P5K;6P5N;6R5Q;6R6G;6R6P;6R7Q;6SGC;6W2S;6W2T;6YAL;6YAM;6YAN;6ZVK;7A01;7JQB;7JQC;
Q8VSC3	IPA9_SHIFL	reviewed	E3 ubiquitin-protein ligase ipaH9.8 (EC 2.3.2.27) (Invasion plasmid antigen ipaH9.8) (RING-type E3 ubiquitin transferase ipaH9.8)	ipaH9.8 CP0226 pWR501_0234 SFLP090	Shigella flexneri	545				DISRUPTION PHENOTYPE: In murine lung infection model, mutants cause severe inflammatory responses, with increased pro-inflammatory cytokine production levels. Colonization is greatly reduced. {ECO:0000269|PubMed:15950937}.	"MUTAGEN 163;  /note=""R->A: Abolishes proteasomal degradation of host proteins; when associated with A-187 and A-210."";  /evidence=""ECO:0000269|PubMed:24248594""; MUTAGEN 187;  /note=""F->A: Abolishes proteasomal degradation of host proteins; when associated with A-163 and A-210."";  /evidence=""ECO:0000269|PubMed:24248594""; MUTAGEN 210;  /note=""H->A: Abolishes proteasomal degradation of host proteins; when associated with A-163 and A-187."";  /evidence=""ECO:0000269|PubMed:24248594""; MUTAGEN 337;  /note=""C->A: Abolishes proteasomal degradation of host proteins."";  /evidence=""ECO:0000269|PubMed:18005683, ECO:0000269|PubMed:20010814, ECO:0000269|PubMed:24248594""; MUTAGEN 337;  /note=""C->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:18005683, ECO:0000269|PubMed:20010814, ECO:0000269|PubMed:24248594"""	Q8VSC3;		3L3P;5B0N;5B0T;6K2D;
Q8A3Q9	Q8A3Q9_BACTN	unreviewed	Endo-1,4-beta-xylanase	BT_2895	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	330							226186.BT_2895;	3KST;
P58687	AROD_SALTY	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (DHQD) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD STM1358	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	252					"MUTAGEN 86;  /note=""E->A: Very strong reduction of the catalytic efficiency and almost the same affinity for 3-dehydroquinate."";  /evidence=""ECO:0000269|PubMed:23341204""; MUTAGEN 86;  /note=""E->Q: Strong reduction of the catalytic efficiency and slight increase of the affinity for 3-dehydroquinate."";  /evidence=""ECO:0000269|PubMed:23341204""; MUTAGEN 170;  /note=""K->M: Abolishes enzyme activity and 1.5-fold reduction of the affinity for 3-dehydroquinate."";  /evidence=""ECO:0000269|PubMed:21087925, ECO:0000269|PubMed:24437575""; MUTAGEN 232;  /note=""S->A: Reduces enzyme activity 50-fold."";  /evidence=""ECO:0000269|PubMed:21291284""; MUTAGEN 236;  /note=""Q->A: Nearly abolishes enzyme activity."";  /evidence=""ECO:0000269|PubMed:21291284"""			3L2I;3LB0;3M7W;3NNT;3O1N;3OEX;3S42;4GFS;4GUF;4GUG;4GUH;4GUI;4GUJ;4IUO;
Q8DWL4	Q8DWL4_STRMU	unreviewed	Uncharacterized protein	SMU_31	Streptococcus mutans serotype c (strain ATCC 700610 / UA159)	206							210007.SMU_31;	3L9T;
A1BB97	A1BB97_PARDP	unreviewed	Methylamine dehydrogenase (amicyanin) (EC 1.4.9.1) (Methylamine dehydrogenase heavy chain)	Pden_4730	Paracoccus denitrificans (strain Pd 1222)	417						A1BB97;	318586.Pden_4730;	3L4M;3L4O;3ORV;3PXS;3PXT;3PXW;3RLM;3RMZ;3RN0;3RN1;3SJL;3SLE;3SVW;3SWS;3SXT;4FA1;4FA4;4FA5;4FA9;4FAN;4FAV;4FB1;4K3I;4L1Q;4L3G;4L3H;4O1Q;4Y5R;
Q9KQT7	PYRF_VIBCH	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF VC_1911	Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)	231							243277.VC_1911;	3LDV;3UWQ;
O60716	CTND1_HUMAN	reviewed	Catenin delta-1 (Cadherin-associated Src substrate) (CAS) (p120 catenin) (p120(ctn)) (p120(cas))	CTNND1 KIAA0384	Homo sapiens (Human)	968			DISEASE: Blepharocheilodontic syndrome 2 (BCDS2) [MIM:617681]: A form of blepharocheilodontic syndrome, a rare autosomal dominant disorder. It is characterized by lower eyelid ectropion, upper eyelid distichiasis, euryblepharon, bilateral cleft lip and palate, and features of ectodermal dysplasia, including hair anomalies, conical teeth and tooth agenesis. An additional rare manifestation is imperforate anus. There is considerable phenotypic variability among affected individuals. {ECO:0000269|PubMed:28301459}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 363;  /note=""W->A: Severely disrupts cadherin interaction."";  /evidence=""ECO:0000269|PubMed:20371349""; MUTAGEN 401;  /note=""K->M: Complete loss of cadherin interaction."";  /evidence=""ECO:0000269|PubMed:20371349""; MUTAGEN 444;  /note=""K->M: Severely disrupts cadherin interaction."";  /evidence=""ECO:0000269|PubMed:20371349""; MUTAGEN 477;  /note=""W->A: Severely disrupts cadherin interaction."";  /evidence=""ECO:0000269|PubMed:20371349""; MUTAGEN 478;  /note=""N->A: Complete loss of cadherin interaction."";  /evidence=""ECO:0000269|PubMed:20371349"""	O60716;	9606.ENSP00000382004;	3L6X;3L6Y;
E9ADW8	E9ADW8_LEIMA	unreviewed	Ankyrin_rpt-contain_dom domain-containing protein	LMJF_29_1100	Leishmania major	360								3LJN;
A6LIG9	A6LIG9_PARD8	unreviewed	AP_endonuc_2 domain-containing protein	BDI_3797	Parabacteroides distasonis (strain ATCC 8503 / DSM 20701 / CIP 104284 / JCM 5825 / NCTC 11152)	283							435591.BDI_3797;	3LMZ;
A6LGH7	A6LGH7_PARD8	unreviewed	DUF2807 domain-containing protein	BDI_3085	Parabacteroides distasonis (strain ATCC 8503 / DSM 20701 / CIP 104284 / JCM 5825 / NCTC 11152)	262							435591.BDI_3085;	3LJY;
Q8DUW4	AROD_STRMU	reviewed	3-dehydroquinate dehydratase (3-dehydroquinase) (EC 4.2.1.10) (Type I DHQase) (Type I dehydroquinase) (DHQ1)	aroD SMU_777	Streptococcus mutans serotype c (strain ATCC 700610 / UA159)	225							210007.SMU_777;	3L9C;
A6THF7	A6THF7_KLEP7	unreviewed	Putative periplasmic protein	KPN_04640	Klebsiella pneumoniae subsp. pneumoniae (strain ATCC 700721 / MGH 78578)	246								3M0Z;
C7B6Y3	C7B6Y3_PETMA	unreviewed	Variable lymphocyte receptor A diversity region (Fragment)		Petromyzon marinus (Sea lamprey)	250								3M18;
Q9PPB4	DAPA_CAMJE	reviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA Cj0806	Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168)	298						Q9PPB4;	192222.Cj0806;	3LER;3M5V;4LY8;4M19;4MLJ;4MLR;4R53;5F1U;5F1V;6TZU;6U01;
C7B6Z3	C7B6Z3_PETMA	unreviewed	Variable lymphocyte receptor A diversity region (Fragment)		Petromyzon marinus (Sea lamprey)	250								3M19;
G0S7T3	G0S7T3_CHATD	unreviewed	Uncharacterized protein	CTHT_0028730	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	329							209285.XP_006693329.1;	3LPZ;
Q812M4	Q812M4_BACCR	unreviewed	4-Hydroxy-2-oxoglutarate aldolase (EC 4.1.3.16)	BC_4844	Bacillus cereus (strain ATCC 14579 / DSM 31 / CCUG 7414 / JCM 2152 / NBRC 15305 / NCIMB 9373 / NCTC 2599 / NRRL B-3711)	251								3M6Y;
A0A0H3JME9	A0A0H3JME9_STAAN	unreviewed	Non-specific serine/threonine protein kinase (EC 2.7.11.1)	SA1063	Staphylococcus aureus (strain N315)	664								3M9G;4EQM;
Q96E29	MTEF3_HUMAN	reviewed	Transcription termination factor 3, mitochondrial (Mitochondrial transcription termination factor 3) (mTERF3) (mTERF domain-containing protein 1, mitochondrial)	MTERF3 MTERFD1 CGI-12	Homo sapiens (Human)	417						Q96E29;	9606.ENSP00000287025;	3M66;
A6LGH6	A6LGH6_PARD8	unreviewed	Putative lipoprotein	BDI_3084	Parabacteroides distasonis (strain ATCC 8503 / DSM 20701 / CIP 104284 / JCM 5825 / NCTC 11152)	266							435591.BDI_3084;	3LYC;
Q6GIL6	TPIS_STAAR	reviewed	Triosephosphate isomerase (TIM) (TPI) (EC 5.3.1.1) (Triose-phosphate isomerase)	tpiA tpi SAR0830	Staphylococcus aureus (strain MRSA252)	253								3M9Y;3UWU;3UWV;3UWW;3UWY;3UWZ;
O35305	TNR11_MOUSE	reviewed	Tumor necrosis factor receptor superfamily member 11A (Osteoclast differentiation factor receptor) (ODFR) (Receptor activator of NF-KB) (CD antigen CD265)	Tnfrsf11a Rank	Mus musculus (Mouse)	625						O35305;	10090.ENSMUSP00000027559;	3ME2;3ME4;3QBQ;4GIQ;5BNQ;
A6ZU46	A6ZU46_YEAS7	unreviewed	Coatomer subunit beta'	SEC27 SCY_1929	Saccharomyces cerevisiae (strain YJM789) (Baker's yeast)	889						A6ZU46;		3MKQ;
Q28104	COPE_BOVIN	reviewed	Coatomer subunit epsilon (Epsilon-coat protein) (Epsilon-COP)	COPE COPE1	Bos taurus (Bovine)	308						Q28104;	9913.ENSBTAP00000001071;	3MKR;
P53622	COPA_YEAST	reviewed	Coatomer subunit alpha (Alpha-coat protein) (Alpha-COP) (Retrieval from endoplasmic reticulum protein 1) (Secretory protein 22) (Suppressor of osmo-sensitivity 1)	COP1 RET1 SEC33 SOO1 YDL145C D1578	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1201						P53622;	4932.YDL145C;	3MKQ;3MV2;3MV3;6U3W;
Q7BCK4	ICSA_SHIFL	reviewed	Outer membrane protein IcsA autotransporter [Cleaved into: Outer membrane protein IcsA; Outer membrane protein IcsA translocator]	icsA virG CP0182	Shigella flexneri	1102					"MUTAGEN 40;  /note=""G->E: Disrupts targeting to outer membrane."";  /evidence=""ECO:0000269|PubMed:14507362""; MUTAGEN 44;  /note=""L->R: Disrupts targeting to outer membrane."";  /evidence=""ECO:0000269|PubMed:14507362""; MUTAGEN 45;  /note=""L->R: Disrupts targeting to outer membrane."";  /evidence=""ECO:0000269|PubMed:14507362""; MUTAGEN 50;  /note=""A->R: Disrupts targeting to outer membrane."";  /evidence=""ECO:0000269|PubMed:8537341""; MUTAGEN 52;  /note=""A->R: Disrupts targeting to outer membrane."";  /evidence=""ECO:0000269|PubMed:8537341""; MUTAGEN 756..762;  /note=""SSRRASS->WQDDAPR: Loss of phosphorylation."";  /evidence=""ECO:0000269|PubMed:1602963""; MUTAGEN 758..759;  /note=""RR->DD: Abolishes cleavage by IcsP. Loss of phosphorylation."";  /evidence=""ECO:0000269|PubMed:7896693""; MUTAGEN 758;  /note=""R->D: Abolishes cleavage by IcsP.""; MUTAGEN 759;  /note=""R->D: Loss of phosphorylation."""			3ML3;5KE1;
Q9USJ7	ETT1_SCHPO	reviewed	Negative regulator of ofd1	nro1 SPCC4B3.07	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	393						Q9USJ7;	4896.SPCC4B3.07.1;	3MSV;3QTM;3QTN;
A9IH93	A9IH93_BORPD	unreviewed	Lipopolysaccharides biosynthesis acetyltransferase (EC 2.3.1.-)	wlbB Bpet4817	Bordetella petrii (strain ATCC BAA-461 / DSM 12804 / CCUG 43448)	190							94624.Bpet4817;	3MQG;3MQH;
Q5LAR6	Q5LAR6_BACFN	unreviewed	Family of uncharacterized function (DUF3836) (Putative exported protein)	BF9343_3026 NCTC9343_00318	Bacteroides fragilis (strain ATCC 25285 / DSM 2151 / CCUG 4856 / JCM 11019 / NCTC 9343 / Onslow)	169							272559.BF9343_3026;	3MSW;
A0A6L7GXV7	A0A6L7GXV7_BACAN	unreviewed	Uncharacterized protein	GBAA_5098	Bacillus anthracis	251								3MUX;
P40509	COPE_YEAST	reviewed	Coatomer subunit epsilon (Epsilon-coat protein) (Epsilon-COP)	SEC28 YIL076W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	296						P40509;	4932.YIL076W;	3MV2;3MV3;6U3W;
A4AFX2	A4AFX2_9ACTN	unreviewed	Mandelate racemase/muconate lactonizing enzyme	A20C1_08358	marine actinobacterium PHSC20C1	388							312284.A20C1_08358;	3MSY;3NO1;4H83;
O22160	TL15A_ARATH	reviewed	Thylakoid lumenal 15 kDa protein 1, chloroplastic (p15)	At2g44920 T13E15.7	Arabidopsis thaliana (Mouse-ear cress)	224						O22160;	3702.AT2G44920.2;	3N90;
P30822	XPO1_YEAST	reviewed	Exportin-1 (Chromosome region maintenance protein 1) (Karyopherin-124)	CRM1 KAP124 XPO1 YGR218W G8514	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1084						P30822;	4932.YGR218W;	3M1I;3VYC;3WYF;3WYG;4GMX;4GPT;4HAT;4HAU;4HAV;4HAW;4HAX;4HAY;4HAZ;4HB0;4HB2;4HB3;4HB4;5DH9;5DHA;5DHF;5DI9;5DIF;5JLJ;5UWH;5UWI;5UWJ;5UWO;5UWP;5UWQ;5UWR;5UWS;5UWT;5UWU;5UWW;5XOJ;5YRO;5YST;5YSU;5YTB;5ZPU;6A38;6A3A;6A3B;6A3C;6A3E;6CIT;6KFT;6LQ9;6M60;6M6X;6X2M;6X2O;6X2P;6X2R;6X2S;6X2U;6X2V;6X2W;6X2X;6X2Y;6XJP;6XJR;6XJS;6XJT;6XJU;7L5E;
Q9I6R5	Q9I6R5_PSEAE	unreviewed	Probable dihydrodipicolinate synthetase	PA0223	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	293								3NA8;
Q9KST7	TRPA_VIBCH	reviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA VC_1169	Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)	268							243277.VC_1169;	3NAV;
P25171	RCC1_DROME	reviewed	Regulator of chromosome condensation (Chromatin-binding protein Bj1) (Regulator of chromosome condensation 1 ortholog)	Rcc1 Bj1 CG10480	Drosophila melanogaster (Fruit fly)	547						P25171;	7227.FBpp0076782;	3MVD;
A0QQY7	A0QQY7_MYCS2	unreviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC MSMEG_0922	Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) (Mycobacterium smegmatis)	227							246196.MSMEI_0900;	3NDO;
A0QLL2	DEOC_MYCA1	reviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC MAV_4672	Mycobacterium avium (strain 104)	223								3NG3;
C4M5C6	C4M5C6_ENTHI	unreviewed	2-deoxy-D-ribose 5-phosphate aldolase (EC 4.1.2.4) (Phosphodeoxyriboaldolase)	EHI_121800	Entamoeba histolytica	218								3NGJ;
Q07866	KLC1_HUMAN	reviewed	Kinesin light chain 1 (KLC 1)	KLC1 KLC KNS2	Homo sapiens (Human)	573					"MUTAGEN 521;  /note=""S->A,D: No effect on motor function; when associated with A/D-524."";  /evidence=""ECO:0000269|PubMed:20074060""; MUTAGEN 524;  /note=""S->A,D: No effect on motor function; when associated with A/D-521."";  /evidence=""ECO:0000269|PubMed:20074060"""	Q07866;	9606.ENSP00000414982;	3NF1;5OJ8;
P78406	RAE1L_HUMAN	reviewed	mRNA export factor (Rae1 protein homolog) (mRNA-associated protein mrnp 41)	RAE1 MRNP41	Homo sapiens (Human)	368						P78406;	9606.ENSP00000379182;	3MMY;4OWR;
Q471D6	Q471D6_CUPPJ	unreviewed	Uncharacterized protein	Reut_A1631	Cupriavidus pinatubonensis (strain JMP 134 / LMG 1197) (Cupriavidus necator (strain JMP 134))	274								3NO5;
P35077	FHAC_BORPE	reviewed	Filamentous hemagglutinin transporter protein FhaC (TpsB transporter)	fhaC BP1884	Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251)	584						P35077;	257313.BP1884;	3NJT;4QKY;4QL0;
Q9I4W3	DAPA_PSEAE	reviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA PA1010	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	292								3NOE;3PS7;3PUO;3QZE;3S8H;6P90;
Q960B1	Q960B1_DROME	unreviewed	SD10334p	unc-45 Tom34 CG2708	Drosophila melanogaster (Fruit fly)	947								3NOW;
Q9XD56	Q9XD56_MORCA	unreviewed	UspA1	uspA1	Moraxella catarrhalis (Branhamella catarrhalis)	863								3NTN;3PR7;6QP4;
O67496	ISPG_AQUAE	reviewed	4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (flavodoxin) (EC 1.17.7.3) (1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase)	ispG gcpE aq_1540	Aquifex aeolicus (strain VF5)	357					"MUTAGEN 26;  /note=""Q->E: Reduces activity 100-fold."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 55;  /note=""R->K: Loss of activity."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 81;  /note=""D->N: Loss of activity."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 101;  /note=""R->K: Reduces activity 500-fold."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 103;  /note=""N->D: Reduces activity 200-fold."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 106;  /note=""N->D: Reduces activity 2-fold."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 128;  /note=""R->K: Loss of activity."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 132;  /note=""N->D: Loss of activity."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 204;  /note=""E->Q: Loss of activity."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 242;  /note=""E->Q: Reduces activity 12-fold."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 256;  /note=""R->K: Reduces activity 2-fold."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 307;  /note=""E->C: Loss of activity."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 307;  /note=""E->D: Reduces activity 500-fold."";  /evidence=""ECO:0000269|PubMed:20932974""; MUTAGEN 307;  /note=""E->Q: Reduces activity 4-fold."";  /evidence=""ECO:0000269|PubMed:20932974"""		224324.aq_1540;	3NOY;
Q9KRB0	AROA_VIBCH	reviewed	3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19) (5-enolpyruvylshikimate-3-phosphate synthase) (EPSP synthase) (EPSPS)	aroA VC_1732	Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)	426							243277.VC_1732;	3NVS;3TI2;
Q8Y6T2	Q8Y6T2_LISMO	unreviewed	3-deoxy-D-arabino-heptulosonate 7-phosphate synthase	aroA	Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e)	361							169963.lmo1600;	3NVT;3TFC;
Q5E1U2	Q5E1U2_ALIF1	unreviewed	2-dehydro-3-deoxyphosphogluconate aldolase (EC 4.1.2.14) (EC 4.1.3.16)	VF_2509	Aliivibrio fischeri (strain ATCC 700601 / ES114) (Vibrio fischeri)	246							312309.VF_2509;	3NZR;
P53038	TEL2_YEAST	reviewed	Telomere length regulation protein TEL2	TEL2 YGR099W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	688					"MUTAGEN 333;  /note=""L->Q: Does not inhibit interaction with TTI1 or TTI2. Inhibits interaction with TTI1 or TTI2; when associated with E-345."";  /evidence=""ECO:0000269|PubMed:20801936""; MUTAGEN 345;  /note=""M->E: Does not inhibit weakly interaction with TTI1 or TTI2. Inhibits interaction with TTI1 or TTI2; when associated with Q-333."";  /evidence=""ECO:0000269|PubMed:20801936"""	P53038;	4932.YGR099W;	3O4Z;
Q92797	SYMPK_HUMAN	reviewed	Symplekin	SYMPK SPK	Homo sapiens (Human)	1274					"MUTAGEN 185;  /note=""K->A: Abolishes stimulation of SSU72 phosphatase activity."";  /evidence=""ECO:0000269|PubMed:20861839"""	Q92797;	9606.ENSP00000245934;	3O2Q;3O2S;3O2T;3ODR;3ODS;4H3H;4H3K;6V4X;
Q8SVZ5	Q8SVZ5_ENCCU	unreviewed	Similarity to HELICASE MOT1	ECU03_1530	Encephalitozoon cuniculi (strain GB-M1) (Microsporidian parasite)	1256						Q8SVZ5;		3OC3;4WZS;
P51534	SHE4_YEAST	reviewed	SWI5-dependent HO expression protein 4	SHE4 YOR035C OR26.26	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	789						P51534;	4932.YOR035C;	3OPB;
Q89YQ8	Q89YQ8_BACTN	unreviewed	Two-component system sensor histidine kinase	BT_4673	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	1182							226186.BT_4673;	3OTT;3VA6;
Q7Q5N3	Q7Q5N3_ANOGA	unreviewed	AGAP006348-PA (Leucine-rich immune protein (Long))	1276956 AgaP_AGAP006348	Anopheles gambiae (African malaria mosquito)	509						Q7Q5N3;	7165.AGAP006348-PA;	3O53;3OJA;
Q96AT9	RPE_HUMAN	reviewed	Ribulose-phosphate 3-epimerase (EC 5.1.3.1) (Ribulose-5-phosphate-3-epimerase)	RPE HUSSY-17	Homo sapiens (Human)	228					"MUTAGEN 10;  /note=""S->A: Nearly abolishes enzyme activity."";  /evidence=""ECO:0000269|PubMed:20923965""; MUTAGEN 12;  /note=""L->A: Reduces enzyme activity by half."";  /evidence=""ECO:0000269|PubMed:20923965""; MUTAGEN 35;  /note=""H->A: Alters protein structure. Nearly abolishes enzyme activity."";  /evidence=""ECO:0000269|PubMed:20923965""; MUTAGEN 37;  /note=""D->A: Alters protein structure. Nearly abolishes enzyme activity."";  /evidence=""ECO:0000269|PubMed:20923965""; MUTAGEN 39;  /note=""M->A: Lowers enzyme activity by 10%."";  /evidence=""ECO:0000269|PubMed:20923965""; MUTAGEN 70;  /note=""H->A: Alters protein structure."";  /evidence=""ECO:0000269|PubMed:20923965""; MUTAGEN 72;  /note=""M->A: Reduces enzyme activity by half."";  /evidence=""ECO:0000269|PubMed:20923965""; MUTAGEN 141;  /note=""M->A: No effect on enzyme activity."";  /evidence=""ECO:0000269|PubMed:20923965""; MUTAGEN 175;  /note=""D->A: Alters protein structure."";  /evidence=""ECO:0000269|PubMed:20923965"""	Q96AT9;	9606.ENSP00000352401;	3OVP;3OVQ;3OVR;3QC3;
Q9GZS3	WDR61_HUMAN	reviewed	WD repeat-containing protein 61 (Meiotic recombination REC14 protein homolog) (SKI8 homolog) (Ski8) [Cleaved into: WD repeat-containing protein 61, N-terminally processed]	WDR61	Homo sapiens (Human)	305						Q9GZS3;	9606.ENSP00000267973;	3OW8;6GMH;6TED;
P9WNU1	DPO3B_MYCTU	reviewed	Beta sliding clamp (Beta clamp) (Sliding clamp) (Beta-clamp processivity factor) (DNA polymerase III beta sliding clamp subunit) (DNA polymerase III subunit beta) (Mtb beta-clamp)	dnaN Rv0002 MTCY10H4.0 MTV029.02	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	402						P9WNU1;	83332.Rv0002;	3P16;3RB9;5AGU;5AGV;
P40368	NUP82_YEAST	reviewed	Nucleoporin NUP82 (Nuclear pore protein NUP82)	NUP82 YJL061W HRB187 J1135	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	713						P40368;	4932.YJL061W;	3PBP;3TKN;
A1YIY3	A1YIY3_9GAMM	unreviewed	Antifreeze protein (Fragment)		Marinomonas primoryensis	1567								3P4G;4KDV;4KDW;5J6Y;5JUH;5K8G;
P21827	RCC1_YEAST	reviewed	Guanine nucleotide exchange factor SRM1 (Pheromone response pathway component SRM1) (Pre-mRNA-processing protein 20) (Regulator of chromosome condensation) (Suppressor of receptor mutations 1) (mRNA transport protein 1)	SRM1 MTR1 PRP20 YGL097W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	482					"MUTAGEN 19;  /note=""K->T: Impairs correct nuclear localization; when associated with T-20 and T-23."";  /evidence=""ECO:0000269|PubMed:11523802""; MUTAGEN 20;  /note=""K->A,Q: Impairs activity."";  /evidence=""ECO:0000269|PubMed:11523802""; MUTAGEN 20;  /note=""K->T: Impairs correct nuclear localization; when associated with T-19 and T-23."";  /evidence=""ECO:0000269|PubMed:11523802""; MUTAGEN 23;  /note=""K->T: Impairs correct nuclear localization; when associated with T-19 and T-20."";  /evidence=""ECO:0000269|PubMed:11523802""; MUTAGEN 282;  /note=""G->S: Leads to temperature-dependent mislocalization of nucleoporins (nups) and the pore-membrane protein POM152."";  /evidence=""ECO:0000269|PubMed:12654904"""	P21827;	4932.YGL097W;	3OF7;4OIH;5HQ2;5T94;
A1JMA5	A1JMA5_YERE8	unreviewed	Oligogalacturonate lyase	ogl YE1876	Yersinia enterocolitica serotype O:8 / biotype 1B (strain NCTC 13174 / 8081)	388							393305.YE1876;	3PE7;
Q75WT9	Q75WT9_9APHY	unreviewed	Ricin B-related lectin	psl1a	Polyporus squamosus	286						Q75WT9;		3PHZ;5MUA;
Q9HXY6	LPXD_PSEAE	reviewed	UDP-3-O-acylglucosamine N-acyltransferase (EC 2.3.1.191)	lpxD PA3646	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	353								3PMO;6UEC;6UED;
Q5LIP7	Q5LIP7_BACFN	unreviewed	Putative lipoprotein	BF9343_0200 NCTC9343_01843	Bacteroides fragilis (strain ATCC 25285 / DSM 2151 / CCUG 4856 / JCM 11019 / NCTC 9343 / Onslow)	244							272559.BF9343_0200;	3PET;
O04197	COI1_ARATH	reviewed	Coronatine-insensitive protein 1 (COI-1) (F-box/LRR-repeat protein 2) (AtCOI1) (AtFBL2)	COI1 FBL2 At2g39940 T28M21.10	Arabidopsis thaliana (Mouse-ear cress)	592				DISRUPTION PHENOTYPE: Mutants coi1-1 to coi1-14 are male sterile, insensitive to MeJA and coronatine, and exhibit enhanced resistance to Pseudomonas syringae atropurpurea (coronatine producing strain). Mutant coi1-16 has reduced sensitivity to jasmonate, but is male fertile when grown below 22 degrees Celsius and male sterile otherwise. {ECO:0000269|PubMed:9582125}.	"MUTAGEN 11;  /note=""L->A: No effects on interactions."";  /evidence=""ECO:0000269|PubMed:12445118""; MUTAGEN 22;  /note=""E->A: Abrogates SFC(COI1) complexes formation, loss of response to jasmonate."";  /evidence=""ECO:0000269|PubMed:12172031""; MUTAGEN 44;  /note=""W->A: Abrogates SFC(COI1) complexes formation and of interactions with RBCS-1B and RPD3B, loss of response to jasmonate."";  /evidence=""ECO:0000269|PubMed:12445118""; MUTAGEN 85;  /note=""R->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 88;  /note=""M->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 89;  /note=""F->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 121;  /note=""R->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 245;  /note=""L->F: In coi1-16; abrogates interactions with RBCS-1B and RPD3B (coi1-16)."";  /evidence=""ECO:0000269|PubMed:12172836, ECO:0000269|PubMed:12445118""; MUTAGEN 301;  /note=""L->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 302;  /note=""Y->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 326;  /note=""R->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 348;  /note=""R->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 351;  /note=""R->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 386;  /note=""Y->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 409;  /note=""R->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 444;  /note=""Y->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 469;  /note=""L->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106""; MUTAGEN 496;  /note=""R->A: Loss of interaction with TIFY10A."";  /evidence=""ECO:0000269|PubMed:20927106"""	O04197;	3702.AT2G39940.1;	3OGK;3OGL;3OGM;
Q44167	Q44167_ACTPL	unreviewed	Transferrin-binding protein B	tfbA tbpB	Actinobacillus pleuropneumoniae (Haemophilus pleuropneumoniae)	547								3PQS;4O3Y;4O3Z;4O49;
Q83UA7	Q83UA7_ACTSU	unreviewed	Transferrin-binding protein B	tbpB	Actinobacillus suis	596								3PQU;4O3W;
A0KF03	A0KF03_AERHH	unreviewed	Qnr	AHA_0291	Aeromonas hydrophila subsp. hydrophila (strain ATCC 7966 / DSM 30187 / BCRC 13018 / CCUG 14551 / JCM 1027 / KCTC 2358 / NCIMB 9240 / NCTC 8049)	216							380703.AHA_0291;	3PSS;3PSZ;
Q59HN8	RAPH_BACSU	reviewed	Response regulator aspartate phosphatase H (EC 3.1.-.-) (PSP28)	rapH yeeH yzqA BSU06830	Bacillus subtilis (strain 168)	376						Q59HN8;	224308.BSU06830;	3Q15;
Q11T61	AAEP_CYTH3	reviewed	D-Ala-D/L-Ala epimerase (EC 5.1.1.-)	tfdD CHU_2140	Cytophaga hutchinsonii (strain ATCC 33406 / DSM 1761 / CIP 103989 / NBRC 15051 / NCIMB 9469 / D465)	368							269798.CHU_2140;	3Q45;3Q4D;
Q5WPU9	Q5WPU9_LUTLO	unreviewed	43.2 kDa salivary protein (Putative major royal jelly protein)	LJM11_Clu9	Lutzomyia longipalpis (Sand fly)	399								3Q6K;3Q6P;3Q6T;
Q55S71	Q55S71_CRYNB	unreviewed	Uncharacterized protein	CNBE3110	Cryptococcus neoformans var. neoformans serotype D (strain B-3501A) (Filobasidiella neoformans)	336								3Q73;3Q75;3Q78;3Q79;3Q7A;3Q7F;3SFX;3SFY;
B3PD60	B3PD60_CELJU	unreviewed	Beta-xylosidase/alpha-L-arabinfuranosidase, putative, gly43N (EC 3.2.1.-)	gly43N CJA_3018	Cellvibrio japonicus (strain Ueda107) (Pseudomonas fluorescens subsp. cellulosa)	334							498211.CJA_3018;	3QED;3QEE;3QEF;
P9WFX7	TRPC_MYCTU	reviewed	Indole-3-glycerol phosphate synthase (IGPS) (EC 4.1.1.48)	trpC Rv1611 MTCY01B2.03	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	272							83332.Rv1611;	3QJA;3T40;3T44;3T55;3T78;4FB7;
D0MFQ0	D0MFQ0_RHOM4	unreviewed	Outer membrane assembly lipoprotein YfiO	Rmar_0679	Rhodothermus marinus (strain ATCC 43812 / DSM 4252 / R-10) (Rhodothermus obamensis)	280							518766.Rmar_0679;	3QKY;
B7DSY7	B7DSY7_9BACL	unreviewed	o-succinylbenzoate synthase (OSB synthase) (OSBS) (EC 4.2.1.113) (4-(2'-carboxyphenyl)-4-oxybutyric acid synthase) (o-succinylbenzoic acid synthase)	menC AaLAA1DRAFT_2112	Alicyclobacillus acidocaldarius LAA1	379								3QLD;
Q9ZC38	Q9ZC38_YERPE	unreviewed	Putative citrate lyase beta chain (Similar to CitE)	YPO1928	Yersinia pestis	280							214092.YPO1928;	3QLL;
Q08199	SIL1_YEAST	reviewed	Nucleotide exchange factor SIL1 (Protein SLS1)	SIL1 PER100 SLS1 YOL031C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	421					"MUTAGEN 365..369;  /note=""Missing: Abrogates interaction with KAR2."";  /evidence=""ECO:0000269|PubMed:10958688"""	Q08199;	4932.YOL031C;	3QML;
B9PVB4	B9PVB4_TOXGV	unreviewed	2-deoxy-D-ribose 5-phosphate aldolase (EC 4.1.2.4) (Phosphodeoxyriboaldolase)	BN1205_010130 TGVEG_318750	Toxoplasma gondii (strain ATCC 50861 / VEG)	286							5811.TGME49_118750;	3QYQ;4EIV;
Q8A1I6	Q8A1I6_BACTN	unreviewed	Endo-1,4-beta-xylanase D	BT_3675	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	333							226186.BT_3675;	3QZ4;
B0TZW0	XEEP_FRAP2	reviewed	L-amino acid-D/L-Glu epimerase (EC 5.1.1.-) (L-Xxx-D/L-Glu epimerase)	Fphi_1647	Francisella philomiragia subsp. philomiragia (strain ATCC 25017 / FSC 153 / O#319-036)	356							484022.Fphi_1647;	3R0K;3R0U;3R10;3R11;3R1Z;
Q9X1P5	DEOC_THEMA	reviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC TM_1559	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	248							243274.THEMA_06485;	3R12;3R13;
Q8Y4C4	MURA1_LISMO	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1 (EC 2.5.1.7) (Enoylpyruvate transferase 1) (UDP-N-acetylglucosamine enolpyruvyl transferase 1) (EPT 1)	murA1 murA lmo2526	Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e)	430							169963.lmo2526;	3R38;
D0CFC3	D0CFC3_ACIB2	unreviewed	4-hydroxy-tetrahydrodipicolinate synthase (HTPA synthase) (EC 4.3.3.7)	dapA HMPREF0010_03414	Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81)	297								3PUD;3PUE;3PUL;3RK8;3TAK;3TCE;3TDF;3U8G;3UQN;4DXV;
Q8A0C7	Q8A0C7_BACTN	unreviewed	Glycosidase	BT_4094	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	377							226186.BT_4094;	3R67;
P19669	TAL_BACSU	reviewed	Transaldolase (EC 2.2.1.2) (20 kDa phosphoprotein OrfU) (CSI9)	tal ywjH BSU37110	Bacillus subtilis (strain 168)	212						P19669;	224308.BSU37110;	3R8R;
E5EVW2	E5EVW2_BOMMO	unreviewed	30K protein 2 (30K protein 2; 30kDa protein) (30kDa protein)	101735447	Bombyx mori (Silk moth)	256								3PUB;4EFP;4EFQ;4EFR;
Q8TB72	PUM2_HUMAN	reviewed	Pumilio homolog 2 (Pumilio-2)	PUM2 KIAA0235 PUMH2	Homo sapiens (Human)	1066						Q8TB72;	9606.ENSP00000338173;	3Q0Q;3Q0R;3Q0S;
P18895	ALGE_PSEAE	reviewed	Alginate production protein AlgE	algE alg76 PA3544	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	490								3RBH;4AFK;4AZL;4B61;4XNK;4XNL;5D5D;5IYU;
Q88KH9	Q88KH9_PSEPK	unreviewed	Mg-dependent cytoplasmic DNase / RNase (EC 3.1.21.-)	tatD PP_2311	Pseudomonas putida (strain ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950 / KT2440)	265							160488.PP_2311;	3RCM;
A6QNK7	A6QNK7_BOVIN	unreviewed	CD180 molecule	CD180	Bos taurus (Bovine)	661								3RG1;
O22476	BRI1_ARATH	reviewed	Protein BRASSINOSTEROID INSENSITIVE 1 (AtBRI1) (EC 2.7.10.1) (EC 2.7.11.1) (Brassinosteroid LRR receptor kinase)	BRI1 At4g39400 F23K16.30	Arabidopsis thaliana (Mouse-ear cress)	1196				DISRUPTION PHENOTYPE: Dwarf phenotype and aberrant leaf shape. {ECO:0000269|PubMed:10557222}.	"MUTAGEN 69;  /note=""C->Y: In bri1-5; brassinosteroid-insensitive semi-dwarf mutant.""; MUTAGEN 611;  /note=""G->E: In bri1-113; brassinosteroid-insensitive semi-dwarf mutant.""; MUTAGEN 613;  /note=""G->S: In bri1-7; brassinosteroid-insensitive semi-dwarf mutant.""; MUTAGEN 644;  /note=""G->D: In bri1-6; brassinosteroid-insensitive semi-dwarf mutant.""; MUTAGEN 662;  /note=""S->F: In bri1-9; brassinosteroid-insensitive semi-dwarf mutant.""; MUTAGEN 750;  /note=""T->I: In bri1-102; brassinosteroid-insensitive dwarf mutant.""; MUTAGEN 831;  /note=""Y->D,E: No effect on kinase activity, flowering time or leaf size, but altered leaf shape."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 831;  /note=""Y->F: No effect on kinase activity but altered flowering time and leaf size and shape."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 838;  /note=""S->A: Decreases peptide phosphorylation, but no effect on autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 838;  /note=""S->D: Increased kinase activity; when associated with D-842; D-846 and D-858."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 842;  /note=""T->A: Decreases peptide phosphorylation, but no effect on autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 842;  /note=""T->D: Increased kinase activity; when associated with D-838; D-846 and D-858."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 846;  /note=""T->A: Decreases peptide phosphorylation, but no effect on autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 846;  /note=""T->D: Increased kinase activity; when associated with D-838; D-842 and D-858."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 858;  /note=""S->A: Decreases peptide phosphorylation, but no effect on autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 858;  /note=""S->D: Increased kinase activity; when associated with D-838; D-842 and D-846."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 872;  /note=""T->A: 10-fold increase in peptide phosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717""; MUTAGEN 898;  /note=""Y->F: No effect on kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 909;  /note=""A->T: In bri1-1; brassinosteroid-insensitive dwarf mutant.""; MUTAGEN 911;  /note=""K->E: Loss of kinase activity; dwarf mutant."";  /evidence=""ECO:0000269|PubMed:11027724""; MUTAGEN 945;  /note=""Y->F: No effect on kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 956;  /note=""Y->F: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 961;  /note=""Y->F: No effect on kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 983;  /note=""R->N: In bri1-8; brassinosteroid-insensitive dwarf mutant.""; MUTAGEN 983;  /note=""R->Q: In bri1-108; brassinosteroid-insensitive dwarf mutant.""; MUTAGEN 989;  /note=""G->I: In bri1-301; impaired kinase activity and loss of autophosphorylation."";  /evidence=""ECO:0000269|PubMed:18332904""; MUTAGEN 1031;  /note=""A->W: In bri1-104; brassinosteroid-insensitive dwarf mutant, but no effect on interaction with TTL.""; MUTAGEN 1039;  /note=""T->A: Abolishes peptide phosphorylation, and to a lower level autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717""; MUTAGEN 1042;  /note=""S->A: Abolishes peptide phosphorylation, and to a lower level autophosphorylation.""; MUTAGEN 1044;  /note=""S->A: Abolishes peptide phosphorylation, and autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717""; MUTAGEN 1045;  /note=""T->A: Abolishes peptide phosphorylation, and autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717""; MUTAGEN 1048;  /note=""G->D: In bri1-115; brassinosteroid-insensitive dwarf mutant and no interaction with TTL.""; MUTAGEN 1049;  /note=""T->A: Abolishes peptide phosphorylation, and autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 1049;  /note=""T->D: Loss of kinase activity and brassinosteroid signaling."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 1052;  /note=""Y->F: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 1057;  /note=""Y->F: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 1058;  /note=""Y->F: No effect on kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 1070;  /note=""Y->F: No effect on kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 1072;  /note=""Y->F: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:19124768""; MUTAGEN 1078;  /note=""E->K: In bri1-101; brassinosteroid-insensitive dwarf mutant and no interaction with TTL.""; MUTAGEN 1139;  /note=""D->N: In bri1-117; brassinosteroid-insensitive dwarf mutant.""; MUTAGEN 1166;  /note=""S->D: Increased kinase activity; when associated with D-1168; D-1172; D-1179 and D-1180."";  /evidence=""ECO:0000269|PubMed:18694562""; MUTAGEN 1168;  /note=""S->A: Decreases peptide phosphorylation, but no effect on autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 1168;  /note=""S->D: Increased kinase activity; when associated with D-1166; D-1172; D-1179 and D-1180."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 1172;  /note=""S->A: Decreases peptide phosphorylation, but no effect on autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 1172;  /note=""S->D: Increased kinase activity; when associated with D-1166; D-1168; D-1179 and D-1180."";  /evidence=""ECO:0000269|PubMed:15894717, ECO:0000269|PubMed:18694562""; MUTAGEN 1179..1180;  /note=""ST->A: Decreases peptide phosphorylation, but no effect on autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717""; MUTAGEN 1179;  /note=""S->D: Increased kinase activity; when associated with D-1166; D-1168; D-1172 and D-1180."";  /evidence=""ECO:0000269|PubMed:18694562""; MUTAGEN 1180;  /note=""T->D: Increased kinase activity; when associated with D-1166; D-1168; D-1172 and D-1179."";  /evidence=""ECO:0000269|PubMed:18694562""; MUTAGEN 1187;  /note=""S->A: Decreases peptide phosphorylation, but no effect on autophosphorylation."";  /evidence=""ECO:0000269|PubMed:15894717"""	O22476;	3702.AT4G39400.1;	3RGX;3RGZ;3RIZ;3RJ0;4LSA;4LSX;4M7E;4OH4;4Q5J;5LPB;5LPV;5LPW;5LPY;5LPZ;6FIF;
G8GV21	G8GV21_9CAUD	unreviewed	Tailspike (Tailspike protein)	9NA_055	Salmonella phage 9NA	673								3RIQ;
Q607C7	KRDE_METCA	reviewed	L-Lys-D/L-Arg epimerase (EC 5.1.1.-) (Cationic dipeptide epimerase)	MCA1834	Methylococcus capsulatus (strain ATCC 33009 / NCIMB 11132 / Bath)	356							243233.MCA1834;	3RIT;3RO6;
Q9H3S7	PTN23_HUMAN	reviewed	Tyrosine-protein phosphatase non-receptor type 23 (EC 3.1.3.48) (His domain-containing protein tyrosine phosphatase) (HD-PTP) (Protein tyrosine phosphatase TD14) (PTP-TD14)	PTPN23 KIAA1471	Homo sapiens (Human)	1636			DISEASE: Neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity (NEDBASS) [MIM:618890]: An autosomal recessive disorder characterized by global developmental delay, brain abnormalities, mainly ventriculomegaly and/or brain atrophy, intellectual disability, absent speech, peripheral spasticity, and microcephaly. Additional variable features include early-onset seizures, optic atrophy, and dysmorphic facial features. Early death may occur. {ECO:0000269|PubMed:25558065, ECO:0000269|PubMed:27848944, ECO:0000269|PubMed:29090338, ECO:0000269|PubMed:29899372, ECO:0000269|PubMed:31395947}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 202;  /note=""L->D: Nearly abolishes interaction with CHMP4B. Abolishes interaction with CHMP4B; when associated with D-206."";  /evidence=""ECO:0000269|PubMed:18434552""; MUTAGEN 206;  /note=""I->D: Abolishes interaction with CHMP4B; when associated with D-202."";  /evidence=""ECO:0000269|PubMed:18434552""; MUTAGEN 678;  /note=""F->S,D: Abolishes interaction with UBAP1."";  /evidence=""ECO:0000269|PubMed:21757351, ECO:0000269|PubMed:27839950"""	Q9H3S7;	9606.ENSP00000265562;	3RAU;5CRU;5CRV;5LM1;5LM2;5MJY;5MJZ;5MK0;5MK1;5MK2;5MK3;
Q18888	Q18888_CAEEL	unreviewed	Aryl hydrocarbon receptor Interacting Protein (AIP) Related	aipr-1 C56C10.10 CELE_C56C10.10	Caenorhabditis elegans	342							6239.C56C10.10;	3RKV;
M4B6G6	ATR1_HYAAE	reviewed	Avirulence protein ATR1 (Arabidopsis thaliana recognized protein 1)	ATR1 ATR1-NdWsB	Hyaloperonospora arabidopsidis (strain Emoy2) (Downy mildew agent) (Peronospora arabidopsidis)	311								3RMR;7CRB;7CRC;
Q9KCA6	AROA1_ALKHC	reviewed	3-phosphoshikimate 1-carboxyvinyltransferase 1 (EC 2.5.1.19) (5-enolpyruvylshikimate-3-phosphate synthase 1) (EPSP synthase 1) (EPSPS 1)	aroA1 aroE BH1667	Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) (Bacillus halodurans)	431							272558.10174284;	3RMT;
Q8VDU0	GPSM2_MOUSE	reviewed	G-protein-signaling modulator 2 (Pins homolog)	Gpsm2 Lgn Pins	Mus musculus (Mouse)	679					"MUTAGEN 210;  /note=""N->F: Nearly abolishes interaction with NUMA1."";  /evidence=""ECO:0000269|PubMed:21816348""; MUTAGEN 228;  /note=""R->A: Abolishes interaction with NUMA1; when associated with A-243. Abolishes interaction with FRMPD1; when associated with A-243."";  /evidence=""ECO:0000269|PubMed:21816348, ECO:0000269|PubMed:23318951""; MUTAGEN 243;  /note=""R->A: Abolishes interaction with NUMA1; when associated with A-228. Abolishes interaction with FRMPD1; when associated with A-228."";  /evidence=""ECO:0000269|PubMed:21816348, ECO:0000269|PubMed:23318951""; MUTAGEN 254;  /note=""F->E: Abolishes interaction with INSC."";  /evidence=""ECO:0000269|PubMed:21816348""; MUTAGEN 290;  /note=""N->E: Abolishes interaction with INSC."";  /evidence=""ECO:0000269|PubMed:21816348""; MUTAGEN 601;  /note=""L->E: Disrupts one GNAI3 binding site."";  /evidence=""ECO:0000269|PubMed:22952234""; MUTAGEN 635;  /note=""I->E: Disrupts one GNAI3 binding site."";  /evidence=""ECO:0000269|PubMed:22952234""; MUTAGEN 642;  /note=""R->A,G: Reduces affinity for GDP-bound GNAI3 50-fold. Reduces affinity for GDP-bound GNAI3 500-fold; when associated with A-647."";  /evidence=""ECO:0000269|PubMed:22952234""; MUTAGEN 647;  /note=""R->A: Reduces affinity for GDP-bound GNAI3 500-fold; when associated with A-642."";  /evidence=""ECO:0000269|PubMed:22952234"""	Q8VDU0;	10090.ENSMUSP00000029482;	3RO2;3RO3;4G2V;4G5O;4G5Q;4G5R;4G5S;4JHR;
Q81MQ2	DAPH_BACAN	reviewed	2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-acetyltransferase (EC 2.3.1.89) (Tetrahydrodipicolinate N-acetyltransferase) (THP acetyltransferase) (Tetrahydropicolinate acetylase)	dapH BA_4194 GBAA_4194 BAS3891	Bacillus anthracis	240							260799.BAS3891;	3R8Y;
Q83E11	AROA_COXBU	reviewed	3-phosphoshikimate 1-carboxyvinyltransferase (EC 2.5.1.19) (5-enolpyruvylshikimate-3-phosphate synthase) (EPSP synthase) (EPSPS)	aroA CBU_0526	Coxiella burnetii (strain RSA 493 / Nine Mile phase I)	438							227377.CBU_0526;	3ROI;3SLH;3TR1;4EGR;4GFP;4ZND;
A6TH02	A6TH02_KLEP7	unreviewed	Uncharacterized protein	yjcO KPN_04481	Klebsiella pneumoniae subsp. pneumoniae (strain ATCC 700721 / MGH 78578)	228								3RJV;
P93193	IPO_IPOBA	reviewed	Ipomoelin (Jacalin related lectin) (JRL)	IPO	Ipomoea batatas (Sweet potato) (Convolvulus batatas)	154					"MUTAGEN 1..10;  /note=""Missing: Loss of homotetramerization."";  /evidence=""ECO:0000269|PubMed:22808208"""			3R50;3R51;3R52;4DDN;
Q9PIC1	PYRF_CAMJE	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF Cj0381c	Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168)	279						Q9PIC1;	192222.Cj0381c;	3RU6;
Q9HKI3	TAL_THEAC	reviewed	Probable transaldolase (EC 2.2.1.2)	tal Ta0616	Thermoplasma acidophilum (strain ATCC 25905 / DSM 1728 / JCM 9062 / NBRC 15155 / AMRC-C165)	223							273075.Ta0616;	3S0C;3S1U;3S1V;3S1W;3S1X;4XZ9;6YR3;6YRE;6YRH;6YRM;6YRT;6YS0;
Q8K368	FANCI_MOUSE	reviewed	Fanconi anemia group I protein homolog (Protein FACI)	Fanci	Mus musculus (Mouse)	1330							10090.ENSMUSP00000044931;	3S4W;3S4Z;3S51;
Q3JFX2	Q3JFX2_BURP1	unreviewed	Hep_Hag family	BURPS1710b_A2381	Burkholderia pseudomallei (strain 1710b)	1626								3S6L;
P17181	INAR1_HUMAN	reviewed	Interferon alpha/beta receptor 1 (IFN-R-1) (IFN-alpha/beta receptor 1) (Cytokine receptor class-II member 1) (Cytokine receptor family 2 member 1) (CRF2-1) (Type I interferon receptor 1)	IFNAR1 IFNAR	Homo sapiens (Human)	557					"MUTAGEN 466;  /note=""Y->F: Impairs internalization in response to interferon."";  /evidence=""ECO:0000269|PubMed:18056411""; MUTAGEN 491..492;  /note=""LL->AA: Impairs interaction with TYK2."";  /evidence=""ECO:0000269|PubMed:24704786""; MUTAGEN 496..497;  /note=""EE->AA: Impairs interaction with TYK2."";  /evidence=""ECO:0000269|PubMed:24704786""; MUTAGEN 500;  /note=""E->A: Impairs interaction with TYK2."";  /evidence=""ECO:0000269|PubMed:24704786""; MUTAGEN 501;  /note=""K->R: Mildly reduces ubiquitination. Nearly abolishes ubiquitination and subsequent degradation; when associated with 525-R-R-526."";  /evidence=""ECO:0000269|PubMed:15337770""; MUTAGEN 525..526;  /note=""KK->RR: Reduces ubiquitination. Nearly abolishes ubiquitination and subsequent degradation; when associated with R-501."";  /evidence=""ECO:0000269|PubMed:15337770""; MUTAGEN 535;  /note=""S->A: Abolishes interaction with FBXW11 and decreases ubiquitination."";  /evidence=""ECO:0000269|PubMed:14532120, ECO:0000269|PubMed:15337770""; MUTAGEN 535;  /note=""S->A: Abolishes phosphorylation at this site and interaction with SHMT2."";  /evidence=""ECO:0000269|PubMed:24075985""; MUTAGEN 539;  /note=""S->A: Abolishes interaction with FBXW11 and decreases ubiquitination."";  /evidence=""ECO:0000269|PubMed:15337770"""	P17181;	9606.ENSP00000270139;	3S98;3SE3;3SE4;4PO6;
A6KZ57	A6KZ57_PHOV8	unreviewed	Uncharacterized protein	BVU_1028	Phocaeicola vulgatus (strain ATCC 8482 / DSM 1447 / JCM 5826 / CCUG 4940 / NBRC 14291 / NCTC 11154) (Bacteroides vulgatus)	394							435590.BVU_1028;	3S9J;
Q8A8C7	Q8A8C7_BACTN	unreviewed	Uncharacterized protein	BT_1240	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	349							226186.BT_1240;	3SB4;
C4ZBG5	C4ZBG5_AGARV	unreviewed	DUF5050 domain-containing protein	EUBREC_1955	Agathobacter rectalis (strain ATCC 33656 / DSM 3377 / JCM 17463 / KCTC 5835 / VPI 0990) (Eubacterium rectale)	330								3S25;
Q5LGG4	Q5LGG4_BACFN	unreviewed	3-carboxymuconate cyclase	BF9343_0994 NCTC9343_02648	Bacteroides fragilis (strain ATCC 25285 / DSM 2151 / CCUG 4856 / JCM 11019 / NCTC 9343 / Onslow)	384								3SCY;
P19573	NOSZ_PSEST	reviewed	Nitrous-oxide reductase (EC 1.7.2.4) (N(2)OR) (N2O reductase)	nosZ	Pseudomonas stutzeri (Pseudomonas perfectomarina)	638							1123519.PSJM300_03110;	3SBP;3SBQ;3SBR;6RKZ;6RL0;6Y6Y;6Y71;6Y72;6Y77;6Y7D;6Y7E;7APY;7AQ0;7AQ2;7AQ3;7AQ4;7AQ5;7AQ6;7AQ7;7AQ8;7AQ9;7AQA;
P81274	GPSM2_HUMAN	reviewed	G-protein-signaling modulator 2 (Mosaic protein LGN)	GPSM2 LGN	Homo sapiens (Human)	684			DISEASE: Chudley-McCullough syndrome (CMCS) [MIM:604213]: An autosomal recessive neurologic disorder characterized by early-onset sensorineural deafness and specific brain anomalies on MRI, including hypoplasia of the corpus callosum, enlarged cysterna magna with mild focal cerebellar dysplasia, and nodular heterotopia. Some patients have hydrocephalus. Psychomotor development is normal. {ECO:0000269|PubMed:20602914, ECO:0000269|PubMed:22578326}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 228;  /note=""R->A: Abolishes location at mitotic spindle poles; when associated with A-243."";  /evidence=""ECO:0000269|PubMed:21816348""; MUTAGEN 228;  /note=""R->E: Strongly reduces interaction with INSC. Abolishes interaction with INSC; when associated with R-290."";  /evidence=""ECO:0000269|PubMed:22074847""; MUTAGEN 243;  /note=""R->A: Abolishes location at mitotic spindle poles; when associated with A-228."";  /evidence=""ECO:0000269|PubMed:21816348""; MUTAGEN 290;  /note=""N->R: Abolishes interaction with INSC; when associated with E-228."";  /evidence=""ECO:0000269|PubMed:22074847"""	P81274;	9606.ENSP00000385510;	3SF4;4WND;4WNE;4WNF;4WNG;5A6C;6HC2;
Q81K13	MURA1_BACAN	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1 (EC 2.5.1.7) (Enoylpyruvate transferase 1) (UDP-N-acetylglucosamine enolpyruvyl transferase 1) (EPT 1)	murA1 BA_5529 GBAA_5529 BAS5137	Bacillus anthracis	434							260799.BAS5137;	3SG1;
P54311	GBB1_RAT	reviewed	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (Transducin beta chain 1)	Gnb1	Rattus norvegicus (Rat)	340						P54311;	10116.ENSRNOP00000044340;	3SN6;5TDH;5VAI;6CMO;6LPB;6NBF;6NBH;6NBI;6WWZ;7BW0;7CZ5;7D3S;7LJC;7LJD;7MBX;7MBY;
O88879	APAF_MOUSE	reviewed	Apoptotic protease-activating factor 1 (APAF-1)	Apaf1	Mus musculus (Mouse)	1249					"MUTAGEN 265;  /note=""R->S: No stimulation of CASP9 activity."";  /evidence=""ECO:0000269|PubMed:21827944"""	O88879;	10090.ENSMUSP00000020157;	3SFZ;3SHF;
Q4WTC0	Q4WTC0_ASPFU	unreviewed	Hsc70 cochaperone (SGT), putative (EC 3.1.3.16)	AFUA_1G09830	Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) (Aspergillus fumigatus)	341							746128.CADAFUBP00000910;	3SZ7;
Q9H9E1	ANRA2_HUMAN	reviewed	Ankyrin repeat family A protein 2 (RFXANK-like protein 2)	ANKRA2 ANKRA	Homo sapiens (Human)	313					"MUTAGEN 31;  /note=""K->R: No effect on interaction with CCDC8."";  /evidence=""ECO:0000269|PubMed:25752541""; MUTAGEN 188;  /note=""W->A: Loss of interaction with CCDC8. Decreased affinity for HDAC4."";  /evidence=""ECO:0000269|PubMed:22649097, ECO:0000269|PubMed:25752541""; MUTAGEN 254;  /note=""Y->A: Decreased affinity for HDAC4."";  /evidence=""ECO:0000269|PubMed:22649097"""	Q9H9E1;	9606.ENSP00000296785;	3SO8;3V2O;3V2X;3V31;4LG6;4QQI;
P70206	PLXA1_MOUSE	reviewed	Plexin-A1 (Plex 1) (Plexin-1)	Plxna1 Kiaa4053	Mus musculus (Mouse)	1894					"MUTAGEN 1266..1268;  /note=""KRK->AAA: Loss of interaction with FARP2."";  /evidence=""ECO:0000269|PubMed:16286926"""	P70206;	10090.ENSMUSP00000131840;	3RYT;5L56;5L59;5L5C;5L7N;
Q12QS6	Q12QS6_SHEDO	unreviewed	Avidin/streptavidin	Sden_0912	Shewanella denitrificans (strain OS217 / ATCC BAA-1090 / DSM 15013)	172							318161.Sden_0912;	3SZH;3SZI;3SZJ;3T2W;3T2X;
O75581	LRP6_HUMAN	reviewed	Low-density lipoprotein receptor-related protein 6 (LRP-6)	LRP6	Homo sapiens (Human)	1613			DISEASE: Coronary artery disease, autosomal dominant, 2 (ADCAD2) [MIM:610947]: A common heart disease characterized by reduced or absent blood flow in one or more of the arteries that encircle and supply the heart. Its most important complication is acute myocardial infarction. {ECO:0000269|PubMed:17332414, ECO:0000269|PubMed:23703864}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Tooth agenesis, selective, 7 (STHAG7) [MIM:616724]: An autosomal dominant form of selective tooth agenesis, a common anomaly characterized by the congenital absence of one or more teeth. Selective tooth agenesis without associated systemic disorders has sometimes been divided into 2 types: oligodontia, defined as agenesis of 6 or more permanent teeth, and hypodontia, defined as agenesis of less than 6 teeth. The number in both cases does not include absence of third molars (wisdom teeth). {ECO:0000269|PubMed:26387593}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 1394;  /note=""C->A: Some reduction of palmitoylation, little change in plasma membrane location in the presence of MESD nor in Wnt-signaling activity. Completely abolishes palmitoylation, no plasma membrane location, greatly reduced Wnt-signaling activity but no effect on ubiquitination; when associated with A-1399. Exhibits full Wnt-signaling activity and no change in plasma membrane location; when associated with A-1399 and R-1403."";  /evidence=""ECO:0000269|PubMed:18378904""; MUTAGEN 1399;  /note=""C->A: Some reduction of palmitoylation, and little change in plasma membrane location in the presence of MESD nor in Wnt-signaling activity. Completely abolishes palmitoylation, no plasma membrane location, greatly reduced Wnt-signaling activity but no effect on ubiquitination; when associated with A-1394. Exhibits full Wnt-signaling activity and no change in plasma membrane location in the in presence of MESD; when associated with A-1394 and R-1403."";  /evidence=""ECO:0000269|PubMed:18378904""; MUTAGEN 1403;  /note=""K->R: Abolishes ubiquitination, no change in plasma membrane location in the presence of MESD but greatly reduced Wnt-signaling activity. Exhibits full Wnt-signaling activity and no change in plasma membrane location; when associated with A-1394 and A-1399.""; MUTAGEN 1420;  /note=""S->A: Enhanced AXIN1 binding and increased beta-catenin activity by 2.2-fold. Further enhanced AXIN1 binding and increases beta-catenin activity by 3.3-fold; when associated with A-1430."";  /evidence=""ECO:0000269|PubMed:16513652""; MUTAGEN 1430;  /note=""S->A: Enhanced AXIN1 binding. Further enhanced AXIN1 binding and increases beta-catenin activity by 3.3-fold; when associated with A-1420."";  /evidence=""ECO:0000269|PubMed:16513652""; MUTAGEN 1485;  /note=""L->A: No change in the phosphorylation state of PPPSP motif. Some reduction in Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1486;  /note=""N->A: No change in the phosphorylation state of PPPSP motif. Increased Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1487;  /note=""P->A: No change in the phosphorylation state of PPPSP motif A. Greatly reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1487;  /note=""P->C: No change in the phosphorylation state of PPPSP motif A. Greatly reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1488;  /note=""P->A: No change in the phosphorylation state of PPPSP motif A. Greatly reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1489;  /note=""P->A: No change in the phosphorylation state of PPPSP motif A. Greatly reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1490;  /note=""S->A: Greatly reduced phosphorylation of PPPSP motif A. Greatly reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1490;  /note=""S->T: Some loss of phosphorylation of PPPSP motif A. Little reduction in Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1491;  /note=""P->A: Greatly reduced phosphorylation of PPPSP motif A. Greatly reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1492;  /note=""A->G: No change in the phosphorylation state of PPPSP motif A. Greatly reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1493;  /note=""T->A: No change in the phosphorylation state of PPPSP motif A. Greatly reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1494;  /note=""E->A: No change in the phosphorylation state of PPPSP motif A. Little reduction of Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1495;  /note=""R->A: No change in the phosphorylation state of PPPSP motif. No reduction of Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1529;  /note=""T->A: No effect on the phosphorylation state of PPPSP motif B."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1530;  /note=""T->A: Abolishes phosphorylation of PPPSP motif B. Reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1531;  /note=""P->A: Abolishes phosphorylation of PPPSP motif B. Reduced Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1572;  /note=""T->A: Abolishes Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1590;  /note=""S->A: Abolishes Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152""; MUTAGEN 1607;  /note=""S->A: Abolishes Wnt/beta-catenin signaling."";  /evidence=""ECO:0000269|PubMed:18362152"""	O75581;	9606.ENSP00000261349;	3S2K;3S8V;3S8Z;3S94;3SOB;3SOQ;3SOV;4A0P;4DG6;4NM5;4NM7;5AIR;5FWW;5GJE;6H15;6H16;6L6R;
Q9HZH0	Q9HZH0_PSEAE	unreviewed	Probable porin	PA3038	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	421								3T24;
P30260	CDC27_HUMAN	reviewed	Cell division cycle protein 27 homolog (Anaphase-promoting complex subunit 3) (APC3) (CDC27 homolog) (CDC27Hs) (H-NUC)	CDC27 ANAPC3 D0S1430E D17S978E	Homo sapiens (Human)	824					"MUTAGEN 821;  /note=""S->A: Abolishes binding to MCPH1."";  /evidence=""ECO:0000269|PubMed:22139841"""	P30260;	9606.ENSP00000434614;	3T1N;4RG6;4RG7;4RG9;4UI9;5A31;5G04;5G05;5KHR;5KHU;5L9T;5L9U;5LCW;6Q6G;6Q6H;6TLJ;6TM5;6TNT;
C7NDE2	C7NDE2_LEPBD	unreviewed	Uncharacterized protein	Lebu_0176	Leptotrichia buccalis (strain ATCC 14201 / DSM 1135 / JCM 12969 / NCTC 10249 / C-1013-b)	183							523794.Lebu_0176;	3T8K;
Q62192	CD180_MOUSE	reviewed	CD180 antigen (Lymphocyte antigen 78) (Ly-78) (Radioprotective 105 kDa protein) (CD antigen CD180)	Cd180 Ly78 Rp105	Mus musculus (Mouse)	661						Q62192;	10090.ENSMUSP00000022124;	3T6Q;
A8B3A8	A8B3A8_RHIMP	unreviewed	Triosephosphate isomerase (EC 5.3.1.1)	TIM	Rhipicephalus microplus (Cattle tick) (Boophilus microplus)	249								3TH6;
Q9PIF1	TRPA_CAMJE	reviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA Cj0349	Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168)	249						Q9PIF1;	192222.Cj0349;	3THA;
P0A9W9	YRDA_ECOLI	reviewed	Protein YrdA	yrdA b3279 JW5710	Escherichia coli (strain K12)	184						P0A9W9;	511145.b3279;	3TIO;3TIS;
P36070	RRN3_YEAST	reviewed	RNA polymerase I-specific transcription initiation factor RRN3	RRN3 YKL125W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	627						P36070;	4932.YKL125W;	3TJ1;5G5L;5N5Y;5N5Z;5N60;5N61;5OA1;6RQH;6RQL;6RQT;6RRD;6RUI;6RUO;6RWE;6TPS;
Q3JR17	Q3JR17_BURP1	unreviewed	2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase (EC 2.3.1.117) (Tetrahydrodipicolinate N-succinyltransferase) (THDP succinyltransferase) (THP succinyltransferase) (Tetrahydropicolinate succinylase)	dapD BURPS1710b_2594	Burkholderia pseudomallei (strain 1710b)	312								3TK8;
P13188	SYQ_YEAST	reviewed	Glutamine--tRNA ligase (EC 6.1.1.18) (Glutaminyl-tRNA synthetase) (GlnRS)	GLN4 YOR168W O3601	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	809						P13188;	4932.YOR168W;	3TL4;4H3S;
Q8A230	Q8A230_BACTN	unreviewed	IPT/TIG domain-containing protein	BT_3476	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	457							226186.BT_3476;	3TC9;
Q5FJB3	PYRF_LACAC	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF LBA1386	Lactobacillus acidophilus (strain ATCC 700396 / NCK56 / N2 / NCFM)	235							272621.LBA1386;	3TFX;
B9MKT4	B9MKT4_CALBD	unreviewed	Pectate lyase (EC 4.2.2.2)	Athe_1854	Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) (Anaerocellum thermophilum)	460							521460.Athe_1854;	3T9G;4EW9;4YZ0;4YZA;4YZQ;4YZX;4Z03;4Z05;4Z06;
Q91VI7	RINI_MOUSE	reviewed	Ribonuclease inhibitor (Ribonuclease/angiogenin inhibitor 1)	Rnh1 Rnh	Mus musculus (Mouse)	456						Q91VI7;	10090.ENSMUSP00000101651;	3TSR;
Q83E06	PYRF_COXBU	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF CBU_0531	Coxiella burnetii (strain RSA 493 / Nine Mile phase I)	236							227377.CBU_0531;	3TR2;
A0A6L8P2U9	A0A6L8P2U9_BACAN	unreviewed	Inosine-5'-monophosphate dehydrogenase (IMP dehydrogenase) (IMPD) (IMPDH) (EC 1.1.1.205)	guaB GBAA_0008	Bacillus anthracis	487							198094.BA_0008;	3TSB;3TSD;3USB;4MJM;4MY1;4MY8;4MY9;4MYA;4MYX;4QM1;5URR;5URS;5UUV;5UUW;5UUZ;6MGU;
O00399	DCTN6_HUMAN	reviewed	Dynactin subunit 6 (Dynactin subunit p27) (Protein WS-3)	DCTN6 WS3	Homo sapiens (Human)	190						O00399;	9606.ENSP00000221114;	3TV0;
Q8G9Q2	Q8G9Q2_LEUME	unreviewed	Dextransucrase (EC 2.4.1.5) (Sucrose 6-glucosyltransferase) (Fragment)	dsrE	Leuconostoc mesenteroides	2835								3TTO;3TTQ;4TTU;4TVC;
A9Z0I5	A9Z0I5_PETMA	unreviewed	Variable lymphocyte receptor B	VLR-B	Petromyzon marinus (Sea lamprey)	270								3TWI;
Q7KLV9	PSD11_DROME	reviewed	26S proteasome non-ATPase regulatory subunit 11 (26S proteasome regulatory complex subunit p42B) (26S proteasome regulatory subunit Rpn6)	Rpn6 CG10149	Drosophila melanogaster (Fruit fly)	422				DISRUPTION PHENOTYPE: Embryos develop and hatch normally but fail to outlive early larval stages. During the first and second instar larval stages larvae become immobile and sluggish and die without any observable defects. Lethality is probably the result of additive defects in overall cell proliferation rather than of distinct developmental disorders. {ECO:0000269|PubMed:12426099}.		Q7KLV9;	7227.FBpp0086603;	3TXM;3TXN;
Q9VB22	Q9VB22_DROME	unreviewed	LD33695p (Partner of inscuteable) (Pins protein) (RE22964p)	pins dLGN Dmel\CG5692 dPins PINS Pins Rad rad RAPS Raps raps rapsyn CG5692 Dmel_CG5692	Drosophila melanogaster (Fruit fly)	658						Q9VB22;	7227.FBpp0084559;	3TVT;4A1S;5A7D;
A0A2S9PLG4	A0A2S9PLG4_YERPE	unreviewed	Dihydropteroate synthase (DHPS) (EC 2.5.1.15) (Dihydropteroate pyrophosphorylase)	dhpS YPO3501	Yersinia pestis	277								3TYU;3TYZ;3TZF;3TZN;5JQ9;
Q9BZZ5	API5_HUMAN	reviewed	Apoptosis inhibitor 5 (API-5) (Antiapoptosis clone 11 protein) (AAC-11) (Cell migration-inducing gene 8 protein) (Fibroblast growth factor 2-interacting factor) (FIF) (Protein XAGL)	API5 MIG8	Homo sapiens (Human)	524						Q9BZZ5;	9606.ENSP00000431391;	3U0R;3V6A;6L4O;
C8VX32	C8VX32_DESAS	unreviewed	Uncharacterized protein	Dtox_1751	Desulfofarcimen acetoxidans (strain ATCC 49208 / DSM 771 / KCTC 5769 / VKM B-1644 / 5575) (Desulfotomaculum acetoxidans)	328							485916.Dtox_1751;	3U4Y;
Q45782	Q45782_BACTU	unreviewed	PlcR protein (Transcriptional regulator) (XRE family transcriptional regulator)	plcR B4918_30015 C6351_13005 CAB88_27845 CN398_18815 COK99_05395 CON12_11885 CON71_19630	Bacillus thuringiensis	285								3U3W;4FSC;
H9KVH9	H9KVH9_MORBO	unreviewed	Transferrin-binding protein B	LbpB	Moraxella bovis	341								3UAQ;
E5D0X5	E5D0X5_SCHOC	unreviewed	Fructofuranosidase (EC 3.2.1.26)		Schwanniomyces occidentalis (Yeast) (Debaryomyces occidentalis)	535								3U14;3U75;6S1T;6S2B;
E3PQS3	E3PQS3_PACTE	unreviewed	Sucrose:(Sucrose/fructan) 6-fructosyltransferase	6-SFT 6-SST	Pachysandra terminalis (Carpet box)	655								3UGF;3UGG;3UGH;
A8TYI5	A8TYI5_9PROT	unreviewed	Probable mandelate racemase	BAL199_22462	alpha proteobacterium BAL199	367							331869.BAL199_22462;	3UGV;
P71002	RAPF_BACSU	reviewed	Response regulator aspartate phosphatase F (EC 3.1.-.-)	rapF ywhJ BSU37460	Bacillus subtilis (strain 168)	381						P71002;	224308.BSU37460;	3ULQ;4I9C;4I9E;
B2SU53	PTHX1_XANOP	reviewed	TAL effector protein PthXo1 (Avirulence protein PthXo1) (TAL effector protein Tal2b)	pthXo1 tal2b PXO_00227	Xanthomonas oryzae pv. oryzae (strain PXO99A)	1373		BIOTECHNOLOGY: By combining the central DNA-binding domain with the catalytic domain of the restriction endonuclease FokI, TALE-nuclease (TALEN) enzymes able to target specific dsDNA sequences can be created that enable eukaryotic genome modification. Other potential uses as transcriptional repressors, for transposon targeting, DNA methylation or histone tail modifictions are also possible. {ECO:0000269|PubMed:20660643, ECO:0000303|PubMed:24602153, ECO:0000303|PubMed:25057889}.		DISRUPTION PHENOTYPE: Reduced virulence in susceptible rice; its introduction into a deletion mutant restores virulence to the bacteria in rice plants. No longer induces SWEET11 (Os8N3, XA13, AC Q6YZF3). {ECO:0000269|PubMed:15553245, ECO:0000269|PubMed:16798873}.			360094.PXO_00227;	3UGM;
B5T007	B5T007_LOLPR	unreviewed	Ice recrystallization inhibition protein-like protein	IRI3	Lolium perenne (Perennial ryegrass)	254								3ULT;
A7LZ30	A7LZ30_BACO1	unreviewed	Tetratricopeptide repeat protein	BACOVA_03105	Bacteroides ovatus (strain ATCC 8483 / DSM 1896 / JCM 5824 / BCRC 10623 / CCUG 4943 / NCTC 11153)	227							411476.BACOVA_03105;	3URZ;
A3DJ21	A3DJ21_ACET2	unreviewed	DUF5071 domain-containing protein	Cthe_2751	Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) (Hungateiclostridium thermocellum)	134							203119.Cthe_2751;	3UT4;3UT7;3UT8;
A1JJ76	A1JJ76_YERE8	unreviewed	Putative pectinesterase	YE0549	Yersinia enterocolitica serotype O:8 / biotype 1B (strain NCTC 13174 / 8081)	361							393305.YE0549;	3UW0;
O14593	RFXK_HUMAN	reviewed	DNA-binding protein RFXANK (Ankyrin repeat family A protein 1) (Regulatory factor X subunit B) (RFX-B) (Regulatory factor X-associated ankyrin-containing protein)	RFXANK ANKRA1 RFXB	Homo sapiens (Human)	260			DISEASE: Bare lymphocyte syndrome 2 (BLS2) [MIM:209920]: A severe combined immunodeficiency disease with early onset. It is characterized by a profound defect in constitutive and interferon-gamma induced MHC II expression, absence of cellular and humoral T-cell response to antigen challenge, hypogammaglobulinemia and impaired antibody production. The consequence include extreme susceptibility to viral, bacterial and fungal infections. {ECO:0000269|PubMed:10072068, ECO:0000269|PubMed:10725724, ECO:0000269|PubMed:22649097, ECO:0000269|PubMed:9806546}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 121;  /note=""D->V: Loss of expression."";  /evidence=""ECO:0000269|PubMed:22649097""; MUTAGEN 224;  /note=""Y->A: Loss of interaction with RFX5."";  /evidence=""ECO:0000269|PubMed:22649097"""	O14593;	9606.ENSP00000305071;	3UXG;3V30;6MEW;
O44169	PUF7_CAEEL	reviewed	Pumilio domain-containing protein 7	puf-7 B0273.2	Caenorhabditis elegans	485				DISRUPTION PHENOTYPE: Simultaneous knockdown of puf-6 and puf-7 results in ectopic primordial germ cells (PGCs) outside the somatic gonads, premature PGC proliferation in L1 larvae and germ cell death. Does not affect germline development in adult hermaphrodites. Disruption with puf-5 and puf-6 results in abnormally small oocytes, disorganization of oocyte nuclei and cells, inefficient yolk uptake by oocytes, embryonic arrest with impaired eggshell formation and cytokinesis defects, impaired repression of glp-1 in late oogenesis, and mislocalization of rme-2 to the cytoplasm instead of the plasma membrane. {ECO:0000269|PubMed:10518502, ECO:0000269|PubMed:17234175, ECO:0000269|PubMed:22542599}.	"MUTAGEN 441;  /note=""S->A: Reduced RNA-binding activity."";  /evidence=""ECO:0000269|PubMed:22205700"""		6239.B0273.2.2;	3V71;
Q6PFX9	TNKS1_MOUSE	reviewed	Poly [ADP-ribose] polymerase tankyrase-1 (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 5) (ARTD5) (Protein poly-ADP-ribosyltransferase tankyrase-1) (EC 2.4.2.-) (TRF1-interacting ankyrin-related ADP-ribose polymerase 1) (Tankyrase I) (Tankyrase-1) (TANK1)	Tnks Tnks1	Mus musculus (Mouse)	1320						Q6PFX9;	10090.ENSMUSP00000033929;	3UTM;4N4T;5HKP;6CF6;
Q86UT6	NLRX1_HUMAN	reviewed	NLR family member X1 (Caterpiller protein 11.3) (CLR11.3) (Nucleotide-binding oligomerization domain protein 26) (Nucleotide-binding oligomerization domain protein 5) (Nucleotide-binding oligomerization domain protein 9)	NLRX1 NOD26 NOD5 NOD9	Homo sapiens (Human)	975						Q86UT6;	9606.ENSP00000387334;	3UN9;
D7U7T8	D7U7T8_VITVI	unreviewed	4-hydroxy-tetrahydrodipicolinate synthase (EC 4.3.3.7)	VIT_15s0048g00750	Vitis vinifera (Grape)	365							29760.VIT_15s0048g00750.t01;	3TUU;4HNN;
Q9K0V0	TBPB_NEIMB	reviewed	Transferrin-binding protein B (TbpB) (Surface lipoprotein TbpB) (Transferrin-binding protein 2) (TBP-2)	tbpB tbp2 NMB0460	Neisseria meningitidis serogroup B (strain MC58)	712					"MUTAGEN 218;  /note=""Q->E: Decreased binding to human transferrin (TF)."";  /evidence=""ECO:0000269|PubMed:22327295""; MUTAGEN 220;  /note=""F->E: Decreased binding to TF."";  /evidence=""ECO:0000269|PubMed:22327295""; MUTAGEN 225;  /note=""Q->A: Significantly decreased binding to TF."";  /evidence=""ECO:0000269|PubMed:22327295""; MUTAGEN 225;  /note=""Q->E: No longer binds TF."";  /evidence=""ECO:0000269|PubMed:22327295""; MUTAGEN 226;  /note=""P->A: Wild-type binding to TF."";  /evidence=""ECO:0000269|PubMed:22327295""; MUTAGEN 226;  /note=""P->E,R,W: No longer binds TF."";  /evidence=""ECO:0000269|PubMed:22327295"""	Q9K0V0;		3V8U;
D2YW47	D2YW47_OLEAN	unreviewed	2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14)		Oleispira antarctica	217								3VCR;
B5F9P4	MURA_ALIFM	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (UDP-N-acetylglucosamine enolpyruvyl transferase) (EPT)	murA VFMJ11_0391	Aliivibrio fischeri (strain MJ11) (Vibrio fischeri)	422								3VCY;
A5VGW5	A5VGW5_SPHWW	unreviewed	Glyoxalase/bleomycin resistance protein/dioxygenase	Swit_4902	Sphingomonas wittichii (strain RW1 / DSM 6014 / JCM 10273)	294								3VB0;
A4YI54	A4YI54_METS5	unreviewed	Orotidine-5'-phosphate decarboxylase (EC 4.1.1.23)	Msed_1966	Metallosphaera sedula (strain ATCC 51363 / DSM 5348 / JCM 9185 / NBRC 15509 / TH2)	215							399549.Msed_1966;	3VE7;3VE9;
Q09057	TBPB1_NEIMI	reviewed	Transferrin-binding protein B (TbpB) (TbpB receptor) (Transferrin-binding protein 2) (TBP-2)	tbpB tbp2	Neisseria meningitidis serogroup B	711					"MUTAGEN 219;  /note=""R->A: Wild-type binding to human transferrin."";  /evidence=""ECO:0000269|PubMed:22343719""; MUTAGEN 241;  /note=""E->R: Dramatically reduced binding to human transferrin."";  /evidence=""ECO:0000269|PubMed:22343719"""	Q09057;		3VE1;3VE2;5KKX;
Q8A3A5	Q8A3A5_BACTN	unreviewed	Two-component system sensor histidine kinase/response regulator, hybrid (One-component system)	BT_3049	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	1376							226186.BT_3049;	3V9F;
P76116	YNCE_ECOLI	reviewed	Uncharacterized protein YncE	yncE b1452 JW1447	Escherichia coli (strain K12)	353						P76116;	511145.b1452;	3VGZ;3VH0;
A0A011	A0A011_STRVD	unreviewed	MoeO5	moeO5	Streptomyces viridosporus	281								3VK5;3VKA;3VKB;3VKC;3VKD;
D0VP31	D0VP31_9BACI	unreviewed	Pectate lyase (Fragment)	pelA	Bacillus sp. N16-5	362								3VMV;3VMW;
P38348	HSM3_YEAST	reviewed	DNA mismatch repair protein HSM3 (Enhanced spontaneous mutability protein 3)	HSM3 YBR272C YBR1740	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	480						P38348;	4932.YBR272C;	3VLD;3VLE;3VLF;4A3T;4A3V;4FP7;4JPO;
P08648	ITA5_HUMAN	reviewed	Integrin alpha-5 (CD49 antigen-like family member E) (Fibronectin receptor subunit alpha) (Integrin alpha-F) (VLA-5) (CD antigen CD49e) [Cleaved into: Integrin alpha-5 heavy chain; Integrin alpha-5 light chain]	ITGA5 FNRA	Homo sapiens (Human)	1049						P08648;	9606.ENSP00000293379;	3VI3;3VI4;4WJK;4WK0;4WK2;4WK4;7NWL;
Q5KW03	Q5KW03_GEOKA	unreviewed	Hypothetical conserved protein	GK2848	Geobacillus kaustophilus (strain HTA426)	182							235909.GK2848;	3VNP;
Q76CE6	IBPKB_TYPIS	reviewed	Ice-binding protein K3-B1 (Antifreeze protein 6) (AFP6) (TAFP-2) (TisAFP6)	K3-B1	Typhula ishikariensis (Gray snow mold fungus)	243					"MUTAGEN 102;  /note=""T->Y: Has 85% thermal hysteresis (TH) activity of that of the wild-type."";  /evidence=""ECO:0000269|PubMed:22645341""; MUTAGEN 198;  /note=""N->Y: Has 40% thermal hysteresis (TH) activity of that of the wild-type."";  /evidence=""ECO:0000269|PubMed:22645341""; MUTAGEN 232;  /note=""S->A: Slight increase in thermal hysteresis (TH) activity (0.48 degrees Celsius) compared with that of the wild-type (0.32 degrees Celsius) at 0.14 mM."";  /evidence=""ECO:0000269|PubMed:27613857""; MUTAGEN 241;  /note=""V->Y: Has 85% thermal hysteresis (TH) activity of that of the wild-type."";  /evidence=""ECO:0000269|PubMed:22645341"""			3VN3;
H1AFK5	H1AFK5_SHEFR	unreviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA	Shewanella frigidimarina	267								3VND;
Q9T1V4	BP45_BPMU	reviewed	Baseplate puncturing device gp45 (Baseplate spike protein) (Gene product 45) (gp45) (Gene product Q) (gpQ)	Mup45	Escherichia phage Mu (Bacteriophage Mu)	197				DISRUPTION PHENOTYPE: No tail is synthesized. {ECO:0000269|PubMed:3904174}.	"MUTAGEN 188;  /note=""D->A: Loss of membrane-binding ability."";  /evidence=""ECO:0000269|PubMed:22922659"""			3VTN;3VTO;
K7N5L8	K7N5L8_9BACT	unreviewed	MamA	MamA	Candidatus Magnetobacterium bavaricum	184								3VTX;3VTY;
J3QW34	J3QW34_KLUMA	unreviewed	KmHsv2		Kluyveromyces marxianus (Yeast) (Candida kefyr)	355								3VU4;
Q12453	CEX1_YEAST	reviewed	Cytoplasmic export protein 1	CEX1 YOR112W O3240 YOR3240w	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	761						Q12453;	4932.YOR112W;	3VWA;
A7X435	PCRB_STAA1	reviewed	Heptaprenylglyceryl phosphate synthase (HepGP synthase) (EC 2.5.1.n9) (Glycerol-1-phosphate heptaprenyltransferase)	pcrB SAHV_1891	Staphylococcus aureus (strain Mu3 / ATCC 700698)	230								3W01;3W02;
P39108	PEX7_YEAST	reviewed	Peroxisomal targeting signal 2 receptor (PTS2 receptor) (Peroxin-7) (Peroxisome import protein PAS7)	PEX7 PAS7 PEB1 YDR142C YD2943.01C YD9302.18C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	375						P39108;	4932.YDR142C;	3W15;
A3DD67	A3DD67_ACET2	unreviewed	Ricin B lectin	Cthe_0661	Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) (Hungateiclostridium thermocellum)	571							203119.Cthe_0661;	3VSF;3VSZ;3VT0;3VT1;3VT2;
P32337	IMB3_YEAST	reviewed	Importin subunit beta-3 (Karyopherin subunit beta-3) (Karyopherin-121) (Protein secretion enhancer 1)	PSE1 KAP121 YMR308C YM9952.10C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1089						P32337;	4932.YMR308C;	3W3T;3W3U;3W3V;3W3W;3W3X;3W3Y;3W3Z;4ZJ7;5H2V;
Q9Y4B6	DCAF1_HUMAN	reviewed	DDB1- and CUL4-associated factor 1 (HIV-1 Vpr-binding protein) (VprBP) (Serine/threonine-protein kinase VPRBP) (EC 2.7.11.1) (Vpr-interacting protein)	DCAF1 KIAA0800 RIP VPRBP	Homo sapiens (Human)	1507					"MUTAGEN 194;  /note=""K->R: Abolishes serine/threonine-protein kinase kinase activity."";  /evidence=""ECO:0000269|PubMed:24140421""; MUTAGEN 361;  /note=""D->A: Abolishes serine/threonine-protein kinase kinase activity."";  /evidence=""ECO:0000269|PubMed:24140421""; MUTAGEN 363;  /note=""K->A: Abolishes serine/threonine-protein kinase kinase activity."";  /evidence=""ECO:0000269|PubMed:24140421"""	Q9Y4B6;	9606.ENSP00000393183;	3WA0;4CC9;4P7I;4PXW;4Z8L;5AJA;5JK7;6N45;
P43629	KI3L1_HUMAN	reviewed	Killer cell immunoglobulin-like receptor 3DL1 (CD158 antigen-like family member E) (HLA-BW4-specific inhibitory NK cell receptor) (MHC class I NK cell receptor) (Natural killer-associated transcript 3) (NKAT-3) (p70 natural killer cell receptor clones CL-2/CL-11) (p70 NK receptor CL-2/CL-11) (CD antigen CD158e)	KIR3DL1 CD158E NKAT3 NKB1	Homo sapiens (Human)	444						P43629;	9606.ENSP00000375608;	3VH8;3WUW;5B38;5B39;5T6Z;5T70;6V3J;7K80;
P30690	OMPB1_NEIMB	reviewed	Major outer membrane protein P.IB (PIB) (Protein IB) (Class 3 protein) (Porin)	porB NMB2039	Neisseria meningitidis serogroup B (strain MC58)	331								3WI4;3WI5;
O74965	EIF2A_SCHPO	reviewed	Eukaryotic translation initiation factor 2A (eIF-2A)	SPBC4B4.04	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	576							4896.SPBC4B4.04.1;	3WJ9;
A2ICH1	A2ICH1_THESW	unreviewed	Parallel beta-helix repeat protein (Xylosidase)	Tsac_0939	Thermoanaerobacterium saccharolyticum (strain DSM 8691 / JW/SL-YS485)	638							1094508.Tsac_0939;	3VST;3VSU;3VSV;
E0D2V6	E0D2V6_LETCA	unreviewed	Variable lymphocyte receptor C	VLRC	Lethenteron camtschaticum (Japanese lamprey) (Lampetra japonica)	320								3WO9;
A0A0A8IK66	A0A0A8IK66_PIG	unreviewed	Heparin-binding protein WGA16	wga16 LOC110259943	Sus scrofa (Pig)	166								3WOB;3WOC;
O75122	CLAP2_HUMAN	reviewed	CLIP-associating protein 2 (Cytoplasmic linker-associated protein 2) (Protein Orbit homolog 2) (hOrbit2)	CLASP2 KIAA0627	Homo sapiens (Human)	1294					"MUTAGEN 106;  /note=""W->E: Decreases affinity for microtubules; when associated with A-191; E-667; E-833; A-838 and A-839."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 191;  /note=""K->A: Decreases affinity for microtubules; when associated with E-106; E-667; E-833; A-838 and A-839."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 496..497;  /note=""IP->AA: No effect on MAPRE1 binding. Abolishes interaction with MAPRE1; when associated with 519-A-A-520."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 496..497;  /note=""IP->SS: Reduced targeting to the growing microtubule plus ends. Loss of interaction with MAPRE1 and targeting to the growing microtubule plus ends; when associated with 519-S-S-520."";  /evidence=""ECO:0000269|PubMed:19632184""; MUTAGEN 499;  /note=""S->D: Phosphomimetic mutant that reduces MAPRE1 binding; when associated with D-503; D-507; D-525; D-529; D-533; D-537 and D-541."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 503;  /note=""S->D: Phosphomimetic mutant that reduces MAPRE1 binding; when associated with D-499; D-507; D-525; D-529; D-533; D-537 and D-541."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 507;  /note=""S->D: Phosphomimetic mutant that reduces MAPRE1 binding; when associated with D-499; D-503; D-525; D-529; D-533; D-537 and D-541."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 519..520;  /note=""IP->AA: No effect on MAPRE1 binding. Abolishes interaction with MAPRE1; when associated with 496-A-A-497."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 519..520;  /note=""IP->SS: Reduced targeting to the growing microtubule plus ends. Loss of interaction with MAPRE1 and targeting to the growing microtubule plus ends; when associated with 496-S-S-497."";  /evidence=""ECO:0000269|PubMed:19632184""; MUTAGEN 525;  /note=""S->D: Phosphomimetic mutant that reduces MAPRE1 binding; when associated with D-499; D-503; D-507; D-529; D-533; D-537 and D-541."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 529;  /note=""S->D: Phosphomimetic mutant that reduces MAPRE1 binding; when associated with D-499; D-503; D-507; D-525; D-533; D-537 and D-541."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 533;  /note=""S->D: Phosphomimetic mutant that reduces MAPRE1 binding; when associated with D-499; D-503; D-507; D-525; D-529; D-537 and D-541."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 537;  /note=""S->D: Phosphomimetic mutant that reduces MAPRE1 binding; when associated with D-499; D-503; D-507; D-525; D-529; D-533 and D-541."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 541;  /note=""S->D: Phosphomimetic mutant that reduces MAPRE1 binding; when associated with D-499; D-503; D-507; D-525; D-529; D-533 and D-537."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 667;  /note=""W->E: Decreases affinity for microtubules; when associated with E-106; A-191; E-833; A-838 and A-839."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 833;  /note=""K->E: Decreases affinity for microtubules; when associated with E-106; A-191; E-667; A-838 and A-839."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 838;  /note=""R->A: Decreases affinity for microtubules; when associated with E-106; A-191; E-667; E-833 and A-839."";  /evidence=""ECO:0000269|PubMed:26003921""; MUTAGEN 839;  /note=""K->A: Decreases affinity for microtubules; when associated with E-106; A-191; E-667; E-833 and A-838."";  /evidence=""ECO:0000269|PubMed:26003921"""	O75122;	9606.ENSP00000417518;	3WOY;5NR4;
Q8BRT1	CLAP2_MOUSE	reviewed	CLIP-associating protein 2 (Cytoplasmic linker-associated protein 2)	Clasp2 Kiaa0627	Mus musculus (Mouse)	1286					"MUTAGEN 6;  /note=""C->S: Impairs Golgi localization; when associated with S-10."";  /evidence=""ECO:0000269|PubMed:11290329""; MUTAGEN 10;  /note=""C->S: Impairs Golgi localization; when associated with S-6."";  /evidence=""ECO:0000269|PubMed:11290329"""	Q8BRT1;	10090.ENSMUSP00000128460;	3WOZ;
K7ZP88	ATAA_ACIS5	reviewed	Trimeric autotransporter adhesin AtaA (TAA AtaA) (Type 5 secretion system autotransporter AtaA)	ataA	Acinetobacter sp. (strain Tol 5)	3630		BIOTECHNOLOGY: Can be used to immobilize bacteria on a solid support; cells can be removed by washing in distilled water, and will reattach as the ionic strength of the medium increases above 10 mM. The attach-detach cycle can be repeated at least 4 times, each time the cells reattach as well as the first time (PubMed:23893702, PubMed:28720107). Expression in the indigo-producing Acinetobacter strain ST-550 leads to cell adherence to a support material and subsequently 5-fold increased levels of indigo production (PubMed:23893702). {ECO:0000269|PubMed:23893702, ECO:0000269|PubMed:28720107}.		DISRUPTION PHENOTYPE: Loss of rapid, irreversible adhesion to polyurethane, loss of both an anchor-like appendage and a peritrichate fibril-type appendage on the cell surface (PubMed:17090933, PubMed:23155410). Cells retain type 1 and Fil fimbriae (defined by FimA and FilA protein respectively) (PubMed:23155410). {ECO:0000269|PubMed:17090933, ECO:0000269|PubMed:23155410}.	"MUTAGEN 326..362;  /note=""Missing: Protein expressed on cell surface, autoagglutination and adherence to glass and polystyrene is normal."";  /evidence=""ECO:0000269|PubMed:27305955""; MUTAGEN 328..362;  /note=""Missing: Protein is expressed, but not present on the cell surface, loss of autoagglutination and adherence."";  /evidence=""ECO:0000269|PubMed:27305955""; MUTAGEN 335..362;  /note=""Missing: Protein expressed on cell surface, decreased autoagglutination, decreased adherence to glass and polystyrene, isolated fiber has slightly altered morphology."";  /evidence=""ECO:0000269|PubMed:27305955""; MUTAGEN 3061;  /note=""P->G: Protects recombinant proteins from degradation in vivo."";  /evidence=""ECO:0000269|PubMed:26698633""; MUTAGEN 3487;  /note=""G->GGGLEVLFLQGPG: Inserts a protease site, allows isolation of the intact, folded passenger domain. Protein behaves like wild-type."";  /evidence=""ECO:0000269|PubMed:27305955"""			3WP8;3WPA;3WPO;3WPP;3WPR;3WQA;
A5XB26	IBP_COLSX	reviewed	Ice-binding protein (Antifreeze protein) (AFP)		Colwellia sp.	253					"MUTAGEN 214;  /note=""T->Y: Has 20% thermal hysteresis (TH) activity of that of the wild-type. Has 2.6% thermal hysteresis (TH) activity of that of the wild-type; when associated with Y-233."";  /evidence=""ECO:0000269|PubMed:24938370""; MUTAGEN 217;  /note=""S->Y: No effect on thermal hysteresis (TH) activity."";  /evidence=""ECO:0000269|PubMed:24938370""; MUTAGEN 232;  /note=""T->K: Increased thermal hysteresis (TH) activity compared to wild-type."";  /evidence=""ECO:0000269|PubMed:24938370""; MUTAGEN 232;  /note=""T->Y: Has 50% thermal hysteresis (TH) activity of that of the wild-type."";  /evidence=""ECO:0000269|PubMed:24938370""; MUTAGEN 233;  /note=""A->Y: Significant decrease in thermal hysteresis (TH) activity compared to wild-type. Has 2.6% thermal hysteresis (TH) activity of that of the wild-type; when associated with Y-214."";  /evidence=""ECO:0000269|PubMed:24938370""; MUTAGEN 235;  /note=""T->Y: Has 17% thermal hysteresis (TH) activity of that of the wild-type."";  /evidence=""ECO:0000269|PubMed:24938370"""			3WP9;
Q2EEY0	TLR9_HORSE	reviewed	Toll-like receptor 9 (CD antigen CD289)	TLR9	Equus caballus (Horse)	1031					"MUTAGEN 47;  /note=""W->A: Significantly decreased binding to agonist CpG-DNA."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 96;  /note=""W->A: Significantly decreased binding to agonist CpG-DNA."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 108;  /note=""F->A: Significantly decreased binding to agonist CpG-DNA."";  /evidence=""ECO:0000269|PubMed:25686612"""			3WPB;3WPC;3WPD;5Y3J;5Y3K;5Y3L;
O54161	EABF_STRCO	reviewed	Extracellular exo-alpha-L-arabinofuranosidase (ABF) (EC 3.2.1.55) (Arabinosidase) (Arabinoxylan arabinofuranohydrolase)	abfB SCO5932 SC7H1.02	Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145)	475							100226.SCO5932;	3WMY;3WMZ;3WN0;3WN1;3WN2;
Q9EQU3	TLR9_MOUSE	reviewed	Toll-like receptor 9 (CD antigen CD289)	Tlr9	Mus musculus (Mouse)	1032				DISRUPTION PHENOTYPE: Reduced proliferation of lymphocytes, reduced interferon-gamma production by splenocytes and reduced neutrophil numbers following Helicobacter infection. {ECO:0000269|PubMed:17474149}.	"MUTAGEN 47;  /note=""W->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 74;  /note=""R->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 104;  /note=""S->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 108;  /note=""F->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 132;  /note=""Y->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 152;  /note=""H->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 179;  /note=""Y->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 229;  /note=""Y->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 499;  /note=""L->P: Highly susceptible to mouse cytomegalovirus infection. Shows low level of cytokine induction and natural killer activation on viral infection."";  /evidence=""ECO:0000269|PubMed:14993594""; MUTAGEN 642;  /note=""H->A: Loss of NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 668;  /note=""F->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612""; MUTAGEN 695;  /note=""N->A: Significantly decreased NF-kappa-B activation."";  /evidence=""ECO:0000269|PubMed:25686612"""	Q9EQU3;	10090.ENSMUSP00000082207;	3WPF;3WPG;3WPH;3WPI;4QDH;5ZLN;
F5HR99	F5HR99_9ACTN	unreviewed	Endoglucanase (EC 3.2.1.4)		Streptomyces thermolilacinus	561								3WSU;4Y7E;
N0DKS8	N0DKS8_9FLAO	unreviewed	Sodium pumping rhodopsin	NaR	Dokdonia eikasta	280								3X3B;3X3C;4XTL;4XTN;4XTO;5JRF;6REW;6REX;6REZ;6RF0;6RF1;6RF3;6RF4;6RF5;6RF6;6RF7;6RF9;6RFA;6RFB;6RFC;6TK1;6TK2;6TK3;6TK4;6TK5;6TK6;6TK7;6XYT;6YBY;6YBZ;6YC0;6YC1;6YC2;6YC3;6YC4;6YT4;
O88448	KLC2_MOUSE	reviewed	Kinesin light chain 2 (KLC 2)	Klc2	Mus musculus (Mouse)	599				DISRUPTION PHENOTYPE: Mutants show a progressive hearing loss with an increase in auditory brainstem response (ABR) thresholds with age, mostly affecting low frequencies, with a sensorineural (not conductive) pathology. At one month old, there is extensive loss of outer hair cell (OHC) hair bundles. {ECO:0000269|PubMed:30973865}.		O88448;	10090.ENSMUSP00000112262;	3ZFW;5FJY;6EJN;
P33896	INAR1_MOUSE	reviewed	Interferon alpha/beta receptor 1 (IFN-R-1) (IFN-alpha/beta receptor 1) (Type I interferon receptor 1)	Ifnar1 Ifar Ifnar	Mus musculus (Mouse)	590				DISRUPTION PHENOTYPE: Mice are protected from the lethal septic effects of intraperitoneal LPS administration observed in wild-type mice (PubMed:23872679). Double knockout with TREX1 does not show a visible phenotype (PubMed:18724932). {ECO:0000269|PubMed:18724932, ECO:0000269|PubMed:23872679}.	"MUTAGEN 526;  /note=""S->A: Abolishes interaction with FBXW11. Prevents interalization from the cell membrane and lysosomal degradation."";  /evidence=""ECO:0000269|PubMed:14532120"""	P33896;	10090.ENSMUSP00000023689;	3WCY;
A0A0H2ZNL3	MURA1_STRP2	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (EPT) (UDP-N-acetylglucosamine enolpyruvyl transferase)	murA1 murA SPD_0967	Streptococcus pneumoniae serotype 2 (strain D39 / NCTC 7466)	419				DISRUPTION PHENOTYPE: No heteroresistance to fosfomycin. {ECO:0000269|PubMed:23571543}.			373153.SPD_0967;	3ZH3;
B1IBM3	MURA1_STRPI	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (EPT) (UDP-N-acetylglucosamine enolpyruvyl transferase)	murA1 murA SPH_1173	Streptococcus pneumoniae (strain Hungary19A-6)	419								3ZH4;
G5ECF1	G5ECF1_CAEEL	unreviewed	Nonsense-mediated mRNA decay protein (PINc domain-containing protein)	smg-5 CELE_W02D3.8 W02D3.8	Caenorhabditis elegans	549						G5ECF1;	6239.W02D3.8;	3ZHE;
Q9H9S4	CB39L_HUMAN	reviewed	Calcium-binding protein 39-like (Antigen MLAA-34) (MO25beta) (Mo25-like protein)	CAB39L	Homo sapiens (Human)	337						Q9H9S4;	9606.ENSP00000479669;	3ZHP;
Q75E93	Q75E93_ASHGO	unreviewed	AAR187Cp	AGOS_AAR187C	Ashbya gossypii (strain ATCC 10895 / CBS 109.51 / FGSC 9923 / NRRL Y-1056) (Yeast) (Eremothecium gossypii)	561						Q75E93;	33169.AAS50554;	3ZIK;3ZIL;
O94556	APC8_SCHPO	reviewed	Anaphase-promoting complex subunit 8 (20S cyclosome/APC complex protein apc8) (Cell untimely torn protein 23)	cut23 apc8 SPAC6F12.14	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	565						O94556;	4896.SPAC6F12.14.1;	3ZN3;5FTP;
Q5I2M5	TLR9_BOVIN	reviewed	Toll-like receptor 9 (CD antigen CD289)	TLR9	Bos taurus (Bovine)	1029							9913.ENSBTAP00000024223;	3WPE;5Y3M;
Q13325	IFIT5_HUMAN	reviewed	Interferon-induced protein with tetratricopeptide repeats 5 (IFIT-5) (Interferon-induced 58 kDa protein) (Retinoic acid- and interferon-inducible 58 kDa protein) (P58)	IFIT5 ISG58 RI58	Homo sapiens (Human)	482					"MUTAGEN 33;  /note=""E->A: No effect on RNA-binding but changes size profile of RNA bound. Reduces PPP-RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420, ECO:0000269|PubMed:25092312""; MUTAGEN 37;  /note=""T->A,V: No effect on RNA-binding but changes size profile of RNA bound."";  /evidence=""ECO:0000269|PubMed:25092312""; MUTAGEN 37;  /note=""T->V: Abolishes PPP-RNA-binding.""; MUTAGEN 41;  /note=""Q->E: No effect on RNA-binding but changes size profile of RNA bound. Abolishes PPP-RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420, ECO:0000269|PubMed:25092312""; MUTAGEN 48;  /note=""K->A,E: Inhibits RNA-binding."";  /evidence=""ECO:0000269|PubMed:25092312""; MUTAGEN 150;  /note=""K->M: Abolishes PPP-RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420""; MUTAGEN 150;  /note=""K->N,E: Inhibits RNA-binding."";  /evidence=""ECO:0000269|PubMed:25092312""; MUTAGEN 150;  /note=""K->R: Reduces RNA-binding."";  /evidence=""ECO:0000269|PubMed:25092312""; MUTAGEN 156;  /note=""Y->F,A: No effect on RNA-binding. Reduces PPP-RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420, ECO:0000269|PubMed:25092312""; MUTAGEN 185..186;  /note=""YR->AE: Reduces binding to RNA and DNA."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 186;  /note=""R->H,A: Abolishes RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420, ECO:0000269|PubMed:25092312""; MUTAGEN 250;  /note=""Y->F: No effect on RNA-binding but changes size profile of RNA bound. Abolishes PPP-RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420, ECO:0000269|PubMed:25092312""; MUTAGEN 253..254;  /note=""RY->EA: Reduces binding to RNA and DNA."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 253;  /note=""R->M: Abolishes RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420, ECO:0000269|PubMed:25092312""; MUTAGEN 254;  /note=""Y->F: Abolishes RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420, ECO:0000269|PubMed:25092312""; MUTAGEN 257;  /note=""K->E: Reduces binding to RNA and DNA."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 260;  /note=""R->E: Abolishes PPP-RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420""; MUTAGEN 284;  /note=""F->A: Strongly reduces binding to dsDNA. No effect on ssRNA binding."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 287;  /note=""H->A: Reduces PPP-RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420""; MUTAGEN 288;  /note=""Q->E: Abolishes RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420, ECO:0000269|PubMed:25092312""; MUTAGEN 291;  /note=""L->A: No effect RNA-binding."";  /evidence=""ECO:0000269|PubMed:23317505, ECO:0000269|PubMed:25092312""; MUTAGEN 294;  /note=""R->E: Strongly reduces binding to dsDNA. No effect on ssRNA binding."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 302;  /note=""K->A: Reduces RNA-binding."";  /evidence=""ECO:0000269|PubMed:23317505""; MUTAGEN 307;  /note=""R->A: Reduces RNA-binding. 25 fold reduction in tRNA-binding."";  /evidence=""ECO:0000269|PubMed:23317505, ECO:0000269|PubMed:25092312""; MUTAGEN 309;  /note=""K->A: Reduces RNA-binding."";  /evidence=""ECO:0000269|PubMed:23317505""; MUTAGEN 334;  /note=""D->A: No effect on RNA-binding but changes size profile of RNA bound."";  /evidence=""ECO:0000269|PubMed:25092312""; MUTAGEN 337..339;  /note=""FAF->AAA: Reduces binding to RNA and DNA."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 337;  /note=""F->A: Abolishes PPP-RNA-binding."";  /evidence=""ECO:0000269|PubMed:23334420""; MUTAGEN 339;  /note=""F->A: Reduces RNA-binding."";  /evidence=""ECO:0000269|PubMed:25092312""; MUTAGEN 384;  /note=""R->E: Reduces binding to RNA and DNA and impairs antiviral activity; when associated with E-415."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 388..389;  /note=""FH->AA: Reduces RNA-binding."";  /evidence=""ECO:0000269|PubMed:23317505""; MUTAGEN 415;  /note=""K->A: Reduces RNA-binding. 25 fold reduction in tRNA-binding."";  /evidence=""ECO:0000269|PubMed:23317505, ECO:0000269|PubMed:25092312""; MUTAGEN 415;  /note=""K->E: Reduces binding to RNA and DNA and impairs antiviral activity; when associated with E-384."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 422..426;  /note=""KLSTK->ELSTE: Reduces binding to RNA and DNA."";  /evidence=""ECO:0000269|PubMed:23774268""; MUTAGEN 422;  /note=""K->A: Reduced RNA-binding."";  /evidence=""ECO:0000269|PubMed:23317505, ECO:0000269|PubMed:25092312""; MUTAGEN 426;  /note=""K->A: Reduces RNA-binding. 5 fold reduction in tRNA-binding."";  /evidence=""ECO:0000269|PubMed:23317505"""	Q13325;	9606.ENSP00000360860;	3ZGQ;4HOQ;4HOR;4HOS;4HOT;4J0U;
Q9HCJ2	LRC4C_HUMAN	reviewed	Leucine-rich repeat-containing protein 4C (Netrin-G1 ligand) (NGL-1)	LRRC4C KIAA1580 NGL1 UNQ292/PRO331	Homo sapiens (Human)	640						Q9HCJ2;	9606.ENSP00000278198;	3ZYJ;
P0C192	LRC4B_MOUSE	reviewed	Leucine-rich repeat-containing protein 4B (Netrin-G3 ligand) (NGL-3)	Lrrc4b Lrig4	Mus musculus (Mouse)	709						P0C192;	10090.ENSMUSP00000053123;	3ZYN;3ZYO;
P03748	FIBER_BPT7	reviewed	Tail fiber protein (Gene product 17) (Gp17) (Tail fiber protein gp17)	17	Escherichia phage T7 (Bacteriophage T7)	553								4A0T;4A0U;7BOZ;
O18423	TXL_EISFE	reviewed	Lysenin (Beta-barrel pore-forming toxin) (Beta-PFT) (Invertebrate cytolysin pore) (efL1)		Eisenia fetida (Red wiggler worm)	297		BIOTECHNOLOGY: This toxin represents an excellent tool for visualizing distribution and dynamics of sphingomyelin in cells. {ECO:0000305|PubMed:27176125}.			"MUTAGEN 20;  /note=""W->A: Loss of ability to bind sphingomyelin, and to induce hemolysis."";  /evidence=""ECO:0000269|PubMed:15274631""; MUTAGEN 21;  /note=""K->A: Decrease in ability to bind sphingomyelin and to lyse cells."";  /evidence=""ECO:0000269|PubMed:22819216""; MUTAGEN 24;  /note=""Y->A: In double Tyr mutant; almost complete loss of ability to bind sphingomyelin and to lyse cells."";  /evidence=""ECO:0000269|PubMed:22819216""; MUTAGEN 26;  /note=""Y->A: In double Tyr mutant; almost complete loss of ability to bind sphingomyelin and to lyse cells."";  /evidence=""ECO:0000269|PubMed:22819216""; MUTAGEN 88;  /note=""V->C: In double Cys mutant; complete loss of ability to form pores when Cys are disulfide-linked."";  /evidence=""ECO:0000269|PubMed:27176125""; MUTAGEN 117;  /note=""Q->A: Decrease in ability to bind sphingomyelin and to lyse cells."";  /evidence=""ECO:0000269|PubMed:22819216""; MUTAGEN 128;  /note=""E->A: Decrease in ability to bind sphingomyelin and to lyse cells."";  /evidence=""ECO:0000269|PubMed:22819216""; MUTAGEN 131;  /note=""Y->C: In double Cys mutant; complete loss of ability to form pores when Cys are disulfide-linked."";  /evidence=""ECO:0000269|PubMed:27176125""; MUTAGEN 187;  /note=""W->A: Loss of ability to bind sphingomyelin, and induces hemolysis only at high concentration."";  /evidence=""ECO:0000269|PubMed:15274631""; MUTAGEN 206;  /note=""W->A: Does not affect binding, and has little loss of hemolytic activity."";  /evidence=""ECO:0000269|PubMed:15274631""; MUTAGEN 245;  /note=""W->A: Loss of ability to bind sphingomyelin, and to induce hemolysis."";  /evidence=""ECO:0000269|PubMed:15274631""; MUTAGEN 291;  /note=""W->A: Loss of ability to bind sphingomyelin, and to induce hemolysis."";  /evidence=""ECO:0000269|PubMed:15274631"""			3ZX7;3ZXD;3ZXG;5EC5;5GAQ;
Q9WYR4	PTLY_THEMA	reviewed	Pectate trisaccharide-lyase (EC 4.2.2.22) (Pectate lyase A) (PelA)	pelA TM_0433	Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8)	367							243274.THEMA_02560;	3ZSC;
P84193	AUD_PHACH	reviewed	Aldos-2-ulose dehydratase (EC 4.2.1.110) (D-arabino-hex-2-ulose dehydratase) (Pyranosone dehydratase)		Phanerodontia chrysosporium (White-rot fungus) (Sporotrichum pruinosum)	900								4A7K;4A7Y;4A7Z;
Q8U092	TRPF_PYRFU	reviewed	N-(5'-phosphoribosyl)anthranilate isomerase (PRAI) (EC 5.3.1.24)	trpF PF1707	Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1)	208							186497.PF1707;	4AAJ;
Q8DQ18	GLMU_STRR6	reviewed	Bifunctional protein GlmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (N-acetylglucosamine-1-phosphate uridyltransferase); Glucosamine-1-phosphate N-acetyltransferase (EC 2.3.1.157)]	glmU spr0891	Streptococcus pneumoniae (strain ATCC BAA-255 / R6)	459							171101.spr0891;	4AAW;4AC3;
Q13216	ERCC8_HUMAN	reviewed	DNA excision repair protein ERCC-8 (Cockayne syndrome WD repeat protein CSA)	ERCC8 CKN1 CSA	Homo sapiens (Human)	396			DISEASE: Cockayne syndrome A (CSA) [MIM:216400]: A rare disorder characterized by cutaneous sensitivity to sunlight, abnormal and slow growth, cachectic dwarfism, progeroid appearance, progressive pigmentary retinopathy and sensorineural deafness. There is delayed neural development and severe progressive neurologic degeneration resulting in mental retardation. Two clinical forms are recognized: in the classical form or Cockayne syndrome type 1, the symptoms are progressive and typically become apparent within the first few years or life; the less common Cockayne syndrome type 2 is characterized by more severe symptoms that manifest prenatally. Cockayne syndrome shows some overlap with certain forms of xeroderma pigmentosum. Unlike xeroderma pigmentosum, patients with Cockayne syndrome do not manifest increased freckling and other pigmentation abnormalities in the skin and have no significant increase in skin cancer. {ECO:0000269|PubMed:14661080, ECO:0000269|PubMed:15744458, ECO:0000269|PubMed:19894250}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: UV-sensitive syndrome 2 (UVSS2) [MIM:614621]: An autosomal recessive disorder characterized by cutaneous photosensitivity and mild freckling in the absence of neurological abnormalities or skin tumors. {ECO:0000269|PubMed:19329487}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q13216;	9606.ENSP00000265038;	4A11;6FCV;
P78972	SLP1_SCHPO	reviewed	WD repeat-containing protein slp1	slp1 SPAC821.08c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	488					"MUTAGEN 131..132;  /note=""AF->PY: Abrogates binding to mad2 and overrides activation of the spindle checkpoint by mad2."";  /evidence=""ECO:0000269|PubMed:9461438"""	P78972;	4896.SPAC821.08c.1;	4AEZ;
Q89YR8	Q89YR8_BACTN	unreviewed	Two-component system sensor histidine kinase/response	BT_4663	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	1353							226186.BT_4663;	4A2L;4A2M;
P63244	RACK1_HUMAN	reviewed	Receptor of activated protein C kinase 1 (Cell proliferation-inducing gene 21 protein) (Guanine nucleotide-binding protein subunit beta-2-like 1) (Guanine nucleotide-binding protein subunit beta-like protein 12.3) (Human lung cancer oncogene 7 protein) (HLC-7) (Receptor for activated C kinase) (Small ribosomal subunit protein RACK1) [Cleaved into: Receptor of activated protein C kinase 1, N-terminally processed (Guanine nucleotide-binding protein subunit beta-2-like 1, N-terminally processed)]	RACK1 GNB2L1 HLC7 PIG21	Homo sapiens (Human)	317					"MUTAGEN 36..38;  /note=""RDK->DDE: In DEmut; abolishes association with the ribosome and ability to initiate the ribosome quality control (RQC)."";  /evidence=""ECO:0000269|PubMed:28132843""; MUTAGEN 52;  /note=""Y->F: No effect on binding to SRC. Abolishes binding to PTK2/FAK1 and reduces cell adhesion and foci formation."";  /evidence=""ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:12400005, ECO:0000269|PubMed:19423701""; MUTAGEN 57;  /note=""R->A: Decreased binding to PTK2/FAK1; when associated with A-60."";  /evidence=""ECO:0000269|PubMed:19423701""; MUTAGEN 60;  /note=""R->A: Decreased binding to PTK2/FAK1; when associated with A-57."";  /evidence=""ECO:0000269|PubMed:19423701""; MUTAGEN 127;  /note=""K->A: Decreased binding to PTK2/FAK1; when associated with A-130."";  /evidence=""ECO:0000269|PubMed:19423701""; MUTAGEN 130;  /note=""K->A: Decreased binding to PTK2/FAK1; when associated with A-127."";  /evidence=""ECO:0000269|PubMed:19423701""; MUTAGEN 140;  /note=""Y->F: No effect on binding to SRC."";  /evidence=""ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:12400005""; MUTAGEN 194;  /note=""Y->F: No effect on binding to SRC."";  /evidence=""ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:12400005""; MUTAGEN 228;  /note=""Y->F: No effect on binding to SRC. Does not abolish phosphorylation by SRC. Abolishes phosphorylation by SRC; when associated with F-246 and F-302."";  /evidence=""ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:12400005""; MUTAGEN 246;  /note=""Y->F: Abolishes binding to SRC. Does not abolish phosphorylation by SRC. Abolishes phosphorylation by SRC; when associated with F-228 and F-302."";  /evidence=""ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:12400005""; MUTAGEN 276..279;  /note=""STSS->EEEE: Enhanced translation of mRNAs containing poly-A leaders."";  /evidence=""ECO:0000269|PubMed:28636603""; MUTAGEN 278;  /note=""S->E: Enhanced translation of mRNAs containing poly-A leaders."";  /evidence=""ECO:0000269|PubMed:28636603""; MUTAGEN 302;  /note=""Y->F: No effect on binding to SRC. Abolishes phosphorylation by SRC; when associated with F-228 and F-246."";  /evidence=""ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:12400005"""	P63244;	9606.ENSP00000426909;	4AOW;4UG0;4V6X;5A2Q;5AJ0;5FLX;5LKS;5OA3;5T2C;5VYC;6EK0;6FEC;6G18;6G51;6G53;6G5H;6G5I;6IP5;6IP6;6IP8;6OLE;6OLF;6OLG;6OLI;6OLZ;6OM0;6OM7;6QZP;6XA1;6Y0G;6Y2L;6Y57;6YBS;6Z6L;6Z6M;6Z6N;6ZLW;6ZM7;6ZME;6ZMI;6ZMO;6ZMT;6ZMW;6ZN5;6ZOJ;6ZOL;6ZON;6ZP4;6ZUO;6ZV6;6ZVH;6ZVJ;6ZXD;6ZXE;6ZXF;6ZXG;6ZXH;7A09;7K5I;
Q4WW81	LECF_ASPFU	reviewed	Fucose-specific lectin (Aspergillus fumigatus lectin) (AFL)	fleA AFUA_5G14740	Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) (Aspergillus fumigatus)	315		BIOTECHNOLOGY: Lectins have particular value as specific probes for investigating the distribution, structure and biological function of carbohydrate chains on the cell surface of animal, plant, and microorganism because of their specificity for defined carbohydrate structures. AFL is suitable for detecting core fucose on cell surface glycoproteins (PubMed:25760594). {ECO:0000305|PubMed:25760594}.		DISRUPTION PHENOTYPE: Increases lung infection and lung injury by A.fumigatus (PubMed:27058347). {ECO:0000269|PubMed:27058347}.				4AGI;4AGT;4AH4;4AHA;4C1Y;4D4U;4D52;4UOU;6Z6C;
I6L8L5	I6L8L5_ANTLO	unreviewed	TAF6		Antonospora locustae (Microsporidian parasite) (Nosema locustae)	196								4ATG;
Q6CN23	HSV2_KLULA	reviewed	SVP1-like protein 2	HSV2 KLLA0E15972g	Kluyveromyces lactis (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-1140 / WM37) (Yeast) (Candida sphaerica)	339							28985.XP_454666.1;	4AV8;4AV9;4EXV;4V16;
P0DQD3	INLB_LISMG	reviewed	Internalin B (InlB) (Invasion protein InlB)	inlB	Listeria monocytogenes serotype 1/2a (strain EGD / Mackaness)	630				DISRUPTION PHENOTYPE: Deletion of both inlA and inlB prevents uptake of Listeria by human enterocyte-like cell line Caco-2 (PubMed:1905979). Single inlB deletion no longer invades various cell lines (PubMed:9282740, PubMed:15049825, PubMed:8864117). Decreased synthesis of phosphatidylinositol 3,4,5-trisphosphate (PIP3) in green monkey cells, decreased infection of host cells, decreased association of host PI3-kinase catalytic subunit with tyrosine-phosphorylated proteins (PubMed:8864117). Deletion no longer Tyr-phosphorylates mammalian MET (PubMed:11081636, PubMed:15049825). {ECO:0000269|PubMed:11081636, ECO:0000269|PubMed:15049825, ECO:0000269|PubMed:1905979, ECO:0000269|PubMed:8864117, ECO:0000269|PubMed:9282740}.	"MUTAGEN 51..59;  /note=""DAFAETIKD->AAFAETIKA: No Ca(2+) binding, no change in Tyr-phosphorylation of host MET, wild-type invasion of host Vero cells."";  /evidence=""ECO:0000269|PubMed:15020228""; MUTAGEN 51;  /note=""D->A: Only binds 1 Ca(2+), no change in Tyr-phosphorylation of host MET, wild-type invasion of host Vero cells."";  /evidence=""ECO:0000269|PubMed:15020228""; MUTAGEN 59;  /note=""D->A: No Ca(2+) binding, no change in Tyr-phosphorylation of host MET, wild-type invasion of host Vero cells."";  /evidence=""ECO:0000269|PubMed:15020228"""			1D0B;1M9S;1OTM;1OTN;1OTO;6GCU;6U12;
Q9NR97	TLR8_HUMAN	reviewed	Toll-like receptor 8 (CD antigen CD288)	TLR8 UNQ249/PRO286	Homo sapiens (Human)	1041					"MUTAGEN 348;  /note=""Y->A: Abolishes activation of NF-kappa-B."";  /evidence=""ECO:0000269|PubMed:23520111""; MUTAGEN 348;  /note=""Y->A: Abolishes responses to both ssRNA and chemical ligands."";  /evidence=""ECO:0000269|PubMed:25599397""; MUTAGEN 378;  /note=""V->A: Increases activation of NF-kappa-B."";  /evidence=""ECO:0000269|PubMed:23520111""; MUTAGEN 405;  /note=""F->A: Abolishes activation of NF-kappa-B."";  /evidence=""ECO:0000269|PubMed:23520111""; MUTAGEN 405;  /note=""F->A: Abolishes responses to both ssRNA and chemical ligands."";  /evidence=""ECO:0000269|PubMed:25599397""; MUTAGEN 452..455;  /note=""RKRR->NQSN: Monomeric and inactive."";  /evidence=""ECO:0000269|PubMed:26929371""; MUTAGEN 520;  /note=""V->A: Strongly decreases activation of NF-kappa-B."";  /evidence=""ECO:0000269|PubMed:23520111""; MUTAGEN 543;  /note=""D->A: Abolishes activation of NF-kappa-B."";  /evidence=""ECO:0000269|PubMed:23520111""; MUTAGEN 543;  /note=""D->A: Abolishes responses to both ssRNA and chemical ligands."";  /evidence=""ECO:0000269|PubMed:25599397""; MUTAGEN 574;  /note=""T->A: Abolishes responses to both ssRNA and chemical ligands."";  /evidence=""ECO:0000269|PubMed:25599397""; MUTAGEN 574;  /note=""T->A: Strongly decreases activation of NF-kappa-B."";  /evidence=""ECO:0000269|PubMed:23520111"""	Q9NR97;	9606.ENSP00000312082;	3W3G;3W3J;3W3K;3W3L;3W3M;3W3N;3WN4;4QBZ;4QC0;4R07;4R08;4R09;4R0A;4R6A;5AWA;5AWB;5AWC;5AWD;5AZ5;5HDH;5WYX;5WYZ;5Z14;5Z15;6KYA;6TY5;6V9U;6WML;6ZJZ;7CRF;
Q2TBA0	KLH40_HUMAN	reviewed	Kelch-like protein 40 (Kelch repeat and BTB domain-containing protein 5) (Sarcosynapsin)	KLHL40 KBTBD5 SRYP	Homo sapiens (Human)	621			DISEASE: Nemaline myopathy 8 (NEM8) [MIM:615348]: A severe form of nemaline myopathy. Nemaline myopathies are muscular disorders characterized by muscle weakness of varying severity and onset, and abnormal thread-like or rod-shaped structures in muscle fibers on histologic examination. NEM8 is characterized by fetal akinesia or hypokinesia, followed by contractures, fractures, respiratory failure, and swallowing difficulties apparent at birth. Most patients die in infancy. Skeletal muscle biopsy shows numerous small nemaline bodies, often with no normal myofibrils. {ECO:0000269|PubMed:23746549, ECO:0000269|PubMed:26754003, ECO:0000269|PubMed:27528495, ECO:0000269|PubMed:27762439}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q2TBA0;	9606.ENSP00000287777;	4ASC;
Q8FNZ7	HIS4_COREF	reviewed	1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase (EC 5.3.1.16) (Phosphoribosylformimino-5-aminoimidazole carboxamide ribotide isomerase)	hisA CE1996	Corynebacterium efficiens (strain DSM 44549 / YS-314 / AJ 12310 / JCM 11189 / NBRC 100395)	246							196164.23493837;	4AXK;
Q96NW4	ANR27_HUMAN	reviewed	Ankyrin repeat domain-containing protein 27 (VPS9 domain-containing protein)	ANKRD27 PP12899	Homo sapiens (Human)	1050					"MUTAGEN 432;  /note=""H->A: Disrupts interaction with VPS29; when associated with A-434."";  /evidence=""ECO:0000269|PubMed:24856514""; MUTAGEN 434;  /note=""L->A: Disrupts interaction with VPS29; when associated with A-432."";  /evidence=""ECO:0000269|PubMed:24856514""; MUTAGEN 509;  /note=""Q->A: Disrupts interaction with RAB32."";  /evidence=""ECO:0000269|PubMed:24856514""; MUTAGEN 513;  /note=""L->D: Disrupts interaction with RAB32."";  /evidence=""ECO:0000269|PubMed:24856514""; MUTAGEN 546;  /note=""K->D: Impairs interaction with RAB32."";  /evidence=""ECO:0000269|PubMed:24856514""; MUTAGEN 550;  /note=""Y->A: Impairs interaction with RAB32."";  /evidence=""ECO:0000269|PubMed:24856514""; MUTAGEN 679;  /note=""D->A: Disrupts interaction with VAMP7."";  /evidence=""ECO:0000269|PubMed:23104059""; MUTAGEN 681;  /note=""D->A: Disrupts interaction with VAMP7."";  /evidence=""ECO:0000269|PubMed:23104059""; MUTAGEN 684;  /note=""M->D: Disrupts interaction with VAMP7."";  /evidence=""ECO:0000269|PubMed:23104059""; MUTAGEN 687;  /note=""Y->S: Disrupts interaction with VAMP7."";  /evidence=""ECO:0000269|PubMed:23104059""; MUTAGEN 712;  /note=""H->A: Disrupts interaction with VPS29; when associated with A-714."";  /evidence=""ECO:0000269|PubMed:24856514""; MUTAGEN 714;  /note=""L->A: Disrupts interaction with VPS29; when associated with A-712."";  /evidence=""ECO:0000269|PubMed:24856514"""	Q96NW4;	9606.ENSP00000304292;	4B93;4CYM;4CZ2;6TL0;
P53197	CDH1_YEAST	reviewed	APC/C activator protein CDH1 (CDC20 homolog 1) (Homolog of CDC twenty 1)	CDH1 HCT1 YGL003C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	566					"MUTAGEN 12;  /note=""T->A: Abolishes phosphorylation; when associated with A-16; A-42; A-157; A-169; A-173; A-176; A-227 and A-239."";  /evidence=""ECO:0000269|PubMed:9831566""; MUTAGEN 16;  /note=""S->A: Abolishes phosphorylation; when associated with A-12; A-42; A-157; A-169; A-173; A-176; A-227 and A-239."";  /evidence=""ECO:0000269|PubMed:9831566""; MUTAGEN 42;  /note=""S->A: Abolishes phosphorylation; when associated with A-12; A-16; A-157; A-169; A-173; A-176; A-227 and A-239."";  /evidence=""ECO:0000269|PubMed:9831566""; MUTAGEN 157;  /note=""T->A: Abolishes phosphorylation; when associated with A-12; A-16; A-42; A-169; A-173; A-176; A-227 and A-239."";  /evidence=""ECO:0000269|PubMed:9831566""; MUTAGEN 169;  /note=""S->A: Abolishes phosphorylation; when associated with A-12; A-16; A-42; A-157; A-173; A-176; A-227 and A-239."";  /evidence=""ECO:0000269|PubMed:9831566""; MUTAGEN 173;  /note=""T->A: Abolishes phosphorylation; when associated with A-12; A-16; A-42; A-157; A-169; A-176; A-227 and A-239."";  /evidence=""ECO:0000269|PubMed:9831566""; MUTAGEN 176;  /note=""T->A: Abolishes phosphorylation; when associated with A-12; A-16; A-42; A-157; A-169; A-173; A-227 and A-239."";  /evidence=""ECO:0000269|PubMed:9831566""; MUTAGEN 227;  /note=""S->A: Abolishes phosphorylation; when associated with A-12; A-16; A-42; A-157; A-169; A-173; A-176 and A-239."";  /evidence=""ECO:0000269|PubMed:9831566""; MUTAGEN 239;  /note=""S->A: Abolishes phosphorylation; when associated with A-12; A-16; A-42; A-157; A-169; A-173; A-176 and A-227."";  /evidence=""ECO:0000269|PubMed:9831566"""	P53197;	4932.YGL003C;	4BH6;5A31;
C6KHT4	C6KHT4_NEIME	unreviewed	Factor H-binding protein	fhbP	Neisseria meningitidis	273								4AYN;
Q5SBL9	Q5SBL9_LACRE	unreviewed	Dextransucrase (EC 2.4.1.5) (Sucrose 6-glucosyltransferase)		Lactobacillus reuteri	1781								4AMC;
O75473	LGR5_HUMAN	reviewed	Leucine-rich repeat-containing G-protein coupled receptor 5 (G-protein coupled receptor 49) (G-protein coupled receptor 67) (G-protein coupled receptor HG38)	LGR5 GPR49 GPR67	Homo sapiens (Human)	907					"MUTAGEN 146;  /note=""D->F: Abolishes activation of Wnt signaling."";  /evidence=""ECO:0000269|PubMed:23809763""; MUTAGEN 170;  /note=""D->F: Abolishes activation of Wnt signaling."";  /evidence=""ECO:0000269|PubMed:23809763""; MUTAGEN 190;  /note=""A->D: Abolishes activation of Wnt signaling."";  /evidence=""ECO:0000269|PubMed:23809763""; MUTAGEN 861;  /note=""S->A: Impaired internalization to the trans-Golgi network; when associated with A-864."";  /evidence=""ECO:0000269|PubMed:23439653""; MUTAGEN 864;  /note=""S->A: Impaired internalization to the trans-Golgi network; when associated with A-861."";  /evidence=""ECO:0000269|PubMed:23439653"""	O75473;	9606.ENSP00000266674;	4BSR;4BSS;4BST;4BSU;4KNG;4UFR;4UFS;
E7F650	E7F650_DANRE	unreviewed	Avidin	avd	Danio rerio (Zebrafish) (Brachydanio rerio)	154							7955.ENSDARP00000105027;	4BJ8;
P25655	NOT1_YEAST	reviewed	General negative regulator of transcription subunit 1 (Cell division cycle protein 39)	CDC39 NOT1 ROS1 YCR093W YCR1151 YCR93W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	2108						P25655;	4932.YCR093W;	4B89;4B8A;4B8B;4B8C;4BY6;4CV5;5AJD;
A0A0H2VDN9	ESIB_ECOL6	reviewed	Secretory immunoglobulin A-binding protein EsiB	esiB c5321	Escherichia coli O6:H1 (strain CFT073 / ATCC 700928 / UPEC)	490		BIOTECHNOLOGY: Immunizes 1/3 of injected mice against subsequent infection with E.coli strain CFT073, suggesting it might be a good vaccine candidate for ExPEC (extraintestinal pathogenic E.coli) strains. {ECO:0000269|PubMed:20439758}.					199310.c5321;	4BWR;
E7FCY1	E7FCY1_DANRE	unreviewed	Centromere protein J	cenpj	Danio rerio (Zebrafish) (Brachydanio rerio)	1124						E7FCY1;	7955.ENSDARP00000117414;	4BXP;4BXQ;4BXR;4LD1;4LD3;4LZF;
Q9VI72	Q9VI72_DROME	unreviewed	Spindle assembly abnormal 4	Sas-4 CPAP d-SAS-4 D-Sas4 D-sas4 Dmel\CG10061 DmSas4 DSAS-4 DSas-4 Dsas-4 dsas-4 DSas4 Dsas4 l(3)S2214 l(3)s2214 SAS-4 sas-4 SAS4 Sas4 sas4 CG10061 Dmel_CG10061	Drosophila melanogaster (Fruit fly)	901						Q9VI72;	7227.FBpp0081088;	4BY2;4MPZ;
O76728	O76728_TRYBB	unreviewed	Prolyl endopeptidase (EC 3.4.21.-)	opb	Trypanosoma brucei brucei	715								4BP8;4BP9;
Q9Y5L0	TNPO3_HUMAN	reviewed	Transportin-3 (Importin-12) (Imp12) (Transportin-SR) (TRN-SR)	TNPO3 IPO12	Homo sapiens (Human)	923			DISEASE: Muscular dystrophy, limb-girdle, autosomal dominant 2 (LGMDD2) [MIM:608423]: An autosomal dominant myopathy characterized by proximal muscle weakness primarily affecting the lower limbs, but also affecting the upper limbs in most patients. Affected individuals also have distal muscle weakness of the hands and lower leg muscles. The disease has generally a benign clinical course but some individuals with childhood or juvenile onset manifest severe widespread myopathy, leading to wheelchair dependency and respiratory insufficiency. Muscle biopsy shows dystrophic changes with abnormal nuclei, rimmed vacuoles, and filamentous inclusions. {ECO:0000269|PubMed:23543484, ECO:0000269|PubMed:23667635, ECO:0000269|PubMed:31071488, ECO:0000269|PubMed:31192305, ECO:0000269|PubMed:31465518}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 145..153;  /note=""EILTVLPEE->QILTALPQQ: Decreased interaction with GTP-bound Ran."";  /evidence=""ECO:0000269|PubMed:23878195""; MUTAGEN 620;  /note=""R->A: In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-660, A-664, A-667, A-671, A-702, A-750, A-751 and A-758."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 660;  /note=""E->A: In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-620, A-664, A-667, A-671, A-702, A-750, A-751 and A-758."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 664;  /note=""R->A: Abolished interaction with SRSF1. In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-620, A-660, A-667, A-671, A-702, A-750, A-751 and A-758."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 667;  /note=""R->A: In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-620, A-660, A-664, A-671, A-702, A-750, A-751 and A-758."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 671;  /note=""R->A: Abolished interaction with SRSF1. In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-620, A-660, A-664, A-667, A-702, A-750, A-751 and A-758."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 702;  /note=""Y->A: Abolished interaction with SRSF1. In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-620, A-660, A-664, A-667, A-671, A-750, A-751 and A-758."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 750;  /note=""D->A: Abolished interaction with SRSF1. In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-620, A-660, A-664, A-667, A-671, A-702, A-751 and A-758."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 751;  /note=""D->A: In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-620, A-660, A-664, A-667, A-671, A-702, A-750 and A-758."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 754;  /note=""R->A: Abolished interaction with SRSF1."";  /evidence=""ECO:0000269|PubMed:24449914""; MUTAGEN 758;  /note=""R->A: Abolished interaction with SRSF1. In 9Ala; abolished interaction with SRSF1 and CPSF6 without affecting interaction with GTP-bound Ran; when associated with A-620, A-660, A-664, A-667, A-671, A-702, A-750 and A-751."";  /evidence=""ECO:0000269|PubMed:24449914"""	Q9Y5L0;	9606.ENSP00000265388;	4C0O;4C0P;4C0Q;4OL0;6GX9;
Q8AWD0	Q8AWD0_DANRE	unreviewed	Voltage-dependent anion-selective channel protein 2	vdac2	Danio rerio (Zebrafish) (Brachydanio rerio)	283							7955.ENSDARP00000014456;	4BUM;
P17883	SKI3_YEAST	reviewed	Superkiller protein 3	SKI3 YPR189W P9677.7	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1432						P17883;	4932.YPR189W;	4BUJ;5MC6;
A5YKK6	CNOT1_HUMAN	reviewed	CCR4-NOT transcription complex subunit 1 (CCR4-associated factor 1) (Negative regulator of transcription subunit 1 homolog) (NOT1H) (hNOT1)	CNOT1 CDC39 KIAA1007 NOT1 AD-005	Homo sapiens (Human)	2376			DISEASE: Holoprosencephaly 12 with or without pancreatic agenesis (HPE12) [MIM:618500]: An autosomal dominant form of holoprosencephaly, a structural anomaly of the brain in which the developing forebrain fails to correctly separate into right and left hemispheres. Holoprosencephaly is genetically heterogeneous and associated with several distinct facies and phenotypic variability. HPE12 clinical features include abnormal forebrain development, dysmorphic features, global developmental delay, learning difficulties, and congenital absence of the pancreas in most patients, resulting in early-onset insulin-dependent diabetes mellitus. Other features may include hearing loss and absence of the gallbladder. {ECO:0000269|PubMed:31006510, ECO:0000269|PubMed:31006513}. Note=The disease may be caused by variants affecting the gene represented in this entry.; DISEASE: Vissers-Bodmer syndrome (VIBOS) [MIM:619033]: An autosomal dominant disorder characterized by global developmental delay, intellectual disability of varying degree, speech delay, motor delay, and hypotonia. Abnormal growth, and cerebral, skeletal, muscle and soft tissue abnormalities are frequently observed. Many patients have behavioral problems, including anxiety, obsessive compulsive disorder, autism spectrum disorder and attention-deficit hyperactivity disorder. {ECO:0000269|PubMed:32553196}. Note=The disease may be caused by variants affecting the gene represented in this entry.		"MUTAGEN 1208;  /note=""K->E: Impairs interaction with CNOT7; when associated with Y-1212 and E-1218."";  /evidence=""ECO:0000269|PubMed:22977175""; MUTAGEN 1209;  /note=""P->Y: Abolishes interaction with CNOT7; when associated with Y-1257.""; MUTAGEN 1212;  /note=""H->Y: Impairs interaction with CNOT7; when associated with E-1208 and E-1218."";  /evidence=""ECO:0000269|PubMed:22977175""; MUTAGEN 1218;  /note=""K->E: Impairs interaction with CNOT7; when associated with E-1208 and Y-1212."";  /evidence=""ECO:0000269|PubMed:22977175""; MUTAGEN 1251;  /note=""V->R: Abolishes interaction with CNOT7.""; MUTAGEN 1257;  /note=""P->Y: Abolishes interaction with CNOT7; when associated with Y-1209."""	A5YKK6;	9606.ENSP00000320949;	4C0D;4CQO;4CRU;4CRV;4CRW;4CT4;4CT6;4CT7;4GMJ;4GML;4J8S;5ANR;5FU6;5FU7;5ONA;
Q01454	CTF4_YEAST	reviewed	DNA polymerase alpha-binding protein (Chromosome replication protein CHL15) (Chromosome transmission fidelity protein 4) (Protein POB1)	CTF4 CHL15 POB1 YPR135W P9659.7	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	927						Q01454;	4932.YPR135W;	4C8H;4C8S;4C93;4C95;5HOG;5HOI;5NXQ;6PTJ;6PTN;6PTO;6SKL;
P31386	ATS1_YEAST	reviewed	Protein KTI13 (Alpha-tubulin suppressor 1) (Kluyveromyces lactis toxin-insensitive protein 13)	ATS1 KTI13 YAL020C FUN28 YAL006	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	333					"MUTAGEN 96;  /note=""W->A: Slightly reduced interaction with KTI11."";  /evidence=""ECO:0000269|PubMed:25543256, ECO:0000269|PubMed:25604895""; MUTAGEN 157;  /note=""K->D: Does not affect interaction with KTI11."";  /evidence=""ECO:0000269|PubMed:25604895""; MUTAGEN 229;  /note=""W->A,C: Abolished interaction with KTI11."";  /evidence=""ECO:0000269|PubMed:25543256, ECO:0000269|PubMed:25604895""; MUTAGEN 294;  /note=""W->A,E: Slightly reduced affinity for KTI11."";  /evidence=""ECO:0000269|PubMed:25604895""; MUTAGEN 296;  /note=""E->A: Does not affect interaction with KTI11."";  /evidence=""ECO:0000269|PubMed:25543256""; MUTAGEN 297;  /note=""H->A: Does not affect interaction with KTI11."";  /evidence=""ECO:0000269|PubMed:25543256, ECO:0000269|PubMed:25604895"""	P31386;	4932.YAL020C;	4D4O;4D4P;4D4Q;4X33;
Q48391	Q48391_KLEOX	unreviewed	CymA protein	cymA	Klebsiella oxytoca	346								4D51;4D5B;4D5D;4V3G;4V3H;
Q01484	ANK2_HUMAN	reviewed	Ankyrin-2 (ANK-2) (Ankyrin-B) (Brain ankyrin) (Non-erythroid ankyrin)	ANK2 ANKB	Homo sapiens (Human)	3957			DISEASE: Long QT syndrome 4 (LQT4) [MIM:600919]: A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy. Long QT syndrome type 4 shows many atypical features compared to classical long QT syndromes, including pronounced sinus bradycardia, polyphasic T waves and atrial fibrillation. Cardiac repolarization defects may be not as severe as in classical LQT syndromes and prolonged QT interval on EKG is not a consistent feature. {ECO:0000269|PubMed:12571597, ECO:0000269|PubMed:15178757, ECO:0000269|PubMed:17940615}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 975..977;  /note=""DAR->AAA: Prevents binding to SPTBN1."";  /evidence=""ECO:0000269|PubMed:15262991""; MUTAGEN 1000;  /note=""A->P: Prevents binding to SPTBN1."";  /evidence=""ECO:0000269|PubMed:15262991""; MUTAGEN 1100..1103;  /note=""ENGD->AAGA: Weak binding to SPTBN1."";  /evidence=""ECO:0000269|PubMed:15262991"""	Q01484;	9606.ENSP00000349588;	4D8O;4RLV;4RLY;5Y4D;5Y4E;5Y4F;5YIR;5YIS;6KZJ;6M3Q;
D0KT28	D0KT28_SACS9	unreviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF Ssol_1680	Saccharolobus solfataricus (strain 98/2) (Sulfolobus solfataricus)	222								4DBD;4DBE;
B1Y9Q9	B1Y9Q9_PYRNV	unreviewed	Orotidine 5'-phosphate decarboxylase	Tneu_0023	Pyrobaculum neutrophilum (strain DSM 2338 / JCM 9278 / NBRC 100436 / V24Sta) (Thermoproteus neutrophilus)	202							444157.Tneu_0023;	4DF0;4DF1;
Q8PXX8	Q8PXX8_METMA	unreviewed	ABC transporter, ATP-binding protein	MM_1088	Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) (Methanosarcina frisia)	407							192952.MM_1088;	4DN7;
Q9HBA0	TRPV4_HUMAN	reviewed	Transient receptor potential cation channel subfamily V member 4 (TrpV4) (Osm-9-like TRP channel 4) (OTRPC4) (Transient receptor potential protein 12) (TRP12) (Vanilloid receptor-like channel 2) (Vanilloid receptor-like protein 2) (VRL-2) (Vanilloid receptor-related osmotically-activated channel) (VR-OAC)	TRPV4 VRL2 VROAC	Homo sapiens (Human)	871			DISEASE: Brachyolmia 3 (BCYM3) [MIM:113500]: A form of brachyolmia, a clinically and genetically heterogeneous skeletal dysplasia primarily affecting the spine and characterized by a short trunk, short stature, and platyspondyly. BCYM3 is an autosomal dominant form with severe scoliosis with or without kyphosis, and flattened irregular cervical vertebrae. {ECO:0000269|PubMed:18587396}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Spondylometaphyseal dysplasia Kozlowski type (SMDK) [MIM:184252]: A form of spondylometaphyseal dysplasia, a group of short stature disorders distinguished by abnormalities in the vertebrae and the metaphyses of the tubular bones. It is characterized by postnatal dwarfism, significant scoliosis and mild metaphyseal abnormalities in the pelvis. The vertebrae exhibit platyspondyly and overfaced pedicles. {ECO:0000269|PubMed:19232556, ECO:0000269|PubMed:20577006, ECO:0000269|PubMed:22702953}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Metatropic dysplasia (MTD) [MIM:156530]: A severe spondyloepimetaphyseal dysplasia characterized by short limbs with limitation and enlargement of joints and usually severe kyphoscoliosis. Radiologic features include severe platyspondyly, severe metaphyseal enlargement and shortening of long bones. {ECO:0000269|PubMed:19232556, ECO:0000269|PubMed:20425821, ECO:0000269|PubMed:20577006, ECO:0000269|PubMed:22702953, ECO:0000269|PubMed:26249260, ECO:0000269|Ref.6}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Neuronopathy, distal hereditary motor, 8 (HMN8) [MIM:600175]: A clinically variable, neuromuscular disorder characterized by congenital lower motor neuron disorder restricted to the lower part of the body. Clinical manifestations include non-progressive muscular atrophy, thigh muscle atrophy, weak thigh adductors, weak knee and foot extensors, minimal jaw muscle and neck flexor weakness, flexion contractures of knees and pes equinovarus. Tendon reflexes are normal. {ECO:0000269|PubMed:20037588, ECO:0000269|PubMed:22526352, ECO:0000269|PubMed:22702953}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Charcot-Marie-Tooth disease 2C (CMT2C) [MIM:606071]: An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. {ECO:0000269|PubMed:20037586, ECO:0000269|PubMed:20037587, ECO:0000269|PubMed:20037588, ECO:0000269|PubMed:21115951, ECO:0000269|PubMed:21288981, ECO:0000269|PubMed:22702953, ECO:0000269|PubMed:25256292}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Scapuloperoneal spinal muscular atrophy (SPSMA) [MIM:181405]: A clinically variable neuromuscular disorder characterized by neurogenic scapuloperoneal amyotrophy, laryngeal palsy, congenital absence of muscles, progressive scapuloperoneal atrophy and progressive distal weakness and amyotrophy. {ECO:0000269|PubMed:20037587, ECO:0000269|PubMed:22702953}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Spondyloepiphyseal dysplasia Maroteaux type (SEDM) [MIM:184095]: A clinically variable spondyloepiphyseal dysplasia with manifestations limited to the musculoskeletal system. Clinical features include short stature, brachydactyly, platyspondyly, short and stubby hands and feet, epiphyseal hypoplasia of the large joints, and iliac hypoplasia. Intelligence is normal. {ECO:0000269|PubMed:20503319, ECO:0000269|PubMed:22702953}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Parastremmatic dwarfism (PSTD) [MIM:168400]: A bone dysplasia characterized by severe dwarfism, kyphoscoliosis, distortion and bowing of the extremities, and contractures of the large joints. Radiographically, the disease is characterized by a combination of decreased bone density, bowing of the long bones, platyspondyly and striking irregularities of endochondral ossification with areas of calcific stippling and streaking in radiolucent epiphyses, metaphyses and apophyses. {ECO:0000269|PubMed:20503319}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Digital arthropathy-brachydactyly, familial (FDAB) [MIM:606835]: A disorder characterized by irregularities in the proximal articular surfaces of the distal interphalangeal joints of the hand. Individuals appear normal at birth, with no clinical or radiographic evidence of a developmental skeletal dysplasia. The earliest changes appear during the first decade of life. By adulthood, all interphalangeal, metacarpophalangeal, and metatarsophalangeal joints are affected by a deforming, painful osteoarthritis. The remainder of the skeleton is clinically and radiographically unaffected. {ECO:0000269|PubMed:21964574}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Avascular necrosis of the femoral head, primary 2 (ANFH2) [MIM:617383]: A disease characterized by mechanical failure of the subchondral bone, and degeneration of the hip joint. It usually leads to destruction of the hip joint in the third to fifth decade of life. The clinical manifestations, such as pain on exertion, a limping gait, and a discrepancy in leg length, cause considerable disability. {ECO:0000269|PubMed:27330106}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 231;  /note=""F->C: Decreased ATP-binding."";  /evidence=""ECO:0000269|PubMed:22702953""; MUTAGEN 251;  /note=""K->E: No effect on channel activity. No effect on interaction with membranes enriched in phosphatidylinositol-2,4-bisphosphate."";  /evidence=""ECO:0000269|PubMed:25256292""; MUTAGEN 296;  /note=""N->D: Loss of interaction with membranes enriched in phosphatidylinositol-2,4-bisphosphate; when associated with P-299."";  /evidence=""ECO:0000269|PubMed:25256292""; MUTAGEN 299;  /note=""H->P: Strongly decreased interaction with membranes enriched in phosphatidylinositol-2,4-bisphosphate. Loss of interaction with membranes enriched in phosphatidylinositol-2,4-bisphosphate; when associated with D-296."";  /evidence=""ECO:0000269|PubMed:25256292""; MUTAGEN 344;  /note=""K->E: No effect on channel activity. No effect on interaction with membranes enriched in phosphatidylinositol-2,4-bisphosphate."";  /evidence=""ECO:0000269|PubMed:25256292""; MUTAGEN 680;  /note=""M->D: Loss of Ca(2+) influx. Loss of DDX3X translocation to the nucleus."";  /evidence=""ECO:0000269|PubMed:29899501""; MUTAGEN 816..821;  /note=""RLRRDR->ELEEDE: Loss of calmodulin binding; when associated with A-828.""; MUTAGEN 821..824;  /note=""RWSS->AASA: Loss of calmodulin binding.""; MUTAGEN 822;  /note=""W->A: Loss of Ca(2+) dependent current potentiation.""; MUTAGEN 828;  /note=""R->A: Loss of calmodulin binding; when associated with 816-ELEEDE-821."";  /evidence=""ECO:0000269|PubMed:12724311"""	Q9HBA0;	9606.ENSP00000406191;	4DX1;4DX2;
A5KUH7	A5KUH7_VIBBS	unreviewed	2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14)	VSWAT3_13722	Vibrionales bacterium (strain SWAT-3)	209								4E38;5IM5;
A0A0H2UP31	A0A0H2UP31_STRPN	unreviewed	Putative pneumococcal surface protein	SP_0667	Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)	332							170187.SP_0667;	4CNL;
Q8ABA0	Q8ABA0_BACTN	unreviewed	Leucine-rich repeat protein	BT_0210	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	904							226186.BT_0210;	4ECN;
Q8C437	PEX5R_MOUSE	reviewed	PEX5-related protein (PEX2-related protein) (PEX5-like protein) (Peroxin-5-related protein) (Tetratricopeptide repeat-containing Rab8b-interacting protein) (Pex5Rp) (TRIP8b)	Pex5l Pex2 Pex5r Pxr2	Mus musculus (Mouse)	567						Q8C437;	10090.ENSMUSP00000103861;	4EQF;
Q9UH77	KLHL3_HUMAN	reviewed	Kelch-like protein 3	KLHL3 KIAA1129	Homo sapiens (Human)	587			DISEASE: Pseudohypoaldosteronism 2D (PHA2D) [MIM:614495]: A disorder characterized by severe hypertension, hyperkalemia, hyperchloremia, hyperchloremic metabolic acidosis, and correction of physiologic abnormalities by thiazide diuretics. PHA2D inheritance is autosomal dominant or recessive. {ECO:0000269|PubMed:22266938, ECO:0000269|PubMed:22406640, ECO:0000269|PubMed:23387299, ECO:0000269|PubMed:23453970, ECO:0000269|PubMed:23576762, ECO:0000269|PubMed:23665031, ECO:0000269|PubMed:26435498, ECO:0000269|PubMed:27026694, ECO:0000269|PubMed:27780982, ECO:0000269|PubMed:28052936, ECO:0000269|PubMed:28511177}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 433;  /note=""S->E,D: Phosphomimetic mutant that shows decreased interaction with WNK4."";  /evidence=""ECO:0000269|PubMed:26435498"""	Q9UH77;	9606.ENSP00000312397;	4CH9;4HXI;5NKP;
E5AV36	BAT1_MYCRK	reviewed	Burkholderia TALE-like protein 1 (Modular DNA-binding domain protein BurrH1)	bat1 RBRH_01844	Mycetohabitans rhizoxinica (strain DSM 19002 / CIP 109453 / HKI 454) (Paraburkholderia rhizoxinica)	771		BIOTECHNOLOGY: After addition of nuclear localization signals (NLS) and a transcription activation domain, can be expressed in both human and plant cells and will recognize and transcribe a target sequence; more than 17 core repeats are necessary for this function. The N-terminal cryptic repeats effect activation, while the C-terminal cryptic repeat is absolutely required. When fused to the FokI restriction endonuclease domain functions as a sequence-specific DNA nuclease in vitro (called TALE-nuclease, TALEN, PubMed:24792163 or BuDN, PubMed:25004980) and with an NLS, in human and yeast cells. The latter construct also allows targeted gene insertion. Modification of the core repeat BSR allows recognition of a user-defined DNA sequence, allowing these constructs to target and modify a DNA sequence of interest, and thus be used for genome engineering. Other potential uses as transcriptional repressors, for transposon targeting, DNA methylation or histone tail modifictions are also possible. {ECO:0000269|PubMed:24452192, ECO:0000269|PubMed:24792163, ECO:0000269|PubMed:25004980, ECO:0000303|PubMed:24602153}.					882378.RBRH_01844;	4CJ9;4CJA;
Q6CII8	RNA14_KLULA	reviewed	mRNA 3'-end-processing protein RNA14	RNA14 KLLA0F26290g	Kluyveromyces lactis (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-1140 / WM37) (Yeast) (Candida sphaerica)	661							28985.XP_456251.1;	4E6H;4E85;4EBA;
A7LUR6	A7LUR6_BACO1	unreviewed	Bacterial group 3 Ig-like protein	BACOVA_01565	Bacteroides ovatus (strain ATCC 8483 / DSM 1896 / JCM 5824 / BCRC 10623 / CCUG 4943 / NCTC 11153)	428							411476.BACOVA_01565;	4FDW;
Q8Z9S7	GLMU_YERPE	reviewed	Bifunctional protein GlmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (N-acetylglucosamine-1-phosphate uridyltransferase); Glucosamine-1-phosphate N-acetyltransferase (EC 2.3.1.157)]	glmU YPO4119 y4133 YP_4026	Yersinia pestis	456						Q8Z9S7;	214092.YPO4119;	4FCE;
Q3BQL2	Q3BQL2_XANC5	unreviewed	Uncharacterized protein	XCV3220	Xanthomonas campestris pv. vesicatoria (strain 85-10)	660							316273.XCV3220;	4FC9;4FCG;
A5ZLA0	A5ZLA0_9BACE	unreviewed	Bacterial group 3 Ig-like protein	BACCAC_03700	Bacteroides caccae ATCC 43185	428							411901.BACCAC_03700;	4FD0;
O36030	YEKI_SCHPO	reviewed	Uncharacterized WD repeat-containing protein C4F10.18	SPAC4F10.18	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	391						O36030;	4896.SPAC4F10.18.1;	4FHL;4FHM;4FHN;4GQ1;4GQ2;
Q9NQS3	NECT3_HUMAN	reviewed	Nectin-3 (CDw113) (Nectin cell adhesion molecule 3) (Poliovirus receptor-related protein 3) (CD antigen CD113)	NECTIN3 PRR3 PVRL3	Homo sapiens (Human)	549						Q9NQS3;	9606.ENSP00000418070;	4FOM;
Q7Z6M4	MTEF4_HUMAN	reviewed	Transcription termination factor 4, mitochondrial (Mitochondrial transcription termination factor 4) (mTERF domain-containing protein 2) [Cleaved into: mTERF domain-containing protein 2 processed]	MTERF4 MTERFD2 HSPC096	Homo sapiens (Human)	381						Q7Z6M4;	9606.ENSP00000480378;	4FP9;4FZV;7O9K;7O9M;7ODR;7ODS;7ODT;7OF0;7OF3;7OF5;7OF7;
O43044	NU120_SCHPO	reviewed	Nucleoporin nup120 (Nuclear pore protein nup120)	nup120 SPBC3B9.16c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	1136						O43044;	4896.SPBC3B9.16c.1;	4FHM;4FHN;4GQ2;
A7M397	A7M397_BACO1	unreviewed	Uncharacterized protein	BACOVA_04585	Bacteroides ovatus (strain ATCC 8483 / DSM 1896 / JCM 5824 / BCRC 10623 / CCUG 4943 / NCTC 11153)	414							411476.BACOVA_04585;	4FS7;
Q5HKE8	Q5HKE8_STAEQ	unreviewed	Accumulation associated protein	aap SERP2398	Staphylococcus epidermidis (strain ATCC 35984 / RP62A)	2397							176279.SERP2398;	4FUM;4FUN;4FUO;4FUP;5TU7;5TU8;5TU9;
Q9NQG5	RPR1B_HUMAN	reviewed	Regulation of nuclear pre-mRNA domain-containing protein 1B (Cell cycle-related and expression-elevated protein in tumor)	RPRD1B C20orf77 CREPT	Homo sapiens (Human)	326					"MUTAGEN 114;  /note=""R->A: Complete loss of binding to POLR2A CTD in vivo."";  /evidence=""ECO:0000269|PubMed:24997600"""	Q9NQG5;	9606.ENSP00000362532;	4FLA;4FU3;4HFG;4NAD;4Q94;4Q96;
Q712I1	Q712I1_STRTE	unreviewed	NikO protein	nikO	Streptomyces tendae	473								4FQD;
Q6NUD0	MEP50_XENLA	reviewed	Methylosome protein 50 (MEP-50) (WD repeat-containing protein 77)	wdr77 mep50	Xenopus laevis (African clawed frog)	333						Q6NUD0;		4G56;
H2QII6	RBP2_PANTR	reviewed	E3 SUMO-protein ligase RanBP2 (EC 2.3.2.-) (358 kDa nucleoporin) (Nuclear pore complex protein Nup358) (Nucleoporin Nup358) (Ran-binding protein 2) (RanBP2)	RANBP2 NUP358	Pan troglodytes (Chimpanzee)	3224							9598.ENSPTRP00000021122;	4GA1;4GA2;
O16259	STIP1_CAEEL	reviewed	Stress-induced-phosphoprotein 1 (CeSTI1) (STI1) (Hsc70/Hsp90-organizing protein) (CeHop) (Hop)	sti-1 R09E12.3	Caenorhabditis elegans	320				DISRUPTION PHENOTYPE: Reduced brood size and decreased fertility under heat stress. Decreased thermotolerance and shortening of life span by 68% and 77% at 20 degrees Celsius and 25 degrees Celsius respectively. Growth of gonads is hampered resulting in shortened arms of the gonads, abnormally shaped spermathecae, lower sperm number and endomitotic oocyte development. {ECO:0000269|PubMed:19467242, ECO:0000269|PubMed:19559711}.		O16259;	6239.R09E12.3;	4GCN;4GCO;
H6QM85	H6QM85_9INFA	unreviewed	Neuraminidase (EC 3.2.1.18)		Influenza A virus (A/little yellow-shouldered bat/Guatemala/164/2009(H17N10))	442								4GDI;4GEZ;
A9CIT6	A9CIT6_AGRFC	unreviewed	Dipeptide epimerase (EC 5.1.1.-)	Atu1648	Agrobacterium fabrum (strain C58 / ATCC 33970) (Agrobacterium tumefaciens (strain C58))	327							176299.Atu1648;	4GFI;
P09913	IFIT2_HUMAN	reviewed	Interferon-induced protein with tetratricopeptide repeats 2 (IFIT-2) (ISG-54 K) (Interferon-induced 54 kDa protein) (IFI-54K) (P54)	IFIT2 CIG-42 G10P2 IFI54 ISG54	Homo sapiens (Human)	472					"MUTAGEN 184;  /note=""R->E: Abolishes RNA-binding."";  /evidence=""ECO:0000269|PubMed:22825553""; MUTAGEN 255;  /note=""K->E: Significantly impairs RNA-binding; when associated with Glu-259."";  /evidence=""ECO:0000269|PubMed:22825553""; MUTAGEN 259;  /note=""R->E: Significantly impairs RNA-binding; when associated with Glu-255."";  /evidence=""ECO:0000269|PubMed:22825553""; MUTAGEN 292;  /note=""R->E: Abolishes RNA-binding."";  /evidence=""ECO:0000269|PubMed:22825553""; MUTAGEN 410;  /note=""K->E: Abolishes RNA-binding."";  /evidence=""ECO:0000269|PubMed:22825553"""	P09913;	9606.ENSP00000360891;	4G1T;
G0RZB7	G0RZB7_CHATD	unreviewed	CRM1_C domain-containing protein	CTHT_0002400	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	1043						G0RZB7;	209285.XP_006690787.1;	4FGV;4HZK;
Q12834	CDC20_HUMAN	reviewed	Cell division cycle protein 20 homolog (p55CDC)	CDC20	Homo sapiens (Human)	499					"MUTAGEN 41;  /note=""S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-72; A-92; A-153; A-157 and A-161."";  /evidence=""ECO:0000269|PubMed:15525512""; MUTAGEN 72;  /note=""S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-41; A-92; A-153; A-157 and A-161."";  /evidence=""ECO:0000269|PubMed:15525512""; MUTAGEN 92;  /note=""S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-41; A-72; A-153; A-157 and A-161."";  /evidence=""ECO:0000269|PubMed:15525512""; MUTAGEN 132;  /note=""R->A: Loss of interaction with MAD2L1."";  /evidence=""ECO:0000269|PubMed:19098431""; MUTAGEN 153;  /note=""S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-42; A-72; A-92; A-157 and A-161."";  /evidence=""ECO:0000269|PubMed:15525512""; MUTAGEN 157;  /note=""T->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-42; A-72; A-92; A-153 and A-161."";  /evidence=""ECO:0000269|PubMed:15525512""; MUTAGEN 161;  /note=""S->A: Loss of BUB1-mediated phosphorylation and inhibition and partially defective spindle-assembly checkpoint; when associated with A-72; A-92; A-153; A-157 and A-161."";  /evidence=""ECO:0000269|PubMed:15525512""; MUTAGEN 485;  /note=""K->R: Does not affect its ability to bind the APC/C complex; when associated with R-490."";  /evidence=""ECO:0000269|PubMed:21926987""; MUTAGEN 490;  /note=""K->R: Does not affect its ability to bind the APC/C complex; when associated with R-485."";  /evidence=""ECO:0000269|PubMed:21926987"""	Q12834;	9606.ENSP00000361540;	4GGA;4GGC;4GGD;4N14;5G04;5KHR;5KHU;5LCW;6F0X;6Q6G;6Q6H;
Q89U61	Q89U61_BRADU	unreviewed	Bll1558 protein	bll1558	Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110)	130							224911.27349810;	4GGR;4GGT;4GGZ;
P08571	CD14_HUMAN	reviewed	Monocyte differentiation antigen CD14 (Myeloid cell-specific leucine-rich glycoprotein) (CD antigen CD14) [Cleaved into: Monocyte differentiation antigen CD14, urinary form; Monocyte differentiation antigen CD14, membrane-bound form]	CD14	Homo sapiens (Human)	375						P08571;	9606.ENSP00000304236;	4GLP;
G0S5S6	G0S5S6_CHATD	unreviewed	Uncharacterized protein	CTHT_0033460	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	676							209285.XP_006693784.1;	4GMN;4GMO;5AFF;
Q3ZD72	Q3ZD72_XANCA	unreviewed	Hax3	hax3	Xanthomonas campestris pv. armoraciae	960								4GG4;4GJP;4GJR;4OSH;4OSI;4OSJ;4OSK;4OSL;4OSM;4OSQ;4OSR;4OSS;4OST;4OSV;4OSW;4OSZ;4OT0;4OT3;4OTO;6JTQ;6JVZ;6JW0;6JW1;6JW2;6JW3;6JW4;6JW5;
I2APN2	I2APN2_9TRYP	unreviewed	Triosephosphate isomerase (EC 5.3.1.1)	tim	Leishmania sp. 'siamensis'	251								4GNJ;5CG7;
Q9BQA1	MEP50_HUMAN	reviewed	Methylosome protein 50 (MEP-50) (Androgen receptor cofactor p44) (WD repeat-containing protein 77) (p44/Mep50)	WDR77 MEP50 WD45 HKMT1069 Nbla10071	Homo sapiens (Human)	342						Q9BQA1;	9606.ENSP00000235090;	4GQB;4X60;4X61;4X63;5C9Z;5EMJ;5EMK;5EML;5EMM;5FA5;6CKC;6K1S;6RLL;6RLQ;6UGH;6UXX;6UXY;6V0N;6V0O;6V0P;7KIB;7KIC;7KID;7L1G;7M05;
L7MTK7	L7MTK7_ECOLX	unreviewed	Anti-ige inhibitor e2_79		Escherichia coli	80								4GRG;
P04506	SIGM1_REOVL	reviewed	Outer capsid protein sigma-1 (Sigma1) (Cell attachment protein) (Hemagglutinin)	S1	Reovirus type 1 (strain Lang) (T1L) (Mammalian orthoreovirus 1)	470								4GU3;4GU4;4ODB;4XC5;5MHS;6GAJ;6GAK;6GAO;
O34327	RAPJ_BACSU	reviewed	Response regulator aspartate phosphatase J (EC 3.1.-.-)	rapJ ycdE BSU02820	Bacillus subtilis (strain 168)	373						O34327;	224308.BSU02820;	4GYO;
A5Z5V6	A5Z5V6_9FIRM	unreviewed	SCP-like protein	EUBVEN_01088	Eubacterium ventriosum ATCC 27560	739							411463.EUBVEN_01088;	4H09;
Q64374	RGN_MOUSE	reviewed	Regucalcin (RC) (Gluconolactonase) (GNL) (EC 3.1.1.17) (Senescence marker protein 30) (SMP-30)	Rgn Smp30	Mus musculus (Mouse)	299				DISRUPTION PHENOTYPE: Mice do not thrive after weaning when kept on a vitamin C-less diet. They develop scurvy, have reduced bone mineral density and brittle bones. Hepatocytes exhibit accumulation of lipid droplets. Mice display increased mortality after about 3 months, and their life span is shorter than normal. {ECO:0000269|PubMed:14975739, ECO:0000269|PubMed:16585534}.			10090.ENSMUSP00000023832;	4GN7;4GN8;4GN9;4GNA;
F1SVL0	F1SVL0_METKA	unreviewed	Topoisomerase V	MK1436	Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938)	984								4GFJ;
Q63ZY3	KANK2_HUMAN	reviewed	KN motif and ankyrin repeat domain-containing protein 2 (Ankyrin repeat domain-containing protein 25) (Matrix-remodeling-associated protein 3) (SRC-1-interacting protein) (SIP) (SRC-interacting protein) (SRC1-interacting protein)	KANK2 ANKRD25 KIAA1518 MXRA3 SIP	Homo sapiens (Human)	851			DISEASE: Palmoplantar keratoderma and woolly hair (PPKWH) [MIM:616099]: A disorder characterized by abnormal thickening of the skin on the palms and soles, in association with woolly scalp hair. Affected individuals manifest a variable degree of striate palmoplantar keratoderma, generally more severe on the soles. Leukonychia is more pronounced on the fingernails than toenails. Scalp hair, body hair, eyebrows, and eyelashes are sparse. The fifth toes show variable degrees of pseudoainhum, ranging from external rotation to a deep sulcus at the digitoplantar fold, accompanied by a bulbous appearance of the distal toe. {ECO:0000269|PubMed:24671081}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Nephrotic syndrome 16 (NPHS16) [MIM:617783]: A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. Some affected individuals have an inherited steroid-resistant form that progresses to end-stage renal failure. NPHS16 inheritance is autosomal recessive. {ECO:0000269|PubMed:25961457}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 510..512;  /note=""SSS->AAA: Impairs phosphorylation; when associated with A-515."";  /evidence=""ECO:0000269|PubMed:17476305""; MUTAGEN 515;  /note=""S->A: Impairs phosphorylation; when associated with 510-A--A-512."";  /evidence=""ECO:0000269|PubMed:17476305""; MUTAGEN 702;  /note=""Y->A: 4-fold decrease in binding to KIF21A."";  /evidence=""ECO:0000269|PubMed:29183992""; MUTAGEN 702;  /note=""Y->L: 33-fold decrease in binding to KIF21A."";  /evidence=""ECO:0000269|PubMed:29183992""; MUTAGEN 803;  /note=""D->A: 26-fold decrease in binding to KIF21A."";  /evidence=""ECO:0000269|PubMed:29183992""; MUTAGEN 805;  /note=""D->A: 20-fold decrease in binding to KIF21A."";  /evidence=""ECO:0000269|PubMed:29183992"""	Q63ZY3;	9606.ENSP00000468002;	4HBD;5YBV;6TMD;
Q10567	AP1B1_HUMAN	reviewed	AP-1 complex subunit beta-1 (Adaptor protein complex AP-1 subunit beta-1) (Adaptor-related protein complex 1 subunit beta-1) (Beta-1-adaptin) (Beta-adaptin 1) (Clathrin assembly protein complex 1 beta large chain) (Golgi adaptor HA1/AP1 adaptin beta subunit)	AP1B1 ADTB1 BAM22 CLAPB2	Homo sapiens (Human)	949			DISEASE: Keratitis-ichthyosis-deafness syndrome, autosomal recessive (KIDAR) [MIM:242150]: An autosomal recessive form of keratitis-ichthyosis-deafness syndrome, a disease characterized by the association of hyperkeratotic skin lesions with vascularizing keratitis and profound sensorineural hearing loss. KIDAR patients manifest ichthyosis, failure to thrive and developmental delay in childhood, thrombocytopenia, photophobia, and progressive hearing loss. Low plasma copper and ceruloplasmin levels have been reported in some patients. {ECO:0000269|PubMed:31630788, ECO:0000269|PubMed:31630791}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q10567;	9606.ENSP00000350199;	4HMY;4P6Z;6CM9;6CRI;6D83;6D84;6DFF;
L7MTL1	L7MTL1_9XANT	unreviewed	dTale2		Xanthomonas	463								4HPZ;
Q8AAM9	Q8AAM9_BACTN	unreviewed	DUF5109 domain-containing protein	BT_0435	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	366							226186.BT_0435;	4H41;
P11655	SEC12_YEAST	reviewed	Guanine nucleotide-exchange factor SEC12 (Protein transport protein SEC12)	SEC12 SED2 YNR026C N3244	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	471						P11655;	4932.YNR026C;	4H5I;4H5J;6X90;
Q66GI4	PRRP1_ARATH	reviewed	Proteinaceous RNase P 1, chloroplastic/mitochondrial (EC 3.1.26.5) (Pentatricopeptide repeat-containing protein At2g32230)	PRORP1 At2g32230 F22D22.2	Arabidopsis thaliana (Mouse-ear cress)	572				DISRUPTION PHENOTYPE: Embryo lethality when homozygous. {ECO:0000269|PubMed:20473316}.	"MUTAGEN 399;  /note=""D->N: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:22991464""; MUTAGEN 474..475;  /note=""DD->AA: Loss of activity."";  /evidence=""ECO:0000269|PubMed:20473316""; MUTAGEN 474;  /note=""D->N: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:22991464""; MUTAGEN 475;  /note=""D->N: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:22991464""; MUTAGEN 493;  /note=""D->N: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:22991464"""		3702.AT2G32230.1;	4G23;4G24;4G25;4G26;6BV5;6BV6;6BV8;6BV9;6LVR;
A7LR39	A7LR39_BACO1	unreviewed	IPT/TIG domain protein	BACOVA_00264	Bacteroides ovatus (strain ATCC 8483 / DSM 1896 / JCM 5824 / BCRC 10623 / CCUG 4943 / NCTC 11153)	465							411476.BACOVA_00264;	4HW6;
Q68XJ3	Q68XJ3_RICTY	unreviewed	Post-proline cleaving enzyme (EC 3.4.21.26)	ppcE RT0165	Rickettsia typhi (strain ATCC VR-144 / Wilmington)	720							257363.RT0165;	4HVT;
P96649	RAPI_BACSU	reviewed	Response regulator aspartate phosphatase I (EC 3.1.-.-)	rapI yddL BSU05010	Bacillus subtilis (strain 168)	391						P96649;	224308.BSU05010;	4I1A;
G5EG62	G5EG62_CAEEL	unreviewed	TPR_REGION domain-containing protein (UNC-45)	unc-45 CELE_F30H5.1 F30H5.1	Caenorhabditis elegans	961						G5EG62;	6239.F30H5.1;	4I2W;4I2Z;5MZU;6QDK;6QDL;6QDM;
Q9UKT7	FBXL3_HUMAN	reviewed	F-box/LRR-repeat protein 3 (F-box and leucine-rich repeat protein 3A) (F-box/LRR-repeat protein 3A)	FBXL3 FBL3A FBXL3A	Homo sapiens (Human)	428			DISEASE: Intellectual developmental disorder with short stature, facial anomalies, and speech defects (IDDSFAS) [MIM:606220]: An autosomal recessive disorder characterized by global developmental delay, mildly to severely impaired intellectual development, delayed or slurred speech, and short stature. Dysmorphic features included a large bulbous nose and variable microretrognathia. Some patients show joint hyperlaxity and dislocations. {ECO:0000269|PubMed:30481285}. Note=The disease is caused by variants affecting the gene represented in this entry.		"MUTAGEN 358;  /note=""C->A: Loss of binding with CRY1."";  /evidence=""ECO:0000269|PubMed:17463251""; MUTAGEN 358;  /note=""C->S: Decrease in binding efficiency with CRY2 and of CRY2 ubiquitination efficiency, loss of binding with CRY1."";  /evidence=""ECO:0000269|PubMed:17463251"""	Q9UKT7;	9606.ENSP00000347834;	4I6J;
Q8NFH3	NUP43_HUMAN	reviewed	Nucleoporin Nup43 (Nup107-160 subcomplex subunit Nup43) (p42)	NUP43	Homo sapiens (Human)	380						Q8NFH3;	9606.ENSP00000342262;	4I79;5A9Q;
O58323	O58323_PYRHO	unreviewed	Peptidase_S9 domain-containing protein	PH0594	Pyrococcus horikoshii (strain ATCC 700860 / DSM 12428 / JCM 9974 / NBRC 100139 / OT-3)	622							70601.3257000;	4HXE;4HXF;4HXG;
B6A880	YENB_YERET	reviewed	Toxin subunit YenB	yenB	Yersinia entomophaga	1487				DISRUPTION PHENOTYPE: Cells with a disrupted yenA1-yenA2-chi2-yenB-yenC1-yenC2 locus are no longer pathogenic in C.zealandica larvae. {ECO:0000269|PubMed:21278295}.		B6A880;		4IGL;5KIS;
B6A882	YENC2_YERET	reviewed	Toxin subunit YenC2	yenC2	Yersinia entomophaga	970				DISRUPTION PHENOTYPE: A double yenC1-yenC2 deletion is no longer pathogenic in C.zealandica larvae. {ECO:0000269|PubMed:21278295}.	"MUTAGEN 650;  /note=""R->A: Loss of auto-proteolytic activity."";  /evidence=""ECO:0000269|PubMed:23913273""; MUTAGEN 663;  /note=""D->N: Loss of auto-proteolytic activity."";  /evidence=""ECO:0000269|PubMed:23913273""; MUTAGEN 686;  /note=""D->N: Loss of auto-proteolytic activity."";  /evidence=""ECO:0000269|PubMed:23913273"""	B6A882;		4IGL;
A7M066	A7M066_BACO1	unreviewed	Uncharacterized protein	BACOVA_03493	Bacteroides ovatus (strain ATCC 8483 / DSM 1896 / JCM 5824 / BCRC 10623 / CCUG 4943 / NCTC 11153)	431							411476.BACOVA_03493;	4IRT;
Q9ZWC8	BRL1_ARATH	reviewed	Serine/threonine-protein kinase BRI1-like 1 (EC 2.7.11.1) (BRASSINOSTEROID INSENSITIVE 1-like protein 1)	BRL1 At1g55610 F20N2.4	Arabidopsis thaliana (Mouse-ear cress)	1166						Q9ZWC8;	3702.AT1G55610.2;	4J0M;
O43818	U3IP2_HUMAN	reviewed	U3 small nucleolar RNA-interacting protein 2 (RRP9 homolog) (U3 small nucleolar ribonucleoprotein-associated 55 kDa protein) (U3 snoRNP-associated 55 kDa protein) (U3-55K)	RRP9 RNU3IP2 U355K	Homo sapiens (Human)	475					"MUTAGEN 12;  /note=""K->Q: Mimics acetylation, leading to impaired rRNA processing; when associated with Q-25."";  /evidence=""ECO:0000269|PubMed:26867678""; MUTAGEN 12;  /note=""K->R: Impaired acetylation, leading to promote rRNA processing; when associated with R-25."";  /evidence=""ECO:0000269|PubMed:26867678""; MUTAGEN 25;  /note=""K->Q: Mimics acetylation, leading to impaired rRNA processing; when associated with Q-12."";  /evidence=""ECO:0000269|PubMed:26867678""; MUTAGEN 25;  /note=""K->R: Impaired acetylation, leading to promote rRNA processing; when associated with R-12."";  /evidence=""ECO:0000269|PubMed:26867678"""	O43818;	9606.ENSP00000232888;	4J0W;4JXM;
Q96WV5	COPA_SCHPO	reviewed	Putative coatomer subunit alpha (Alpha-coat protein) (Alpha-COP)	SPBPJ4664.04	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	1207						Q96WV5;	4896.SPBPJ4664.04.1;	4J87;4J8B;4J8G;
B6R2Z8	B6R2Z8_9HYPH	unreviewed	Mandelate racemase / muconate lactonizing enzyme, C-terminal domain protein	PJE062_892	Pseudovibrio sp. JE062	374								4JHM;
Q496J9	SV2C_HUMAN	reviewed	Synaptic vesicle glycoprotein 2C	SV2C KIAA1054	Homo sapiens (Human)	727					"MUTAGEN 559;  /note=""N->A: No change in interaction with C.botulinum neurotoxin type A heavy chain (botA, BoNT/A HC). Decreased molecular weight probably due to glycosylation loss, decreased interaction with BoNT/A HC."";  /evidence=""ECO:0000269|PubMed:24240280, ECO:0000269|PubMed:27313224, ECO:0000269|PubMed:28252640""; MUTAGEN 559;  /note=""N->Q: Decreased molecular weight probably due to glycosylation loss, decreased binding to BoNT/A HC. Greater reduction in weight; when associated with Q-565."";  /evidence=""ECO:0000269|PubMed:27313224""; MUTAGEN 561;  /note=""S->A: Decreased molecular weight probably due to glycosylation loss, decreased binding to BoNT/A HC."";  /evidence=""ECO:0000269|PubMed:27313224""; MUTAGEN 563;  /note=""F->A: No longer interacts with BoNT/A HC."";  /evidence=""ECO:0000269|PubMed:24240280, ECO:0000269|PubMed:28252640""; MUTAGEN 565;  /note=""N->Q: Decreased molecular weight probably due to glycosylation loss, no change in binding to BoNT/A heavy chain. Greater reduction in weight; when associated with Q-559."";  /evidence=""ECO:0000269|PubMed:27313224"""	Q496J9;	9606.ENSP00000423541;	4JRA;5JLV;5MOY;6ES1;
Q9BVC4	LST8_HUMAN	reviewed	Target of rapamycin complex subunit LST8 (TORC subunit LST8) (G protein beta subunit-like) (Gable) (Protein GbetaL) (Mammalian lethal with SEC13 protein 8) (mLST8)	MLST8 GBL LST8	Homo sapiens (Human)	326					"MUTAGEN 72;  /note=""S->D: Impairs interaction with MTOR."";  /evidence=""ECO:0000269|PubMed:12718876""; MUTAGEN 192;  /note=""G->D: Abolishes interaction with MTOR."";  /evidence=""ECO:0000269|PubMed:12718876""; MUTAGEN 320;  /note=""F->S: Impairs interaction with MTOR."";  /evidence=""ECO:0000269|PubMed:12718876"""	Q9BVC4;	9606.ENSP00000456405;	4JSN;4JSP;4JSV;4JSX;4JT5;4JT6;5FLC;5H64;5WBU;5WBY;5ZCS;6BCU;6BCX;6SB0;6SB2;6ZWM;6ZWO;
K0IE77	K0IE77_PETMA	unreviewed	Variable lymphocyte receptor (Fragment)		Petromyzon marinus (Sea lamprey)	219								4K5U;4K79;
Q9NQV7	PRDM9_HUMAN	reviewed	Histone-lysine N-methyltransferase PRDM9 (PR domain zinc finger protein 9) (PR domain-containing protein 9) (Protein-lysine N-methyltransferase PRDM9) (EC 2.1.1.-) ([histone H3]-lysine36 N-trimethyltransferase PRDM9) (EC 2.1.1.359) ([histone H3]-lysine4 N-trimethyltransferase PRDM9) (EC 2.1.1.354) ([histone H3]-lysine9 N-trimethyltransferase PRDM9) (EC 2.1.1.355) ([histone H4]-N-methyl-L-lysine20 N-methyltransferase PRDM9) (EC 2.1.1.362) ([histone H4]-lysine20 N-methyltransferase PRDM9) (EC 2.1.1.361)	PRDM9 PFM6	Homo sapiens (Human)	894					"MUTAGEN 199;  /note=""D->Y: Increases histone-lysine N-methyltransferase activity; when associated with D-374."";  /evidence=""ECO:0000269|PubMed:24095733""; MUTAGEN 357;  /note=""Y->S: Loss of histone-lysine N-methyltransferase activity."";  /evidence=""ECO:0000269|PubMed:27129774""; MUTAGEN 374;  /note=""K->D: Increases histone-lysine N-methyltransferase activity; when associated with Y-199."";  /evidence=""ECO:0000269|PubMed:24095733"""	Q9NQV7;	9606.ENSP00000296682;	4IJD;5EGB;5EH2;5EI9;6NM4;
Q5LCY3	Q5LCY3_BACFN	unreviewed	Photosystem I assembly protein Ycf3 (Putative exported protein)	BF9343_2249 NCTC9343_03926	Bacteroides fragilis (strain ATCC 25285 / DSM 2151 / CCUG 4856 / JCM 11019 / NCTC 9343 / Onslow)	245							272559.BF9343_2249;	4I17;
Q09778	TSC1_SCHPO	reviewed	Tuberous sclerosis 1 protein homolog	tsc1 SPAC22F3.13	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	899						Q09778;	4896.SPAC22F3.13.1;	4KK0;4KK1;
B6YW62	B6YW62_THEON	unreviewed	Uncharacterized protein	TON_1937	Thermococcus onnurineus (strain NA1)	265							523850.TON_1937;	4L7M;
Q9UMS4	PRP19_HUMAN	reviewed	Pre-mRNA-processing factor 19 (EC 2.3.2.27) (Nuclear matrix protein 200) (PRP19/PSO4 homolog) (hPso4) (RING-type E3 ubiquitin transferase PRP19) (Senescence evasion factor)	PRPF19 NMP200 PRP19 SNEV	Homo sapiens (Human)	504					"MUTAGEN 405;  /note=""Y->A: Loss of interaction with the RPA complex and loss of recruitment to sites of DNA damage."";  /evidence=""ECO:0000269|PubMed:24332808"""	Q9UMS4;	9606.ENSP00000227524;	4LG8;5MQF;5XJC;5YZG;5Z56;5Z57;6FF7;6ICZ;6ID0;6ID1;6QDV;7A5P;
A0A0H3LUZ2	A0A0H3LUZ2_BARQU	unreviewed	Surface protein/Bartonella adhesin	badA1 BQ01390	Bartonella quintana (strain Toulouse) (Rochalimaea quintana)	1065							283165.BQ01390;	4LGO;
O74985	NAT1_SCHPO	reviewed	N-terminal acetyltransferase A complex subunit nat1 (NatA complex subunit nat1)	nat1 SPCC338.07c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	729						O74985;	4896.SPCC338.07c.1;	4KVM;4KVO;
Q57700	PYRF_METJA	reviewed	Orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) (OMP decarboxylase) (OMPDCase) (OMPdecase)	pyrF MJ0252	Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) (Methanococcus jannaschii)	213							243232.MJ_0252;	4LUI;4LUJ;
Q94AG2	SERK1_ARATH	reviewed	Somatic embryogenesis receptor kinase 1 (AtSERK1) (EC 2.7.10.1) (EC 2.7.11.1) (Somatic embryogenesis receptor-like kinase 1)	SERK1 At1g71830 F14O23.21 F14O23_24	Arabidopsis thaliana (Mouse-ear cress)	625				DISRUPTION PHENOTYPE: No visible phenotype. Serk1 and serk2 double mutants are completely male sterile due to a failure in tapetum specification. Delayed floral abscission (PubMed:27058169). {ECO:0000269|PubMed:16284305, ECO:0000269|PubMed:16284306, ECO:0000269|PubMed:27058169}.	"MUTAGEN 330;  /note=""K->E: Loss of kinase activity."";  /evidence=""ECO:0000269|PubMed:11509554""; MUTAGEN 459;  /note=""T->A,E: No effect."";  /evidence=""ECO:0000269|PubMed:11509554""; MUTAGEN 462;  /note=""T->A,E: Decreased kinase activity. Loss of kinase activity; when associated with A,E-463 and A,E-468."";  /evidence=""ECO:0000269|PubMed:11509554""; MUTAGEN 463;  /note=""T->A,E: Loss of autophosphorylation. Loss of kinase activity; when associated with A,E-462 and A,E-468."";  /evidence=""ECO:0000269|PubMed:11509554""; MUTAGEN 468;  /note=""T->A,E: Loss of kinase activity. Loss of kinase activity; when associated with A,E-462 and A,E-463."";  /evidence=""ECO:0000269|PubMed:11509554""; MUTAGEN 541;  /note=""T->A: No effect. Reduction of autophosphorylation; when associated with A-570."";  /evidence=""ECO:0000269|PubMed:19105183""; MUTAGEN 562;  /note=""S->A: Loss of autophosphorylation."";  /evidence=""ECO:0000269|PubMed:19105183""; MUTAGEN 570;  /note=""S->A: No effect. Reduction of autophosphorylation; when associated with A-541."";  /evidence=""ECO:0000269|PubMed:19105183"""	Q94AG2;	3702.AT1G71830.1;	4LSC;4LSX;4Z64;5IYX;6FG8;
B0V6J7	B0V6J7_ACIBY	unreviewed	Putative acetyltransferase (WeeI) (EC 2.3.1.-)	ABAYE3807	Acinetobacter baumannii (strain AYE)	216								4M9C;
Q9I741	VGR1A_PSEAE	reviewed	Type VI secretion system spike protein VgrG1a (T6SS spike protein VgrG1a)	vgrG1a PA0091	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	643				DISRUPTION PHENOTYPE: Deletion of vgrG1a shows residual type VI secretion (PubMed:21325275). However, simultaneous deletion of all three vgrG genes (vgrG1a, vgrG1b and vgrG1c) totally abrogates bacterial killing (PubMed:24794869). {ECO:0000269|PubMed:21325275, ECO:0000269|PubMed:24794869}.				4MTK;4UHV;6H3L;6H3N;
I6YE93	I6YE93_CLODI	unreviewed	TcdA	tcdA	Clostridioides difficile (Peptoclostridium difficile)	2710								4NBX;4NBZ;
Q887Q3	ALGG_PSESM	reviewed	Mannuronan C5-epimerase (EC 5.1.3.37) (Alginate epimerase) (Poly(beta-D-mannuronate) C5 epimerase)	algG PSPTO_1238	Pseudomonas syringae pv. tomato (strain ATCC BAA-871 / DC3000)	536					"MUTAGEN 294;  /note=""Y->A: Retains 24% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 294;  /note=""Y->F: Retains 66% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 296;  /note=""Y->A: Retains 66% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 314;  /note=""Y->F: Retains 5% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 317;  /note=""D->A: Retains 5% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 319;  /note=""H->A: Loss of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 320;  /note=""D->A: Loss of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 338;  /note=""K->A: Retains 87% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 339;  /note=""H->A: Retains 49% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 344;  /note=""S->A: Retains 54% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 345;  /note=""R->A,Q: Retains 10% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 345;  /note=""R->E: Loss of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 345;  /note=""R->K: Retains 36% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 368;  /note=""D->N: Retains 5% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 369;  /note=""R->A: Retains 23% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 392;  /note=""Y->F,A: Retains 65% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 415;  /note=""R->C: Loss of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681""; MUTAGEN 452;  /note=""D->A: Retains 63% of epimerase activity."";  /evidence=""ECO:0000269|PubMed:24398681"""		223283.PSPTO_1238;	4NK6;4NK8;4OZY;4OZZ;
Q06078	UTP21_YEAST	reviewed	U3 small nucleolar RNA-associated protein 21 (U3 snoRNA-associated protein 21) (U three protein 21)	UTP21 YLR409C L8084.22	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	939						Q06078;	4932.YLR409C;	4HNX;4NSX;5JPQ;5TZS;5WLC;5WYJ;5WYK;6KE6;6LQP;6LQQ;6LQR;6LQS;6LQT;6LQU;6LQV;6ND4;6ZQA;6ZQB;6ZQC;6ZQD;6ZQE;6ZQF;7AJT;7AJU;
G0T4F6	G0T4F6_ACTPL	unreviewed	Transferrin-binding protein B	tbpB	Actinobacillus pleuropneumoniae (Haemophilus pleuropneumoniae)	547								4O3X;
Q8Y7I7	Q8Y7I7_LISMO	unreviewed	Lmo1290 protein	lmo1290	Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e)	598							169963.lmo1290;	4L3A;4L3F;
Q8GF97	Q8GF97_PHOLU	unreviewed	TccC3	TccC3	Photorhabdus luminescens (Xenorhabdus luminescens)	960								4O9X;6H6E;6H6F;6H6G;6SUE;6SUF;6SUP;6SUQ;
G2NFJ9	LAM55_STREK	reviewed	Exo-beta-1,3-glucanase (EC 3.2.1.58) (Glucan 1,3-beta-glucosidase) (Laminarinase) (SacteLam55A)	SACTE_4363	Streptomyces sp. (strain SirexAA-E / ActE)	605					"MUTAGEN 174;  /note=""Q->A: 1300-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:25752603""; MUTAGEN 174;  /note=""Q->N: 280-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:25752603""; MUTAGEN 198;  /note=""S->A: 13-fold decrease in catalytic efficiency while nearly no effect on substrate affinity."";  /evidence=""ECO:0000269|PubMed:25752603""; MUTAGEN 449;  /note=""D->A: 1200-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:25752603""; MUTAGEN 449;  /note=""D->N: 330-fold decrease in catalytic efficiency while only 2-fold decrease in substrate affinity."";  /evidence=""ECO:0000269|PubMed:25752603""; MUTAGEN 480;  /note=""E->A,Q: Loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:25752603""; MUTAGEN 502;  /note=""E->A,Q: Loss of enzymatic activity."";  /evidence=""ECO:0000269|PubMed:25752603""; MUTAGEN 505;  /note=""Y->A: 150-fold decrease in catalytic efficiency."";  /evidence=""ECO:0000269|PubMed:25752603"""		862751.SACTE_4363;	4PEW;4PEX;4PEY;4PEZ;4PF0;4TYV;4TZ1;4TZ3;4TZ5;
P62873	GBB1_HUMAN	reviewed	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (Transducin beta chain 1)	GNB1	Homo sapiens (Human)	340			DISEASE: Mental retardation, autosomal dominant 42 (MRD42) [MIM:616973]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD42 patients manifest global developmental delay commonly accompanied by hypotonia, seizures of various types, ophthalmological manifestations, and poor growth. {ECO:0000269|PubMed:25485910, ECO:0000269|PubMed:27108799, ECO:0000269|PubMed:27668284, ECO:0000269|PubMed:28087732}. Note=The disease is caused by variants affecting the gene represented in this entry.			P62873;	9606.ENSP00000481878;	4KFM;4PNK;5HE0;5HE1;5HE2;5HE3;5UKK;5UKL;5UKM;5UZ7;6B3J;6CRK;6D9H;6DDE;6DDF;6E3Y;6EG8;6G79;6GDG;6KPF;6KPG;6LFM;6LFO;6LI3;6LMK;6LML;6M1H;6M1I;6M8S;6N4B;6NI3;6NIY;6OIJ;6OIK;6OMM;6ORV;6OS9;6OSA;6OT0;6P9X;6P9Y;6PB0;6PB1;6PT0;6UUN;6UUS;6UVA;6VCB;6VMS;6VN7;6WHA;6WHC;6WI9;6WPW;6WZG;6X18;6X19;6X1A;6XBJ;6XBK;6XBL;6XBM;6XOX;7AUE;7BB6;7BB7;7C2E;7CFM;7CFN;7CKW;7CKX;7CKY;7CKZ;7CMU;7CMV;7CRH;7CX2;7CX3;7CX4;7D76;7D77;7D7M;7DFL;7E2X;7E2Y;7E2Z;7E32;7E33;7E9G;7E9H;7EB2;7JOZ;7JV5;7JVP;7JVQ;7JVR;7K7L;7K7Z;7KH0;7L0P;7L0Q;7L0R;7L0S;7L1U;7L1V;7LCI;
Q92NR7	Q92NR7_RHIME	unreviewed	Putative oxidoreductase (EC 1.1.1.-)	SMc01429	Rhizobium meliloti (strain 1021) (Ensifer meliloti) (Sinorhizobium meliloti)	281							266834.SMc01429;	4PMJ;4XAP;5C7H;
Q9XD84	TIBA_ECOH1	reviewed	Adhesin/invasin TibA autotransporter [Cleaved into: Adhesin/invasin TibA (Glycoprotein TibA); Adhesin/invasin TibA translocator]	tibA ETEC_2141	Escherichia coli O78:H11 (strain H10407 / ETEC)	989								4Q1Q;
Q83SQ0	LPTD_SHIFL	reviewed	LPS-assembly protein LptD	lptD imp ostA SF0051 S0053	Shigella flexneri	784						Q83SQ0;		4Q35;
A0A0H2UKY6	A0A0H2UKY6_HAEPR	unreviewed	Transferrin-binding protein B		Haemophilus parasuis (Glaesserella parasuis)	532								4O4X;
A0A0H2UKY5	A0A0H2UKY5_HAEPR	unreviewed	Transferrin-binding protein B		Haemophilus parasuis (Glaesserella parasuis)	532								4O4U;
A0A6L7H2E6	A0A6L7H2E6_BACAN	unreviewed	Putative glycerophosphoryl diester phosphodiesterase	GBAA_3560	Bacillus anthracis	314								4R7O;
A7AK45	A7AK45_9BACT	unreviewed	Tetratricopeptide repeat protein	PARMER_03812	Parabacteroides merdae ATCC 43184	275							411477.PARMER_03812;	4R7S;
Q9KP62	MURA_VIBCH	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (UDP-N-acetylglucosamine enolpyruvyl transferase) (EPT)	murA VC_2514	Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)	419							243277.VC_2514;	4R7U;
A0A6L8Q3J2	A0A6L8Q3J2_BACAN	unreviewed	Copper homeostasis protein CutC	cutC GBAA_3100	Bacillus anthracis	225						A0A6L8Q3J2;		4R9X;
Q58499	MFNB_METJA	reviewed	(5-formylfuran-3-yl)methyl phosphate synthase (EC 4.2.3.153) (4-(hydroxymethyl)-2-furancarboxaldehyde-phosphate synthase) (4-HFC-P synthase)	mfnB MJ1099	Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) (Methanococcus jannaschii)	235					"MUTAGEN 25;  /note=""D->N: Lack of activity."";  /evidence=""ECO:0000269|PubMed:25905665""; MUTAGEN 27;  /note=""K->R: Lack of activity."";  /evidence=""ECO:0000269|PubMed:25905665""; MUTAGEN 85;  /note=""K->R: Lack of activity."";  /evidence=""ECO:0000269|PubMed:25905665""; MUTAGEN 151;  /note=""D->N: Lack of activity."";  /evidence=""ECO:0000269|PubMed:25905665""; MUTAGEN 155;  /note=""K->R: Almost no change in activity."";  /evidence=""ECO:0000269|PubMed:25905665"""		243232.MJ_1099;	4RC1;4U9P;
Q96PX8	SLIK1_HUMAN	reviewed	SLIT and NTRK-like protein 1 (Leucine-rich repeat-containing protein 12)	SLITRK1 KIAA1910 LRRC12 UNQ233/PRO266	Homo sapiens (Human)	696			DISEASE: Trichotillomania (TTM) [MIM:613229]: A neuropsychiatric disorder characterized by chronic, repetitive, or compulsive hair pulling resulting in noticeable hair loss. Affected individuals may develop physical complications and often have overlapping psychological disorders, such as Gilles de la Tourette syndrome or obsessive-compulsive disorder. {ECO:0000269|PubMed:16224024, ECO:0000269|PubMed:17003809, ECO:0000269|PubMed:27812321}. Note=The disease may be caused by variants affecting the gene represented in this entry.		"MUTAGEN 85;  /note=""V->M: Does not affect surface expression."";  /evidence=""ECO:0000269|PubMed:27812321""; MUTAGEN 695;  /note=""S->A: Loss of phosphorylation. Not able to promote neurite outgrowth."";  /evidence=""ECO:0000269|PubMed:19640509""; MUTAGEN 695;  /note=""S->E: Able to promote neurite outgrowth as the wild-type."";  /evidence=""ECO:0000269|PubMed:19640509"""	Q96PX8;	9606.ENSP00000366288;	4RCA;4RCW;
Q9JZN9	Y964_NEIMB	reviewed	Probable TonB-dependent receptor NMB0964	NMB0964	Neisseria meningitidis serogroup B (strain MC58)	758								4RDR;4RDT;4RVW;
P31554	LPTD_ECOLI	reviewed	LPS-assembly protein LptD (Organic solvent tolerance protein)	lptD imp ostA yabG b0054 JW0053	Escherichia coli (strain K12)	784				DISRUPTION PHENOTYPE: Mutations alter the permeability of the outer membrane resulting in increased sensitivity to detergents, antibiotics and dyes. Depletion leads to filamentation followed by membrane rupture and cell lysis. {ECO:0000269|PubMed:12207697, ECO:0000269|PubMed:2547691}.	"MUTAGEN 529..538;  /note=""Missing: Impairs assembly of the LptD/LptE complex. Does not form native disulfide bonds. Severely compromises outer membrane integrity."";  /evidence=""ECO:0000269|PubMed:21257904"""	P31554;	511145.b0054;	4RHB;
A5W3Z9	A5W3Z9_PSEP1	unreviewed	Protein involved in meta-pathway of phenol degradation-like protein	Pput_2725	Pseudomonas putida (strain ATCC 700007 / DSM 6899 / BCRC 17059 / F1)	288							351746.Pput_2725;	4RL8;
Q80TS3	AGRL3_MOUSE	reviewed	Adhesion G protein-coupled receptor L3 (Latrophilin-3) (Lectomedin-3)	Adgrl3 Kiaa0768 Lec3 Lphn3	Mus musculus (Mouse)	1537				DISRUPTION PHENOTYPE: Mutant mice are viable and present no obvious physical phenotype. Compared to wild-type, mutants are hyperactive, and their dorsal striatum contains higher levels of the neurotransmitters dopamine and serotonin. Cocaine treatment causes a higher increase in locomotor activity than in wild-type. {ECO:0000269|PubMed:22575564}.	"MUTAGEN 244;  /note=""P->N: Strongly reduces FLRT2 binding; when associated with T-246."";  /evidence=""ECO:0000269|PubMed:25728924""; MUTAGEN 246;  /note=""R->T: Strongly reduces FLRT2 binding; when associated with N-244."";  /evidence=""ECO:0000269|PubMed:25728924""; MUTAGEN 267;  /note=""T->N: Strongly reduces FLRT2 binding; when associated with T-269."";  /evidence=""ECO:0000269|PubMed:25728924""; MUTAGEN 269;  /note=""K->T: Strongly reduces FLRT2 binding; when associated with N-267."";  /evidence=""ECO:0000269|PubMed:25728924""; MUTAGEN 292;  /note=""R->N: Abolishes interaction with FLRT2; when associated with T-294."";  /evidence=""ECO:0000269|PubMed:25728924""; MUTAGEN 294;  /note=""R->T: Abolishes interaction with FLRT2; when associated with N-292."";  /evidence=""ECO:0000269|PubMed:25728924""; MUTAGEN 323;  /note=""Y->A: Abolishes FLRT3 binding."";  /evidence=""ECO:0000269|PubMed:26235031""; MUTAGEN 324;  /note=""R->N: Abolishes interaction with FLRT2; when associated with T-326."";  /evidence=""ECO:0000269|PubMed:25728924""; MUTAGEN 326;  /note=""G->T: Abolishes interaction with FLRT2; when associated with N-324."";  /evidence=""ECO:0000269|PubMed:25728924""; MUTAGEN 332;  /note=""D->A: Strongly reduces FLRT3 binding."";  /evidence=""ECO:0000269|PubMed:26235031"""	Q80TS3;	10090.ENSMUSP00000113482;	4RMK;4RML;4YEB;5AFB;5FTT;5FTU;6JBU;
P76578	A2MG_ECOLI	reviewed	Alpha-2-macroglobulin (ECAM)	yfhM b2520 JW2504	Escherichia coli (strain K12)	1653						P76578;	511145.b2520;	4RTD;4ZIQ;4ZIU;4ZJG;4ZJH;5A42;
Q0E5W5	Q0E5W5_9CAUD	unreviewed	Putative tail fiber protein	gp49	Pseudomonas phage LKA1	769								4RU4;
H2BD96	H2BD96_9CAUD	unreviewed	Uncharacterized protein	phi297_00061	Pseudomonas phage phi297	746								4RU5;
P68512	FEL_CYPCA	reviewed	Fish-egg lectin (FEL)		Cyprinus carpio (Common carp)	238								4RUQ;4RUS;
Q9C2K9	Q9C2K9_NEUCS	unreviewed	Importin subunit alpha	3H10.030 GE21DRAFT_7666	Neurospora crassa	548							5141.EFNCRP00000004389;	4RXH;5VQI;
O04294	IMPA3_ARATH	reviewed	Importin subunit alpha-3 (IMPa-3) (Karyopherin subunit alpha-2) (KAP-alpha-2) (Protein MODIFIER OF SNC1 6)	IMPA3 KAP2 MOS6 At4g02150 T10M13.16	Arabidopsis thaliana (Mouse-ear cress)	531				DISRUPTION PHENOTYPE: No visible phenotype under normal growth conditions, but mutant plants show enhanced disease susceptibility to the virulent pathogen H.arabidopsidis isolate NOCO2. {ECO:0000269|PubMed:15964279}.		O04294;	3702.AT4G02150.1;	4TNM;
H6CS64	H6CS64_AGRAE	unreviewed	Lectin 2	aal-2	Agrocybe aegerita (Black poplar mushroom) (Agaricus aegerita)	407								4TQJ;4TQK;4TQM;
Q5LH16	Q5LH16_BACFN	unreviewed	Putative acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase (EC 2.3.1.129)	lpxA lpxA_2 BF9343_0789 NCTC9343_02447	Bacteroides fragilis (strain ATCC 25285 / DSM 2151 / CCUG 4856 / JCM 11019 / NCTC 9343 / Onslow)	255							272559.BF9343_0789;	4R36;4R37;
Q9I7C4	DPO3B_PSEAE	reviewed	Beta sliding clamp (Beta clamp) (Sliding clamp) (Beta-clamp processivity factor) (DNA polymerase III beta sliding clamp subunit) (DNA polymerase III subunit beta)	dnaN PA0002	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	367								4TR8;4TSZ;6AMS;6PTH;
Q9RYE8	Q9RYE8_DEIRA	unreviewed	Beta sliding clamp	DR_0001	Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)	393							243230.DR_0001;	4TRT;
Q9SAR5	AKR2A_ARATH	reviewed	Ankyrin repeat domain-containing protein 2A (AtAKR2)	AKR2A AFT AKR2 At4g35450 F15J1.20	Arabidopsis thaliana (Mouse-ear cress)	342				DISRUPTION PHENOTYPE: Lethal chlorotic phenotype when homozygote (PubMed:20215589). Reduced levels of chloroplast proteins, including outer envelope membrane (OEM) proteins. Defective chloroplast biogenesis (PubMed:18193034). Reduced APX3 levels and reduced targeting of APX3 to peroxisomes. Compromised peroxisomal function leading to increased sensitivity to aminotriazole during seed germination and shorter hypocotyls in darkness in the absence of sucrose (PubMed:20215589). {ECO:0000269|PubMed:18193034, ECO:0000269|PubMed:20215589}.	"MUTAGEN 25;  /note=""S->F: In akr2a-1; small plants with small and curled rosette leaves, as well as delayed flowering, especially in chilling temperature conditions. Abnormal abaxial epidermal wavy cell shape and absence of cell boundaries between the neighboring surface cells. Impaired interaction with APX3."";  /evidence=""ECO:0000269|PubMed:20215589""; MUTAGEN 113;  /note=""P->L: In akr2a-3; small plants with small and curled rosette leaves, as well as delayed flowering, especially in chilling temperature conditions.Abnormal abaxial epidermal wavy cell shape and absence of cell boundaries between the neighboring surface cells. Impaired interaction with APX3."";  /evidence=""ECO:0000269|PubMed:20215589""; MUTAGEN 150;  /note=""E->K: In akr2a-6; small plants with small and curled rosette leaves, as well as delayed flowering, especially in chilling temperature conditions. Reduced interaction with APX3."";  /evidence=""ECO:0000269|PubMed:20215589""; MUTAGEN 223;  /note=""H->A: Reduced binding to monogalactosyldiacylglycerol (MGDG)."";  /evidence=""ECO:0000269|PubMed:25203210""; MUTAGEN 246;  /note=""E->A: Reduced binding to monogalactosyldiacylglycerol (MGDG) and phosphatidylglycerol (PG)."";  /evidence=""ECO:0000269|PubMed:25203210""; MUTAGEN 294;  /note=""Y->A: Reduced binding to phosphatidylglycerol (PG)."";  /evidence=""ECO:0000269|PubMed:25203210""; MUTAGEN 296;  /note=""R->A: Reduced binding to phosphatidylglycerol (PG)."";  /evidence=""ECO:0000269|PubMed:25203210"""	Q9SAR5;	3702.AT4G35450.5;	4TUM;5EID;
E7CIP7	PME_SITOR	reviewed	Pectinesterase (EC 3.1.1.11) (Pectin methylesterase)	CE8-1	Sitophilus oryzae (Rice weevil) (Curculio oryzae)	382								4PMH;
P18146	EGR1_HUMAN	reviewed	Early growth response protein 1 (EGR-1) (AT225) (Nerve growth factor-induced protein A) (NGFI-A) (Transcription factor ETR103) (Transcription factor Zif268) (Zinc finger protein 225) (Zinc finger protein Krox-24)	EGR1 KROX24 ZNF225	Homo sapiens (Human)	543						P18146;	9606.ENSP00000239938;	4R2A;4R2C;4R2D;4X9J;5N14;
G8XR50	G8XR50_LEUME	unreviewed	Dextransucrase (EC 2.4.1.5) (Sucrose 6-glucosyltransferase)	dsrE563	Leuconostoc mesenteroides	2836								4TVD;
Q72TC3	Q72TC3_LEPIC	unreviewed	Uncharacterized protein	LIC_11098	Leptospira interrogans serogroup Icterohaemorrhagiae serovar copenhageni (strain Fiocruz L1-130)	426								4U08;
Q72NS0	Q72NS0_LEPIC	unreviewed	Cytoplasmic membrane protein	LIC_12759	Leptospira interrogans serogroup Icterohaemorrhagiae serovar copenhageni (strain Fiocruz L1-130)	423								4U09;
Q8DLC2	LIPA2_THEEB	reviewed	Lipoyl synthase 2 (EC 2.8.1.8) (Lip-syn 2) (LS 2) (Lipoate synthase 2) (Lipoic acid synthase 2) (Sulfur insertion protein LipA 2)	lipA2 tll0574	Thermosynechococcus elongatus (strain BP-1)	290							197221.22294295;	4U0O;4U0P;
Q8ZN46	Q8ZN46_SALTY	unreviewed	Alpha-2-macroglobulin	STM2532	Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)	1644								4U48;4U4J;4U59;
Q47465	Q47465_PECCA	unreviewed	Pectate lyase (EC 4.2.2.2)	pel-3	Pectobacterium carotovorum (Erwinia carotovora)	347								4U49;4U4B;
Q04660	ERB1_YEAST	reviewed	Ribosome biogenesis protein ERB1 (Eukaryotic ribosome biogenesis protein 1)	ERB1 YMR049C YM9796.02C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	807					"MUTAGEN 465;  /note=""E->R: Disrupts the interaction with YTM1 and cannot sustain growth."";  /evidence=""ECO:0000269|PubMed:26476442, ECO:0000269|PubMed:26657628""; MUTAGEN 470;  /note=""R->E: Weakens the interaction with YTM1, impairs pre-rRNA processing and leads to a deficiency in 60S ribosomal subunits. Disrupts the interaction with YTM1 and cannot sustain growth; when associated with R-790."";  /evidence=""ECO:0000269|PubMed:26476442, ECO:0000269|PubMed:26657628""; MUTAGEN 790;  /note=""E->R: Disrupts the interaction with YTM1 and cannot sustain growth; when associated with E-470."";  /evidence=""ECO:0000269|PubMed:26657628"""	Q04660;	4932.YMR049C;	4U7A;6C0F;6CB1;6ELZ;6EM1;6EM3;6EM4;6EM5;
Q96JA1	LRIG1_HUMAN	reviewed	Leucine-rich repeats and immunoglobulin-like domains protein 1 (LIG-1)	LRIG1 LIG1	Homo sapiens (Human)	1093						Q96JA1;	9606.ENSP00000273261;	4U7L;4U7M;
O60684	IMA7_HUMAN	reviewed	Importin subunit alpha-7 (Karyopherin subunit alpha-6)	KPNA6 IPOA7	Homo sapiens (Human)	536						O60684;	9606.ENSP00000362728;	4UAD;
O00629	IMA3_HUMAN	reviewed	Importin subunit alpha-3 (Importin alpha Q1) (Qip1) (Karyopherin subunit alpha-4)	KPNA4 QIP1	Homo sapiens (Human)	521						O00629;	9606.ENSP00000334373;	4UAE;5TBK;5XZX;6BVV;6BVZ;6BW9;6BWA;6BWB;6WX8;7JJL;
A0A0J9X219	A0A0J9X219_LACKL	unreviewed	Rack1		Lachancea kluyveri (Yeast) (Saccharomyces kluyveri)	318								4UER;
I0E093	I0E093_9MONO	unreviewed	Glycoprotein	G	Bat Paramyxovirus Eid_hel/GH-M74a/GHA/2009	632								4UF7;
Q72U33	Q72U33_LEPIC	unreviewed	Uncharacterized protein	LIC_10831	Leptospira interrogans serogroup Icterohaemorrhagiae serovar copenhageni (strain Fiocruz L1-130)	377								4U06;
Q72Q78	Q72Q78_LEPIC	unreviewed	Uncharacterized protein	LIC_12234	Leptospira interrogans serogroup Icterohaemorrhagiae serovar copenhageni (strain Fiocruz L1-130)	167								4TZH;
Q9UJX2	CDC23_HUMAN	reviewed	Cell division cycle protein 23 homolog (Anaphase-promoting complex subunit 8) (APC8) (Cyclosome subunit 8)	CDC23 ANAPC8	Homo sapiens (Human)	597					"MUTAGEN 339;  /note=""N->A: Inhibits APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-374."";  /evidence=""ECO:0000269|PubMed:26083744""; MUTAGEN 374;  /note=""E->A: Inhibits APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-339."";  /evidence=""ECO:0000269|PubMed:26083744"""	Q9UJX2;	9606.ENSP00000378350;	4UI9;5A31;5G04;5G05;5KHR;5KHU;5L9T;5L9U;5LCW;6Q6G;6Q6H;6TLJ;6TM5;6TNT;
Q60AR6	Q60AR6_METCA	unreviewed	Methanol dehydrogenase protein, large subunit	mxaF MCA0779	Methylococcus capsulatus (strain ATCC 33009 / NCIMB 11132 / Bath)	601							243233.MCA0779;	4TQO;
Q9H1A4	APC1_HUMAN	reviewed	Anaphase-promoting complex subunit 1 (APC1) (Cyclosome subunit 1) (Mitotic checkpoint regulator) (Testis-specific gene 24 protein)	ANAPC1 TSG24	Homo sapiens (Human)	1944			DISEASE: Rothmund-Thomson syndrome 1 (RTS1) [MIM:618625]: An autosomal recessive disorder characterized by sparse hair, bilateral juvenile cataracts, and poikiloderma, a genodermatosis presenting with mottled pigmentation, telangiectasia and epidermal atrophy. Additional features are short stature, dystrophic and thin nails, and genital, skeletal and dental abnormalities. RTS1 is not associated with an increased risk of cancer. {ECO:0000269|PubMed:31303264}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q9H1A4;	9606.ENSP00000339109;	4UI9;5A31;5G04;5G05;5KHR;5KHU;5L9T;5L9U;5LCW;5LGG;6Q6G;6Q6H;6TLJ;6TM5;6TNT;
Q8XNZ3	NANE_CLOPE	reviewed	Putative N-acetylmannosamine-6-phosphate 2-epimerase (EC 5.1.3.9) (ManNAc-6-P epimerase)	nanE nanP CPE0184	Clostridium perfringens (strain 13 / Type A)	221								4UTU;4UTW;
Q9UJX4	APC5_HUMAN	reviewed	Anaphase-promoting complex subunit 5 (APC5) (Cyclosome subunit 5)	ANAPC5 APC5	Homo sapiens (Human)	755						Q9UJX4;	9606.ENSP00000261819;	4UI9;5A31;5G04;5G05;5KHR;5KHU;5L9T;5L9U;5LCW;6Q6G;6Q6H;6TLJ;6TM5;6TNT;
Q9HVV7	Q9HVV7_PSEAE	unreviewed	Lipopolysaccharide export system protein LptA	lptA PA4460	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	175								4UU4;
Q6KZI8	KDGA_PICTO	reviewed	2-dehydro-3-deoxy-D-gluconate/2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14) (EC 4.1.2.51) (2-dehydro-3-deoxy-galactonate/2-dehydro-3-deoxy-6-phosphogalactonate aldolase) (EC 4.1.2.-) (EC 4.1.2.21)	PTO1279	Picrophilus torridus (strain ATCC 700027 / DSM 9790 / JCM 10055 / NBRC 100828)	266							263820.PTO1279;	4UXD;
Q8WXH4	ASB11_HUMAN	reviewed	Ankyrin repeat and SOCS box protein 11 (ASB-11)	ASB11	Homo sapiens (Human)	323							9606.ENSP00000417914;	4UUC;
A8ITN7	A8ITN7_CHLRE	unreviewed	Flagellar associated protein	FAP259 CHLRE_07g342200v5 CHLREDRAFT_128801	Chlamydomonas reinhardtii (Chlamydomonas smithii)	647							3055.EDP03884;	4UZY;
A8JEA1	A8JEA1_CHLRE	unreviewed	Bardet-biedl syndrome 1 protein	BBS1 CHLREDRAFT_132537	Chlamydomonas reinhardtii (Chlamydomonas smithii)	611						A8JEA1;	3055.EDO97795;	4V0M;4V0N;4V0O;
Q8UB77	KDGD_AGRFC	reviewed	Probable 5-dehydro-4-deoxyglucarate dehydratase (EC 4.2.1.41) (5-keto-4-deoxy-glucarate dehydratase) (KDGDH)	Atu3140 AGR_L_3338	Agrobacterium fabrum (strain C58 / ATCC 33970) (Agrobacterium tumefaciens (strain C58))	303							176299.Atu3140;	4UR7;4UR8;5HWJ;5HWM;5HWN;
B4V386	B4V386_9ACTN	unreviewed	Phosphoribosyl isomerase A (1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase) (EC 5.3.1.16) (N-(5'-phosphoribosyl)anthranilate isomerase) (PRAI) (EC 5.3.1.24) (Phosphoribosylformimino-5-aminoimidazole carboxamide ribotide isomerase)	priA hisA M444_10495 SSAG_02214	Streptomyces sp. Mg1	243							465541.ATCJ01000005_gene2815;	4W9T;4X9S;
A0A0D6HUA0	A0A0D6HUA0_STAAU	unreviewed	Glycosyl transferase family 1 (Glycosyltransferase) (Glycosyltransferase, group 1 family protein) (Putative glycosyl transferases) (EC 2.4.1.52)	tagE_1 tagE_3 BTN44_07615 DQU54_05680 ELP52_03455 EP54_04825 EQ90_04835 FA040_03600 GO814_05215 GO942_02110 GQX37_05620 GZ145_13305 HMPREF3211_01868 NCTC10654_01079 RK64_05510 SAGV51_01115 SAHC1335_01873 SAMEA1029536_00158 SAMEA103891420_00850 SAMEA2076468_00124 SAMEA2076503_01641 SAMEA2077334_00495 SAMEA2078260_00435 SAMEA2078588_00185 SAMEA2079501_00093 SAMEA2080344_00125 SAMEA2081063_00125 SAMEA4008569_00125 SAMEA70146418_01876	Staphylococcus aureus	493								4WAC;4WAD;
G0SC29	NLE1_CHATD	reviewed	Ribosome assembly protein 4 (Notchless protein homolog 1) (Ribosome biogenesis factor RSA4)	CTHT_0055700	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	517							209285.XP_006695900.1;	4WJS;6QTA;
A0A0R4I968	A0A0R4I968_9ROSA	unreviewed	Frutalin		Artocarpus	157								4WOG;
Q8BGT1	FLRT3_MOUSE	reviewed	Leucine-rich repeat transmembrane protein FLRT3 (Fibronectin leucine rich transmembrane protein 3)	Flrt3 Kiaa1469	Mus musculus (Mouse)	649				DISRUPTION PHENOTYPE: Heterozygous mice are viable and fertile, but homozygous mice display nearly complete embryonic lethality. Most embryos die at about 10.5 dpc (PubMed:18448090, PubMed:19056886). A majority present disruption of the basement membrane and ruptures of the anterior visceral endoderm (PubMed:19056886). About one third display a pronounced defect in the fusion of the lateral edges of the body wall, resulting in cardia bifida. Mutant mice display also a defect in proepicardial cell migration. About one third of the mutants display abnormal morphogenesis of the neuroepithelium and headfold fusion defects. Besides, mutant embryos display defects in definitive endoderm migration, resulting in anterior axis truncations. Each of these phenotypes has partial penetrance, and many mutant embryos present a spectrum of defects. About 3% of the mutants develop into viable and fertile adults (PubMed:18448090, PubMed:19056886). {ECO:0000269|PubMed:18448090, ECO:0000269|PubMed:19056886}.	"MUTAGEN 160;  /note=""F->A,N: Abolishes interaction with ADGRL3."";  /evidence=""ECO:0000269|PubMed:26235031""; MUTAGEN 165;  /note=""H->N: Abolishes interaction with UNC5B."";  /evidence=""ECO:0000269|PubMed:25374360""; MUTAGEN 181;  /note=""R->N: Abolishes homooligomerization and FLRT3-mediated cell-cell adhesion; when associated with T-183."";  /evidence=""ECO:0000269|PubMed:25374360""; MUTAGEN 183;  /note=""D->N: Abolishes homooligomerization and FLRT3-mediated cell-cell adhesion; when associated with N-181."";  /evidence=""ECO:0000269|PubMed:25374360"""	Q8BGT1;	10090.ENSMUSP00000053399;	4V2E;4YEB;
Q15397	PUM3_HUMAN	reviewed	Pumilio homolog 3 (HBV X-transactivated gene 5 protein) (HBV XAg-transactivated protein 5) (Minor histocompatibility antigen HA-8) (HLA-HA8)	PUM3 cPERP-C KIAA0020 PUF-A XTP5	Homo sapiens (Human)	648						Q15397;	9606.ENSP00000380982;	4WZR;4WZW;
A0A0H2WWV6	TARM_STAAC	reviewed	Poly(ribitol-phosphate) alpha-N-acetylglucosaminyltransferase (EC 2.4.1.70) (WTA GlcNAc-transferase)	tarM SACOL1043	Staphylococcus aureus (strain COL)	493				DISRUPTION PHENOTYPE: Inactivation of the gene leads to resistance to serogroup B phages. Disruption leads to altered WTA that lacks the alpha-GlcNAc residues. Mutant exhibits no major changes in growth kinetics, microscopic appearance or antibiotic susceptibility. {ECO:0000269|PubMed:20185825}.	"MUTAGEN 117;  /note=""G->R: Forms monomers. No change in activity."";  /evidence=""ECO:0000269|PubMed:25624472""; MUTAGEN 136;  /note=""K->S: Decrease in activity."";  /evidence=""ECO:0000269|PubMed:25697358""; MUTAGEN 138;  /note=""N->Q: Slight decrease in activity."";  /evidence=""ECO:0000269|PubMed:25697358""; MUTAGEN 180;  /note=""N->W: No change in activity."";  /evidence=""ECO:0000269|PubMed:25697358""; MUTAGEN 249;  /note=""H->A: Severe decrease in activity."";  /evidence=""ECO:0000269|PubMed:25624472, ECO:0000269|PubMed:25697358""; MUTAGEN 326;  /note=""R->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:25624472""; MUTAGEN 326;  /note=""R->S: Strong decrease in activity."";  /evidence=""ECO:0000269|PubMed:25697358""; MUTAGEN 331;  /note=""K->A,S: Loss of activity."";  /evidence=""ECO:0000269|PubMed:25624472, ECO:0000269|PubMed:25697358""; MUTAGEN 403;  /note=""E->A: Loss of activity."";  /evidence=""ECO:0000269|PubMed:25624472, ECO:0000269|PubMed:25697358""; MUTAGEN 411;  /note=""E->A: Severe decrease in activity."";  /evidence=""ECO:0000269|PubMed:25624472, ECO:0000269|PubMed:25697358""; MUTAGEN 487..493;  /note=""Missing: In 52B2; loss of activity. Phage-resistant phenotype."";  /evidence=""ECO:0000269|PubMed:20185825"""			4WAC;4WAD;4X6L;4X7M;4X7P;4X7R;
Q9UM11	FZR1_HUMAN	reviewed	Fizzy-related protein homolog (Fzr) (CDC20-like protein 1) (Cdh1/Hct1 homolog) (hCDH1)	FZR1 CDH1 FYR FZR KIAA1242	Homo sapiens (Human)	496					"MUTAGEN 7..14;  /note=""RRLLRQIV->AAAAAQAA: Reduced interaction with CCNF. Impaired degradation."";  /evidence=""ECO:0000269|PubMed:27653696""; MUTAGEN 40;  /note=""S->A: Constitutively active; when associated with A-121; A-151 and A-163. Does not affect APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-121; A-151 and A-163. Decreases APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-121 and A-151. Decreases APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-121 and A-163."";  /evidence=""ECO:0000269|PubMed:18662541, ECO:0000269|PubMed:26083744""; MUTAGEN 47;  /note=""R->A: Inhibits APC/FZR1 E3 ubiquitin-protein ligase complex activity."";  /evidence=""ECO:0000269|PubMed:26083744""; MUTAGEN 52;  /note=""R->A: Inhibits APC/FZR1 E3 ubiquitin-protein ligase complex activity."";  /evidence=""ECO:0000269|PubMed:26083744""; MUTAGEN 121;  /note=""T->A: Constitutively active; when associated with A-40; A-151 and A-163. Does not affect APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-40; A-151 and A-163. Decreases APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-40 and A-151. Decreases APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-40 and A-163. Decreases APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-151 and A-163."";  /evidence=""ECO:0000269|PubMed:18662541, ECO:0000269|PubMed:26083744""; MUTAGEN 151;  /note=""S->A: Constitutively active; when associated with A-40; A-121 and A-163. Does not affect ubiquitination; when associated with A-40; A-121 and A-163. Decreases ubiquitination; when associated with A-40 and A-163. Decreases ubiquitination; when associated with A-121 and A-163."";  /evidence=""ECO:0000269|PubMed:18662541, ECO:0000269|PubMed:26083744""; MUTAGEN 163;  /note=""S->A: Constitutively active; when associated with A-40; A-121 and A-151. Does not affect APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-40; A-121 and A-151. Decreases APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-40 and A-121. Decreases APC/FZR1 E3 ubiquitin-protein ligase complex activity; when associated with A-121 and A-151. Decreases ubiquitination; when associated with A-40 and A-151."";  /evidence=""ECO:0000269|PubMed:18662541, ECO:0000269|PubMed:26083744""; MUTAGEN 445..447;  /note=""RVL->AVA: Reduced interaction with CCNF."";  /evidence=""ECO:0000269|PubMed:27653696"""	Q9UM11;	9606.ENSP00000378529;	4UI9;5L9T;5L9U;
A0A0M3KL00	A0A0M3KL00_STRMG	unreviewed	Uncharacterized protein	ALKD2	Streptococcus mutans	210								4X8Q;6M9M;
Q0E9K9	Q0E9K9_DROME	unreviewed	Down syndrome cell adhesion molecule 1, isoform AO	Dscam1 43Bc CT39257 Dm_2R:13579 Dm_2R:13612 DmDscam Dmel\CG17800 DSCAM DScam DsCam Dscam dScam dscam Dscam-hv dscam1 Dsm l(2)05518 l(2)43Bc Neu1 p270 CG17800 Dmel_CG17800	Drosophila melanogaster (Fruit fly)	2032								4X83;
C7R2I5	C7R2I5_JONDD	unreviewed	N-(5'-phosphoribosyl)anthranilate isomerase (PRAI) (EC 5.3.1.24)	trpF Jden_0894	Jonesia denitrificans (strain ATCC 14870 / DSM 20603 / BCRC 15368 / CIP 55.134 / JCM 11481 / NBRC 15587 / NCTC 10816 / Prevot 55134) (Listeria denitrificans)	204							471856.Jden_0894;	4WUI;
Q8BLU0	FLRT2_MOUSE	reviewed	Leucine-rich repeat transmembrane protein FLRT2 (Fibronectin leucine rich transmembrane protein 2)	Flrt2 Kiaa0405	Mus musculus (Mouse)	660				DISRUPTION PHENOTYPE: Heterozygous mice are viable and fertile, but homozygous mice display nearly complete embryonic lethality. Most embryos die at about 12.5 dpc, probably due to impaired expansion of the ventricular myocardium during development, reduced endocardial volume and heart insufficiency. Contrary to wild-type, the epicardium appears ruffled and presents numerous holes, due to defective formation of cell-cell adhesions. Still, there is a very small percentage of life-born pups that survive at least up to weaning. {ECO:0000269|PubMed:21350012}.	"MUTAGEN 170;  /note=""H->E,N: Abolishes interaction with UNC5D."";  /evidence=""ECO:0000269|PubMed:25374360""; MUTAGEN 186;  /note=""R->N: Abolishes homooligomerization and FLRT2-mediated cell-cell adhesion; when associated with T-188."";  /evidence=""ECO:0000269|PubMed:25374360""; MUTAGEN 188;  /note=""D->T: Abolishes homooligomerization and FLRT2-mediated cell-cell adhesion; when associated with N-186."";  /evidence=""ECO:0000269|PubMed:25374360""; MUTAGEN 248;  /note=""D->N: No effect on interaction with UNC5D; when associated with T-250."";  /evidence=""ECO:0000269|PubMed:25374360""; MUTAGEN 250;  /note=""P->T: No effect on interaction with UNC5D; when associated with N-248."";  /evidence=""ECO:0000269|PubMed:25374360"""	Q8BLU0;	10090.ENSMUSP00000062171;	4V2C;4V2D;5FTT;5FTU;
F8RC03	F8RC03_9GAMM	unreviewed	Qdtf	qdtf	Providencia alcalifaciens	397								4XCZ;4XD0;4XD1;
P42935	ELP2_YEAST	reviewed	Elongator complex protein 2 (Gamma-toxin target 2)	ELP2 TOT2 YGR200C G7725	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	788						P42935;	4932.YGR200C;	4XFV;5M2N;6QK7;
F2YBL9	F2YBL9_ANOGA	unreviewed	APL1B	APL1B	Anopheles gambiae (African malaria mosquito)	555								4XGO;
G0S143	G0S143_CHATD	unreviewed	Importin N-terminal domain-containing protein	CTHT_0012280	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	877							209285.XP_006691745.1;	4XRI;4XRK;
C4XPQ7	C4XPQ7_DESMR	unreviewed	Magnetosome protein MamA	mamA DMR_41160	Desulfovibrio magneticus (strain ATCC 700980 / DSM 13731 / RS-1)	217							573370.DMR_41160;	4XI0;5LFL;5LFM;
B6K598	B6K598_SCHJY	unreviewed	Kinetochore protein Mis16	SJAG_03867	Schizosaccharomyces japonicus (strain yFS275 / FY16936) (Fission yeast)	427							4897.EEB08702;	4XYH;4XYI;
Q810C0	SLIK2_MOUSE	reviewed	SLIT and NTRK-like protein 2	Slitrk2	Mus musculus (Mouse)	846					"MUTAGEN 114;  /note=""R->A: No effect on interaction with PTPRD. No effect on synapse assembly."";  /evidence=""ECO:0000269|PubMed:25989451""; MUTAGEN 167;  /note=""D->A: Abolishes interaction with PTPRD. Abolishes synapse assembly."";  /evidence=""ECO:0000269|PubMed:25989451""; MUTAGEN 187;  /note=""D->A: Abolishes interaction with PTPRD. Abolishes synapse assembly."";  /evidence=""ECO:0000269|PubMed:25989451""; MUTAGEN 215;  /note=""E->A: Abolishes interaction with PTPRD. Significantly reduces synapse assembly."";  /evidence=""ECO:0000269|PubMed:25989451""; MUTAGEN 247..250;  /note=""FRLH->ARLA: No effect on interaction with PTPRD. No effect on synapse assembly."";  /evidence=""ECO:0000269|PubMed:25989451"""		10090.ENSMUSP00000130057;	4Y61;
A0A090CRQ5	A0A090CRQ5_PODAN	unreviewed	Putative Kinesin light chain		Podospora anserina (strain S / ATCC MYA-4624 / DSM 980 / FGSC 10383) (Pleurage anserina)	1067							5145.XP_003437295.1;	4Y6C;4Y6W;
Q64487	PTPRD_MOUSE	reviewed	Receptor-type tyrosine-protein phosphatase delta (Protein-tyrosine phosphatase delta) (R-PTP-delta) (EC 3.1.3.48)	Ptprd	Mus musculus (Mouse)	1912					"MUTAGEN 68;  /note=""R->A: Reduces affinity with IL1RAPL1. Reduces the synaptogenic activity to ~7%."";  /evidence=""ECO:0000269|PubMed:25908590""; MUTAGEN 189;  /note=""R->A: Decreases affinity for interaction with IL1RAPL1."";  /evidence=""ECO:0000269|PubMed:25908590""; MUTAGEN 229;  /note=""R->E: Abolishes interaction with SLITRK2."";  /evidence=""ECO:0000269|PubMed:25989451""; MUTAGEN 266;  /note=""Y->A: No effect on interaction with SLITRK2. Decreases the affinity for IL1RAPL1. Abolishes interaction with IL1RAP."";  /evidence=""ECO:0000269|PubMed:25908590, ECO:0000269|PubMed:25989451""; MUTAGEN 279;  /note=""E->A: Decreases affinity for IL1RAP."";  /evidence=""ECO:0000269|PubMed:25908590"""	Q64487;	10090.ENSMUSP00000099898;	4Y61;4YFD;4YFE;4YFG;4YH7;5XWT;5XWU;5Y32;6KIP;7CEG;
B0R5N9	B0R5N9_HALS3	unreviewed	Bacteriorhodopsin	bop OE_3106F	Halobacterium salinarum (strain ATCC 29341 / DSM 671 / R1)	262								4Y9H;5B35;
O43043	SCAP_SCHPO	reviewed	Sterol regulatory element-binding protein cleavage-activating protein (SCAP) (SREBP cleavage-activating protein)	scp1 SPBC3B9.15c	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	1086				DISRUPTION PHENOTYPE: Cells show absence of mature sre1 as well as inability to grow in the absence of oxygen. {ECO:0000269|PubMed:17595166}.	"MUTAGEN 247;  /note=""Y->C: Loss of sterol dependence of sre1 proteolysis. Constitutive maturation of sre1."";  /evidence=""ECO:0000269|PubMed:17595166""; MUTAGEN 264;  /note=""L->F: Loss of sterol dependence of sre1 proteolysis. Constitutive maturation of sre1."";  /evidence=""ECO:0000269|PubMed:17595166""; MUTAGEN 392;  /note=""D->N: Loss of sterol dependence of sre1 proteolysis. Constitutive maturation of sre1."";  /evidence=""ECO:0000269|PubMed:17595166""; MUTAGEN 617;  /note=""R->E: In Scp1-M1; strongly reduced interaction with sre1."";  /evidence=""ECO:0000269|PubMed:25771684""; MUTAGEN 618;  /note=""C->S: In Scp1-M4; reduced interaction with sre1; when associated with S-680."";  /evidence=""ECO:0000269|PubMed:25771684""; MUTAGEN 635..643;  /note=""KEQMPRTLK->EEQMPETLE: In Scp1-M2; strongly reduced interaction with sre1."";  /evidence=""ECO:0000269|PubMed:25771684""; MUTAGEN 659;  /note=""K->E: In Scp1-M3; strongly reduced interaction with sre1; when associated with E-685."";  /evidence=""ECO:0000269|PubMed:25771684""; MUTAGEN 680;  /note=""C->S: In Scp1-M4; reduced interaction with sre1; when associated with S-618."";  /evidence=""ECO:0000269|PubMed:25771684""; MUTAGEN 685;  /note=""K->E: In Scp1-M3; strongly reduced interaction with sre1; when associated with E-659."";  /evidence=""ECO:0000269|PubMed:25771684""; MUTAGEN 1023;  /note=""D->K: In Scp1-M5; reduced interaction with sre1."";  /evidence=""ECO:0000269|PubMed:25771684"""		4896.SPBC3B9.15c.1;	4YHC;5GRS;
D3GUX1	D3GUX1_ECO44	unreviewed	Putative type VI secretion protein	EC042_4540	Escherichia coli O44:H18 (strain 042 / EAEC)	532						D3GUX1;		4YO3;4YO5;
O43660	PLRG1_HUMAN	reviewed	Pleiotropic regulator 1	PLRG1	Homo sapiens (Human)	514						O43660;	9606.ENSP00000424417;	4YVD;5MQF;5XJC;5YZG;5Z56;5Z57;5Z58;6FF4;6FF7;6ICZ;6ID0;6ID1;6QDV;6ZYM;7AAV;7ABF;7ABG;7ABI;7DH6;7DVQ;
Q940U6	FLU_ARATH	reviewed	Protein FLUORESCENT IN BLUE LIGHT, chloroplastic	FLU At3g14110 MAG2.7	Arabidopsis thaliana (Mouse-ear cress)	316				DISRUPTION PHENOTYPE: Loss of ability to restrict the accumulation of protochloro-phyllide (Pchlide) and delta-amin-olevulinic acid (ALA) in the dark, leading to a strong Pchlide fluorescence in etiolated mutant seedlings exposed to blue light. Rapid bleaching and death of plants transferred from the dark to the light, mediated by singlet oxygen production and enzymatic peroxidation of linolenic acid. {ECO:0000269|PubMed:11606728, ECO:0000269|PubMed:14508004, ECO:0000269|PubMed:15584960, ECO:0000269|PubMed:18182022}.	"MUTAGEN 146;  /note=""A->V: In flu1-4; rapid bleaching and death when transferred from the dark to the light, accumulation of Pchlide and ALA."";  /evidence=""ECO:0000269|PubMed:11606728""; MUTAGEN 262;  /note=""A->V: In flu1-1; rapid bleaching and death when transferred from the dark to the light, accumulation of Pchlide and ALA, and impaired HEMA1 interaction."";  /evidence=""ECO:0000269|PubMed:11606728, ECO:0000269|PubMed:15584960"""	Q940U6;	3702.AT3G14110.3;	4YVO;4YVQ;5CHE;
A0A0H2UQE4	A0A0H2UQE4_STRPN	unreviewed	Putative neuraminidase (EC 3.2.1.18)	SP_1326	Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)	740							170187.SP_1326;	4YW1;4YW2;4YW3;4YW5;4YZ1;4YZ2;4YZ3;4YZ4;4YZ5;
Q6R5N8	TLR13_MOUSE	reviewed	Toll-like receptor 13 (EC 3.2.2.6)	Tlr13	Mus musculus (Mouse)	991							10090.ENSMUSP00000043101;	4Z0C;
Q6VS32	Q6VS32_NEIME	unreviewed	Factor H binding protein variant A10_001 (Lipoprotein) (Putative lipoprotein) (Fragment)	fhbp	Neisseria meningitidis	254								4Z3T;
A9D857	HOAVI_HOEPD	reviewed	Hoefavidin	HPDFL43_17171	Hoeflea phototrophica (strain DSM 17068 / NCIMB 14078 / DFL-43)	164		BIOTECHNOLOGY: The specific properties of hoefavidin make it an attractive target for novel biotechnological applications, including drug delivery, nanotechnology, and molecular labeling. {ECO:0000305|PubMed:26126731}.						4Z27;4Z28;4Z2O;4Z2P;4Z2V;4Z6J;6RTQ;
A4XGA6	A4XGA6_CALS8	unreviewed	Cellobiose 2-epimerase (CE) (EC 5.1.3.11)	Csac_0294	Caldicellulosiruptor saccharolyticus (strain ATCC 43494 / DSM 8903 / Tp8T 6331)	390							351627.Csac_0294;	4Z4J;4Z4L;
Q8LPB4	PSKR1_DAUCA	reviewed	Phytosulfokine receptor 1 (DcPSKR1) (EC 2.7.11.1) (Phytosulfokine LRR receptor kinase 1)	PSKR	Daucus carota (Wild carrot)	1021					"MUTAGEN 503..517;  /note=""Missing: Loss of PSK binding activity."";  /evidence=""ECO:0000269|PubMed:17092941""; MUTAGEN 518..538;  /note=""Missing: Loss of PSK binding activity."";  /evidence=""ECO:0000269|PubMed:17092941"""	Q8LPB4;		4Z5W;4Z61;4Z62;
Q9XIC7	SERK2_ARATH	reviewed	Somatic embryogenesis receptor kinase 2 (AtSERK2) (EC 2.7.11.1) (Somatic embryogenesis receptor-like kinase 2)	SERK2 At1g34210 F23M19.11	Arabidopsis thaliana (Mouse-ear cress)	628				DISRUPTION PHENOTYPE: No visible phenotype. Serk1 and serk2 double mutants are completely male sterile due to a failure in tapetum specification. {ECO:0000269|PubMed:16284305, ECO:0000269|PubMed:16284306}.		Q9XIC7;	3702.AT1G34210.1;	4Z61;5GQR;6G3W;
Q5ZWY8	Q5ZWY8_LEGPH	unreviewed	Gala protein type 1, 3 or 4	legL1 lpg0945	Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC 33152 / DSM 7513)	296							272624.lpg0945;	4XA9;
P29536	LMOD1_HUMAN	reviewed	Leiomodin-1 (64 kDa autoantigen 1D) (64 kDa autoantigen 1D3) (64 kDa autoantigen D1) (Leiomodin, muscle form) (Smooth muscle leiomodin) (SM-Lmod) (Thyroid-associated ophthalmopathy autoantigen)	LMOD1	Homo sapiens (Human)	600						P29536;	9606.ENSP00000356257;	4Z79;4Z8G;4Z94;
Q9ZVR7	PSKR1_ARATH	reviewed	Phytosulfokine receptor 1 (AtPSKR1) (EC 2.7.11.1) (EC 4.6.1.2) (Guanylate cyclase) (Phytosulfokine LRR receptor kinase 1) (Protein serine-threonine kinase)	PSKR1 PSKR At2g02220 F5O4.1	Arabidopsis thaliana (Mouse-ear cress)	1008				DISRUPTION PHENOTYPE: Gradual loss of individual cells potential to form callus as the tissues mature (PubMed:16829587). Premature senescence of the leaves (PubMed:17989228). Limitted root growth (PubMed:19076296). Enhanced resistance to bacterial biotrophic pathogens, but increased susceptibility to necrotrophic fungal infection (PubMed:23062058). {ECO:0000269|PubMed:16829587, ECO:0000269|PubMed:17989228, ECO:0000269|PubMed:19076296, ECO:0000269|PubMed:23062058}.	"MUTAGEN 596;  /note=""F->D: Decreased responsiveness to PSK for interaction with BAK1 and decreased root length."";  /evidence=""ECO:0000269|PubMed:26308901""; MUTAGEN 598;  /note=""S->Y: Decreased responsiveness to PSK for interaction with BAK1 and decreased root length."";  /evidence=""ECO:0000269|PubMed:26308901""; MUTAGEN 619;  /note=""T->Y: Decreased responsiveness to PSK for interaction with BAK1 and decreased root length."";  /evidence=""ECO:0000269|PubMed:26308901""; MUTAGEN 623;  /note=""S->Y: No effect on responsiveness to PSK for interaction with BAK1 and no effect on root length."";  /evidence=""ECO:0000269|PubMed:26308901""; MUTAGEN 923;  /note=""G->K: Decreased guanylate cyclase activity and impaired PSK receptor function."";  /evidence=""ECO:0000269|PubMed:21504901, ECO:0000269|PubMed:26071421"""	Q9ZVR7;	3702.AT2G02220.1;	4Z63;4Z64;
Q8BMF8	GLDN_MOUSE	reviewed	Gliomedin (Cancer-related gene liver 2 protein) (CRG-L2) [Cleaved into: Gliomedin shedded ectodomain]	Gldn Crgl2	Mus musculus (Mouse)	549				DISRUPTION PHENOTYPE: Mutant mice present no obvious neurological phenotype and have normal nerve conduction. Nerves from their peripheral nervous system have myelin sheets that are indistinguishable from wild-type. In contrast, they present impaired and disorganized attachment of Schwann cell microvilli to the axolemma at nodes of Ranvier. Mature nodes are formed by the fusion of two heminodes. During development, mutant mice present defective clustering of sodium channels at heminodes, but display normal sodium channel clustering at mature nodes (PubMed:20188654). Mice lacking both Gldn and Nrcam are born at the expected Mendelian rate, but are smaller than control littermates and display important neurological impairments, in spite of seemingly normal nerve myelination. Motor abnormalities vary between individuals, ranging from ataxia, uncoordinated movements and premature death to weakness of the hind limbs, hypomotility, strongly impaired ability to hang from a horizontal bar with their forelimbs and a tendency to stumble. The motor defects correlate with decreased velocity of nerve conduction and slower propagation of action potentials. Most mice die within 60 days after birth, and none are fertile. Mutant mice display delayed formation of mature nodes of Ranvier; 15 days after birth about 20% of the nodes lack detectable sodium channel clusters. Sodium channel clustering and nerve conduction appear normal 60 and 75 days after birth, but subsequently a gradual disintegration of the nodal protein complexes is seen. About 70% of the mutant nodes present high-density sodium channel clustering at 120 days after birth, as opposed to nearly 100% for wild-type. Contrary to wild-type, in adult nodes of Ranvier the sodium channels are often clustered near the paranode border with an empty gap in the middle. At nodes of Ranvier, Schwann cell microvilli are sparse or absent and show defects in their orientation, resulting in various structural abnormalities at the node and the paranode border (PubMed:24719088). {ECO:0000269|PubMed:20188654, ECO:0000269|PubMed:24719088}.	"MUTAGEN 91;  /note=""R->A: Abolishes furin-mediated cleavage and shedding of ectodomain."";  /evidence=""ECO:0000269|PubMed:17293346""; MUTAGEN 278..279;  /note=""DD->AA: Abolishes BMP1-mediated cleavage of ectodomain release of olfactomedin-like domain."";  /evidence=""ECO:0000269|PubMed:17293346"""		10090.ENSMUSP00000056080;	4XAV;
B7X8M2	B7X8M2_MOMCH	unreviewed	rRNA N-glycosidase (EC 3.2.2.22)	MCL1 LOC111023549	Momordica charantia (Bitter gourd) (Balsam pear)	547								4Z8S;4Z9W;4ZA3;4ZBV;4ZFU;4ZFW;4ZFY;4ZGR;4ZLB;
Q8IDQ2	Q8IDQ2_PLAF7	unreviewed	Kelch protein K13	PF3D7_1343700	Plasmodium falciparum (isolate 3D7)	726						Q8IDQ2;		4ZGC;
P83052	BBKI_BAUBA	reviewed	Kunitz-type serine protease inhibitor BbKI		Bauhinia bauhinioides (Perlebia bauhinoides)	164								4ZOT;
G0S0R0	G0S0R0_CHATD	unreviewed	Uncharacterized protein	CTHT_0010920	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	533							209285.XP_006691612.1;	4ZN4;4ZOY;4ZOZ;
P35184	SQT1_YEAST	reviewed	Ribosome assembly protein SQT1	SQT1 YIR012W YIB12W	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	431						P35184;	4932.YIR012W;	4ZOV;4ZOX;5AMS;
E1F4V5	E1F4V5_GIAIA	unreviewed	14-3-3 protein	GLP15_1412	Giardia intestinalis (strain P15) (Giardia lamblia)	236								4ZQ0;
G1SLW8	G1SLW8_RABIT	unreviewed	Eukaryotic translation initiation factor 3 subunit M (eIF3m)	EIF3M	Oryctolagus cuniculus (Rabbit)	374						G1SLW8;	9986.ENSOCUP00000003873;	5A5T;6W2S;6W2T;6YAM;
G1SZ03	G1SZ03_RABIT	unreviewed	Eukaryotic translation initiation factor 3 subunit B (eIF3b) (Eukaryotic translation initiation factor 3 subunit 9) (eIF-3-eta)	EIF3B EIF3S9	Oryctolagus cuniculus (Rabbit)	679						G1SZ03;	9986.ENSOCUP00000008873;	5A5U;
Q24367	Q24367_DROME	unreviewed	Inscuteable	insc inscuteable CG11312	Drosophila melanogaster (Fruit fly)	859								5A7D;
Q21KE5	Q21KE5_SACD2	unreviewed	Putative retaining b-glycosidase	cel5F Sde_1572	Saccharophagus degradans (strain 2-40 / ATCC 43961 / DSM 17024)	365							203122.Sde_1572;	5A8M;5A8N;5A8O;5A8P;5A8Q;5A94;5A95;
Q12769	NU160_HUMAN	reviewed	Nuclear pore complex protein Nup160 (160 kDa nucleoporin) (Nucleoporin Nup160)	NUP160 KIAA0197 NUP120	Homo sapiens (Human)	1436			DISEASE: Nephrotic syndrome 19 (NPHS19) [MIM:618178]: A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show non-specific histologic changes such as focal segmental glomerulosclerosis and diffuse mesangial proliferation. Some affected individuals have an inherited steroid-resistant form that progresses to end-stage renal failure. NPHS19 is an autosomal recessive, steroid-resistant form with onset in the first or second decade of life, resulting in chronic kidney disease. {ECO:0000269|PubMed:30179222, ECO:0000269|PubMed:30910934}. Note=The disease may be caused by variants affecting the gene represented in this entry.			Q12769;	9606.ENSP00000367721;	5A9Q;
Q9QZE5	COPG1_MOUSE	reviewed	Coatomer subunit gamma-1 (Gamma-1-coat protein) (Gamma-1-COP)	Copg1 Copg	Mus musculus (Mouse)	874							10090.ENSMUSP00000109237;	5A1U;5A1V;5A1W;5A1X;5A1Y;5NZR;5NZS;5NZT;5NZU;5NZV;
Q8NFH4	NUP37_HUMAN	reviewed	Nucleoporin Nup37 (p37) (Nup107-160 subcomplex subunit Nup37)	NUP37	Homo sapiens (Human)	326			DISEASE: Microcephaly 24, primary, autosomal recessive (MCPH24) [MIM:618179]: A form of microcephaly, a disease defined as a head circumference more than 3 standard deviations below the age, sex and ethnically matched mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. MCPH24 patients additionally manifest mildly impaired intellectual development, cerebellar vermis hypoplasia, and fifth finger clinodactyly. {ECO:0000269|PubMed:30179222}. Note=The disease may be caused by variants affecting the gene represented in this entry.			Q8NFH4;	9606.ENSP00000448054;	5A9Q;
Q96EE3	SEH1_HUMAN	reviewed	Nucleoporin SEH1 (GATOR complex protein SEH1) (Nup107-160 subcomplex subunit SEH1) (SEC13-like protein)	SEH1L SEC13L SEH1	Homo sapiens (Human)	360						Q96EE3;	9606.ENSP00000382779;	5A9Q;
Q551M2	IF6_DICDI	reviewed	Eukaryotic translation initiation factor 6 (eIF-6)	eif6 DDB_G0276493	Dictyostelium discoideum (Slime mold)	244							44689.DDB0234038;	5AN9;5ANB;6QKL;
J7HDY4	J7HDY4_PHARH	unreviewed	Beta-fructofuranosidase	INV	Phaffia rhodozyma (Yeast) (Xanthophyllomyces dendrorhous)	665								5ANN;5FIX;5FK7;5FK8;5FKB;5FKC;5FMB;5FMC;5FMD;5NSL;5O47;6FJE;6FJG;6S2G;6S2H;6S3Z;6S82;
P77522	SUFB_ECOLI	reviewed	FeS cluster assembly protein SufB	sufB ynhE b1683 JW5273	Escherichia coli (strain K12)	495						P77522;	511145.b1683;	5AWF;5AWG;
E6UIS7	MGP_RUMA7	reviewed	4-O-beta-D-mannosyl-D-glucose phosphorylase (MGP) (Mannosylglucose phosphorylase) (EC 2.4.1.281) (RaMP1)	Rumal_0852	Ruminococcus albus (strain ATCC 27210 / DSM 20455 / JCM 14654 / NCDO 2250 / 7)	386							697329.Rumal_0852;	5AY9;5AYC;
E6UBR9	MOSP_RUMA7	reviewed	Beta-1,4-mannooligosaccharide phosphorylase (EC 2.4.1.319) (RaMP2)	Rumal_0099	Ruminococcus albus (strain ATCC 27210 / DSM 20455 / JCM 14654 / NCDO 2250 / 7)	335							697329.Rumal_0099;	5AYD;5AYE;
A0A010	A0A010_STRVD	unreviewed	MoeN5	moeN5	Streptomyces viridosporus	260								5B00;5B01;5B02;5B03;5B0I;5B0J;5B0K;5B0L;5B0M;5GWV;5GWW;6J8V;6J8W;
P56288	EI2BG_SCHPO	reviewed	Probable translation initiation factor eIF-2B subunit gamma (eIF-2B GDP-GTP exchange factor subunit gamma)	tif223 SPAC4D7.09	Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	458						P56288;	4896.SPAC4D7.09.1;	5B04;6JLY;6JLZ;
Q9Z2G6	SE1L1_MOUSE	reviewed	Protein sel-1 homolog 1 (Suppressor of lin-12-like protein 1) (Sel-1L)	Sel1l Sel1h	Mus musculus (Mouse)	790				DISRUPTION PHENOTYPE: Taxomifen-inducible gene disruption in adult mice leads to premature death within 3 weeks after the onset of taxomifen treatment. Mice progressively loose weight and become moribund despite increased food intake and normal blood glucose levels, suggesting nutrient maladsorption. After eight days of treatment, the pancreas was diffusely dark red and soft, suggesting severe pancreas atrophy. Still, the endocrine parts of the pancreas were not affected. Pancreas weight was about half of that of wild-type, the size of secretory zymogen granules was reduced and pancreatic lipase and alpha-amylase levels were strongly reduced. Besides, the morphology of the endoplasmic reticulum in pancreas acinar cells was abnormal, with swollen and fragmented cisternae. Likewise, SYVN1 protein levels are decreased, while those of other ERAD markers are increased (PubMed:24453213). Adipocyte-specific gene disruption does not give rise to any obvious phenotype when mice are kept on a low-fat diet. Mutant mice are resistant to diet-induced obesity when kept on a high-fat diet, in spite of normal food intake and physical activity. Mutant mice show dramatically reduced accumulation of fat mass relative to wild-type, while lean mass is not affected. Intriguingly, mutant mice display enlarged livers that develop steatosis and increased triglyceride levels. Mutant mice display increased fasting serum triglyceride and insulin levels. Likewise, mutant mice display hypertriglyceridemia after feeding, especially on a high-fat diet. In spite of increased cellular LPL levels, LPL secretion is reduced by 80 to 90% (PubMed:25066055). {ECO:0000269|PubMed:24453213, ECO:0000269|PubMed:25066055}.	"MUTAGEN 512..513;  /note=""GG->KK: Abolishes homodimerization."";  /evidence=""ECO:0000269|PubMed:27064360""; MUTAGEN 515..516;  /note=""IL->AA: Abolishes homodimerization; when associated with A-519."";  /evidence=""ECO:0000269|PubMed:27064360""; MUTAGEN 519;  /note=""Y->A: Abolishes homodimerization; when associated with 515-A-A-516."";  /evidence=""ECO:0000269|PubMed:27064360""; MUTAGEN 521;  /note=""L->A: Abolishes homodimerization."";  /evidence=""ECO:0000269|PubMed:27064360"""	Q9Z2G6;	10090.ENSMUSP00000021347;	5B26;
Q93HT5	Q93HT5_CLOBO	unreviewed	HA-33	ha-33	Clostridium botulinum	285								5B2H;
Q9HAR2	AGRL3_HUMAN	reviewed	Adhesion G protein-coupled receptor L3 (Calcium-independent alpha-latrotoxin receptor 3) (CIRL-3) (Latrophilin-3) (Lectomedin-3)	ADGRL3 KIAA0768 LEC3 LPHN3	Homo sapiens (Human)	1447					"MUTAGEN 249..252;  /note=""YHDT->AHAA: Strongly reduces FLRT3 binding. Abolishes FLRT3 binding; when associated with A-308."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 308;  /note=""R->A: Abolishes FLRT3 binding; when associated with 249-A--A-252."";  /evidence=""ECO:0000269|PubMed:26235030"""	Q9HAR2;	9606.ENSP00000422533;	5CMN;6VHH;
Q38720	Q38720_ARTHE	unreviewed	Jacalin		Artocarpus heterophyllus (Jackfruit)	217								5BN6;
A0QND6	DPO3B_MYCS2	reviewed	Beta sliding clamp (Beta clamp) (Sliding clamp) (Beta-clamp processivity factor) (DNA polymerase III beta sliding clamp subunit) (DNA polymerase III subunit beta)	dnaN MSMEG_0001 MSMEI_0003	Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) (Mycobacterium smegmatis)	397						A0QND6;	246196.MSMEI_0003;	5AH2;5AH4;
A8HQH2	A8HQH2_CHLRE	unreviewed	Predicted protein (Fragment)	CGL41 CHLREDRAFT_162607	Chlamydomonas reinhardtii (Chlamydomonas smithii)	201							3055.EDP09788;	5BS1;5BS2;
B5TV91	B5TV91_LEIDO	unreviewed	Proliferating cell nuclear antigen	PCNA	Leishmania donovani	292								5B7O;5CFK;5H0T;5HAC;6J0J;6K2M;
F6BL85	F6BL85_THEXL	unreviewed	Glucosylceramidase (EC 3.2.1.45)	Thexy_2211	Thermoanaerobacterium xylanolyticum (strain ATCC 49914 / DSM 7097 / LX-11)	806							858215.Thexy_2211;	5BVU;5BX2;5BX3;5BX4;5BX5;5FJS;5NCX;5NPF;5O0S;5OST;
P39016	MPT5_YEAST	reviewed	Suppressor protein MPT5 (Protein HTR1) (Pumilio homology domain family member 5)	MPT5 HTR1 PUF5 YGL178W BIC834	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	859						P39016;	4932.YGL178W;	5BYM;5BZ1;5BZ5;5BZU;5BZV;
A0A0J9X2A1	A0A0J9X2A1_PIG	unreviewed	Dynein tail		Sus scrofa (Pig)	350								5AFU;
Q9HVW7	MURA_PSEAE	reviewed	UDP-N-acetylglucosamine 1-carboxyvinyltransferase (EC 2.5.1.7) (Enoylpyruvate transferase) (UDP-N-acetylglucosamine enolpyruvyl transferase) (EPT)	murA PA4450	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	421								5BQ2;
A7SDD2	A7SDD2_NEMVE	unreviewed	Predicted protein	v1g114158	Nematostella vectensis (Starlet sea anemone)	242								5C2M;
Q483R4	Q483R4_COLP3	unreviewed	2-deoxy-D-ribose 5-phosphate aldolase (EC 4.1.2.4)	deoC CPS_1972	Colwellia psychrerythraea (strain 34H / ATCC BAA-681) (Vibrio psychroerythus)	257								5C2X;5C5Y;
B0TQ91	DEOC_SHEHH	reviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC Shal_3136	Shewanella halifaxensis (strain HAW-EB4)	257							458817.Shal_3136;	5C6M;
Q8NMD2	Q8NMD2_CORGL	unreviewed	Dihydrodipicolinate synthase/N-acetylneuraminate lyase (EC 4.3.3.7)	Cgl2646	Corynebacterium glutamicum (strain ATCC 13032 / DSM 20300 / BCRC 11384 / JCM 1318 / LMG 3730 / NCIMB 10025)	312							196627.cg2931;	5C54;5C55;
Q6MHS9	Q6MHS9_BDEBA	unreviewed	Uncharacterized protein	Bd3460	Bdellovibrio bacteriovorus (strain ATCC 15356 / DSM 50701 / NCIMB 9529 / HD100)	220							264462.Bd3460;	5CEA;5CEC;5CED;5CER;
Q05022	RRP5_YEAST	reviewed	rRNA biogenesis protein RRP5 (Ribosomal RNA-processing protein 5) (U3 small nucleolar RNA-associated protein RRP5) (U3 snoRNA-associated protein RRP5)	RRP5 FMI1 YMR229C YM9959.11C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1729						Q05022;	4932.YMR229C;	5C9S;5NLG;5WLC;5WWM;5WYJ;6LQQ;6LQR;6LQS;6LQT;6LQU;6ZQC;6ZQD;7AJT;7AJU;
Q1Q0T4	HZSB_KUEST	reviewed	Hydrazine synthase subunit beta (HZS-beta)	kuste2859	Kuenenia stuttgartiensis	386						Q1Q0T4;		5C2V;5C2W;
Q9HLB6	TPIS_THEAC	reviewed	Triosephosphate isomerase (TIM) (TPI) (EC 5.3.1.1) (Triose-phosphate isomerase)	tpiA Ta0313	Thermoplasma acidophilum (strain ATCC 25905 / DSM 1728 / JCM 9062 / NBRC 15155 / AMRC-C165)	216							273075.Ta0313;	5CSR;5CSS;
Q9NZU0	FLRT3_HUMAN	reviewed	Leucine-rich repeat transmembrane protein FLRT3 (Fibronectin-like domain-containing leucine-rich transmembrane protein 3)	FLRT3 KIAA1469 UNQ856/PRO1865	Homo sapiens (Human)	649			DISEASE: Hypogonadotropic hypogonadism 21 with or without anosmia (HH21) [MIM:615271]: A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). {ECO:0000269|PubMed:23643382}. Note=The disease is caused by variants affecting distinct genetic loci, including the gene represented in this entry. Some patients carrying mutations in FLRT3 also have a mutation in another HH-associated gene including FGFR1, HS6ST1 and FGF17 (PubMed:23643382). {ECO:0000269|PubMed:23643382}.		"MUTAGEN 38;  /note=""D->A: Abolishes ADGRL3 binding; when associated with A-43; A-45 and A-47."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 43;  /note=""Y->A: Abolishes ADGRL3 binding; when associated with A-64. Abolishes ADGRL3 binding; when associated with A-38; A-43 and A-47."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 45;  /note=""N->A: Abolishes ADGRL3 binding; when associated with A-38; A-43 and A-47."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 47;  /note=""R->A: Abolishes ADGRL3 binding; when associated with A-38; A-43 and A-45."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 64;  /note=""Y->A: Abolishes ADGRL3 binding; when associated with A-43."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 89;  /note=""Y->A: Abolishes ADGRL3 binding; when associated with A-91."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 91;  /note=""Y->A: Abolishes ADGRL3 binding; when associated with A-89."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 181;  /note=""R->A: No effect on homodimerization; when associated with A-183."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 181;  /note=""R->N: Adds a glycosylation site that strongly reduces homodimerization; when associated with T-183."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 183;  /note=""D->A: No effect on homodimerization; when associated with A-181."";  /evidence=""ECO:0000269|PubMed:26235030""; MUTAGEN 183;  /note=""D->T: Adds a glycosylation site that strongly reduces homodimerization; when associated with T-183."";  /evidence=""ECO:0000269|PubMed:26235030"""	Q9NZU0;	9606.ENSP00000367292;	5CMN;5CMP;6JBU;
J7QLC0	CYAA_BORP1	reviewed	Bifunctional hemolysin/adenylate cyclase (AC-HLY) (ACT) (Cyclolysin) [Cleaved into: Calmodulin-sensitive adenylate cyclase (EC 4.6.1.1) (ATP pyrophosphate-lyase) (Adenylyl cyclase); Hemolysin]	cya cyaA BN118_0468	Bordetella pertussis (strain ATCC 9797 / DSM 5571 / NCTC 10739 / 18323)	1706							568706.BN118_0468;	5CVW;6RFM;
G0SFB5	YTM1_CHATD	reviewed	Ribosome biogenesis protein YTM1	YTM1 CTHT_0061460	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	495							209285.XP_006696462.1;	5CXB;5CXC;5CYK;5EM2;6QTB;
G0SCK6	ERB1_CHATD	reviewed	Ribosome biogenesis protein ERB1 (Eukaryotic ribosome biogenesis protein 1)	ERB1 CTHT_0057570	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	801					"MUTAGEN 486;  /note=""R->A: Weakens, but does not disrupt the interaction with YTM1."";  /evidence=""ECO:0000269|PubMed:26476442""; MUTAGEN 486;  /note=""R->E: Disrupts the interaction with YTM1."";  /evidence=""ECO:0000269|PubMed:26476442"""		209285.XP_006696077.1;	5CXB;5CXC;5CYK;5EM2;
B0VB33	B0VB33_ACIBY	unreviewed	Uncharacterized protein	ABAYE2397	Acinetobacter baumannii (strain AYE)	236								5D66;
Q95YI4	Q95YI4_PHOPY	unreviewed	Luciferin regenerating enzyme		Photinus pyralis (Common eastern firefly) (Lampyris pyralis)	308								5D9B;5D9C;5D9D;5GTQ;5GX1;5GX2;5GX3;5GX4;5GX5;5XFE;
M1Q3P9	M1Q3P9_BACTU	unreviewed	Transcriptional regulator/TPR domain protein	H175_ch0523	Bacillus thuringiensis serovar thuringiensis str. IS5056	423								5DBK;
G3YAL0	G3YAL0_ASPNA	unreviewed	Pectinesterase (EC 3.1.1.11)	ASPNIDRAFT_214857	Aspergillus niger (strain ATCC 1015 / CBS 113.46 / FGSC A1144 / LSHB Ac4 / NCTC 3858a / NRRL 328 / USDA 3528.7)	327								5C1C;5C1E;
A0A0D5YKR4	A0A0D5YKR4_ACIBA	unreviewed	OprD family porin (Outer membrane porin, OprD family) (Porin) (EC 3.4.21.-)	oprD_3 ABUW_2771 C6N18_06420 F2P40_18690 NCTC13421_02712	Acinetobacter baumannii	426								5DL7;
Q680B9	PRRP2_ARATH	reviewed	Proteinaceous RNase P 2 (EC 3.1.26.5)	PRORP2 At2g16650 T24I21.6	Arabidopsis thaliana (Mouse-ear cress)	528				DISRUPTION PHENOTYPE: No visible phenotype; due to the redundancy with PRORP3. Prorp2 and prorp3 double mutant is lethal. {ECO:0000269|PubMed:22549728}.	"MUTAGEN 343;  /note=""D->A: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:26655022""; MUTAGEN 421..422;  /note=""DD->AA: Loss of activity."";  /evidence=""ECO:0000269|PubMed:22549728""; MUTAGEN 421;  /note=""D->A: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:26655022""; MUTAGEN 422;  /note=""D->A: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:26655022""; MUTAGEN 440;  /note=""D->A: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:26655022""; MUTAGEN 445;  /note=""H->A: Abolishes ribonuclease activity."";  /evidence=""ECO:0000269|PubMed:26655022"""		3702.AT2G16650.1;	5DIZ;5FT9;
A0A0D5YI36	A0A0D5YI36_ACIBA	unreviewed	Benzoate transport porin BenP (OprD family porin) (Outer membrane porin, OprD family) (Putative porin for benzoate transport (BenP)) (EC 3.4.21.-)	benP1 oprD_1 ABUW_1854 C6N18_10720 GNY86_02815 NCTC13421_01741	Acinetobacter baumannii	418								5DL8;
H2FH31	LEC_CREGR	reviewed	Galactose-binding lectin (CGL) (GalNAc/Gal-specific lectin)		Crenomytilus grayanus (Gray mussel) (Mytilus grayanus)	150		BIOTECHNOLOGY: This protein may have potential in cancer diagnosis and treatment (PubMed:28636877, PubMed:27010847, PubMed:30486373, PubMed:31905927). A synthetic analog of this protein with enhanced carbohydrate-binding properties may be designed for the purpose of constructing a biosensor for cancer diagnostics or anticancer therapy (PubMed:30486373). May potentially be used as an immune modulator in mammals, because of its effects on macrophages and its ability to promote secretion of cytokines (PubMed:28740170). {ECO:0000305|PubMed:27010847, ECO:0000305|PubMed:28636877, ECO:0000305|PubMed:28740170, ECO:0000305|PubMed:30486373, ECO:0000305|PubMed:31905927}.			"MUTAGEN 16;  /note=""H->A: Loss of hemagglutinating and porcine stomach mucin-binding activities; when associated with A-17 and A-19."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 17;  /note=""P->A: Loss of hemagglutinating and porcine stomach mucin-binding activities; when associated with A-16 and A-19."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 19;  /note=""G->A: Loss of hemagglutinating and porcine stomach mucin-binding activities; when associated with A-16 and A-17."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 27;  /note=""N->A: 5.9-fold decreased porcine stomach mucin-binding activity compared to wild-type."";  /evidence=""ECO:0000269|PubMed:30486373""; MUTAGEN 37;  /note=""H->A: 1.4-fold decreased porcine stomach mucin-binding activity compared to wild-type."";  /evidence=""ECO:0000269|PubMed:30486373""; MUTAGEN 64;  /note=""H->A: Loss of hemagglutinating and porcine stomach mucin-binding activities; when associated with A-65 and A-67."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 65;  /note=""P->A: Loss of hemagglutinating and porcine stomach mucin-binding activities; when associated with A-64 and A-67."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 67;  /note=""G->A: Loss of hemagglutinating and porcine stomach mucin-binding activities; when associated with A-64 and A-65."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 75;  /note=""E->A: 3.2-fold decreased porcine stomach mucin-binding activity compared to wild-type."";  /evidence=""ECO:0000269|PubMed:30486373""; MUTAGEN 85;  /note=""H->A: 5.0-fold decreased porcine stomach mucin-binding activity compared to wild-type."";  /evidence=""ECO:0000269|PubMed:30486373""; MUTAGEN 108;  /note=""H->A: Retains slight hemagglutinating activity and has 6-fold decreased porcine stomach mucin-binding activity; when associated with A-109 and A-111."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 109;  /note=""P->A: Retains slight hemagglutinating activity and has 6-fold decreased porcine stomach mucin-binding activity; when associated with A-108 and A-111."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 111;  /note=""G->A: Retains slight hemagglutinating activity and has 6-fold decreased porcine stomach mucin-binding activity; when associated with A-108 and A-109."";  /evidence=""ECO:0000269|PubMed:26439416""; MUTAGEN 119;  /note=""N->A: 11.1-fold decreased porcine stomach mucin-binding activity compared to wild-type."";  /evidence=""ECO:0000269|PubMed:30486373""; MUTAGEN 127;  /note=""D->A: 4.5-fold decreased porcine stomach mucin-binding activity compared to wild-type."";  /evidence=""ECO:0000269|PubMed:30486373""; MUTAGEN 129;  /note=""H->A: 2.3-fold decreased porcine stomach mucin-binding activity compared to wild-type."";  /evidence=""ECO:0000269|PubMed:30486373"""			5DUY;5F8S;5F8W;5F8Y;5F90;
Q6A070	TGRM1_MOUSE	reviewed	TOG array regulator of axonemal microtubules protein 1 (Crescerin-1) (Protein FAM179B)	Togaram1 Fam179b Kiaa0423	Mus musculus (Mouse)	1776					"MUTAGEN 364;  /note=""Y->E: Expected to disrupt microtubule binding. Abolishes the ability to promote microtubule polymerization."";  /evidence=""ECO:0000269|PubMed:26378256""; MUTAGEN 1274;  /note=""W->E: Abolishes association with microtubules."";  /evidence=""ECO:0000269|PubMed:26378256""; MUTAGEN 1559;  /note=""F->E: Abolishes association with microtubules and the ability to promote microtubule polymerization."";  /evidence=""ECO:0000269|PubMed:26378256"""		10090.ENSMUSP00000070382;	5DN7;
Q91Y13	PCDA7_MOUSE	reviewed	Protocadherin alpha-7 (PCDH-alpha-7)	Pcdha7	Mus musculus (Mouse)	937					"MUTAGEN 138;  /note=""K->Q: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with L-284."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 284;  /note=""D->L: No effect on homophilic interaction. Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with Q-138."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 328;  /note=""P->F: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself."";  /evidence=""ECO:0000269|PubMed:27161523"""			5DZV;
Q91XZ4	PCDB6_MOUSE	reviewed	Protocadherin beta-6 (PCDH-beta-6)	Pcdhb6	Mus musculus (Mouse)	772					"MUTAGEN 67;  /note=""H->V: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself;when associated with D-69 and R-368."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 69;  /note=""R->D: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself;when associated with V-67 and R-368."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 141;  /note=""K->E: No effect on homophilic interaction. Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with R-323."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 143;  /note=""Q->P: Changed homophilic interaction; when associated with F-326."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 145;  /note=""S->I: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 185;  /note=""R->N: No effect on homophilic interaction. Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with K-317."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 317;  /note=""E->K: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with N-185."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 323;  /note=""S->R: Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with E-141."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 326;  /note=""L->F: No effect on homophilic interaction. Changed homophilic interaction; when associated with P-143."";  /evidence=""ECO:0000269|PubMed:27161523""; MUTAGEN 368;  /note=""S->R: No effect on homophilic interaction. Changed homophilic interaction, being unable to interact with the wild-type protein but able to bind itself; when associated with V-67 and D-69."";  /evidence=""ECO:0000269|PubMed:27161523"""		10090.ENSMUSP00000058592;	5DZX;
A7LXT4	Y2650_BACO1	reviewed	IPT/TIG domain-containing protein BACOVA_02650	BACOVA_02650	Bacteroides ovatus (strain ATCC 8483 / DSM 1896 / JCM 5824 / BCRC 10623 / CCUG 4943 / NCTC 11153)	489							411476.BACOVA_02650;	5E7G;5E7H;
F0EX68	F0EX68_9NEIS	unreviewed	Uncharacterized protein	HMPREF9098_0447	Kingella denitrificans ATCC 33394	340								5EC6;5EE4;
D5AHU8	D5AHU8_STRGZ	unreviewed	Deoxyribose-phosphate aldolase (DERA) (EC 4.1.2.4) (2-deoxy-D-ribose 5-phosphate aldolase) (Phosphodeoxyriboaldolase) (Deoxyriboaldolase)	deoC SSGZ1_0956	Streptococcus suis (strain GZ1)	220								5DBT;5DBU;
G2SI47	G2SI47_RHOMG	unreviewed	Outer membrane assembly lipoprotein YfiO	Rhom172_2204	Rhodothermus marinus (strain SG0.5JP17-172)	280								5EFR;
A0A0H4IWK3	A0A0H4IWK3_NEIG1	unreviewed	Hemoglobin-haptoglobin-utilization protein	NGO_11390	Neisseria gonorrhoeae (strain ATCC 700825 / FA 1090)	331								5EE2;
Q2UNX8	LECF_ASPOR	reviewed	Fucose-specific lectin (Aspergillus oryzea lectin) (AOL)	fleA AO090001000189	Aspergillus oryzae (strain ATCC 42149 / RIB 40) (Yellow koji mold)	311		BIOTECHNOLOGY: Lectins have particular value as specific probes for investigating the distribution, structure and biological function of carbohydrate chains on the cell surface of animal, plant, and microorganism because of their specificity for defined carbohydrate structures (PubMed:17383961). FleA is suitable for detecting core fucose on cell surface glycoproteins and/or a useful vehicle for delivery of substances to the inside of cells (PubMed:17383961, PubMed:21892597). {ECO:0000269|PubMed:21892597, ECO:0000305|PubMed:17383961}.						5EO7;5EO8;5H47;
W7FPA1	W7FPA1_PLAFA	unreviewed	Uncharacterized protein	PFAG_00718	Plasmodium falciparum Santa Lucia	275								5EWP;
O53532	Y2258_MYCTU	reviewed	Uncharacterized S-adenosylmethionine-dependent methyltransferase Rv2258c (EC 2.1.1.-)	Rv2258c	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	353							83332.Rv2258c;	5F8C;5F8E;5F8F;
Q04781	LTN1_YEAST	reviewed	E3 ubiquitin-protein ligase listerin (EC 2.3.2.27) (RING domain mutant killed by rtf1 deletion protein 1) (RING-type E3 ubiquitin transferase listerin)	RKR1 LTN1 YMR247C YM9408.09C YM9920.01C	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	1562					"MUTAGEN 1508;  /note=""C->A: Abolishes catalytic activity."";  /evidence=""ECO:0000269|PubMed:17283062""; MUTAGEN 1542;  /note=""W->A,E: Abolishes ability to control levels of proteins with 'non-stop'."";  /evidence=""ECO:0000269|PubMed:20835226"""	Q04781;	4932.YMR247C;	5FG0;5FG1;
Q93K99	Q93K99_ENTCL	unreviewed	OmpC porin (Porin)	ompC EGK68_01615 NCTC10005_03257	Enterobacter cloacae	363								5FVN;
Q91XZ2	PCDB8_MOUSE	reviewed	Protocadherin beta-8 (PCDH-beta-8)	Pcdhb8	Mus musculus (Mouse)	779							10090.ENSMUSP00000054371;	5DZY;
Q9ET47	ESPN_MOUSE	reviewed	Espin (Ectoplasmic specialization protein)	Espn	Mus musculus (Mouse)	871						Q9ET47;	10090.ENSMUSP00000030785;	5ET0;5ET1;
P84908	DAIP_STRMB	reviewed	Dispase autolysis-inducing protein	daip	Streptomyces mobaraensis (Streptoverticillium mobaraense)	374								5FZP;6FHP;
A9CB85	LH3_ADES1	reviewed	Hexon-interlacing protein LH3		Snake adenovirus serotype 1 (SnAdV-1)	373								5G5N;5G5O;
P0A432	PSBO_SYNEL	reviewed	Photosystem II manganese-stabilizing polypeptide (MSP)	psbO	Synechococcus elongatus	272								5G38;5G39;5G3A;
W8CR80	W8CR80_9BACL	unreviewed	Pectate lyase (EC 4.2.2.2)	pelN	Paenibacillus sp. 0602	475								5GT5;
Q8TAF3	WDR48_HUMAN	reviewed	WD repeat-containing protein 48 (USP1-associated factor 1) (WD repeat endosomal protein) (p80)	WDR48 KIAA1449 UAF1	Homo sapiens (Human)	677					"MUTAGEN 30;  /note=""R->A: In UAF1(3A); impaired DNA-binding; when associated with A-50 and A-168. In UAF1(3A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-50 and A-168. In UAF1(11A); impaired DNA-binding; when associated with A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 50;  /note=""R->A: In UAF1(3A); impaired DNA-binding; when associated with A-30 and A-168. In UAF1(3A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30 and A-168. In UAF1(11A); impaired DNA-binding; when associated with A-30, A-117, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-117, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 77;  /note=""W->A: Impaired binding to USP12; when associated with Ala-256."";  /evidence=""ECO:0000269|PubMed:27373336""; MUTAGEN 117;  /note=""K->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-161, A-168, A-230, A-272, A-274, A-275, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 119;  /note=""Y->A: Impaired binding to USP12; when associated with Ala-172."";  /evidence=""ECO:0000269|PubMed:27373336""; MUTAGEN 161;  /note=""T->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-168, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-168, A-230, A-272, A-274, A-275, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 168;  /note=""K->A: In UAF1(3A); impaired DNA-binding; when associated with A-30 and A-50. In UAF1(3A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30 and A-50. In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-230, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-230, A-272, A-274, A-275, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 170;  /note=""S->Y: Strongly reduces interaction with USP46 and abolishes stimulation of USP46 enzyme activity."";  /evidence=""ECO:0000269|PubMed:26388029""; MUTAGEN 172;  /note=""Y->A: Impaired binding to USP12; when associated with Ala-119."";  /evidence=""ECO:0000269|PubMed:27373336""; MUTAGEN 214;  /note=""K->E: Strongly reduces interaction with USP12 or USP46 and abolishes stimulation of their enzyme activity; when associated with A-256 and D-272."";  /evidence=""ECO:0000269|PubMed:26388029, ECO:0000269|PubMed:27650958""; MUTAGEN 230;  /note=""S->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-272, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-272, A-274, A-275, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 256;  /note=""W->A: Strongly reduces interaction with USP12 or USP46 and abolishes stimulation of their enzyme activity; when associated with E-214 and D-272. Impaired binding to USP12; when associated with Ala-77."";  /evidence=""ECO:0000269|PubMed:26388029, ECO:0000269|PubMed:27373336, ECO:0000269|PubMed:27650958""; MUTAGEN 272;  /note=""R->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-274, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-274, A-275, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 272;  /note=""R->D: Strongly reduces interaction with USP12 or USP46 and abolishes stimulation of their enzyme activity; when associated with E-214 and A-256."";  /evidence=""ECO:0000269|PubMed:26388029, ECO:0000269|PubMed:27650958""; MUTAGEN 274;  /note=""R->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-275, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-275, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 275;  /note=""K->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-318 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-318 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 318;  /note=""K->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275 and A-363. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275 and A-363."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 363;  /note=""I->A: In UAF1(11A); impaired DNA-binding; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275 and A-318. In UAF1(11A); does not affect ability to promote USP1-mediated deubiquitination of FANCD2 and stimulate RAD51-mediated homologous recombination, because of DNA-binding mediated by RAD51AP1; when associated with A-30, A-50, A-117, A-161, A-168, A-230, A-272, A-274, A-275 and A-318."";  /evidence=""ECO:0000269|PubMed:31253762""; MUTAGEN 459;  /note=""K->E: Decreased interaction with RAD51AP1."";  /evidence=""ECO:0000269|PubMed:27239033""; MUTAGEN 580;  /note=""L->F: Impaired binding to PHLPP1. Defective in stabilizing PHLPP1."";  /evidence=""ECO:0000269|PubMed:24145035""; MUTAGEN 595..599;  /note=""KVMEH->EVMEA: Decreased interaction with RAD51AP1."";  /evidence=""ECO:0000269|PubMed:27239033""; MUTAGEN 595;  /note=""K->E: Does not affect interaction with RAD51AP1."";  /evidence=""ECO:0000269|PubMed:27239033""; MUTAGEN 599;  /note=""H->A: Does not affect interaction with RAD51AP1."";  /evidence=""ECO:0000269|PubMed:27239033"""	Q8TAF3;	9606.ENSP00000307491;	5CVL;5CVN;5CVO;5K1A;5K1B;5K1C;5L8E;5L8W;6JLQ;7AY0;7AY1;7AY2;
A0A1S4NYD7	A0A1S4NYD7_9ALTE	unreviewed	AlyGC		Paraglaciecola chathamensis	726								5GKD;
G0SFF5	G0SFF5_CHATD	unreviewed	GTPase activator-like protein	CTHT_0061860	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	1734							209285.XP_006696502.1;	5HIU;6SSH;
Q12417	PRP46_YEAST	reviewed	Pre-mRNA-splicing factor PRP46 (Complexed with CEF1 protein 1) (PRP nineteen-associated complex protein 50) (PRP19-associated complex protein 50) (Pre-mRNA-processing protein 46)	PRP46 CWC1 NTC50 YPL151C P2594	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	451						Q12417;	4932.YPL151C;	5GM6;5GMK;5LJ3;5LJ5;5LQW;5MPS;5MQ0;5WSG;5Y88;5YLZ;6BK8;6EXN;6J6G;6J6H;6J6N;6J6Q;
A0A0C4WVM3	A0A0C4WVM3_9INFA	unreviewed	Neuraminidase (EC 3.2.1.18)		Influenza A virus (A/gyrfalcon/Washington/41088-6/2014(H5N8))	470								5HUN;
Q5VMP0	MAX2_ORYSJ	reviewed	F-box/LRR-repeat MAX2 homolog (F-box and leucine-rich repeat MAX2 homolog) (Protein DWARF 3)	D3 Os06g0154200 LOC_Os06g06050 OSJNBa0085L11.6-1	Oryza sativa subsp. japonica (Rice)	720				DISRUPTION PHENOTYPE: Increased number of tillers and reduced plant height. {ECO:0000269|PubMed:15659436, ECO:0000269|PubMed:17655651, ECO:0000269|PubMed:18690207, ECO:0000269|PubMed:24616269}.	"MUTAGEN 21;  /note=""P->S: In d3; dwarf and high tillering phenotypes; when associated with W-36."";  /evidence=""ECO:0000269|PubMed:24336200""; MUTAGEN 36;  /note=""R->W: In d3; dwarf and high tillering phenotypes; when associated with S-21."";  /evidence=""ECO:0000269|PubMed:24336200"""		4530.OS06T0154200-01;	5HYW;5HZG;6BRO;6BRP;6BRQ;
Q12M27	Q12M27_SHEDO	unreviewed	Nitrous-oxide reductase (EC 1.7.2.4) (N(2)OR) (N2O reductase)	nosZ Sden_2219	Shewanella denitrificans (strain OS217 / ATCC BAA-1090 / DSM 15013)	628							318161.Sden_2219;	5I5I;5I5J;5I5M;
Q04JH4	TPIS_STRP2	reviewed	Triosephosphate isomerase (TIM) (TPI) (EC 5.3.1.1) (Triose-phosphate isomerase)	tpiA SPD_1404	Streptococcus pneumoniae serotype 2 (strain D39 / NCTC 7466)	252							373153.SPD_1404;	5IBX;
G0SBN9	G0SBN9_CHATD	unreviewed	Uncharacterized protein	CTHT_0054250	Chaetomium thermophilum (strain DSM 1495 / CBS 144.50 / IMI 039719)	618						G0SBN9;	209285.XP_006695760.1;	5IC7;5OQL;6RXT;6RXU;6RXV;6RXX;6RXY;6RXZ;
A0A0C4WXC5	A0A0C4WXC5_9INFA	unreviewed	Neuraminidase (EC 3.2.1.18)		Influenza A virus (A/Northern pintail/Washington/40964/2014(H5N2))	469								5HUK;
Q8NHY2	COP1_HUMAN	reviewed	E3 ubiquitin-protein ligase COP1 (EC 2.3.2.27) (Constitutive photomorphogenesis protein 1 homolog) (hCOP1) (RING finger and WD repeat domain protein 2) (RING finger protein 200) (RING-type E3 ubiquitin transferase RFWD2)	COP1 RFWD2 RNF200	Homo sapiens (Human)	731					"MUTAGEN 111..113;  /note=""RKR->AKA: Abolishes localization to the nucleus."";  /evidence=""ECO:0000269|PubMed:12615916""; MUTAGEN 136;  /note=""C->A: Abolishes p53 ubiquitination and degradation but not that of JUN; when associated with A-139."";  /evidence=""ECO:0000269|PubMed:12615916, ECO:0000269|PubMed:14739464, ECO:0000269|PubMed:19805145, ECO:0000269|PubMed:21625211""; MUTAGEN 136;  /note=""C->S: Loss of SFN and MTA1 ubiquitination and degradation; when associated with S-139. Loss of stabilization by COPS6; when associated with S-139."";  /evidence=""ECO:0000269|PubMed:12615916, ECO:0000269|PubMed:14739464, ECO:0000269|PubMed:19805145, ECO:0000269|PubMed:21625211""; MUTAGEN 139;  /note=""C->A: Abolishes p53 ubiquitination and degradation but not that of JUN; when associated with A-136."";  /evidence=""ECO:0000269|PubMed:12615916, ECO:0000269|PubMed:14739464, ECO:0000269|PubMed:19805145, ECO:0000269|PubMed:21625211""; MUTAGEN 139;  /note=""C->S: Loss of SFN and MTA1 ubiquitination and degradation; when associated with S-136. Loss of stabilization by COPS6; when associated with S-136."";  /evidence=""ECO:0000269|PubMed:12615916, ECO:0000269|PubMed:14739464, ECO:0000269|PubMed:19805145, ECO:0000269|PubMed:21625211""; MUTAGEN 156;  /note=""C->S: Loss of MTA1 ubiquitination and degradation; when associated with S-159."";  /evidence=""ECO:0000269|PubMed:19805145""; MUTAGEN 159;  /note=""C->S: Loss of MTA1 ubiquitination and degradation; when associated with S-156."";  /evidence=""ECO:0000269|PubMed:19805145"""	Q8NHY2;	9606.ENSP00000356641;	5HQG;5IGQ;
A0A0B4N5Z5	A0A0B4N5Z5_9INFA	unreviewed	Neuraminidase (EC 3.2.1.18)		Influenza A virus (A/chicken/Sichuan/NCJPL1/2014(H5N6))	470								5HUM;
Q9R186	TRPV6_RAT	reviewed	Transient receptor potential cation channel subfamily V member 6 (TrpV6) (Calcium transport protein 1) (CaT1) (Epithelial calcium channel 2) (ECaC2)	Trpv6	Rattus norvegicus (Rat)	767					"MUTAGEN 201;  /note=""Y->F: Prevents up-regulation of the channel by phosphorylation; when associated with F-202."";  /evidence=""ECO:0000269|PubMed:17197020""; MUTAGEN 202;  /note=""Y->F: Prevents up-regulation of the channel by phosphorylation; when associated with F-201."";  /evidence=""ECO:0000269|PubMed:17197020""; MUTAGEN 535;  /note=""L->Q: Alters subunit assembly via domain swapping and reduces channel activity."";  /evidence=""ECO:0000269|PubMed:28878326"""	Q9R186;	10116.ENSRNOP00000020616;	5IWK;5IWP;5IWR;5IWT;5WO6;5WO7;5WO8;5WO9;5WOA;6BOB;6D7O;6D7P;6D7Q;6D7V;6D7X;6E2G;
C4T9I0	C4T9I0_KLEPN	unreviewed	LPS-assembly protein LptD	imp lptD B4U61_00430 BANRA_01971 BANRA_03252 BL124_00028160 BN49_4289 BS595_22660 C3F39_10720 DD583_03520 DDJ63_07490 DRB11_12110 EHZ17_06310 G7Z27_23030 GJJ08_022765 GNG14_00855 NCTC11679_04806 NCTC13443_01619 NCTC13465_04526 NCTC3279_04956 NCTC8849_00994 NCTC9637_05670 SAMEA3499874_03033 SAMEA3499901_00861 SAMEA3512100_03573 SAMEA3515130_02658 SAMEA3538828_00900 SAMEA3649648_02001 SAMEA3649733_02890 SAMEA3649758_01637 SAMEA3720909_02220 SAMEA3727643_01181 SAMEA3727679_02260 SAMEA3729663_01459	Klebsiella pneumoniae	782								5IV8;5IV9;
P47735	RLK5_ARATH	reviewed	Receptor-like protein kinase 5 (EC 2.7.10.1) (EC 2.7.11.1) (Protein HAESA)	RLK5 HAE At4g28490 F21O9.180	Arabidopsis thaliana (Mouse-ear cress)	999				DISRUPTION PHENOTYPE: No visible phenotype; due to the redundancy with HSL2. Hae and hsl2 double mutants have a strong abscission defect. {ECO:0000269|PubMed:18660431, ECO:0000269|PubMed:18809915}.	"MUTAGEN 711;  /note=""K->E: Loss of catalytic activity."";  /evidence=""ECO:0000269|PubMed:8086440"""	P47735;	3702.AT4G28490.1;	5IXO;5IXQ;5IXT;5IYV;5IYX;
E1C2W2	E1C2W2_CHICK	unreviewed	TOG domain-containing protein	CEP104	Gallus gallus (Chicken)	950							9031.ENSGALP00000001443;	5JO8;
Q96HA7	TONSL_HUMAN	reviewed	Tonsoku-like protein (Inhibitor of kappa B-related protein) (I-kappa-B-related protein) (IkappaBR) (NF-kappa-B inhibitor-like protein 2) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 2)	TONSL IKBR NFKBIL2	Homo sapiens (Human)	1378			DISEASE: Spondyloepimetaphyseal dysplasia, sponastrime type (SEMDSP) [MIM:271510]: An autosomal recessive bone disease characterized by spine abnormalities, mid-face hypoplasia with a depressed nasal bridge, and striation of the metaphyses. Additional features include disproportionate short stature with exaggerated lumbar lordosis, scoliosis, coxa vara, limited elbow extension, small dysplastic epiphyses, childhood cataracts, short dental roots, and hypogammaglobulinemia. Disease severity and clinical manifestations are variable. Some patients have mental retardation. {ECO:0000269|PubMed:30773277, ECO:0000269|PubMed:30773278}. Note=The disease is caused by variants affecting the gene represented in this entry.			Q96HA7;	9606.ENSP00000386239;	5JA4;
A0A159BDB5	A0A159BDB5_9CAUD	unreviewed	Tail fiber	phiAB6_gp40	Acinetobacter phage phiAB6	699								5JS4;5JSD;5JSE;
R4NFR6	R4NFR6_9INFA	unreviewed	Neuraminidase (EC 3.2.1.18)		Influenza A virus (A/Shanghai/02/2013(H7N9))	465								5JYY;5L14;5L15;5L17;5L18;6PZD;6PZE;6PZF;
Q8TBZ3	WDR20_HUMAN	reviewed	WD repeat-containing protein 20 (Protein DMR)	WDR20	Homo sapiens (Human)	569					"MUTAGEN 262;  /note=""F->A: Impaired binding to USP12."";  /evidence=""ECO:0000269|PubMed:27373336""; MUTAGEN 306;  /note=""W->A: Impaired binding to USP12."";  /evidence=""ECO:0000269|PubMed:27373336"""	Q8TBZ3;	9606.ENSP00000406084;	5K19;5K1C;6JLQ;
Q5IH81	EIF3I_RABIT	reviewed	Eukaryotic translation initiation factor 3 subunit I (eIF3i) (Eukaryotic translation initiation factor 3 subunit 2) (eIF-3-beta) (eIF3 p36)	EIF3I EIF3S2	Oryctolagus cuniculus (Rabbit)	333						Q5IH81;	9986.ENSOCUP00000006589;	5K0Y;
P43254	COP1_ARATH	reviewed	E3 ubiquitin-protein ligase COP1 (EC 2.3.2.27) (Constitutive photomorphogenesis protein 1) (RING-type E3 ubiquitin transferase COP1)	COP1 At2g32950 T21L14.11	Arabidopsis thaliana (Mouse-ear cress)	675				DISRUPTION PHENOTYPE: The double mutant shw1 cop1 displays an enhanced photomorphogenic growth in the darkness as well as abnormal accumulation of HY5. {ECO:0000269|PubMed:26474641}.	"MUTAGEN 52;  /note=""C->S: Abolishes LAF1 ubiquitination and degradation; when associated with S-55."";  /evidence=""ECO:0000269|PubMed:12827204""; MUTAGEN 55;  /note=""C->S: Abolishes LAF1 ubiquitination and degradation; when associated with S-52."";  /evidence=""ECO:0000269|PubMed:12827204""; MUTAGEN 294..296;  /note=""RKK->SKT: Abolishes localization to the nucleus."";  /evidence=""ECO:0000269|PubMed:10072396""; MUTAGEN 312..314;  /note=""KRR->TRS: Abolishes localization to the nucleus."";  /evidence=""ECO:0000269|PubMed:10072396""; MUTAGEN 422;  /note=""K->E: 5-fold increase in interaction with HY5, weak interaction with BBX24/STO and BBX25/STH, and at low light intensity shorter hypocotyl."";  /evidence=""ECO:0000269|PubMed:11226162""; MUTAGEN 465;  /note=""R->E: No interaction with BBX24/STO and BBX25/STH, and at low light intensity shorter hypocotyl."";  /evidence=""ECO:0000269|PubMed:11226162""; MUTAGEN 467;  /note=""W->A: No interaction with HY5, BBX24/STO and BBX25/STH and at low light intensity shorter hypocotyl."";  /evidence=""ECO:0000269|PubMed:11226162""; MUTAGEN 523..584;  /note=""Missing: In COP1-8; no interaction with SPA1 and lethal.""; MUTAGEN 524;  /note=""G->E: In COP1-9; no interaction with HY5, SPA1, BBX25/STH or BBX24/STO and lethal.""; MUTAGEN 550;  /note=""K->E: No interaction with HY5, BBX24/STO and BBX25/STH and at low light intensity shorter hypocotyl."";  /evidence=""ECO:0000269|PubMed:11226162""; MUTAGEN 592;  /note=""E->R: Better interaction with HY5, BBX24/STO and BBX25/STH and slightly longer hypocotyls."";  /evidence=""ECO:0000269|PubMed:11226162"""	P43254;	3702.AT2G32950.1;	5IGO;5KWN;6QTO;6QTQ;6QTR;6QTS;6QTT;6QTU;6QTV;6QTW;6QTX;
Q80UG2	PLXA4_MOUSE	reviewed	Plexin-A4	Plxna4 Kiaa1550	Mus musculus (Mouse)	1893				DISRUPTION PHENOTYPE: No visible phenotype. Mice exhibit defasciculation of the facial branchiomotor nerve and of the ophthalmic branch of the trigeminus, with variable severity. In mice lacking both Plxna3 and Plxna4, migrating neurons do not show the normal response to Sema3A and Sema3F and do not migrate away from these semaphorins (in vitro). {ECO:0000269|PubMed:18262512, ECO:0000269|PubMed:18804103}.		Q80UG2;	10090.ENSMUSP00000110748;	5L5K;5L5L;5L5M;5L5N;7M0R;
Q8A915	Q8A915_BACTN	unreviewed	Pectin lyase fold/virulence factor	BT_1002	Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 / VPI-5482 / E50)	619							226186.BT_1002;	5MQP;
P35828	SLAP_CAUVC	reviewed	S-layer protein (Paracrystalline surface layer protein)	rsaA CC_1007	Caulobacter vibrioides (strain ATCC 19089 / CB15) (Caulobacter crescentus)	1026							190650.CC_1007;	5N8P;6P5T;6T72;6Z7P;
Q9I5U2	LPTD_PSEAE	reviewed	LPS-assembly protein LptD	lptD imp ostA PA0595	Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)	924								5IVA;
Q9P8C9	Q9P8C9_PIRSE	unreviewed	Xylose isomerase (EC 5.3.1.5)	xylA	Piromyces sp. (strain E2)	437								5NH4;5NH5;5NH6;5NH7;5NH8;5NH9;5NHA;5NHB;5NHC;5NHD;5NHE;5NHM;5YN3;6T8E;6T8F;
P9WFY1	TRPA_MYCTU	reviewed	Tryptophan synthase alpha chain (EC 4.2.1.20)	trpA Rv1613 MTCY01B2.05	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	270							83332.Rv1613;	5OCW;5TCF;5TCG;5TCH;5TCI;5TCJ;6DWE;6E9P;6U6C;6UAP;6UB9;6USA;
Q91YS4	Q91YS4_MOUSE	unreviewed	Kinesin light chain	Klc2	Mus musculus (Mouse)	619						Q91YS4;		5OJF;6F9I;
G3M190	G3M190_9CAUD	unreviewed	Putative tail fiber	orf211	Escherichia virus CBA120	921								5W6P;5W6S;6W4Q;
Q68FD5	CLH1_MOUSE	reviewed	Clathrin heavy chain 1	Cltc	Mus musculus (Mouse)	1675						Q68FD5;	10090.ENSMUSP00000099475;	5ODS;
A0A0H4TJ34	A0A0H4TJ34_9CAUD	unreviewed	Tail spike protein	Fri1_49	Acinetobacter phage Fri1	783								6C72;
I7I026	I7I026_9CAUD	unreviewed	Phi92_gp150	PHI92_gene_150 PHI92_150	Enterobacteria phage phi92	804								6E0V;6E0W;
P0A6V1	GLGC_ECOLI	reviewed	Glucose-1-phosphate adenylyltransferase (EC 2.7.7.27) (ADP-glucose pyrophosphorylase) (ADPGlc PPase) (ADP-glucose synthase)	glgC b3430 JW3393	Escherichia coli (strain K12)	431					"MUTAGEN 39;  /note=""K->E: The level of activation by pyridoxal phosphate and fructose-1,6-phosphate is only approximately 2-fold compared to activation of 15- to 28-fold respectively, for the wild-type. NADPH is unable to activate the mutant enzyme."";  /evidence=""ECO:0000269|PubMed:2162151""; MUTAGEN 74;  /note=""Q->A: Insensitive to activation by fructose-1,6-bisphosphate, but still binds fructose-1,6-bisphosphate with similar affinity as the wild-type. AMP causes similar inhibition on the wild-type and mutant."";  /evidence=""ECO:0000269|PubMed:21741429""; MUTAGEN 74;  /note=""Q->E: Insensitive to activation by fructose-1,6-bisphosphate."";  /evidence=""ECO:0000269|PubMed:21741429""; MUTAGEN 74;  /note=""Q->N: The enzyme is activated 35-fold by fructose-1,6-bisphosphate."";  /evidence=""ECO:0000269|PubMed:21741429""; MUTAGEN 113;  /note=""W->A: Insensitive to activation by fructose-1,6-bisphosphate, but still binds fructose-1,6-bisphosphate, with similar affinity as the wild-type. AMP causes similar inhibition on the wild-type and mutant."";  /evidence=""ECO:0000269|PubMed:21741429""; MUTAGEN 113;  /note=""W->L: The enzyme is activated only 3-fold by fructose-1,6-bisphosphate."";  /evidence=""ECO:0000269|PubMed:21741429""; MUTAGEN 113;  /note=""W->Y: The enzyme is activated 15-fold by fructose-1,6-bisphosphate."";  /evidence=""ECO:0000269|PubMed:21741429""; MUTAGEN 114;  /note=""Y->F: Shows a decrease of affinity for the substrates and less than 2-fold activation by fructose 1,6-bisphosphate in the ADP-glucose synthesis direction. In contrast, in the pyrophosphorolysis direction, the mutant shoqws about a 30-fold activation by fructose 1,6-bisphosphate."";  /evidence=""ECO:0000269|PubMed:2844780""; MUTAGEN 195;  /note=""K->E,I,H,R: Decrease of the affinity for alpha-D-glucose 1-phosphate, but no loss in adenylyltransferase activity."";  /evidence=""ECO:0000269|PubMed:1648099""; MUTAGEN 195;  /note=""K->Q: 600-fold decrease of the affinity for alpha-D-glucose 1-phosphate compared to the wild-type. In contrast, kinetic constants for ATP, magnesium and fructose-1,6-bisphosphate are similar in mutant and wild-type cases. The catalytic efficiency is 2-fold lower in the mutant."";  /evidence=""ECO:0000269|PubMed:1648099"""	P0A6V1;	511145.b3430;	5L6S;5L6V;5MNI;6R8B;6R8U;6SHJ;6SHN;6SHQ;6SI8;
E4S4B2	E4S4B2_CALKI	unreviewed	Uncharacterized protein	Calkr_0826	Caldicellulosiruptor kristjanssonii (strain ATCC 700853 / DSM 12137 / I77R1B)	634							632335.Calkr_0826;	6N2B;
A0A0C5PVE3	A0A0C5PVE3_9CAUD	unreviewed	Tailspike	208 DET7_208	Salmonella phage Det7	798								6F7D;6F7K;
Q9DBG3	AP2B1_MOUSE	reviewed	AP-2 complex subunit beta (AP105B) (Adaptor protein complex AP-2 subunit beta) (Adaptor-related protein complex 2 subunit beta) (Beta-2-adaptin) (Beta-adaptin) (Clathrin assembly protein complex 2 beta large chain) (Plasma membrane adaptor HA2/AP2 adaptin beta subunit)	Ap2b1 Clapb1	Mus musculus (Mouse)	937						Q9DBG3;	10090.ENSMUSP00000018875;	6OWO;6OXL;
H2VFG5	H2VFG5_NEIMI	unreviewed	N-acetylneuraminate synthase (EC 2.5.1.56) (SynC protein)	synC	Neisseria meningitidis serogroup B	349								6PPW;6PPX;6PPY;6PPZ;
L8I535	L8I535_9CETA	unreviewed	WD repeat-containing protein 20	M91_05678	Bos mutus (wild yak)	595								6JLQ;
Q5SHG1	Q5SHG1_THET8	unreviewed	Uncharacterized protein	TTHA1769	Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8)	123							300852.55773151;	6RIA;6RIB;
P31539	HS104_YEAST	reviewed	Heat shock protein 104 (Protein aggregation-remodeling factor HSP104)	HSP104 YLL026W L0948	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	908					"MUTAGEN 184;  /note=""D->A,D,F,N,L,Q,S: Confers resistance to prion-curing by guanidine."";  /evidence=""ECO:0000269|PubMed:12105276""; MUTAGEN 184;  /note=""D->K,W,Y: Impairs prion propagation."";  /evidence=""ECO:0000269|PubMed:12105276""; MUTAGEN 217;  /note=""G->S: Largely reduces ATP hydrolysis. Alters bud morphology and causes septin mislocalization; when associated with I-499."";  /evidence=""ECO:0000269|PubMed:11158570, ECO:0000269|PubMed:14978213, ECO:0000269|PubMed:9624144""; MUTAGEN 217;  /note=""G->V: Completely abolishes ATP hydrolysis."";  /evidence=""ECO:0000269|PubMed:11158570, ECO:0000269|PubMed:14978213, ECO:0000269|PubMed:9624144""; MUTAGEN 218;  /note=""K->T: Abolishes substrate binding. Unable to confer thermotolerance. Reduces ATP hydrolysis by 98%; when associated with T-315. Comletely abolishes ATPase activity; when associated with T-620."";  /evidence=""ECO:0000269|PubMed:11158570, ECO:0000269|PubMed:11442834, ECO:0000269|PubMed:11983167, ECO:0000269|PubMed:12101251, ECO:0000269|PubMed:16135516, ECO:0000269|PubMed:17259993, ECO:0000269|PubMed:17543332, ECO:0000269|PubMed:1896074, ECO:0000269|PubMed:8308017, ECO:0000269|PubMed:9624144""; MUTAGEN 257;  /note=""Y->A: Reduces thermotolerance 10-fold."";  /evidence=""ECO:0000269|PubMed:15128736""; MUTAGEN 285;  /note=""E->Q: In HSP104(TRAP); completely abolishes ATP hydrolysis, but does not affect nucleotide binding, thus keeping HSP104 in an ATP-bound state; when associated with Q-687."";  /evidence=""ECO:0000269|PubMed:16135516, ECO:0000269|PubMed:17543332""; MUTAGEN 315;  /note=""A->T: Reduces ATP hydrolysis by 98%; when associated with T-218."";  /evidence=""ECO:0000269|PubMed:11983167""; MUTAGEN 317;  /note=""T->A: Reduces rate of ATP hydrolysis at NBD1 nearly 10-fold. No effect on oligomerization."";  /evidence=""ECO:0000269|PubMed:11782421, ECO:0000269|PubMed:17259993""; MUTAGEN 334;  /note=""R->M: Reduces ATPase activity by 80%. Impairs oligomerization."";  /evidence=""ECO:0000269|PubMed:18160044""; MUTAGEN 419;  /note=""R->M: Reduces ATPase activity by 80%."";  /evidence=""ECO:0000269|PubMed:18160044""; MUTAGEN 444;  /note=""R->M: Reduces ATPase activity by 80%."";  /evidence=""ECO:0000269|PubMed:18160044""; MUTAGEN 462;  /note=""L->R: Impairs prion propagation, but does not affect thermotolerance."";  /evidence=""ECO:0000269|PubMed:17367387""; MUTAGEN 495;  /note=""R->M: Increases ATPase activity 3-fold."";  /evidence=""ECO:0000269|PubMed:18160044""; MUTAGEN 499;  /note=""T->I: Reduces ATP hydrolysis by 50%. Alters bud morphology and causes septin mislocalization; when associated with S-217."";  /evidence=""ECO:0000269|PubMed:14978213""; MUTAGEN 503;  /note=""A->V: Increases basal level of ATPase activity and abolishes stimulation of ATP hydrolysis upon substrate binding. Inhibits growth at 37 degrees Celsius."";  /evidence=""ECO:0000269|PubMed:11983167, ECO:0000269|PubMed:14978213""; MUTAGEN 509;  /note=""A->D: Reduces thermotolerance."";  /evidence=""ECO:0000269|PubMed:14978213""; MUTAGEN 557;  /note=""P->L: Impairs prion propagation, but does not affect thermotolerance."";  /evidence=""ECO:0000269|PubMed:17367387""; MUTAGEN 619;  /note=""G->V: Impairs oligomerization at low protein concentrations."";  /evidence=""ECO:0000269|PubMed:11158570, ECO:0000269|PubMed:9624144""; MUTAGEN 620;  /note=""K->T: Impairs oligomerization at low protein concentrations. Reduces ATP hydrolysis rate. Unable to confer thermotolerance. Comletely abolishes ATPase activity; when associated with T-218."";  /evidence=""ECO:0000269|PubMed:11158570, ECO:0000269|PubMed:11442834, ECO:0000269|PubMed:12101251, ECO:0000269|PubMed:16135516, ECO:0000269|PubMed:17259993, ECO:0000269|PubMed:17543332, ECO:0000269|PubMed:1896074, ECO:0000269|PubMed:8308017, ECO:0000269|PubMed:9624144""; MUTAGEN 621;  /note=""T->A: Reduces ATP hydrolysis, but does not affect oligomerization."";  /evidence=""ECO:0000269|PubMed:11158570""; MUTAGEN 645;  /note=""E->K: Abolishes the ability to refold aggregated protein in vitro and to provide thermotolerance in vivo."";  /evidence=""ECO:0000269|PubMed:15128736""; MUTAGEN 662;  /note=""Y->A,K: Abolishes the ability to refold aggregated protein in vitro and to provide thermotolerance in vivo."";  /evidence=""ECO:0000269|PubMed:15128736""; MUTAGEN 662;  /note=""Y->F,W: No effect."";  /evidence=""ECO:0000269|PubMed:15128736""; MUTAGEN 687;  /note=""E->Q: In HSP104(TRAP); completely abolishes ATP hydrolysis, but does not affect nucleotide binding, thus keeping HSP104 in an ATP-bound state; when associated with Q-285."";  /evidence=""ECO:0000269|PubMed:16135516, ECO:0000269|PubMed:17543332""; MUTAGEN 704;  /note=""D->N: Impairs prion propagation, but does not affect thermotolerance."";  /evidence=""ECO:0000269|PubMed:17367387""; MUTAGEN 728;  /note=""N->A: Almost completely abolishes ATP hydrolysis at NBD2, but does not affect nucleotide binding, thus keeping NBD2 in an ATP-bound state. Reduces stimulation of ATP hydrolysis upon substrate binding."";  /evidence=""ECO:0000269|PubMed:11782421, ECO:0000269|PubMed:11983167, ECO:0000269|PubMed:17259993, ECO:0000269|PubMed:18160044""; MUTAGEN 765;  /note=""R->M: Can oligomerize in the absence of nucleotides."";  /evidence=""ECO:0000269|PubMed:18160044""; MUTAGEN 778;  /note=""K->A: In NLS17KA; fails to concentrate in the nucleus; when associated with A-782 and A-789."";  /evidence=""ECO:0000269|PubMed:17973656""; MUTAGEN 782;  /note=""K->A: In NLS17KA; fails to concentrate in the nucleus; when associated with A-778 and A-789."";  /evidence=""ECO:0000269|PubMed:17973656""; MUTAGEN 789;  /note=""K->A: In NLS17KA; fails to concentrate in the nucleus; when associated with A-778 and A-782."";  /evidence=""ECO:0000269|PubMed:17973656""; MUTAGEN 819;  /note=""Y->W: Site-specific fluorescent probe in an otherwise Trp-less HSP104. Fluorescence of this Trp changes in response to ATP and ADP binding at NBD2. Has no effect on ATP hydrolysis or protein stability."";  /evidence=""ECO:0000269|PubMed:11867765""; MUTAGEN 826;  /note=""R->M: Reduces ATP and ADP binding at NBD2 6-fold, but does not affect ATP hydrolysis at NBD2. Reduces catalytic rate at NBD1."";  /evidence=""ECO:0000269|PubMed:11867765"""	P31539;	4932.YLL026W;	5KNE;5U2U;5VJH;5VY8;5VY9;5VYA;5WBW;6AHF;6AMN;6N8T;6N8V;6N8Z;
